<SEC-DOCUMENT>0001628280-25-015673.txt : 20250331
<SEC-HEADER>0001628280-25-015673.hdr.sgml : 20250331
<ACCEPTANCE-DATETIME>20250331163245
ACCESSION NUMBER:		0001628280-25-015673
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		89
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250331
DATE AS OF CHANGE:		20250331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Carisma Therapeutics Inc.
		CENTRAL INDEX KEY:			0001485003
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				262025616
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36296
		FILM NUMBER:		25793888

	BUSINESS ADDRESS:	
		STREET 1:		3675 MARKET STREET
		STREET 2:		SUITE 401
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104
		BUSINESS PHONE:		2674916422

	MAIL ADDRESS:	
		STREET 1:		3675 MARKET STREET
		STREET 2:		SUITE 401
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Sesen Bio, Inc.
		DATE OF NAME CHANGE:	20180516

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Eleven Biotherapeutics, Inc.
		DATE OF NAME CHANGE:	20100223
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>carm-20241231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:1dec34d0-de78-478e-a130-81bf7fce6e30,g:762837ba-4cc2-4d5a-8343-3052f0231779,d:280a0966ad034c5090dd46bd303d2259-->
<html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:carm="http://carismatx.com/20241231" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>carm-20241231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-33">0001485003</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-34">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-35">2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-36">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-33" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-325">http://fasb.org/us-gaap/2024#GeneralAndAdministrativeExpense</ix:nonNumeric><ix:nonNumeric contextRef="c-34" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-326">http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense</ix:nonNumeric><ix:nonNumeric contextRef="c-44" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="f-366">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="c-67" name="carm:AgreementTerm" id="f-509">P5Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="carm-20241231.xsd"/></ix:references><ix:resources><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="employee"><xbrli:measure>carm:employee</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>carm:segment</xbrli:measure></xbrli:unit><xbrli:unit id="seat"><xbrli:measure>carm:seat</xbrli:measure></xbrli:unit><xbrli:unit id="target"><xbrli:measure>carm:target</xbrli:measure></xbrli:unit><xbrli:unit id="product"><xbrli:measure>carm:product</xbrli:measure></xbrli:unit><xbrli:unit id="obligation"><xbrli:measure>carm:obligation</xbrli:measure></xbrli:unit><xbrli:unit id="item"><xbrli:measure>carm:item</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">carm:CashPreservationPlan2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">carm:ReportingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">carm:ReportingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">carm:CarismaTherapeuticsIncLegacyStockholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">carm:CarismaTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">carm:CarismaTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">carm:CarismaTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-07</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:TrusteesOfUniversityOfPennsylvaniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:PennLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:TrusteesOfUniversityOfPennsylvaniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:PennLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:TrusteesOfUniversityOfPennsylvaniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:PennLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-26</xbrli:startDate><xbrli:endDate>2024-06-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-07</xbrli:startDate><xbrli:endDate>2023-03-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">carm:AtTheMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">carm:AtTheMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">carm:AtTheMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:TwoThousandSeventeenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:TwoThousandFourteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:TwoThousandFourteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:TwoThousandFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:TwoThousandFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:RevisedOperatingPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">carm:SesenBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">carm:Pre2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">carm:Post2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">carm:StateJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">carm:LocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">carm:StateJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:ModernaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:ModernaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:ModernaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:ModernaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:OptionRightCollaborationRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:MilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:ModernaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-01</xbrli:startDate><xbrli:endDate>2025-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">carm:CashPreservationPlan2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-31</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i280a0966ad034c5090dd46bd303d2259_1"></div><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________________________________________________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________________________________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(Mark One)</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">x</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-4">December 31</ix:nonNumeric>, 2024</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">For the transition period from _________________to _________________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-36296</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">Carisma Therapeutics Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________________________________________________</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">26-2025616</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(State or other jurisdiction<br/>of incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(IRS Employer<br/>Identification No.)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">3675 Market Street</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-11">Suite 401</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-12">Philadelphia</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-13">PA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-14">19104</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(Zip Code)</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-15">267</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-16">491-6422</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________________________________________________</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:36.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.384%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Trading<br/>Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Name of exchange<br/>on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, $0.001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">CARM</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(g) of the Act: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">None</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:112%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-20">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:112%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:112%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-21">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:112%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-22">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-23">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.235%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-24">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-25">x</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-26">o</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="f-27">o</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-28">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;&#8201;240.10D-1(b). </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:112%">o</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:112%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-29">x</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">The aggregate market value of the voting and non-voting common equity held by non-affiliates based on the closing sale price as reported on The Nasdaq Stock Market LLC, as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter, June 28, 2024, was $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="0" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="f-30">53,095,128</ix:nonFraction>.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The registrant had <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-31">41,788,096</ix:nonFraction> shares of common stock, $0.001 par value per share, outstanding as of March&#160;26, 2025.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-32" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">The registrant intends to file a definitive proxy statement pursuant to Regulation 14A within 120 days of the end of the fiscal year ended December 31, 2024. Portions of such definitive proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K.</span></div></ix:nonNumeric><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;margin-top:24pt;text-align:center"><span><br/></span></div></div></div><div id="i280a0966ad034c5090dd46bd303d2259_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:75.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.931%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_13">PART I.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib5803e6e1ac4433894f1ec76f5efc360_11">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_16">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_16">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i864c50ffc9504e649750a996caecbca2_21">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_70">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_70">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if01f0055e0694c72b88254a6ce1c2a90_1751004">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_73">Item 1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_73">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia1cb3ac5fe7040c7acbf1ce51bd8506b_55">96</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_76">Item 1C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_76">Cybersecurity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ic7b1cef4dbcb4c0caf7f656a4b3e8d20_3658">96</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_79">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_79">Properties </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ic5e43f46b3f74e8e96038728ba954458_414">97</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_82">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_82">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7c8af2420fbb4874b3b9e71b79e65f0c_93">97</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_85">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_85">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia551be224cd346b7b0e657c46531840b_53">97</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_88">PART II.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i50dd8415e59d4bd49c6d70b77bb81560_12">98</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_91">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_91">Market for Registrant's Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7422626828204722af10aeb0ba8c931f_1655">98</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_94">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_94">[Reserved]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if626673dd152468288b49d61f76068c7_24">98</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_97">Item 7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_97">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i6facfa7cbc8042f4949c58b815b4f561_665">99</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_127">Item 7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_127">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idbaea266c22b411984f104e93ec66429_971">110</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_130">Item 8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_130">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia4639bfee660467caba0d6ec793162ce_57">112</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_196">Item 9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_196">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i3992972c2537445c9a8278ca5aa7cfbe_105">137</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_199">Item 9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_199">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4982873c415d490da8ea53474049452b_4077">137</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_202">Item 9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_202">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4be3894fcef7484d83412378c8681dd0_4676">137</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_205">Item 9C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_205">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i68db24f8b2ea4b9895aca26d8a81e3ec_100">138</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_208">PART III.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i6d5fad6165814471bc18a49b4a701ecc_12">138</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_211">Item 10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_211">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8bada215eff9499da3d487f8b281eebd_1009">138</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_214">Item 11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_214">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i271f870ee7e94e5ba26ed3b1bef6bab0_357">138</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_217">Item 12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_217">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i0f43c508acb34e1296107293c773a415_429">139</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_220">Item 13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_220">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i43f4eebf46b64b41852c4cee5dfd4c37_408">139</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_223">Item 14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_223">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#iab184d24f86c43088a52a9ca669878c2_382">139</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_226">PART IV.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i34a77c2ed03a4253a75975a083269a7a_12">140</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_229">Item 15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_229">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i148ff4caf1064319aaff172ed3826681_851">140</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_232">Item 16.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_232">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i280a0966ad034c5090dd46bd303d2259_232">142</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_235">SIGNATURES</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if90c2d5e6aa24ffea52f912b5c8da07c_436">143</a></span></div></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i280a0966ad034c5090dd46bd303d2259_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains express or implied forward-looking statements that are based on our management&#8217;s belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by these forward-looking statements. Forward-looking statements in this Annual Report on Form 10-K may include, but are not limited to, statements about:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to identify, evaluate and execute a strategic transaction;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">our ability to preserve our existing cash resources so that we may pursue an orderly wind down of our operations; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to successfully execute a planned orderly wind down;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our expectations regarding the value or recovery that may be available to our stockholders and other stakeholders in connection with a potential strategic transaction or as part of a wind down process; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to obtain additional financing;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">our ability to continue as a going concern;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the potential benefits and advantages of our platform technology, CT-2401, our pre-clinical stage product </span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">candidate targeting liver fibrosis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and CT-1119, our product candidate targeting mesothelin-positive solid tumors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">our potential to receive future milestones and royalty payments under our collaboration with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ModernaTX, Inc., or Moderna or to realize value from such collaboration</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">our ability to resume research and development activities if we were to execute a strategic transaction or obtain significant additional funding;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">if we were to resume research and development activities, our ability to conduct discovery and pre-clinical testing of product candidates, and initiate, enroll patients in and complete clinical trials of product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">our ability to replicate in any such later clinical trials positive results found in pre-clinical studies and early-stage clinical trials of our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to enter into and realize the anticipated benefits of our research and development programs, strategic partnerships, research and licensing programs and academic and other collaborations;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">if we were to resume research and development activities, the timing of applying for and receiving, and our ability to maintain, marketing approvals from applicable regulatory authorities for our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to obtain and maintain intellectual property protection and regulatory exclusivity for our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">acceptance of product candidates, if approved, by patients, the medical community, and third-party payors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our expectations regarding our ability to fund our operating expenses and capital expenditure requirements with our cash and cash equivalents;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our estimates regarding the potential market opportunity for our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the potential impact of public health epidemics or pandemics and of global economic developments on our business, operations, strategy and goals;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our competitive position;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to maintain compliance with Nasdaq listing standards;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the impact of government laws and regulations;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">political and economic developments; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">such other matters as discussed on this Annual Report on Form 10-K, including Part I, Item 1A, &#8220;Risk Factors.&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, forward-looking statements can be identified by terminology such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;goals,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;continue&#8221; or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the section titled &#8220;Risk Factors&#8221; and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">elsewhere in this Annual Report on Form 10-K. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those expressed or implied by the forward-looking statements. No forward-looking statement is a promise or a guarantee of future performance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read this Annual Report on Form 10-K and the documents that we have filed as exhibits to this Annual Report on Form 10-K completely and with the understanding that our actual future results may be materially different from what we expect. The forward-looking statements in this Annual Report on Form 10-K represent our views as of the date of this Annual Report on Form 10-K. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Annual Report on Form 10-K.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this Annual Report on Form 10-K, unless otherwise stated or the context otherwise requires, references to the &#8220;Company,&#8221; &#8220;Carisma,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Carisma Therapeutics Inc. (formerly Sesen Bio, Inc.) and its consolidated subsidiaries.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to &#8220;Legacy Carisma&#8221; refer to CTx Operations, Inc. (formerly CARISMA Therapeutics Inc.) and references to &#8220;Sesen Bio&#8221; refer to Sesen Bio, Inc. prior to completion of the business combination on March 7, 2023 in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of September 20, 2022, as amended, by and among the Company, Legacy Carisma and Seahawk Merger Sub, Inc., a wholly owned subsidiary of the Company, pursuant to which Seahawk Merger Sub, Inc. merged with and into Legacy Carisma, with Legacy Carisma continuing as a wholly owned subsidiary of the Company and the surviving corporation of the merger, or the Merger.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Merger Agreement, we changed our name from &#8220;Sesen Bio, Inc.&#8221; to &#8220;Carisma Therapeutics Inc.&#8221; Following the completion of the Merger, the business conducted by us became primarily the business conducted by Legacy Carisma, which is a biotechnology company dedicated to developing a differentiated and proprietary platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</span></div></div></div><div id="i280a0966ad034c5090dd46bd303d2259_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span id="ib5803e6e1ac4433894f1ec76f5efc360_11"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part I</span></div><div id="i280a0966ad034c5090dd46bd303d2259_16"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. <span id="i864c50ffc9504e649750a996caecbca2_21"></span>Business.</span></div><div id="i280a0966ad034c5090dd46bd303d2259_19"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biotechnology company focused on applying our industry leading expertise in macrophage engineering to develop transformative therapies to treat serious diseases including liver fibrosis and cancer. We have created a comprehensive set of platform technologies to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells. We seek to apply our ability to engineer macrophages and monocytes, either</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, using approaches and delivery systems most appropriate to each specific indication, to meaningfully alter the course of the disease. Our proprietary CAR-M platform uses chimeric antigen receptors, or CARs, to redirect macrophages or monocytes against specific tumor associated antigens with the goal of targeted anti-tumor immunity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 7, 2023, we completed a business combination in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of September 20, 2022, pursuant to which the Merger was consummated. Pursuant to the Merger Agreement, we changed our name from &#8220;Sesen Bio, Inc.&#8221; to &#8220;Carisma Therapeutics Inc.&#8221; Following the completion of the Merger, our business became primarily the business conducted by Legacy Carisma.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2024 Revised Operating Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024, following a strategic review of our operating plan for 2024 and future periods, we approved a revised operating plan intended to balance value creation and expense management with our available cash resources. The objective of our revised operating plan was to focus our clinical development efforts on high potential value programs with meaningful near-term milestones and eliminate non-essential expenses and headcount to extend our cash runway. Under that plan, we intended to focus our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">oncology clinical development efforts on our follow-on product candidate CT-0525, a CAR-Monocyte intended to treat solid tumors that over-express human epidermal growth factor receptor 2, or HER2 and cease development of CT-0508, our macrophage-based product candidate, and initial lead product candidate. In addition, at that time, we decided to continue to focus on our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> mRNA/lipid nanoparticle, or LNP, CAR-M programs in partnership with Moderna and pause development of CT-1119, amesothelin-targeted CAR-Monocyte, pending additional financing, reduce our workforce and decrease spending on other non-essential activities. All clinical activities of CT-0508 have ceased.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2024, following a strategic review of our operating plan for 2025 and our future pipeline, we approved another revised operating plan intended to reduce monthly operating expenses, conserve cash, and refocus our efforts on strategic priorities. First, we decided to cease development of our HER2 directed autologous cell therapy platform including CT-0525. Our decision was based on an assessment of the competitive landscape in anti-HER2 treatments, including the impact of recently approved anti-HER2 therapies on HER2 antigen loss/downregulation, and the effects on the future development strategy of any anti-HER2 product. We dosed the last patient in our Phase 1 clinical trial of CT-0525 in November 2024 and all clinical activity ended in January 2025.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further pursuant to the December 2024 revised operating plan, we pivoted our focus to developing product candidates targeting two indications &#8211; liver fibrosis and solid tumor oncology, while retaining the potential to receive milestones and royalties from our collaboration with Moderna. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Developments - 2025 Cash Preservation Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of a further revised plan approved by our board of directors on March 25, 2025 to preserve our existing cash resources following our reduction in workforce, or our cash preservation plan, we have reduced our operations to those necessary to identify and explore a range of strategic alternatives to maximize value and prepare to wind down our business. Potential strategic alternatives to be explored and evaluated may include, among other transactions, the sale, license, monetization or divestiture of one or more of our assets or technologies, a strategic collaboration or partnership with one or more parties or the merger or sale of our company. We cannot provide any commitment regarding when or if this strategic review process will result in any type of transaction. We currently have no intention of resuming research and development activities. Any future resumption of research and development activities would depend on completing a strategic transaction that would support our prior operating plans or otherwise obtaining significant additional funding.</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">part of our cash preservation plan, our board of directors determined to terminate all of our employees not deemed necessary to pursue strategic alternatives and execute an orderly wind down of our operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We may retain a financial advisor to advise on our exploration of a range of strategic alternatives. We plan to work with this advisor on identifying and evaluating potential strategic alternatives with the goal of maximizing the value of our assets, including CT-2401, CT-1119, our macrophage and monocyte engineering platform and our CAR-M platform and realizing value for the potential milestone and royalty payments under the Moderna collaboration. However, our exploration of strategic alternatives may not result in the consummation of any transaction or the realization of any value for our company or our stockholders.</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our Product Candidates and Pipeline</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our liver fibrosis program is based upon the discovery of a key efferocytosis defect in the macrophages that reside within the livers of patients with fibrosis. Using a novel mRNA LNP approach, our product candidate aims to reverse fibrotic disease and improve the outcomes of patients with advanced liver fibrosis. In the second quarter of 2024, we achieved pre-clinical proof of concept in our liver fibrosis program, demonstrating the anti-fibrotic potential of engineered macrophages in two liver fibrosis models. Prior to pausing our research and development activities, we planned to continue to conduct pre-clinical development of our product candidate, CT-2401, sufficient to enable a regulatory submission to initiate a clinical trial.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our oncology program leverages our considerable expertise and experience in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> cell therapy. CT-1119 is designed to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. Prior to pausing our research and development activities, we planned to initiate a Phase 1 clinical trial of CT-1119, a mesothelin-targeted CAR-Monocyte, in combination with tislelizumab, an anti-PD-1 antibody, in adult patients with mesothelin-positive solid tumors in China. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our collaboration with Moderna utilizes Moderna's mRNA/LNP technology, together with our CAR-M platform technology, to create novel </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> oncology off-the-shelf gene therapy product candidates. In June 2024, we announced that Moderna nominated the first development candidate under the collaboration and paid us a $2.0 million milestone. This development candidate targets Glypican-3, or GPC3, and is designed to treat solid tumors, including hepatocellular carcinoma. In November 2024, we announced new pre-clinical data on our anti-GPC3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> CAR-M therapy for treating hepatocellular carcinoma. These pre-clinical data demonstrated robust anti-tumor activity. In February 2025, Moderna nominated ten additional oncology research targets, four of which replaced two oncology research targets and two autoimmune research targets, which Moderna concurrently ceased developing. As of February 2025, Moderna has nominated all 12 oncology research targets under the collaboration for which we have the potential to receive future milestones and royalty payments. We will not be conduct any additional research activities under the collaboration agreement and we will not be receiving any further research funding from Moderna under the collaboration agreement. Moderna also agreed to terminate the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">in-vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> oncology field exclusivity, which would allow us to pursue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> in vivo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">CAR-M programs, outside of the 12 nominated oncology targets and product polypeptides. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Our Product Candidates and Discovery Programs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Using our industry leading expertise and proprietary technology in macrophage and monocyte engineering, we have developed a pipeline of product candidates, with a focus on liver fibrosis and solid tumor oncology. Our fibrosis and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">vivo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">oncology programs are wholly owned while the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CAR-M therapies are being developed by Moderna under our collaboration agreement . Our current pipeline is summarized below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><img src="carm-20241231_g1.jpg" alt="Screenshot 2025-03-25 213307.jpg" style="height:192px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liver Fibrosis</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidate for liver fibrosis, CT-2401, is based upon the discovery of a key defect in the macrophages that reside within the livers of patients with fibrosis. Working in collaboration with researchers at Columbia University, we have identified that the macrophages that normally reside in the liver (Kupfer cells) become defective in patients with metabolic associated liver disease, or MASH. Specifically, they lose the ability to perform a normal, maintenance function called efferocytosis. Efferocytosis is the clearance of dead and dying cells by macrophages and is a critical normal function in the body, including within the liver. In MASH, the accumulation of fat in liver cells (hepatocytes) leads to a fatty liver (steatohepatitis). This accumulation of fat in hepatocytes ultimately leads to dead and dying cells. Efferocytosis should clear these cells in a manner that does not cause inflammation or additional disease. However, as efferocytosis is defective in MASH, these dead and dying cells accumulate and cause inflammation and ultimately liver fibrosis.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This defect in efferocytosis can be ascribed to the loss of a single receptor on the cell surfaces of Kupffer cells called TIM4. Although multiple factors are involved in efferocytosis, pre-clinical studies suggest that TIM4 is the major efferocytosis receptor that is lost in MASH and is responsible for the defective efferocytosis seen in the disease. Samples of liver tissue from patients with MASH demonstrated a loss of TIM4. In pre-clinical studies conducted in the laboratory of Dr. Ira Tabas at Columbia University (published in Biorxiv), deleting TIM4 in Kupffer cells was observed to cause liver fibrosis. Restoring TIM4 expression caused a significant reduction of the fibrosis seen in these models.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-clinical data have consistently demonstrated that TIM4 replacement with TIM4 engineered macrophage cell therapy or with TIM4 mRNA/LNP lead to robust anti-fibrotic activity as evaluated by liver biopsy. TIM4 replacement therapy has demonstrated significant reduction of multiple independent biomarkers of MASH liver fibrosis, including overall liver collagen content, hepatic Collagen-1a1, hepatic osteopontin (a liver-specific fibrotic biomarker), and hepatic alpha-smooth muscle actin (a hepatic stellate cell activation marker associated with MASH) in mild and advanced MASH animal models.   </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CT-2401 is intended to be developed as an off-the-shelf, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA/LNP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approach designed to deliver mRNA encoding for TIM4 via LNPs that efficiently transfect Kupffer cells. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proposed indication for CT-2401 is patients with MASH and later stage liver fibrosis (F3 and F4 compensated cirrhosis on a 4-point scale). By directly targeting a key driver of liver fibrosis in these later stage patients, we aim to show more robust benefit on fibrosis than the current types of metabolic directed agents on the market or in development. These agents generally show efficacy on steatosis, but only a small fraction of patients achieve reduction or reversal of fibrosis. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Prior to pausing research and development activities, we planned to continue to conduct pre-clinical development of CT-2401 sufficient to enable a regulatory submission to initiate a clinical trial. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Ex Vivo Oncology</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. CT-1119 incorporates two key enhancements as compared to CT-0508 and CT-0525: (1) a next-generation CAR that, in pre-clinical studies, led to a significant increase in tumor killing and cytokine release when compared to our first generation construct, and (2) the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">incorporation of a signal-regulatory protein alpha, or SIRP&#945;, knockdown to overcome the cluster of differentiation, or CD47 immune checkpoint.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Prior to pausing our research and development activities, we planned to initiate a Phase 1 clinical trial of CT-1119, a mesothelin-targeted CAR-Monocyte, in combination with tislelizumab, an anti-PD-1 antibody, in adult patients with mesothelin-positive solid tumors, in China. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition to utilizing an enhanced CAR construct and SIRP&#945; knockdown technology, the Phase 1 clinical trial design built on observations from our prior Phase 1 clinical trials. For example, the dosing schedule was based on the previously presented data from our HER2 program, in which we observed reductions in circulating tumor (ct) DNA. ctDNA is a marker of overall tumor burden and decreases can be viewed as evidence of reductions in tumor. The reductions observed in some patients after receiving CT-0508 had a nadir approximately three weeks after infusion and then rebounded. Based on this observation, repeat dosing is intended to keep therapeutic pressure on tumors and potentially provide meaningful clinical benefit. Additionally, pre-clinical data suggests a potential for synergy between CAR-M approaches and check point inhibitors, particularly PD-1. Data from the clinical trials of CT-0508 showed markers of T-cell exhaustion as having correlation with limited efficacy from HER2 CAR-M therapy. Based on the initial data from Phase 1 clinical trial of CT-0508, co-administration of a PD-1 checkpoint inhibitor and CT-0508 was generally well-tolerated in cancer patients. Therefore, the CT-1119 trial was designed to incorporate the addition of the PD-1 checkpoint inhibitor tislelizumab to the repeat administration of CT-1119.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In Vivo Oncology</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To advance our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CAR-M therapeutics, we established a strategic collaboration with Moderna, which utilizes Moderna's mRNA/LNP technology, together with our CAR-M platform technology, to create novel </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> oncology off-the-shelf gene therapy product candidates. Since entering into the agreement, we have made significant progress advancing this program. In the fourth quarter of 2023, we presented pre-clinical data from this collaboration demonstrating that CAR-M can be directly produced </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, successfully redirecting endogenous myeloid cells against tumor-associated antigens using mRNA/LNP. Additionally, the pre-clinical data demonstrated feasibility, tolerability, and early efficacy of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CAR-M against metastatic solid tumors. In December 2023, we announced the nomination of the collaboration's first lead candidate. In June 2024, we announced the achievement of the first development candidate under the collaboration with Moderna, triggering a $2.0 million milestone payment from Moderna. This development candidate targets GPC3 and is designed to treat solid tumors, including hepatocellular carcinoma. In November 2024, we presented pre-clinical data characterizing the efficacy of the development candidate targeting GPC3 for hepatocellular carcinoma. These pre-clinical data demonstrated robust anti-tumor activity. In February 2025, Moderna nominated 10 additional oncology targets, four of which replaced two oncology research targets and two autoimmune targets, which Moderna concurrently ceased developing. As of February 2025, all 12 oncology targets under the collaboration agreement were nominated by Moderna for which we have the potential to receive future milestones and royalty payments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> W</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e will not conduct any additional research activities under the collaboration agreement and we will not be receiving any further payments from Moderna for research and development services under the collaboration agreement. Moderna also agreed to terminate the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> oncology field exclusivity, which would allow us to pursue </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CAR-M programs, outside of the 12 nominated oncology targets, and to product polypeptides.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i280a0966ad034c5090dd46bd303d2259_25"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Background</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Limitations of Current CAR-T or CAR-NK Therapies</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cellular immunotherapy is a type of immuno-oncology approach whereby human immune cells are utilized to recognize and destroy cancer cells in a targeted manner.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the incredible promise shown by cell therapies for hematologic malignancies, the success has not been replicated in the solid tumor setting. There are numerous challenges impacting T and NK cell immunotherapy in patients with solid tumors, such as the inability of cells to appropriately access the tumor microenvironment, or TME, overcome immunosuppression in the TME, and overcome target antigen heterogeneity. Importantly, there have been challenges in targeting solid tumors with CAR-T cells without inducing toxicities against normal tissues or inducing severe systemic cytokine release syndrome, or CRS. To date, no CAR therapies for the treatment of solid tumors have received marketing approval.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Opportunity for Engineered Macrophages in Treating Cancer and Liver Fibrosis</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that macrophage and monocyte cell therapies hold promise in addressing the limitations of other cell types and transforming the cell therapy treatment paradigm for solid tumors and fibrotic diseases. The inherent biology of macrophages and monocytes offers several potential advantages that directly apply to current barriers for cell therapy efficacy in the solid tumor context. Macrophages and monocytes are actively recruited into solid tumors, while other immune cells, such as T cells, are often actively excluded. Macrophages are professional phagocytic cells capable of directly killing tumor cells through this unique mechanism. In addition to direct killing, macrophages can secrete pro-inflammatory factors that convert the immunosuppressive TME into an environment that promotes immunity. Importantly, macrophages and monocytes are professional antigen presenting cells, meaning they can directly present tumor-derived antigens to T cells leading to anti-tumor T cell responses, a phenomenon known as epitope spreading. Epitope spreading enables activity against tumor cells which either lack or lose expression of the initial antigen targeted by the CAR&#8201;&#8212;&#8201;a key challenge for cell therapies&#8201;&#8212;&#8201;and ultimately enables macrophages and monocytes to overcome target antigen heterogeneity within the patient&#8217;s cancer.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to acting as a first line of defense in the innate immune system, macrophages and monocytes are found in all tissues in the body where they serve key regulatory functions such as wound healing, termination of immune responses and tissue regeneration. The prevalence and diversity of function of macrophages and monocytes make them an attractive potential therapeutic delivery cell. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our liver fibrosis product candidate is designed with the goal of correcting acquired macrophage deficiencies, such as the loss of efferocytosis in MASH via the downregulation of the receptor TIM4. By aiming to restore TIM4 expression in hepatic macrophages (Kupffer cells), liver fibrosis as a result of MASH or other chronic liver injury may be significantly reduced. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CAR-M Pre-clinical data</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CAR-M have the potential to address the key challenges involved in treating solid tumors. Pre-clinical studies with CAR-M have demonstrated the ability to infiltrate solid tumors, phagocytose and destroy tumor cells directly, and present tumor-derived antigens leading to activation of the adaptive immune system. CAR-M mount anti-tumor immunity in numerous ways. First, CAR-M leverage the natural tumor-homing ability of macrophages and monocytes, the naturally most abundant immune cells in the TME, to traffic to both primary tumors and metastases, enabling engineered macrophages to act as a &#8220;Trojan horse,&#8221; tricking the tumor into recruiting engineered, anti-tumor CAR-M as if they were normal monocytes or macrophages. Once within the tumor, CAR-M directly kill antigen-expressing tumor cells through phagocytosis and secretion of cytotoxic factors. CAR-M secrete inflammatory cytokines and chemokines that promote a pro-inflammatory environment and lead to the recruitment of T cells and other leukocytes. Finally, CAR-M serve as professional antigen presenting cells for T cells, inducing epitope spreading, systemic anti-tumor immunity, and immune memory against tumor antigens, expanding anti-tumor immunity to target negative tumor cells and potentially preventing antigen negative relapse.</span></div><div id="i280a0966ad034c5090dd46bd303d2259_28"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pipeline of Product Candidates and Discovery Programs</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Using our industry leading expertise and proprietary technology in macrophage and monocyte engineering, we have developed a broad pipeline of product candidates, with a focus on liver fibrosis and solid tumor oncology.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i280a0966ad034c5090dd46bd303d2259_31"></div><div><span><br/></span></div><div id="i280a0966ad034c5090dd46bd303d2259_34"></div><div style="margin-top:12pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lead oncology product candidate CT-1119 (Next generation Anti-Mesothelin CAR-Monocyte)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CT-1119 is a mesothelin-targeted CAR-Monocyte developed for study in patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. CT-1119 incorporates two key enhancements: (i) a next-generation CAR that, as demonstrated in pre-clinical studies, lead to a significant increase in tumor killing and cytokine release, and (ii) the incorporation of SIRP&#945; knockdown to overcome the CD47 immune checkpoint. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mesothelin is a well validated tumor associated antigen. Mesothelin has been shown to be aberrantly expressed on the surface of tumor cells and plays an important role in promoting cancer invasion and proliferation. Mesothelin has been demonstrated to be expressed at high levels in mesothelioma, lung cancer, ovarian cancer, pancreatic cancer, and other </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">solid tumors with limited expression in normal tissue. Mesothelin positive solid tumors represent a significant unmet medical need.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CT-1119 Next-Gen CAR Design</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We developed additional next generation CAR-M improvements utilizing enhanced CAR constructs to increase potency and functionality of the engineered cells. This includes optimization of each element of the CAR itself&#8201;&#8212;&#8201;the binder (which gives the CAR specificity to a target antigen), the hinge (which connects the binder to the transmembrane domain and gives the CAR length and flexibility), the transmembrane domain (which spans the cell membrane), and the intracellular signaling domains (which are responsible for activation of immune cell function). These changes can lead to increased proinflammatory cytokine release and more potent </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> killing relative to the first-generation CAR construct. A next generation CAR incorporating an optimized hinge, transmembrane, and signaling domain is incorporated into CT-1119.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CT-1119 SIRP&#945; Knockdown</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also developed gene editing technologies for enhancing anti-tumor CAR-M functions. Macrophages naturally express the inhibitory receptor SIRP&#9082;, which suppresses phagocytosis after stimulation with CD47. Solid tumors can over-express CD47 to evade phagocytosis by macrophages. We have previously demonstrated using CRISPR/Cas9 that SIRP&#9082; knockout, or KO, can enhance CAR-M killing and phagocytosis of tumor cells.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have now developed a proprietary single-vector system to simultaneously deliver CAR and targeted gene knockdown. A novel vector was designed to introduce custom shRNA into a synthetic CAR intron under a shared promoter. Expression of this vector concomitantly produces CAR mRNA and SIRP&#9082;-targeting shRNA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We demonstrated that the intronic shRNA vector could deliver HER2-targeting CAR, reduce SIRP&#9082; expression, and enhance anti-tumor functions of primary human CAR-M. Importantly, the one-step vector design was as proficient as transduction followed by CRISPR/Cas9 editing. We also demonstrated that the intronic shRNA vector improved tumor clearance </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as compared to unedited CAR-M.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intronic shRNA design is a generalizable technology that is valuable for additional CAR designs, target tumor antigens, and gene knockdown targets. The modular adenoviral vector introduces gene editing capabilities while remaining compatible with pre-existing manufacturing strategies. We have incorporated our proprietary intronic shRNA vector into the CT-1119 platform to enhance anti-tumor functions and overcome the CD47 checkpoint.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SIRP&#9082; knockdown is incorporated into CT-1119 utilizing intronic shRNA.</span></div><div id="i280a0966ad034c5090dd46bd303d2259_37"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Synergistic Potential of CAR-M Therapy with T Cell Checkpoint Inhibitors</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Blocking the immune checkpoint molecule PD-1 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">checkpoint inhibitor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, has revolutionized cancer treatment for patients with a multitude of solid tumor indications. Pembrolizumab is a potent humanized immunoglobulin G4, or IgG4, mAb, with high specificity of binding to the PD-1 checkpoint inhibitor receptor, inhibiting its interaction with programmed cell death ligand 1, or PD-L1, and programmed cell death ligand 2, or PD-L2. While pembrolizumab is currently indicated for the treatment of patients across several solid tumor indications, the majority of patients have either primary or secondary resistance to immune checkpoint blockade and may benefit from combinatorial therapy that could overcome immune cell exclusion, poor antigen presentation, low T cell infiltration, high tumor-associated macrophages, or TAM, infiltration, a lack of productive co-stimulation, low mutational burden, intra-tumoral, or IT, immunosuppression, and a low frequency of tumor reactive T cell clones. Multiple additional PD-1 checkpoints, including tislelizumab, have also been approved for multiple oncology indications.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the data generated during pre-clinical development, CT-0508 was able to specifically recognize cancer cells through the binding of the CAR to HER2 expressed on the surface of the cancer cells. This interaction triggered activation of the CAR-M and resulted in direct anti-tumor effect by killing and phagocytosis of the tumor cells. In addition, CT-0508 recruited T cells, activated the TME, and as professional antigen presenting cells, processed and presented tumor associated antigen and/or neoantigens expressed by the tumor cells, leading to T cell immunity against these specific antigens. However, this indirect anti-tumor effect involves the engagement of T cells that may be actively suppressed, or exhausted, within the TME by a variety of factors including secreted immune-modulatory factors and inhibitory ligands expressed on </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">both immune and tumor cells. Additionally, several studies have demonstrated that patients with low mutational burden, low major histocompatibility complex expression, defective antigen presentation, low CD8+ T cell infiltration, or minimal Type 1 T helper, or Th1, cytokine signatures tend to be unresponsive to PD-1 checkpoint inhibitor blockade. Therefore, based on the mechanism of action of CAR-M and the limitations of PD-1 checkpoint inhibitor blockade, the combination of CAR-M therapy with PD-1 checkpoint inhibitor blockade therapy may be beneficial as CAR-M will drive TME remodeling and enhance antigen presentation (innate immunity) to initiate an anti-tumor T cell response (adaptive immunity) which will be strengthened by inhibiting the PD-1 checkpoint inhibitor pathway. Pre-clinical data demonstrating the synergy between CAR-M and PD-1 checkpoint blockade were published in Nature Communications in 2025 (Pierini S, et al. Nature Communications. 2025). These data lay the groundwork for exploration of combination therapies consisting of CAR-M therapies (such as CT-1119) and T cell checkpoint inhibitors (such as anti-PD1). </span></div><div id="i280a0966ad034c5090dd46bd303d2259_40"></div><div style="margin-top:12pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">mRNA/LNP Platform </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In collaboration with Moderna, we have developed an mRNA based </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CAR-M platform for oncology. This approach is highly differentiated in the cell therapy space&#8201;&#8212;&#8201;not only because it relies on myeloid cells as the engineered effectors, but also because it utilizes direct </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reprogramming of patients&#8217; own cells with a well-validated mRNA/LNP platform. By engineering patients&#8217; own cells directly within their body, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> autologous or allogeneic cell manufacturing is entirely bypassed. Importantly, while this approach enables an off-the-shelf therapy, the engineered cells are autologous, as it is the patients&#8217; own cells being engineered into CAR-M </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or directly within their body. .</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Studies with the LNP have shown mRNA delivery leads to CAR expression on myeloid cells (monocytes, macrophages, and dendritic cells). Preliminary data have demonstrated that the LNP is efficient in transfecting myeloid cells </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, preliminary data confirms high CAR expression, viability, and CAR-M function. In the fourth quarter of 2023, we presented pre-clinical data from this collaboration demonstrating that CAR-M can be directly produced </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, successfully redirecting endogenous myeloid cells against tumor-associated antigens using mRNA/LNP. Additionally, the data demonstrated feasibility and early efficacy of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CAR-M against metastatic solid tumors. In 2024, we announced nomination of the collaboration's first development candidate, which will target the GPC3 antigen present on hepatocellular carcinoma, an indication with significant unmet medical need. In November 2024, we announced new pre-clinical data on our anti-GPC3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CAR-M therapy for treating hepatocellular carcinoma. These pre-clinical data demonstrated robust anti-tumor activity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2025, Moderna nominated ten additional oncology research targets, four of which replaced two oncology research targets and two autoimmune research targets, which Moderna concurrently ceased developing. As of February 2025, Moderna has nominated all 12 oncology research targets under the collaboration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for which we have the potential to receive future milestones and royalty payments. We will not conduct any additional research activities under the collaboration agreement and we will not be receiving any further research funding from Moderna under the collaboration agreement. </span></div><div id="i280a0966ad034c5090dd46bd303d2259_43"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liver Fibrosis  </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a research program designed for liver fibrosis caused by advanced MASH. CT-2401 is designed to address defective efferocytosis, a novel pathway believed to drive the accumulation of dead hepatocytes in the liver of MASH patients leading to collagen deposition and chronic inflammation, resulting in liver fibrosis and MASH progression. Pre-clinical data identified TIM4 as a key downregulated/lost efferocytosis receptor in MASH. CT-2401, aims to restore TIM4 expression using mRNA/LNP technology. Pre-clinical proof of concept has been established. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ex Vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Oncology </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Past Product Candidate: CT-0508 (anti-HER2 CAR-Macrophage)</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CT-0508 is a cell product comprised of autologous, peripheral blood monocyte-derived, pro inflammatory macrophages, transduced with a chimeric adenoviral vector, Ad5f35, containing an anti-HER2 CAR. HER2 is a protein on the cell surface that promotes the growth of cancer cells. The anti-HER2 CAR is a first-generation CAR composed of a fully human single-chain variable fragment, or scFv, derived from the monoclonal antibody, or mAb, trastuzumab, which is specific for human HER2. The anti-HER2 scFv is fused to a CAR backbone containing a CD8 hinge, CD8 transmembrane domain, and a CD3&#950; intracellular domain. The CAR is cloned into an adenoviral vector backbone and transduced into monocyte-derived macrophages. Based on the pre-clinical data generated to date, CT-0508 CAR-Macrophages are able to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">specifically recognize HER2 over-expressing tumor cells, which triggers both direct killing of tumor cells and phagocytosis. Additionally, CAR engagement to HER2 on tumor cells results in the secretion of a broad array of pro-inflammatory cytokines and chemokines, which contribute to the recruitment and activation of additional immune cells to the TME, including effector T cells and other antigen presenting cells. CT-0508 CAR-Macrophages are antigen presenting cells, and after phagocytosing tumor cells they process tumor-derived antigens and present them to T cells, leading to T cell immunity against tumor antigens. This additional activation of the adaptive immune system amplifies anti-tumor immune response and can lead to long term immune memory not only against HER2, the primary target, but other tumor specific neoantigens as well.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CT-0508 was studied in a multi-center open label Phase 1 clinical trial in the United States. A total of 20 patients received infusions of CT-0508 during either the primary portion of the trial (n=14) or during the expansion cohort in combination with pembrolizumab (n=6). The primary endpoints of safety and feasibility were met while the best overall response observed in any subject was stable disease (SD). The trial was closed to enrollment in April 2024 and closed in its entirety in August 2024. The final presentation of data from this trial was made in the third quarter of 2024 and results from the monotherapy portion of the trial were published in Nature Medicine in 2025 (Reiss KA, et al. Nature Medicine, 2025).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Past Product Candidate: CT-0525 </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CT-0525 is a cell product comprised of autologous, peripheral blood derived CD14+ monocytes transduced with a chimeric adenoviral vector, Ad5f35, containing an anti-HER2 CAR. Unlike CT-0508, CT-0525 is a non-differentiated monocyte that is not fully matured during an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cell culture process. Based on pre-clinical studies, CT-0525 is expected to differentiate into a CAR-Macrophage directly </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, subsequently carrying out the same mechanism of action as described above for CT-0508. CT-0525 enables potentially higher dosing, improved trafficking, and enhanced persistence. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CT-0525 was evaluated in a multi-center open label Phase 1 clinical trial in the United States. The Phase 1 clinical trial for CT-0525 was a single-arm, open-label study of systemic intravenous administration of CT-0525 intended to evaluate safety, tolerability, and the manufacturing feasibility of CT-0525. Secondary endpoints included cellular kinetics, overall response rate and duration of response. This trial enrolled participants with locally advanced (unresectable) or metastatic solid tumors over-expressing HER2 whose disease has progressed on standard approved therapies. The study consisted of two cohorts: Cohort 1 received IV administration of three billion CAR-positive cells, while Cohort 2 received IV administration of up to 10 billion CAR-positive cells. The first patient was dosed in May 2024. Three subjects were treated in Cohort 1 and two were treated in Cohort 2. The last patient was dosed in November 2024 and all clinical activity ended in January 2025 due to the decision to cease development of CT-0525. </span></div><div><span><br/></span></div><div id="i280a0966ad034c5090dd46bd303d2259_46"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing and Delivery</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate, and currently have no plans to establish, our own manufacturing facilities. We have relied on, and if we resume research and development activities, expect to rely on third-party contract manufacturing organizations for manufacturing of our product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established, and if we resume research and development activities, will continue to establish arrangements with contract manufacturers to supply clinical materials and manufacturing capabilities for our clinical trials. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we resume research and development activities and scale to commercialization, we expect to increase our capacity with our current, or yet to be identified, suppliers and evaluate other options to secure commercial scale capacity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="i280a0966ad034c5090dd46bd303d2259_49"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to protect and enhance our proprietary technology, inventions and improvements that we believe are commercially important to the development of our business, including through seeking, maintaining and defending patent rights, whether developed internally or licensed from third parties. We also intend to rely on trade secrets related to our proprietary technology platform and our know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen and maintain our proprietary position in the fields of cancer and other indications including those related to fibrosis and other immunologic and inflammatory diseases, which may be important for the development of our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business. We also may rely on regulatory protection afforded through data exclusivity, market exclusivity and patent term extensions, where available.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success may depend, in part, on our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how related to our business, defend, and enforce our patents, preserve the confidentiality of our trade secrets and operate without infringing the valid enforceable patents and proprietary rights of third parties. Our ability to stop third parties from making, using, selling, offering to sell or importing our products may depend on the extent to which we have rights under valid and enforceable licenses, patents or trade secrets that cover these activities. With respect to both our owned and licensed intellectual property, we cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications we file in the future, nor can we be sure that any of our existing patents or any patents that may be granted us in the future will be commercially useful in protecting our commercial products and methods of manufacturing such products, as well as being held valid if challenged.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We currently control over 40 granted patents, which are expected to expire at various times between 2033 and 2042, and over 100 patent applications pending in several jurisdictions, including the United States, Europe, Australia, Brazil, Canada, China, Israel, Japan, Korea, Mexico, New Zealand, and Singapore. Intellectual property is a critical component of our business plan for maximizing return on our investments. We are actively developing intellectual property and will continue to maintain and defend United States and international patent rights for our products, technology, and development and improvement of our discovery platforms.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To maintain our competitive position in the market, we have spent considerable effort and resources securing intellectual property rights, including several patent rights related to our proprietary CAR technology and myeloid cell engineering technology.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exclusively Licensed Intellectual Property&#8201;&#8212; Penn</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have exclusive rights to four patent families, and non-exclusive rights to related know-how by virtue of a license agreement with the Trustees of the University of Pennsylvania, or Penn. These patent families are directed to, among other things, methods of efficiently expressing CARs in myeloid cells, including monocytes, macrophages, and dendritic cells and enhancing effector activity, as well as the modified cells and compositions including such modified cells for use in several indications including various oncology targets. The applications will have an expiration date of no earlier than 2034. This licensed patent portfolio includes:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">A patent family that includes nine issued U.S. patents and three pending U.S. patent applications relating to modified macrophages, monocytes and dendritic cells comprising CARs. These U.S. patents are expected to expire in 2036, absent any term adjustments or extensions. Corresponding foreign patents and pending applications include one issued patent in Australia, one issued patent in Brazil, one issued patent in China, two issued patents in Israel, two issued patents in Japan, one issued patent in Mexico, one issued patent in Russia, one issued patent in Singapore, and pending applications in Australia, Brazil, Canada, China, Europe, Israel, India, Japan, Korea, Mexico, New Zealand, Russia, Singapore, Thailand and South Africa.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">A patent family that includes one pending U.S. patent application relating to modified macrophages, monocytes and dendric cells in protein aggregate-associated disorders. Patent applications in this family are expected to expire in 2039, absent any term adjustments or extensions. Corresponding foreign patents and pending applications include one issued patent in Australia, one issued patent in Japan, and pending applications in Canada, China, Europe, Israel, Korea, New Zealand, and Singapore.  </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A patent family that includes one pending U.S. patent application relating to activation of antigen presenting cells. Patent applications in this family are expected to expire in 2040, absent any term adjustments or extensions.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">A patent family that includes one issued U.S. patent and one pending U.S. patent application relating to CARs comprising human anti-mesothelin binding domains. Patent applications in this family are expected to expire in 2034, absent any adjustments or extensions. Corresponding foreign patents and pending applications include three issued patents in Australia, one issued patent in China, one issued patent in Colombia, one issued patent in Germany, two issued patents in Europe, one issued patent in Spain, one issued patent in France, one issued patent in the United Kingdom, one issued patent in Italy, two issued patents in Japan, one issued patent in Russia, and pending applications in Australia, Canada, China, Europe, and Japan. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exclusively Licensed Intellectual Property&#8201;&#8212;&#8201;NYU</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have exclusive rights to one patent family, and non-exclusive rights to related know-how by virtue of a license agreement with New York University, or NYU. The rights granted under the NYU license are to all indications for human use. This licensed patent portfolio includes:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A patent family that includes one U.S. patent relating to a chimeric human immunodeficiency virus type 1, or HIV-1, vector with a simian immunodeficiency virus, or SIV, minimal Vpx packaging domain and method of making virions with enhanced infectivity for macrophages and dendritic cells. The U.S. patent is expected to expire in 2033, absent any term adjustments or extensions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Carisma Owned Intellectual Property</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently own ten U.S. patent families. This owned patent portfolio includes:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">A patent family that includes two issued U.S. patent and one pending U.S. patent applications relating to macrophages, monocytes and dendritic cells comprising novel CAR constructs. Patent applications in this family are expected to expire in 2041, absent any term adjustments or extensions. Corresponding foreign patent applications have been filed and are pending in Australia, Brazil, Canada, China, Europe, Israel, Japan, Korea, Mexico, New Zealand, Singapore, and South Africa.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">A patent family that includes one pending U.S. application relating to mRNA transfection of macrophages, monocytes and dendritic cells comprising CARs. Patent applications in this family are expected to expire in 2041, absent any term adjustments or extensions. Corresponding foreign patent applications have been filed and are pending in Australia, China, Eurasia, Europe, Israel, India, Japan, Korea, Mexico, New Zealand, Singapore, and South Africa.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">A patent family that includes one pending U.S. application relating to modified immune cells for fibrosis and inflammation. Patent applications in this family are expected to expire in 2041, absent any term adjustments or extensions. Corresponding foreign patent applications have been filed and are pending in Australia, China, Eurasia, Europe, Israel, India, Japan, Korea, Mexico, New Zealand, Singapore, and South Africa.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">A patent family that includes one pending U.S. application relating to self-polarizing immune cells. Patent applications in this family are expected to expire in 2042, absent any term adjustments or extensions. Corresponding foreign patent applications have been filed and are pending in Australia, Brazil, Canada, China, Eurasia, Europe, Israel, India, Japan, Korea, Mexico, New Zealand, Singapore, and South Africa.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">A patent family that includes one pending U.S. application relating to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> delivery of, among other things, CARs to macrophages, monocytes, and dendritic cells. Patent applications in this family are expected to expire in 2042, absent any term adjustments or extensions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Corresponding foreign patent applications have been filed and are pending in Australia, Europe, and Japan.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">A patent family that includes one pending U.S. application relating to methods and constructs for modifying the response of certain cells to environmental and other stimuli. Patent applications in this family are expected to expire in 2043, absent any term adjustments or extensions. Corresponding foreign patent applications have been filed and are pending in Australia, Europe, and Japan.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">A patent family that includes one pending PCT application relating to modified macrophages, monocytes, and dendritic cells including anti-mesothelin CARs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Patent applications in this family are expected to expire in 2043, absent any term adjustments or extensions. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">A patent family that includes one pending PCT application relating to modified constructs including JAK/STAT binding domains.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Patent applications in this family are expected to expire in 2043, absent any term adjustments or extensions.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">A patent family that includes one pending PCT application relating to modified constructs including DAP10 and/or DAP12 domains.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Patent applications in this family are expected to expire in 2044, absent any term adjustments or extensions.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">A patent family that includes one pending PCT application relating to modified constructs including cassettes engineered to produce one or more inhibitory RNAs and a CAR.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Patent applications in this family are expected to expire in 2044, absent any term adjustments or extensions.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will also seek to generate additional intellectual property that covers enhancements to all aspects of the platform, including novel CARs, combinations, gene editing and manufacturing improvements. Where appropriate, we will also look to in-license relevant technology from third parties.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent Term and Patent Term Extensions</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of individual patents depends upon the legal term for patents in the countries in which they are obtained. In most countries, including the United States, the patent term is 20 years from the earliest filing date of a non-provisional patent application. In the United States, a patent&#8217;s term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the U.S. Patent and Trademark Office, or USPTO, in examining and granting a patent or may be shortened if a patent is terminally disclaimed over an earlier filed patent. The term of a patent that covers a drug, biological product or medical device approved pursuant to a pre- market approval may also be eligible for patent term extension when FDA approval is granted, provided statutory and regulatory requirements are met. The length of the patent term extension is related to the length of time the drug is under regulatory review while the patent is in force. The Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, permits a patent term extension of up to five years beyond the expiration date set for the patent. Patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent applicable to each regulatory review period may be granted an extension and only those claims regarding the approved drug are extended. Similar provisions are available in Europe and other foreign jurisdictions to extend the term of a patent that covers an approved drug.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trademarks</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our trademark portfolio currently includes registered U.S. trademarks for Carisma in the United States, Europe, Great Britain and Japan. All of our trademarks are renewed on an ongoing basis. In order to supplement the protection of our brand, we also have a registered internet domain name. Going forward, we will consider additional trademarks to enhance our brand and support our products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade Secrets</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely, in some circumstances, on trade secrets to protect our unpatented technology. However, trade secrets can be difficult to protect in certain circumstances. We seek to protect our trade secrets and proprietary technology and processes, including through confidentiality agreements with our employees, consultants, scientific advisors and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached. We may not have adequate remedies for any breach and could lose our trade secrets through such a breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our consultants, contractors or collaborators use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting trade secrets, know-how and inventions.</span></div><div id="i280a0966ad034c5090dd46bd303d2259_52"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Moderna Collaboration and License Agreement</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In collaboration with Moderna, we have established an approach that uses Moderna&#8217;s mRNA/LNP technology, together with our CAR-M platform technology, to create novel </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> oncology gene therapies. We believe this approach has the potential to enable a series of off-the-shelf product candidates to target a patient's own myeloid cells against cancer cells directly within their body.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, Legacy Carisma and Moderna established this collaboration by entering into a Collaboration and License Agreement, or the Moderna License Agreement, which provides for a broad strategic collaboration to discover, develop and commercialize </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> engineered CAR-M therapeutics. Under the Moderna License Agreement, the parties initiate research programs during a research term, focused on the discovery and research of products directed to biological targets. Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. In February 2025, Moderna nominated ten additional oncology research targets, four of which replaced two oncology research targets and two autoimmune research targets, which Moderna concurrently ceased developing. As of February 2025, Moderna has nominated all 12 oncology research targets under the Moderna License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for which we have the potential to receive future milestones and royalty payments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will not conduct any additional research activities under the Moderna License Agreement and we will not </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be receiving any further research funding from Moderna under the Moderna License Agreement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received the final research and development payment of $2.9 million from Moderna in January 2025.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Moderna has the right to designate up to 12 research targets as development targets during a specified development target nomination period upon payment of a development target designation milestone payment. To date, Moderna has designated one research target as a development target. This development candidate targets GPC3 and is designed to treat solid tumors, including hepatocellular carcinoma. Moderna can replace development targets with research targets during a specified period of time. If Moderna exercises its right to designate a development target, Moderna will have a worldwide, exclusive license under patents and know-how controlled by us to develop and commercialize products directed to the applicable development target, subject to certain diligence obligations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing a specified time after the effective date of the Moderna License Agreement, Moderna will have the right to nominate targets relating to diseases outside the field of oncology for inclusion in research programs in specified circumstances. Such right is subject to the same exclusions as Moderna&#8217;s right to nominate other targets for inclusion in research programs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the term of the Moderna License Agreement, we and our affiliates are subject to various exclusivity obligations under which we are not permitted to research, develop or commercialize particular products outside of the collaboration, including products directed to any target included in the collaboration, or products containing a polypeptide provided by us to Moderna in connection with a research program that are directed to any development target. Moderna agreed to terminate the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> oncology field exclusivity, which would allow us to pursue </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CAR-M programs outside of the 12 nominated oncology targets and product polypeptides.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Moderna License Agreement, we received a $45.0 million up-front cash payment. Assuming Moderna develops and commercializes 12 products, each directed to a different development target, we are also eligible to receive up to between $247.0 million and $253.0 million per product in development target designation, development, regulatory and commercial milestone payments. In addition, we are eligible to receive tiered mid-to-high single digit royalties on net product sales, subject to adjustment. Moderna has also agreed to cover the cost of certain milestone payments and royalties we owe as a licensor under one of our intellectual property in-license agreements with Penn that we are sublicensing to Moderna under the Moderna License Agreement, which royalties Moderna may deduct in part from any royalties owed to us.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the Moderna License Agreement will expire upon the expiration of all royalty obligations thereunder. The royalty period for each product developed under the Moderna License Agreement will expire on a country-by-country basis upon the later of (i) the expiration of the last-to-expire valid patent claim of specified patents, (ii) the expiration of regulatory-based exclusivity for such product in such country or (iii) ten years after the first commercial sale with respect to such product in such country. Moderna has the right to terminate the Moderna License Agreement for convenience in its entirety or with respect to a specific product or target on ninety days&#8217; prior notice. Either we or Moderna may terminate the Moderna License Agreement in its entirety if the other party is in material breach and such breach is not cured within the specified cure period, except in the case of Moderna&#8217;s breach of its diligence obligations, termination by us is limited to the applicable target and product. In addition, either we or Moderna may terminate the Moderna License Agreement in the event of specified insolvency events involving the other party. As an alternative to termination in the event of our uncured material breach of certain sections of the agreement, Moderna has the option to continue the collaboration under the agreement with reduced payment obligations.</span></div><div id="i280a0966ad034c5090dd46bd303d2259_55"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Penn License Agreement</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, Legacy Carisma entered into a license agreement, or the Penn License Agreement, with Penn, which was amended in February 2018, January 2019, March 2020 and June 2021. Pursuant to the Penn License Agreement, Penn granted us (i) an exclusive, worldwide license, with specified rights to sublicense, under Penn&#8217;s interest in specified patents related to CAR macrophages, monocytes or dendritic cells, (ii) an exclusive, worldwide license, with specified rights to sublicense, under Penn&#8217;s interest in specified patents related to CAR-M directed to mesothelin, and (iii) a nonexclusive, worldwide license under Penn&#8217;s interest in specified know-how related to CAR-M, with limited rights to sublicense only in combination with specified products or patents. These licensed patents and know-how arose primarily from research conducted by Dr. Saar Gill and Dr. Michael Klichinsky at the University of Pennsylvania, co-founders of Carisma. The foregoing licenses are subject to rights retained by Penn for specified non-commercial uses and rights retained by the U.S. government. Under the Penn License Agreement, we are obligated to use commercially reasonable efforts to pursue development and commercialization of at least one CAR-M product in oncology and non-oncology fields.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are responsible for paying Penn an annual license maintenance fee in the low tens of thousands of dollars, payable until our first payment of a royalty. We are required to pay Penn up to $10.9 million per product in development and regulatory milestone payments, up to $30.0 million per product in commercial milestone payments, and up to an additional $1.7 million in development and regulatory milestone payments for the first CAR-M product directed to mesothelin. While the agreement remains in effect, we are required to pay Penn low to mid-single digit percentage tiered royalties on annual net sales of licensed products, which may be subject to reductions. Penn is guaranteed a minimum royalty payment amount in the low hundreds of thousands of dollars for each year after the first commercial sale of a licensed product. We must also pay Penn a percentage in the mid-single digits to low double digits of certain types of income we receive from sublicensees. In addition, we are required to pay Penn an annual alliance management fee in the low tens of thousands of dollars, ending after several years, unless we provide funding to Penn for research and development activities that extend beyond a specified date, in which case we will continue to owe the alliance management fee for each year in which we continue to fund such activities. We also paid Penn an upfront fee in the low hundreds of thousands of dollars for the license to the patents related to the mesothelin binder that is incorporated into the CAR design for our mesothelin product candidate. We are responsible for a pro rata share of costs relating to the prosecution and maintenance of the licensed patents.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The royalty period for each licensed product will expire on a product-by-product basis upon the later of (i) the expiration of the last-to-expire valid patent claim of the licensed patents covering such product in the country of sale or in the country of manufacture, or (ii) the expiration of regulatory-based exclusivity for such product in the country of sale. The license agreement remains in effect until the later of (i) expiration or abandonment of the last licensed patent or (ii) loss of regulatory exclusivity. We may terminate the agreement for convenience upon thirty days&#8217; prior notice. Penn may terminate the agreement for our material breach, subject to a specified cure period, except for certain breaches for which Penn may terminate immediately. Penn may also terminate if we become the subject of a specified insolvency event.</span></div><div id="i280a0966ad034c5090dd46bd303d2259_58"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NYU License Agreement</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, Legacy Carisma entered into a license agreement with NYU, or the NYU License Agreement. Pursuant to the NYU License Agreement, NYU granted us (i) an exclusive, worldwide license, with specified rights to sublicense, under NYU&#8217;s interest in specified patents related to the Vpx-LV and (ii) a nonexclusive, worldwide license, with specified rights to sublicense, under NYU&#8217;s interest in specified know-how related to the Vpx-LV, in each case to develop, manufacture, use and sell products developed using the Vpx-LV, or Licensed Products. The foregoing licenses are subject to rights retained by NYU to use, and to permit other non-commercial entities to use, the licensed patents and licensed know-how for educational and research purposes, as well as rights retained by the U.S. government. Under the NYU License Agreement, we are obligated to use reasonable diligence to carry out a specified development plan and to obtain regulatory approval for Licensed Products in the United States and each of the other countries in which we or our sublicensees intend to produce, use, and/or sell Licensed Products, as well as to begin the regular commercial production, use, and sale of the Licensed Products in good faith in accordance with the development plan and to continue diligently thereafter to commercialize the Licensed Products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to pay NYU an annual license maintenance fee in the mid tens of thousands of dollars; up to $1,685,000 per Licensed Product in development and regulatory milestone payments; and low single digit percentage tiered royalties on annual net sales of Licensed Products on a country-by-country basis until the later of (i) 12 years after first commercial sale of a Licensed Product in such country or (ii) expiration of the last to expire licensed patent. We must also pay NYU a percentage in the low single digits to low double digits of certain types of income we receive from sublicensees or assignees of the agreement. We are also responsible for all costs relating to the prosecution, maintenance, and defense of the licensed patents.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The NYU License Agreement remains in effect until the expiration of all royalty terms in all countries. Either party may terminate the NYU License Agreement for the other party&#8217;s uncured material breach or insolvency or bankruptcy.</span></div><div id="i280a0966ad034c5090dd46bd303d2259_61"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biopharmaceutical industry, and in particular the cell therapy field and liver fibrosis field, is characterized by intense investment and competition aimed at rapidly advancing new technologies, intense competition, and a strong emphasis on intellectual property and proprietary products. Our platform and therapeutic product candidates are expected to face substantial competition from multiple technologies, marketed products, and numerous other therapies being developed by other biopharmaceutical companies, academic research institutions, governmental agencies, and public and private research institutions. Many of our potential competitors have substantially greater financial, technical, and other resources, such as </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">larger research and development staff, established manufacturing capabilities and facilities, and experienced marketing organizations with well-established sales forces, and any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. In addition, there is substantial patent infringement litigation in the biopharmaceutical industry, and, in the future, we may bring or defend such litigation against our competitors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key competitive factors affecting the success of our product candidates, if approved, are likely to be their efficacy, safety, convenience and price, the level of competition, and the availability of coverage and adequate reimbursement from third-party payors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unlike other cell therapy approaches, our CAR-M platform is based on engineering macrophages and monocytes with proprietary vectors, constructs, and processes, enabling a differentiated platform from other cell therapy competitors that primarily focus on T or natural killer cells, or NK cells. While we believe that our scientific expertise, novel technology, and intellectual property position offer competitive advantages, we face competition from multiple other cell therapy technologies and companies. Other companies developing engineered myeloid cell therapies include, among others, Myeloid Therapeutics, Shoreline Biosciences, Inceptor Bio, Thunder Bio, Resolution Therapeutics, CellOrigin, Deverra, BobcatBio, and others.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the broad promise of cell therapies, and the potential of myeloid cell-based approaches to expand cell therapy efficacy into solid tumors and liver fibrosis, we expect increasing competition from new and existing companies across several fronts, which include, among others:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Myeloid cell therapies: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CellOrigin, Deverra, Inceptor Bio, Myeloid Therapeutics, Resolution Therapeutics, Shoreline Biosciences, Thunder Bio, among others</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Autologous </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">T cell</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> therapies: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2seventy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adaptimmune, Autolus, Bristol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Myers Squibb, Cabaletta, Gracell, Kite/Gilead, Novartis, Poseida, TScan, Vor, among others</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Allogeneic </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">T cell</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> therapies: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allogene, Atara, Caribou, Century, Cellectis, Celyad, CRISPR, Fate, Gracell, Kite/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead, Legend, Poseida, Precision Bio, Sana, TScan, Vor, among others</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">NK and other cell therapies: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adicet, Artiva, Celularity, Century, Editas, Fate, Fortress, Gamida Cell, ImmunityBio, Nkarta,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NKGen, Takeda, among others</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Direct in vivo reprogrammed cell therapies: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BioNTech, Ensoma, Interius, Sanofi, Umoja, Orna Therapeutics, among others</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:13.8pt">Liver fibrosis therapies: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Madrigal, Akero, 89Bio, Resolution Therapeutics, among others and major pharmaceutical companies developing incretin therapies such as Eli Lilly, NovoNordisk, and others. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to competition from other cell therapy companies, any products that we develop may also face competition from other types of therapies. Other companies developing non-cell therapies, including gene therapies, in relevant therapeutic areas include Gilead, ALX Oncology, Five-Prime, Immune-Onc, Pionyr, Infinity, NextCure, OncoResponse, Curis, Faron, Apexigen, Pfizer, Dren, and multiple biotechnology and pharmaceutical companies developing other directly competitive technologies such as small molecules, immune agonists, antibodies, bi/tri specific antibodies, antibody drug conjugates, and other solid tumor therapeutics.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have competed, and if we resume research and development activities will continue to compete with third parties for retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. If we were to resume research and development activities, we may pursue the in-license or acquisition of rights to complementary technologies and product candidates on an opportunistic basis. The acquisition and licensing of technologies and product candidates is a competitive area, and a number of more established companies also have similar strategies to in-license or acquire technologies and product candidates that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to in-license or acquire the relevant technology or product candidate on terms that would allow it to make an appropriate return on our investment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, including as result of our decision to pause research and development </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">activities, which could result in our competitors establishing a strong market position before it is able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic products.</span></div><div id="i280a0966ad034c5090dd46bd303d2259_64"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions, including the European Union, or EU, extensively regulate, among other things, the research, development, testing, manufacture, pricing, reimbursement, sales, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, and import and export of pharmaceutical products, including biological products. The processes for obtaining marketing approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources and may have a substantial impact on our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensure and Regulation of Biologics in the United States</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, our product candidates are regulated as biological products, or biologics, under the Public Health Service Act, or the PHSA, and the Food, Drug and Cosmetic Act, or FDCA, and its implementing regulations and guidance. A company, institution, or organization which takes responsibility for the initiation and management of a clinical development program for such products, and for their regulatory approval, is typically referred to as a sponsor. The failure of a sponsor to comply with the applicable U.S. requirements at any time during the product development process, including pre-clinical testing, clinical testing, the approval process, or post-approval process, may subject a sponsor to delays in the conduct of the study, regulatory review, and approval, and/or administrative or judicial sanctions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A sponsor seeking approval to market and distribute a new biologic in the United States generally must satisfactorily complete each of the following steps:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">pre-clinical laboratory tests, animal studies, and formulation studies all performed in accordance with the FDA&#8217;s good laboratory practice, or GLP, regulations and standards and other applicable regulations;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">completion of the manufacture, under current good manufacturing practice, or cGMP, conditions, of the drug substance and drug product that the sponsor intends to use in human clinical trials along with required analytical and stability testing;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">design of a clinical protocol and submission to the FDA of an IND for human clinical testing, which must become effective before human clinical trials may begin;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approval by an independent institutional review board, or IRB, representing each clinical site before each clinical trial may be initiated;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">performance of adequate and well-controlled human clinical trials to establish the safety, potency, and purity of the product candidate for each proposed indication, in accordance with current IND and good clinical practice, or GCP;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">preparation and submission to the FDA of a Biologic License Application, or BLA, for a biologic product requesting marketing for one or more proposed indications, including submission of detailed information on the chemistry, manufacturing and controls, or CMC, for the product in clinical development and proposed labeling;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">review of the product by an FDA advisory committee, where appropriate or if applicable;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities, including those of third parties, at which the product, or components thereof, are produced to assess compliance with cGMP requirements and to assure that the facilities, methods, and controls are adequate to preserve the product&#8217;s identity, strength, quality, and purity;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of any FDA audits of the pre-clinical studies and clinical trial sites to assure compliance with GLP, as applicable, and GCP, and the integrity of clinical data in support of the BLA;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">payment of substantial application and program fees under the Prescription Drug User Fee Act, or PDUFA;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">FDA review and approval of the BLA authorizing the licensure and marketing of the new biologic product for particular indications in the United States; and </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">compliance with any post-approval requirements, including the potential requirement to implement a risk evaluation and mitigation strategy, or REMS, and any post-approval studies or other post-marketing commitments required by the FDA.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pre-clinical Studies</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Before testing any biologic product candidate in humans, the product candidate must undergo pre-clinical testing. Pre-clinical tests include laboratory evaluations of product chemistry, formulation and stability, as well as studies to evaluate the potential for efficacy and toxicity in animal studies. These studies are often referred to as IND-enabling studies. The conduct of the pre-clinical tests and formulation of the compounds for testing must comply with federal regulations and requirements, including GLP regulations and standards and the U.S. Department of Agriculture&#8217;s Animal Welfare Act, if applicable. The results of the pre-clinical tests, together with manufacturing information and analytical data, are submitted to the FDA as part of an IND application. With passage of the FDA&#8217;s Modernization Act 2.0 in December 2022, Congress eliminated provisions in both the FDCA and PHSA, that required animal testing in support of a BLA. While animal testing may still be conducted, the FDA was authorized to rely on alternative non-clinical tests, including cell-based assays, micro-physiological systems or bio-printed or computer models.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investigational New Drug Application</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An IND is an exemption from the FDCA that allows an unapproved product candidate to be shipped in interstate commerce for use in an investigational clinical trial and a request for FDA authorization to administer such investigational product to humans. The IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions about the product or conduct of the proposed clinical trial, including concerns that human research subjects will be exposed to unreasonable health risks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or any issues surrounding CMC for the proposed product. In that case, the IND sponsor and the FDA must resolve any outstanding FDA concerns before the clinical trials can begin or recommence. As a result, submission of the IND may result in the FDA not allowing the trials to commence or allowing the trial to commence on the terms originally specified by the sponsor in the IND.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA raises concerns or questions either during this initial 30-day period, or at any time following allowance of an IND, it may choose to impose a partial or complete clinical hold. Clinical holds are imposed by the FDA whenever there is concern for patient safety and may be a result of new data, findings, or developments in preclinical and/or clinical trials, and/or CMC. This order issued by the FDA would delay either a proposed clinical trial or cause suspension of an ongoing trial, until all outstanding concerns have been adequately addressed and the FDA has notified the company that investigations may proceed. This could cause significant delays or difficulties in completing a planned clinical trial or future clinical trials in a timely manner.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the issuance of a clinical hold or partial clinical hold, a clinical investigation may only resume once the FDA has notified the sponsor that the investigation may proceed. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that the investigation can proceed or recommence. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expanded Access to an Investigational Drug for Treatment Use</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expanded access, sometimes called &#8220;compassionate use,&#8221; is the use of investigational products outside of clinical trials to treat patients with serious or immediately life-threatening diseases or conditions when there are no comparable or satisfactory alternative treatment options. The rules and regulations related to expanded access are intended to improve access to investigational products for patients who may benefit from investigational therapies. FDA regulations allow access to investigational products under an IND by the company or the treating physician for treatment purposes on a case-by-case basis for: individual patients (single-patient IND applications for treatment in emergency settings and non-emergency settings); intermediate-size patient populations; and larger populations for use of the investigational product under a treatment protocol or treatment IND application.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When considering an IND application for expanded access to an investigational product with the purpose of treating a patient or a group of patients, the sponsor and treating physicians or investigators will determine suitability when all of the following criteria apply: patient(s) have a serious or immediately life-threatening disease or condition, and there is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition; the potential patient benefit justifies the potential risks of the treatment and the potential risks are not unreasonable in the context or condition to be treated; and the expanded use of the investigational drug for the requested treatment will not interfere with initiation, conduct, or completion of clinical investigations that could support marketing approval of the product or otherwise compromise the potential development of the product.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no obligation for a sponsor to make its drug products available for expanded access; however, as required by the 21st Century Cures Act, or Cures Act, passed in 2016, if a sponsor has a policy regarding how it evaluates and responds to expanded access requests, sponsors are required to make such policies publicly available upon the earlier of initiation of a Phase 2 or Phase 3 clinical trial, or 15 days after the investigational drug or biologic receives designation as a breakthrough therapy, fast track product, or regenerative medicine advanced therapy.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to and separate from expanded access, the Right to Try Act, among other things, provides a federal framework for certain patients to access certain investigational products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a manufacturer to make its investigational products available to eligible patients as a result of the Right to Try Act.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Human Clinical Trials in Support of a BLA</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve the administration of the investigational product candidate to healthy volunteers or patients with the disease or condition to be treated under the supervision of a qualified principal investigator in accordance with GCP requirements. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, inclusion and exclusion criteria, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, each clinical trial must be reviewed and approved by an IRB either centrally or individually at each institution at which the clinical trial will be conducted. The IRB will consider, among other things, clinical trial design, patient informed consent, ethical factors, the safety of human subjects, and the possible liability of the institution. An IRB must operate in compliance with FDA regulations. The FDA, IRB, or the clinical trial sponsor may suspend or discontinue a clinical trial at any time for various reasons, including a finding that the clinical trial is not being conducted in accordance with FDA requirements or that the participants are being exposed to an unacceptable health risk. Clinical testing also must satisfy extensive GCP rules and the requirements for informed consent.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data monitoring committee, or DMC. A DMC may recommend continuation of the trial as planned, changes in trial conduct, or cessation of the trial at designated check points based on access that only the group maintains to available data from the study. Suspension or termination of development during any phase of clinical trials can occur if it is determined that the participants or patients are being exposed to an unacceptable health risk on the basis of data and information to which only the DMC has access.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials typically are conducted in three sequential phases, but the phases may overlap or be combined. Additional studies may be required after approval.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical trials are initially conducted in a limited population to test the product candidate for</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">safety, including adverse effects, dose tolerance, absorption, metabolism, distribution, excretion, and pharmacodynamics in healthy humans or, on occasion, in patients, such as cancer patients.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical trials are generally conducted in a limited patient population to identify possible</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adverse effects and safety risks, evaluate the potency and purity of the product candidate for specific targeted indications and determine dose tolerance and optimal dosage. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more costly Phase 3 clinical trials.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical trials proceed if the Phase 2 clinical trials demonstrate that a dose range of the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product candidate is potentially effective and has an acceptable safety profile. Phase 3 clinical trials are undertaken within an expanded patient population to further evaluate dosage, provide substantial evidence of clinical efficacy, and further test for safety in an expanded and diverse patient population at multiple, geographically dispersed clinical trial sites. A well-controlled, statistically robust Phase 3 trial may be designed to deliver the data that regulatory authorities will use to decide whether or not to approve, and, if approved, how to appropriately label a biologic; such Phase 3 studies are referred to as &#8220;pivotal.&#8221;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, the FDA may approve a BLA for a product but require the sponsor to conduct additional clinical trials to further assess the product&#8217;s safety, potency and purity after approval. Such trials are typically referred to as post approval or post marketing clinical trials. These studies are used to gain additional experience from the treatment of patients in the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">intended therapeutic indication and to document a clinical benefit in the case of biologics approved under accelerated approval regulations. If the FDA approves a product while a company has ongoing clinical trials that were not necessary for approval, a company may be able to use the data from these clinical trials to meet all or part of any post marketing clinical trial requirement or to request a change in the product labeling. The failure to exercise due diligence with regard to conducting post approval clinical trials could result in withdrawal of approval for products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A clinical trial may combine the elements of more than one phase and the FDA often requires more than one Phase 3 trial to support marketing approval of a product candidate. A company&#8217;s designation of a clinical trial as being of a particular phase is not necessarily indicative that the study will be sufficient to satisfy the FDA requirements of that phase because this determination cannot be made until the protocol and data have been submitted to and reviewed by the FDA. Generally, pivotal trials are Phase 3 trials, but they may be Phase 2 trials if the design provides a well-controlled and reliable assessment of clinical benefit, particularly in an area of unmet medical need.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2022, with the passage of the Food and Drug Omnibus Reform Act, or FDORA, Congress required sponsors to develop and submit a diversity action plan for each phase 3 clinical trial or any other &#8220;pivotal study&#8221; of a new drug or biological product. These plans are meant to encourage the enrollment of more diverse patient populations in late-stage clinical trials of FDA-regulated products. Specifically, action plans must include the sponsor&#8217;s goals for enrollment, the underlying rationale for those goals, and an explanation of how the sponsor intends to meet them. In addition to these requirements, the legislation directs the FDA to issue new guidance on diversity action plans. In June 2024, as mandated by FDORA, the FDA issued draft guidance outlining the general requirements for diversity action plans. Unlike most guidance documents issued by the FDA, the diversity action plan guidance when finalized will have the force of law because FDORA specifically dictates that the form and manner for submission of diversity action plans are specified in FDA guidance. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, the FDA issued draft guidance with updated recommendations for GCPs aimed at modernizing the design and conduct of clinical trials. The updates are intended to help pave the way for more efficient clinical trials to facilitate the development of medical products. The draft guidance is adopted from the International Council for Harmonisation&#8217;s recently updated E6(R3) draft guideline that was developed to enable the incorporation of rapidly developing technological and methodological innovations into the clinical trial enterprise. That guideline was finalized by the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use on January 6, 2025. In addition, the FDA issued draft guidance outlining recommendations for the implementation of decentralized clinical trials.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Finally, sponsors of clinical trials are required to register and disclose certain clinical trial information on a public registry, clinicaltrials.gov, maintained by the U.S. National Institutes of Health, or NIH. In particular, information related to the product, patient population, phase of investigation, study sites and investigators and other aspects of the clinical trial is made public as part of the registration of the clinical trial. Although sponsors are also obligated to disclose the results of their clinical trials after completion, disclosure of the results can be delayed in some cases for up to two years after the date of completion of the trial. The NIH&#8217;s final rule on registration and reporting requirements for clinical trials became effective in 2017. The PHSA grants the Secretary of the U.S. Department of Health and Human Services, or HHS, the authority to issue a notice of noncompliance to a responsible party to failure to submit clinical trial information as required. The responsible party, however, is allowed 30 days to correct the noncompliance and submit the required information. As of December 19, 2024, the FDA has issued six notices of non-compliance, signaling the government&#8217;s willingness to enforce these requirements against non-compliant clinical trial sponsors. While these notices of non-compliance did not result in civil monetary penalties, the failure to submit clinical trial information to clinicaltrials.gov, as required, is a prohibited act under the FDCA with violations subject to potential civil monetary penalties of up to $10,000 for each day the violation continues.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Studies Outside the United States in Support of FDA Approval</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with a clinical development program, a sponsor may conduct trials at sites outside the United States.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When a foreign clinical study is conducted under an IND, all IND requirements must be met unless waived. When a foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with certain regulatory requirements of the FDA in order to use the study as support for an IND or application for marketing approval. Specifically, the studies must be conducted in accordance with GCP, including undergoing review and receiving approval by an independent ethics committee, or IEC, and seeking and receiving informed consent from subjects. GCP requirements encompass both ethical and data integrity standards for clinical studies. The FDA&#8217;s regulations are intended to help ensure the protection of human subjects enrolled in non-IND foreign clinical studies, as well as the quality and integrity of the resulting data. They further help ensure that non-IND foreign studies are conducted in a manner comparable to that required for IND studies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acceptance by the FDA of study data from clinical trials conducted outside the United States in support of U.S. approval may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the United States., the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S. medical practice; (ii) the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations; and (iii) the data may be considered valid without the need for an on-site inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, even where the foreign study data are not intended to serve as the sole basis for approval, the FDA will not accept the data as support for an application for marketing approval unless the study is well-designed and well-conducted in accordance with GCP requirements and the FDA is able to validate the data from the study through an onsite inspection if deemed necessary. Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials are subject to the applicable local laws of the foreign jurisdictions where the trials are conducted.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interactions with FDA During the Clinical Development Program</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the clearance of an IND and the commencement of clinical trials, the sponsor will continue to have interactions with the FDA. A development safety update report detailing the results of clinical trials must be submitted annually within 60 days of the anniversary dates that the IND went into effect. In addition, IND safety reports must be submitted to the FDA for any of the following: serious and unexpected suspected adverse reactions; findings from other trials or animal or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> testing that suggest a significant risk in humans exposed to the product; and any clinically important increase in the occurrence of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. The FDA will typically inspect one or more clinical sites to assure compliance with GCP and the integrity of the clinical data submitted.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, sponsors are given opportunities to meet with the FDA at certain points in the clinical development program. Specifically, there are five types of meetings that occur between sponsors and the FDA. Type A meetings are those that are necessary for an otherwise stalled product development program to proceed or to address an important safety issue. Type B meetings include pre-IND and pre-BLA meetings, as well as end of phase meetings such as End of Phase 2 meetings. A Type C meeting is any meeting other than a Type A or Type B meeting regarding the development and review of a product. A Type D meeting is focused on a narrow set of issues, which should be limited to no more than two focused topics, and should not require input from more than three disciplines or divisions. Finally, INitial Targeted Engagement for Regulatory Advice on CBER/CDER ProducTs, or INTERACT, meetings are intended for novel products and development programs that present unique challenges in the early development of an investigational product. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These meetings provide an opportunity for the sponsor to share information about the data gathered to date with the FDA and for the FDA to provide advice on the next phase of development. At the conclusion of these meetings, the FDA will typically provide its responses to questions posed by the sponsor regarding the clinical development program.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FDA will not indicate whether a BLA will be approved, but it will provide guidance to the sponsor on various questions, including whether an application should be submitted in the first place on the basis of the studies and data proposed by the sponsor. The FDA has indicated that its responses, as conveyed in meeting minutes and advice letters, only constitute mere recommendations and/or advice made to a sponsor and, as such, sponsors are not bound by such recommendations and/or advice. Nonetheless, from a practical perspective, a sponsor&#8217;s failure to follow the FDA&#8217;s recommendations for design of a clinical program may put the program at significant risk of failure.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Special Regulations and Guidance Governing Gene Therapy Products</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has defined a gene therapy product as one that mediates its effects by transcription and/or translation of transferred genetic material and/or by integrating into the host genome and which is administered as nucleic acids, viruses, or genetically engineered microorganisms. The products may be used to modify cells </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or transferred to cells </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> prior to administration to the recipient. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the FDA, the Center for Biologics Evaluation and Research, or CBER, regulates gene therapy products. Within CBER, the FDA has established the Office of Tissues and Advanced Therapies, or the OTAT, to consolidate the review of gene therapy and related products, and has established the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER in its review. In September 2022, the FDA announced renaming of the OTAT to the Office of Therapeutic </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products, or the OTP, and elevation of the OTP to a &#8220;Super Office&#8221; to meet its growing cell and gene therapy workload and new commitments under the PDUFA for fiscal years 2023 to 2027. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has issued various guidance documents regarding gene therapies, including a November 2024 draft guidance to address frequently asked questions surrounding the development of cellular and gene therapy products and final guidance documents released in January 2020 relating to CMC information for gene therapy INDs, gene therapies for rare diseases and gene therapies for retinal disorders, as well as draft guidance in January 2021 for Human Gene Therapy for Neurodegenerative Diseases. Although the FDA has indicated that these and other guidance documents it previously issued are not legally binding, we believes that our compliance with them is likely necessary to gain approval for any gene therapy product candidate we may develop. The guidance documents provide additional factors that the FDA will consider at each of the above stages of development and relate to, among other things, the proper pre-clinical assessment of gene therapies; the chemistry, manufacturing, and control information that should be included in an IND application; the proper design of tests to measure product potency in support of an IND or BLA application; and measures to observe delayed adverse effects in subjects who have been exposed to investigational gene therapies when the risk of such effects is high. Further, the FDA usually recommends that sponsors observe subjects for potential gene therapy-related delayed adverse events for a 15-year period, including a minimum of five years of annual examinations followed by 10 years of annual queries, either in person or by questionnaire.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, for a gene therapy product, the FDA also will not approve the product if the manufacturer is not in compliance with good tissue practices, or GTP. These standards are found in FDA regulations and guidance that govern the methods used in, and the facilities and controls used for, the manufacture of human cells, tissues, and cellular and tissue-based products, or HCT/Ps, which are human cells or tissue intended for implantation, transplant, infusion, or transfer into a human recipient. The primary intent of the GTP requirements is to ensure that T cell and tissue-based products are manufactured in a manner designed to prevent the introduction, transmission, and spread of communicable disease. FDA regulations also require tissue establishments to register and list their HCT/Ps with the FDA and, when applicable, to evaluate donors through screening and testing.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pediatric Studies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Pediatric Research Equity Act of 2003, or PREA, a BLA or supplement thereto must contain data that are adequate to assess the safety, potency and purity of the product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. Sponsors must also submit pediatric study plans prior to the assessment data. Those plans must contain an outline of the proposed pediatric study or studies the sponsor plans to conduct, including study objectives and design, any deferral or waiver requests, and other information required by regulation. The sponsor, the FDA, and the FDA&#8217;s internal review committee must then review the information submitted, consult with each other, and agree upon a final plan. The FDA or the sponsor may request an amendment to the plan at any time. In May 2023, the FDA issued new draft guidance that further describes the pediatric study requirements under PREA.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may, on its own initiative or at the request of the sponsor, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. A deferral may be granted for several reasons, including a finding that the product or therapeutic candidate is ready for approval for use in adults before pediatric trials are completed. The FDA is required to send a PREA Non-Compliance letter to sponsors who have failed to submit their pediatric assessments under PREA, have failed to seek or obtain a deferral or deferral extension or have failed to request approval for a required pediatric formulation. Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation, although the FDA has recently taken steps to limit what it considers abuse of this statutory exemption in PREA. The FDA also maintains a list of diseases that are exempt from PREA requirements due to low prevalence of disease in the pediatric population.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation, although the FDA has taken steps to limit what it considers abuse of this statutory exemption in PREA. Further, Section 505B of the FDCA, as amended by the FDA Reauthorization Act of 2017, or FDARA, requires that any original NDA or BLA submitted on or after August 18, 2020, for a new active ingredient, must contain reports on the molecularly targeted pediatric cancer investigation, unless the requirement is waived or deferred, if the drug that is the subject of the application is: (i) intended for the treatment of an adult cancer, and (ii) directed at a molecular target that the Secretary determines to be substantially relevant to the growth or progression of a pediatric cancer in accordance with FDA guidance. The FDA also maintains a list of diseases that are exempt from PREA requirements due to low prevalence of disease in the pediatric population. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compliance with cGMP Requirements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with clinical trials, sponsors usually complete additional animal safety studies, develop additional information about the chemistry and physical characteristics of the product candidate and finalize a process for manufacturing commercial quantities of the product candidate in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other criteria, the sponsor must develop methods for testing the identity, strength, quality, and purity of the finished product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, the FDA&#8217;s regulations require that pharmaceutical products be manufactured in specific approved facilities and in accordance with cGMPs. The cGMP regulations include requirements relating to organization of personnel, buildings and facilities, equipment, control of components and product containers and closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls, records and reports and returned or salvaged products. Manufacturers and other entities involved in the manufacture and distribution of approved pharmaceuticals are required to register their establishments with the FDA and some state agencies, and they are subject to periodic unannounced inspections by the FDA for compliance with cGMPs and other requirements. The Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics Act, or PREVENT Pandemics Act, which was enacted in December 2022, clarifies that foreign drug manufacturing establishments are subject to registration and listing requirements even if a drug or biologic undergoes further manufacture, preparation, propagation, compounding, or processing at a separate establishment outside the United States prior to being imported or offered for import into the United States. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers and others involved in the manufacture and distribution of products must also register their establishments with the FDA and certain state agencies. Both domestic and foreign manufacturing establishments must register and provide additional information to the FDA upon their initial participation in the manufacturing process. Any product manufactured by or imported from a facility that has not registered, whether foreign or domestic, is deemed misbranded under the FDCA. Establishments may be subject to periodic unannounced inspections by government authorities to ensure compliance with cGMPs and other laws. Inspections must follow a &#8220;risk-based schedule&#8221; that may result in certain establishments being inspected more frequently. Manufacturers may also have to provide, on request, electronic or physical records regarding their establishments. Delaying, denying, limiting, or refusing inspection by the FDA may lead to a product being deemed to be adulterated. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Submission and Review of a BLA</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of product candidate development, pre-clinical testing, and clinical trials, including negative or ambiguous results as well as positive findings, are submitted to the FDA as part of a BLA requesting license to market the product. The BLA must contain extensive manufacturing information and detailed information on the composition of the product and proposed labeling as well as payment of a user fee. Under federal law, the submission of most BLAs is subject to an application user fee, which for federal fiscal year 2025 is $4,310,002 for an application requiring clinical data. The sponsor of a licensed BLA is also subject to an annual program fee, which for federal fiscal year 2025 is $403,889. Certain exceptions and waivers are available for some of these fees, such as an exception from the application fee for products with orphan designation and a waiver for certain small businesses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following submission of a BLA, the FDA has 60 days to conduct a preliminary review of the application and it must inform the sponsor within that period of time whether the BLA is sufficiently complete to permit substantive review. In the event that the FDA determines that an application does not satisfy this standard, it will issue a Refuse to File, or RTF, determination to the sponsor. The FDA may request additional information and studies, and the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the submission has been accepted for filing, the FDA begins an in-depth review of the application. Under the goals and policies agreed to by the FDA under the PDUFA, the FDA has ten months in which to complete its initial review of a standard application and respond to the sponsor, and six months for a priority review of the application. The FDA does not always meet its PDUFA goal dates for standard and priority BLAs. The review process may often be significantly extended by the FDA requests for additional information or clarification. The review process and the PDUFA goal date may be extended by three months if the FDA requests or if the sponsor otherwise provides additional information or clarification regarding information already provided in the submission within the last three months before the PDUFA goal date.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA seeks to meet these timelines for review of an application but its ability to do so may be affected by a variety of factors. While the costs associated with review of an application are typically covered by the PDUFA user fee program, other activities, including government budget and funding levels, the ability to hire and retain key personnel and statutory, regulatory and policy changes, may impact the FDA&#8217;s review and approval of marketing applications.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Average review times at the FDA have fluctuated in recent years as a result. For example, during the past decade, the U.S. government has shut down several times and certain regulatory agencies, including the FDA, has had to furlough critical employees and stop critical activities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, there is substantial uncertainty as to how measures being implemented by the new Trump administration across the government will impact the FDA and other federal agencies with jurisdiction over biologics. For example, the potential loss of FDA personnel could lead to further disruptions and delays in the FDA&#8217;s operations and activities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with its review of a BLA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in full compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. The PHSA emphasizes the importance of manufacturing control for products like biologics whose attributes cannot be precisely defined.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA also may inspect the sponsor and one or more clinical trial sites to assure compliance with IND and GCP requirements and the integrity of the clinical data submitted to the FDA. With passage of the FDORA, Congress clarified the FDA&#8217;s authority to conduct inspections by expressly permitting inspections of facilities involved in the preparation, conduct, or analysis of clinical and non-clinical studies submitted to the FDA as well as other persons holding study records or involved in the study process.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may also refer the application to an advisory committee for review, evaluation, and recommendation as to whether the application should be approved. In particular, the FDA may refer applications for novel biologic products or biologic products that present difficult questions of safety, potency or purity to an advisory committee. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates, and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions on approval. Data from clinical trials are not always conclusive, and the FDA or its advisory committee may interpret data differently than the sponsor interprets the same data. The FDA may also re-analyze the clinical trial data, which could result in extensive discussions between the FDA and the sponsor during the review process.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Moreover, the FDA will review a sponsor&#8217;s financial relationship with the principal investigators who conducted the clinical trials in support of the BLA. That is because, under certain circumstances, principal investigators at a clinical trial site may also serve as scientific advisors or consultants to a sponsor and receive compensation in connection with such services. Depending on the level of that compensation and any other financial interest a principal investigator may have in a sponsor, the sponsor may be required to report these relationships to the FDA. The FDA will then evaluate that financial relationship and determine whether it creates a conflict of interest or otherwise affects the interpretation of the trial or the integrity of the data generated at the principal investigator&#8217;s clinical trial site. If so, the FDA may exclude data from the clinical trial site in connection with its determination of safety, potency and purity of the investigational product.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA also may require submission of a REMS if it determines that a REMS is necessary to ensure that the benefits of the product outweigh its risks and to assure the safe use of the product. The REMS could include medication guides, physician communication plans, assessment plans and/or elements to assure safe use, or ETASU, such as restricted distribution methods, patient registries or other risk minimization tools. The FDA determines the requirement for a REMS, as well as the specific REMS provisions, on a case-by-case basis. If the FDA concludes a REMS is needed, the sponsor of the application must submit a proposed REMS and the FDA will not approve the application without a REMS.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The FDA&#8217;s Decision on a BLA</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the PHSA the FDA may approve a BLA if it determines that the product is safe, pure, and potent, and the facility where the product will be manufactured meets standards designed to ensure that it continues to be safe, pure, and potent. Specifically, the FDA must determine that the expected benefits of the proposed product outweigh its potential risks to patients. This &#8220;benefit- risk&#8221; assessment is informed by the extensive body of evidence about the proposed product in the BLA. On the basis of the FDA&#8217;s evaluation of the application and accompanying information, including the results of the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inspection of the manufacturing facilities and any FDA audits of pre-clinical and clinical trial sites to assure compliance with GCPs, the FDA may issue a complete response letter, or CRL, or an approval letter.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the application is not approved, the FDA will issue a CRL, which will contain the conditions that must be met in order to secure final approval of the application and will outline recommended actions the sponsor might take to obtain approval of the application. Sponsors that receive a CRL may submit to the FDA information that represents a complete response to the issues identified by the FDA, withdraw the application or request a hearing. The FDA will not approve an application until issues identified in the CRL have been addressed. If a CRL is issued, the sponsor will have one year to respond to the deficiencies identified by the FDA, at which time the FDA can deem the application withdrawn or, in its discretion, grant the sponsor an additional six-month extension to respond.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An approval letter, on the other hand, authorizes commercial marketing of the product with specific prescribing information for specific indications. The FDA may limit the approved indication(s) for use of the product. It may also require that contraindications, warnings, or precautions be included in the product labeling. In addition, the FDA may call for post -approval studies, including Phase 4 clinical trials, to further assess the product&#8217;s efficacy and/or safety after approval. The agency may also require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, including REMS, to help ensure that the benefits of the product outweigh the potential risks. REMS can include medication guides, communication plans for healthcare professionals, and ETASU. ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patent registries. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. After approval, many types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expedited Review Programs</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA is authorized to expedite the review of applications in several ways. None of these expedited programs changes the standards for approval but each may help expedite the development or approval process governing product candidates.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Fast Track designation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The sponsor of a product candidate may request the FDA to designate the product for a specific indication as a Fast Track product concurrent with or after the filing of the IND. Candidate products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to the combination of the product candidate and the specific indication for which it is being studied. In addition to other benefits, such as the ability to have greater interactions with the FDA, the FDA may initiate review of sections of a Fast Track application before the application is complete, a process known as rolling review.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Breakthrough therapy designation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. To qualify for the breakthrough therapy program, product candidates must be intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence must indicate that such product candidates may demonstrate substantial improvement on one or more clinically significant endpoints over existing therapies. The FDA will seek to ensure the sponsor of a breakthrough therapy product candidate receives intensive guidance on an efficient drug development program, intensive involvement of senior managers and experienced staff on a proactive, collaborative and cross-disciplinary review and rolling review.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.5pt">Priority review</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. A product candidate is eligible for priority review if it treats a serious condition and, if approved, it would be a significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention compared to marketed products. The FDA determines, on a case-by-case basis, whether the proposed product represents a significant improvement when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting product reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, and evidence of safety, potency and purity in a new subpopulation. The FDA aims to complete its review of priority review applications within six months as opposed to 10 months for standard review.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Accelerated approval</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Drug or biologic products studied for their safety, potency and purity in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval. Accelerated approval means that a product candidate may be approved on the basis of adequate and well controlled clinical trials establishing that the product candidate has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity and prevalence of the condition and the availability or lack of alternative treatments. As a condition of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approval, the FDA may require that a sponsor of a drug or biologic product candidate receiving accelerated approval perform adequate and well controlled post-marketing clinical trials. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">With the passage of FDORA in December 2022, Congress modified certain provisions governing accelerated approval of drug and biologic products. Specifically, the new legislation authorized the FDA to require a sponsor to have its confirmatory clinical trial underway before accelerated approval is awarded and require a sponsor of a product granted accelerated approval to submit progress reports on its post-approval studies to the FDA every six months (until the study is completed). Moreover, FDORA established expedited procedures authorizing the FDA to withdraw an accelerated approval if certain conditions are met, including where a required confirmatory study fails to verify and describe the predicted clinical benefit or where evidence demonstrates the product is not shown to be safe or effective under the conditions of use. The FDA may also use such procedures to withdraw an accelerated approval if a sponsor fails to conduct any required post-approval study of the product with due diligence, including with respect to &#8220;conditions specified by the Secretary.&#8221; The new procedures include the provision of due notice and an explanation for a proposed withdrawal, and opportunities for a meeting with the FDA Commissioner or the Commissioner&#8217;s designee and a written appeal, among other things.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">In March 2023, the FDA issued draft guidance that outlines its current thinking and approach to accelerated approval. The agency indicated that the accelerated approval pathway is commonly used for approval of oncology drugs due to the serious and life-threatening nature of cancer. Although single-arm trials have been commonly used to support accelerated approval, a randomized controlled trial is the preferred approach as it provides a more robust efficacy and safety assessment and allows for direct comparisons to an available therapy. To that end, the FDA outlined considerations for designing, conducting, and analyzing data for trials intended to support accelerated approvals of oncology therapeutics. Subsequently, in December 2024 and January 2025, the FDA issued additional draft guidance relating to accelerated approval. This guidance describes the FDA&#8217;s latest thinking on what it means to conduct a confirmatory trial with due diligence and how the agency plans to interpret whether such a study needs to be underway at the time of approval. While this guidance is currently only in draft form and will ultimately not be legally binding even when finalized, sponsors typically observe the FDA&#8217;s guidance closely to ensure that their investigational products qualify for accelerated approval. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Regenerative advanced therapy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. With passage of the Cures Act, Congress authorized the FDA to accelerate review and approval of products designated as regenerative advanced therapies. A product is eligible for this designation if it is a regenerative medicine therapy that is intended to treat, modify, reverse or cure a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product candidate has the potential to address unmet medical needs for such disease or condition. The benefits of a regenerative advanced therapy designation include early interactions with the FDA to expedite development and review, benefits available to breakthrough therapies, potential eligibility for priority review and accelerated approval based on surrogate or intermediate endpoints.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Post-Approval Regulation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If regulatory approval for marketing of a product or new indication for an existing product is obtained, the sponsor will be required to comply with all regular post-approval regulatory requirements as well as any post-approval requirements that the FDA have imposed as part of the approval process. The sponsor will be required to report certain adverse reactions and production problems to the FDA, provide updated safety, potency and purity information and comply with requirements concerning advertising and promotional labeling requirements. Manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including cGMP regulations, which impose certain procedural and documentation requirements upon manufacturers. Accordingly, the sponsor and its third-party manufacturers must continue to expend time, money, and effort in the areas of production and quality control to maintain compliance with cGMP regulations and other regulatory requirements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A product may also be subject to official lot release, meaning that the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official lot release, the manufacturer must submit samples of each lot, together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#8217;s tests performed on the lot, to the FDA. The FDA may in addition perform certain confirmatory tests on lots of some products before releasing the lots for distribution. Finally, the FDA will conduct laboratory research related to the safety, purity, potency, and effectiveness of pharmaceutical products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, warning letters or holds on post-approval clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of products; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. In September 2021, the FDA published final regulations which describe the types of evidence that the agency will consider in determining the intended use of a biologic product. Products may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If a company is found to have promoted off-label uses, it may become subject to adverse public relations and administrative and judicial enforcement by the FDA, the Department of Justice, or the Office of the Inspector General of the HHS as well as state authorities. This could subject a company to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes drug products. The federal government has levied large civil and criminal fines against companies for alleged improper promotion, and has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">It may be permissible, under very specific, narrow conditions, for a manufacturer to engage in non-promotional, non-misleading communication regarding off-label information, such as distributing scientific or medical journal information. Moreover, with passage of the Pre-Approval Information Exchange Act, or PIE Act, in December 2022, sponsors of products that have not been approved may proactively communicate to payors certain information about products in development to help expedite patient access upon product approval. Previously, such communications were permitted under FDA guidance but the new legislation explicitly provides protection to sponsors who convey certain information about products in development to payors, including unapproved uses of approved products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, in January 2025, the FDA published final guidance outlining its policies governing the distribution of scientific information to healthcare providers about unapproved uses of approved products. The final guidance calls for such communications to be truthful, non-misleading and scientifically sound and to include all information necessary for healthcare providers to interpret the strengths and weaknesses and validity and utility of the information about the unapproved use of the approved product. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, and its implementing regulations, as well as the Drug Supply Chain Security Act, or DSCSA, which regulate the distribution and tracing of prescription drug samples at the federal level, and set minimum standards for the regulation of distributors by the states. The PDMA, its implementing regulations and state laws limit the distribution of prescription pharmaceutical product samples, and the DSCSA imposes requirements to ensure accountability in distribution and to identify and remove counterfeit and other illegitimate products from the market. Manufacturers were required by November 2023 to have such systems and processes in place to comply with the DSCSA, but, so as not to disrupt supply chains, the FDA has granted certain exemptions from enhanced drug distribution security requirements for eligible trading partners for particular periods of time.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Orphan Drug Designation and Exclusivity</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Orphan drug designation in the United States is designed to encourage sponsors to develop products intended for rare diseases or conditions. In the United States, a rare disease or condition is statutorily defined as a condition that affects fewer than 200,000 individuals in the United States or that affects more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making available the biologic for the disease or condition will be recovered from sales of the product in the United States.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Orphan drug designation qualifies a company for tax credits and market exclusivity for seven years following the date of the product&#8217;s marketing approval if granted by the FDA. An application for designation as an orphan product can be made </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any time prior to the filing of an application for approval to market the product. A product becomes an orphan when it receives orphan drug designation from the Office of Orphan Products Development at the FDA based on acceptable confidential requests made under the regulatory provisions. The product must then go through the review and approval process like any other product.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A sponsor may request orphan drug designation of a previously unapproved product or new orphan indication for an already marketed product. In addition, a sponsor of a product that is otherwise the same product as an already approved orphan drug may seek and obtain orphan drug designation for the subsequent product for the same rare disease or condition if it can present a plausible hypothesis that its product may be clinically superior to the first drug. More than one sponsor may receive orphan drug designation for the same product for the same rare disease or condition, but each sponsor seeking orphan drug designation must file a complete request for designation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product with orphan designation receives the first FDA approval for the disease or condition for which it has such designation or for a select indication or use within the rare disease or condition for which it was designated, the product generally will receive orphan drug exclusivity. Orphan drug exclusivity means that the FDA may not approve another sponsor&#8217;s marketing application for the same product for the same indication for seven years, except in certain limited circumstances. If a product designated as an orphan drug ultimately receives marketing approval for an indication broader than what was designated in its orphan drug application, it may not be entitled to exclusivity.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The period of exclusivity begins on the date that the marketing application is approved by the FDA. Orphan drug exclusivity will not bar approval of another product under certain circumstances, including if a subsequent product with the same drug for the same condition is shown to be clinically superior to the approved product on the basis of greater efficacy or safety, or providing a major contribution to patient care, or if the company with orphan drug exclusivity is not able to meet market demand. Under Omnibus legislation enacted in December 2020, the requirement for a product to show clinical superiority applies to drugs and biologics that received orphan drug designation before enactment of FDARA in 2017, but have not yet been approved or licensed by the FDA. In addition, the FDA may approve a second application for the same product for a different use or a second application for a clinically superior version of the product for the same use.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and Congress may further reevaluate the Orphan Drug Act and its regulations and policies. This may be particularly true in light of a decision from the Court of Appeals for the 11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Circuit in September 2021 finding that, for the purpose of determining the scope of exclusivity, the term &#8220;same disease or condition&#8221; means the designated &#8220;rare disease or condition&#8221; and could not be interpreted by the FDA to mean the &#8220;indication or use.&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 23, 2023, the FDA announced that, in matters beyond the scope of that court order, the FDA will continue to apply its existing regulations tying orphan-drug exclusivity to the uses or indications for which the orphan drug was approved. However, on February 14, 2025, a federal district court in Washington, D.C. fully embraced the reasoning of the court decision in another decision challenging the scope of orphan drug exclusivity. The implications of this decision, and its impact on the FDA&#8217;s implementation of the Orphan Drug Act, are unclear at this point</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pediatric Exclusivity</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pediatric exclusivity is another type of non-patent exclusivity in the United States and for biologics, if granted, provides for the attachment of an additional six months of regulatory exclusivity to the term of any existing regulatory exclusivity, including orphan exclusivity. This six-month exclusivity may be granted if a BLA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#8217;s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity that cover the product are extended by six months.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Biosimilars and Exclusivity</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2010 Patient Protection and Affordable Care Act, or ACA, which was signed into law in March 2010, included a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA. The BPCIA established a regulatory scheme authorizing the FDA to approve biosimilars and interchangeable biosimilars. A biosimilar is a biological product that is highly similar to an existing FDA-licensed &#8220;reference product.&#8221; The FDA has approved a number of biosimilar products and interchangeable biosimilar products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the BPCIA, a manufacturer may submit an application for licensure of a biologic product that is &#8220;biosimilar to&#8221; or &#8220;interchangeable with&#8221; a previously approved biological product or &#8220;reference product.&#8221; In order for the FDA to approve a </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">biosimilar product, it must find that there are no clinically meaningful differences between the reference product and proposed biosimilar product in terms of safety, purity, and potency. For the FDA to approve a biosimilar product as interchangeable with a reference product, the agency must find that the biosimilar product can be expected to produce the same clinical results as the reference product, and (for products administered multiple times) that the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An application for a biosimilar product may not be submitted to the FDA until four years following the date of approval of the reference product. The FDA may not approve a biosimilar product until 12 years from the date on which the reference product was approved. Even if a product is considered to be a reference product eligible for exclusivity, another company could market a competing version of that product if the FDA approves a full BLA for such product containing the sponsor&#8217;s own pre-clinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity, and potency of their product. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BPCIA also includes provisions to protect reference products that have patent protection. The biosimilar product sponsor and reference product sponsor may exchange certain patent and product information for the purpose of determining whether there should be a legal patent challenge. Based on the outcome of negotiations surrounding the exchanged information, the reference product sponsor may bring a patent infringement suit and injunction proceedings against the biosimilar product sponsor. The biosimilar applicant may also be able to bring an action for declaratory judgment concerning the patent.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The FDA maintains a publicly-available online database of licensed biological products, which is commonly referred to as the &#8220;Purple Book.&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Purple Book lists product names, dates of licensure, and applicable periods of exclusivity.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Further, the reference product sponsor must provide patent information and patent expiry dates to FDA following the exchange of patent information between biosimilar and reference product sponsors. This information is then published in the Purple Book.</span></div><div><span><br/></span></div><div><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In an effort to increase competition in the drug and biologic product marketplace, Congress, the executive branch, and the FDA have taken certain legislative and regulatory steps. For example, the 2020 Further Consolidated Appropriations Act included provisions requiring that sponsors of approved drug and biologic products, including those subject to REMS, provide samples of the approved products to persons developing biosimilar products within specified timeframes, in sufficient quantities, and on commercially reasonable market-based terms. Failure to do so can subject the approved product sponsor to civil actions, penalties, and responsibility for attorney&#8217;s fees and costs of the civil action. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There have been recent government proposals to reduce the 12-year reference product exclusivity period, but none has been enacted to date. At the same time, since passage of the BPCIA, many states have passed laws or amendments to laws, which address pharmacy practices involving biosimilar products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Federal and State Data Privacy and Security Laws</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are multiple privacy and data security laws that may impact our business activities, in the United States and in other countries where we conduct trials or where we may do business in the future. These laws are evolving and may increase both our obligations and our regulatory risks in the future. In the health care industry generally, under the Health Insurance Portability and Accountability Act, or HIPAA, the HHS, has issued regulations to protect the privacy and security of protected health information, or PHI, used or disclosed by covered entities including certain healthcare providers, health plans, and healthcare clearinghouses. HIPAA also regulates standardization of data content, codes and formats used in healthcare transactions and standardization of identifiers for health plans and providers. HIPAA also imposes certain obligations on the business associates of covered entities that obtain protected health information in providing services to or on behalf of covered entities. HIPAA may apply to us in certain circumstances and may also apply to our business partners in ways that may impact our relationships with them. Our clinical trials are regulated by the Common Rule, which also includes specific privacy-related provisions. In addition to federal privacy regulations, there are a number of state laws governing confidentiality and security of health information that may be applicable to our business. In addition to possible federal civil and criminal penalties for HIPAA violations, state attorneys general are authorized to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. In addition, state attorneys general (along with private plaintiffs) have brought civil actions seeking injunctions and damages resulting from alleged violations of HIPAA&#8217;s privacy and security rules. State attorneys general also have authority to enforce state privacy and security laws. New laws and regulations governing privacy and security may be adopted in the future as well.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">States are also active in creating specific rules relating to the processing of personal information. In 2018 California passed into law the California Consumer Privacy Act, or the CCPA, which took effect on January 1, 2020, and imposed many requirements on businesses that process the personal information of California residents. Many of the CCPA&#8217;s requirements are similar to those found in the General Data Protection Regulation, or the GDPR, including requiring businesses to provide notice to data subjects regarding the information collected about them and how such information is used and shared, and providing data subjects the right to request access to such personal information and, in certain cases, request the erasure of such personal information. The CCPA also affords California residents the right to opt-out of &#8220;sales&#8221; of their personal information. The CCPA contains significant penalties for companies that violate its requirements. In November 2020, California voters passed a ballot initiative for the California Privacy Rights Act, or the CPRA, which went into effect on January 1, 2023, and significantly expanded the CCPA to incorporate additional GDPR-like provisions including requiring that the use, retention, and sharing of personal information of California residents be reasonably necessary and proportionate to the purposes of collection or processing, granting additional protections for sensitive personal information, and requiring greater disclosures related to notice to residents regarding retention of information. The CPRA also created a new enforcement agency&#8212;the California Privacy Protection Agency&#8212;whose sole responsibility is to enforce the CPRA, which will further increase compliance risk. The provisions in the CPRA may apply to some of our business activities. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to California, a number of other states have passed comprehensive privacy laws similar to the CCPA and CPRA. These laws are either in effect or will go into effect sometime over the next several years. Like the CCPA and CPRA, these laws create obligations related to the processing of personal information, as well as special obligations for the processing of &#8220;sensitive&#8221; data, which includes health data in some cases. Some of the provisions of these laws may apply to our business activities. There are also states that are strongly considering or have already passed comprehensive privacy laws that will go into effect in 2025 and beyond. Other states will be considering similar laws in the future, and Congress has also been debating passing a federal privacy law. There are also states that are specifically regulating health information that may affect our business. For example, the State of Washington passed the My Health My Data Act in 2023 which specifically regulates the collecting and sharing of health information that is not otherwise regulated by the HIPAA rules, and the law also has a private right of action, which further increases the relevant compliance risk. Connecticut and Nevada have also passed similar laws regulating consumer health data, and more states are considering such legislation in 2025. These laws may impact our business activities, including our identification of research subjects, relationships with business partners and ultimately the marketing and distribution of our product candidates, if approved.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plaintiffs&#8217; lawyers are also increasingly using privacy-related statutes at both the state and federal level to bring lawsuits against companies for their data-related practices. In particular, there have been a significant number of cases filed against companies for their use of pixels and other web trackers. These cases often allege violations of the California Invasion of Privacy Act and other state laws regulating wiretapping, as well as the federal Video Privacy Protection Act.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Term Restoration and Extension</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, a patent claiming a new biologic product, its method of use or its method of manufacture may be eligible for a limited patent term extension under the Hatch-Waxman Act, which permits a patent extension of up to five years for patent term lost during product development and FDA regulatory review. Assuming grant of the patent for which the extension is sought, the restoration period for a patent covering a product is typically one-half the time between the effective date of the IND clearing clinical studies and the submission date of the BLA, plus the time between the submission date of the BLA and the ultimate approval date. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14 years from the product&#8217;s approval date in the United States. Only one patent applicable to an approved product is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent for which extension is sought. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. The USPTO reviews and approves the application for any patent term extension in consultation with the FDA.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FDA Approval of Companion Diagnostics</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2014, the FDA issued final guidance clarifying the requirements that will apply to approval of therapeutic products and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> companion diagnostics. According to the guidance, for novel drugs, a companion diagnostic device and its corresponding therapeutic should be approved or cleared contemporaneously by the FDA for the use indicated in the therapeutic product&#8217;s labeling. Approval or clearance of the companion diagnostic device will ensure that the device has been adequately evaluated and has adequate performance characteristics in the intended population. In July 2016, the FDA issued a draft guidance intended to assist sponsors of the drug therapeutic and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> companion diagnostic device </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on issues related to co-development of the products. The 2014 guidance also explains that a companion diagnostic device used to make treatment decisions in clinical trials of a biologic product candidate generally will be considered an investigational device, unless it is employed for an intended use for which the device is already approved or cleared. If used to make critical treatment decisions, such as patient selection, the diagnostic device generally will be considered a significant risk device under the FDA&#8217;s Investigational Device Exemption, or IDE, regulations. Thus, the sponsor of the diagnostic device will be required to comply with the IDE regulations. According to the guidance, if a diagnostic device and a product are to be studied together to support their respective approvals, both products can be studied in the same investigational study, if the study meets both the requirements of the IDE regulations and the IND regulations. The guidance provides that depending on the details of the study plan and subjects, a sponsor may seek to submit an IND alone, or both an IND and an IDE.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the FDA issued additional guidance which describes considerations for the development and labeling of companion diagnostic devices to support the indicated uses of multiple biological oncology products, when appropriate. The 2020 guidance expands on the policy statement in the 2014 guidance by recommending that companion diagnostic developers consider a number of factors when determining whether their test could be developed, or the labeling for approved companion diagnostics could be revised through a supplement, to support a broader labeling claim such as use with a specific group of oncology therapeutic products (rather than listing an individual therapeutic product(s)).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the FDCA, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> diagnostics, including companion diagnostics, are regulated as medical devices. In the United States, the FDCA and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, pre-clinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post market surveillance. Unless an exemption applies, diagnostic tests require marketing clearance or approval from the FDA prior to commercial distribution.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA previously has required </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> companion diagnostics intended to select the patients who will respond to the product candidate to obtain pre-market approval, or PMA, simultaneously with approval of the therapeutic product candidate. The PMA process, including the gathering of clinical and pre-clinical data and the submission to and review by the FDA, can take several years or longer. It involves a rigorous premarket review during which the sponsor must prepare and provide the FDA with reasonable assurance of the device&#8217;s safety, potency and purity and information about the device and its components regarding, among other things, device design, manufacturing and labeling. PMA applications are subject to an application fee. For federal fiscal year 2025, the standard fee is $540,783 and the small business fee is $135,196.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> companion diagnostic device could be subject to FDA enforcement discretion from compliance with the FDCA if it meets the definition of a Laboratory Developed Test, or LDT. However, FDA issued a final rule in April 2024 to end enforcement discretion for LDTs and actively regulate such products as medical devices. Under this final rule, LDTs are required to come into compliance with the FDA&#8217;s medical device regulatory requirements in a staged approach over the course of four years. The implementation of this LDT final rule could potentially be affected by the Executive Order, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Freeze Pending Review</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, issued by President Trump on January 20, 2025 and/or the anticipated change in leadership at the FDA under the new administration. Further, while the final regulation is set to take effect on May 6, 2025, a number of parties have challenged the legality of the LDT regulation in a federal district court. That court held a hearing on this matter on February 19, 2025, and is expected to issue a ruling shortly thereafter.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage, Pricing, and Reimbursement</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we may seek regulatory approval by the FDA or other government authorities. In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use any product candidates a sponsor may develop unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of such product candidates. Even if any product candidates a sponsor may develop are approved, sales of such product candidates will depend, in part, on the extent to which third-party payors, including government health programs in the United States such as Medicare and Medicaid, commercial health insurers, and managed care organizations, provide coverage, and establish adequate reimbursement levels for, such product candidates. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging the prices charged, examining the medical necessity, and reviewing the cost-effectiveness of medical products and services and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a particular indication.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable marketing approvals. Nonetheless, product candidates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover any product candidates a sponsor may develop could reduce physician utilization of such product candidates once approved and have a material adverse effect on a sponsor&#8217;s sales, results of operations and financial condition. Additionally, a payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payor to payor. Third-party reimbursement and coverage may not be available to enable a sponsor to maintain price levels sufficient to realize an appropriate return on a sponsor&#8217;s investment in product development. In addition, any companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to any companion diagnostics.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The containment of healthcare costs also has become a priority of federal, state and foreign governments and the prices of pharmaceuticals have been a focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement, and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#8217;s revenue generated from the sale of any approved products. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive marketing approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, ensuring adequate coverage and payment for any product candidates a sponsor may develop will face challenges. Pricing of prescription pharmaceuticals is subject to governmental control in many countries. Pricing negotiations with governmental authorities can extend well beyond the receipt of regulatory marketing approval for a product and may require a sponsor to conduct a clinical trial that compares the cost effectiveness of any product candidates a sponsor may develop to other available therapies. The conduct of such a clinical trial could be expensive and result in delays in a sponsor&#8217;s commercialization efforts.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies (so called health technology assessments) in order to obtain reimbursement or pricing approval. For example, the European Union provides options for its member states to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. EU member states may approve a specific price for a product or they may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other member states allow companies to fix their own prices for products but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the European Union have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the European Union. The downward pressure on healthcare costs in general, particularly prescription products, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. Political, economic, and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU member states, and parallel trade (arbitrage between low-priced and high-priced member states), can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of a sponsor&#8217;s products, if approved in those countries.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare Law and Regulation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers and third-party payors play a primary role in the recommendation and prescription of pharmaceutical products that are granted marketing approval. Arrangements with providers, consultants, third-party payors, and customers </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are subject to broadly applicable fraud and abuse, anti-kickback, false claims laws, reporting of payments to physicians and teaching physicians and patient privacy laws and regulations and other healthcare laws and regulations that may constrain a sponsor&#8217;s business and/or financial arrangements. Restrictions under applicable federal and state healthcare laws and regulations, include the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, paying, receiving, or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalties laws, which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false, fictitious, or fraudulent or knowingly making, using, or causing to made or used a false record or statement to avoid, decrease, or conceal an obligation to pay money to the federal government;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Foreign Corrupt Practices Act, or the FCPA, which prohibits companies and their intermediaries from making, or offering or promising to make improper payments to non-U.S. officials for the purpose of obtaining or retaining business or otherwise seeking favorable treatment; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal transparency requirements under the ACA, which require certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the Centers for Medicare &amp; Medicaid Services, or the CMS, within the HHS, information related to payments and other transfers of value made by that entity to physicians, other healthcare providers, and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring pharmaceutical manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures. In addition, certain state and local laws require drug manufacturers to register pharmaceutical sales representatives in the jurisdiction. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a sponsor&#8217;s operations are found to be in violation of any of these laws or any other governmental regulations that may apply to a sponsor, a sponsor may be subject to significant civil, criminal, and administrative penalties, damages, fines, disgorgement, exclusion from government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, and the curtailment or restructuring of a sponsor&#8217;s operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare Reform</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. There have been a number of federal and state proposals during the last few years regarding the pricing of pharmaceutical and biopharmaceutical products, limiting coverage and reimbursement for drugs and other medical products, government control and other changes to the healthcare system in the United States.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2010, the U.S. Congress enacted the ACA, which, among other things, includes changes to the coverage and payment for products under government healthcare programs. Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, in August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2012 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of up to 2% per fiscal year, which will remain in effect through 2031 pursuant to the Coronavirus Aid, Relief and Economic Security Act, or the CARES Act. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The American Taxpayer Relief Act of 2012, which was enacted in January 2013, among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers, and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Further, with passage of the Inflation Reduction Act in August 2022, or IRA, Congress extended the expansion of ACA premium tax credits through 2025. Those subsidies were originally extended through 2022 under the American Rescue Plan Act of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021. These laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices a sponsor may obtain for any of a sponsor&#8217;s product candidates for which a sponsor may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since enactment of the ACA, there have been, and continue to be, numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, with enactment of the Tax Cuts and Jobs Act of 2017, or the TCJA, which was signed by President Trump on December 22, 2017, Congress repealed the &#8220;individual mandate.&#8221; The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, became effective in 2019 Further, on June 17, 2021, the U.S. Supreme Court dismissed a lawsuit after finding that the plaintiffs do not have standing to challenge the constitutionality of the ACA. Shortly after taking office in January 2025, President Trump revoked numerous executive orders issued by President Biden, including at least two executive orders (e.g., EO 14009, Strengthening Medicaid and the Affordable Care Act, and EO 14070, Continuing to Strengthen Americans&#8217; Access to Affordable, Quality Health Coverage) which were designed to further implement the ACA. We anticipate similar efforts to undermine the ACA, and litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharmaceutical Prices</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The prices of prescription pharmaceuticals have also been the subject of considerable discussion in the United States. There have been U.S. congressional inquiries, as well as proposed and enacted state and federal legislation designed to, among other things, bring more transparency to pharmaceutical pricing, review the relationship between pricing and manufacturer patient programs, and reduce the costs of pharmaceuticals under Medicare and Medicaid. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, in October 2020, the HHS and the FDA published a final rule allowing states and other entities to develop a Section 804 Importation Program, or SIP, to import certain prescription drugs from Canada into the United States. That regulation was challenged in a lawsuit by the Pharmaceutical Research and Manufacturers of America, or PhRMA, but the case was dismissed by a federal district court in February 2023 after the court found that PhRMA did not have standing to sue the HHS. Several states have passed legislation establishing workgroups to examine the impact of a state importation program. Several states have also passed laws allowing for the importation of drugs from Canada. Certain of these states have submitted Section 804 Importation Program proposals and are awaiting FDA approval. On January 5, 2024, the FDA approved Florida&#8217;s plan for Canadian drug importation. Florida now has authority to import certain products from Canada for a period of two years once certain conditions are met. Florida will first need to submit a pre-import request for each product selected for importation, which must be approved by the FDA. Florida will also need to relabel the products and perform quality testing of the products to meet FDA standards.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, on November 20, 2020, the HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. Pursuant to court order, the removal and addition of the aforementioned safe harbors were delayed, and recent legislation imposed a moratorium on implementation of the rule until January 1, 2026. The IRA, further delayed implementation of this rule to January 1, 2032.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The IRA has implications for Medicare Part D, which is a program available to individuals who are entitled to Medicare Part A or enrolled in Medicare Part B to give them the option of paying a monthly premium for outpatient prescription drug coverage. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare beginning in 2026, with prices that can be negotiated subject to a cap; and it replaces the Part D coverage gap discount program with a new discounting program beginning in 2025. In addition, the IRA established inflation rebate programs under Medicare Part B and Part D. These programs require manufacturers to pay rebates to Medicare if they raise their prices for certain Part B and Part D drugs faster than the rate of inflation. On December 9, 2024, with issuance of its 2025 Physician Fee Schedule final regulation, CMS finalized its rules governing the IRA inflation rebate programs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Further, the legislation subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law or for taking price increases that exceed inflation. The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, with respect to price negotiations, Congress authorized Medicare to negotiate lower prices for certain costly single-source drug and biologic products that do not have competing generics or biosimilars and are reimbursed under Medicare Part B and Part D. The CMS may negotiate prices for ten high-cost drugs paid for by Medicare Part D starting in 2026, followed by 15 additional Part D drugs in 2027, 15 additional Part B or Part D drugs in 2028, and 20 additional Part </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B or Part D drugs in 2029 and beyond. This provision applies to drug products that have been approved for at least nine years and biologics that have been licensed for 13 years. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IRA includes a provision exempting orphan drugs from Medicare price negotiations but this exclusion has been interpreted by CMS in final guidance issued in July 2023 to apply only to those orphan drugs with an approved indication (or indications) for a single rare disease or condition. Thus, a biologic that is designated for more than one rare disease or condition will not qualify for the orphan drug exclusion, even if it is not approved for any indications for the additional diseases or conditions. The final guidance clarifies that CMS will consider only active designations/approvals when evaluating a drug for the exclusion, such that designations/indications withdrawn before the selected drug publication date will not be considered. CMS also clarified that, if a drug loses its orphan drug exclusion status, the agency will use the earliest date of approval/licensure to determine whether the product is a qualifying single source drug subject to price negotiations. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first cycle of negotiations for the Medicare Drug Price Negotiation Program commenced in the summer of 2023. On August 15, 2024, the HHS published the results of the first Medicare drug price negotiations for ten selected drugs that treat a range of conditions, including diabetes, chronic kidney disease, and rheumatoid arthritis. The prices of these ten drugs will become effective January 1, 2026. On January 17, 2025, shortly before the new administration took office, CMS announced its selection of 15 additional drugs covered by Part D for the second cycle of negotiations. There has been uncertainty about the extent to which the new administration would support the price negotiation program. Following the change in administrations, CMS issued a public statement on January 29, 2025, declaring that lowering the cost of prescription drugs is a top priority of the new administration and CMS is committed to considering opportunities to bring greater transparency in the negotiation program. The second cycle of negotiations with participating drug companies will occur during 2025, and any negotiated prices for this second set of drugs will be effective starting January 1, 2027.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 6, 2023, Merck &amp; Co. filed a lawsuit against the HHS and the CMS asserting that, among other things, the IRA&#8217;s Drug Price Negotiation Program for Medicare constitutes an uncompensated taking in violation of the Fifth Amendment of the Constitution. Subsequently, a number of other parties, including the U.S. Chamber of Commerce and pharmaceutical companies, also filed lawsuits in various courts with similar constitutional claims against the HHS and the CMS. HHS has generally won the substantive disputes in these cases, and various federal district court judges have expressed skepticism regarding the merits of the legal arguments being pursued by the pharmaceutical industry. Certain of these cases are now on appeal and, on October 30, 2024, the Court of Appeals for the Third Circuit heard oral argument in three of these cases. We expect that litigation involving these and other provisions of the IRA will continue, with unpredictable and uncertain results.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. A number of states, for example, require pharmaceutical manufacturers and other entities in the supply chain, including health carriers, pharmacy benefit managers, wholesale distributors, to disclose information about pricing of pharmaceuticals. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. These measures could reduce the ultimate demand for a sponsor&#8217;s products, once approved, or put pressure on a sponsor&#8217;s product pricing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures. This is increasingly true with respect to products approved pursuant to the accelerated approval pathway. State Medicaid programs and other payers are developing strategies and implementing significant coverage barriers, or refusing to cover these products outright, arguing that accelerated approval drugs have insufficient or limited evidence despite meeting the FDA&#8217;s standards for accelerated approval.</span></div><div id="i280a0966ad034c5090dd46bd303d2259_67"></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Matters</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December 31, 2024, we had 46 full-time employees, including a total of 22 employees with M.D. or Ph.D. degrees, all of whom are located in the United States. Of these full-time employees, 40 were engaged in research and development activities. On March 31, 2025, in connection with our cash preservation plan, we reduced our employee base to 6 employees, each of whom we believe is necessary to evaluate our strategic alternatives and execute an orderly wind down </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">of our operations. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our existing employees to be good.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the wind down process, our human capital objectives are focused on retaining and incentivizing our management team and other employees as we continue to evaluate our strategic alternatives and prepare for wind down of our operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Cost Reduction Measures</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2024, our board of directors approved a reduction in force of 39 full-time employees (representing approximately 37% of our total workforce), including certain employees engaged in research and development activities and certain finance and corporate employees. In December 2024, our board of directors approved a further reduction in force of 23 full-time employees (representing approximately 34% of our total workforce) including certain employees engaged in research and development and manufacturing activities and certain finance and corporate employees. In March 2025, in connection with approving our cash preservation plan, our board of directors approved a further reduction in force of 42 full-time employees (representing approximately 95% of our total workforce at that time including certain employees engaged in research and development and manufacturing activities and certain finance and corporate employees).</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Corporate Information </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal executive offices are located at 3675 Market Street, Suite 401, Philadelphia, PA, and our telephone number is (267) 491-6422. Our website address is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">httpp://www.carismatx.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The information contained on, or that can be accessed through, our website is not a part of this Annual Report on Form 10-K. We have included our website address in this Annual Report on Form 10-K solely as an inactive textual reference.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own or have rights to, or have applied for, trademarks, service marks and trade names that we use in connection with the operation of our business, including our corporate name, logos and website names. Other trademarks, service marks and trade names appearing in this Annual Report on Form 10-K are the property of their respective owners. Solely for convenience, some of the trademarks, service marks and trade names referred to in this Annual Report on Form 10-K are listed without the &#174; and &#8482; symbols.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make available, through our website </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">httpp://www.carismatx.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended as soon as reasonably practicable after we electronically file such material with the Securities and Exchange Commission, or the SEC.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have included our website address in this Annual Report on Form 10-K solely as an inactive textual reference.</span></div><div id="i280a0966ad034c5090dd46bd303d2259_70"></div><div style="margin-top:12pt;text-align:justify"><span id="if01f0055e0694c72b88254a6ce1c2a90_1751004"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing in our common stock involves a high degree of risk. You should carefully consider the risk factors set forth below, as well as the other information in this Annual Report on Form 10-K, including our financial statements and the related notes and the section of this Annual Report on Form 10-K titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; before deciding whether to purchase our securities. The risks and uncertainties we describe below and in the documents mentioned above are not the only ones we face. Although we currently have no intention of resuming research and development activities, certain risks and uncertainties we describe below relate to our prior operations and historical activities. Additional risks and uncertainties not presently known to us could adversely affect our business, operating results and financial condition, as well as adversely affect the value of an investment in our securities, and the occurrence of any of these risks might cause you to lose all or part of your investment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Risk Factors<br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Risks Related to Our Evaluation of Strategic Alternatives and Wind Down</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our exploration and pursuit of strategic alternatives may not be successful. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we do not successfully identify a strategic alternative or, if such a strategic alternative is identified, consummate such a transaction, it is highly unlikely that there will be cash available for distribution to our stockholders.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if we do consummate a strategic alternative, the amount of cash available for distribution to our stockholders, if any, will depend heavily on the proceeds derived from the strategic transaction, the timing of any distribution to stockholders, whether as a dividend or through a liquidation and dissolution of our business, as well as the amount of cash that will need to be reserved for commitments and contingent liabilities.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may elect to commence bankruptcy or liquidation and dissolution proceedings, and such proceedings may delay our wind down timeframe, increase our costs, and decrease the cash, if any, that may be available for stockholders.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may experience difficulties, delays or unexpected costs and not achieve anticipated benefits and savings from our cash preservation plan, and our wind down activities may adversely affect our ability to consummate a strategic transaction that enhances stockholder value.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will be substantially dependent on our remaining employees and consultants, along with any other advisors and consultants we may engage, to facilitate the consummation of a strategic transaction and orderly wind down process. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Any future resumption of research and development activities would depend on completing a strategic transaction that would support our prior operating plans or otherwise obtaining significant additional funding. Significant additional financing may not be available to us on acceptable terms, or at all.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred significant losses since our inception. We expect to continue to incur losses while we explore strategic alternatives and carry out the orderly wind down of our operations and may never achieve or maintain profitability. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Our independent registered public accounting firm has included an explanatory paragraph relating to our ability to continue as a going concern in its report on our audited consolidated financial statements included in this Annual Report on Form 10-K. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We have never generated revenue from product sales and may never achieve or maintain profitability.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our limited operating history and our cash preservation plan may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Historical Discovery Programs and Research and Development of Our Product Candidates</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cell therapy is a rapidly evolving area of science, and the approach we have taken to discover and develop product cand</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">idates by utilizing genetically modified macrophages is novel and may never lead to approved or marketable products.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are early in our development efforts. If we are unable to commercialize our product candidates or experiences significant delays in doing so, our business will be materially harmed.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we experience delays or difficulties in the enrollment of patients in clinical trials our product candidates, our receipt of necessary marketing approvals could be delayed or prevented.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may conduct clinical trials at sites outside the United States. The FDA may not accept data from trials conducted in such locations, and the conduct of trials outside the United States could subject us to additional delays and expense.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Commercialization of Our Product Candidates</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if any of our product candidates receives marketing approval, we may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success, and the market opportunity for any of our product candidates, if approved, may be smaller than we estimate.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do, thus rendering our products non-competitive, obsolete or reducing the size of the market for our product candidates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Dependence on Third Parties</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">We currently rely, and may in the future rely, on single-source suppliers for certain materials and components used in the manufacturing of our product candidates. Any disruption in supply from these single-source suppliers could lead to supply delays or interruptions which would materially adversely affect our business, financial condition and results of operations. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:13.8pt">We expect to depend on collaborations with third parties for the research, development and commercialization of certain of our product candidates, including our collaboration agreement with Moderna.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We cannot be certain Moderna will take the steps to achieve any of the milestones under the collaboration agreement, all of which are outside of our control, and as such, we may not be entitled to receive any remaining milestone payments or any royalty payments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">If our collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates and our business could be adversely affected.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Risks Related to Our Intellectual Property</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to obtain, maintain and enforce patent protection for our technology and product candidates or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and any ability to successfully develop and commercialize our technology and product candidates and to compete effectively may be adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Common Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The market price of our common stock is volatile, and the market price of our common stock may drop in the future. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We do not currently meet the requirements for continued listing on the Nasdaq Global Market. If we fail to meet the requirements for continued listing on the Nasdaq Global Market, our common stock could be delisted from trading, which would have a negative effect on the price of our common stock and our ability to raise additional capital.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We incur and will continue to incur additional costs and increased demands upon management as a result of complying with the laws and regulations affecting public companies.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If at some point we are no longer a &#8220;smaller reporting company&#8221; or otherwise no longer qualify for applicable exemptions, we will be subject to additional laws and regulations affecting public companies that will increase our costs and the demands on management and could harm our operating results. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Risks Related to Our Evaluation of Strategic Alternatives and Wind Down</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our exploration and pursuit of strategic alternatives may not be successful.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of a further revised plan approved by our board of directors on March 25, 2025 to preserve our existing cash resources following reduction in workforce, or our cash preservation plan, we have reduced our operations to those necessary to identify and explore a range of strategic alternatives to maximize value and prepare to wind down our business. Our cash preservation plan prioritizes payments necessary and appropriate for those reduced operations and those that will help to evaluate our strategic alternatives. Potential strategic alternatives to be explored and evaluated may include, among other transactions, the sale, license, monetization or divestiture of one or more of our assets or technologies, a strategic collaboration or partnership with one or more parties or the merger or sale of our company. We cannot provide any commitment regarding when or if this strategic review process will result in any type of transaction. </span></div><div><span><br/></span></div><div><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We may retain a financial advisor to advise on our exploration of a range of strategic alternatives. We plan to work with the financial advisor on identifying and evaluating potential strategic alternatives with the goal of maximizing the value of our assets, including CT-2401, CT-1119, our macrophage and monocyte engineering platform and our CAR-M platform and realizing value for the potential milestone and royalty payments under the Moderna collaboration.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">However, our exploration of strategic alternatives may not result in the consummation of any transaction or the realization of any value for our company or our stockholders.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Although we believe that our current cash and cash equivalents are sufficient to sustain our operating expenses and capital expenditure requirements into the second half of 2025, we do not expect that our cash and cash equivalents will support our operations for more than one year following the date of this Annual Report on Form 10-K. As such, we only have a short period of time to identify and explore a range of strategic alternatives before we deplete our resources. The process may not result in any definitive offer to consummate such a transaction, or, if we receive such a definitive offer, the terms may not be as favorable as anticipated or may not result in the execution or approval of a definitive agreement. Even if we enter into </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">a definitive agreement, we may not be successful in completing a transaction or, if we complete such a transaction, it may not enhance stockholder value or deliver expected benefits. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Any strategic alternatives may involve or may be pursued through legal proceedings including bankruptcy or liquidation and dissolution proceedings, and such proceedings may also be necessary or appropriate in the absence of any strategic alternatives. In the event that our board of directors determines that a liquidation and dissolution of our business approved by stockholders is desirable or the best method to maximize value, we would prepare proxy materials and schedule a special meeting of our stockholders to seek approval of such a plan. For a discussion of the actions we have taken to date in connection with our cash preservation Plan, please see &#8220;Business &#8211; Recent Developments &#8211; 2025 Cash Preservation Plan.&#8221;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">If we do not successfully identify a strategic alternative or, if such a strategic alternative is identified, consummate such a transaction, it is highly unlikely that there will be cash available for distribution to our stockholders.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our available cash resources continue to decrease in connection with our wind down activities as we evaluate our strategic alternatives.  There can be no assurance that the process to identify a strategic alternative for our business will result in a successfully consummated transaction. If we do not successfully identify a strategic alternative or, if such a strategic alternative is identified, it is highly unlikely that there will be cash available for distribution to our stockholders. Accordingly, holders of our common stock and other securities would lose all of their investment in the company.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Even if we do consummate a strategic alternative, the amount of cash available for distribution to our stockholders, if any, will depend heavily on the proceeds derived from the strategic transaction, the timing of any distribution to stockholders, whether as a dividend or through a liquidation and dissolution of our business, as well as the amount of cash that will need to be reserved for commitments and contingent liabilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Even if we do consummate a strategic alternative, the amount of cash available for distribution to our stockholders, if any, will depend heavily on the proceeds derived from the strategic transaction, the timing of any distribution to stockholders, whether as a dividend or through a liquidation and dissolution of our business, as well as the amount of cash that will need to be reserved for commitments and contingent liabilities. Our available cash resources continue to decrease in connection with our wind down activities as we evaluate our strategic alternatives. We cannot assure our stockholders of any recovery, or any specific level of recovery, on their claims and interests if we were to determine to pay a dividend or seek a liquidation or dissolution in connection with a strategic transaction. Our estimates of these amounts may be inaccurate. Accordingly, holders of our common stock and other securities could lose all or a significant portion of their investment in the company.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We may elect to commence bankruptcy or liquidation and dissolution proceedings, and such proceedings may delay our wind down timeframe, increase our costs, and decrease the cash, if any, that may be available for stockholders. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Any strategic alternatives may involve or may be pursued through legal proceedings including bankruptcy or liquidation and dissolution proceedings, and such proceedings may also be necessary or appropriate in the absence of any strategic alternatives. In the event that our board of directors determines that a liquidation and dissolution of our business approved by stockholders is desirable or the best method to maximize value, we would prepare proxy materials and schedule a special meeting of our stockholders to seek approval of such a plan. Any such proceedings may increase the timeframe for executing strategic alternative transactions or otherwise winding down the company, may increase the costs of those actions, and may decrease the cash, if any, that may be available for stockholders.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We may experience difficulties, delays or unexpected costs and not achieve anticipated benefits and savings from our cash preservation plan, and our wind down activities may adversely affect our ability to consummate a strategic transaction that enhances stockholder value.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of our cash preservation plan, our board of directors determined to terminate all of our employees not deemed necessary to pursue strategic alternatives and execute an orderly wind down of our operations. The reduction in workforce was effective on March 31, 2025. The reduction in workforce includes 37 of our full-time employees (representing approximately 84% of our total workforce), including certain employees engaged in research and development, manufacturing and corporate activities. We expect to incur approximately $3.8 million in connection with the reduction in workforce, which primarily represents one-time employee termination benefits directly associated with the workforce reduction. We also expect to pay the majority of related reduction in workforce amounts by the end of this year. We may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, this reduction in workforce.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">While we have retained employees we deemed necessary to pursue strategic alternatives and execute an orderly wind down of our operations, the reduction in workforce resulted in the loss of a number of long-term employees, the loss of institutional knowledge and expertise, and the reallocation of certain job responsibilities, all of which could negatively </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">affect operational efficiencies and increase our operating expenses such that we may not fully realize anticipated savings from the wind down and complete a potential strategic transaction on terms that are favorable to us, or at all. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Further, if we were to resume research and development activities, this reduction in workforce could also make it difficult for us to pursue, or prevent us from pursuing, new opportunities and initiatives due to insufficient personnel, or require us to incur additional and unanticipated costs to hire new personnel to pursue such opportunities or initiatives. If we are unable to realize the anticipated benefits from the reduction in force, or if we experience significant adverse consequences from the reduction in force, our business, financial condition and results of operations may be materially adversely affected.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We will be substantially dependent on our remaining employees and consultants, along with any other advisors and consultants we may engage, to facilitate the consummation of a strategic transaction.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with our cash preservation plan, we have terminated all but seven of our employees as of March 31, 2025. Our ability to successfully identify, evaluate and pursue a strategic alternative and any consummation of such a transaction depends in large part on our ability to retain our remaining employees and consultants along with any other advisors and consultants we may engage. One or more may terminate their engagement with us on short notice. It is also possible that we will determine to undertake future reductions in workforce. The loss of the services of any of these individuals could potentially harm our ability to identify, evaluate and pursue strategic alternatives, as well as engage in orderly wind down activities fulfill our continuing reporting obligations as a public company.</span></div><div><span><br/></span></div><div><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We may become involved in securities class action litigation that could divert management&#8217;s attention and harm our business, and insurance coverage may not be sufficient to cover all costs and damages.</span></div><div><span><br/></span></div><div><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the past, securities class action litigation has often followed certain significant business transactions, such as the sale of a company or announcement of any other strategic transaction, or the announcement of negative events, such as negative regulatory decisions or a determination to wind down operations. These events may also result in investigations by the Securities and Exchange Commission. We may be exposed to such litigation or investigation even if no wrongdoing occurred. Litigation and investigations are usually expensive and divert management&#8217;s attention and resources, which could adversely affect our cash resources and our ability to consummate a potential strategic transaction.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div><span><br/></span></div><div><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Any future resumption of research and development activities would depend on completing a strategic transaction that would support our prior operating plans or otherwise obtaining significant additional funding. Significant additional financing may not be available to us on acceptable terms, or at all. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">While we currently have no intention of resuming research and development activities, any future resumption of such activities would depend on completing a strategic transaction that would support our prior operating plans or otherwise obtaining significant additional funding. Our exploration of strategic alternatives may not result in the consummation of any transaction that provides additional funding to our company.</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Significant additional financing may not be available to us on acceptable terms, or at all, and may be impacted by the economic climate and market conditions. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To the extent that we are able to raise additional capital through the public or private sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of those securities may include liquidation or other preferences that adversely affect your rights as a holder of our common stock. Debt financing and preferred equity financing, if available, would increase our fixed payment obligations and may involve agreements that include covenants limiting or restricting our operations and ability to take specific actions, such as incurring additional debt, making acquisitions, engaging in acquisition, merger or collaboration transactions, selling or licensing our assets, making capital expenditures, redeeming our stock, making certain investments, declaring dividends or other operating restrictions that could adversely impact our ability to conduct business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are able to raise funds through</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a strategic collaboration or partnership with one or more parties, we may have to relinquish valuable rights to our intellectual property, future revenue streams, discovery programs or product candidates, grant licenses on terms that may not be favorable to us or grant rights to develop and market product candidates that we would otherwise prefer to develop and market on our own, any of which may have a material adverse effect on our business, operating results and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we were to resume research and development activities, our future capital requirements will depend on many factors, including:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the progress, costs and results of pre-clinical testing of our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the progress, costs and results of clinical trials of our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the number of and development requirements for additional indications for our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the success of our collaborations with Moderna or others;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to scale up our manufacturing processes and capabilities to support clinical trials of the product candidates we are developing and may develop in the future;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the costs, timing and outcome of regulatory review of our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">potential changes in the regulatory environment and enforcement rules;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such arrangements;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the payment of license fees and other costs of our technology license arrangements;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the costs and timing of future commercialization activities, including product manufacturing, sales, marketing and distribution, for our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to obtain and maintain acceptance of any approved products by patients, the medical community and third-party payors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the amount and timing of revenue, if any, received from commercial sales of any of our product candidates for which we receive marketing approval;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">potential changes in pharmaceutical pricing and reimbursement infrastructure;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the availability of raw materials for use in production of our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property and proprietary rights and defending any intellectual property-related claims; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the extent to which we in-license or acquire additional technologies or product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant losses since our inception. We have very limited cash resources remaining and a very short operating runway before we deplete our cash resources. We expect to continue to incur significant expenses and operating losses while we explore strategic alternatives and carry out the orderly wind down of our operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred significant operating losses. Our net losses were </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$60.5 million and $86.9 million for the years ended December 31, 2024 and 2023, respectively</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We expect to continue to incur significant expenses and operating losses while we explore strategic alternatives and carry out the orderly wind down of our operations, including the payment one-time employee termination benefits to terminated employees. We may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, our reduction in workforce.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December 31, 2024, we had cash and cash equivalents of $17.9 million. Although we believe that our current cash and cash equivalents are sufficient to sustain our operating expenses and capital expenditures requirements into the second half of 2025, we do not expect that our cash and cash equivalents will support our operations for more than one year following the date of this Annual Report on Form 10-K. As a result of these conditions, substantial doubt exists about our ability to continue as a going concern. We have based this estimate on assumptions that may prove to be wrong. In addition, changing circumstances could cause us to consume capital significantly faster than we currently anticipate, and we may need to spend more than currently expected because of circumstances beyond our control. As a result, we could deplete our capital resources sooner than we currently expect, including before we are able to consummate a strategic alternative. Our exploration of strategic alternatives may not result in the consummation of any transaction that provides additional funding to our company.    </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not yet commercialized any products or generated any revenue from product sales and have financed our operations primarily with proceeds from sales of our preferred stock, proceeds from our collaboration with Moderna, research tax credits, convertible debt financing and completion of the Merger and related financing. Because Moderna nominated all 12 oncology research targets under the collaboration agreement as of February 2025, we will no longer be conducting any additional research activities under the collaboration agreement and we will not be receiving any further payments from Moderna for research and development services under the collaboration agreement. Significant additional financing may not be available to us on acceptable terms, or at all, and may be impacted by the economic climate and market conditions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically devoted substantially all of our financial resources and efforts to pursuing discovery, research and early clinical development of our product candidates. As part of our cash preservation plan, we determined to pause all of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our research and development activities. Although we currently have no intention of resuming research and development activities, any future resumption of research and development activities would depend on completing a strategic transaction that would support our prior operating plans or otherwise obtaining significant additional funding.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we were to resume research and development activities, we anticipate that our expenses will increase substantially if and as we:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enhance the capabilities of our CAR-M platform;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conduct discovery and pre-clinical testing of our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">submit investigational new drug, or IND, applications in order to commence clinical trials;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">initiate, enroll patients in and conduct clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conduct discovery and pre-clinical testing of our autologous cell therapy pipeline to gather information to apply to the development of off-the-shelf engineered macrophage therapeutics;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">develop iPSC-derived CAR-M, and other macrophage therapies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">develop </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reprogrammed mRNA/LNP CAR-M therapies for cancer;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">develop viral vectors to effectively engineer human monocytes and macrophages, including the Vpx lentiviral vector and our Ad5f35 vector;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek marketing approval for our product candidates if we successfully complete clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">scale up our external manufacturing capabilities and capabilities to support clinical trials of our product candidates and for commercialization of any product candidate for which we may obtain marketing approval;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish a sales, marketing and distribution infrastructure to commercialize any product candidate for which we may obtain marketing approval;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in-license or acquire additional technologies or product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make any payments under our existing or future strategic collaboration agreements, global exclusive rights licensing agreements or sponsored research agreements, including with Moderna;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain, expand, enforce and protect our intellectual property portfolio;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire additional clinical, regulatory, manufacturing, quality control, development and scientific personnel; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add operational, financial and management information systems and personnel, including personnel to support our discovery, product development and planned future commercialization efforts and our operations as a public company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve or maintain profitability. If we were to resume our research and development activities, our expenses could increase beyond our expectations if, among other things:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we are required by regulatory authorities in the United States, Europe, or other jurisdictions to perform trials or studies in addition to, or different than, those that we currently expect;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">there are any delays in establishing appropriate manufacturing arrangements for or completing the development of any of our product candidates; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">there are any third-party challenges to our intellectual property or our needs to defend against any intellectual property-related claim.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain marketing approval for and are successful in commercializing one or more of our product candidates, we expect to incur substantial additional discovery and product development and other expenditures to develop and market additional product candidates or to expand the approved indications of any marketed product. We may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our independent registered public accounting firm has included an explanatory paragraph relating to our ability to continue as a going concern in its report on our audited consolidated financial statements included in this Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The report from our independent registered public accounting firm for the year ended December 31, 2024 includes an explanatory paragraph stating that our recurring losses raise substantial doubt about our ability to continue as a going concern. In connection with our cash preservation plan, we expect to continue to incur significant expenses and operating losses while we explore strategic alternatives and carry out the orderly wind down of our operations. Our exploration of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">strategic alternatives may not result in the consummation of any transaction that provides additional funding to our company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span></div><div><span><br/></span></div><div><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We may retain a financial advisor to advise on our exploration of a range of strategic alternatives. We plan to identify and evaluate potential strategic alternatives with the goal of maximizing the value of our assets, including CT-2401, CT-1119, our macrophage and monocyte engineering platform and our CAR-M platform and realizing value for the potential milestone and royalty payments under the Moderna collaboration. However, our exploration of strategic alternatives may not result in the consummation of any transaction or the realization of any value for our company or our stockholders.</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we are unable to continue as a going concern, we may have to liquidate our assets and may receive less than the value at which those assets are carried on our audited financial statements, and it is likely that investors will lose all or a part of their investment. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We have never generated revenue from product sales and may never achieve or maintain profitability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Prior to pausing research and development activities, we were in the early stages of development of our product candidates. If we were to resume research and development activities, we expect that it will be a number of years, if ever, before we have a product candidate ready for commercialization. To become and remain profitable, we must succeed in completing development of, obtaining marketing approval for and eventually commercializing, one or more products that generate significant revenue. The ability to achieve this success would require us to be effective in a range of challenging activities, including completing pre-clinical testing and clinical development, timely filing and receiving acceptance of our IND applications in order to commence clinical trials, initiating, enrolling patients in and completing clinical development of our product candidates, scaling up our manufacturing processes and capabilities to support clinical trials, obtaining marketing approval for our product candidates, manufacturing, marketing and selling any products for which we may obtain marketing approval and maintaining a continued acceptable safety profile of our products following approval. We may never succeed in these activities and, even if we do, we may never generate revenues that are significant enough to achieve profitability.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we were to achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our discovery and product development efforts, diversify our pipeline of product candidates or even continue our operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our limited operating history and our cash preservation plan may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We were formed as Carma Therapeutics LLC, a Pennsylvania limited liability company, in April 2016 and converted to a Delaware corporation in May 2017 under the name CARISMA Therapeutics Inc. In connection with the Merger consummated in March 2023, CARISMA Therapeutics Inc. merged with and into a wholly-owned subsidiary of Sesen Bio and was renamed &#8220;CTx Operations, Inc.&#8221; Sesen Bio's name was changed to &#8220;Carisma Therapeutics Inc.&#8221; Following the completion of the Merger, the business conducted by the public company became primarily the business conducted by us. We are a biotechnology company with a limited operating history. Cell therapy product development is a highly speculative undertaking and involves a substantial degree of risk. Our operations historically have been limited to organizing and staffing our company, business planning, capital raising, establishing and maintaining our intellectual property portfolio, building our pipeline of product candidates, conducting drug discovery activities, undertaking pre-clinical studies, manufacturing process development studies, conducting early-stage clinical trials, and providing general and administrative support for these operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with our cash preservation plan, we have reduced our operations to those necessary to identify and explore a range of strategic alternatives to maximize value and prepare to wind down our business. Potential strategic alternatives to be explored and evaluated may include, among other transactions, the sale, license, monetization or divestiture of one or more of our assets or technologies, a strategic collaboration or partnership with one or more parties or the merger or sale of our company. We cannot provide any commitment regarding when or if this strategic review process will result in any type of transaction. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We currently have no intention of resuming research and development activities. Any future resumption of research and development activities would depend on completing a strategic transaction that would support our prior operating plans or otherwise obtaining significant additional funding.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of our cash preservation plan, our board of directors determined to terminate all of our employees not deemed necessary to pursue strategic alternatives and execute an orderly wind down of our operations.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our prospects must be considered in light the foregoing and in light of the uncertainties, risks, expenses and difficulties frequently encountered by companies in their early stages of operations. Prior to pausing our research and development </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">activities, we had not yet demonstrated our ability to successfully develop any product candidate, obtain marketing approvals, manufacture a commercial scale product or arrange for a third party to do so on our behalf, or conduct sales, marketing and distribution activities necessary for successful product commercialization. We may retain a financial advisor to advise on our exploration of a range of strategic alternatives. We plan to identify and evaluate potential strategic alternatives with the goal of maximizing the value of our assets, including CT-2401, CT-1119, our macrophage and monocyte engineering platform and our CAR-M platform and realizing value for the potential milestone and royalty payments under the Moderna collaboration. Our exploration of strategic alternatives may not result in the consummation of any transaction or the realization of any value for our company or our stockholders.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Consequently, any predictions you make about our future success or viability may not be as accurate. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown obstacles. If resume research and clinical activities, we will need to transition at some point from a company with a discovery and pre-clinical focus to a company capable of supporting commercial activities. We may not be successful in such a transition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our financial condition and operating results to fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any quarterly or annual periods as indications of future operating performance.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax law may adversely affect us or our investors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rules dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service, and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many such changes have been made and changes are likely to continue to occur in the future. It cannot be predicted whether, when, in what form or with what effective dates tax laws, regulations and rulings may be enacted, promulgated or issued, which could result in an increase in our or our stockholders&#8217; tax liability or require changes in the manner in which we operate in order to minimize or mitigate any adverse effects of changes in tax law. Prospective investors should consult their tax advisors regarding the potential consequences of changes in tax law on our business and on the ownership and disposition of our common stock.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating losses and research and development tax credit carryforwards to offset future taxable income may be subject to certain limitations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Merger, we had a history of cumulative losses and anticipate that we will continue to incur significant losses in the foreseeable future. As a result, we do not know whether or when we will generate taxable income necessary to utilize our net operating losses, or NOLs, or research and development tax credit carryforwards. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, under Section 382 of the Code and corresponding provisions of state law, a corporation that undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50 percentage point change (by value) in our equity ownership by certain stockholders over a three-year period, is subject to limitations on our ability to utilize our pre-change NOLs and research and development tax credit carryforwards to offset future taxable income. We have not conducted a study to assess whether any such ownership changes have occurred. We may have experienced such ownership changes in the past and may experience such ownership changes in the future (which may be outside our control). As a result, if and to the extent we earn net taxable income, our ability to use our pre-change NOLs and research and development tax credit carryforwards to offset such taxable income may be subject to limitations.</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">***</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We currently have no intention of resuming research and development activities independently or as a standalone company, and the following are risks primarily relating to our prior operations and historical activities, unless otherwise noted. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Historical Discovery Programs and Research and Development of Our Product Candidates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cell therapy is a rapidly evolving area of science, and the approach we have taken to discover and develop product candidates by utilizing genetically modified macrophages and monocytes is novel and may never lead to approved or marketable products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cell therapy has yet to be broadly applied to solid tumors, inflammatory disease, fibrotic disease or neurodegeneration. The discovery, research and development of engineered macrophages and monocytes to treat disease is an emerging field and our CAR-M platform, which is the first CAR-M to be evaluated in a human clinical trial, is a relatively new technology. Our future success depends on the successful development of this novel therapeutic approach. The scientific evidence to support the feasibility of developing product candidates based on these discoveries is both preliminary and limited. As such, there may be adverse effects or limited favorable results from treatment with any of our product candidates that we cannot predict at this time.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success also depends on our successful application of our proprietary macrophage engineering platform in the combination setting and to other indications by reprogramming the target specificity of our CAR-M cell product and developing product candidates against a plethora of tumor associated antigens, including in therapeutic areas beyond oncology. However, our macrophage engineering platform may not allow us to generate new INDs to expand our pipeline on our anticipated timeline or in a cost-efficient manner or at all, which could cause the potential value of our business to decline and materially harm our business prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these factors, it is more difficult for us to predict the time and cost of product candidate development, and we cannot predict whether the application of macrophage engineering platform will result in the development and marketing approval of any products. Any development problems we experience in the future related to our macrophage engineering platform or any of our discovery programs may cause significant delays or unanticipated costs or may prevent the development of a commercially viable product. Any of these factors may prevent us from completing our clinical trials or pre-clinical studies or commercializing any product candidates we may develop on a timely or profitable basis, if at all.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are early in our development efforts. If we are unable to commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed.<br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are early in our development efforts.  Prior to pausing research and development activities as part of our cash preservation plan, we were focusing our development efforts on CT-2401, our product candidate in development for liver fibrosis, and CT-1119, our product candidate in development for mesothelin-positive solid tumors. We have not initiated clinical development of either CT-2401 or CT-1119. We had planned to conduct pre-clinical development of CT-2401 sufficient to enable a regulatory submission to initiate a clinical trial. We had also planned to initiate a Phase 1 clinical trial of CT-1119, a mesothelin-targeted CAR-Monocyte, in combination with tislelizumab, an anti-PD-1 antibody, in adult patients with mesothelin-positive solid tumors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to generate revenues from product sales, which we do not expect will occur for a number of years, if ever, will depend heavily on the successful development, marketing approval and eventual commercialization of our product candidates, which may never occur. The success of our product candidates will depend on many factors, including the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully completing pre-clinical studies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">timely filing and receiving clearance of IND applications to commence clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully initiating, enrolling patients in and completing clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">scaling up manufacturing processes and capabilities to support clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">applying for and receiving marketing approvals from applicable regulatory authorities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining intellectual property protection and regulatory exclusivity for our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">making arrangements with third-party manufacturers, or establishing commercial manufacturing capabilities, for both clinical and commercial supplies of our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing sales, marketing and distribution capabilities and launching commercial sales of our products, if and when approved, whether alone or in collaboration with others;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of our product candidates, if and when approved, by patients, the medical community and third-party payors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effectively competing with other therapies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining coverage, adequate pricing and adequate reimbursement from third-party payors, including government payors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining, enforcing, defending and protecting our rights in our intellectual property portfolio;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">not infringing, misappropriating or otherwise violating others&#8217; intellectual property or proprietary rights; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining a continued acceptable safety profile of our products following receipt of any marketing approvals.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully develop and commercialize our product candidates, which would materially harm our business. As a company, we have limited experience in clinical development. Any predictions about the future success or viability of our product candidates we are developing or may develop in the future may not be as accurate as they could be if we had a longer history of conducting clinical trials.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Drug development involves a lengthy and expensive process, with an uncertain outcome. The results of pre-clinical studies and early clinical trials may not be predictive of future results. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk of failure for our product candidates is high. It is impossible to predict when or if any of our product candidates will prove effective or safe in humans or will receive marketing approval. Before obtaining marketing approval from regulatory authorities for the sale of a product candidate, we must complete pre-clinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of such product candidate in humans. Clinical trials may fail to demonstrate that our product candidates are safe for humans and effective for indicated uses. Even if the clinical trials are successful, changes in marketing approval policies during the development period, changes in or the enactment or promulgation of additional statutes, regulations or guidance or changes in regulatory review for each submitted product application may cause delays in the approval or rejection of an application.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before we can commence clinical trials for a product candidate, we must complete extensive pre-clinical testing and studies, manufacturing process development studies, and analytical development studies that support our planned INDs and other applications to regulatory authorities in the United States or similar applications in other jurisdictions. We cannot be certain of the timely completion or outcome of our pre-clinical testing and studies and cannot predict if the outcome of our pre-clinical testing and studies will ultimately support the further development of our product candidates or whether regulatory authorities will accept our proposed clinical programs. As a result, we may not be able to submit applications to initiate clinical development of product candidates on the timelines we expect, if at all, and the submission of these applications may not result in regulatory authorities allowing clinical trials to begin. Furthermore, product candidates are subject to continued pre-clinical safety studies, which may be conducted concurrently with our clinical testing. The outcomes of these safety studies may delay the launch of or enrollment in future clinical trials and could impact our ability to continue to conduct our clinical trials.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to the outcome. We cannot guarantee that any of our clinical trials will be conducted as planned or completed on schedule, or at all. A failure of one or more clinical trials can occur at any stage of testing, which may result from a multitude of factors, including, among other things, flaws in study design, dose selection issues, placebo effects, patient enrollment criteria and failure to demonstrate favorable safety or efficacy traits.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, pre-clinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in pre-clinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. Furthermore, the failure of any of our product candidates to demonstrate safety and efficacy in any clinical trial could negatively impact the perception of our other product candidates or cause regulatory authorities to require additional testing before approving any of our product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize any product candidates, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators or institutional review boards, or IRBs, may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site or at all;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators may determine that the planned design of our clinical trials is flawed or inadequate;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to establish clinical endpoints that applicable regulatory authorities consider clinically meaningful, or, if we seek accelerated approval, biomarker efficacy endpoints that applicable regulatory authorities consider likely to predict clinical benefit;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pre-clinical testing may produce results based on which we may decide, or regulators may require us, to conduct additional pre-clinical studies before we proceed with certain clinical trials, limit the scope of our clinical trials, halt clinical trials or abandon product development programs;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate (including because of a decrease in the pool of available patients) or participants may drop out of these clinical trials at a higher rate than we anticipate;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may decide, or regulators or IRBs may require us, to suspend or terminate clinical trials of our product candidates for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators or IRBs may require us to perform additional or unanticipated clinical trials to obtain approval or we may be subject to additional post-marketing testing requirements to maintain marketing approval;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators may revise the requirements for approving our product candidates, or such requirements may not be as we anticipate;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of clinical trials of our product candidates may be greater than we anticipate;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our clinical investigators, regulators or IRBs to suspend or terminate the trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators may withdraw their approval of a product or impose restrictions on its distribution; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">business interruptions resulting from any health epidemics, pandemics or other contagious outbreaks may result in adverse effects on our business and operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive, if there are safety concerns or if we determine that the observed safety or efficacy profile would not be competitive in the marketplace, we may:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incur unplanned costs;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be delayed in obtaining marketing approval for our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">not obtain marketing approval at all;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain marketing approval in some countries and not in others;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain approval for indications or patient populations that are not as broad as intended or desired;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be subject to additional post-marketing testing requirements; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">have the product removed from the market after obtaining marketing approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product development costs will also increase if we experience delays in pre-clinical studies or clinical trials or in obtaining marketing or other regulatory approvals. We do not know whether any of our pre-clinical studies or clinical trials will begin timely, will need to be restructured or will be completed on schedule, or at all. We may also determine to change the design or protocol of one or more of our clinical trials, including to add additional patients or arms, which could result in increased costs and expenses or delays. Significant pre-clinical study or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, the FDA&#8217;s and other regulatory authorities&#8217; policies with respect to clinical trials may change and additional government regulations may be enacted. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies governing clinical trials, our development plans may be impacted. For example, in December 2022, with the passage of the Food and Drug Omnibus Reform Act of 2022, or FDORA, Congress required </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">sponsors to develop and submit a diversity action plan, or DAP, for each phase 3 clinical trial or any other &#8220;pivotal study&#8221; of a new drug or biological product. These plans are meant to encourage the enrollment of more diverse patient populations in late-stage clinical trials of FDA-regulated products. Specifically, DAPs must include the sponsor&#8217;s goals for enrollment, the underlying rationale for those goals, and an explanation of how the sponsor intends to meet them. In June 2024, as mandated by FDORA, the FDA issued draft guidance outlining the general requirements for DAPs. Unlike most guidance documents issued by the FDA, the DAP guidance when finalized will have the force of law because FDORA specifically dictates that the form and manner for submission of DAPs are specified in FDA guidance.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, the regulatory landscape related to clinical trials in the European Union recently evolved. The EU Clinical Trials Regulation, or the EU-CTR, which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January 31, 2022. While the Clinical Trials Directive required a separate Clinical Trial Application, or CTA, to be submitted in each member state, to both the competent national health authority and an independent ethics committee, the EU-CTR introduces a centralized process and only requires the submission of a single application to all member states concerned. The EU-CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#8217;s decision is communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed. If we are not able to adapt to these and other changes in existing requirements or the adoption of new requirements or policies governing clinical trials, our development plans may be impacted.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, cancer therapies are sometimes characterized as first-line, second-line, or third-line, and the FDA often approves new therapies initially only for second-line or third-line use. When cancer is detected early enough, first-line therapy, usually hormone therapy, surgery, radiation therapy, chemotherapy or a combination of these, is sometimes adequate to cure the cancer or prolong life without a cure. Second- and third-line therapies are administered to patients when prior therapy is not effective. For any of our products that prove to be sufficiently beneficial, we would expect to seek approval potentially as a first-line therapy, but any product candidates we develop, even if approved, may not be approved for first-line therapy, and, prior to any such approvals, we may have to conduct additional clinical trials.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may conduct clinical trials at sites outside the United States. The FDA may not accept data from trials conducted in such locations, and the conduct of trials outside the United States could subject us to additional delays and expense. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may conduct one or more clinical trials with one or more trial sites that are located outside the United States. The acceptance by the FDA or other regulatory authorities of study data from clinical trials conducted outside their jurisdiction may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the U.S., the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S. medical practice; (ii) the trials were performed by clinical investigators of recognized competence and pursuant good clinical practices, or to GCP, regulations; and (iii) the data may be considered valid without the need for an on-site inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, even where the foreign study data are not intended to serve as the sole basis for approval, the FDA will not accept the data as support for an application for marketing approval unless the study is well-designed and well-conducted in accordance with GCP requirements and the FDA is able to validate the data from the study through an onsite inspection if deemed necessary. Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the U.S. or the applicable jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which could be costly and time-consuming, and which may result in current or future product candidates that we may develop not receiving approval for commercialization in the applicable jurisdiction.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conducting clinical trials outside the U.S. also exposes us to additional risks, including risks associated with: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">additional foreign regulatory requirements; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">foreign exchange fluctuations; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">compliance with foreign manufacturing, customs, shipment and storage requirements; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">cultural differences in medical practice and clinical research; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">diminished protection of intellectual property in some countries; and </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">interruptions or delays in our trials resulting from geopolitical events, such as war or terrorism.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The results of early-stage clinical trials and pre-clinical studies may not be predictive of future results. Initial success in clinical trials may not be indicative of results obtained when these trials are completed or in later stage trials.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outcome of pre-clinical testing and early clinical trials may not be predictive of the success of later clinical trials, and preliminary or interim results of a clinical trial do not necessarily predict final results. In addition, initial success in clinical trials may not be indicative of results obtained when such trials are completed. In particular, the small number of patients in our early clinical trials may make the results of these trials less predictive of the outcome of later clinical trials. Our product candidates may also fail to show the desired safety and efficacy in clinical development despite positive results in pre-clinical studies or having successfully advanced through initial clinical trials.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, pre-clinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in pre-clinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. Our clinical trials may not ultimately be successful or support further clinical development of any of our product candidates and we cannot assure you that any clinical trials that we may conduct will demonstrate consistent or adequate efficacy and safety to support marketing approval. There is a high failure rate for product candidates proceeding through clinical trials. Many companies in the biopharmaceutical industry have suffered significant setbacks in late-stage clinical trials even after achieving promising results in pre-clinical testing and earlier-stage clinical trials, and we cannot be certain that we will not face similar setbacks. Any such setbacks in our clinical development could materially harm our business and results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim and preliminary results from our clinical trials that we announce or publish from time to time may change as more participant data become available and are subject to audit and verification procedures, which could result in material changes in the final data.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may announce or publish interim or preliminary results from our clinical trials. Interim results from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as participant enrollment continues and more participant data become available. We also make assumptions, estimations, calculations, and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully evaluate all data. Preliminary or interim results also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could be material and could significantly harm our reputation and business prospects and may cause the trading price of our common stock to fluctuate significantly.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we experience delays or difficulties in the enrollment of patients in our clinical trials for any of our product candidates, our receipt of necessary marketing approvals could be delayed or prevented.<br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Identifying and qualifying patients to participate in our clinical trials of any of our product candidates in the future is critical to our success. Successful and timely completion of clinical trials will require that we enroll a sufficient number of patients who remain in the trial until its conclusion. We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside of the United States.  In addition, some of our competitors have ongoing clinical trials for product candidates that treat the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; product candidates. We cannot predict how successful we will be at enrolling subjects in future clinical trials. Patient enrollment is affected by a variety of other factors, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of the disease under investigation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the eligibility criteria for the trial in question;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the perceived risks and benefits of the product candidate under trial;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the requirements of the trial protocols;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of existing treatments for the indications for which we are conducting clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efforts to facilitate timely enrollment in clinical trials;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to identify specific patient populations based on specific genetic mutations or other factors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patient referral practices of physicians;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to monitor patients adequately during and after treatment;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain patient consents;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the proximity and availability of clinical trial sites for prospective patients;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the conduct of clinical trials by competitors for product candidates that treat the same indications or address the same patient populations as our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost to, or lack of adequate compensation for, prospective patients; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the impact of any health epidemics, pandemics or other contagious outbreaks.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to locate and enroll a sufficient number of patients for our clinical trials would result in significant delays, could require us to abandon one or more clinical trials altogether and could delay or prevent our receipt of necessary marketing approvals. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, which could cause the value of our business to decline and limit our ability to obtain additional financing.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If serious adverse events, undesirable side effects or unexpected characteristics are identified during the development of any of our product candidates, we may need to abandon or limit our further clinical development of those product candidates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If any of our product candidate are associated with serious adverse events or undesirable side effects in clinical trials or have characteristics that are unexpected in clinical trials or pre-clinical testing, we may need to abandon development of such product candidate or limit development to more narrow uses or subpopulations in which the serious adverse events, undesirable side effects or unexpected characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. In pharmaceutical development, many compounds that initially show promise in early-stage or clinical testing are later found to cause side effects that delay or prevent further development of the compound or decrease the size of the patient population for whom the compound could ultimately be prescribed. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if results of our clinical trials reveal undesirable side effects, we, regulatory authorities or the IRBs at the institutions in which our studies are conducted could suspend or terminate our clinical trials, regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications or we could be forced to materially modify the design of our clinical trials. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete any of our clinical trials or result in potential liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we elect or are forced to suspend or terminate any clinical trial of our product candidates, the commercial prospects of such product candidate will be harmed, and our ability to generate revenues from sales of such product candidate will be delayed or eliminated. Any of these occurrences could materially harm our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If any of our product candidates receives marketing approval and we, or others, later discover that the drug is less effective than previously believed or causes undesirable side effects that were not previously identified, our ability to market the drug could be compromised.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials will be conducted in carefully defined subsets of patients who have agreed to enter into clinical trials. Consequently, it is possible that our clinical trials may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable side effects. If one or more of our product candidates receives marketing approval, and we, or others, later discover that they are less effective than previously believed, or cause undesirable side effects, a number of potentially significant negative consequences could result, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal or limitation by regulatory authorities of approvals of such product;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seizure of the product by regulatory authorities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recall of the product;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing of the product or the manufacturing process for any component thereof;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requirement by regulatory authorities of additional warnings on the label;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requirement that we implement a risk evaluation and mitigation strategy or create a medication guide outlining the risks of such side effects for distribution to patients;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commitment to expensive post-marketing studies as a prerequisite of approval by regulatory authorities of such product;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product may become less competitive;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiation of regulatory investigations and government enforcement actions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiation of legal action against us to hold us liable for harm caused to patients; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">harm to our reputation and resulting harm to physician or patient acceptance of our products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us from achieving or maintaining market acceptance of a particular product candidate, if approved, and could significantly harm our business, financial condition, and results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Because we have limited financial and managerial resources, we have historically focused on discovery programs and product candidates that we identify for specific indications. As a result, we have and may in the future forego or delay the pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. For example, in 2024, we determined to cease further development of CT-0525 and CT-0508 to refocus our efforts on other strategic priorities at the time. In the future we may further curtail, pause, delay or cease development of other product candidates at any stage of pre-clinical or clinical development based on a variety of factors, including our judgments regarding costs or timing of further development, probability of success of pre-clinical and clinical development, regulatory requirements, competitive landscapes, commercial potential, relative benefits and costs compared to other product candidates in our portfolio, and our overall strategy. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our resource allocation decisions in the future may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Spending on discovery and product development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. Failure to allocate resources or capitalize on strategies in a successful manner will have an adverse impact on our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of our cash preservation plan, we have reduced our operations to those necessary to identify and explore a range of strategic alternatives to maximize value and prepare to wind down our business. We plan to work on identifying and evaluating potential strategic alternatives with the goal of maximizing the value of our assets, including CT-2401, CT-1119, our macrophage and monocyte engineering platform and our CAR-M platform and realizing value for the potential milestone and royalty payments under the Moderna collaboration. However, our exploration of strategic alternatives may not result in the consummation of any transaction or the realization of any value for our company or our stockholders.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may evaluate certain of our product candidates in combination with other drugs. If the FDA or similar regulatory authorities outside of the United States do not approve these other drugs, revoke their approval of such drugs, or if safety, efficacy, manufacturing or supply issues arise with the drugs we choose to evaluate in combination with our product candidates, we may be unable to obtain approval of our product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We may evaluate certain of our product candidates in combination with other drugs. For example, prior to pausing research and development activities, we planned to initiate a Phase 1 clinical trial of CT-1119, in combination with tislelizumab, in adult patients with mesothelin-positive solid tumors.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have not developed or obtained marketing approval for, nor have we manufactured or sold, any approved drug that we may study in combination with our product candidates. If the FDA or similar regulatory authorities outside of the United States revokes their approval of any drug or drugs in combination with which we determine to develop any of our product candidates, we will not be able to market such product candidates in combination with such revoked drugs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If safety or efficacy issues arise with any of these drugs, we could experience significant regulatory delays, and the FDA or similar regulatory authorities outside of the United States may require us to redesign or terminate the applicable clinical trials. If the drugs we use are replaced as the standard of care for the indications we choose for our product candidates, the FDA or similar regulatory authorities outside of the United States may require us to conduct additional clinical trials. In addition, if manufacturing or other issues result in a shortage of supply of the drugs with which we determine to combine with any of our product candidates, we may not be able to initiate or complete clinical development of such product candidates on a desired timeline or at all.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if any of our product candidates were to receive marketing approval or be commercialized for use in combination with other existing drugs, we would continue to be subject to the risks that the FDA or similar regulatory authorities </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outside of the United States could revoke approval of the drugs used in combination with our product candidates or that safety, efficacy, manufacturing or supply issues could arise with these existing drugs. Combination therapies are commonly used for the treatment of cancer, and we would be subject to similar risks if we develop any of our other product candidates for use in combination with other drugs for cancer or for indications other than cancer. This could result in our own products being removed from the market or being less successful commercially.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in our efforts to identify or discover additional potential product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A key element of our strategy is to apply our macrophage engineering platform to address a broad array of indications and targets to generate next-generation therapeutics, including programs for indications outside of liver fibrosis and oncology. The discovery efforts that we are conducting may not be successful in identifying product candidates that are useful in treating cancer or other diseases. Our discovery engine may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential product candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be drugs that will receive marketing approval or achieve market acceptance; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential product candidates may not be effective in treating their targeted diseases.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discovery programs to identify new product candidates require substantial technical, financial and human resources. We may choose to focus our efforts and resources on a potential product candidate that ultimately proves to be unsuccessful. If we are unable to identify additional suitable product candidates for pre-clinical and clinical development, it will limit our potential to obtain revenues from sale of products in future periods, which likely would result in significant harm to our financial position and adversely impact our stock price.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adverse public perception of genetic medicine, and gene therapy in particular, may negatively impact regulatory approval of, or demand for, our potential products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical and commercial success of our potential products will depend in part on public acceptance of the use of gene therapy for the prevention or treatment of human diseases. Public attitudes may be influenced by claims that gene therapy is unsafe, unethical, or immoral, and, consequently, our products may not gain the acceptance of the public or the medical community. Adverse public attitudes may adversely impact our ability to enroll clinical trials. Moreover, our success will depend upon physicians prescribing, and their patients being willing to receive, treatments that involve the use of product candidates that we may develop in lieu of, or in addition to, existing treatments with which they are already familiar and for which greater clinical data may be available.</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">***</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We currently have no intention of resuming research and development activities independently or as a standalone company, and the following are risks primarily relating to our prior operations and historical activities, unless otherwise noted. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Commercialization of Our Product Candidates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if any of our product candidates receives marketing approval, we may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success, and the market opportunity for any of our product candidates, if approved, may be smaller than we estimate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our product candidates receives marketing approval, we may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. For example, current cancer treatments, such as chemotherapy and radiation therapy, are well established in the medical community and doctors may continue to rely on these and similar treatments. Efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may not be successful. If our product candidates do not achieve an adequate level of acceptance, we may not generate significant revenues from product sales and we may not become </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efficacy and potential advantages of our product candidates compared to the advantages and relative risks of alternative treatments;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of sales and marketing efforts;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to offer our products, if approved, for sale at competitive prices;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the clinical indications for which the product is approved;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of treatment in relation to alternative treatments;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the convenience and ease of administration compared to alternative treatments;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the strength of marketing and distribution support;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of market introduction of competitive products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of third-party coverage and adequate reimbursement, and patients&#8217; willingness to pay out of pocket for required co-payments or in the absence of third-party coverage or adequate reimbursement;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product labeling or product insert requirements of the FDA, the European Medical Agency, or the EMA, or other regulatory authorities, including any limitations or warnings contained in a product&#8217;s approved labeling;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any side effects;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">support from patient advocacy groups; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any restrictions on the use of our products, if approved, together with other medications.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our assessment of the potential market opportunity for our product candidates is based on industry and market data that we obtained from industry publications, research, surveys and studies conducted by third parties and our analysis of these data, research, surveys and studies. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. While we believe these industry publications and third-party research, surveys and studies are reliable, we have not independently verified such data. Our estimates of the potential market opportunities for our product candidates include a number of key assumptions based on our industry knowledge, industry publications and third-party research, surveys and studies, which may be based on a small sample size and fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions. If any of our assumptions or estimates, or these publications, research, surveys or studies prove to be inaccurate, then the actual market for any of our product candidates may be smaller than we expect, and as a result our revenues from product sales may be limited and it may be more difficult for us to achieve or maintain profitability.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to establish sales, marketing and distribution capabilities or enter into sales, marketing and distribution agreements with third parties, we may not be successful in commercializing our product candidates if and when they are approved.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have a sales or marketing infrastructure and have no experience as a company in the sale, marketing or distribution of biopharmaceutical products. To achieve commercial success for any product for which we may obtain marketing approval, we will need to establish a sales, marketing and distribution organization, either ourselves or through collaborations or other arrangements with third parties.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently expect that we would build our own focused, specialized sales and marketing organization to support the commercialization in the United States of product candidates for which we receive marketing approval and that can be commercialized with such capabilities. There are risks involved with us establishing our own sales, marketing and distribution capabilities. For example, recruiting and training a sales force is expensive and time-consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. These efforts may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. In general, the cost of establishing and maintaining a sales and marketing organization may exceed the cost-effectiveness of doing so.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that may inhibit our efforts to commercialize our products on our own include:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to recruit, train and retain adequate numbers of effective sales, marketing, market access, distribution, customer service, medical affairs and other support personnel;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to equip sales personnel with effective materials;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to effectively manage a geographically dispersed sales and marketing team;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability of reimbursement professionals to negotiate arrangements for formulary access, reimbursement and other acceptance by payors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to price our products at a sufficient price point to ensure an adequate and attractive level of profitability;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restricted or closed distribution channels that make it difficult to distribute our products to segments of the patient population;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unforeseen costs and expenses associated with creating an independent commercialization organization.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to establish our own sales, marketing and distribution capabilities and we enter into arrangements with third parties to perform these services, our revenues from product sales and our profitability, if any, are likely to be lower than if we were to market, sell and distribute any products that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell, market and distribute our product candidates or may be unable to do so on terms that are acceptable to us. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish sales, marketing and distribution capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do, thus rendering our products non-competitive, obsolete or reducing the size of the market for our products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biopharmaceutical industry, and in particular the cell therapy field and the liver fibrosis fields, is characterized by intense investment and competition aimed at rapidly advancing new technologies. Our platform and therapeutic product candidates are expected to face substantial competition from multiple technologies, marketed products and numerous other therapies being developed by third parties that use protein degradation, antibody therapy, inhibitory nucleic acid, gene editing or gene therapy development platforms and from companies focused on more traditional therapeutic modalities, such as small molecule inhibitors. The competition is likely to come from multiple sources, including biopharmaceutical companies, academic research institutions, governmental agencies and private research institutions that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. The competition is likely to come from multiple sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions, government agencies and public and private research institutions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of a number of companies generally pursuing the development of myeloid cell therapies, including, among others Myeloid Therapeutics, Shoreline Biosciences, Inceptor Bio, Thunder Bio, Resolution Therapeutics, CellOrigin, and others. We are also facing competition from companies pursuing autologous T cell therapies, allogeneic T cell therapies, NK and other cell therapies, direct </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reprogrammed cell therapies, liver fibrosis therapies and other macrophage-targeted oncology therapeutics.<br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we are aware of a number of companies either marketing or pursuing the development of liver fibrosis/MASH therapies, including Madrigal, Akero, 89bio, Resolution Therapeutics, and major pharmaceutical companies developing incretin therapies such as Eli Lilly, NovoNordisk, and others.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, pre-clinical testing, conducting clinical trials, obtaining marketing approvals and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our development programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other marketing approval for their products more rapidly than we may obtain approval for our products, including as a result of our decision to pause research and development activities, which could result in our competitors establishing a strong market position before we </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic products. There are generic products currently on the market for certain of the indications that we are pursuing, and additional products are expected to become available on a generic basis over the coming years. If our product candidates are approved, we expect that they will be priced at a significant premium over competitive generic products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Technology in the biopharmaceutical industry has undergone rapid and significant change, and we expect that it will continue to do so. Any products or processes that we develop may become obsolete or uneconomical before we recover any expenses incurred in connection with their development.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mergers and acquisitions in the biopharmaceutical industry may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have pursued and, if we were to resume research and development activities, may in the future pursue the in-license or acquisition of rights to complementary technologies and product candidates on an opportunistic basis. However, we may be unable to in-license or acquire any additional technologies or product candidates from third parties. The acquisition and licensing of technologies and product candidates is a competitive area, and a number of more established companies also have similar strategies to in-license or acquire technologies and product candidates that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to in-license or acquire the relevant technology or product candidate on terms that would allow us to make an appropriate return on our investment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we are able to commercialize any product candidates, the products may become subject to unfavorable pricing regulations, third-party coverage or reimbursement practices or healthcare reform initiatives, which could harm our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drug products vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost effectiveness of our product candidate to other available therapies. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we may obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues, if any, we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to commercialize any product candidates successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. The availability of coverage and adequacy of reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford medical services and pharmaceutical products, including our product candidates. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, government authorities and third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Coverage and reimbursement may not be available for any product that we commercialize and, even if these are available, the level of reimbursement may not be satisfactory. Reimbursement may affect the demand for, or the price of, any product candidate for which we obtain marketing approval. Obtaining and maintaining adequate reimbursement for our products may be difficult. We may be required to conduct expensive pharmacoeconomic studies to justify coverage and reimbursement or the level of reimbursement relative to other therapies. If coverage and adequate reimbursement are not available or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reimbursement is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or similar regulatory authorities outside of the United States. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers its costs, including research, development, intellectual property, manufacture, sale and distribution expenses. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. In the United States, third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases on short notice, and we believe that changes in these rules and regulations are likely.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that our product candidates, even if they are approved for sale in the United States, in the European Union or in other countries, will be considered medically reasonable and necessary for a specific indication or cost-effective by third-party payors, or that coverage and an adequate level of reimbursement will be available or that third-party payors&#8217; reimbursement policies will not adversely affect our ability to sell our product candidates profitably.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trial and product liability lawsuits against us could divert our resources and could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of clinical trial and product liability exposure related to the testing of our product candidates in human clinical trials and will face an even greater risk if we commercially sell any products that we may develop. While we currently have no products that have been approved for commercial sale, the use of product candidates by us in clinical trials, and the sale of any approved products in the future, may expose us to liability claims. These claims might be made by patients that use the product, healthcare providers, pharmaceutical companies or others selling such products. On occasion, large judgments have been awarded in class action lawsuits based on products that had unanticipated adverse effects. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for any product candidates or products that we may develop;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">termination of clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of marketing approval, recall, restriction on the approval or a &#8220;black box&#8221; warning or contraindication for an approved drug;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial participants;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant costs to defend any related litigation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to trial participants or patients;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenue;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injury to our reputation and significant negative media attention;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced resources of our management to pursue our business strategy;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">distraction of management&#8217;s attention from our primary business; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to commercialize any products that we may develop.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently hold $10.0 million in product liability insurance coverage in the aggregate, with a per incident limit of $10.0 million, which may not be adequate to cover all liabilities that we may incur. We may need to increase our insurance </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">coverage if we initiate and expand our clinical trials or commence commercialization of our product candidates. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. If a successful clinical trial or product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired.</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">***</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We currently have no intention of resuming research and development activities independently or as a standalone company. The following are risks primarily relating to our prior operations and historical activities, expect for the risks relating to our ongoing collaboration with Moderna or as other otherwise noted below. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Dependence on Third Parties</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have relied, and if we resume research and development activities expect to continue to rely, on third parties to conduct our clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, which may prevent or delay our ability to seek or obtain marketing approval for or commercialize our product candidates or otherwise harm our business. If we are not able to maintain these third-party relationships or if these arrangements are terminated, we may have to alter our development and commercialization plans and our business could be adversely affected.<br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We historically relied on, and if we resume research and development activities expect to continue to rely on third-party clinical research organizations, in addition to other third parties such as research collaboratives, clinical data management organizations, medical institutions and clinical investigators, to conduct our clinical trials. We currently have no plans to independently conduct any clinical trials of our product candidates. These contract research organizations, or CROs, and other third parties play a significant role in the conduct and timing of these trials and subsequent collection and analysis of data. These third-party arrangements might terminate for a variety of reasons, including a failure to perform by the third parties. If we need to enter into alternative arrangements, our product development activities might be delayed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on these third parties for discovery and product development activities reduces our control over these activities but does not relieve us of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with standards, commonly referred to as GCPs for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. Regulatory authorities in Europe and other jurisdictions have similar requirements. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs or trial sites fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We are also required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within specified timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully develop and commercialize our product candidates. Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected the interpretation of the trial, the integrity of the data generated at the applicable clinical trial site may be questioned, and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of any marketing application we submit to the FDA. Any such delay or rejection could prevent us from commercializing our product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative third parties or do so on commercially reasonable terms. Switching or adding more CROs, investigators and other third parties involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays can occur, which could materially impact our ability to meet our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">desired clinical development timelines. Although we plan to carefully manage our relationships with our CROs, investigators and other third parties, we may nonetheless encounter challenges or delays in the future, which could have a material and adverse impact on our business, financial condition and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have relied on, and if we resume research and development activities expect to continue to rely on third-party CMOs for the manufacture of both drug substance and finished drug product of our product candidates for pre-clinical and clinical testing and expect to continue to do so for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We have relied on, and if we resume research and development activities, expect to continue to rely, on third-party CMOs for both drug substance and finished drug product, as well as for commercial manufacture if any of our product candidates receive marketing approval. We have relied on these third parties for the manufacture of plasmid and viral vectors, patient leukapheresis material logistics, as well as packaging, labeling, sterilization, storage, distribution and other production logistics. We continue to rely on these third parties for storage, distribution and other logistics of manufactured plasmid and viral vectors.  This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts. We may be unable to establish any agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reliance on the third party for regulatory compliance and quality assurance;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the possible breach of the manufacturing agreement by the third party;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential failure to manufacture our product candidate or product according to our specifications;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential failure to manufacture our product candidate or product according to our schedule or at all;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the possible misappropriation of our proprietary information, including our trade secrets and know-how; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our third-party manufacturers may encounter shortages in the raw materials or active pharmaceutical ingredients necessary to produce our product candidates in the quantities needed for our clinical trials or, if our product candidates are approved, in sufficient quantities for commercialization or to meet an increase in demand, as a result of capacity constraints or delays or disruptions in the market for the raw materials or active pharmaceutical ingredients, including shortages caused by the purchase of such raw materials or active pharmaceutical ingredients by our competitors or others. Our or our third-party manufacturers' failure to obtain the raw materials or active pharmaceutical ingredients necessary to manufacture sufficient quantities of our product candidates may have a material adverse effect on our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our third-party manufacturers are subject to inspection and approval by regulatory authorities before we can commence the manufacture and sale of any of our product candidates, and thereafter subject to ongoing inspection from time to time. Third-party manufacturers may not be able to comply with current good manufacturing practices, or cGMP, regulations or similar regulatory requirements outside of the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities. As a result, we may not obtain access to these facilities on a priority basis or at all. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. We do not currently have arrangements in place for redundant supply or a second source for bulk drug substance. If any of our contract manufacturers cannot perform as agreed, we may be required to replace such manufacturers. Although we believe that there are several potential alternative manufacturers who could manufacture our product candidates, we may incur added costs and delays in identifying and qualifying any such replacement or be unable to reach agreement with an alternative manufacturer. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future dependence upon others for the manufacture of our product candidates or products may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">We currently, and may in the future, rely on single-source suppliers for certain materials and components used in the manufacturing of our product candidates. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relied, and may in the future, rely on single-source suppliers for certain materials and components used in the manufacturing of our product candidates. There are, for certain of these materials and components, few, if any, alternative sources of supply and there is limited need for multiple suppliers at this stage of our business. We cannot ensure that these suppliers will remain in business, have sufficient capacity or supply to meet our needs, be able to supply materials to us at costs that are acceptable to us, or that they will not be purchased by one of our competitors or another company that is not interested in continuing to work with us. Our use of single-source suppliers of certain materials and components exposes us to several risks, including disruptions in supply, price increases or late deliveries. This supplier may be unable or unwilling to meet our future demands for our clinical trials. Establishing additional or replacement suppliers for these materials and components could take a substantial amount of time and it may be difficult to establish replacement suppliers who meet regulatory requirements. Any disruption in supply from these single-source suppliers could lead to supply delays or interruptions which would materially adversely affect our business, financial condition and results of operations. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to depend on collaborations with third parties for the research, development and commercialization of certain of our product candidates, including our collaboration agreement with Moderna. If our collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates and our business could be adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may depend on collaborations with third parties for the research, development and commercialization of certain of our product candidates. For example, we entered into a strategic collaboration with Moderna in January 2022 focused on the development of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CAR-M therapeutics. In collaboration with Moderna, we have established a mRNA/LNP </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CAR-M platform for research targets, which enables an off-the-shelf approach wherein the patient&#8217;s own myeloid cells are engineered directly within their body via the administration of a LNP encapsulating macrophage reprogramming mRNA CAR constructs, removing the requirement for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cell manufacturing entirely. In June 2024, we announced the nomination of the first development candidate under the collaboration with Moderna. The development candidate targets GPC3. In February 2025, Moderna nominated ten additional oncology research targets, four of which replaced two oncology research targets and two autoimmune research targets, which Moderna concurrently ceased developing. As of February 2025, Moderna has nominated all 12 oncology research targets under the collaboration for which we have the potential to receive future milestones and royalties. We will not conduct any additional research activities under the collaboration agreement and we will not be receiving any further payments from Moderna for research and development services under the collaboration agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Moderna collaboration agreement, assuming Moderna develops and commercializes 12 products, each directed to a different development target, we are eligible to receive up to between $247.0 million and $253.0 million per product in development target designation, development, regulatory and commercial milestone payments. We are also eligible to receive tiered mid-to-high single digit royalties of net sales of any products that are commercialized under the agreement, which may be, subject to reductions. We cannot be certain that Moderna will take the steps to achieve any of these development, regulatory and commercial milestones, all of which are outside of our control. Therefore, we may not be entitled to receive from Moderna any remaining milestone payments or any royalty payments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our cash preservation plan, we have reduced our operations to those necessary to identify and explore a range of strategic alternatives to maximize value and prepare to wind down our business. Potential strategic alternatives to be explored and evaluated may include, among other transactions, a strategic collaboration or partnership with one or more parties. If we were to resume research and development activities, we may also seek third-party collaborators for the research, development and commercialization of certain of our product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaborators for collaboration arrangements may include large and mid-size pharmaceutical companies and biotechnology companies, among others.  We cannot provide any commitment that we will enter into any collaboration. Any such arrangements with third parties will likely limit our control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates we may seek to develop with them. Our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities and efforts to successfully perform the functions assigned to them in these arrangements. We cannot predict the success of any collaboration that we enter into and we cannot be certain that they provide any value for our company or our stockholders.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaborations involving our discovery programs or any product candidates we may develop, including our collaboration with Moderna pose the following risks to us:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators have significant discretion in determining the amount and timing of efforts and resources that they will apply to these collaborations; for example, our collaboration with Moderna is managed by a JSC, which is comprised of representatives from the Company and Moderna, with Moderna having final decision-making authority, subject to specified limitations;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not perform their obligations as expected;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not pursue development of our product candidates or may elect not to continue or renew development programs based on results of clinical trials or other studies, changes in the collaborators&#8217; strategic focus or available funding, or external factors, such as an acquisition or business combination, that divert resources or create competing priorities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not pursue development and commercialization of any product candidates that achieve marketing approval or may elect not to continue or renew commercialization programs based on results of clinical trials or other studies, changes in the collaborators&#8217; strategic focus or available funding, or external factors, such as an acquisition or business combination, that may divert resources or create competing priorities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not have access to, or may be restricted from disclosing, certain information regarding product candidates being developed or commercialized under a collaboration and, consequently, may have limited ability to inform our stockholders about the status of such product candidates on a discretionary basis; for example, data, results and know-how generated in the performance of the Moderna collaboration is deemed the confidential information of Moderna, which we may not disclose except under limited circumstances;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates and products if the collaborators believe that the competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a collaborator may fail to comply with applicable regulatory requirements regarding the development, manufacture, distribution or marketing of a product candidate or product;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a collaborator may seek to renegotiate or terminate their relationship with us due to unsatisfactory clinical results, manufacturing issues, a change in business strategy, a change of control or other reasons;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve marketing approval may not commit sufficient resources to the marketing and distribution of such product or products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disagreements with collaborators, including disagreements over intellectual property or proprietary rights, contract interpretation or the preferred course of development, might cause delays or terminations of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may lose certain valuable rights under circumstances identified in our collaborations, including if we undergo a change of control;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not properly obtain, maintain, enforce, defend or protect our intellectual property or proprietary rights or may use our proprietary information in such a way as to potentially lead to disputes or legal proceedings that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; for example, Moderna has the first right to prosecute, enforce or defend certain patent rights under its agreement with us, and although we may have the right to assume the prosecution, enforcement or defense of such patent rights if Moderna does not, our ability to do so may be compromised by Moderna&#8217;s actions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes may arise with respect to the ownership of intellectual property developed pursuant to our collaborations;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may infringe, misappropriate or otherwise violate the intellectual property or proprietary rights of third parties, which may expose us to litigation and potential liability;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborations may be terminated, and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates; for example, Moderna has the right to terminate its agreement with us for convenience in its entirety or with respect to a specific product or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">target on ninety days&#8217; prior notice, in connection with a material breach of the agreement by us that remains uncured for a specified period of time or in the event of specified insolvency events involving us; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner, or at all. If a present or future collaborator of ours was to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program under such collaboration could be delayed, diminished or terminated.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any collaborations that we enter into do not result in the successful development and commercialization of products or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, or receive it in the timeframe in which we expect to receive it, the development of our product candidates could be delayed, and we may need additional resources to develop our product candidates. All of the risks relating to product development, marketing approval and commercialization described herein also apply to the activities of our collaborators.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may in the future decide to collaborate with biopharmaceutical companies for the development and potential commercialization of any product candidates we may develop. These relationships, or those like them, may require us to incur non-recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business. In addition, we could face significant competition in seeking appropriate collaborators, and the negotiation process is time-consuming and complex. Our ability to reach a definitive collaboration agreement will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator&#8217;s evaluation of several factors. If we license rights to any product candidates we or our collaborators may develop, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are not able to establish or maintain additional collaborations, on commercially reasonable terms, we may have to alter our development and commercialization plans, and our business could be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face significant competition in attracting appropriate collaborators, and a number of more established companies may also be pursuing strategies to license or acquire third-party intellectual property rights that we consider attractive. These established companies may have a competitive advantage over us due to their size, financial resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or other regulatory authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, the terms of any existing collaboration agreements, and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. We may also be restricted under future license agreements from entering into agreements on certain terms with potential collaborators. Collaborations are complex and time-consuming to negotiate, document and execute. In addition, there have been a significant number of recent business combinations among large biopharmaceutical companies that have resulted in a reduced number of potential future collaborators. Any collaboration we may enter into may limit our ability to enter into future agreements on particular terms or covering similar target indications with other potential collaborators.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms or at all, we may have to curtail the development of a product candidate, reduce or delay our development program or one or more of our other development programs, delay our potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market and generate revenue from product sales, which could have an adverse effect on our business, prospects, financial condition and results of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a number of academic collaborations to supplement our internal discovery and product development programs. If any such collaborator decides to discontinue or devote less resources to such research, our discovery programs could be diminished.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our discovery engine is supplemented by academic collaborations to expand our platform, which we rely upon to advance our development and commercialization plans for our product candidates. For example, in August 2020, we entered into a scientific research and licensing agreement with Nathaniel R. Landau, Ph.D. and NYU Langone Health through which we obtained exclusive rights to develop their Vpx lentiviral vector globally for all indications. In addition, we, from time to time, may enter into academic research collaborations to explore the development of new technologies and indications.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While these academic institutions have contractual obligations to us, they are independent entities and are not under our control or the control of our officers or directors. Our research and licensing agreements with academic collaborators generally provide academic collaborators with license maintenance fees, development and regulatory milestone payments, royalties on net sales of products and a portion of sublicense income that we receive. Upon the scheduled expiration of any academic collaboration, we may not be able to renew the related agreement, or any renewal could be on terms less favorable to us than those contained in the existing agreement. Furthermore, either we or the academic institution generally may terminate the sponsored research agreement for convenience following a specified notice period. If any of these academic institutions decides to not renew or to terminate the related agreement or decides to devote fewer resources to such activities, our discovery efforts would be diminished, while our royalty obligations, if any, would continue unmodified.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any acquisitions or in-license transactions that we complete could disrupt our business, cause dilution to our stockholders or reduce our financial resources.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have licensed four patent families from Penn and one patent family from NYU and may enter into transactions to in-license or acquire other businesses, intellectual property, technologies, product candidates or products. If we determine to pursue a particular transaction, we may not be able to complete the transaction on favorable terms, or at all. Any in-licenses or acquisitions we complete may not strengthen our competitive position, and these transactions may be viewed negatively by customers or investors. We may decide to incur debt in connection with an in-license or acquisition or issue our common stock or other equity securities to the stockholders of the target company, which would reduce the percentage ownership of our existing stockholders. We could incur losses resulting from undiscovered liabilities that are not covered by the indemnification we may obtain from the seller. In addition, we may not be able to successfully integrate the acquired personnel, technologies and operations into our existing business in an effective, timely and nondisruptive manner. In-license and acquisition transactions may also divert management attention from day-to-day responsibilities, increase our expenses and reduce our cash available for operations and other uses. We cannot predict the number, timing or size of additional future in-licenses or acquisitions or the effect that any such transactions might have on our operating results.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The FDA, EMA, or other comparable foreign regulatory authorities could require the clearance or approval of a companion diagnostic device as a condition of approval for any product candidate that requires or would commercially benefit from such tests. Failure to successfully validate, develop and obtain regulatory clearance or approval for companion diagnostics on a timely basis or at all could harm our product development strategy and we may not realize the commercial potential of any such product candidate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If safe and effective use of any of our other product candidates depends on an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> diagnostic, then the FDA generally will require approval or clearance of that diagnostic, known as a companion diagnostic, at the same time that the FDA approves our product candidates. The process of obtaining or creating such diagnostic is time consuming and costly. Companion diagnostics, which provide information that is essential for the safe and effective use of a corresponding therapeutic product, are subject to regulation by the FDA, EMA and other comparable foreign regulatory authorities as medical devices and require separate regulatory approval from therapeutic approval prior to commercialization. The FDA previously has required </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> companion diagnostics intended to select the patients who will respond to a product candidate to obtain pre-market approval, or PMA, simultaneously with approval of the therapeutic candidate. The PMA process, including the gathering of pre-clinical and clinical data and the submission and review by the FDA, can take several years or longer. It involves a rigorous pre-market review during which the sponsor must prepare and provide the FDA with reasonable assurance of the device&#8217;s safety and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing, and labeling. After a device is placed on the market, it remains subject to significant regulatory requirements, including requirements governing development, testing, manufacturing, distribution, marketing, promotion, labeling, import, export, record-keeping, and adverse event reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given our limited experience in developing and commercializing diagnostics, we do not plan to develop companion diagnostics internally and thus will be dependent on the sustained cooperation and effort of third-party collaborators in developing and obtaining approval for these companion diagnostics. We may not be able to enter into arrangements with a provider to develop a companion diagnostic for use in connection with a registrational trial for our product candidates or for commercialization of our product candidates, or do so on commercially reasonable terms, which could adversely affect and/or delay the development or commercialization of our product candidates. We and our future collaborators may encounter difficulties in developing and obtaining approval for the companion diagnostics, including issues relating to selectivity/specificity, analytical validation, reproducibility, or clinical validation. Any delay or failure by our collaborators to develop or obtain regulatory approval of the companion diagnostics could delay or prevent approval of our product candidates. In addition, we, our collaborators or third parties may encounter production difficulties that could constrain the supply of the companion diagnostics, and both they and we may have difficulties gaining acceptance of the use of the companion diagnostics by physicians.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any companion diagnostic collaborator or third party with whom we contract may decide not to commercialize or to discontinue selling or manufacturing the companion diagnostic that we anticipate using in connection with development and commercialization of our product candidates, or our relationship with such collaborator or third party may otherwise terminate. We may not be able to enter into arrangements with another provider to obtain supplies of an alternative diagnostic test for use in connection with the development and commercialization of our product candidates or do so on commercially reasonable terms, which could adversely affect and/or delay the development or commercialization of our product candidates.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">***</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We currently have no intention of resuming research and development activities independently or as a standalone company, and the following are risks primarily relating to our prior operations and historical activities, unless otherwise noted. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain, maintain and enforce patent protection for our technology and product candidates or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully develop and commercialize our technology and product candidates may be adversely affected and we may not be able to compete effectively in our market.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in part on our ability to obtain, maintain and enforce protection of the intellectual property we may own solely and jointly with others or may license from others, particularly patents, in the United States and other countries with respect to any proprietary technology and product candidates. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our technologies and product candidates that are important to our business and by in-licensing intellectual property related to such technologies and product candidates. If we are unable to obtain, maintain or enforce patent protection with respect to any proprietary technology or product candidate, our business, financial condition, results of operations and prospects could be materially harmed. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, thus eroding our competitive position in our market. Moreover, the patent applications we own, co-own or license may fail to result in issued patents in the United States or in other foreign countries.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain, defend or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we do not have the right to control the preparation, filing and prosecution of patent applications, or to maintain, enforce and defend the patents, covering technology that we license from third parties. Therefore, these in-licensed patents and applications may not be prepared, filed, prosecuted, maintained, defended and enforced in a manner consistent with the best interests of our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. In addition, the scope of patent protection outside of the United States is uncertain and laws of foreign countries may not protect our rights to the same extent as the laws of the United States or vice versa. For example, European patent law restricts the patentability of methods of treatment of the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">human body more than U.S. law does. With respect to both owned and in-licensed patent rights, we cannot predict whether the patent applications we and our licensors are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors. Further, we may not be aware of all third-party intellectual property rights potentially relating to our product candidates. In addition, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not published at all. Therefore, neither we nor our licensors can know with certainty whether either we or our licensors were the first to make the inventions claimed in the patents and patent applications we own or in-license now or in the future, or that either we or our licensors were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Moreover, our owned or in-licensed pending and future patent applications may not result in patents being issued which protect our technology and product candidates, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents and our ability to obtain, protect, maintain, defend and enforce our patent rights, narrow the scope of our patent protection and, more generally, could affect the value or narrow the scope of our patent rights.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, we or our licensors may be subject to a third-party preissuance submission of prior art to the United States Patent and Trademark Office, or USPTO, or become involved in opposition, derivation, revocation, reexamination, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. If the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our owned or licensed patent estate includes patent applications, many of which are at an early-stage of prosecution. The coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if our owned or in-licensed patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. The issuance of a patent is not conclusive as to our inventorship, scope, validity or enforceability, and our owned and in-licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. Such proceedings also may result in substantial costs and require significant time from our management and employees, even if the eventual outcome is favorable to us. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. Furthermore, our competitors may be able to circumvent our owned or in-licensed patents by developing similar or alternative technologies or products in a non-infringing manner. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing technology and products similar or identical to any of our technology and product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent terms may be inadequate to protect our competitive position with respect to our current or future product candidates for an adequate amount of time.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but there is no assurance that any such extensions will be obtained, and the life of a patent, and the protection it affords, is limited. Even if patents covering our current or future product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, patent term can also be adjusted due to delays that occur during examination of patent applications, which may extend the term of a patent beyond 20 years. There is a risk that we may take action that reduces any accrued patent term adjustment.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is necessary to pay certain maintenance fees, also referred to as annuities or renewal fees in some countries, throughout the lifetime of a patent at regular intervals. Failure to pay these fees can cause a granted patent to prematurely expire, without an opportunity for revival. There is a risk that we may be unable to maintain patent protection for certain patents in all markets due to finite availability of resources.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain licenses from third parties on commercially reasonable terms or fail to comply with our obligations under such agreements, our business could be harmed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our products, in which case we would be required to obtain a license from these third parties. If we are unable to license such technology, or if we are forced to license such technology on unfavorable terms, our business could be materially harmed. If we are unable to obtain a necessary license, we may be unable to develop or commercialize the affected product candidate(s), which could materially harm our business and the third parties owning such intellectual property rights could seek either an injunction prohibiting our sales or an obligation on our part to pay royalties and/or other forms of compensation. Even if we are able to obtain a license, we may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected technology and product candidates, which could harm our business, financial condition, results of operations and prospects significantly.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if we fail to comply with our obligations under any license agreements, our counterparties may have the right to terminate these agreements, in which event we might not be able to develop, manufacture or market, or may be forced to cease developing, manufacturing or marketing, any product that is covered by these agreements or may face other penalties under such agreements. Such an occurrence could materially adversely affect the value of the product candidate being developed under any such agreement. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Termination of these agreements or reduction or elimination of our rights under these agreements, or restrictions on our ability to freely assign or sublicense our rights under such agreements when it is in the interest of our business to do so, may result in us having to negotiate new or restated agreements with less favorable terms, cause us to lose our rights under these agreements, including our rights to important intellectual property or technology or impede, or delay or prohibit the further development or commercialization of one or more product candidates that rely on such agreements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain patent term extension for any product candidates we may develop, our business may be materially harmed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the term of a patent that covers an FDA-approved drug may, in certain cases, be eligible for a patent term extension under the Hatch-Waxman Act, as compensation for the loss of a patent term during the FDA regulatory review process for a drug product subject to the provisions of the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent term extension of up to five years, but patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. Only one patent among those eligible for an extension and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar provisions are available in Europe and certain other non-United States jurisdictions to extend the term of a patent that covers an approved drug. While, in the future, if and when our product candidates receive FDA approval, we expect to apply for patent term extensions on patents covering those product candidates. There is no guarantee that the applicable authorities, including the FDA, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions could be for a shorter period than we anticipate. We may not be granted patent term extension either in the United States or in any foreign country because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the term of extension, as well as the scope of patent protection during any such extension, afforded by the governmental authority could be less than we request. If we are unable to obtain any patent term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing products following the expiration of our patent rights, and our business, financial condition, results of operations and prospects could be materially harmed.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in either the patent laws or interpretation of patent laws in the United States could increase the uncertainties and costs surrounding the prosecution of our owned or in-licensed patent applications and the maintenance, enforcement or defense of our owned or in-licensed issued patents.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the patent positions of companies in the development and commercialization of pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our patent rights and our ability to protect, defend and enforce our patent rights in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions, changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we own or have licensed or that we may obtain in the future.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal government retains certain rights in inventions created using its financial assistance under the Bayh-Dole Act. The federal government retains a &#8220;nonexclusive, nontransferable, irrevocable, paid-up license&#8221; for its own benefit. The Bayh-Dole Act also provides federal agencies with &#8220;march-in rights&#8221;. March-in rights allow the government, in specified circumstances, to require the contractor or successors in title to the patent to grant a &#8220;nonexclusive, partially exclusive, or exclusive license&#8221; to a &#8220;responsible applicant or applicants.&#8221; If the patent owner refuses to do so, the government may grant the license itself. We collaborate with a number of universities with respect to certain of our research and development. We cannot be sure that any co-developed intellectual property will be free from government rights pursuant to the Bayh-Dole Act. If, in the future, we co-own or in-license technology which is critical to our business that is developed in whole or in part with federal funds subject to the Bayh-Dole Act, our ability to enforce or otherwise exploit patents covering such technology may be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Although we or our licensors are not currently involved in any intellectual property litigation, we may become involved in lawsuits to protect or enforce our patents, the patents of our licensors or other intellectual property rights, which could be expensive, time-consuming and unsuccessful.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors and other third parties may infringe, misappropriate or otherwise violate our or our licensor&#8217;s issued patents, the patents of our licensors or other intellectual property. It may be difficult to detect infringers who do not advertise the components that are used in their products. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor&#8217;s product. To counter infringement or misappropriation, we or our licensors may need to file infringement, misappropriation or other intellectual property related claims, which can be expensive and time-consuming and can distract our management and scientific personnel. There can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Any claims we assert against perceived infringers could provoke such parties to assert counterclaims against us, alleging that we infringe, misappropriate or otherwise violate their intellectual property.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in a patent infringement proceeding, such parties could counterclaim that the patents we or our licensors have asserted are invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including novelty, non-obviousness, enablement, or written description. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may institute such claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post-grant review, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions, such as opposition proceedings. The outcome following legal assertions of invalidity and unenforceability is unpredictable. Similarly, if we or our licensors assert trademark infringement claims, a court may determine that the marks we or our licensors have asserted are invalid or unenforceable, or that the party against whom we or our licensors have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks, which could materially harm our business and negatively affect our position in the marketplace.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An adverse result in any such proceeding could put one or more of our owned or in-licensed patents at risk of being invalidated, held unenforceable or interpreted narrowly, could put any of our owned or in-licensed patent applications at risk of not yielding an issued patent, and could limit our or our licensor&#8217;s ability to assert those patents against those parties, or other competitors, and curtail or preclude our ability to exclude third parties from developing and commercializing similar or competitive products. A court may also refuse to stop the third party from using the technology at issue in a proceeding on the grounds that our owned or in-licensed patents do not cover such technology. Even if we establish infringement, a court may not order the third party to stop using the technology at issue and instead award only monetary damages to us, which may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information or trade secrets could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. Any of the foregoing could allow such third parties to develop and commercialize competing technologies and products and have a material adverse impact on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to us from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same technology. Our defense of litigation or interference or derivation proceedings may fail and, even if successful, may result in substantial costs and distract our management, technical personnel and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development partnerships that would help us bring our product candidates to market.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources in one or more aspects, or for other reasons. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A third party may hold intellectual property, including patent rights, that are important or necessary to the development of our products. It may be necessary for us to use the patented or proprietary technology of a third party to commercialize our own technology or products, in which case we would be required to obtain a license from such third party. A license to such intellectual property may not be available or may not be available on commercially reasonable terms, which could have a material adverse effect on our business and financial condition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The licensing and acquisition of third-party intellectual property rights is a competitive practice, and companies that may be more established, or have greater resources than us, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their larger size and cash resources or greater clinical development and commercialization capabilities. We may not be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends upon our ability and the ability of our collaborators to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property and proprietary rights of third parties. There is considerable patent and other intellectual property </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">litigation in the biopharmaceutical industry. We may become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our technology and product candidates, including interference proceedings, post grant review, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, and derivation proceedings before the USPTO and similar proceedings in foreign jurisdictions, such as opposition proceedings before the European Patent Office. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. As the biopharmaceutical industry expands and more patents are issued, the risk increases that our technologies or product candidates that we may identify may be subject to claims of infringement of the patent rights of third parties.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The legal threshold for initiating litigation or contested proceedings is low, so even lawsuits or proceedings with a low probability of success might be initiated and require significant resources to defend. Litigation and contested proceedings can also be expensive and time-consuming, and our adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we can. The risks of being involved in such litigation and proceedings may increase if and as our product candidates near commercialization and as we gain the greater visibility associated with being a public company. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of merit. Even if we diligently search third-party patents for potential infringement by our products or product candidates, we may not successfully find patents our products or product candidates may infringe. We may not be aware of all such intellectual property rights potentially relating to our technology and product candidates and their uses, or we may incorrectly conclude that third-party intellectual property is invalid or that our activities and product candidates do not infringe such intellectual property. Thus, we do not know with certainty that our technology and product candidates, or our development and commercialization thereof, do not and will not infringe, misappropriate or otherwise violate any third party&#8217;s intellectual property.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations or methods, such as methods of manufacture or methods for treatment, related to the discovery, use or manufacture of the product candidates that we may identify or related to our technologies. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that the product candidates that we may identify may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Moreover, as noted above, there may be existing patents that we are not aware of or that we have incorrectly concluded are invalid or not infringed by our activities. If any third-party patents were held by a court of competent jurisdiction to cover, for example, the manufacturing process of the product candidates that we may identify, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize the product candidates that we may identify. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may choose to take a license or, if we are found to infringe, misappropriate or otherwise violate a third party&#8217;s intellectual property rights, we could also be required to obtain a license from such third party to continue developing, manufacturing and marketing our technology and product candidates. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we are able to obtain a license, we could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us and could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or product. In addition, we could be found liable for significant monetary damages, including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent or other intellectual property right, we could be forced to indemnify our customers or collaborators. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. In addition, we may be forced to redesign our product candidates, seek new regulatory approvals and indemnify third parties pursuant to contractual agreements. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we seek to protect the trademarks and trade names we use in the United States and in other countries, we may be unsuccessful in obtaining registrations or otherwise protecting these trademarks and trade names, which we need to build name recognition in our markets of interest and among potential partners or customers. We rely on both registration and common law protection for our trademarks. Our registered or unregistered trademarks or trade names may be challenged, infringed, diluted or declared generic, or determined to be infringing on other marks. At times, competitors may adopt trademarks and trade names similar to ours, or our collaborators may fail to use our trade names or trademarks, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks. If we are unable to protect our rights to trademarks and trade names, we may be prevented from using such marks and names unless we enter into appropriate royalty, license or coexistence agreements, which may not be available or may not be available on commercially reasonable terms.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During trademark registration proceedings, we may receive rejections. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. Effective trademark protection may not be available or may not be sought in every country in which our products are made available. Any name we propose to use for our products in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA objects to any of our proposed product names, we may be required to expend significant additional resources in an effort to identify a usable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively, and our business may be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may license our trademarks and trade names to third parties, such as distributors and collaborators. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of or failure to use our trademarks and trade names by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, trade secrets, know-how, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property litigation or other legal proceedings relating to intellectual property could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and may also have an advantage in such proceedings due to their more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of intellectual property litigation or other proceedings could compromise our ability to compete in the marketplace.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance, renewal and annuity fees and various other government fees on any issued patent and pending patent application must be paid to the USPTO and foreign patent agencies in several stages or annually over the lifetime of our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patents and patent applications. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In certain circumstances, we rely on our licensing partners to pay these fees to, or comply with the procedural and documentary rules of, the relevant patent agency. With respect to our patents, we rely on an annuity service, outside firms and outside counsel to remind us of the due dates and to make payment after we instruct them to do so. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, potential competitors might be able to enter the market with similar or identical products or technology. If we or our licensors fail to maintain the patents and patent applications covering our product candidates, it would have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations in our current and future intellectual property licenses and funding arrangements with third parties, or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to a number of license and research agreements. Some of these agreements provide us with the intellectual property rights required for the development of our product candidates, including the license agreement with Penn. These licenses and research agreements and similar agreements in the future may impose diligence, development and commercialization timelines, and milestone payment, royalty, insurance and other obligations on us. If we fail to comply with such obligations, the parties to these agreements may decide to terminate the agreements or require us to grant them certain rights, in which we may not be able to develop, manufacture, or market any products without the rights granted to us by these agreements and may face other penalties. Any such occurrences could adversely affect the value of any product candidate being developed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a variety of purposes, we will likely enter into additional licensing and funding arrangements with third parties that may impose similar obligations on us. Termination of these agreements or reduction or elimination of our rights under these agreements may result in us having to negotiate new or restated agreements with less favorable terms, or cause us to lose our rights under these agreements, including our rights to important intellectual property or technology, which would have a material adverse effect on our business, financial condition, results of operations and prospects. While we still face all of the risks described herein with respect to such agreements, we cannot prevent third parties from also accessing those technologies. In addition, our licenses may place restrictions on our future business opportunities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above risks, intellectual property rights that our licenses in the future may include sublicenses under intellectual property owned by third parties, in some cases through multiple tiers. The actions of our licensors may therefore affect our rights to use our sublicensed intellectual property, even if we are in compliance with all of the obligations under our license agreements. Should our licensors or any of the upstream licensors fail to comply with their obligations under the agreements pursuant to which they obtain the rights that are sublicensed to us, or should such agreements be terminated or amended, our ability to develop and commercialize our product candidates may be materially harmed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disputes may arise regarding intellectual property subject to a licensing agreement, including:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of rights granted under the license agreement and other interpretation related issues;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sublicensing of patent and other rights under our collaborative development relationships;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the payment obligations with respect to licensed technology.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected technology and product candidates, which could have a material adverse effect on our business, financial conditions, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, licensors could retain the right to prosecute and defend the intellectual property rights licensed to us, in which case we would depend on our licensors to control the prosecution, maintenance and enforcement of all of our licensed and sublicensed intellectual property, and even when we do have such rights, we may require the cooperation of our licensors and upstream licensors, which may not be forthcoming. Licensors may determine not to pursue litigation against other companies or may pursue such litigation less aggressively than we would. Our business could be adversely affected if we or our licensors are unable to prosecute, maintain and enforce our licensed and sublicensed intellectual property effectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current or future licensors may have relied on third-party consultants or collaborators or on funds from third parties such that our licensors are not the sole and exclusive owners of the patents and patent applications of our in-licenses. If other third parties have ownership rights to patents or patent applications of our in-licenses, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In spite of our best efforts, our licensors might conclude that we have materially breached our license agreements and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize product candidates and technology covered by these license agreements. If these in-licenses are terminated, or if the underlying intellectual property fails to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, products and technologies identical to ours. This could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property and proprietary rights throughout the world.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States, and even where such protection is nominally available, judicial and governmental enforcement of such intellectual property rights may be lacking. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection or licenses, but enforcement is not as strong as that in the United States. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. In addition, certain jurisdictions do not protect to the same extent or at all inventions that constitute new methods of treatment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated, held unenforceable or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors are forced to grant a license to third parties with respect to any patents relevant to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or in-licensed patents, trade secrets or other intellectual property as an inventor or co-inventor. For example, we or our licensors may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our product candidates. Although it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own, and we cannot be certain that our agreements with such parties will be upheld in the face of a potential challenge, or that they will not be breached, for which we may not have an adequate remedy. The assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached, and litigation may be necessary to defend against these and other claims challenging inventorship or our or our licensors&#8217; ownership of our owned or in-licensed patents, trade secrets or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to our management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims by third parties asserting that our employees, consultants or contractors have wrongfully used or disclosed confidential information of third parties, including of their current or former employers or claims asserting we have misappropriated their intellectual property, or is claiming ownership of what we regard as our own intellectual property.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our employees, consultants and contractors have been previously employed at universities or other biopharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Litigation may be necessary to defend against these claims.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could have a material adverse effect on our competitive business position and prospects. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products, which license may not be available on commercially reasonable terms, or at all, or such license may be non-exclusive. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our management and employees.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking patents for some of our technology and product candidates, we also rely on trade secrets and confidentiality agreements to protect our unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect our trade secrets and other proprietary technology, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties. We may have also entered into confidentiality and invention or patent assignment agreements with our employees and consultants, but we cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary technology. To the extent we become involved in litigation that may require discovery of our trade secrets, know-how and other proprietary technology, we will seek to secure protective orders from the court that bind the parties with access to the discovered information. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Detecting the disclosure or misappropriation of a trade secret and enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outcome is unpredictable. In addition, some courts inside and outside of the United States are less willing or unwilling to protect trade secrets. In addition, we cannot be certain that proprietary technical information and related confidential documents that we have shared with our collaborators and/or submitted to governmental agencies, including regulatory agencies for evaluation and supervision of pharmaceutical products, will be kept confidential. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be materially and adversely harmed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights do not necessarily address all potential threats to us.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may be able to make product candidates that are similar to ours but that are not covered by the claims of the patents that we own or license;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we, or our license partners or current or future collaborators, might not have been the first to make the inventions covered by the issued patent or pending patent applications that we license or may own in the future;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we, or our license partners or current or future collaborators, might not have been the first to file patent applications covering our inventions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or in-licensed intellectual property rights;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it is possible that our owned or in-licensed pending patent applications or those we may own or in-license in the future will not lead to issued patents;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">claims of issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitors might conduct research, development, testing or commercialization activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we cannot ensure that any of our patents, or any of our pending patent applications, if issued, or those of our licensors, will include claims having a scope sufficient to protect our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we cannot ensure that any patents issued to us or our licensors will provide a basis for an exclusive market for our commercially viable product candidates or will provide us with any competitive advantages;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. Supreme Court, other federal courts, Congress, the USPTO or similar foreign authorities may change the standards of patentability and any such changes could narrow or invalidate, or change the scope of, our or our licensors&#8217; patents;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we cannot ensure that our commercial activities or product candidates will not infringe upon the patents of others;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we cannot ensure that we will be able to successfully commercialize our product candidates on a substantial scale, if approved, before the relevant patents that we own or license expire;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop additional proprietary technologies that are patentable;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patents of others may harm our business; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If approved, our product candidates that are licensed and regulated as biologics may face competition from biosimilars approved through an abbreviated regulatory pathway.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Biologics Price Competition and Innovation Act of 2009, or BPCIA, was enacted as part of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or collectively, the ACA, to establish an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity to an approved biologic. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the BPCIA, a reference biological product is granted 12 years of data exclusivity from the time of first licensure of the product, and the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product In addition, the licensure of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still develop and receive approval of a competing biologic, so long as its biologics license application, or BLA, does not reply on the reference product, sponsor&#8217;s data or submit the application as a biosimilar application. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe that any of the product candidates we develop as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider the subject product candidates to be reference products for competing products, potentially creating the opportunity for biosimilar competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of the reference products in a way that is similar to traditional generic substitution for non-biological products will depend on a number of marketplace and regulatory factors that are still developing. Nonetheless, the approval of a biosimilar to our product candidates would have a material adverse impact on our business due to increased competition and pricing pressure.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, foreign regulatory authorities may change their approval policies and new regulations may be enacted. For instance, the EU pharmaceutical legislation is currently undergoing a complete review process, in the context of the Pharmaceutical Strategy for Europe initiative, launched by the European Commission in November 2020. The European Commission&#8217;s proposal for revision of several legislative instruments related to medicinal products (potentially reducing the duration of regulatory data protection, revising the eligibility for expedited pathways, etc.) was published on April 26, 2023. On April 10, 2024, the European Parliament adopted a position on the proposal requesting several amendments to the package. The proposed revisions remain to be agreed and adopted by the European Parliament and European Council and the proposals may therefore be substantially revised before adoption, which is not anticipated before early 2026. The revisions may, however, have a significant impact on the pharmaceutical industry and our business in the long term.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">***</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We currently have no intention of resuming research and development activities independently or as a standalone company, and the following are risks primarily relating to our prior operations and historical activities, unless otherwise noted. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Regulatory Approval and Other Legal Compliance Matters</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The regulatory approval process of the FDA is lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain marketing approval for our product candidates, our business will be substantially harmed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The time required to obtain approval by the FDA is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained marketing approval for any product candidate, and it is possible that none of our existing product candidates, or any product candidates we may seek to develop in the future will ever obtain marketing approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates could fail to receive marketing approval for many reasons, including the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA may disagree with the design or implementation of our clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate to the satisfaction of the FDA that a product candidate is safe and effective for our proposed indication;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results of clinical trials may not meet the level of statistical significance required by the FDA for approval;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA may disagree with our interpretation of data from pre-clinical studies or clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">data collected from clinical trials of our product candidates may not be sufficient to support the submission of biologics licensing application, or BLA to the FDA or other submission or to obtain marketing approval in the United States;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA may find deficiencies with or fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the approval policies or regulations of the FDA may significantly change in a manner rendering our clinical data insufficient for approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This lengthy approval process as well as the unpredictability of future clinical trial results may result in us failing to obtain marketing approval to market any of our product candidates, which would significantly harm our business, results of operations and prospects. The FDA has substantial discretion in the approval process and determining when or whether marketing approval will be obtained for any of our product candidates. Even if we believe the data collected from clinical trials of our product candidates are promising, such data may not be sufficient to support approval by the FDA. Risks similar to those outlined above exist with regard to regulatory authorities outside the United States.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we complete the necessary pre-clinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may prevent us from obtaining approvals for the commercialization of some or all of our product candidates. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue will be materially impaired.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, export and import are subject to comprehensive regulation by the FDA and other regulatory authorities in the United States and by the EMA and other regulatory authorities outside of the United States. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate. We have not submitted an application for or received marketing approval for any of our product candidates in the United States or in any other jurisdiction.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have only limited experience in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third-party clinical research organizations or other third-party consultants or vendors to assist us in this process. Securing marketing approval requires the submission of extensive pre-clinical and clinical data and supporting information, including manufacturing information, to the various regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude us from obtaining marketing approval or prevent or limit commercial use. New cancer drugs frequently are indicated only for patient populations that have not responded to an existing therapy or have relapsed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of obtaining marketing approvals, both in the United States and abroad, is expensive, may take many years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data is insufficient for approval and require additional pre-clinical, clinical or other studies. In addition, varying interpretations of the data obtained from pre-clinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Further, under the Pediatric Research Equity Act of 2003, or PREA, a BLA or supplement to a BLA for certain biological products must contain data to assess the safety and effectiveness of the biological product in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective, unless the sponsor receives a deferral or waiver from the FDA. A deferral may be granted for several reasons, including a finding that the product or therapeutic candidate is ready for approval for use in adults before pediatric trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric trials begin. The applicable legislation in the European Union also requires sponsors to either conduct clinical trials in a pediatric population in accordance with a Pediatric Investigation Plan approved by the Pediatric Committee of the EMA or to obtain a waiver or deferral from the conduct of these studies by this Committee. For any of our product candidates for which we are seeking </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">regulatory approval in the United States or the European Union, we cannot guarantee that we will be able to obtain a waiver or alternatively complete any required studies and other requirements in a timely manner, or at all, which could result in associated reputational harm and subject us to enforcement action, invalidation of the marketing application, and/or financial penalties. Our collaborators are also subject to similar requirements outside of the United States and the European Union and thus the attendant risks and uncertainties.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, we could be adversely affected by several significant administrative law cases decided by the U.S. Supreme Court in 2024. In </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Loper Bright Enterprises v. Raimondo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, for example, the court overruled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Chevron U.S.A., Inc. v. Natural Resources Defense Council, Inc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">., which for 40 years required federal courts to defer to permissible agency interpretations of statutes that are silent or ambiguous on a particular topic. The U.S. Supreme Court stripped federal agencies of this presumptive deference and held that courts must exercise their independent judgment when deciding whether an agency such as the FDA acted within its statutory authority under the Administrative Procedure Act, or the APA. Additionally, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Corner Post, Inc. v. Board of Governors of the Federal Reserve System</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, the court held that actions to challenge a federal regulation under the APA can be initiated within six years of the date of injury to the plaintiff, rather than the date the rule is finalized. The decision appears to give prospective plaintiffs a personal statute of limitations to challenge longstanding agency regulations. Another decision,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> Securities and Exchange Commission v. Jarkesy,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> overturned regulatory agencies' ability to impose civil penalties in administrative proceedings. These decisions could introduce additional uncertainty into the regulatory process and may result in additional legal challenges to actions taken by federal regulatory agencies, including the FDA and CMS, that we rely on. In addition to potential changes to regulations as a result of legal challenges, these decisions may result in increased regulatory uncertainty and delays and other impacts, any of which could adversely impact our business and operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Finally, our ability to develop and market new drug products may be impacted if litigation challenging the FDA&#8217;s approval of another company&#8217;s drug continues. In April 2023, the U.S. District Court for the Northern District of Texas invalidated the approval by the FDA of mifepristone, a drug product which was originally approved in 2000 and whose distribution is governed by various measures adopted under a REMS. The Court of Appeals for the Fifth Circuit declined to order the removal of mifepristone from the market but did hold that plaintiffs were likely to prevail in their claim that changes allowing for expanded access of mifepristone, which the FDA authorized in 2016 and 2021, were arbitrary and capricious. In June 2024, the Supreme Court reversed and remanded that decision after unanimously finding that the plaintiffs did not have standing to bring this legal action against the FDA. In October 2024, the Attorneys General of three states filed an amended complaint in the district court in Texas challenging FDA&#8217;s actions. In January 2025, the district court agreed to allow these states to file an amended complaint and continue to pursue this challenge</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Depending on the outcome of this litigation, if it continues, our ability to develop new drug product candidates and to maintain approval of existing drug products is at risk and could be delayed, undermined or subject to protracted litigation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to obtain marketing approval in foreign jurisdictions would prevent our product candidates from being marketed in such jurisdictions, which, in turn, would materially impair our ability to generate revenue.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market and sell our products in the European Union and many other foreign jurisdictions, we and our collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The marketing approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. We or these third parties may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. The failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval elsewhere. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our products in any jurisdiction, which would materially impair our ability to generate revenue.<br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, we could face heightened risks with respect to obtaining marketing authorization in the United Kingdom as a result of the withdrawal of the United Kingdom from the European Union, commonly referred to as Brexit. The United Kingdom is no longer part of the European Single Market and EU Customs Union. As of January 1, 2025, the Medicines and Healthcare products Regulatory Agency, or MHRA, is responsible for approving all medicinal products destined for the United Kingdom market (i.e., Great Britian and Northern Ireland).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At the same time, a new international recognition procedure, or IRP, will apply, which intends to facilitate approval of pharmaceutical products in the UK. The IRP is open to applicants that have already received an authorization for the same product from one of the MHRA&#8217;s specified Reference Regulators, or RRs. The RRs notably include EMA and regulators in the EU/European Economic Area, or EEA, member states for approvals in the EU centralized procedure and mutual recognition procedure as well as the FDA (for </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">product approvals granted in the U.S. However, the concrete functioning of the IRP is currently unclear. Any delay in obtaining, or an inability to obtain, any marketing authorizations may force us to restrict or delay efforts to seek regulatory approval in the United Kingdom for our product candidates, which could significantly and materially harm our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that we will be subject to additional risks in commercializing any of our product candidates that receive marketing approval outside the United States, including tariffs, trade barriers and regulatory requirements; economic weakness, including inflation, or political instability in particular foreign economies and markets; compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country; and workforce uncertainty in countries where labor unrest is more common than in the United States.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inadequate funding for the FDA, the SEC and other government agencies, including from government shutdowns, funding shortages, personnel losses, regulatory reform or other disruptions to these agencies&#8217; operations, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the FDA have fluctuated in recent years as a result. Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, disruptions may result from events similar to the COVID-19 pandemic. During the COVID-19 pandemic, a number of companies announced receipt of complete response letters due to the FDA&#8217;s inability to complete required inspections for their applications. In the event of a similar public health emergency in the future, the FDA may not be able to continue its current pace and review timelines could be extended. Regulatory authorities outside the United States facing similar circumstances may adopt similar restrictions or other policy measures in response to a similar public health emergency and may also experience delays in their regulatory activities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is also substantial uncertainty as to how measures being implemented by the new Trump Administration across the government will impact the FDA, CMS and other federal agencies with jurisdiction over our activities. For example, since taking office, President Trump has issued a number of executive orders, which could have a significant impact on the manner in which the FDA conducts its operations and engages in regulatory and oversight activities. Further, while the FDA&#8217;s review of BLAs and other applications is funded through the user fee program established under PDUFA, the Trump Administration has indicated that it will be reviewing that program and its implementation. If these or other orders or executive actions impose constraints on FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted. In addition, the loss of FDA personnel could lead to further disruptions and delays in FDA review and oversight of our product candidates.</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, if a prolonged government shutdown or other disruption occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Future shutdowns or other disruptions could also affect other government agencies such as the SEC, which may also impact our business by delaying review of our public filings, to the extent such review is necessary, and our ability to access the public markets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory requirements governing gene therapy products are periodically updated and may continue to change in the future.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has established the Office of Tissues and Advanced Therapies, or the OTAT, within the Center for Biologics Evaluation and Research, or the CBER, to consolidate the review of gene therapy and related products, and has established the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER in its review. In September 2022, the FDA announced retitling of the OTAT to the Office of Therapeutic Products, or the OTP, and elevation of the OTP to a &#8220;Super Office&#8221; to meet its growing cell and gene therapy workload and new commitments under the Prescription Drug User Fee Act agreement for fiscal years 2023 to 2027. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gene therapy clinical trials conducted at institutions that receive funding for recombinant DNA research from the NIH also are potentially subject to review by the Office of Biotechnology Activities&#8217; Recombinant DNA Advisory Committee, or the RDAC; however, the NIH announced that the RDAC will only publicly review clinical trials if the trials cannot be evaluated by standard oversight bodies and pose unusual risks. Although the FDA decides whether individual gene therapy protocols may proceed, the RDAC public review process, if undertaken, can delay the initiation of a clinical trial, even if the FDA has reviewed the trial design and details and approved its initiation. Conversely, the FDA can put an IND on a clinical hold even if the RDAC has provided a favorable review or an exemption from in-depth, public review. If we were to engage an NIH-funded institution to conduct a clinical trial, that institution&#8217;s Institutional Biosafety Committee, or IBC, as well as our IRB would need to review the proposed clinical trial to assess the safety of the trial. In addition, adverse developments in clinical trials of gene therapy products conducted by others may cause the FDA or other oversight bodies to change the requirements for approval of our product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has issued various guidance documents regarding gene therapies, including a draft guidance from November 2024 addressing various questions and final guidance documents released in January 2020 relating to CMC information for gene therapy INDs, gene therapies for rare diseases and gene therapies for retinal disorders. Although the FDA has indicated that these and other guidance documents it previously issued are not legally binding, we believe that our compliance with them is likely necessary to gain approval for any gene therapy product candidate that we may develop. The guidance documents provide additional factors that the FDA will consider at each of the above stages of development and relate to, among other things, the proper pre-clinical assessment of gene therapies; the chemistry, manufacturing, and control information that should be included in an IND; the proper design of tests to measure product potency in support of an IND or BLA; and measures to observe delayed adverse effects in subjects who have been exposed to investigational gene therapies when the risk of such effects is high. Further, the FDA usually recommends that sponsors observe subjects for potential gene therapy-related delayed adverse events for a 15-year period, including a minimum of five years of annual examinations followed by 10 years of annual queries, either in person or by questionnaire.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, for a gene therapy product, the FDA also will not approve the product if the manufacturer is not in compliance with good tissue practices, or GTP. These standards are found in FDA regulations and guidance that govern the methods used in, and the facilities and controls used for, the manufacture of human cells, tissues, and cellular and tissue-based products, or HCT/Ps, which are human cells or tissue intended for implantation, transplant, infusion, or transfer into a human recipient. The primary intent of the GTP requirements is to ensure that cell and tissue-based products are manufactured in a manner designed to prevent the introduction, transmission, and spread of communicable disease. FDA regulations also require tissue establishments to register and list their HCT/Ps with the FDA and, when applicable, to evaluate donors through screening and testing.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, ethical, social and legal concerns about gene therapy, genetic testing and genetic research could result in additional regulations or prohibiting the processes that we may use. Federal and state agencies, congressional committees and foreign governments have expressed their intentions to further regulate biotechnology. More restrictive regulations or claims that our product candidates are unsafe or pose a hazard could prevent us from commercializing any products. New government requirements may be established that could delay or prevent regulatory approval of our product candidates under development. It is impossible to predict whether legislative changes will be enacted, regulations, policies or guidance changed, or interpretations by agencies or courts changed, or what the impact of such changes, if any, may be.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we advance our product candidates through clinical development, we will be required to consult with these regulatory and advisory groups and comply with applicable guidelines. These regulatory review committees and advisory groups and any new guidelines they promulgate may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any product for which we obtain marketing approval in the future could be subject to post-marketing restrictions or withdrawal from the market and we may be subject to substantial penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with any such product following approval.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any product for which we obtain marketing approval, as well as the manufacturing processes, post-approval studies and measures, labeling, advertising and promotional activities for such product, among other things, will be subject to ongoing requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, requirements relating to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing approval of a product is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, including the requirement to implement a Risk Evaluation and Mitigation Strategy, or REMS.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product. The FDA and other agencies, including the Department of Justice, closely regulate and monitor the post-approval marketing and promotion of products to ensure that they are manufactured, marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding off-label use and if we market any product for an indication that is not approved, we may be subject to warnings or enforcement action for off-label marketing. Violation of the Federal Food, Drug, and Cosmetic Act, or FDCA, and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription drugs may lead to investigations or allegations of violations of federal and state health care fraud and abuse laws and state consumer protection laws.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, later discovery of previously unknown adverse events or other problems with any product for which we may obtain marketing approval and its manufacturers or manufacturing processes or failure to comply with regulatory requirements, may yield various results, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">restrictions on such product, manufacturers or manufacturing processes;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">restrictions on the labeling or marketing of the product;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">restrictions on product distribution or use;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">requirements to conduct post-marketing studies or clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">warning letters or untitled letters;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">withdrawal of the product from the market;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">refusal to approve pending applications or supplements to approved applications that we submit;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">recall of the product;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">restrictions on coverage by third-party payors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">fines, restitution or disgorgement of profits or revenues;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">suspension or withdrawal of marketing approvals;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">refusal to permit the import or export of the product;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">product seizure; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Similar restrictions apply to the approval of our products in the EU. The holder of a marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of medicinal products. These include: compliance with the EU&#8217;s stringent pharmacovigilance or safety reporting rules, which can impose post-authorization studies and additional monitoring obligations; the manufacturing of authorized medicinal products, for which a separate manufacturer&#8217;s license is mandatory; and the marketing and promotion of authorized drugs, which are strictly regulated in the European Union and are also subject to EU Member State laws. The failure to comply with these and other EU requirements can also lead to significant penalties and sanctions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any regulatory approval to market our products will be limited by indication. If we fail to comply or are found to be in violation of FDA regulations restricting the promotion of our products for unapproved uses, we could be subject to criminal penalties, substantial fines or other sanctions and damage awards.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulations relating to the promotion of products for unapproved uses are complex and subject to substantial interpretation by the FDA, EMA, MHRA and other government agencies. In September 2021, the FDA published final regulations which describe the types of evidence that the agency will consider in determining the intended use of a drug product. Physicians may nevertheless prescribe our products off-label to their patients in a manner that is inconsistent with the approved label. We intend to implement compliance and training programs designed to ensure that our sales and marketing practices comply with applicable regulations. Notwithstanding these programs, the FDA or other government agencies may allege or find that our practices constitute prohibited promotion of our products for unapproved uses. We also cannot be sure that our employees will comply with company policies and applicable regulations regarding the promotion of products for unapproved uses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the regulatory restrictions on off-label promotion, the FDA and other regulatory authorities allow companies to engage in truthful, non-misleading, and non-promotional scientific communications concerning their products in certain circumstances. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will also need to carefully navigate the FDA&#8217;s various regulations, guidance and policies, along with recently enacted legislation, to ensure compliance with restrictions governing promotion of our products. In September 2021, the FDA published final regulations which describe the types of evidence that the Agency will consider in determining the intended use of a drug or biologic. Moreover, with passage of the Pre-Approval Information Exchange Act in December 2022, sponsors of products that have not been approved may proactively communicate to payors certain information about products in development to help expedite patient access upon product approval. In addition, in January 2025, the FDA published final guidance outlining its policies governing the distribution of scientific information to healthcare providers about unapproved uses of approved products. The final guidance calls for such communications to be truthful, non-misleading and scientifically sound and to include all information necessary for healthcare providers to interpret the strengths and weaknesses and validity and utility of the information about the unapproved use of the approved product. If a company engages in such communications consistent with the guidance&#8217;s recommendations, the FDA indicated that it will not treat such communications as evidence of unlawful promotion of a new intended use for the approved product.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, a significant number of pharmaceutical and biotechnology companies have been the target of inquiries and investigations by various federal and state regulatory, investigative, prosecutorial and administrative entities in connection with the promotion of products for unapproved uses and other sales practices, including the Department of Justice and various U.S. Attorneys&#8217; Offices, the Office of Inspector General of the HHS, the FDA, the Federal Trade Commission, or the FTC, and various state Attorneys General offices. These investigations have alleged violations of various federal and state laws and regulations, including claims asserting antitrust violations, violations of the FDCA, the False Claims Act, the Prescription Drug Marketing Act and anti-kickback laws and other alleged violations in connection with the promotion of products for unapproved uses, pricing and Medicare and/or Medicaid reimbursement. Many of these investigations originate as &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; actions under the False Claims Act. Under the False Claims Act, any individual can bring a claim on behalf of the government alleging that a person or entity has presented a false claim or caused a false claim to be submitted to the government for payment. The person bringing a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> suit is entitled to a share of any recovery or settlement. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> suits, also commonly referred to as &#8220;whistleblower suits,&#8221; are often brought by current or former employees. In a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> suit, the government must decide whether to intervene and prosecute the case. If it declines, the individual may pursue the case alone.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA or any other governmental agency initiates an enforcement action against us or if we are the subject of a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> suit and it is determined that we violated prohibitions relating to the promotion of products for unapproved uses, we could be subject to substantial civil or criminal fines or damage awards and other sanctions such as consent decrees and corporate integrity agreements pursuant to which our activities would be subject to ongoing scrutiny and monitoring to ensure compliance with applicable laws and regulations. Any such fines, awards or other sanctions would have an adverse effect on our revenue, business, financial prospects and reputation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may seek certain designations for our product candidates, including Breakthrough Therapy, Fast Track and Priority Review designations in the United States, but we might not receive such designations, and even if we do, such designations may not lead to a faster development or regulatory review or approval process.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek certain designations for one or more of our product candidates that could expedite review and approval by the FDA. A Breakthrough Therapy product is defined as a product that is intended, alone or in combination with one or more other products, to treat a serious condition, and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For products that have been designated as Breakthrough Therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may also designate a product for Fast Track review if it is intended, whether alone or in combination with one or more other products, for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. For Fast Track products, sponsors may have greater interactions with the FDA and the FDA may initiate review of sections of a Fast Track product&#8217;s application before the application is complete. This rolling review may be available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a Fast Track product may be effective. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also seek a priority review designation for one or more of our product candidates. If the FDA determines that a product candidate offers major advances in treatment or provides a treatment where no adequate therapy exists, the FDA </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may designate the product candidate for priority review. A priority review designation means that the goal for the FDA to review an application is six months, rather than the standard review period of ten months.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These designations are within the discretion of the FDA. Accordingly, even if we believe that one of our product candidates meets the criteria for these designations, the FDA may disagree and instead determine not to make such designation. Further, even if we receive a designation, the receipt of such designation for a product candidate may not result in a faster development or regulatory review or approval process compared to products considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualifies for these designations, the FDA may later decide that the product candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may seek PRIME Designation in the European Union for our product candidates, but we might not receive such designations, and even if we do, such designations may not lead to a faster development or regulatory review or approval </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">process</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the EU, we may seek PRIME designation for some of our product candidates in the future. PRIME is a voluntary program aimed at enhancing the EMA&#8217;s role to reinforce scientific and regulatory support in order to optimize development and enable accelerated assessment of new medicines that are of major public health interest with the potential to address unmet medical needs. The program focuses on medicines that target conditions for which there exists no satisfactory method of treatment in the European Union or even if such a method exists, it may offer a major therapeutic advantage over existing treatments. PRIME is limited to medicines under development and not authorized in the European Union and where the sponsor intends to apply for an initial marketing authorization application through the centralized procedure. To be accepted for PRIME, a product candidate must meet the eligibility criteria in respect of its major public health interest and therapeutic innovation based on information that is capable of substantiating the claims. The benefits of a PRIME designation include the appointment of a rapporteur under the EMA's Committee for Human Medicinal Products to provide continued support and help to build knowledge ahead of a marketing authorization application, early dialogue and scientific advice at key development milestones, and the potential to qualify products for accelerated review, meaning reduction in the review time for an opinion on approvability to be issued earlier in the application process. PRIME enables a sponsor to request parallel EMA scientific advice and health technology assessment advice to facilitate timely market access. Even if we receive PRIME designation for any of our product candidates, the designation may not result in a materially faster development process, review or approval compared to conventional EMA procedures. Further, obtaining PRIME designation does not assure or increase the likelihood of EMA&#8217;s grant of a marketing authorization.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We, or our collaborators, may seek approval from the FDA or comparable foreign regulatory authorities to use accelerated development pathways for our product candidates. If we, or our collaborators, are not able to use such pathways, we, or they, may be required to conduct additional clinical trials beyond those that are contemplated, which would increase the expense of obtaining, and delay the receipt of, necessary marketing approvals, if we, or they, receive them at all. In addition, even if an accelerated approval pathway is available to us, or our collaborators, it may not lead to expedited approval of our product candidates, or approval at all.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the FDCA and implementing regulations, the FDA may grant accelerated approval to a product candidate to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies, upon a determination that the product has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a drug. The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage but is a clinically important improvement from a patient and public health perspective. Prior to seeking such accelerated approval, we, or our collaborators, will continue to seek feedback from the FDA or comparable foreign regulatory agencies and otherwise evaluate our, or their, ability to seek and receive such accelerated approval.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There can be no assurance that we will satisfy all FDA requirements, including new provisions that govern accelerated approval. For example, with passage of the FDORA in December 2022, Congress modified certain provisions governing accelerated approval of drug and biologic products. Specifically, the new legislation authorized the FDA to: require a sponsor to have its confirmatory clinical trial underway before accelerated approval is awarded, require a sponsor of a </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">product granted accelerated approval to submit progress reports on its post-approval studies to the FDA every six months (until the study is completed; and use expedited procedures to withdraw accelerated approval of an BLA if certain conditions are met, including where a required confirmatory study fails to verify and describe the predicted clinical benefit or where evidence demonstrates the product is not shown to be safe or effective under the conditions of use. The FDA may also use such procedures to withdraw an accelerated approval if a sponsor fails to conduct any required post-approval study of the product with due diligence, including with respect to &#8220;conditions specified by the Secretary.&#8221; The new procedures include the provision of due notice and an explanation for a proposed withdrawal, and opportunities for a meeting with the Commissioner or the Commissioner&#8217;s designee and a written appeal, among other things. We will need to fully comply with these and other requirements in connection with the development and approval of any product candidate that qualifies for accelerated approval.<br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2023, the FDA issued draft guidance that outlines its current thinking and approach to accelerated approval. The FDA indicated that the accelerated approval pathway is commonly used for approval of oncology drugs due to the serious and life-threatening nature of cancer. Although single-arm trials have been commonly used to support accelerated approval, a randomized controlled trial is the preferred approach as it provides a more robust efficacy and safety assessment and allows for direct comparisons to an available therapy. To that end, the FDA outlined considerations for designing, conducting, and analyzing data for trials intended to support accelerated approvals of oncology therapeutics. Subsequently, in December 2024 and January 2025, the FDA issued additional draft guidance relating to accelerated approval. These guidances describe FDA&#8217;s views on what it means to conduct a confirmatory trial with due diligence and how the agency plans to interpret whether such a study needs to be underway at the time of approval. While these guidances are currently only in draft form and will ultimately not be legally binding even when finalized, sponsors typically observe the FDA&#8217;s guidance closely to seek accelerated approval for any product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union, a &#8220;conditional&#8221; marketing authorization may be granted in cases where all the required safety and efficacy data are not yet available. A conditional marketing authorization is subject to conditions to be fulfilled for generating missing data or ensuring increased safety measures. A conditional marketing authorization is valid for one year and has to be renewed annually until fulfillment of all relevant conditions. Once the applicable pending studies are provided, a conditional marketing authorization can become a &#8220;standard&#8221; marketing authorization. However, if the conditions are not fulfilled within the timeframe set by the EMA, the marketing authorization will cease to be renewed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that the FDA or comparable foreign regulatory agencies will agree with our, or our collaborators&#8217;, surrogate endpoints or intermediate clinical endpoints in any of our, or their, clinical trials, or that we, or our collaborators, will decide to pursue or submit any additional application for accelerated approval or any other form of expedited development, review or approval. Similarly, there can be no assurance that, after feedback from the FDA or comparable foreign regulatory agencies, we, or our collaborators, will continue to pursue or apply for accelerated approval or any other form of expedited development, review or approval. Furthermore, for any submission of an application for accelerated approval or application under another expedited regulatory designation, there can be no assurance that such submission or application will be accepted for filing or that any expedited development, review or approval will be granted on a timely basis, or at all.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A failure to obtain accelerated approval or any other form of expedited development, review or approval for our product candidates, or withdrawal of a product candidate, would result in a longer time period until commercialization of such product candidate, could increase the cost of development of such product candidate and could harm our competitive position in the marketplace.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to obtain orphan drug exclusivity for any product candidates we may develop, and even if we do, that exclusivity may not prevent the FDA or the EMA from approving other competing products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug or biologic intended to treat a rare disease or condition. A similar regulatory scheme governs approval of orphan products by the EMA in the European Union. Generally, if a product candidate with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving another marketing application for the same product for the same therapeutic indication for that time period. The applicable period is seven years in the United States and ten years in the European Union. The exclusivity period in the European Union can be reduced to six years if a product no longer meets the criteria for orphan drug designation, in particular if the product is sufficiently profitable so that market exclusivity is no longer justified.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order for the FDA to grant orphan drug exclusivity to one of our products, the FDA must find that the product is indicated for the treatment of a condition or disease with a patient population of fewer than 200,000 individuals in the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States. The FDA may conclude that the condition or disease for which we seek orphan drug exclusivity does not meet this standard. Even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different products can be approved for the same condition. In addition, even after an orphan drug is approved, the FDA and comparable foreign regulatory authorities such as the EMA can subsequently approve the same product for the same condition if the FDA or such other authorities conclude that the later product is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug exclusivity may also be lost if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of the patients with the rare disease or condition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the Congress passed the FDA Reauthorization Act, or FDARA. The FDARA, among other things, codified the FDA&#8217;s pre-existing regulatory interpretation, to require that a drug sponsor demonstrate the clinical superiority of an orphan drug that is otherwise the same as a previously approved drug for the same rare disease in order to receive orphan drug exclusivity. Under omnibus legislation signed by former President Trump in December 2020, the requirement for a product to show clinical superiority applies to drugs and biologics that received orphan drug designation before enactment of the FDARA in 2017, but have not yet been approved or licensed by the FDA.<br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and Congress may further reevaluate the Orphan Drug Act and its regulations and policies. This may be particularly true in light of a decision from the Court of Appeals for the 11th Circuit in September 2021 finding that, for the purpose of determining the scope of exclusivity, the term &#8220;same disease or condition&#8221; means the designated &#8220;rare disease or condition&#8221; and could not be interpreted by the FDA to mean the &#8220;indication or use.&#8221; Thus, the court concluded, orphan drug exclusivity applies to the entire designated disease or condition rather than the &#8220;indication or use.&#8221; Although there have been legislative proposals to overrule this decision, they have not been enacted into law. On January 23, 2023, the FDA announced that, in matters beyond the scope of that court order, the FDA will continue to apply its existing regulations tying orphan-drug exclusivity to the uses or indications for which the orphan drug was approved. However, on February 14, 2025, a federal district court in Washington, D.C. fully embraced the reasoning of the court decision in another decision challenging the scope of orphan drug exclusivity. The implications of this decision, and its impact on the FDA&#8217;s implementation of the Orphan Drug Act, are unclear at this point.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not know if, when, or how the FDA or Congress may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be adversely impacted.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, to obtain orphan drug designation in the EU, we would need to demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the EU or, if such method exists, the medicinal product will be of significant benefit to those affected by that condition. There is no assurance that we would be able to meet that standard for any of our product candidates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, if we do obtain orphan drug designation for a product candidate in the EU, we will not be able to maintain that designation if we are not able to show, to the satisfaction of the EU regulatory authorities, that the product candidate is of significant benefit to patients over available commercial products for the indication in the European Union and any additional products that are ahead of our product candidate in clinical development for the indication.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are required by the FDA, EMA or comparable regulatory authority to obtain clearance or approval of a companion diagnostic test in connection with approval of any of our product candidates or a group of therapeutic products, and we do not obtain or we face delays in obtaining clearance or approval of a diagnostic test, we may not be able to commercialize the product candidate and our ability to generate revenue may be materially impaired.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are required by the FDA, EMA or a comparable regulatory authority to obtain clearance or approval of a companion diagnostic test in connection with approval of any of our product candidates, such companion diagnostic test would be used during our more advanced phase clinical trials as well as in connection with the commercialization of our product candidates. To be successful in developing and commercializing product candidates in combination with these companion diagnostics, we or our collaborators will need to address a number of scientific, technical, regulatory and logistical challenges. According to FDA guidance, if the FDA determines that a companion diagnostic device is essential to ensuring the safe and effective use of a novel therapeutic product or new indication, the FDA generally will not approve the therapeutic product or new therapeutic product indication if the companion diagnostic is not also approved or cleared. In certain circumstances (for example, when a therapeutic product is intended to treat a serious or life-threatening condition for which no satisfactory available therapy exists or when the labelling of an approved product needs to be revised to address a serious safety issue), however, the FDA may approve a therapeutic product without the prior or contemporaneous </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">marketing authorization of a companion diagnostic. In this case, approval of a companion diagnostic may be a post-marketing requirement or commitment.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Co-development of companion diagnostics and therapeutic products is critical to the advancement of precision medicine. Whether initiated at the outset of development or at a later point, co-development should generally be conducted in a way that will facilitate obtaining contemporaneous marketing authorizations for the therapeutic product and the associated companion diagnostic. If a companion diagnostic is required to identify patients who are most likely to benefit from receiving the product, to be at increased risk for serious adverse events as a result of treatment with a particular therapeutic product, or to monitor response to treatment with a particular therapeutic product for the purpose of adjusting treatment to achieve improved safety or effectiveness, then the FDA has required marketing approval of all companion diagnostic tests essential for the safe and effective use of a therapeutic product for cancer therapies. Various foreign regulatory authorities also regulate in vitro companion diagnostics as medical devices and, under those regulatory frameworks, will likely require the conduct of clinical trials to demonstrate the safety and effectiveness of any future diagnostics we may develop, which we expect will require separate regulatory clearance or approval prior to commercialization in those countries.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The approval of a companion diagnostic as part of the therapeutic product&#8217;s labeling limits the use of the therapeutic product to only those patients who express the specific genomic alteration or mutation alteration that the companion diagnostic was developed to detect. If the FDA, EMA or a comparable regulatory authority requires clearance or approval of a companion diagnostic for any of our product candidates, whether before, concurrently with approval, or post-approval of the product candidate, we, and/or future collaborators, may encounter difficulties in developing and obtaining clearance or approval for these companion diagnostics. The process of obtaining or creating such companion diagnostics is time consuming and costly. The FDA previously has required in vitro companion diagnostics intended to select the patients who will respond to a product candidate to obtain PMA, simultaneously with approval of the therapeutic candidate. The PMA process, including the gathering of pre-clinical and clinical data and the submission and review by the FDA, can take several years or longer. It involves a rigorous pre-market review during which the sponsor must prepare and provide FDA with reasonable assurance of the device&#8217;s safety and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing, and labeling. After a device is placed on the market, it remains subject to significant regulatory requirements, including requirements governing development, testing, manufacturing, distribution, marketing, promotion, labeling, import, export, record-keeping, and adverse event reporting.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that an in vitro companion diagnostic device could be subject to FDA enforcement discretion from</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compliance with the FDCA if it meets the definition of a Laboratory Developed Test, or LDT. However, FDA issued a</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">final rule in April 2024 to end enforcement discretion for LDTs and actively regulate such products as medical devices.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this final rule, LDTs are required to come into compliance with FDA&#8217;s medical device regulatory requirements in a</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">staged approach over the course of four years. The implementation of this LDT final rule could potentially be affected by</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Executive Order, Regulatory Freeze Pending Review, issued by President Trump on January 20, 2025 and/or the</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">anticipated change in leadership at FDA under the new administration. Further, while the final regulation is set to take</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effect on May 6, 2025, a number of parties have challenged the legality of the LDT regulation in a federal district court.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">That court held a hearing on this matter on February 19, 2025, and is expected to issue a ruling soon.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any delay or failure by us or third-party collaborators to develop or obtain regulatory clearance or approval of a companion diagnostic could delay or prevent approval or continued marketing of our related product candidates. Further, in April 2020, the FDA issued new guidance on developing and labeling companion diagnostics for a specific group of oncology therapeutic products, including recommendations to support a broader labeling claim rather than individual therapeutic products. We will continue to evaluate the impact of this guidance on our companion diagnostic development and strategy. This guidance and future issuances from the FDA, EMA and other regulatory authorities may impact our development of a companion diagnostic for our product candidates and could result in delays in regulatory clearance or approval or a change in the determination for whether or not a companion diagnostic is still required for our product candidates. We may be required to conduct additional studies to support a broader claim or more narrowed claim for a subset population. Also, to the extent other approved diagnostics are able to broaden their labeling claims to include any of our future approved product candidates covered indications, we may no longer need to continue our companion diagnostic development plans or we may need to alter those companion diagnostic development strategies, which could adversely impact our ability to generate revenue from the sale of our companion diagnostic test.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we may rely on third parties for the design, development and manufacture of companion diagnostic tests for our product candidates. If we enter into such collaborative agreements, we will be dependent on the sustained cooperation and effort of our future collaborators in developing and obtaining clearance or approval for these companion diagnostics. It may be necessary to resolve issues such as selectivity/specificity, analytical validation, reproducibility, or clinical </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">validation of companion diagnostics during the development and regulatory clearance or approval processes. Moreover, even if data from pre-clinical studies and early clinical trials appear to support development of a companion diagnostic for a product candidate, data generated in later clinical trials may fail to support the analytical and clinical validation of the companion diagnostic. We and our future collaborators may encounter difficulties in developing, obtaining regulatory clearance or approval for, manufacturing and commercializing companion diagnostics similar to those we face with respect to our product candidates themselves, including issues with achieving regulatory clearance or approval, production of sufficient quantities at commercial scale and with appropriate quality standards, and in gaining market acceptance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to successfully develop companion diagnostics for our product candidates, or experience delays in doing so, the development of our product candidates may be adversely affected, our product candidates may not obtain marketing approval, and we may not realize the full commercial potential of any of our product candidates that obtain marketing approval. As a result, our business, results of operations and financial condition could be materially harmed. In addition, a diagnostic company with whom we contract may decide to discontinue selling or manufacturing the companion diagnostic test that we anticipate using in connection with development and commercialization of product candidates or our relationship with such diagnostic company may otherwise terminate. We may not be able to enter into arrangements with another diagnostic company to obtain supplies of an alternative diagnostic test for use in connection with the development and commercialization of our product candidates or do so on commercially reasonable terms, which could adversely affect and/or delay the co-development or commercialization of our companion diagnostic and therapeutic product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our relationships with healthcare providers, physicians and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to civil, criminal and administrative sanctions, contractual damages, reputational harm and diminished future profits and earnings.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any drugs for which we obtain marketing approval. Our future arrangements with third-party payors, healthcare providers and physicians may expose us to broadly applicable state and federal fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any drugs for which we obtain marketing approval. These include the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Anti-Kickback Statute - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, paying, or receiving remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchasing, ordering, leasing, arranging for, or recommending the purchasing, ordering, or leasing of, any good or service for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare or Medicaid;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">False Claims Act -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the federal civil and criminal false claims laws, including the civil False Claims Act, and Civil Monetary Penalties Law, which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, false or fraudulent claims for payment or knowingly making, using or causing to made or used a false record or statement material to a false or fraudulent claim or to avoid, decrease or conceal an obligation to pay money to the federal government, or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay money to the federal government;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Health Insurance Portability and Accountability Act, or HIPAA -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the federal HIPAA, which created additional federal criminal statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters, and apply regardless of the payor (e.g., public or private);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA and HITECH -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations, which impose obligations on HIPAA covered entities and their business associates, including mandatory contractual terms and required implementation of administrative, physical and technical safeguards to maintain the privacy and security of individually identifiable health information;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Transparency Requirements -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the federal physician transparency requirements known as the Physician Payments Sunshine Act, under the ACA, as amended by the Health Care Education Reconciliation Act, which requires manufacturers of drugs, medical devices, biological and medical supplies covered by Medicare, Medicaid, or State Children&#8217;s Health Insurance Program to report annually to the CMS, within the HHS information related to payments and other transfers of value made by that entity to physicians, other healthcare providers and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Analogous State, Local and Foreign Laws -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> analogous state, local and foreign fraud and abuse laws and regulations, such as state anti-kickback and false claims laws, which may be broader than similar federal laws, can </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">apply to claims involving healthcare items or services regardless of payor, and are enforced by many different federal and state agencies as well as through private actions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures. State and foreign laws also govern the privacy and security of health information in some circumstances, as well as tracking and reporting of transfers of value by pharmaceutical manufacturers to physicians and healthcare organizations, many of which differ from each other in significant ways and often are not pre-empted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and/or administrative penalties, damages, fines, individual imprisonment, disgorgement, exclusion from government funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the European Union. The provision of benefits or advantages to physicians is governed by the national anti-bribery laws of EU Member States.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current and future legislation may increase the difficulty and cost for us and any of our collaborators to obtain marketing approval of and commercialize product candidates and affect the prices we, or any of our collaborators, may obtain.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities, impact pricing and reimbursement and affect our ability, or the ability of any of our collaborators, to profitably sell or commercialize any product candidates for which we, or any of our collaborators, obtain marketing approval. The pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by legislative initiatives. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. Current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we, or any of our collaborators, may receive for any FDA approved products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the MMA, changed the way Medicare covers and pays for pharmaceutical products. The legislation expanded Medicare coverage for prescription drugs purchased through a pharmacy by the elderly and disabled and introduced a new reimbursement methodology based on average sales prices for physician-administered drugs. In addition, this statute provides authority for limiting the number of drugs that will be covered in any therapeutic class, subject to certain exceptions. Cost reduction initiatives and other provisions of this statute could decrease the coverage and price that we receive for any approved products. While the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from the MMA may result in a similar reduction in payments from private payors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2010, then-President Obama signed into law the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or collectively the ACA. In addition, other legislative changes have been proposed and adopted since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. These changes included aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and will remain in effect through 2031 under the CARES Act. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Under current legislation, the actual reductions in Medicare payments may vary up to 4%.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Appropriations Act, or the Appropriations Act, which was signed into law by President Biden in December 2022, made several changes to sequestration of the Medicare program. Section 1001 of the Appropriations Act delays the 4% Statutory Pay-As-You-Go Act of 2010 sequester for two years, through the end of calendar year 2024. Triggered by enactment of the American Rescue Plan Act of 2021, the 4% cut to the Medicare program would have taken effect in January 2023. The Appropriation Act&#8217;s health care offset title includes Section 4163, which extends the 2% Budget Control Act of 2011 Medicare sequester for six months into fiscal year 2032 and lowers the payment reduction percentages in fiscal years 2030 and 2031.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, with passage of the Inflation Reduction Act, or the IRA, Congress extended the expansion of the Patient Protection and Affordable Care Act premium tax credits through 2025. Those subsidies were originally extended through 2022 under the American Rescue Plan Act of 2021. These laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Since enactment of the ACA, there have been and continue to be, numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, with enactment of the Tax Cuts and Jobs Act of 2017, Congress repealed the &#8220;individual mandate.&#8221; The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, became effective in 2019. Further, in June 2021, the U.S. Supreme Court dismissed a lawsuit challenging the constitutionality of the ACA after finding that the plaintiffs do not have standing to bring the litigation. Shortly after taking office in January 2025, President Trump revoked numerous executive orders issued by President Biden, including at least two executive orders which where were designed to further implement the ACA.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We anticipate similar efforts to undermine the ACA, and the accompanying uncertainty, for the foreseeable future. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the recent election of President Trump, coupled with a consolidation of party control of both chambers of the U.S. Congress, has led to new legislative and regulatory initiatives in the United States and the roll-back of many initiatives of the previous presidential administration, which may impact our business in unpredictable ways. Market uncertainty and volatility have been magnified and may intensify due to the statements and actions of the new U.S. presidential administration and resulting uncertainties regarding actual and potential shifts in U.S. and foreign, trade, economic and other policies, including with respect to treaties and tariffs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, on December 13, 2021, Regulation No 2021/2282 on Health Technology Assessment, or HTA, amending Directive 2011/24/EU, was adopted. While the Regulation entered into force in January 2022, it will only begin to apply from January 2025 onwards, with preparatory and implementation-related steps to take place in the interim. Once applicable, it will have a phased implementation depending on the products concerned. The Regulation intends to boost cooperation among EU member states in assessing health technologies, including new medicinal products as well as certain high-risk medical devices, and provide the basis for cooperation at the EU level for joint clinical assessments in these areas. It will permit EU member states to use common HTA tools, methodologies, and procedures across the EU, working together in four main areas, including joint clinical assessment of the innovative health technologies with the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">highest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU member states will continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) aspects of health technology, and making decisions on pricing and reimbursement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that these healthcare reforms, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product and/or the level of reimbursement physicians receive for administering any approved product we might bring to market. Reductions in reimbursement levels may negatively impact the prices we receive or the frequency with which our products are prescribed or administered. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. Accordingly, such reforms, if enacted, could have an adverse effect on </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">anticipated revenue from product candidates that we may successfully develop and for which we may obtain marketing approval and may affect our overall financial condition and ability to develop or commercialize product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The prices of prescription pharmaceuticals in the United States and foreign jurisdictions are subject to scrutiny and considerable legislative and executive actions that could impact the prices we obtain for our drug products, if and when approved.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The prices of prescription pharmaceuticals have also been the subject of considerable discussion in the United States and foreign jurisdictions. There have been several U.S. congressional inquiries, as well as proposed and enacted state and federal legislation designed to, among other things, bring more transparency to pharmaceutical pricing, review the relationship between pricing and manufacturer patient programs, and reduce the costs of pharmaceuticals under Medicare and Medicaid. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, in October 2020, the HHS and the FDA published a final rule allowing states and other entities to develop a Section 804 Importation Program, or SIP, to import certain prescription drugs from Canada into the United States. That regulation was challenged in a lawsuit by the Pharmaceutical Research and Manufacturers of America, or PhRMA, but the case was dismissed by a federal district court in February 2023 after the court found that PhRMA did not have standing to sue the HHS. Several states have passed laws allowing for the importation of drugs from Canada and a few states have passed legislation establishing workgroups to examine the impact of the state importation program. Several states have submitted Section 804 Importation Program proposals to the FDA. On January 5, 2024, the FDA approved Florida&#8217;s plan for Canadian drug importation. That state now has authority to import certain drugs from Canada for a period of two years once certain conditions are met. Florida will first need to submit a pre-import request for each drug selected for importation, which must be approved by the FDA. Florida will also need to relabel the drugs and perform quality testing of the products to meet FDA standards. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, on November 20, 2020, the HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. Pursuant to court order, the removal and addition of the aforementioned safe harbors were delayed, and recent legislation imposed a moratorium on implementation of the rule until January 1, 2026. The IRA further delayed implementation of this rule to January 1, 2032. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IRA has implications for Medicare Part D, which is a program available to individuals who are entitled to Medicare Part A or enrolled in Medicare Part B to give them the option of paying a monthly premium for outpatient prescription drug coverage. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare beginning in 2026, with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation; and replaces the Part D coverage gap discount program with a new discounting program beginning in 2025. The IRA permits the Secretary of the HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, with respect to price negotiations, Congress authorized Medicare to negotiate lower prices for certain costly single-source drug and biologic products that do not have competing generics or biosimilars and are reimbursed under Medicare Part B and Part D. CMS may negotiate prices for ten high-cost drugs paid for by Medicare Part D starting in 2026, followed by 15 Part D drugs in 2027, 15 Part B or Part D drugs in 2028, and 20 Part B or Part D drugs in 2029 and beyond. This provision applies to drug products that have been approved for at least 9 years and biologics that have been licensed for 13 years, but it does not apply to drugs and biologics that have been approved for a single rare disease or condition. Nonetheless, since CMS may establish a maximum price for these products in price negotiations, we would be fully at risk of government action if our products are the subject of Medicare price negotiations. Moreover, given the risk that could be the case, these provisions of the IRA may also further heighten the risk that we would not be able to achieve the expected return on our drug products or full value of our patents protecting our products if prices are set after such products have been on the market for nine years. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The first cycle of negotiations for the Medicare Drug Price Negotiation Program commenced in the summer of 2023. On August 15, 2024, HHS published the results of the first Medicare drug price negotiations for ten selected drugs that treat a range of conditions. The prices of these ten drugs will become effective January 1, 2026. In January 2025, CMS announced the selection of up to 15 additional drugs covered by Part D for the second cycle of negotiations. This second cycle of negotiations with participating drug companies will occur during 2025, and any negotiated prices for this second set of drugs will be effective starting January 1, 2027. CMS issued a public statement on January 29, 2025, declaring that </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">lowering the cost of prescription drugs is a top priority of the new administration and CMS is committed to considering opportunities to bring greater transparency in the negotiation program.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Further, the legislation subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law or for taking price increases that exceed inflation. In addition, the IRA established inflation rebate programs under Medicare Part B and Part D. The legislation also requires manufacturers to pay rebates for drugs in Medicare Part D whose price increases exceed inflation. On December 9, 2024, with issuance of its 2025 Physician Fee Schedule final regulation, CMS finalized its rules governing the IRA inflation rebate programs. The new law also caps Medicare out-of-pocket drug costs at an estimated $24,000 a year beginning in 2025. In addition, the IRA potentially raises legal risks with respect to individuals participating in a Medicare Part D prescription drug plan who may experience a gap in coverage if they required coverage above their initial annual coverage limit before they reached the higher threshold, or &#8220;catastrophic period&#8221; of the plan. Individuals requiring services exceeding the initial annual coverage limit and below the catastrophic period, must pay 100% of the cost of their prescriptions until they reach the catastrophic period. Among other things, the IRA contains many provisions aimed at reducing this financial burden on individuals by reducing the co-insurance and co-payment costs, expanding eligibility for lower income subsidy plans, and price caps on annual out-of-pocket expenses, each of which could have potential pricing and reporting implications.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 6, 2023, Merck &amp; Co. filed a lawsuit against the HHS and CMS asserting that, among other things, the IRA&#8217;s Drug Price Negotiation Program for Medicare constitutes an uncompensated taking in violation of the Fifth Amendment of the Constitution. Subsequently, a number of other parties, including the U.S. Chamber of Commerce and certain, also filed lawsuits in various courts with similar constitutional claims against the HHS and CMS. HHS has generally won the substantive disputes in these cases, and various federal district court judges have expressed skepticism regarding the merits of the legal arguments being pursued by the pharmaceutical industry. Certain of these cases are now on appeal and, on October 30, 2024, the Court of Appeals for the Third Circuit heard oral argument in three of these cases. We expect that litigation involving these and other provisions of the IRA will continue, with unpredictable and uncertain results.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, while it is currently unclear how the IRA will be effectuated, we cannot predict with certainty what impact any federal or state health reforms will have on us, but such changes could impose new or more stringent regulatory requirements on our activities or result in reduced reimbursement for our products, any of which could adversely affect our business, results of operations and financial condition.<br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, health care organizations and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures. This is increasingly true with respect to products approved pursuant to the accelerated approval pathway. State Medicaid programs and other payers are developing strategies and implementing significant coverage barriers, or refusing to cover these products outright, arguing that accelerated approval drugs have insufficient or limited evidence despite meeting the FDA&#8217;s standards for accelerated approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In other countries, particularly the countries of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a drug. To obtain reimbursement or pricing approval in some countries, we, or our collaborators, may be required to conduct a clinical trial that compares the cost-effectiveness of our drug to other available therapies. If reimbursement of our drugs is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be materially harmed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to anti-corruption laws, as well as export control laws, customs laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures and legal expenses, which could adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are subject to anti-corruption laws, including the Foreign Corrupt Practices Act, or the FCPA, the Bribery Act, and other anti-corruption laws that apply in countries where we do business and may do business in the future. The </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FCPA, the Bribery Act, and these other laws generally prohibit us, our officers and our employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage. We may in the future operate in jurisdictions that pose a high risk of potential FCPA or Bribery Act violations, and we may participate in collaborations and relationships with third parties whose actions could potentially subject us to liability under the FCPA, the Bribery Act, or local anti-corruption laws. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to other laws and regulations governing our international operations, including regulations administered by the governments of the United States, United Kingdom, and authorities in the European Union, including applicable export control regulations, economic sanctions on countries and persons, customs requirements and currency exchange regulations, which is collectively referred to as Trade Control Laws.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the FCPA, the Bribery Act, or other legal requirements, including Trade Control Laws. If we are not in compliance with the FCPA, the Bribery Act, and other anti-corruption laws or Trade Control Laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have a material adverse impact on our business, financial condition, results of operations and liquidity. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions. Likewise, any investigation of any potential violations of the FCPA, the Bribery Act, other anti-corruption laws or Trade Control Laws by the United States, the United Kingdom or other authorities could also have an adverse impact on our reputation, business, results of operations and financial condition.<br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 10, 2025, President Trump issued an executive order directing the Attorney General to review the guidelines and policies governing FCPA investigations and enforcement actions. Per the executive order, this review will result in new DOJ FCPA guidelines intended to enhance American economic competitiveness and to safeguard national security interests. During the 180-day review period, any new FCPA investigations and enforcement actions are to be suspended absent authorization from the Attorney General, and all existing FCPA investigations and enforcement actions will be reviewed. Additionally, after the Attorney General issues revised guidelines, the executive order directs the Attorney General to assess whether &#8220;remedial measures&#8221; related to past FCPA actions are warranted. We will need to carefully monitor the implementation of this order.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to stringent privacy laws, information security laws, regulations, policies and contractual obligations related to data privacy and security and changes in such laws, regulations, policies, contractual obligations and failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to data privacy and protection laws and regulations that apply to the collection, transmission, storage and use of personally-identifying information, which among other things, impose certain requirements relating to the privacy, security and transmission of personal information, including comprehensive regulatory systems in the United States, the European Union and the United Kingdom. The legislative and regulatory landscape for privacy and data protection continues to evolve in jurisdictions worldwide, and there has been an increasing focus on privacy and data protection issues with the potential to affect our business. Failure to comply with any of these laws and regulations could result in an enforcement action against us, including fines, imprisonment of company officials and public censure, claims for damages by affected individuals, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations or prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There are numerous U.S. federal and state laws and regulations related to the privacy and security of personal information. In particular, regulations promulgated pursuant to HIPAA establish privacy and security standards that limit the use and disclosure of individually identifiable health information, or protected health information, and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and availability of electronic protected health information. Determining whether protected health information has been handled in compliance with applicable privacy standards and our contractual obligations can be complex and may be subject to changing interpretation. These obligations may be applicable to some or all of our business activities now or in the future. In recent months, the Office of Civil Rights at HHS, or OCR, has been especially active in enforcing the HIPAA rules. Additionally, OCR is looking to amend the HIPAA Security Rule, which (if and when finalized) could create additional compliance obligations and risk for our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to properly protect the privacy and security of protected health information, we could be found to have breached our contracts. Further, if we fail to comply with applicable privacy laws, including applicable HIPAA privacy and security standards, we could face civil and criminal penalties. The HHS enforcement activity can result in financial liability and reputational harm, and responses to such enforcement activity can consume significant internal resources. In addition, state attorneys general are authorized to bring civil actions seeking either injunctions or damages in response to violations that threaten the privacy of state residents. We cannot be sure how these regulations will be interpreted, enforced or applied to our operations. In addition to the risks associated with enforcement activities and potential contractual liabilities, our ongoing efforts to comply with evolving laws and regulations at the federal and state level may be costly and require ongoing modifications to our policies, procedures and systems.<br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition to potential enforcement by the HHS, we are also potentially subject to privacy enforcement from the FTC. The FTC has been particularly focused on the unpermitted processing of health and genetic data through its recent enforcement actions and is expanding the types of privacy violations that it interprets to be &#8220;unfair&#8221; under Section 5 of the FTC Act, as well as the types of activities it views to trigger the Health Breach Notification Rule (which the FTC also has the authority to enforce). The agency is also in the process of developing rules related to commercial surveillance and data security that may impact our business. We will need to account for the FTC&#8217;s evolving rules and guidance for proper privacy and data security practices in order to mitigate our risk for a potential enforcement action, which may be costly. If we are subject to a potential FTC enforcement action, we may be subject to a settlement order that requires us to adhere to very specific privacy and data security practices, which may impact our business. We may also be required to pay fines as part of a settlement (depending on the nature of the alleged violations). If we violate any consent order that we reach with the FTC, we may be subject to additional fines and compliance requirements. Finally, both the FTC and HHS&#8217;s enforcement priorities (as well as those of other federal regulators) may be impacted by the change in administration and new leadership. These shifts in enforcement priorities may also impact our business. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There are also increased restrictions at the federal level relating to transferring sensitive data outside of the United States to certain foreign countries. For example, in 2024, Congress passed H.B. 815, which included the Protecting Americans&#8217; Data from Foreign Adversaries Act of 2024. This law creates certain restrictions for entities that disclose sensitive data (including potential health data) to countries such as China. Failure to comply with these rules can lead to a potential FTC enforcement action. Additionally, the DOJ recently finalized a rule implementing Executive Order 14117, which creates similar restrictions related to the transfer of sensitive U.S. data to countries such as China. These data transfer restrictions (and others that may pass in the future) may create operational challenges and legal risks for our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">States are also active in creating specific rules relating to the processing of personal information. In 2018, California passed into law the CCPA which took effect on January 1, 2020 and imposed many requirements on businesses that process the personal information of California residents. Many of the CCPA&#8217;s requirements are similar to those found in the General Data Protection Regulation, or the GDPR, including requiring businesses to provide notice to data subjects regarding the information collected about them and how such information is used and shared, and providing data subjects the right to request access to such personal information and, in certain cases, request the erasure of such personal information. The CCPA also affords California residents the right to opt-out of &#8220;sales&#8221; of their personal information. The CCPA contains significant penalties for companies that violate its requirements. In November 2020, California voters passed a ballot initiative for the CPRA, which will significantly expand the CCPA to incorporate additional GDPR-like provisions including requiring that the use, retention, and sharing of personal information of California residents be reasonably necessary and proportionate to the purposes of collection or processing, granting additional protections for sensitive personal information, and requiring greater disclosures related to notice to residents regarding retention of information. Most CPRA provisions took effect on January 1, 2023, though the obligations apply to any personal information collected after January 1, 2022. These provisions may apply to some of our business activities. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to California, a number of states have passed comprehensive privacy laws similar to the CCPA and CPRA. These laws are either in effect or will go into effect sometime over the next few years. Like the CCPA and CPRA, these laws create obligations related to the processing of personal information, as well as special obligations for the processing of &#8220;sensitive&#8221; data, which includes health data in some cases. Some of the provisions of these laws may apply to our business activities. There are also states that are strongly considering or have already passed comprehensive privacy laws during the 2025 legislative sessions. Other states will be considering similar laws in the future, and Congress has also been debating passing a federal privacy law. There are also states that are specifically regulating health information that may affect our business. For example, the State of Washington passed the My Health My Data Act in 2023 which specifically regulated health information that is not otherwise regulated by the HIPAA rules, and the law also has a private right of action, which further increases the relevant compliance risk. Connecticut and Nevada have also passed similar laws regulating consumer health data, and more states are considering such legislation in 2025. These laws may impact our business activities, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including our identification of research subjects, relationships with business partners and ultimately the marketing and distribution of our products, if approved.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Plaintiffs&#8217; lawyers in the United States are also increasingly using privacy-related statutes at both the state and federal level to bring lawsuits against companies for their data-related practices. In particular, there have been a significant number of cases filed against companies for their use of pixels and other web trackers. These cases often allege violations of the California Invasion of Privacy Act and other state laws regulating wiretapping, as well as the federal Video Privacy Protection Act. The rise in these types of lawsuits creates potential risk for our business. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, laws in all 50 states require businesses to provide notice to customers whose personal information has been disclosed as a result of a data breach. These laws are not consistent, and compliance in the event of a widespread data breach is difficult and may be costly. Moreover, states have been frequently amending existing laws, requiring attention to changing regulatory requirements. We also may be contractually required to notify affected individuals or other counterparties of a security breach, incident, or compromise. Although we may have contractual protections with our vendors, any actual or perceived security breach, incident, or compromise could harm our reputation and brand, expose us to potential liability or require us to expend significant resources on data security and in responding to any such actual or perceived breach, incident, or compromise. Any contractual protections we may have from our vendors may not be sufficient to adequately protect us from any such liabilities and losses, and we may be unable to enforce any such contractual protections. In addition to government regulation, privacy advocates and industry groups have and may in the future propose self-regulatory standards from time to time. These and other industry standards may legally or contractually apply to us, or we may elect to comply.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to the laws in the United States, there are significant privacy and data security laws that apply in Europe and other countries. The collection, use, disclosure, transfer, or other processing of personal data, including personal health data, regarding individuals who are located in the European Economic Area, or the EEA, and the processing of personal data that takes place in the EEA, is regulated by the GDPR, which went into effect in May 2018 and which imposes obligations on companies that operate in our industry with respect to the processing of personal data and the cross-border transfer of such data. The GDPR imposes onerous accountability obligations requiring data controllers and processors to maintain a record of their data processing and policies. If our or our partners&#8217; or service providers&#8217; privacy or data security measures fail to comply with the GDPR requirements, we may be subject to litigation, regulatory investigations, enforcement notices requiring us to change the way we use personal data and/or fines of up to 20.0 million Euros or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, as well as compensation claims by affected individuals, negative publicity, reputational harm and a potential loss of business and goodwill.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The GDPR places restrictions on the cross-border transfer of personal data from the European Union to countries that have not been found by the European Commission to offer adequate data protection legislation, such as the United States. There are ongoing concerns about the ability of companies to transfer personal data from the European Union to other countries. In July 2020, the Court of Justice of the EU, or the CJEU, invalidated the European Union-United States Privacy Shield, or Privacy Shield, one of the mechanisms used to legitimize the transfer of personal data from the EEA to the United States. The CJEU decision also drew into question the long-term viability of an alternative means of data transfer, the standard contractual clauses, for transfers of personal data from the EEA to the United States. While we are not self-certified under the Privacy Shield, this CJEU decision may lead to increased scrutiny on data transfers from the EEA to the United States, generally, and increase our costs of compliance with data privacy legislation as well as our costs of negotiating appropriate privacy and security agreements with our vendors and business partners.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the CJEU decision, in October 2022, President Biden signed an executive order to implement the EU-U.S. Data Privacy Framework, which would serve as a replacement to the EU-U.S. Privacy Shield. The European Union initiated the process to adopt an adequacy decision for the EU-U.S. Data Privacy Framework in December 2022, and the European Commission adopted the adequacy decision in July 2023. The adequacy decision permits U.S. companies who self-certify to the EU-U.S. Data Privacy Framework to rely on it as a valid data transfer mechanism for data transfers from the European Union to the United States. However, some privacy advocacy groups have already suggested that they will be challenging the EU-U.S. Data Privacy Framework. If these challenges are successful, they may not only impact the EU-U.S. Data Privacy Framework, but also further limit the viability of the standard contractual clauses and other data transfer mechanisms. The uncertainty around this issue has the potential to impact our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 23, 2016, the electorate in the United Kingdom. voted in favor of leaving the European Union, commonly referred to as Brexit. As with other issues related to Brexit, there are open questions about how personal data will be protected in the United Kingdom. and whether personal information can transfer from the European Union to the United Kingdom. Following the withdrawal of the United Kingdom from the European Union, the UK Data Protection Act 2018 applies to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the processing of personal data that takes place in the United Kingdom and includes parallel obligations to those set forth by GDPR. While the Data Protection Act of 2018 in the United Kingdom that &#8220;implements&#8221; and complements the GDPR has achieved Royal Assent on May 23, 2018 and is now effective in the United Kingdom, it is unclear whether transfer of data from the EEA to the United Kingdom will remain lawful under the GDPR, although these transfers currently are permitted by an adequacy decision from the European Commission. The United Kingdom government has already determined that it considers all European Union 27 and EEA member states to be adequate for the purposes of data protection, ensuring that data flows from the United Kingdom. to the EU/EEA remain unaffected. In addition, a recent decision from the European Commission appears to deem the United Kingdom. as being &#8220;essentially adequate&#8221; for purposes of data transfer from the European Union to the United Kingdom., although this decision may be re-evaluated in the future. The United Kingdom. and the United States. have also agreed to a U.S.-UK &#8220;Data Bridge,&#8221; which functions similarly to the EU-U.S. Data Privacy Framework and provides an additional legal mechanism for companies to transfer data from the United Kingdom to the United States. In addition to the United Kingdom., Switzerland is also in the process of approving an adequacy decision in relation to the Swiss-U.S. Data Privacy Framework (which would function similarly to the EU-U.S. Data Privacy Framework and the U.S.-UK Data Bridge in relation to data transfers from Switzerland to the United States). Any changes or updates to these developments have the potential to impact our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beyond GDPR, there are privacy and data security laws in a growing number of countries around the world. While many loosely follow GDPR as a model, other laws contain different or conflicting provisions. These laws will impact our ability to conduct our business activities, including both our clinical trials and any eventual sale and distribution of commercial products, through increased compliance costs, costs associated with contracting and potential enforcement actions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we continue to address the implications of the recent changes to data privacy regulations, data privacy remains an evolving landscape at both the domestic and international level, with new regulations coming into effect and continued legal challenges, and our efforts to comply with the evolving data protection rules may be unsuccessful. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices. We must devote significant resources to understanding and complying with this changing landscape. Failure to comply with laws regarding data protection would expose us to risk of enforcement actions taken by data protection authorities in the EEA and elsewhere and carries with it the potential for significant penalties if we are found to be non-compliant. Similarly, failure to comply with federal and state laws in the United States regarding privacy and security of personal information could expose us to penalties under such laws. Any such failure to comply with data protection and privacy laws could result in government-imposed fines or orders requiring that we change our practices, claims for damages or other liabilities, regulatory investigations and enforcement action, litigation and significant costs for remediation, any of which could adversely affect our business. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our business, financial condition, results of operations or prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our employees, independent contractors, consultants, collaborators and vendors engage in misconduct or other improper activities, including non-compliance with regulatory standards and/or requirements and insider trading, we could sustain significant liability and harm to our reputation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of fraud or other misconduct by our employees, independent contractors, consultants, collaborators and vendors. Misconduct by these partners could include intentional failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, provide accurate information to the FDA or comparable foreign regulatory authorities, comply with manufacturing standards, comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, report financial information or data accurately or disclose unauthorized activities to us. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. This could include violations of HIPAA, other U.S. federal and state laws, and requirements of foreign jurisdictions, including the GDPR. We are also exposed to risks in connection with any insider trading violations by employees or others affiliated with us. It is not always possible to identify and deter employee or third-party misconduct, and the precautions that we take to detect and prevent these activities may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, standards, regulations, guidance or codes of conduct. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other sanctions.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or any third-party manufacturer we engage now or in the future fails to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs or liabilities that could significantly harm our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and third-party manufacturers we engage now are, and any third-party manufacturer we may engage in the future will be, subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. Although we contract with third parties for the disposal of these materials and waste products, we cannot completely eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain general liability insurance as well as workers&#8217; compensation insurance to cover costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, but this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. Current or future environmental laws and regulations may impair our research, development or production efforts, which could adversely affect our business, financial condition, results of operations or prospects. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Employee Matters</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our internal computer systems, or those of our collaborators, vendors, suppliers, contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal computer systems and those of any of our collaborators, vendors, suppliers, contractors or consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Such systems are also vulnerable to service interruptions or to security breaches from inadvertent or intentional actions by our employees, third-party vendors and/or business partners, or from cyber-attacks by malicious third parties. Cyber-attacks are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect. Cyber-attacks could include the deployment of harmful malware, ransomware, denial-of-service attacks, unauthorized access to or deletion of files, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information. Cyber-attacks also could include phishing attempts or email fraud to cause payments or information to be transmitted to an unintended recipient.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience any material system failure, accident, cyber-attack or security that causes interruptions in our operations, it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our marketing approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed, and the further development and commercialization of our product candidates could be delayed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, including principal investigators, consultants and vendors and any third parties we may engage in connection with discovery programs, research, development, regulatory, manufacturing, quality assurance and other pharmaceutical functions and commercialization may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading, which could cause significant liability for us and harm our reputation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of fraud or other misconduct by our employees, independent contractors, including principal investigators, consultants and vendors and any other third parties we engage. Misconduct by these parties could include intentional, reckless or negligent conduct or unauthorized activities that include failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, provide complete and accurate information to the FDA or comparable foreign regulatory authorities, comply with manufacturing standards, comply with federal and state data </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">privacy, security, fraud and other healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, report complete financial information or data accurately or disclose unauthorized activities to us. Misconduct by employees and other third parties could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. This could include violations of HIPAA, other U.S. federal and state law, and requirements of non-U.S. jurisdictions, including the EU Data Protection Directive. We are also exposed to risks in connection with any insider trading violations by employees or others affiliated with us. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, standards, regulations, guidance or codes of conduct. Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid, other U.S. federal healthcare programs or healthcare programs in other jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Ownership of Our Common Stock</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market price of our common stock is volatile, and the market price of our common stock may drop in the future.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock has been and could be subject to significant fluctuations. Some of the factors that may cause the market price of our common stock to fluctuate include:<br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to successfully implement our cash preservation plan </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our determination to pause research and development activities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to identify, evaluate, pursue and consummate a strategic alternative;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to conduct an orderly wind down of our operations; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if we were to resume research and development activities, results of clinical trials and pre-clinical studies of our product candidates, or those of our collaborators;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results of clinical trials and pre-clinical studies of our competitors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to meet or exceed financial and development projections we may provide to the public;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to meet or exceed the financial and development projections of the investment community;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by our competitors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actions taken by regulatory agencies with respect to our product candidates, clinical studies, manufacturing process or sales and marketing terms;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes or other developments relating to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our technologies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of qualified scientific and management personnel;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant lawsuits, including patent or stockholder litigation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if securities or industry analysts do not publish research or reports about our business, or if they issue adverse or misleading opinions regarding our business and stock;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the market valuations of similar companies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general market or macroeconomic conditions or market conditions in the biopharmaceutical sector;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of securities by us or our stockholders in the future;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if we fail to raise an adequate amount of capital to fund our operations and continued development of our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trading volume of our common stock;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements with respect to compliance with the Nasdaq listing requirements;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by competitors of new commercial products, clinical progress or lack thereof, significant contracts, commercial relationships or capital commitments;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse publicity relating to product candidates, including with respect to other products in such markets;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the introduction of technological innovations or new therapies that compete with our products and services; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">period-to-period fluctuations in our financial results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The price of our shares of common stock may experience increased volatility as we provide updates regarding our cash preservation plan and the wind down of our operations. For additional discussion of the risks related to our evaluation of strategic alternatives and the wind down of our operations, see &#8220;Risk Factors - Risks Related to Our Evaluation of Strategic Alternatives and Wind Down.&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of our common stock. In addition, a recession, depression or other sustained adverse market event could materially and adversely affect our business and the value of our common stock. In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against such companies. Furthermore, market volatility may lead to increased stockholder activism if we experience a market valuation that activists believe is not reflective of its intrinsic value. Activist campaigns that contest or conflict with our strategic direction or seek changes in the composition of our board of directors could have an adverse effect on our operating results and financial condition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We incur additional costs and increased demands upon management as a result of complying with the laws and regulations affecting public companies.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incur significant legal, accounting and other expenses as a public company that we did not incur as a private company, including costs associated with public company reporting obligations under the Exchange Act. Some of our management team has not previously managed and operated a public company. These executive officers and other personnel will need to devote substantial time to gaining expertise related to public company reporting requirements and compliance with applicable laws and regulations to ensure that we comply with all of these requirements. Any changes we make to comply with these obligations may not be sufficient to allow us to satisfy our obligations as a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for us to attract and retain qualified persons to serve on the board of directors or on board committees or to serve as executive officers, or to obtain certain types of insurance, including directors&#8217; and officers&#8217; insurance, on acceptable terms.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not currently meet the requirements for continued listing on The Nasdaq Global Market. If we fail to meet the requirements for continued listing on The Nasdaq Global Market, trading in our common stock could be suspended and our common stock delisted from Nasdaq, which would have a negative effect on the price of our common stock and our ability to raise additional capital.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our common stock is currently listed on The Nasdaq Global Market. We are required to meet specified requirements to maintain our listing on The Nasdaq Global Market, including, among others, a minimum market value of listed securities , or MVLS, of $50,000,000 under Nasdaq Listing Rule 5450(b)(2)(A), or the MVLS Requirement and a minimum bid price of $1.00 per share under Nasdaq Listing Rule 5450(a)(1), or the Bid Price Rule.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On October 10, 2024, we received written notice from the Listing Qualifications Department, or the Staff, of The Nasdaq Stock Market LLC, or Nasdaq, notifying us that our common stock was not in compliance with the MVLS Requirements for the previous 30 consecutive business days.  In accordance with the Nasdaq Listing Rules, we were granted 180 calendar days, or until April 8, 2025, to regain compliance with the MVLS Requirement. If we do not regain compliance with the MVLS Requirement by April 8, 2025, which we do not expect to, we will receive written notification from the Staff on our about April 9, 2025, that our securities are subject to delisting. At that time, we may request a hearing before the Nasdaq Hearnings Panel (the "Panel") pursuant to the procedures set forth in the 5800 Series of the Nasdaq Listing Rules. Our request for a hearing before the Panel would stay any further action by the Staff to delist our common stock from Nasdaq at least pending the hearing and the expiration of any extension the Panel may grant to us following the hearing.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On January 6, 2025, we received separate written notice from the Staff notifying us that, based upon the closing bid price of our common stock for the prior 38 consecutive business days, we were not in compliance with the Bid Price Rule, and were granted 180 calendar days, or until July 7, 2025, to regain compliance with the Bid Price Rule. If, at any time the closing bid price of our common stock is at least $1.00 per share for a minimum of ten, through generally not more than 20, consecutive days, the Staff will provide written notification to us that we have regained compliance with the Bid Price Rule. If we do not regain compliance with the Bid Price Rule by July 7, 2025, we may be eligible for an additional 180 calendar day period to regain compliance. To qualify for a second grace period, we would need to transfer the listing of our common stock to The Nasdaq Capital Market, evidence compliance with the initial listing criteria for The Nasdaq Capital Market, namely the $50 million MVLS rule or the $5 million stockholders&#8217; equity rule for initial listing on The Nasdaq Capital Market, with the exception of the $15 million market value of publicly held shares requirement, and provide written </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">notice to the Staff of our intention to cure the bid price deficiency during the second compliance period by effecting a reverse stock split, if necessary. If we do not regain compliance with the Bid Price Rule or are not eligible to transfer the listing of our common stock to The Nasdaq Capital Market by July 7, 2025, the Staff will provide separate written notification that our securities are subject to delisting, which we would address with the Panel.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The delisting of our common stock from Nasdaq could materially reduce the liquidity of our common stock and result in a corresponding material reduction in the price of our common stock. In addition, delisting could harm our ability to raise capital through alternative financing sources on terms acceptable to us, or at all, and would also make it more difficult for our stockholders to sell or purchase our common stock when they wish to do so. If delisted, we will likely trade on the OTC Markets system, which could make it more difficult to dispose of, or obtain accurate quotations for the price of, our common stock, and may lead to a reduction in coverage by securities analysts and the news media, which could cause the price of our common stock to decline further.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If a significant portion of our total outstanding shares are sold into the market, the market price of our common stock could drop significantly, even if our business is doing well. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of shares of our common stock in the public market, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. Certain of our</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stockholders have rights, subject to specified conditions, under our resale registration statement on Form S-3 registering 3,730,608 shares of our common stock under which they may sell their shares of common stock in the public market, so long as the resale registration statement on Form S-3 remains effective.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also filed registrations statement registering all shares of common stock that we may issue under our equity compensation plans. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, we are also party to the Sale Agreement with Jefferies, as sales agent, pursuant to which we may offer and sell shares of our common stock having an aggregate offering price of up to $100.0 million from time to time through Jefferies under an &#8220;at-the-market offering&#8221; program, or ATM. The number of shares that are sold by Jefferies after we request that sales be made will fluctuate based on the market price of our common stock during the sales period and limits we set with Jefferies. Therefore, it is not possible to predict the number of shares that will ultimately be issued by us, if any, pursuant to the sales agreement. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we have sold 1,362,917 shares of our common stock under the ATM for net proceeds of $3.0 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If at some point we are no longer a &#8220;smaller reporting company&#8221; or otherwise no longer qualify for applicable exemptions, we will be subject to additional laws and regulations affecting public companies that will increase our costs and the demands on management and could harm our operating results.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will be subject to the reporting requirements of the Exchange Act, which requires, among other things, that we file with the SEC annual, quarterly and current reports with respect to our business and financial condition as well as other disclosure and corporate governance requirements. However, as a &#8220;smaller reporting company,&#8221; as defined in Item 10(f)(1) of Regulation S-K, we may take advantage of certain exemptions from disclosure requirements, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2022 and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. If at some point we are no longer qualified as a smaller reporting company or otherwise no longer qualify for these exemptions, we will be required to comply with these additional legal and regulatory requirements applicable to public companies and will incur significant legal, accounting and other expenses to do so. If we are not able to comply with the requirements in a timely manner or at all, our financial condition or the market price of our common stock may be harmed. For example, if we or our independent auditor identify deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, then we could face additional costs to remedy those deficiencies, the market price of our stock could decline or we could be subject to sanctions or investigations by the SEC or other regulatory authorities, which would require additional financial and management resources.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our executive officers, directors and principal stockholders may have the ability to significantly influence all matters submitted to our stockholders for approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, our executive officers, directors and principal stockholders, in the aggregate, beneficially owned 45.3% of our outstanding shares of common stock. As a result, if these stockholders were to choose to act together, they would be able to significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would significantly influence the election of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of voting power could delay or prevent an acquisition of the Company on terms that other stockholders may desire.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have broad discretion in the use of our cash and cash equivalents and may invest or spend the proceeds in ways with which you do not agree and in ways that may not increase the value of your investment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have broad discretion over the use of our cash and cash equivalents and have adopted a cash preservation plan. You may not agree with our decisions, and our use of the proceeds may not yield any return on your investment. Our failure to apply these resources effectively could compromise our ability to pursue our growth strategy and we may not be able to yield a significant return, if any, on our investment of these net proceeds. You do not have the opportunity to influence our decisions on how to use our cash resources.</span></div><div id="i280a0966ad034c5090dd46bd303d2259_73"></div><div style="margin-top:12pt;text-align:justify"><span id="ia1cb3ac5fe7040c7acbf1ce51bd8506b_55"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B. Unresolved Staff Comments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i280a0966ad034c5090dd46bd303d2259_76"></div><div><span><br/></span></div><div><span id="ic7b1cef4dbcb4c0caf7f656a4b3e8d20_3658"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1C. Cybersecurity</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Cybersecurity Risk Management and Strategy</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="f-37" continuedAt="f-37-1" escape="true"><div style="text-align:justify"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="f-39" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true" id="f-38">We have established processes for assessing, identifying and managing cybersecurity risks, which are built into our overall risk management program and are designed to help protect our information assets and operations from internal and external cyber threats, protect employee and patient information from unauthorized access or attack, as well as secure our networks and systems.</ix:nonNumeric> Such processes include physical, procedural and technical safeguards. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true" id="f-40">We engage certain third parties to enhance and assist with our cybersecurity oversight, including a 24/7 Security Operation Center, or SOC, that monitors network devices and computer systems in real time.</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true" id="f-41">We include confidentiality and data protection provisions in certain contracts with third-party service providers to help protect us and our patients from any related vulnerabilities.</ix:nonNumeric></span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </span></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify"><ix:continuation id="f-37-1" continuedAt="f-37-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false" id="f-42">We do not believe that there are currently any known risks from cybersecurity threats that have or are reasonably likely to materially affect us or our business strategy, results of operations or financial condition. However, despite our efforts, we cannot eliminate all risks from cybersecurity threats, or provide assurances that we have not experienced undetected cybersecurity incidents.</ix:nonNumeric> For more information on the most pertinent risks we may experience from cybersecurity threats, please refer to Part I, Item 1A, &#8220;Risk Factors&#8221; &#8211; &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our internal computer systems, or those of our collaborators, vendors, suppliers, contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-37-2">.&#8221;</ix:continuation> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Cybersecurity Governance and Oversight</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="f-46" continuedAt="f-46-1" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="f-45" continuedAt="f-45-1" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-43" continuedAt="f-43-1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="f-44" escape="true">The audit committee of our <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true" id="f-47">board of directors</ix:nonNumeric> provides oversight over cybersecurity risk and updates the full board of directors periodically regarding such oversight. The audit committee reviews and discusses with management the Company&#8217;s major risk exposures, including cybersecurity matters, and is notified between such updates regarding significant new cybersecurity threats or incidents, if any.</ix:nonNumeric> </span></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-49" continuedAt="f-49-1" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="f-48" continuedAt="f-48-1" escape="true"><ix:continuation id="f-43-1" continuedAt="f-43-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true" id="f-50">Chief Executive Officer, or CEO</ix:nonNumeric>, leads the operational oversight of company-wide cybersecurity strategy, policy, standards and processes and works across relevant departments to assess and help prepare us and our employees to address cybersecurity risks. The consultant that operates our SOC updates the CEO regarding the detection of cybersecurity risk exposure and provides advice on the prevention, mitigation and remediation of such risks.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></ix:continuation></ix:nonNumeric></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-48-1"><ix:continuation id="f-43-2"><ix:continuation id="f-49-1">The CEO keeps the senior executive leadership team apprised, including our Vice President of Finance, on assessments of risk exposure to ensure that the highest levels of management are kept abreast of potential risks we are facing.</ix:continuation> <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="f-51" escape="true">The CEO has significant prior business experience in compliance and risk management and coordinates directly with the third party who operates our SOC on issues involving particular cybersecurity expertise.</ix:nonNumeric></ix:continuation></ix:continuation> </span></div></ix:nonNumeric></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-46-1"><ix:continuation id="f-45-1">In an effort to help deter and detect cyber threats, we regularly provide all employees, including part-time and temporary employees, with data protection cybersecurity and incident prevention training throughout the year, which covers timely and relevant topics, including social engineering, phishing, password protection, confidential data protection, asset use and mobile security, and educates employees on the importance of reporting all incidents immediately. We also use technology-based tools to mitigate cybersecurity risks and to bolster our employee-based cybersecurity programs.</ix:continuation></ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div id="i280a0966ad034c5090dd46bd303d2259_79"></div><div><span id="ic5e43f46b3f74e8e96038728ba954458_414"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Properties</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal facilities consist of office and laboratory space in Philadelphia, Pennsylvania. We occupy approximately 4,369 square feet of office space under a lease that is expected to expire in October 2029 and laboratory space leases which expire in June 2025. We believe that our facilities are sufficient to meet our current needs.</span></div><div id="i280a0966ad034c5090dd46bd303d2259_82"></div><div style="margin-top:12pt"><span id="i7c8af2420fbb4874b3b9e71b79e65f0c_93"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Legal Proceedings</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently not a party to any material legal proceedings.</span></div><div id="i280a0966ad034c5090dd46bd303d2259_85"></div><div style="margin-top:12pt"><span id="ia551be224cd346b7b0e657c46531840b_53"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div id="i280a0966ad034c5090dd46bd303d2259_88"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span id="i50dd8415e59d4bd49c6d70b77bb81560_12"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part II</span></div><div id="i280a0966ad034c5090dd46bd303d2259_91"></div><div><span id="i7422626828204722af10aeb0ba8c931f_1655"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders of Our Common Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is currently listed on the Nasdaq Global Market under the symbol &#8220;CARM.&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of stockholders of record of our common stock as of March 26, 2025 was 28. This number does not include stockholders for whom shares are held in &#8220;nominee&#8221; or &#8220;street&#8221; name.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings to fund the development and expansion of our business. We do not anticipate paying any cash dividends for the foreseeable future, and future debt financing arrangements may contain terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. Any future determination to declare and pay dividends will be made at the discretion of our board of directors and will depend on then-existing conditions including our results of operations, financial condition, contractual restrictions, capital requirements, business prospects and other factors our board of directors may deem relevant.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not issue any securities that were not registered under the Securities Act of 1933, as amended, or the Securities Act, during the twelve months ended December 31, 2024, other than pursuant to transactions previously disclosed in our Current Reports on Form 8-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchase</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> of Equity Securities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not purchase any of our registered equity securities during the period covered by this Annual Report on Form 10-K. </span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i280a0966ad034c5090dd46bd303d2259_94"></div><div><span id="if626673dd152468288b49d61f76068c7_24"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. [Reserved]</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><div id="i280a0966ad034c5090dd46bd303d2259_97"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span id="i6facfa7cbc8042f4949c58b815b4f561_665"></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read together with our consolidated financial statements and the related notes appearing elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements that involve risks and uncertainties. As a result of many factors, such as those set forth in the section titled &#8220;Risk Factors&#8221; and elsewhere in this Annual Report on Form 10-K, our actual results may differ materially from those anticipated by these forward-looking statements.</span></div><div id="i280a0966ad034c5090dd46bd303d2259_100"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biotechnology company focused on applying our industry leading expertise in macrophage engineering to develop transformative therapies to treat serious diseases including liver fibrosis and cancer. We have created a comprehensive set of platform technologies to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells. We seek to apply our ability to engineer macrophages and monocytes, either</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, using approaches and delivery systems most appropriate to each specific indication, to meaningfully alter the course of the disease. Our proprietary CAR-M platform uses chimeric antigen receptors, or CARs, to redirect macrophages or monocytes against specific tumor associated antigens with the goal of targeted anti-tumor immunity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2024 Revised Operating Plans</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In late March 2024, following a strategic review of our operating plan for 2024 and future periods, we approved a revised operating plan intended to balance value creation and expense management with our available cash resources. The objective of our revised operating plan was to focus our clinical development efforts on high potential value programs with meaningful near-term milestones and eliminate non-essential expenses and headcount to extend our cash runway. Under that plan, we intended to focus our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">oncology clinical development efforts on our follow-on product candidate CT-0525, a CAR-Monocyte intended to treat solid tumors that over-express human epidermal growth factor receptor 2, or HER2 and cease development of CT-0508, our macrophage-based product candidate, and initial lead product candidate. In addition, at that time, we decided to continue to focus on our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> mRNA/lipid nanoparticle, or LNP, CAR-M programs in partnership with Moderna and pause development of CT-1119, amesothelin-targeted CAR-Monocyte, pending additional financing, reduce our workforce and decrease spending on other non-essential activities. All clinical activities of CT-0508 have ceased.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2024, following another strategic review of our operating plan for 2025 and our future pipeline, we approved another revised operating plan intended to reduce monthly operating expenses, conserve cash, and refocus our efforts on strategic priorities. First, we decided to cease development of our HER2 directed autologous cell therapy platform including CT-0525. Our decision was based on an assessment of the competitive landscape in anti-HER2 treatments, including the impact of recently approved anti-HER2 therapies on HER2 antigen loss/downregulation, and the effects on the future development strategy of any anti-HER2 product. We dosed the last patient in our Phase 1 clinical trial of CT-0525, in November 2024 and all clinical activity ended in January 2025.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further pursuant to the December 2024 revised operating plan, we pivoted our focus to developing product candidates targeting two indications &#8211; liver fibrosis and solid tumor oncology, while retaining the potential to receive milestones and royalties from our collaboration with Moderna. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our cost-reduction initiatives in 2024, we implemented workforce reductions resulting in the termination of 62 full-time employees (representing approximately 58% of our total workforce), across research and development and general and administrative functions. The workforce reductions resulted in $4.1 million of severance related costs. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2024, we accrued for </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.7 million in severance costs from our workforce reduction, $2.3 million of which was paid in January 2025. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the 2024 reduction in workforce.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 26, 2024, we notified Novartis Pharmaceuticals Corporation, or Novartis, of our termination of the Manufacturing and Supply Agreement, dated March 1, 2023, relating to the manufacture of our first product candidate to enter clinical development, CT-0508, or the Manufacturing Agreement. The termination was effective July 31, 2024. As a result of the termination of the Manufacturing Agreement, we incurred a termination fee of $4.0 million, or the Termination Fee, which we paid in the third quarter of 2024. We separately agreed with Novartis that if we enter into an agreement for the tech transfer of another product, or a Substitute Product, to Novartis on or before December 31, 2024, then the Termination Fee </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shall be credited in full or in part against any amounts due to Novartis under such agreement relating to the Substitute Product. We did not enter into an agreement relating to the Substitute Product with Novartis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and we expensed the $4.0 million prepaid asset in the fourth quarter of 2024 to research and development in the consolidated statements of operations and comprehensive loss.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Developments &#8211; 2025 Cash Preservation Plan</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of a further revised plan approved by our board of directors on March 25, 2025 to preserve our existing cash resources following our reduction in workforce, or our cash preservation plan, we have reduced our operations to those necessary to identify and explore, a range of strategic alternatives to maximize value and prepare to wind down our business.  Potential strategic alternatives to be explored and evaluated may include, among other transactions, the sale, license, monetization or divestiture of one or more of our assets or technologies, a strategic collaboration or partnership with one or more parties or the merger or sale of our company. We cannot provide any commitment regarding when or if this strategic review process will result in any type of transaction. We currently have no intention of resuming research and development activities. Any future resumption of research and development activities would depend on completing a strategic transaction that would support our prior operating plans or otherwise obtaining significant additional funding.  As part of our cash preservation plan, our board of directors determined to terminate all of our employees not deemed necessary to pursue strategic alternatives and execute an orderly wind down of our operations. Our cash preservation plan prioritizes payments necessary and appropriate for those reduced operatio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ns and those that will help us to evaluate our strategic alternatives.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We may retain a financial advisor to advise on our exploration of a range of strategic alternatives. We plan to work with a financial advisor on identifying and evaluating potential strategic alternatives with the goal of maximizing the value of our assets, including CT-2401, CT-1119, our macrophage and monocyte engineering platform and our CAR-M platform and realizing value for the potential milestone and royalty payments under the Moderna collaboration. However, our exploration of strategic alternatives may not result in the consummation of any transaction or the realization of any value for our company or our stockholders. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our Product Candidates and Pipeline</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our liver fibrosis program is based upon the discovery of a key efferocytosis defect in the macrophages that reside within the livers of patients with fibrosis. Using a novel mRNA LNP approach, our product candidate aims to reverse fibrotic disease and improve the outcomes of patients with advanced liver fibrosis. In the second quarter of 2024, we achieved pre-clinical proof of concept in our liver fibrosis program, demonstrating the anti-fibrotic potential of engineered macrophages in two liver fibrosis models. Prior to pausing our research and development activities, we planned to continue to conduct pre-clinical development of our product candidate, CT-2401, sufficient to enable a regulatory submission to initiate a clinical trial.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our oncology program leverages our considerable expertise and experience in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> cell therapy. CT-1119 is designed to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. Prior to pausing our research and development activities, we planned to initiate a Phase 1 clinical trial of CT-1119, a mesothelin-targeted CAR-Monocyte, in combination with tislelizumab, an anti-PD-1 antibody, in adult patients with mesothelin-positive solid tumors, in China. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our collaboration with Moderna utilizes Moderna's mRNA/LNP technology, together with our CAR-M platform technology, to create novel </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> oncology off-the-shelf gene therapy product candidates. In June 2024, we announced that Moderna nominated the first development candidate under the collaboration and paid us a $2.0 million milestone. This development candidate targets Glypican-3, or GPC3, and is designed to treat solid tumors, including hepatocellular carcinoma. In November 2024, we announced new pre-clinical data on our anti-GPC3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> CAR-M therapy for treating hepatocellular carcinoma. These pre-clinical data demonstrated robust anti-tumor activity. In February 2025, Moderna nominated ten additional oncology research targets, four of which replaced two oncology research targets and two autoimmune research targets, which Moderna concurrently ceased developing. As of February 2025, Moderna has nominated all 12 oncology research targets under the collaboration for which we have the potential to receive future milestones and royalty payments. As such, we will not be conducting any additional research activities under the collaboration agreement and we will not be receiving any further research funding from Moderna under the collaboration agreement. Moderna also agreed to terminate the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">in-vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> oncology field exclusivity, which would allow us to pursue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> in vivo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">CAR-M programs outside of the 12 nominated targets and product polypeptides.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not yet commercialized any products or generated any revenue from product sales and have financed our operations primarily with proceeds from sales of our preferred stock, proceeds from our collaboration with Moderna, research tax credits, convertible debt financing, and completion of the Merger and related financing. Our operations have </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">historically been limited to organizing and staffing the Company, business planning, capital raising, establishing and maintaining our intellectual property portfolio, building our pipeline of product candidates, conducting drug discovery activities, undertaking pre-clinical studies, manufacturing process development studies, conducting early-stage clinical trials, and providing general and administrative support for these operations. We have historically devoted substantially all of our financial resources and efforts to pursuing discovery, research and development of our product candidates. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Financial Operations</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our net losses were $60.5 million and $86.9 million for the years ended December 31, 2024 and 2023, respectively. As of December&#160;31, 2024, we had $17.9 million in cash and cash equivalents and an accumulated deficit of $305.6 million. We expect to continue to incur significant expenses and operating losses while we explore strategic alternatives and carry out the orderly wind down of our operations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Although we believe our current cash and cash equivalents are sufficient to sustain our operating expenses and capital expenditure requirements into the second half of 2025, we do not expect that our cash and cash equivalents will support our operations for more than one year following the date of this Annual Report on Form 10-K. As a result of these conditions, substantial doubt exists about our ability to continue as a going concern.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have based this estimate on assumptions that may prove to be wrong. In addition, changing circumstances could cause us to consume capital significantly faster than we currently anticipate, and we may need to spend more than currently expected because of circumstances beyond our control. As a result, we could deplete our capital resources sooner than we currently expect. </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our exploration of strategic alternatives may not result in the consummation of any transaction that provides additional funding to our company. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Any future resumption of research and development activities would depend on completing a strategic transaction that would support our prior operating plans or otherwise obtaining significant additional funding. However, our exploration of strategic alternatives may not result in the consummation of any transaction or the realization of any value for our company or our stockholders and there can be no assurance that we would be able to generate funds on terms acceptable to us, on a timely basis, or at all.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve or maintain profitability. We may never succeed in these activities and, even if we do, may never generate revenues that are significant enough to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand business, maintain discovery and product development efforts, diversify our pipeline of product candidates or even continue operations.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Nasdaq Compliance</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 10, 2024, we received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying us that our common stock was not in compliance with Nasdaq Listing Rule 5450(b)(2)(A), or the Minimum MVLS Requirement, which requires us to maintain a minimum market value of listed securities of $50,000,000. We have 180 calendar days, or until April 8, 2025, to regain compliance with the Minimum MVLS Requirement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 6, 2025, we received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying us that, based upon the closing bid price of our common stock for the last 38 consecutive business days, we were not in compliance with Nasdaq Listing Rule 5450(a)(1), or the Bid Price Rule, which requires us to maintain a minimum bid price of $1.00 per share. We have 180 calendar days, or until July 7, 2025, to regain compliance with the Bid Price Rule. We intend to continue to monitor our MLVS and bid price and consider available options to regain compliance with Nasdaq listing rules. For more information about our Nasdaq listing deficiencies, see the following risk factor in Item 1A, Risk Factors &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We do not currently meet the requirements for continued listing on the Nasdaq Global Market. If we fail to meet the requirements for continued listing on the Nasdaq Global Market, our common stock could be delisted from trading, which would have a negative effect on the price of our common stock and our ability to raise additional capital</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;. </span></div><div><span><br/></span></div><div id="i280a0966ad034c5090dd46bd303d2259_106"></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial Operations Overview</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenues</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products for the foreseeable future. Our revenues to date have been generated from the Moderna collaboration agreement. Moderna reimburses us for all costs incurred by it in connection with its research and development activities under the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moderna collaboration agreement plus a reasonable margin for the respective services performed. As of February 2025, Moderna has nominated all 12 oncology research targets under the Moderna License Agreement. As such, we will not be conducting any additional research activities under the collaboration agreement and we will not be receiving any further research funding from Moderna under the collaboration agreement. We are eligible to receive potential milestone and royalty payments from Moderna in the future. To date, we have received $2.0 million in milestone payments and we have not received any royalties under the Moderna collaboration agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred for our research activities, including discovery efforts and the development of product candidates, and include:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred to conduct the necessary pre-clinical studies and clinical trials required to obtain regulatory approval;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">salaries, benefits and other related costs, including stock-based compensation expense, for personnel engaged in research and development functions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of funding research performed by third parties, including pursuant to agreements with contract research organizations, or CROs, as well as investigative sites and consultants that conduct our pre-clinical studies and clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred under agreements with contract manufacturing organizations, or CMOs, including manufacturing scale-up expenses and the cost of acquiring and manufacturing pre-clinical study and clinical trial materials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of outside consultants, including their fees, stock-based compensation and related travel expenses;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of laboratory supplies and acquiring materials for pre-clinical studies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facility-related expenses, which include direct depreciation costs of equipment and expenses for rent and maintenance of facilities and other operating costs; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third-party licensing fees.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Research and development activities are central to our business model. Product candidates in later stages of clinical development will generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect our research and development expenses to significantly decrease in 2025 as a result of our decision to pause our research and development activities as part of our cash preservation plan. If we were to resume research and development activities, our research and development expenses would increase; however, any future resumption of research and development activities would depend on completing a strategic transaction that would support our prior operating plans or otherwise obtaining significant additional funding.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The successful development of our current or future product candidates is highly uncertain. At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that would be necessary to complete the development of any product candidates. If we were to resume research and development activities, the success of any of our product candidates will depend on several factors, including the following:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">successfully completing pre-clinical studies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">timely filing and receiving clearance of investigational new drug applications to commence clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">successfully initiating, enrolling patients in and completing clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">scaling up manufacturing processes and capabilities to support clinical trials of any of our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">applying for and receiving marketing approvals from applicable regulatory authorities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">obtaining and maintaining intellectual property protection and regulatory exclusivity for any product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">making arrangements with third-party manufacturers, or establishing commercial manufacturing capabilities, for both clinical and commercial supplies of our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing sales, marketing and distribution capabilities and launching commercial sales of our products, if and when approved, whether alone or in collaboration with others;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of any of our product candidates, if and when approved, by patients, the medical community and third-party payors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effectively competing with other therapies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining coverage, adequate pricing and adequate reimbursement from third-party payors, including government payors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining, enforcing, defending and protecting our rights in our intellectual property portfolio;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">not infringing, misappropriating or otherwise violating others&#8217; intellectual property or proprietary rights; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining a continued acceptable safety profile of our products following receipt of any marketing approvals.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in the outcome of any of these variables with respect to the development, manufacture or commercialization activities of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive, if there are safety concerns or if we determine that the observed safety or efficacy profile would not be competitive in the marketplace, we could be required to expend significant additional financial resources and time on the completion of clinical development. Product commercialization will take several years, and we expect to spend a significant amount in development costs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of personnel expenses, including salaries, benefits and stock-based compensation expense for employees in executive, finance, accounting, business development and human resource functions. General and administrative expense also includes corporate facility costs, including rent, utilities, depreciation and maintenance, and costs not otherwise included in research and development expenses, legal fees related to intellectual property and corporate matters as well as fees for accounting and consulting services.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expect that our general and administrative expenses will decrease in 2025, as we have terminated all of our employees not deemed necessary to pursue strategic alternatives and execute an orderly wind down of our operations. If we were to identify and pursue a strategic alternative, we expect our general and administrative expenses to increase.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income, net</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income, net consists of interest earned on our excess cash, net of interest expense. Interest expense consisted of interest on our finance leases and our convertible promissory note that was converted into common stock upon the closing of the Merger in 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Derivative Liability</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value of the derivative liability for the redemption feature of our convertible promissory note reflected the non-cash charge for changes in the fair value of the derivative liability that was subject to re-measurement at each balance sheet date through the settlement of the convertible promissory note upon the closing of the Merger at which time the redemption feature was derecognized.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred significant net losses. As of December&#160;31, 2024, we had net operating loss carryforwards, or NOLs, for federal income tax purposes of $374.7&#160;million. We have provided a valuation allowance against the full amount of our deferred tax assets since, in our opinion, based upon our historical and anticipated future losses, it is more likely than not that the benefits will not be realized. As of December&#160;31, 2024, we remained in a full valuation allowance position.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The utilization of our NOLs may be subject to a substantial annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50 percent, as defined under Sections 382 and 383 of the Internal Revenue Code of 1986, or the Code, respectively, as well as similar state provisions. We have recorded a valuation allowance on all of our deferred tax assets, including deferred tax assets related to NOLs.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><div id="i280a0966ad034c5090dd46bd303d2259_109"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Years Ended December 31, 2024 and 2023 (in thousands)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,632&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,919&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59,673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81,811&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103,650&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(62,179)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(88,731)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value of derivative liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(60,477)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(86,879)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenues</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenues were $19.6 million and $14.9 million for the years ended December 31, 2024 and 2023, respectively. The increase was primarily related to Moderna's development candidate nomination which resulted in $5.8 million of collaboration revenue consisting of $3.8 million of deferred option rights revenue recognition and $2.0 million of milestone revenue.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We track outsourced development, outsourced personnel costs and other external research and development costs of our CT-0508, CT-0525, and CT-1119 programs. We do not track internal research and development costs on a program-by-program basis. The following table summarizes our research and development expenses (in thousands). Certain amounts related to prior period results were reclassified to conform to current period presentation. These reclassifications have not changed total research and development expenses.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended<br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CT-0508 (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,652&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,354&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,702)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CT-0525 (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CT-1119 (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">928&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(353)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personnel costs, including stock-based compensation (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(525)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other clinical and pre-clinical development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,673)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facilities and other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,516)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total research and development expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59,673&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74,125&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14,452)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1) The revised operating plans that were implemented in 2024, adjusted our research and development focus. For the Phase 1 clinical trial of CT-0525, the last patient was dosed in November 2024 and all clinical activity ended in January 2025. All clinical activities related to CT-0508 also ceased in 2024.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> In connection with our 2024 revised operating plans, we had also elected to pause further development of CT-1119, a mesothelin-targeted CAR-Monocyte, pending additional financing. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:117%">(2) Our revised operating plans, which were implemented in 2024, included reductions in workforce which resulted in severance costs. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in research and development expenses was primarily attributable to a decrease in our clinical and pre-clinical development expenses and facility costs due to less laboratory supplies and laboratory space needs in connection with our revised operating plans. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our general and administrative expenses (in thousands). Certain amounts related to prior period results were reclassified to conform to current period presentation. These reclassifications have not changed total general and administrative expenses.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended<br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personnel costs, including stock-based compensation (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,748&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,671&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(923)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,763)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facilities and supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Insurance, taxes, and fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,351&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,890&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,539)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(440)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total general and administrative expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,138&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,525&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,387)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(1) Our revised operating plans, which were implemented in 2024, included reductions in workforce which resulted in severance costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The decrease in general and administrative expenses was primarily attributable to a decrease in our professional fees as a result of non-recurring legal costs associated with the Merger and a decrease in director and officer insurance costs. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Income, net</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We recognized $1.7 million in interest income, net for the year ended December 31, 2024, which was primarily attributable to interest earned on excess cash, partially offset by interest on our finance leases.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized $1.9 million in interest income, net for the year ended December 31, 2023, which was primarily attributable to interest earned on excess cash, partially offset by interest expense on the convertible promissory note issued to Moderna, including non-cash interest expense associated with the amortization of the debt discount.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Fair Value of Derivative Liability</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We recognized a $0.1 million non-cash charge for the year ended December 31, 2023, for the increase in fair value of the derivative liability associated with the redemption feature of the convertible promissory note with Moderna, which was attributable to the timing in which we expected the accrued settlement event to occur. There was no change in fair value of derivative liability during the year ended December 31, 2024 because the derivative was redeemed in 2023.</span></div><div id="i280a0966ad034c5090dd46bd303d2259_112"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, we had $17.9 million in cash and cash equivalents and an accumulated deficit of $305.6 million. To date, we have not yet commercialized any products or generated any revenue from product sales and have financed operations primarily with proceeds from sales of preferred stock, proceeds from our collaboration with Moderna, research tax credits, convertible debt financing, and completion of the Merger and related financing. Through December 31, 2024, we have generated $44.4&#160;million of collaboration revenues related to research and development services, deferred option rights, and milestones. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of February 2025, Moderna has nominated all 12 oncology research targets under the collaboration. As such, we will not be conducting any additional research activities under the collaboration agreement and we will not be receiving any further research funding from Moderna under the collaboration agreement. We received the final research and development payment of $2.9 million from Moderna in January 2025.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the terms of the Moderna collaboration agreement, assuming Moderna develops and commercializes 12 products, each directed to a different development target, we are eligible to receive up to between $247.0 million and $253.0 million per product in development target designation, development, regulatory and commercial milestone payments. We are also eligible to receive tiered mid-to-high single </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">digit royalties of net sales of any products that are commercialized under the agreement, which may be, subject to reductions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 17, 2023, we filed a universal shelf registration statement on Form S-3, which was declared effective on May 2, 2023, or the Registration Statement. Under the Registration Statement, we may offer and sell up to $300.0 million of a variety of securities, including debt securities, common stock, preferred stock, depository shares, subscription rights, warrants and units from time to time in one or more offerings at prices and on terms to be determined at the time of the offering. On May 12, 2023, we entered into an Amended and Restated Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or the Sale Agreement, with Jefferies LLC, as sales agent, pursuant to which we may offer and sell shares of our common stock with an aggregate offering price of up to $100.0 million under an &#8220;at-the-market" offering program. As of December&#160;31, 2024, we have sold 1,362,917 shares of our common stock for net proceeds of $3.0 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a summary of our cash flows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(59,917)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(81,177)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(123)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72,408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net change in cash and cash equivalents</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(59,696)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53,411&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows from Operating Activities</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the year ended December 31, 2024, we used $59.9 million of net cash in operating activities. Cash used in operating activities reflected our net loss of $60.5 million and a $12.0 million net change in our operating assets and liabilities attributable to the timing in which we pay our vendors for research and development activities that was offset by $12.5 million of non-cash charges primarily related to depreciation and amortization expense, stock-based compensation and reductions in the operating right of use, or ROU assets.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the year ended December 31, 2023, we used $81.2 million of net cash in operating activities. Cash used in operating activities reflected our net loss of $86.9 million and a $5.4 million net change in our operating assets and liabilities attributable to the timing in which we pay our vendors for research and development activities that was offset by $11.1 million of non-cash charges related to depreciation and amortization expense, stock-based compensation, reductions in the operating ROU assets, amortization of the debt discount on the convertible promissory note, change in fair value of the derivative liability, accretion on marketable securities, and non-cash interest on the finance lease liability.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows from Investing Activities</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2024, we used $0.1 million of net cash in investing activities which reflected purchases of property and equipment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the year ended December 31, 2023, we received $72.4 million of net cash from investing activities. Cash provided by investing activities reflected $108.0 million of proceeds from the sale of marketable securities, partially offset by purchases of marketable securities of $34.5 million and the purchase of property and equipment of $1.1 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows from Financing Activities</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the year ended December 31, 2024, we received $0.3 million of net cash from financing activities, primarily attributable to $2.4 million from the sale of common stock in connection with the Sale Agreement, net of issuance costs, and $0.7 million in proceeds from failed-sale leaseback arrangements, partially offset by $1.4 million in payments of principal related to finance lease liabilities, and $1.3 million in payments to our finance liability from failed-sale leaseback arrangements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the year ended December 31, 2023, we received $62.2 million of net cash from financing activities, primarily attributable to the $37.9 million in the cash and cash equivalents acquired in connection with the Merger, $30.6 million in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">proceeds from the issuance of common stock in pre-closing financing, $1.2 million in proceeds from failed-sale leaseback arrangements, $0.6 million from the sale of common stock in connection with the Sale Agreement, partially offset by $5.8 million in payments of financing costs, $1.3 million in payments of principal related to finance lease liabilities, and $1.1 million in payments to our finance liability from failed sale-leaseback arrangements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December 31, 2024, we had cash and cash equivalents of $17.9 million.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expect to continue to incur significant expenses and operating losses while we explore strategic alternatives and carry out the orderly wind down of our operations.   Although we believe our current cash and cash equivalents are sufficient to sustain our operating expenses and capital expenditure requirements into the second half of 2025, we do not expect that our cash and cash equivalents will support our operations for more than one year following the date of this Annual Report on Form 10-K. As a result of these conditions, substantial doubt exists about our ability to continue as a going concern. We hav</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">e based this estimate on assumptions that may prove to be wrong. In addition, changing circumstances could cause us to consume capital significantly faster than we currently anticipate, and we may need to spend more than currently expected because of circumstances beyond our control. As a result, we could deplete our capital resources sooner than we currently expect. </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our exploration of strategic alternatives may not result in the consummation of any transaction that provides additional funding to our company. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of our cash preservation plan, we have reduced our operations to those necessary to identify and explore a range of strategic alternatives to maximize value and prepare to wind down our business. Potential strategic alternatives to be explored and evaluated may include, among other transactions, the sale, license, monetization or divestiture of one or more of our assets or technologies, a strategic collaboration or partnership with one or more parties or the merger or sale of our company. We cannot provide any commitment regarding when or if this strategic review process will result in any type of transaction.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of our cash preservation plan, our board of directors determined to terminate all of our employees not deemed necessary to pursue strategic alternatives and execute an orderly wind down of our operations. Our cash preservation plan prioritizes payments necessary and appropriate for those reduced operations and those that will help us to evaluate our strategic alternatives.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We may retain a financial advisor to advise on our exploration of a range of strategic alternatives. We plan to work with the advisor on identifying and evaluating potential strategic alternatives with the goal of maximizing the value of our assets, including CT-2401, CT-1119, our macrophage and monocyte engineering platform and our CAR-M platform and realizing value for the potential milestone and royalty payments under the Moderna collaboration. However, our exploration of strategic alternatives may not result in the consummation of any transaction or the realization of any value for our company or our stockholders. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Any strategic alternatives may involve or may be pursued through legal proceedings including bankruptcy or liquidation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and dissolution proceedings, and such proceedings may also be necessary or appropriate in the absence of any strategic</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">alternatives. In the event that our board of directors determines that a liquidation and dissolution of our business approved</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">by stockholders is desirable or the best method to maximize value, we would prepare proxy materials and schedule a</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">special meeting of our stockholders to seek approval of such a plan.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We currently have no intention of resuming research and development activities. Any future resumption of research and development activities would depend on completing a strategic transaction that would support our prior operating plans or otherwise obtaining significant additional funding. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Significant additional financing may not be available to us on acceptable terms, or at all, and may be impacted by the economic climate and market conditions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we are able to raise additional capital through the public or private sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of those securities may include liquidation or other preferences that adversely affect your rights as a holder of our common stock. Debt financing and preferred equity financing, if available, would increase our fixed payment obligations and may involve agreements that include covenants limiting or restricting our operations and ability to take specific actions, such as incurring additional debt, making acquisitions, engaging in acquisition, merger or collaboration transactions, selling or licensing our assets, making capital expenditures, redeeming our stock, making certain investments, declaring dividends or other operating restrictions that could adversely impact our ability to conduct business.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are able to raise funds through a strategic collaboration or partnership with one or more parties, we may have to relinquish valuable rights to our intellectual property, future revenue streams, discovery programs or product candidates, grant licenses on terms that may not be favorable to us or grant rights to develop and market product candidates that we </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">would otherwise prefer to develop and market on our own, any of which may have a material adverse effect on our business, operating results and prospects. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we were to resume research and development activities, our expenses would increase and our future capital requirements would depend on many factors, including:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the progress, costs and results of pre-clinical testing of our product candidates; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the progress, costs and results of clinical trials of our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the number of and development requirements for additional indications for our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the success of our collaborations with Moderna or others;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to scale up our manufacturing processes and capabilities to support clinical trials of the product candidates we are developing and may develop in the future;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs, timing and outcome of regulatory review of our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential changes in the regulatory environment and enforcement rules;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such arrangements;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the payment of license fees and other costs of our technology license arrangements;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of future commercialization activities, including product manufacturing, sales, marketing and distribution, for the product candidates we are developing and may develop in the future for which we may receive marketing approval;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain acceptance of any approved products by patients, the medical community and third-party payors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amount and timing of revenue, if any, received from commercial sales of the product candidates we are developing or develop in the future for which we receive marketing approval;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential changes in pharmaceutical pricing and reimbursement infrastructure;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of raw materials for use in production of our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property and proprietary rights and defending any intellectual property-related claims; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we in-license or acquire additional technologies or product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifying potential product candidates and conducting pre-clinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. We will not generate commercial revenues unless and until we can achieve sales of products, which we do not anticipate for a number of years, if at all. </span></div><div id="i280a0966ad034c5090dd46bd303d2259_115"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations and Commitments</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our contractual obligations and commitments at December 31, 2024 (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Less<br/>than<br/>1 Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1 to 3<br/>Years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4 to 5<br/>Years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">More<br/>than<br/>5 Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual obligations:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease commitments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total contractual obligations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,772&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,869&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">719&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">184&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Reflects obligations pursuant to our office and laboratory leases in Philadelphia, Pennsylvania.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commitment amounts in the table above are associated with contracts that are enforceable and legally binding and that specify all significant terms, including fixed or minimum services to be used, fixed, minimum or variable price provisions, and the approximate timing of the actions under the contracts. Our contracts with CMOs, CROs and other third parties for the manufacture of our product candidates and to support pre-clinical research studies and clinical testing are generally cancelable by us upon prior notice and do not contain any minimum purchase commitments. Payments due upon cancellation consisting only of payments for services provided or expenses incurred, including noncancelable obligations </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our service providers, up to the date of cancellation are not included in the table above as the amount and timing of such payments are not known. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table above does not include any potential milestone or royalty payments that we may be required to make under our license agreement with Penn and under licensing agreements with other third parties not considered material. We excluded these milestone and royalty payments given that the timing and likelihood of any such payments cannot be reasonably estimated at this time. For further information about our lease arrangements, our license agreement with Penn and our other licensing agreements, see Note 8 to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the 2025 cash preservation plan, we expect to incur approximately $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="6" id="f-52">3.8</ix:nonFraction>&#160;million, which primarily represents one-time employee termination benefits directly associated with the workforce reduction. We also expect to pay the majority of related reduction in workforce amounts by the end of 2025. </span></div><div id="i280a0966ad034c5090dd46bd303d2259_118"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on our limited historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our significant accounting policies are described in more detail in Note 3 to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K, we believe the following accounting policies are the most critical to the judgments and estimates used in the preparation of our consolidated financial statements for the year ended December 31, 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Revenues from Contracts</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for our revenue in accordance with Accounting Standards Codification, or ASC, 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC 606. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps at inception of the agreement or upon material modification of the agreement: (i) identifies the contract(s) with a customer; (ii) identifies the performance obligations in the contract; (iii) determines the transaction price, including variable consideration, if any; (iv) allocates the transaction price to the performance obligations in the contract; and (v) recognizes revenue when (or as) the entity satisfies a performance obligation.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider the pattern of satisfaction of the performance obligations under step (v) above to be a critical accounting estimate. More specifically, the determination of the level of achievement of research and development service performance obligations, whose pattern of satisfaction is measured using costs incurred to date as compared to total costs incurred and expected to be incurred in the future is driven by a critical accounting estimate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In estimating the costs expected to be incurred in the future, we use our most recent budget and long-range plan, adjusted for any pertinent information. While this is our best estimate as of the reporting period, costs expected to be incurred in the future require managements judgment as the scope and timing of research and development activities may change significantly over time. We may adjust the scope of our research and development activities based on several factors, such as additional work needed to support advancement of product candidate or change in the number of patients in trials. Further, research and development services may no longer be within the scope of a collaboration agreement, as has been the case with certain of our programs. The timing of when research and development costs are expected to be incurred may change as a result of external factors, such as delays caused by manufacturing or supply chain, or difficulty in enrolling patients; or internal factors, such as prioritization of programs. Our estimate of the scope and timing of research and development services performed relative to the actual scope and timing may have a significant impact on revenue recognition.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Accruals</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred in connection with the development of our product candidates. We expense research and development costs as incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue expenses for pre-clinical studies and activities performed by third parties based upon estimates of the proportion of work completed over the term of the individual trial and patient enrollment rates in accordance with agreements with third parties. We determine the estimates by reviewing contracts, vendor agreements and purchase orders, and through discussions with our internal clinical personnel and external service providers as to the progress or stage of completion of activities or services and the agreed-upon fee to be paid for such services. However, actual costs and timing of clinical trials are highly uncertain, subject to risks and may change depending upon a number of factors, including our clinical development plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make estimates of our accrued expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances known at that time. If the actual timing of the performance of services or the level of effort varies from the estimate, we will adjust the accrual accordingly. Non-refundable advance payments for goods and services, including fees for process development or manufacturing and distribution of pre-clinical supplies that will be used in future research and development activities, are deferred and recognized as expense in the period that the related goods are consumed or services are performed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone payments within our licensing and collaboration arrangements are recognized when achievement of the milestone is deemed probable to occur. To the extent products are commercialized and future economic benefit has been established, commercial milestones that become probable are capitalized and amortized over the estimated remaining useful life of the intellectual property. In addition, we accrue royalty expense and sublicense non-royalty payments, as applicable, for the amount we are obligated to pay, with adjustments as sales are made.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Stock-Based Compensation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We measure compensation expense for all stock-based awards based on the estimated fair value of the award on the grant date. We use the Black-Scholes option pricing model to value our stock option awards. We recognize compensation expense on a straight-line basis over the requisite service period, which is generally the vesting period of the award. We have not issued awards where vesting is subject to a market or performance condition.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%">The Black-Scholes option pricing model requires the use of subjective assumptions that include the expected stock price volatility and prior to the Merger, the fair value of the underlying common stock on the date of grant. See Note 9 to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K for information concerning certain of the specific assumptions we used in applying the Black-Scholes option pricing model to determine the estimated fair value of our stock options granted during the years ended December 31, 2024 and 2023.</span></div><div><span><br/></span></div><div id="i280a0966ad034c5090dd46bd303d2259_121"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 3 to our consolidated financial statements found in this Annual Report on Form 10-K for a description of recent accounting pronouncements applicable to our financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div id="i280a0966ad034c5090dd46bd303d2259_124"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Off-Balance Sheet Arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any relationships with unconsolidated entities or financial partnerships, including entities sometimes referred to as structured finance or special purpose entities that were established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. We do not engage in off-balance sheet financing arrangements. In addition, we do not engage in trading activities involving non-exchange traded contracts. We therefore believe that we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in these relationships.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i280a0966ad034c5090dd46bd303d2259_127"></div><div><span id="idbaea266c22b411984f104e93ec66429_971"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities. Our interest-earning assets consist of cash and cash equivalents for the year ended December 31, 2024 and cash, cash equivalents and marketable securities for the year ended December 31, 2023. Interest income earned on these assets was $2.1 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $3.7 million for the years ended December 31, 2024 and 2023, respectively. Our interest income is sensitive to changes in the general level of interest rates, primarily U.S. interest rates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently exposed to significant market risk related to changes in foreign currency exchange rates; however, we have contracts with foreign vendors. As such, our operations may be subject to fluctuations in foreign currency exchange rates in the future.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflation generally affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation had a material effect on our business, financial condition or results of operations during the years ended December 31, 2024 and 2023.</span></div><div id="i280a0966ad034c5090dd46bd303d2259_130"></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div><span id="ia4639bfee660467caba0d6ec793162ce_57"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8. Financial Statements and Supplementary Data.</span></div><div id="i280a0966ad034c5090dd46bd303d2259_133"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:90.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.931%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_136">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (KPMG LLP, Philadelphia, PA, Audit Firm ID: <ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-53">185</ix:nonNumeric>)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8accd16b02d74de6b83ca677bff60f51_3369">113</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_139">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i256a4c05df5c4594ba8d245d2b6442a3_168">114</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_142">Consolidated Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i390b02cb7a214440b3fdfb8fbc0b013d_202">115</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_145">Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; (Deficit) Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ida9b45f5197e483b9359dcc790c4be98_231">116</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_148">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib3498af2cfc64323a7f30db3d3235e62_294">117</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_151">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i1ab4d60ed7ee451b826203efe8b0e99f_10105">119</a></span></div></td></tr></table></div><div id="i280a0966ad034c5090dd46bd303d2259_136"></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div style="text-align:center"><span id="i8accd16b02d74de6b83ca677bff60f51_3369"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and Board of Directors </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Carisma Therapeutics Inc.:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Opinion on the Consolidated Financial Statements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Carisma Therapeutics Inc. and subsidiaries (the Company) as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders&#8217; (deficit) equity, and cash flows for the years then ended, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024, and 2023, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Going Concern</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 of the consolidated financial statements, the Company has incurred losses and negative cash flows from operations since inception that raise substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis for Opinion</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Critical Audit Matters</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical audit matters are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-54">KPMG LLP</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company's auditor since 2018.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-55">Philadelphia, Pennsylvania</ix:nonNumeric></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2025</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i280a0966ad034c5090dd46bd303d2259_139"></div><div style="margin-top:12pt;text-align:center"><span id="i256a4c05df5c4594ba8d245d2b6442a3_168"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-56">17,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-57">77,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-58">5,916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-59">2,866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-60">23,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-61">80,471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-62">4,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-63">6,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use assets &#8211; operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-64">2,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-65">2,173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="carm:DeferredFinancingCostsNoncurrent" scale="3" id="f-66">208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="carm:DeferredFinancingCostsNoncurrent" scale="3" id="f-67">146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-68">30,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-69">89,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities and Stockholders' (Deficit) Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-70">2,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-71">3,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-72">7,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-73">7,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredRevenueCurrent" format="ixt:num-dot-decimal" scale="3" id="f-74">3,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredRevenueCurrent" format="ixt:num-dot-decimal" scale="3" id="f-75">1,413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-76">832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-77">1,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="f-78">905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="f-79">544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-80">1,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="f-81">965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-82">16,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-83">15,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredRevenueNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-84">41,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredRevenueNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-85">45,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-86">724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-87">860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="f-88">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="f-89">328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-90">318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-91">926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-92">58,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-93">63,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commitments and contingencies (Note 8)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-5" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-94"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-6" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-95"></ix:nonFraction></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217; (deficit) equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:16.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preferred stock $<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-96"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-97">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-98"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-99">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-100"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-101"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-102"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-103">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> issued or outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-104">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-105">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:16.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock $<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-106"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-107">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-108"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-109">350,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-110"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-111">41,750,109</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-112"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-113">40,609,915</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2024 and 2023, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-114">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-115">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-116">277,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-117">271,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-118">305,579</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-119">245,102</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stockholders&#8217; (deficit) equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-120">27,909</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-121">26,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities and stockholders&#8217; (deficit) equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-122">30,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-123">89,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><div id="i280a0966ad034c5090dd46bd303d2259_142"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated <span id="i390b02cb7a214440b3fdfb8fbc0b013d_202"></span>Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-124">19,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-125">14,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-126">59,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-127">74,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-128">22,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-129">29,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-130">81,811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-131">103,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-132">62,179</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-133">88,731</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value of derivative liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" format="ixt:fixed-zero" scale="3" id="f-134">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="3" id="f-135">84</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="f-136">1,702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="f-137">1,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-138">60,477</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-139">86,879</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share of common stock, basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-140"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-141">1.46</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-142"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-143">2.59</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares of common stock outstanding, basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-144"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-145">41,456,210</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-146"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-147">33,524,197</ix:nonFraction></ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-148">60,477</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-149">86,879</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized gain on marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-150">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-151">440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: reclassification to net loss of previous unrealized gain on marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-152">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="3" id="f-153">399</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-154">60,477</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-155">86,838</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><div id="i280a0966ad034c5090dd46bd303d2259_145"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of <span id="ida9b45f5197e483b9359dcc790c4be98_231"></span>Convertible Preferred Stock and Stockholders&#8217; (Deficit) Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share data)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.839%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.025%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Convertible preferred stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Stockholders&#8217; (Deficit) Equity</span></div></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Common stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Additional<br/>paid-in <br/>capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Accumulated<br/>other<br/>comprehensive<br/>loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Accumulated<br/>deficit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Noncontrolling<br/>interests</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Total</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Balance, December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-156">8,700,885</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="f-157">107,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-158">2,217,737</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-159">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-160">1,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-161">41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-162">158,223</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-163">14,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-164">142,670</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-165">128,716</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-166">187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-167">187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-168">2,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-169">2,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Unrealized gain on marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-170">440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-171">440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Reclassification to net loss of previous unrealized gain on marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="3" id="f-172">399</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="3" id="f-173">399</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Issuance of common stock for cash in pre-closing financing</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="carm:StockIssuedDuringPeriodSharesPreclosureFinancingTransaction" format="ixt:num-dot-decimal" scale="0" id="f-174">3,730,608</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="carm:StockIssuedDuringPeriodValuesPreclosureFinancingTransaction" scale="3" id="f-175">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="carm:StockIssuedDuringPeriodValuesPreclosureFinancingTransaction" format="ixt:num-dot-decimal" scale="3" id="f-176">30,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="carm:StockIssuedDuringPeriodValuesPreclosureFinancingTransaction" format="ixt:num-dot-decimal" scale="3" id="f-177">30,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Issuance of common stock upon settlement of<br/>convertible promissory note, accrued interest, and related derivative liability</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-178">5,059,338</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="f-179">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-180">42,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-181">42,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Issuance of common stock to Sesen Bio shareholders in reverse capitalization</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="0" id="f-182">10,374,272</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="f-183">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="f-184">72,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="f-185">72,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Conversion of convertible preferred stock and non-controlling interests to common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" sign="-" name="carm:ReclassificationsOfTemporaryToPermanentEquityShares" format="ixt:num-dot-decimal" scale="0" id="f-186">8,700,885</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" format="ixt:num-dot-decimal" scale="3" id="f-187">107,808</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="carm:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" format="ixt:num-dot-decimal" scale="0" id="f-188">18,872,711</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="carm:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" scale="3" id="f-189">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="carm:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" format="ixt:num-dot-decimal" scale="3" id="f-190">122,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="carm:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" format="ixt:num-dot-decimal" scale="3" id="f-191">14,395</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="carm:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" format="ixt:num-dot-decimal" scale="3" id="f-192">107,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Sale of common stock under Open Market Sales Agreement, net of issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-193">226,533</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-194">597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-195">597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-196">86,879</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-197">86,879</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Balance, December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" format="ixt:fixed-zero" scale="3" id="f-198">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:fixed-zero" scale="3" id="f-199">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-200">40,609,915</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-201">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-202">271,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-203">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-204">245,102</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-205">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-206">26,532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Exercise of stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-207">3,810</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-208">4</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-209">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-210">3,649</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-211">3,649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Sale of common stock under Open Market Sales Agreement, net of issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-212">1,136,384</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-213">1</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-214">2,382</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-215">2,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-216">60,477</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-217">60,477</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Balance, December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" format="ixt:fixed-zero" scale="3" id="f-218">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:fixed-zero" scale="3" id="f-219">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-220">41,750,109</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-221">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-222">277,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-223">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-224">305,579</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-225">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-226">27,909</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.               </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><div id="i280a0966ad034c5090dd46bd303d2259_148"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of <span id="ib3498af2cfc64323a7f30db3d3235e62_294"></span>Cash Flows (in thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-227">60,477</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-228">86,879</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Adjustment to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Depreciation and amortization expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-229">3,354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-230">2,837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Loss on disposal of property and equipment </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="3" id="f-231">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="f-232">159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-233">3,649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-234">2,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reduction in the operating right of use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="f-235">4,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="f-236">5,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amortization of debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:fixed-zero" scale="3" id="f-237">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="f-238">1,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Change in fair value of derivative liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" format="ixt:fixed-zero" scale="3" id="f-239">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="3" id="f-240">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accretion on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="carm:AccretionOnMarketableSecurities" format="ixt:fixed-zero" scale="3" id="f-241">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="carm:AccretionOnMarketableSecurities" scale="3" id="f-242">709</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Write-off of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="carm:WriteOffOfPropertyAndEquipment" scale="3" id="f-243">362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="carm:WriteOffOfPropertyAndEquipment" format="ixt:fixed-zero" scale="3" id="f-244">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Realized gain on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" format="ixt:fixed-zero" scale="3" id="f-245">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" scale="3" id="f-246">399</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="carm:NoncashInterestExpense" scale="3" id="f-247">217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="carm:NoncashInterestExpense" scale="3" id="f-248">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Loss on sale of equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="carm:GainLossOnSaleOfEquipment" scale="3" id="f-249">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="carm:GainLossOnSaleOfEquipment" format="ixt:fixed-zero" scale="3" id="f-250">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Gain on sale of sale-leaseback </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SaleAndLeasebackTransactionGainLossNet" scale="3" id="f-251">82</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:SaleAndLeasebackTransactionGainLossNet" format="ixt:fixed-zero" scale="3" id="f-252">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-253">3,120</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-254">1,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-255">1,852</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-256">2,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="f-257">213</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-258">2,899</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="f-259">1,434</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="f-260">1,046</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-261">5,525</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-262">4,941</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other long term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="f-263">192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="f-264">213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-265">59,917</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-266">81,177</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Purchase of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:fixed-zero" scale="3" id="f-267">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-268">34,460</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Proceeds from the sale of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="carm:PaymentsForProceedsFromMarketableSecurities" format="ixt:fixed-zero" scale="3" id="f-269">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="carm:PaymentsForProceedsFromMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-270">108,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-271">123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-272">1,132</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net cash (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-273">123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-274">72,408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash acquired in connection with the reverse recapitalization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="carm:CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-275">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="carm:CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-276">37,903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Payment of reverse recapitalization finance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="carm:PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-277">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="carm:PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-278">5,814</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Proceeds from the issuance of common stock in pre-closing financing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="carm:ProceedsFromIssuanceOfCommonStockPreClosingFinancing" format="ixt:fixed-zero" scale="3" id="f-279">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="carm:ProceedsFromIssuanceOfCommonStockPreClosingFinancing" format="ixt:num-dot-decimal" scale="3" id="f-280">30,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Payment of principal related to finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="3" id="f-281">1,429</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="3" id="f-282">1,301</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Proceeds from failed sale-leaseback arrangement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="carm:ProceedsFromFailedSaleLeasebackTransaction" scale="3" id="f-283">686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="carm:ProceedsFromFailedSaleLeasebackTransaction" format="ixt:num-dot-decimal" scale="3" id="f-284">1,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Payment of finance liability from failed sale-leaseback arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="carm:PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction" format="ixt:num-dot-decimal" scale="3" id="f-285">1,309</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="carm:PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction" format="ixt:num-dot-decimal" scale="3" id="f-286">1,069</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Payment of deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfFinancingCosts" format="ixt:fixed-zero" scale="3" id="f-287">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsOfFinancingCosts" scale="3" id="f-288">146</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Proceeds from the exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-289">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-290">187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sale of common stock under Open Market Sales Agreement, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-291">2,392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="f-292">597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="f-293">344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-294">62,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net (decrease) increase in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-295">59,696</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-296">53,411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash and cash equivalents at beginning of the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-297">77,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-298">24,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash and cash equivalents at end of the year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-299">17,909</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-300">77,605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows (in thousands)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Supplemental disclosures of cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash paid for interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="f-301">192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="f-302">352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Supplemental disclosure of non-cash financing and investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Conversion of convertible preferred stock and non-controlling interests upon Merger</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="carm:NoncashOrPartNoncashAcquisitionEquityAssumed" format="ixt:fixed-zero" scale="3" id="f-303">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="carm:NoncashOrPartNoncashAcquisitionEquityAssumed" format="ixt:num-dot-decimal" scale="3" id="f-304">122,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Conversion of convertible promissory note, accrued interest and derivative liability upon Merger</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NotesReduction" format="ixt:fixed-zero" scale="3" id="f-305">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:NotesReduction" format="ixt:num-dot-decimal" scale="3" id="f-306">42,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unrealized gain on marketable securities</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="carm:NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities" format="ixt:fixed-zero" scale="3" id="f-307">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="carm:NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities" scale="3" id="f-308">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reclassification of deferred financing costs to additional paid-in-capital</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="carm:NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts" scale="3" id="f-309">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="carm:NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts" format="ixt:fixed-zero" scale="3" id="f-310">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Right-of-use assets obtained in exchange for new financing lease liabilities</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-311">1,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-312">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-313">6,411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-314">2,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Modification of operating lease right-of-use asset and operating lease liabilities</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="carm:NonCashEffectOfModificationOfOperatingLeaseRightOfUseAssetsOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-315">1,581</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="carm:NonCashEffectOfModificationOfOperatingLeaseRightOfUseAssetsOperatingLeaseLiabilities" format="ixt:fixed-zero" scale="3" id="f-316">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Disposal of property and equipment in exchange for reduction in financing lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="carm:DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability" scale="3" id="f-317">396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="carm:DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-318">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div></div></div><div id="i280a0966ad034c5090dd46bd303d2259_151"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div id="i280a0966ad034c5090dd46bd303d2259_154"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1)&#160;&#160;&#160;&#160;<span id="i1ab4d60ed7ee451b826203efe8b0e99f_10105"></span><ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-319" continuedAt="f-319-1" escape="true">Background</ix:nonNumeric></span></div><ix:continuation id="f-319-1" continuedAt="f-319-2"><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Carisma Therapeutics Inc., a Delaware corporation (collectively with its subsidiaries, the Company), biotechnology company focused on applying its industry leading expertise in macrophage engineering to develop transformative therapies to treat serious diseases including liver fibrosis and cancer. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March and December 2024, the Company and its board of directors approved revised operating plans to reduce monthly operating expenses, conserve cash, and refocus its efforts on strategic priorities. As part of these plans, in March 2024 the Company elected to cease further development of its first lead product candidate, CT-0508. In December 2024 as part of the plan, the Company elected to cease further development of its then lead product candidate, CT-0525, following an assessment of the competitive landscape in anti-HER2 treatments and the impact of recently approved therapies on HER2 antigen loss/downregulation, and the effects on the future development strategy of any anti-HER2 product. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of its cost-reduction initiatives in 2024, the Company implemented workforce reductions during 2024, resulting in the termination of <ix:nonFraction unitRef="employee" contextRef="c-32" decimals="INF" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" scale="0" id="f-320">62</ix:nonFraction> full-time employees (representing approximately <ix:nonFraction unitRef="number" contextRef="c-32" decimals="2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="f-321">58</ix:nonFraction>% of the Company's total workforce), across research and development and general and administrative functions. The workforce reduction resulted in $<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-322">4.1</ix:nonFraction>&#160;million of severance related costs, of which $<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-323">2.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-324">2.1</ix:nonFraction>&#160;million are included within <span style="-sec-ix-hidden:f-325">general and administrative</span> and <span style="-sec-ix-hidden:f-326">research and development</span> expense, respectively, in the accompanying consolidated statement of operations and comprehensive loss. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2024, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="6" id="f-327">2.7</ix:nonFraction>&#160;million in severance costs were accrued in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accompanying</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consolidated balance sheets. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the 2024 reduction in workforce. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 10, 2024, the Company received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq) notifying the Company that our common stock was not in compliance with Nasdaq Listing Rule 5450(b)(2)(A), or the MVLS Requirement, which requires the Company to maintain a minimum market value of listed securities of $50,000,000. The Company has 180 calendar days, or until April 8, 2025, to regain compliance with the MVLS Requirement. </span></div></ix:continuation><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-319-2">On January 6, 2025, the Company received a separate written notice from Nasdaq notifying the Company that, based upon the closing bid price of its common stock for the last 38 consecutive business days, the Company was not in compliance with Nasdaq Listing Rule 5450(a)(1) (the Bid Price Rule), which requires the Company to maintain a minimum bid price of $1.00 per share. The Company has 180 calendar days, or until July 7, 2025, to regain compliance with the Bid Price Rule.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div id="i280a0966ad034c5090dd46bd303d2259_157"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="carm:DevelopmentStageRisksAndLiquidityTextBlock" id="f-328" continuedAt="f-328-1" escape="true">Development-Stage Risks and Liquidity</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-328-1" continuedAt="f-328-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred losses and negative cash flows from operations since inception and has an accumulated deficit of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="f-329">305.6</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as of December&#160;31, 2024. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales from its product candidates currently in development. As of December 31, 2024, the Company had cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="f-330">17.9</ix:nonFraction> million. Based on current projections, the Company believes that it does not have sufficient cash and cash equivalents to support its operations for more than one year following the date that these financial statements are issued. As a result of these conditions, substantial doubt exists about the Company&#8217;s ability to continue as a going concern. In addition, changing circumstances could cause the Company to consume capital significantly faster than currently anticipated, and the Company may need to spend more than currently expected because of circumstances beyond its control.  The Company's cash forecast contains estimates and assumptions, and management cannot predict the timing of all cash receipts and expenditures with certainty. The accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments related to </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-328-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the recoverability and classification of recorded asset amounts or the amounts and classification of liability that might result from the outcome of this uncertainty. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is currently evaluating different strategies to maximize value and prepare to wind down the Company's business. Potential strategic alternatives to be explored and evaluated may include, among other transactions, the sale, license, monetization or divestiture of one or more of the Company's assets or technologies, a strategic collaboration or partnership with one or more parties or the merger or sale of the Company. There is no assurance regarding when or if this strategic review process will result in any type of transaction.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to those risks associated with any specialty biotechnology company that has substantial expenditures for research and development. There can be no assurance that the Company&#8217;s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants.</span></div></ix:continuation><div><span><br/></span></div><div id="i280a0966ad034c5090dd46bd303d2259_160"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-331" continuedAt="f-331-1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="f-331-1" continuedAt="f-331-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-332" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). Any references in these notes to applicable guidance is meant to refer to GAAP as found in Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) promulgated by the Financial Accounting Standards Board (FASB). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-333" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant areas that require management&#8217;s estimates include estimated research and development revenue, stock-based compensation assumptions, the estimated useful lives of property and equipment, and accrued research and development expenses.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="f-334" continuedAt="f-334-1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-334-1">Management believes that the carrying amounts of the Company&#8217;s financial instruments, including cash equivalents and accounts payable, approximate fair value due to the short-term nature of those instruments.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-335" continuedAt="f-335-1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-331-2" continuedAt="f-331-3"><ix:continuation id="f-335-1"><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-336" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table presents information about the Company&#8217;s assets measured at fair value on a recurring basis:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair value measurement at reporting date using</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents &#8211; money markets accounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-337">14,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-338">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-339">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents &#8211; money markets accounts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-340">62,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-341">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-342">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2024 and 2023, there were no transfers between Level 1, Level 2 and Level 3.</span></div></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-343" continuedAt="f-343-1" escape="true"><div><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue in accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 606). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaboration and licensing agreements with strategic partners, which are within the scope of ASC 606, under which it may exclusively license rights to research, develop, manufacture, and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: (1) non-refundable, upfront license fees (2) reimbursement of certain costs; (3) customer option fees for additional goods or services; (4) development milestone payments, (5) regulatory and commercial milestone payments; and (6) royalties on net sales of licensed products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use its judgment to determine: (a) the number of performance obligations based on the determination under step (i) above; (b) the transaction price under step (iii) above; (c) the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above; and (d) the contract term and pattern of satisfaction of the performance obligations under step (v) above. The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Upfront license fees</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license to the Company's intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-331-3" continuedAt="f-331-4"><ix:continuation id="f-343-1"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, manufacturing, and commercialization capabilities of the customer; the retention of any key rights by the Company; and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promises, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company exercises judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Customer options</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the customer options for material rights or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If an option is not exercised and the research and development target is terminated, the Company will accelerate and recognize all remaining revenue related to the material right performance obligation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Research and development services</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promises under the Company's collaboration agreements may include research and development services to be performed by the Company for or on behalf of the customer. Payments or reimbursements resulting from the Company's research and development efforts are recognized as the services are performed and presented on a gross basis because the Company is the principal for such efforts. Reimbursements from and payments to the customer that are the result of a collaborative relationship with the customer, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Milestone payments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-344" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of credit risk</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-345" continuedAt="f-345-1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment information</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-331-4" continuedAt="f-331-5"><ix:continuation id="f-345-1" continuedAt="f-345-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (CODM), or decision-making group, in deciding how to allocate resources in assessing performance. The Company has <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-346">one</ix:nonFraction> operating segment. The Company&#8217;s CODM is the chief executive officer. The Company&#8217;s CODM manages the Company&#8217;s operations on a consolidated basis for the purpose of allocating resources.</span></div></ix:continuation><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="f-345-2">The accounting policies of its segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance for its segment based on net loss, which is reported on the consolidated statements of operations and comprehensive loss. The measure of segment assets is reported on the balance sheet as total assets. The CODM uses cash forecast models in deciding how to invest into the segment. The CODM analyzes the Company&#8217;s net loss and monitors budget versus actual results to assess the performance of the Company.</ix:continuation> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-347" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The table below summarizes the significant expense categories regularly reviewed by the CODM for the years ended December 31, 2024 and 2023:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-348">19,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-349">14,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development, excluding facilities, personnel, depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="carm:ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses" format="ixt:num-dot-decimal" scale="3" id="f-350">33,147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="carm:ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses" format="ixt:num-dot-decimal" scale="3" id="f-351">45,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative, excluding facilities and personnel expenses, depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="carm:GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses" format="ixt:num-dot-decimal" scale="3" id="f-352">14,829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="carm:GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses" format="ixt:num-dot-decimal" scale="3" id="f-353">19,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facilities expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="carm:FacilitiesExpense" format="ixt:num-dot-decimal" scale="3" id="f-354">5,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="carm:FacilitiesExpense" format="ixt:num-dot-decimal" scale="3" id="f-355">7,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personnel expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:LaborAndRelatedExpense" format="ixt:num-dot-decimal" scale="3" id="f-356">24,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:LaborAndRelatedExpense" format="ixt:num-dot-decimal" scale="3" id="f-357">27,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation, amortization and interest on finance and sale-leaseback lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="carm:DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-358">3,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="carm:DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-359">3,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other segment items(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" sign="-" name="us-gaap:SegmentReportingOtherItemAmount" format="ixt:num-dot-decimal" scale="3" id="f-360">2,242</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" sign="-" name="us-gaap:SegmentReportingOtherItemAmount" format="ixt:num-dot-decimal" scale="3" id="f-361">2,204</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-362">60,477</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-363">86,879</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(a) Other segment items include changes in warrant liability and interest income.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-364" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Cash and Cash Equivalents</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly-liquid investments that have maturities of three months or less when acquired to be cash equivalents. As of December&#160;31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2023, cas</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h equivalents consisted of investments in a money market account.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-365" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Property and Equipment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets ranging from <span style="-sec-ix-hidden:f-366">two</span> to <ix:nonNumeric contextRef="c-45" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-367">five years</ix:nonNumeric>. Leasehold improvements are amortized over the shorter of the life of the lease or the estimated useful life of the assets. Lab equipment that are classified as finance leases are amortized over the lease term.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="f-368" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-lived Assets</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. When events indicate a triggering event occurred, the recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, then an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Considerable management judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could vary significantly from such estimates.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company did <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="0" id="f-369"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="0" id="f-370">not</ix:nonFraction></ix:nonFraction> recognize any impairment of long-lived assets during th</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">e years ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December&#160;31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> or 2023.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-331-5" continuedAt="f-331-6"><ix:nonNumeric contextRef="c-1" name="carm:DeferredFinancingCostsPolicyPolicyTextBlock" id="f-371" continuedAt="f-371-1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Financing Costs</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-371-1">The Company capitalizes costs that are directly associated with in-process equity financings until such financings are consummated, at which time such costs are recorded against the gross proceeds from the applicable financing. If a financing is abandoned, deferred financing costs are expensed immediately.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-372" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether an arrangement is or contains a lease, its classification, and its term at the lease commencement date. Leases with a term greater than one year will be recognized on the balance sheet as right-of-use (ROU) assets, current lease liabilities, and if applicable, long-term lease liabilities. The Company includes renewal options to extend the lease term where it is reasonably certain that it will exercise these options. Lease liabilities and the corresponding ROU assets are recorded based on the present values of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rates, which are the rates that would be incurred to borrow on a collateralized basis, over similar terms, amounts equal to the lease payments in a similar economic environment. Payments for non-lease components or that are variable in nature that do not depend on a rate or index are not included in the lease liability and are typically expensed as incurred. If significant events, changes in circumstances, or other events indicate that the lease term or other inputs have changed, the Company would reassess lease classification, remeasure the lease liability using revised inputs as of the reassessment date, and adjust the ROU assets. Lease expense is recognized on a straight-line basis over the expected lease term for operating classified leases.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-373" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to expense as incurred. Up-front and milestone payments made to third parties who perform research and development services on the Company's behalf are expensed as services are rendered.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-374" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company measures stock-based awards, including stock options, at their grant-date fair value and records compensation expense over the requisite service period, which is the vesting period of the awards. The Company accounts for forfeitures as they occur.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating the fair value of stock options requires the use of subjective assumptions, including the fair value of the Company's common stock prior to the Merger (as defined in Note 4), and, for stock options, the expected term of the option and expected stock price volatility. The Company uses the Black-Scholes option-pricing model to value its stock option awards. The assumptions used in calculating the fair value of stock options represent management's best estimates and involve inherent uncertainties and the application of management's judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Merger (as defined in Note 4), the fair value of the Company's common stock was estimated by the Company's board of directors, with input by management considering the Company's most recently available third-party valuation of the Company's common stock. The expected term of stock options for employees is estimated using the simplified method, as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The simplified method is the midpoint between the vesting date and the contractual term of the option. The contractual term is used as the expected term for stock options granted to nonemployees. For stock price volatility, the Company uses comparable public companies as a basis for the expected volatility to calculate the fair value of option grants. The risk-free rate is based on the U.S. Treasury yield curve commensurate with the expected term of the option. The expected dividend yield is zero given the Company does not expect to pay dividends for the foreseeable future.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-375" continuedAt="f-375-1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Income taxes </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company's assets and liabilities, and the expected benefits of net operating loss and income tax credit carryforwards. The impact of changes in </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-331-6"><ix:continuation id="f-375-1"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tax rates and laws on deferred taxes, if any, applied during the period in which temporary differences are expected to be settled, is reflected in the Company's consolidated financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on weight of the evidence, it is more likely than not that some, or all, of the deferred tax assets will not be realized. As of December 31, 2024 and 2023, the Company has concluded that a full valuation allowance is necessary for all of its net deferred tax assets. The Company had no amounts recorded for uncertain tax positions, interest, or penalties in the accompanying consolidated financial statements. Although there are no unrecognized income tax benefits, when applicable, the Company&#8217;s policy is to report interest and penalties related to unrecognized income tax benefits as a component of income tax expense.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-376" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net loss per share</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, potentially dilutive securities are not included in the calculation as their impact is anti-dilutive.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-377" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-46" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-378">7,746,991</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-47" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-379">6,023,370</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-380" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently adopted accounting pronouncements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2023, the FASB issued ASU 2023-07, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (ASU 2023-07), which requires disclosure of incremental segment information on an annual and interim basis. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 on a retrospective basis. The Company incorporated the improved segment disclosures in the summary of significant accounting policies, herein.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently issued but not yet adopted accounting pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2023-09), which expands the disclosures required for income taxes. This ASU is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendment should be applied on a prospective basis while retrospective application is permitted. The Company is currently evaluating the effect of this pronouncement on its disclosures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is intended to provide more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation and amortization) included in certain expense captions presented on the consolidated statement of operations. The guidance in this ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the consolidated financial statements. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its consolidated financial statements and disclosures.</span></div></ix:nonNumeric></ix:continuation><div id="i280a0966ad034c5090dd46bd303d2259_163"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(4)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="f-381" continuedAt="f-381-1" escape="true">Merger with Sesen Bio</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-381-1" continuedAt="f-381-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">On March&#160;7, 2023, the Company (formerly publicly-held Sesen Bio, Inc.) consummated a merger with CTx Operations, Inc. (formerly privately-held CARISMA Therapeutics Inc.) (Legacy Carisma) pursuant to an Agreement and Plan of Merger and Reorganization, as amended (the Merger Agreement), by and among the Company, Legacy Carisma and </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-381-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Seahawk Merger Sub, Inc. (Merger Sub), a Delaware corporation and wholly-owned subsidiary of the Company. The Merger Agreement provided for the merger of Merger Sub with and into Legacy Carisma, with Legacy Carisma continuing as a wholly-owned subsidiary of the Company and the surviving corporation of the merger (the Merger). The Merger was accounted for as a reverse recapitalization under GAAP because the primary assets of Sesen Bio were cash, cash equivalents and marketable securities. For financial reporting purposes Legacy Carisma was determined to be the accounting acquirer based upon the terms of the Merger and other factors, including: (i) Legacy Carisma stockholders own approximately <ix:nonFraction unitRef="number" contextRef="c-48" decimals="3" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="f-382">74.2</ix:nonFraction>% of the Combined Company, (ii) Legacy Carisma holds the majority (<ix:nonFraction unitRef="seat" contextRef="c-49" decimals="INF" name="carm:NumberOfBoardMembers" format="ixt-sec:numwordsen" scale="0" id="f-383">six</ix:nonFraction> of <ix:nonFraction unitRef="seat" contextRef="c-5" decimals="INF" name="carm:NumberOfBoardMembers" format="ixt-sec:numwordsen" scale="0" id="f-384">seven</ix:nonFraction>) of board seats of the Combined Company and (iii) Legacy Carisma management holds all key positions of management. Accordingly, the Merger was treated as the equivalent of Legacy Carisma issuing stock to acquire the net assets of Sesen Bio. As a result of the Merger, the net assets of Sesen Bio were recorded at their acquisition-date fair value in the consolidated financial statements and the reported operating results prior to the Merger are those of Legacy Carisma. Immediately after the Merger, there were <ix:nonFraction unitRef="shares" contextRef="c-48" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-385">40,254,666</ix:nonFraction> shares of the Company&#8217;s common stock outstanding.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="f-386" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the net assets acquired in the Merger (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 7, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-387">37,873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-388">44,588</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-389">1,316</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="carm:Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash" scale="3" id="f-390">30</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-391">3,499</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total net assets acquired</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" format="ixt:num-dot-decimal" scale="3" id="f-392">80,308</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Transaction costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" format="ixt:num-dot-decimal" scale="3" id="f-393">8,264</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total net assets acquired less transaction costs</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="f-394">72,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to March&#160;7, 2023, the Company paid $<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="f-395">4.6</ix:nonFraction> million of severance and personnel costs related to Sesen Bio.</span></div></ix:continuation><div id="i280a0966ad034c5090dd46bd303d2259_169"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(5)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:OtherAssetsDisclosureTextBlock" id="f-396" continuedAt="f-396-1" escape="true">Prepaid Expenses and Other Assets</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="f-397" escape="true"><ix:continuation id="f-396-1"><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets consisted of the following (in thousands):</span></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="carm:PrepaidResearchAndDevelopmentCurrent" format="ixt:num-dot-decimal" scale="3" id="f-398">1,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="carm:PrepaidResearchAndDevelopmentCurrent" scale="3" id="f-399">278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration receivable </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="carm:ReceivableDueFromCollaborativeArrangementCurrent" format="ixt:num-dot-decimal" scale="3" id="f-400">2,864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="carm:ReceivableDueFromCollaborativeArrangementCurrent" format="ixt:fixed-zero" scale="3" id="f-401">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Insurance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PrepaidInsurance" scale="3" id="f-402">340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PrepaidInsurance" scale="3" id="f-403">402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DepositsAssetsCurrent" scale="3" id="f-404">925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DepositsAssetsCurrent" scale="3" id="f-405">891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="f-406">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-407">1,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-408">5,916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-409">2,866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="margin-top:12pt;padding-left:27pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126</span></div></div></div><div id="i280a0966ad034c5090dd46bd303d2259_166"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(6)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-410" continuedAt="f-410-1" escape="true">Property and Equipment, net</ix:nonNumeric></span></div><ix:continuation id="f-410-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-411" continuedAt="f-411-1" escape="true"><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer software</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="f-412">508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="f-413">903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lab equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-414">11,157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-415">11,392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Office furniture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="f-416">267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="f-417">267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="f-418">340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="f-419">340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:fixed-zero" scale="3" id="f-420">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="f-421">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-422">12,272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-423">12,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: accumulated depreciation and amortization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-424">7,887</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-425">6,151</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-426">4,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-427">6,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Lab equipment includes failed sale lease-back assets of $<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-5" name="us-gaap:SaleLeasebackTransactionNetBookValue" format="ixt:num-dot-decimal" scale="6" id="f-428"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-5" name="us-gaap:SaleLeasebackTransactionNetBookValue" format="ixt:num-dot-decimal" scale="6" id="f-429">3.4</ix:nonFraction></ix:nonFraction>&#160;million as of December&#160;31, 2024 and 2023. Lab equipment includes finance lease ROU assets of $<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-430">3.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-431">2.9</ix:nonFraction>&#160;million, respectively, as of December&#160;31, 2024 and 2023.</span></div></ix:nonNumeric><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><ix:continuation id="f-411-1" continuedAt="f-411-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The accumulated amortization balance includes $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:SaleLeasebackTransactionAccumulatedDepreciation" format="ixt:num-dot-decimal" scale="6" id="f-432">1.5</ix:nonFraction>&#160;million and</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-411-2">$<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:SaleLeasebackTransactionAccumulatedDepreciation" format="ixt:num-dot-decimal" scale="6" id="f-433">0.9</ix:nonFraction>&#160;million, respectively, related to failed sale-leaseback assets as of December&#160;31, 2024 and 2023. The accumulated amortization balance includes $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-434">2.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-435">1.7</ix:nonFraction>&#160;million, respectively, related to finance lease ROU assets as of December&#160;31, 2024 and 2023.</ix:continuation>  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-436">3.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-437">2.8</ix:nonFraction>&#160;million for the years ended December&#160;31, 2024 and 2023, respectively.</span></div></ix:continuation><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span><br/></span></div><div id="i280a0966ad034c5090dd46bd303d2259_5497558139546"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(7)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="f-438" continuedAt="f-438-1" escape="true">Accrued Expenses</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-439" escape="true"><ix:continuation id="f-438-1"><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="carm:AccruedResearchAndDevelopmentExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-440">1,845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="carm:AccruedResearchAndDevelopmentExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-441">3,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="f-442">537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-443">1,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation and related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-444">4,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-445">3,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-446">187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-447">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-448">7,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-449">7,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="i280a0966ad034c5090dd46bd303d2259_172"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(8)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-450" continuedAt="f-450-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="f-450-1" continuedAt="f-450-2"><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for its laboratory and office space in Philadelphia, Pennsylvania. The Company&#8217;s operating leases have term end dates ranging from 2025 to 2029. The Company also has obligations under an arrangement for the use of certain laboratory equipment that are classified as finance leases that commenced in 2022 and have end dates ranging from 2025 to 2026. Effective February 2024, the Company renewed an existing operating lease with an end date through 2026. In April 2024, in connection with the revised operating plan, the Company notified the lessor that it would terminate the lease effective August 2024. In July 2024, the Company entered into an amendment extending the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-450-2" continuedAt="f-450-3"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">termination date of the lease to June 2025 with an option to extend to December 2025. The Company did not incur any penalties or fees in connection with the termination.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2024, the Company modified existing finance leases and failed sale-leaseback arrangements by assigning the rights and obligations of certain underlying assets to an unrelated third party. The modifications resulted in a reduction of its finance lease ROU assets and related lease liability of $<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-5" sign="-" name="carm:IncreaseDecreaseInFinanceLeaseRightOfUseAssetLeaseModification" format="ixt:num-dot-decimal" scale="6" id="f-451"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-5" sign="-" name="carm:IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification" format="ixt:num-dot-decimal" scale="6" id="f-452">0.4</ix:nonFraction></ix:nonFraction>&#160;million. In addition, the Company recorded a reduction of its failed sale-leaseback liability and gain on the sale of the corresponding assets of $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="us-gaap:SaleAndLeasebackTransactionGainLossNet" format="ixt:num-dot-decimal" scale="6" id="f-453">0.1</ix:nonFraction>&#160;million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s operating and finance lease ROU assets and the related lease liabilities are initially measured at the present value of future lease payments over the lease term. The Company is responsible for payment of certain real estate taxes, insurance and other expenses on certain of its leases. These amounts are generally considered to be variable and are not included in the measurement of the ROU assets and lease liability. The Company accounts for non-lease components, such as maintenance, separately from lease components.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company carries laboratory equipment from failed sale-leasebacks, as property and equipment, net on the accompanying consolidated balance sheets. The ongoing lease payments are recorded as reductions to the finance liability and interest expense. As of December&#160;31, 2024, the Company had a $<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-5" name="us-gaap:FinanceLeaseLiability" scale="6" id="f-454">1.4</ix:nonFraction> million financing liability recorded in other current liabilities and other long-term liabilities on the consolidated balance sheets. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-455" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The elements of the lease costs were as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-456">5,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-457">5,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="3" id="f-458">1,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="3" id="f-459">1,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="f-460">217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="f-461">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total finance lease cost</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="carm:FinanceLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-462">1,801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="carm:FinanceLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-463">1,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-464">1,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-465">1,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short term lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="f-466">671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ShortTermLeaseCost" format="ixt:fixed-zero" scale="3" id="f-467">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-468">8,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-469">8,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="carm:LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock" id="f-470" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease term and discount rate information related to leases was as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-5" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-471">2.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-6" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-472">2.6</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-5" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-473">0.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-6" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-474">1.5</ix:nonNumeric></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-475">9.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-476">9.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-477">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-478">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-450-3" continuedAt="f-450-4"><ix:nonNumeric contextRef="c-1" name="carm:LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock" id="f-479" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information was as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash used in operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-480">5,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-481">5,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash used in finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="f-482">217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="f-483">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash used in finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="carm:FinancingCashUsedInFinanceLeases" format="ixt:num-dot-decimal" scale="3" id="f-484">1,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="carm:FinancingCashUsedInFinanceLeases" format="ixt:num-dot-decimal" scale="3" id="f-485">1,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="carm:LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock" id="f-486" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future maturities of lease liabilities were as follows as of December&#160;31, 2024 (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Operating <br/>Leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Finance <br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fiscal year ending:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="f-487">927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="f-488">942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="f-489">225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="f-490">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="f-491">233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" format="ixt:fixed-zero" scale="3" id="f-492">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="f-493">240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" format="ixt:fixed-zero" scale="3" id="f-494">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="f-495">184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" format="ixt:fixed-zero" scale="3" id="f-496">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:fixed-zero" scale="3" id="f-497">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:fixed-zero" scale="3" id="f-498">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-499">1,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="f-500">963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="f-501">253</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="f-502">38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Present value of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-503">1,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiability" scale="3" id="f-504">925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing and Sponsored Research Agreements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under a license agreement with The Trustees of the University of Pennsylvania (Penn), entered into in November 2017 (Penn License Agreement),</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company is required to make annual payments of $<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="carm:CommitmentsAnnualPaymentsRequiredToBePaid" format="ixt:num-dot-decimal" scale="3" id="f-505">25,000</ix:nonFraction>. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Penn is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-5" name="carm:AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents" scale="6" id="f-506">10.9</ix:nonFraction> million per product in development upon the achievement of certain clinical, regulatory and commercial milestone events. There are additional milestone payments required to be paid of up to $<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-5" name="carm:AdditionalMilestonePaymentsRequiredToBePaid" scale="6" id="f-507">30.0</ix:nonFraction> million per product in commercial milestones and up to an additional $<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-5" name="carm:AdditionalMilestonePaymentsForFirstCarMProduct" scale="6" id="f-508">1.7</ix:nonFraction> million in development and regulatory milestone payments for the first CAR-M product directed to mesothelin. Additionally, the Company is obligated to pay Penn single-digit royalties based on its net sales.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, the Company entered into a manufacturing and supply agreement with Novartis Pharmaceuticals Corporation (Novartis) for the manufacturing of the Company&#8217;s CT-0508 product candidate (Novartis Agreement). The Novartis Agreement had a <span style="-sec-ix-hidden:f-509">five</span> year term. On June 26, 2024, in furtherance of its revised operating plan approved in late March 2024, the Company terminated the Novartis Agreement. Upon termination, the Company incurred a termination fee equal to $<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-5" name="us-gaap:LossOnContractTermination" format="ixt:num-dot-decimal" scale="6" id="f-510">4.0</ix:nonFraction>&#160;million, which was paid in the third quarter of 2024. A prepaid asset was recorded as the Company separately agreed with Novartis that if Novartis and the Company re-negotiate the agreement for a substitute product on or before December 31, 2024, then the $<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-5" name="us-gaap:LossOnContractTermination" format="ixt:num-dot-decimal" scale="6" id="f-511">4.0</ix:nonFraction>&#160;million termination fee would be credited in full or in part against any amounts due from the Company to Novartis under such agreement relating to the substitute product. The Company did not re-negotiate the agreement and expensed the $<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-5" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="6" id="f-512">4.0</ix:nonFraction>&#160;million prepaid asset in the fourth quarter of 2024 to research and development in the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities for loss contingencies, arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment and/or remediation can be reasonably estimated. As of December&#160;31, 2024, the Company was in negotiations with a vendor to determine the total costs owed for research and development services provided. While the negotiations are ongoing, the Company believes a </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-450-4"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liability is probable. The Company has estimated the amount to be owed to be $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="f-513">1.2</ix:nonFraction>&#160;million which is included within accrued expenses on the accompanying consolidated balance sheets. The final amount owed may differ from the estimate as negotiations progress. The Company will continue to evaluate the matter and will adjust the liability as necessary based on any new information or agreements reached with the vendor.</span></div></ix:continuation><div id="i280a0966ad034c5090dd46bd303d2259_178"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(9)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-514" continuedAt="f-514-1" escape="true">Stockholders&#8217; (Deficit) Equity</ix:nonNumeric></span></div><ix:continuation id="f-514-1"><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;7, 2023, in connection with the closing of the Mer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ger, the following is reflected on the consolidated statements of convertible preferred stock and stockholders&#8217; (deficit) equity for the year ended December 31, 2023: (i) the sale of <ix:nonFraction unitRef="shares" contextRef="c-70" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-515">3,730,608</ix:nonFraction> shares of common stock in a pre-closing funding at $<ix:nonFraction unitRef="usdPerShare" contextRef="c-50" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="f-516">8.21</ix:nonFraction> per share for total proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="f-517">30.6</ix:nonFraction> million, (ii) the issuance of <ix:nonFraction unitRef="shares" contextRef="c-70" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-518">5,059,338</ix:nonFraction> shares of common stock upon the settlement of the Company&#8217;s $<ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="6" id="f-519">35.0</ix:nonFraction> million convertible promissory note, accrued interest and related derivative liability, (iii) the conversion of convertible preferred stock and exchangeable shares previously presented as noncontrolling interests into <ix:nonFraction unitRef="shares" contextRef="c-70" decimals="INF" name="carm:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests" format="ixt:num-dot-decimal" scale="0" id="f-520">18,872,711</ix:nonFraction> shares of common stock, (iv) the issuance of <ix:nonFraction unitRef="shares" contextRef="c-70" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="0" id="f-521">10,374,272</ix:nonFraction> shares of common stock to Sesen Bio stockholders as consideration for the Merger.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 17, 2023, the Company filed a universal shelf registration statement on Form S-3, which was declared effective on May 2, 2023 (Registration Statement). Under the Registration Statement, the Company may offer and sell up to $<ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-5" name="carm:SaleOfStockStockOfferingAmount" format="ixt:num-dot-decimal" scale="6" id="f-522">300.0</ix:nonFraction>&#160;million of a variety of securities, including debt securities, common stock, preferred stock, depositary shares, subscription rights, warrants and units from time to time in one or more offerings at prices and on terms to be determined at the time of the offering. On May 12, 2023, the Company entered into an Amended and Restated Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (Sale Agreement) with Jefferies LLC, as sales agent, pursuant to which the Company may offer and sell shares of common stock with an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="INF" name="carm:SaleOfStockMaximumOfferingAmount" format="ixt:num-dot-decimal" scale="6" id="f-523">100.0</ix:nonFraction>&#160;million under an &#8220;at-the-market" offering program. During the years ended December 31, 2024 and 2023, the Company sold <ix:nonFraction unitRef="shares" contextRef="c-73" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-524">1,136,384</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-74" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-525">226,533</ix:nonFraction> shares of common stock, respectively, for gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" format="ixt:num-dot-decimal" scale="6" id="f-526">2.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" format="ixt:num-dot-decimal" scale="6" id="f-527">0.6</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2023, the Company's stockholders approved an amendment to the Company's Restated Certificate of Incorporation to increase the number of authorized shares of the Company's common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-528">0.001</ix:nonFraction> par value, from <ix:nonFraction unitRef="shares" contextRef="c-75" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-529">100,000,000</ix:nonFraction> shares to <ix:nonFraction unitRef="shares" contextRef="c-76" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-530">350,000,000</ix:nonFraction> shares and authorized <ix:nonFraction unitRef="shares" contextRef="c-76" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-531">5,000,000</ix:nonFraction> shares of preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-76" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-532">0.001</ix:nonFraction> par value.</span></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div id="i280a0966ad034c5090dd46bd303d2259_181"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(10)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-533" continuedAt="f-533-1" escape="true">Stock-based Compensation</ix:nonNumeric></span></div><ix:continuation id="f-533-1" continuedAt="f-533-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2017 Stock Incentive Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted the CARISMA Therapeutics Inc. 2017 Stock Incentive Plan, as amended (the Legacy Carisma Plan), that provided for the grant of incentive stock options to employees, directors, and consultants. The maximum term of options granted under the Legacy Carisma Plan was <ix:nonNumeric contextRef="c-77" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-534">ten years</ix:nonNumeric>, and stock options typically vested over a <ix:nonNumeric contextRef="c-77" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-535">four-year</ix:nonNumeric> period. The Company&#8217;s stock options vest based on the terms in the awards agreements and generally vest over <ix:nonNumeric contextRef="c-77" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-536">four years</ix:nonNumeric>. Upon completion of the Merger, the Company assumed the Legacy Carisma Plan and the outstanding and unexercised options issued thereunder, and ceased granting awards under the Legacy Carisma Plan.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2014 Stock Incentive Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Amended and Restated 2014 Stock Incentive Plan, as amended, provides for the grant of incentive and non-qualified stock options, restricted stock awards and restricted stock units, stock appreciation rights and other stock-based awards to the Company&#8217;s employees, officers, directors, consultants, and advisors, with amounts and terms of grants determined by the Company&#8217;s board of directors at the time of grant. Stock options outstanding under the 2014 Amended and Restated Stock Incentive Plan (the 2014 Plan) generally vest over a <ix:nonNumeric contextRef="c-78" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-537">four-year</ix:nonNumeric> period and are exercisable for a period of <ix:nonNumeric contextRef="c-78" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-538">ten years</ix:nonNumeric> from the date of grant. As of December&#160;31, 2024, approximately <ix:nonFraction unitRef="shares" contextRef="c-79" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="6" id="f-539">4.8</ix:nonFraction> million shares of common stock remained available for issuance.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2014 Employee Stock Purchase Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Carisma Therapeutics Inc. 2014 Employee Stock Purchase Plan (the Carisma 2014 ESPP) provides employees with the opportunity to purchase shares of common stock at a <ix:nonFraction unitRef="number" contextRef="c-80" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" scale="-2" id="f-540">15</ix:nonFraction>% discount to the market price through payroll deductions or lump sum cash investments. The purpose of the Carisma 2014 ESPP is to enhance employee interest in the success and progress </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-533-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">of the Company by encouraging employee ownership of common stock. The Carisma 2014 ESPP had <ix:nonFraction unitRef="shares" contextRef="c-81" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="6" id="f-541">0.2</ix:nonFraction> million shares of common stock available for issuance as of December&#160;31, 2024.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-542" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>average<br/>exercise<br/>price </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>average<br/>remaining<br/>contractual<br/>term (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate <br/>Intrinsic <br/>Value (in <br/>thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-543">6,023,370</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-544">3.94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-545">3,810</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-546">0.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="f-547">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-548">3,805,465</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-549">1.76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-550">2,078,034</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-551">4.17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-552">7,746,991</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-553">2.81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-554">7.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="f-555">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable as of December 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-556">4,414,750</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-557">2.44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-558">6.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="f-559">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date per share fair values of options granted during the years ended December 31, 2024 and 2023 were $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-560">1.36</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-561">4.29</ix:nonFraction>, respectively. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-562" continuedAt="f-562-1" escape="true">The fair values in the years ended December 31, 2024 and 2023 were estimated using the Black-Scholes option-pricing model based on the following assumptions:</ix:nonNumeric></span></div><ix:continuation id="f-562-1"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-82" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-563">3.77</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-83" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-564">4.59</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-84" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-565">2.92</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-85" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-566">4.76</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-86" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-567">6</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-87" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-568">6</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-82" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-569">86.55</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-83" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-570">112.12</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-84" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-571">57.77</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-85" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-572">103.00</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-86" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-573">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-87" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-574">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-575" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following expense categories in the accompanying consolidated statements of operations:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:71.240%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.125%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-576">1,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-577">1,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-578">2,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-579">1,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-580">3,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-581">2,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the reductions in force, <ix:nonFraction unitRef="shares" contextRef="c-92" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-582">1,898,297</ix:nonFraction> options were forfeited during the year ended December 31, 2024. The Company recognized stock-based compensation expense of $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-583">0.2</ix:nonFraction> million related to the modification of Sesen Bio options assumed in connection with the Merger during the year ended December 31, 2023. Compensation cost for awards not vested as of December&#160;31, 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="f-584">7.2</ix:nonFraction> million and will be expensed over a weighted-average period of <ix:nonNumeric contextRef="c-1" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-585">2.5</ix:nonNumeric> years.</span></div></ix:continuation><div id="i280a0966ad034c5090dd46bd303d2259_184"></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(11)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-586" continuedAt="f-586-1" escape="true">Income Taxes</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-587" continuedAt="f-587-1" escape="true"><ix:continuation id="f-586-1" continuedAt="f-586-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A reconciliation of income tax benefit at the statutory federal income tax rate and income taxes as reflected in the consolidated financial statements is as follows:</span></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-586-2" continuedAt="f-586-3"><ix:continuation id="f-587-1"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.809%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.678%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.769%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.682%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal tax benefit at statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-588">21.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-7" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-589">21.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State and local tax, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-590">8.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-591">8.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State and local tax rate change</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal" scale="-2" id="f-592">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal" scale="-2" id="f-593">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Permanent differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="carm:EffectiveIncomeTaxRateReconciliationPermanentDifferences" scale="-2" id="f-594">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" sign="-" name="carm:EffectiveIncomeTaxRateReconciliationPermanentDifferences" scale="-2" id="f-595">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-596">5.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-597">0.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="f-598">33.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="f-599">28.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" id="f-600">1.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" format="ixt:fixed-zero" scale="-2" id="f-601">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total provision</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="f-602">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="f-603">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are determined based on the differences between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect for years in which differences are expected to reverse.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-604" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company's deferred tax assets for federal income taxes consisted of the following (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-605">87,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-606">72,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized research and development costs, net of amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="carm:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization" format="ixt:num-dot-decimal" scale="3" id="f-607">35,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="carm:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization" format="ixt:num-dot-decimal" scale="3" id="f-608">33,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="f-609">13,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="f-610">9,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Start-up costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="carm:DeferredTaxAssetsStartUpCosts" format="ixt:num-dot-decimal" scale="3" id="f-611">4,051</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="carm:DeferredTaxAssetsStartUpCosts" format="ixt:num-dot-decimal" scale="3" id="f-612">4,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="3" id="f-613">12,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="3" id="f-614">13,353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="carm:DeferredTaxAssetsLeaseLiability" scale="3" id="f-615">733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="carm:DeferredTaxAssetsLeaseLiability" scale="3" id="f-616">668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" scale="3" id="f-617">405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" format="ixt:fixed-zero" scale="3" id="f-618">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortizable assets and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="carm:DeferredTaxAssetsAmortizableAssetsAndOther" scale="3" id="f-619">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="carm:DeferredTaxAssetsAmortizableAssetsAndOther" scale="3" id="f-620">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="carm:DeferredTaxAssetsEquityCompensation" format="ixt:num-dot-decimal" scale="3" id="f-621">1,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="carm:DeferredTaxAssetsEquityCompensation" scale="3" id="f-622">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-623">155,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-624">134,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-625">153,855</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-626">133,580</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets, net of valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-627">1,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-628">1,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:21pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="carm:DeferredTaxLiabilitiesRightOfUseAsset" scale="3" id="f-629">848</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="carm:DeferredTaxLiabilitiesRightOfUseAsset" scale="3" id="f-630">645</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="f-631">429</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="f-632">524</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-633">1,277</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-634">1,169</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred tax assets and liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-635">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-636">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company has net operating loss carryforwards (NOLs) for federal income tax purposes of $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-637">374.7</ix:nonFraction>&#160;million, which are available to offset future federal taxable income. The pre-2018 federal NOLs of $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-638">120.0</ix:nonFraction>&#160;million will begin to expire in 2031, if not utilized. The post-2017 federal NOLs of $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-639">254.7</ix:nonFraction>&#160;million carry forward indefinitely. The Company also has NOLs for state and local income tax purposes of $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-640">280.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-641">65.1</ix:nonFraction>&#160;million, respectively that are available to offset future taxable income. The state NOLs will begin to expire in 2031 while the city of Philadelphia NOLs begin to expire in 2042. As of December&#160;31, 2024, the Company also had federal and state research and development tax credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-642">12.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-643">0.8</ix:nonFraction>&#160;million that will begin to expire in 2029 and 2032, respectively, unless previously utilized.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">132</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-586-3"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the need for a valuation allowance, management must determine that there will be sufficient taxable income to allow for the realization of deferred tax assets. Based upon the historical and anticipated future losses, management has determined that the deferred tax assets do not meet the more-likely-than-not threshold for realizability. Accordingly, a full valuation allowance has been recorded against the Company's net deferred tax assets as of December&#160;31, 2024. The valuation allowance increased by $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="f-644">20.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="f-645">84.5</ix:nonFraction>&#160;million during the years ended December 31, 2024 and 2023, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The NOLs and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOLs and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50 percent, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The Company has not done an analysis to determine whether or not ownership changes have occurred since inception. Certain state NOLs may also be limited, including Pennsylvania, which limits net operating loss utilization as a percentage of apportioned taxable income.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will recognize interest and penalties related to uncertain tax positions as a component of income tax expense/(benefit). As of December&#160;31, 2024, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company's financial statements. Tax years from 2021 and after remain subject to examination by all of the taxing jurisdictions. The NOLs and research credit carryforwards remain subject to review until utilized.</span></div></ix:continuation><div id="i280a0966ad034c5090dd46bd303d2259_187"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(12)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="f-646" continuedAt="f-646-1" escape="true">Related-Party Transactions</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-646-1">The Company has a collaboration and license agreement with Moderna, a significant shareholder (Note 13).</ix:continuation> </span></div><div id="i280a0966ad034c5090dd46bd303d2259_190"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(13)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-647" continuedAt="f-647-1" escape="true">Moderna Collaboration and License Agreement</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-647-1" continuedAt="f-647-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Company entered into the Moderna License Agreement, which provides for a broad strategic collaboration to discover, develop and commercialize </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> engineered CAR-M therapeutics in oncology. Moderna has the right to designate up to <ix:nonFraction unitRef="target" contextRef="c-101" decimals="INF" name="carm:MaximumNumberOfResearchTargets" format="ixt-sec:numwordsen" scale="0" id="f-648">twelve</ix:nonFraction> research targets as development targets under this collaboration. While the collaboration was initially limited to oncology, in September 2024, the companies agreed to expand the collaboration to discover, develop and commercialize</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> engineered CAR-M therapeutics in specific autoimmune diseases. As a result, Moderna nominated <ix:nonFraction unitRef="target" contextRef="c-102" decimals="INF" name="carm:NumberOfResearchTargetsNominatedAutoimmune" format="ixt-sec:numwordsen" scale="0" id="f-649">two</ix:nonFraction> autoimmune research targets. As of February 2025, in connection with Moderna's nomination of all <ix:nonFraction unitRef="target" contextRef="c-103" decimals="INF" name="carm:NumberOfResearchTargetsGrossOncology" scale="0" id="f-650">12</ix:nonFraction> oncology research targets (Note 14), the Company will not be conducting any additional research activities under the collaboration agreement and will not be receiving any further payments from Moderna for research and development services under the collaboration agreement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to the nomination of a research target, Moderna may designate the research target as a development target. Upon Moderna&#8217;s designation of a development target (and payment of a related development target designation milestone) for commencement of pre-clinical development of a product candidate, the Company will grant Moderna an exclusive worldwide, sublicensable royalty bearing license to develop, manufacture and commercialize the product candidate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Moderna License Agreement, Moderna made an upfront non-refundable payment of $<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-5" name="carm:UpfrontNonRefundablePaymentReceived" scale="6" id="f-651">45.0</ix:nonFraction> million to the Company. Assuming Moderna develops and commercializes <ix:nonFraction unitRef="product" contextRef="c-104" decimals="INF" name="carm:NumberOfPotentialProductsToDevelopAndCommercialize" scale="0" id="f-652">12</ix:nonFraction> products, each directed to a different development target, the Company is eligible to receive up to between $<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-5" name="carm:AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments" scale="6" id="f-653">247.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" name="carm:AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments" scale="6" id="f-654">253.0</ix:nonFraction> million per product in development target designation, development, regulatory and commercial milestone payments. Moderna also reimbursed the Company for all costs incurred by the Company in connection with its research and development activities under the Moderna License Agreement plus a reasonable margin for the respective services performed (with a minimum commitment to reimburse $<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-5" name="carm:MinimumCommitmentToReimburseResearchAndDevelopmentCosts" scale="6" id="f-655">10.0</ix:nonFraction> million in research and development costs over the first <ix:nonNumeric contextRef="c-104" name="carm:PeriodOfReimbursementOfResearchAndDevelopmentCosts" format="ixt-sec:durwordsen" id="f-656">three years</ix:nonNumeric> from execution of the Moderna License Agreement). The Company is also eligible to receive tiered mid-to-high single digit royalties of net sales of any products that are commercialized under the agreement, which may be, subject to reductions. In addition, Moderna has agreed to cover the cost the Company incurs for certain milestone payments and royalties that the Company owes as a licensor under one of its intellectual property in-license agreements with Penn, which is sublicensed to Moderna under the Moderna License Agreement. Moderna may deduct these royalties in part from any royalties owed to the Company. The </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">133</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-647-2" continuedAt="f-647-3"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moderna License Agreement terminates on a product-by-product basis upon the latest of expiration of the applicable product patents, expiration of regulatory exclusivity and the tenth anniversary of first commercial sale, unless terminated earlier by the Company or Moderna.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At commencement, the Company identified several potential performance obligations within the Moderna License Agreement, including research and development services on research targets, option rights held by Moderna, a non-exclusive royalty-free license to use the Company&#8217;s intellectual property to conduct research and development activities and participation on the joint steering committee (JSC). The Company determined that there were <ix:nonFraction unitRef="obligation" contextRef="c-108" decimals="INF" name="carm:NumberOfPerformanceObligations" scale="0" id="f-657">2</ix:nonFraction> performance obligations comprised of (i) research and development services and (ii) option rights.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the research and development services, the stand-alone selling price was determined considering the expected passthrough costs and cost of the research and development services and a reasonable margin for the respective services. The material rights from the option rights were valued based on the estimated discount at which the option is priced and the Company&#8217;s estimated probability of the options&#8217; exercise as of the time of the agreement. The transaction price allocated to research and development services is recognized as collaboration revenues as the research and development services are provided to satisfy the underlying obligation related to the research and development target. The transfer of control occurs over this period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price of $<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-5" name="carm:UpfrontNonRefundablePaymentReceived" format="ixt:num-dot-decimal" scale="6" id="f-658">45.0</ix:nonFraction>&#160;million allocated to the options rights, which are considered material rights, will be recognized in the period that Moderna exercises or determines not to exercise its option right to license and commercialize the designated development target.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2024, the Company received notice from Moderna that Moderna had designated the first development candidate, an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CAR-macrophage targeting GPC3 that is designed to treat solid tumors, including hepatocellular carcinoma. Pursuant to the terms of the Moderna License Agreement, the designation triggered a $<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-5" name="carm:CollaborativeArrangementRightsAndObligationsMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-659">2.0</ix:nonFraction>&#160;million milestone payment from Moderna to the Company. As a result, the Company recognized collaboration revenue of $<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-660">2.0</ix:nonFraction>&#160;million. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company reduced its $<ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-661">45.0</ix:nonFraction>&#160;million deferred revenue liability associated with the option rights by recognizing $<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-5" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-662">3.8</ix:nonFraction>&#160;million in collaboration revenue, which represents a proportional reduction based on the <ix:nonFraction unitRef="target" contextRef="c-113" decimals="INF" name="carm:NumberOfPotentialResearchTargetDesignations" scale="0" id="f-663">12</ix:nonFraction> potential early-stage research targets. As of December 31, 2024, the Company recorded a collaboration receivable of $<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-5" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-664">2.9</ix:nonFraction>&#160;million related to the reimbursement of costs incurred in connection with the Company's research and development activities. The Company received the $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="us-gaap:ProceedsFromCollectionOfOtherReceivables" format="ixt:num-dot-decimal" scale="6" id="f-665">2.9</ix:nonFraction>&#160;million in January 2025.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company included the $<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-5" name="carm:UpfrontNonRefundablePaymentReceived" scale="6" id="f-666">45.0</ix:nonFraction> million up-front and nonrefundable payment and $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="carm:VariableConsideration" scale="6" id="f-667">73.9</ix:nonFraction> million of variable consideration for expected research and development services to be performed during the <ix:nonNumeric contextRef="c-116" name="carm:ContractTerm" format="ixt-sec:durwordsen" id="f-668">five-year</ix:nonNumeric> contract term, inclusive of passthrough costs, in the transaction price as of the outset of the arrangement. During the years ended December 31, 2024 and 2023, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-669">19.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-670">14.9</ix:nonFraction> million, respectively, of collaboration revenues. Collaboration revenues for the year ended December&#160;31, 2024 include $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-671">3.8</ix:nonFraction>&#160;million of deferred option rights revenue recognition and $<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-672">2.0</ix:nonFraction>&#160;million of milestones.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-5" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="f-673">38.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-674">3.8</ix:nonFraction>&#160;million, respectively, of research and development services and option right collaboration revenues since inception of the Moderna License Agreement through December&#160;31, 2024. <ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" id="f-675" continuedAt="f-675-1" escape="true">The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied as of December&#160;31, 2024 (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-675-1"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Transaction <br/>price unsatisfied</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance obligations:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="carm:RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount" format="ixt:num-dot-decimal" scale="3" id="f-676">35,301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="carm:RevenueRemainingPerformanceObligationOptionRightsAmount" format="ixt:num-dot-decimal" scale="3" id="f-677">41,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total performance obligations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="3" id="f-678">76,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due to the Company for satisfying the revenue recognition criteria or that are contractually due based upon the terms of the collaboration agreements are recorded as accounts receivable in the Company&#8217;s consolidated balance sheets. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-647-3"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities consist of amounts received prior to satisfying the revenue recognition criteria, which are recorded as deferred revenue in the Company&#8217;s consolidated balance sheets.</span></div><ix:nonNumeric contextRef="c-1" name="carm:ScheduleOfChangesInDeferredRevenueTableTextBlock" id="f-679" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in deferred revenue (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at the beginning of the period </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-680">46,413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-681">47,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferral of revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="carm:ContractWithCustomerLiabilityDeferralOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-682">16,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="carm:ContractWithCustomerLiabilityDeferralOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-683">13,873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recognition of unearned revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="f-684">17,632</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="f-685">14,919</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at the end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-686">44,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-687">46,413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current portion of deferred revenue represents advanced payments received from Moderna for costs expected to be incurred by the Company within the next twelve months. The noncurrent portion of deferred revenue represents the $<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="f-688">41.3</ix:nonFraction> million upfront, non-refundable and non-creditable payment allocated to customer option right which is not expected to be recognized within the next 12 months.</span></div></ix:continuation><div id="i280a0966ad034c5090dd46bd303d2259_193"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(14)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-689" continuedAt="f-689-1" escape="true">Subsequent Events</ix:nonNumeric></span></div><ix:continuation id="f-689-1" continuedAt="f-689-2"><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated subsequent events from the balance sheet date through March&#160;31, 2025, the issuance date of these consolidated financial statements, and has identified the following matter requiring disclosure. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Moderna Collaboration and License Agreement</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2025, Moderna nominated <ix:nonFraction unitRef="item" contextRef="c-121" decimals="INF" name="carm:NumberOfResearchTargetsNominatedOncology" format="ixt-sec:numwordsen" scale="0" id="f-690">ten</ix:nonFraction> additional oncology research targets, <ix:nonFraction unitRef="target" contextRef="c-121" decimals="INF" name="carm:NumberOfResearchTargetsNominatedReplacements" format="ixt-sec:numwordsen" scale="0" id="f-691">four</ix:nonFraction> of which replaced <ix:nonFraction unitRef="target" contextRef="c-121" decimals="INF" name="carm:NumberOfResearchTargetsTerminatedOncology" format="ixt-sec:numwordsen" scale="0" id="f-692">two</ix:nonFraction> oncology research targets and <ix:nonFraction unitRef="target" contextRef="c-121" decimals="INF" name="carm:NumberOfResearchTargetsTerminatedAutoimmune" format="ixt-sec:numwordsen" scale="0" id="f-693">two</ix:nonFraction> autoimmune research targets, which Moderna concurrently ceased developing. As of February 2025, Moderna has nominated all <ix:nonFraction unitRef="target" contextRef="c-103" decimals="INF" name="carm:NumberOfResearchTargetsGrossOncology" scale="0" id="f-694">12</ix:nonFraction> oncology research targets under the collaboration for which the Company has the potential to receive future milestones and royalty payments. The Company will not conduct any additional research activities under the collaboration agreement and the Company will not be receiving any further research funding from Moderna under the collaboration agreement. Moderna also agreed to terminate the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> oncology field exclusivity, which would allow the Company to pursue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> in vivo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">CAR-M programs outside of the  <ix:nonFraction unitRef="target" contextRef="c-103" decimals="INF" name="carm:NumberOfResearchTargetsGrossOncology" scale="0" id="f-695">12</ix:nonFraction> nominated oncology targets and product polypeptides. The final research and development payment of $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="us-gaap:ProceedsFromCollectionOfOtherReceivables" format="ixt:num-dot-decimal" scale="6" id="f-696">2.9</ix:nonFraction>&#160;million was received in January 2025 which will be recognized as collaboration revenue for research and development services in the first quarter of 2025. The Company does not expect to recognize any additional unsatisfied research and development performance obligations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">2025 Cash Preservation Plan</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of a further revised plan approved by the Company's board of directors, on Marc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">h 25</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, 2025, to preserve the Company's existing cash resou</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">rces</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">following its reduction in workforce (the "cash preservation plan"), the Company reduced its operations to those necessary to identify and explore a range of strategic alternatives to maximize value and prepare to wind down its business. The cash preservation plan prioritizes payments necessary and appropriate for those reduced operations and those that will help to evaluate our strategic alternatives. </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Potential strategic alternatives to be explored and evaluated may include, among other transactions, the sale, license, monetization or divestiture of one or more of the Company's assets or technologies, a strategic collaboration or partnership with one or more parties or the merger or sale of the Company. Any future resumption of research and development activities would depend on completing a strategic transaction that would support the Company's prior operating plans or otherwise obtaining significant additional funding.</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of the cash preservation plan, the board of directors determined to terminate all of its employees not deemed necessary to pursue strategic alternatives and execute an orderly wind down of our operations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Affected employees were informed of the reduction in workforce on March 25, 2025. The reduction in workforce was effective on March 31, 2025. The reduction in workforce includes <ix:nonFraction unitRef="employee" contextRef="c-122" decimals="INF" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" id="f-697">37</ix:nonFraction> of the Company's full-time employees representing approximately <ix:nonFraction unitRef="number" contextRef="c-122" decimals="2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="f-698">84</ix:nonFraction>% of our total workforce, including certain employees engaged in research and development, manufacturing and corporate activities. The Company expects to incur approximately $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="6" id="f-699">3.8</ix:nonFraction>&#160;million in connection with the reduction in workforce, which primarily represents one-time employee termination benefits directly associated with the workforce reduction. The Company also expects to pay the majority of related reduction in workforce amounts by the end of 2025. The Company may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i280a0966ad034c5090dd46bd303d2259_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-689-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">with, the reduction in workforce, including (but not limited to) impairment charges relating to the balances of property and equipment, net, prepaid research and development costs and right of use assets &#8211; operating lease.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136</span></div></div></div><div id="i280a0966ad034c5090dd46bd303d2259_196"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span id="i3992972c2537445c9a8278ca5aa7cfbe_105"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">None.</span></div><div><span><br/></span></div><div id="i280a0966ad034c5090dd46bd303d2259_199"></div><div><span id="i4982873c415d490da8ea53474049452b_4077"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A. Controls and Procedures.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive officer and our principal financial officer has evaluated the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as of December&#160;31, 2024. The term &#8220;disclosure controls and procedures,&#8221; as defined in the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the evaluation of our disclosure controls and procedures as of December&#160;31, 2024, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management's Annual Report on Internal Control Over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over our financial reporting. Internal control over financial reporting is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act as a process designed by, or under the supervision of, our principal executive officer and our principal financial officer, and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of our financial statements for external purposes in accordance with generally accepted accounting principles, and includes those policies and procedures that:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of assets;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with the authorizations of management and directors; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide reasonable assurance regarding the prevention or timely detection of unauthorized acquisition, use or disposition of assets that could have a material effect on our financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the supervision and with the participation of our management, including our principal executive officer and our principal financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework provided in Internal Control &#8212; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, our management concluded that our internal control over financial reporting were effective as of December 31, 2024.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the three months ended December 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div><span><br/></span></div><div id="i280a0966ad034c5090dd46bd303d2259_202"></div><div><span id="i4be3894fcef7484d83412378c8681dd0_4676"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. Other Information.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">137</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a) 2025 Cash Preservation Plan</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of a further revised plan approved by our board of directors on Marc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">h 25</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, 2025 to preserve our existing cash resou</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">rces</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">following our reduction in workforce, or our cash preservation plan, we have reduced our operations to those necessary to identify and explore a range of strategic alternatives to maximize value and prepare to wind down our business. Our cash preservation plan prioritizes payments necessary and appropriate for those reduced operations and those that help to evaluate our strategic alternatives. </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Potential strategic alternatives to be explored and evaluated may include, among other transactions, the sale, license, monetization or divestiture of one or more of our assets or technologies, a strategic collaboration or partnership with one or more parties or the merger or sale of our company. We cannot provide any commitment regarding when or if this strategic review process will result in any type of transaction. We currently have no intention of resuming research and development activities. Any future resumption of research and development activities would depend on completing a strategic transaction that would support our prior operating plans or otherwise obtaining significant additional funding.</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of our cash preservation plan, our board of directors determined to terminate all of our employees not deemed necessary to pursue strategic alternatives and execute an orderly wind down of our operations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Affected employees were informed of the reduction in workforce on March 25, 2025. The reduction in workforce was effective on March 31, 2025. The reduction in workforce includes 37 of our full-time employees (representing approximately 84% of our total workforce), including certain employees engaged in research and development, manufacturing and corporate activities. We expect to incur approximately </span><span style="background-color:#ffff00;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$3.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> million in connection with the reduction in workforce, which primarily represents one-time employee termination benefits directly associated with the workforce reduction. We also expect to pay the majority of related reduction in workforce amounts by the end of this 2025. We may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the reduction in workforce.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">(b) Director and Officer Trading Arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of our directors or officers <ix:nonNumeric contextRef="c-123" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-700"><ix:nonNumeric contextRef="c-123" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-701">adopted</ix:nonNumeric></ix:nonNumeric> or <ix:nonNumeric contextRef="c-123" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-702"><ix:nonNumeric contextRef="c-123" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-703">terminated</ix:nonNumeric></ix:nonNumeric> a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the fourth quarter of 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div id="i280a0966ad034c5090dd46bd303d2259_205"></div><div><span id="i68db24f8b2ea4b9895aca26d8a81e3ec_100"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i280a0966ad034c5090dd46bd303d2259_208"></div><div style="text-align:center"><span id="i6d5fad6165814471bc18a49b4a701ecc_12"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part III</span></div><div id="i280a0966ad034c5090dd46bd303d2259_211"></div><div><span><br/></span></div><div><span id="i8bada215eff9499da3d487f8b281eebd_1009"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10. Directors, Executive Officers and Corporate Governance.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except to the extent provided below, the information required under this Item 10 is incorporated by reference to our definitive proxy statement for our 2025 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission not later than 120 days after the end of the fiscal year ended December 31, 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We post our Code of Business Conduct and Ethics, which applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions, in the &#8220;Governance Overview&#8221; sub-section of the &#8220;Governance&#8221; section on the "For Investors" page of our corporate website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">http://www.carismatx.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We intend to disclose on our website any amendments to, or waivers from, the Code of Business Conduct and Ethics that are required to be disclosed pursuant to the disclosure requirements of Item 5.05 of Form 8-K.</span></div><div><span><br/></span></div><div id="i280a0966ad034c5090dd46bd303d2259_214"></div><div><span id="i271f870ee7e94e5ba26ed3b1bef6bab0_357"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11. Executive Compensation.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required under this Item 11 is incorporated by reference to our definitive proxy statement for our 2025 Annual Meeting of Stockholders, which proxy statement we intend to file with the Securities and Exchange Commission not later than 120 days after the end of the fiscal year ended December 31, 2024.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138</span></div></div></div><div id="i280a0966ad034c5090dd46bd303d2259_217"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span id="i0f43c508acb34e1296107293c773a415_429"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required under this Item 12 is incorporated by reference to our definitive proxy statement for our 2025 Annual Meeting of Stockholders, which proxy statement we intend to file with the Securities and Exchange Commission not later than 120 days after the end of the fiscal year ended December 31, 2024.</span></div><div><span><br/></span></div><div id="i280a0966ad034c5090dd46bd303d2259_220"></div><div><span id="i43f4eebf46b64b41852c4cee5dfd4c37_408"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13. Certain Relationships and Related Transactions, and Director Independence.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required under this Item 13 is incorporated by reference to our definitive proxy statement for our 2025 Annual Meeting of Stockholders, which proxy statement we intend to file with the Securities and Exchange Commission not later than 120 days after the end of the fiscal year ended December 31, 2024.</span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i280a0966ad034c5090dd46bd303d2259_223"></div><div><span id="iab184d24f86c43088a52a9ca669878c2_382"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14. Principal Accountant Fees and Services.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required under this Item 14 is incorporated by reference to our definitive proxy statement for our 2025 Annual Meeting of Stockholders, which proxy statement will be filed with the Securities and Exchange Commission not later than 120 days after the close of the end of the fiscal year ended December 31, 2024.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139</span></div></div></div><div id="i280a0966ad034c5090dd46bd303d2259_226"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span id="i34a77c2ed03a4253a75975a083269a7a_12"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part IV</span></div><div id="i280a0966ad034c5090dd46bd303d2259_229"></div><div style="-sec-extract:summary;margin-top:12pt;text-align:justify"><span id="i148ff4caf1064319aaff172ed3826681_851"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15. Exhibits and Financial Statement Schedules.</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:10.5pt">Financial Statements</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a list of financial statements included herein, see Index to the Consolidated Financial Statements on page F-1 of this Annual Report on Form 10-K.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:10.5pt">Financial Statement Schedules</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All financial statement schedules have been omitted because they are not applicable, not required, or the information required is shown in the consolidated financial statements or the notes thereto.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:10.5pt">Exhibits</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following is a list of exhibits filed as part of this Annual Report on Form 10-K.</span></div><div style="text-align:center;text-indent:36pt"><span><br/></span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">EXHIBIT INDEX</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.173%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="carm-exx31.htm">Restated Certificate of Incorporation of Carisma Therapeutics Inc., dated March 7, 2023, as amended</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex3-2.htm">Amended and Restated By-Laws of Carisma Therapeutics Inc., dated March 7, 2023 (incorporated by reference to Exhibit 3.2 to the registrant&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on March 8, 2023).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="carm-exx41.htm">Description of the Registrant's Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923069917/tm2318211d1_ex99-1.htm">Amendment and Restatement of Carisma Therapeutics Inc. Amended and Restated 2014 Stock Incentive Plan (incorporated by reference to Exhibit 99.1 to the registrant&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on June 9, 2023).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923059849/tm2315501d2_ex1-1.htm">Amended and Restated Open Market Sale Agreement</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923059849/tm2315501d2_ex1-1.htm">SM</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923059849/tm2315501d2_ex1-1.htm">, dated May 12, 2023 (incorporated by reference to Exhibit 1.1 to the registrant&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on May 12, 2023).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.3&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465922120867/sesn-20220930xex10d32.htm">Collaboration and License Agreement, dated January 7, 2022, by and between Carisma Therapeutics Inc. and ModernaTX, Inc. (incorporated by reference to Exhibit 10.32 to the registrant&#8217;s Registration Statement on Form S-4/A (File No. 333-267891), filed on January 18, 2023).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.4&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465922108912/sesn-20211231xex10d33.htm">License Agreement, dated as of November 10, 2017, by and between Carisma Therapeutics Inc. and the Trustees of the University of Pennsylvania, as amended (incorporated by reference to Exhibit 10.33 to the registrant&#8217;s Registration Statement on Form S-4 (File No. 333-267891), filed on October 14, 2022).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.5&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465922108912/sesn-20211231xex10d34.htm">License Agreement, dated as of July 24, 2020, by and between Carisma Therapeutics Inc. and New York University (incorporated by reference to Exhibit 10.34 to the registrant&#8217;s Registration Statement on Form S-4 (File No. 333-267891), filed on October 14, 2022).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex10-4.htm">Registration Rights Agreement, dated March 7, 2023 (incorporated by reference to Exhibit 10.4 to the registrant&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on March 8, 2023).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex10-5.htm">Contingent Value Rights Agreement, dated March 7, 2023 (incorporated by reference to Exhibit 10.5 to the registrant&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on March 8, 2023).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.8#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex10-6.htm">Form of Indemnification Agreement for Directors and Officers of Carisma Therapeutics Inc. (incorporated by reference to Exhibit 10.6 to the registrant&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on March 8, 2023).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.9#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex10-7.htm">Employment Agreement, dated March 7, 2023, by and between Carisma Therapeutics Inc. and Steven Kelly (incorporated by reference to Exhibit 10.7 to the registrant&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on March 8, 2023).</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.173%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.10#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex10-8.htm">Employment Agreement, dated March 7, 2023, by and between Carisma Therapeutics Inc. and Richard Morris (incorporated by reference to Exhibit 10.8 to the registrant&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on March 8, 2023).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.11#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex10-9.htm">Employment Agreement, dated March 7, 2023, by and between Carisma Therapeutics Inc. and Michael Klichinsky (incorporated by reference to Exhibit 10.9 to the registrant&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on March 8, 2023).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.12#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex10-10.htm">CARISMA Therapeutics Inc. 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.10 to the registrant&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on March 8, 2023).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.13#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex10-11.htm">Form of Nonstatutory Stock Option Agreement under the CARISMA Therapeutics Inc. 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.11 to the registrant&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on March 8, 2023).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.14#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex10-12.htm">Form of Incentive Stock Option Agreement under the CARISMA Therapeutics Inc. 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.12 to the registrant&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on March 8, 2023).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.15#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex10-13.htm">Carisma Therapeutics Inc. Amended and Restated 2014 Stock Incentive Plan (incorporated by reference to Exhibit 10.13 to the registrant&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on March 8, 2023).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.16#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001485003/000110465923029687/tm238578d1_8k.htm">2023 Form of Stock Option Agreement under the Carisma Therapeutics Inc. 2014 Amended and Restated Stock Incentive Plan (incorporated by reference to Exhibit 10.14 to the registrant&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on March 8, 2023).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.17</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="carm-20241231xexx1017.htm">2024 Form of Stock Option Agreement under the Carisma Therapeutics Inc. 2014 Amended and Restated Stock Incentive Plan (incorporated by reference to Exhibit 10.17 to the registrant&#8217;s Annual Report on Form 10-K (File No. 001-36296) filed on April 1, 2024).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.18#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex10-15.htm">Form of Restricted Stock Unit Agreement under the Carisma Therapeutics Inc. 2014 Amended and Restated Stock Incentive Plan (incorporated by reference to Exhibit 10.15 to the registrant&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on March 8, 2023).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.19#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex10-16.htm">Carisma Therapeutics Inc. 2014 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.16 to the registrant&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on March 8, 2023).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.20</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923058778/carm-20230331xex10d18.htm">Lease, dated April 22, 2019, by and between Wexford-SCEC 3675 Market Street, LLC and CARISMA Therapeutics Inc. (incorporated by reference to Exhibit 10.18 to the registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-36296) filed on May 11, 2023).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.21#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465924131705/tm2432018d1_ex10-1.htm">Master Services Agreement, dated December 24, 2024, by and between Carisma Therapeutics Inc. and Danforth Global, Inc. and Danforth Advisors, LLC (incorporated by reference to Exhibit 10.1 to the registrant&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on December 26, 2024).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="carm-exx191.htm"><ix:nonNumeric contextRef="c-1" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true" id="f-704">Insider Trading Policy</ix:nonNumeric></a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.1*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="carm-20241231xexx211.htm">Subsidiaries of the Registrant</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.1*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="carm-20241231xexx231.htm">Consent of KPMG LLP, independent registered public accounting firm </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="carm-20241231xexx311.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="carm-20241231xexx312.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.1+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="carm-20241231xexx321.htm">Certifications of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.2+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="carm-20241231xexx322.htm">Certifications of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="carm-20241231xexx97.htm">Compensation Recovery Policy (incorporated by reference to Exhibit 97 to the registrant's Annual Report on Form 10-K (File No. 001-36296) filed on April 1, 2024).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">141</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.173%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________________</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith.</span></div><div style="padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">+&#160;&#160;&#160;&#160;Furnished herewith.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicates a management contract or any compensatory plan, contract or arrangement.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span><br/></span></div><div id="i280a0966ad034c5090dd46bd303d2259_232"></div><div style="-sec-extract:summary;margin-top:12pt;text-align:justify"><span id="i8c3bf0e8e1164ee7b0f2aabfb79de140_36"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16. Form 10-K Summary</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">142</span></div></div></div><div id="i280a0966ad034c5090dd46bd303d2259_235"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span id="if90c2d5e6aa24ffea52f912b5c8da07c_436"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.629%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: March&#160;31, 2025</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Steven Kelly</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name: Steven Kelly</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title: President and Chief Executive Officer</span></div></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.834%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.834%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.836%"/><td style="width:0.1%"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signature</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Title</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Steven Kelly</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President, Chief Executive Officer and Director (Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2025</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Steven Kelly</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Natalie McAndrew</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vice President of Finance (Principal Financial Officer and Principal Accounting Officer)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2025</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Natalie McAndrew</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Sanford Zweifach</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director and Chair of the Board</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2025</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sanford Zweifach</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Sohanya Cheng</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2025</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sohanya Cheng</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ John Hohneker, M.D.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2025</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">John Hohneker, M.D.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Briggs Morrison, M.D.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2025</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Briggs Morrison, M.D.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ David Scadden, M.D.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2025</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">David Scadden, M.D.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Marella Thorell</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2025</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marella Thorell</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">143</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>carm-exx31.htm
<DESCRIPTION>EX-3.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i122d59993cac4d53a9b6afa1e3e744e7_36"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Exhibit 3.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">RESTATED CERTIFICATE OF INCORPORATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">SESEN BIO, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(to be renamed Carisma Therapeutics Inc.)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(originally incorporated on February 25, 2008)</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Sesen Bio, Inc. (the &#8220;Corporation&#8221;), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the &#8220;General Corporation Law&#8221;), does hereby certify as follows&#58;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A. The current name of the Corporation is Sesen Bio, Inc. The original Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on February 25, 2008 under the name Newco LS14, Inc. The Certificate of Incorporation was mostly recently amended and restated on February 11, 2014 (as further amended, including most recently on March 7, 2023, the &#8220;Prior Certificate of Incorporation&#8221;).</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">B. This Restated Certificate of Incorporation has been duly adopted by the Board of Directors of the Corporation pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware to change the name of the Corporation to Carisma Therapeutics Inc. and to restate and integrate all amendments to the Prior Certificate of Incorporation and does not further amend (except as permitted under Sections 242(a)(1), 242(a)(7) and 242(b)(1) of the General Corporation Law of the State of Delaware) the provisions of the Prior Certificate of Incorporation as theretofore amended.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">C. This Restated Certificate of Incorporation shall become effective as of 5&#58;03 p.m. Eastern Standard Time on March 7, 2023 (the &#8220;Effective Time&#8221;).</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Accordingly, as of the Effective Time, the Prior Certificate of Incorporation of the Corporation, as theretofore amended, is hereby amended, integrated and restated in its entirety to read as follows&#58;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">First&#58; The name of the Corporation is Carisma Therapeutics Inc.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Second&#58; The address of the Corporation&#8217;s registered office in the State of Delaware is Corporation Trust Center, 1209 Orange Street, in the City of Wilmington, County of New Castle, 19801. The name of its registered agent at that address is The Corporation Trust Company.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Third&#58; The nature of the business or purposes to be conducted or promoted by the Corporation is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Fourth&#58; The total number of shares of all classes of stock which the Corporation shall have authority to issue is 105,000,000 shares, consisting of (i) 100,000,000 shares of Common Stock, $0.001 par value per share (&#8220;Common Stock&#8221;), and (ii) 5,000,000 shares of Preferred Stock, $0.001 par value per share (&#8220;Preferred Stock&#8221;).</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following is a statement of the designations and the powers, privileges and rights, and the qualifications, limitations or restrictions thereof in respect of each class of capital stock of the Corporation.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">COMMON STOCK</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. The voting, dividend and liquidation rights of the holders of the Common Stock are subject to and qualified by the rights of the holders of the Preferred Stock of any series as may be designated by the Board of Directors upon any issuance of the Preferred Stock of any series.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Voting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. The holders of the Common Stock shall have voting rights at all meetings of stockholders, each such holder being entitled to one vote for each share thereof held by such holder&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, that, except as otherwise required by law, holders of Common Stock shall not be entitled to vote on any amendment to this Certificate of Incorporation (which, as used herein, shall mean the certificate of incorporation of the Corporation, as amended from time to time, including the terms of any certificate of designations of any series of Preferred Stock) that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more other such series, to vote thereon pursuant to this Certificate of Incorporation. There shall be no cumulative voting.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The number of authorized shares of Common Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the stock of the Corporation entitled to vote, irrespective of the provisions of Section 242(b)(2) of the General Corporation Law of the State of Delaware.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Dividends</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Dividends may be declared and paid on the Common Stock from funds lawfully available therefor as and when determined by the Board of Directors and subject to any preferential dividend or other rights of any then outstanding Preferred Stock.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Liquidation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Upon the dissolution or liquidation of the Corporation, whether voluntary or involuntary, holders of Common Stock will be entitled to receive all assets of the Corporation available for distribution to its stockholders, subject to any preferential or other rights of any then outstanding Preferred Stock.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">B. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">PREFERRED STOCK</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Preferred Stock may be issued from time to time in one or more series, each of such series to have such terms as stated or expressed herein and in the resolution or resolutions providing for the issue of such series adopted by the Board of Directors of the Corporation as hereinafter provided. Any shares of Preferred Stock which may be redeemed, purchased or acquired by the Corporation may be reissued except as otherwise provided by law.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Authority is hereby expressly granted to the Board of Directors from time to time to issue the Preferred Stock in one or more series, and in connection with the creation of any such series, by adopting a resolution or resolutions providing for the issuance of the shares thereof and by filing a certificate of designations relating thereto in accordance with the General Corporation Law of the State of Delaware, to determine and fix the number of shares of such series and such voting powers, full or limited, or no voting powers, and such designations, preferences and relative participating, optional or other special rights, and qualifications, limitations or restrictions thereof, including without limitation thereof, dividend rights, conversion rights, redemption privileges and liquidation preferences, as shall be stated and expressed in such resolutions, all to the full extent now or hereafter permitted by the General Corporation Law of the State of Delaware. Without limiting the generality of the foregoing, the resolutions providing for issuance of any series of Preferred Stock may provide that such series shall be superior or rank equally or be junior to any other series of Preferred Stock to the extent permitted by law.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The number of authorized shares of Preferred Stock may be increased or decreased (but not below the number of shares then outstanding) by the affirmative vote of the holders of a majority of the voting power of the capital stock of the Corporation entitled to vote thereon, voting as a single class, irrespective of the provisions of Section 242(b)(2) of the General Corporation Law of the State of Delaware.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Fifth&#58; Except as otherwise provided herein, the Corporation reserves the right to amend, alter, change or repeal any provision contained in this Certificate of Incorporation, in the manner now or hereafter prescribed by statute and this Certificate of Incorporation, and all rights conferred upon stockholders herein are granted subject to this reservation. </font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Sixth&#58; In furtherance and not in limitation of the powers conferred upon it by the General Corporation Law of the State of Delaware, and subject to the terms of any series of Preferred Stock, the Board of Directors shall have the power to adopt, amend, alter or repeal the By-laws of the Corporation by the affirmative vote of a majority of the directors present at any regular or special meeting of the Board of Directors at which a quorum is present. The stockholders may not adopt, amend, alter or repeal the By-laws of the Corporation, or adopt any provision inconsistent therewith, unless such action is approved, in addition to any other vote required by this Certificate of Incorporation, by the affirmative vote of the holders of at least seventy-five percent (75%) of the votes that all the stockholders would be entitled to cast in any annual election of directors or class of directors. Notwithstanding any other provisions of law, this Certificate of Incorporation or the By-laws of the Corporation, and notwithstanding the fact that a lesser percentage may be specified by law, the affirmative vote of the holders of at least seventy-five percent (75%) of the votes which all the stockholders would be entitled to cast in any annual election of directors or class of directors shall be required to amend or repeal, or to adopt any provision inconsistent with, this Article SIXTH.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Seventh&#58; Except to the extent that the General Corporation Law of the State of Delaware prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty, no director of the Corporation shall be personally liable to the Corporation or its stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability. No amendment to or repeal of this provision shall apply to or have any effect on the liability or alleged liability of any director of the Corporation for or with respect to any acts or omissions of such director occurring prior to such amendment or repeal. If the General Corporation Law of the State of Delaware is amended to permit further elimination or limitation of the personal liability of directors, then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by the General Corporation Law of the State of Delaware as so amended.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Eighth&#58; The Corporation shall provide indemnification as follows&#58;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Actions, Suits and Proceedings Other than by or in the Right of the Corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. The Corporation shall indemnify each person who was or is a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the Corporation) by reason of the fact that he or she is or was, or has agreed to become, a director or officer of the Corporation, or is or was serving, or has agreed to serve, at the request of the Corporation, as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (including any employee benefit plan) (all such persons being referred to hereafter as an &#8220;Indemnitee&#8221;), or by reason of any action alleged to have been taken or omitted in such capacity, against all </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">expenses (including attorneys&#8217; fees), liabilities, losses, judgments, fines (including excise taxes and penalties arising under the Employee Retirement Income Security Act of 1974), and amounts paid in settlement actually and reasonably incurred by or on behalf of Indemnitee in connection with such action, suit or proceeding and any appeal therefrom, if Indemnitee acted in good faith and in a manner which Indemnitee reasonably believed to be in, or not opposed to, the best interests of the Corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. The termination of any action, suit or proceeding by judgment, order, settlement, conviction or upon a plea of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">nolo contendere</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> or its equivalent, shall not, of itself, create a presumption that Indemnitee did not act in good faith and in a manner which Indemnitee reasonably believed to be in, or not opposed to, the best interests of the Corporation, and, with respect to any criminal action or proceeding, had reasonable cause to believe that his or her conduct was unlawful.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Actions or Suits by or in the Right of the Corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. The Corporation shall indemnify any Indemnitee who was or is a party to or threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the Corporation to procure a judgment in its favor by reason of the fact that Indemnitee is or was, or has agreed to become, a director or officer of the Corporation, or is or was serving, or has agreed to serve, at the request of the Corporation, as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (including any employee benefit plan), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys&#8217; fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred by or on behalf of Indemnitee in connection with such action, suit or proceeding and any appeal therefrom, if Indemnitee acted in good faith and in a manner which Indemnitee reasonably believed to be in, or not opposed to, the best interests of the Corporation, except that no indemnification shall be made under this Section 2 in respect of any claim, issue or matter as to which Indemnitee shall have been adjudged to be liable to the Corporation, unless, and only to the extent, that the Court of Chancery of Delaware or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of such liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnity for such expenses (including attorneys&#8217; fees) which the Court of Chancery of Delaware or such other court shall deem proper. </font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Indemnification for Expenses of Successful Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Notwithstanding any other provisions of this Article EIGHTH, to the extent that an Indemnitee has been successful, on the merits or otherwise, in defense of any action, suit or proceeding referred to in Sections 1 and 2 of this Article EIGHTH, or in defense of any claim, issue or matter therein, or on appeal from any such action, suit or proceeding, Indemnitee shall be indemnified against all expenses (including attorneys&#8217; fees) actually and reasonably incurred by or on behalf of Indemnitee in connection therewith. Without limiting the foregoing, if any action, suit or proceeding is disposed of, on the merits or otherwise (including a disposition without prejudice), without (i) the disposition being adverse to Indemnitee, (ii) an adjudication that Indemnitee was liable to the Corporation, (iii) a plea of guilty or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">nolo contendere</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> by Indemnitee, (iv) an adjudication that Indemnitee did not act in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Corporation, and (v) with respect to any criminal proceeding, an adjudication that Indemnitee had reasonable cause to believe his or her conduct was unlawful, Indemnitee shall be considered for the purposes hereof to have been wholly successful with respect thereto.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Notification and Defense of Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. As a condition precedent to an Indemnitee&#8217;s right to be indemnified, such Indemnitee must notify the Corporation in writing as soon as practicable of any action, suit, proceeding or investigation involving such Indemnitee for which indemnity will or could be sought. With respect to any action, suit, proceeding or investigation of which the Corporation is so notified, the Corporation will be entitled to participate therein at its own expense and&#47;or to assume the defense thereof at its own expense, with legal counsel reasonably acceptable to Indemnitee. After notice from the Corporation to Indemnitee of its election so to assume such defense, the Corporation shall not be liable to Indemnitee for any legal or other expenses subsequently incurred by Indemnitee in connection with such action, suit, proceeding or investigation, other than as provided below in this Section 4. Indemnitee shall have the right to employ his or her own counsel in connection with such action, suit, proceeding or investigation, but the fees and expenses of such counsel incurred after notice from the Corporation of its assumption of the defense thereof shall be at the expense of Indemnitee unless (i) the employment of counsel by Indemnitee has been authorized by the Corporation, (ii) counsel to Indemnitee shall have reasonably concluded that there may be a conflict of interest or position on any significant issue between the Corporation and Indemnitee in the conduct of the defense of such action, suit, proceeding or investigation or (iii) the Corporation shall not in fact have employed counsel to assume the defense of such action, suit, proceeding or investigation, in each of which cases the fees and expenses of counsel for Indemnitee shall be at the expense of the Corporation, except as otherwise expressly provided by this Article EIGHTH. The Corporation shall not be entitled, without the consent of Indemnitee, to assume the defense of any claim brought by or in the right of the Corporation or as to which counsel for Indemnitee shall have reasonably made the conclusion provided for in clause (ii) above. The Corporation shall not be required to indemnify Indemnitee under this Article EIGHTH for any amounts paid in settlement of any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">action, suit, proceeding or investigation effected without its written consent. The Corporation shall not settle any action, suit, proceeding or investigation in any manner which would impose any penalty or limitation on Indemnitee without Indemnitee&#8217;s written consent. Neither the Corporation nor Indemnitee will unreasonably withhold or delay its consent to any proposed settlement.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Advancement of Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Subject to the provisions of Section 6 of this Article EIGHTH, in the event of any threatened or pending action, suit, proceeding or investigation of which the Corporation receives notice under this Article EIGHTH, any expenses (including attorneys&#8217; fees) incurred by or on behalf of Indemnitee in defending an action, suit, proceeding or investigation or any appeal therefrom shall be paid by the Corporation in advance of the final disposition of such matter&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, that the payment of such expenses incurred by or on behalf of Indemnitee in advance of the final disposition of such matter shall be made only upon receipt of an undertaking by or on behalf of Indemnitee to repay all amounts so advanced in the event that it shall ultimately be determined by final judicial decision from which there is no further right to appeal that Indemnitee is not entitled to be indemnified by the Corporation as authorized in this Article EIGHTH&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">provided further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> that no such advancement of expenses shall be made under this Article EIGHTH if it is determined (in the manner described in Section 6) that (i) Indemnitee did not act in good faith and in a manner he or she reasonably believed to be in, or not opposed to, the best interests of the Corporation, or (ii) with respect to any criminal action or proceeding, Indemnitee had reasonable cause to believe his or her conduct was unlawful. Such undertaking shall be accepted without reference to the financial ability of Indemnitee to make such repayment. </font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Procedure for Indemnification and Advancement of Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. In order to obtain indemnification or advancement of expenses pursuant to Section 1, 2, 3 or 5 of this Article EIGHTH, an Indemnitee shall submit to the Corporation a written request. Any such advancement of expenses shall be made promptly, and in any event within 60 days after receipt by the Corporation of the written request of Indemnitee, unless (i) the Corporation has assumed the defense pursuant to Section 4 of this Article EIGHTH (and none of the circumstances described in Section 4 of this Article EIGHTH that would nonetheless entitle the Indemnitee to indemnification for the fees and expenses of separate counsel have occurred) or (ii) the Corporation determines within such 60-day period that Indemnitee did not meet the applicable standard of conduct set forth in Section 1, 2 or 5 of this Article EIGHTH, as the case may be. Any such indemnification, unless ordered by a court, shall be made with respect to requests under Section 1 or 2 only as authorized in the specific case upon a determination by the Corporation that the indemnification of Indemnitee is proper because Indemnitee has met the applicable standard of conduct set forth in Section 1 or 2, as the case may be. Such determination shall be made in each instance (a) by a majority vote of the directors of the Corporation consisting of persons who are not at that time parties to the action, suit or proceeding in question (&#8220;disinterested directors&#8221;), whether or not a quorum, (b) by a committee of disinterested directors designated by majority vote of disinterested directors, whether or not a quorum, (c) if there are no disinterested directors, or if the disinterested directors so direct, by independent legal counsel (who may, to the extent permitted by law, be regular legal counsel to the Corporation) in a written opinion, or (d) by the stockholders of the Corporation.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">7. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. The right to indemnification or advancement of expenses as granted by this Article EIGHTH shall be enforceable by Indemnitee in any court of competent jurisdiction. Neither the failure of the Corporation to have made a determination prior to the commencement of such action that indemnification is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor an actual determination by the Corporation pursuant to Section 6 of this Article EIGHTH that Indemnitee has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct. In any suit brought by Indemnitee to enforce a right to indemnification, or brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the Corporation shall have the burden of proving that Indemnitee is not entitled to be indemnified, or to such advancement of expenses, under this Article EIGHTH. Indemnitee&#8217;s expenses (including attorneys&#8217; fees) reasonably incurred in connection with successfully establishing Indemnitee&#8217;s right to indemnification, in whole or in part, in any such proceeding shall also be indemnified by the Corporation. Notwithstanding the foregoing, in any suit brought by Indemnitee to enforce a right to indemnification hereunder it shall be a defense that the Indemnitee has not met any applicable standard for indemnification set forth in the General Corporation Law of the State of Delaware.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Limitations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Notwithstanding anything to the contrary in this Article EIGHTH, except as set forth in Section 7 of this Article EIGHTH, the Corporation shall not indemnify an Indemnitee pursuant to this Article EIGHTH in connection with a proceeding (or part thereof) initiated by such Indemnitee unless the initiation thereof was approved by the Board of Directors of the Corporation. Notwithstanding anything to the contrary in this Article EIGHTH, the Corporation shall not indemnify an Indemnitee to the extent such Indemnitee is reimbursed from the proceeds of insurance, and in the event the Corporation makes any indemnification payments to an Indemnitee and such Indemnitee is subsequently reimbursed from the proceeds of insurance, such Indemnitee shall promptly refund indemnification payments to the Corporation to the extent of such insurance reimbursement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Subsequent Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. No amendment, termination or repeal of this Article EIGHTH or of the relevant provisions of the General Corporation Law of the State of Delaware or any other applicable laws shall adversely affect or diminish in any way the rights of any Indemnitee to indemnification under the provisions hereof with respect to any action, suit, proceeding or investigation arising out of or relating to any actions, transactions or facts occurring prior to the final adoption of such amendment, termination or repeal.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Other Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. The indemnification and advancement of expenses provided by this Article EIGHTH shall not be deemed exclusive of any other rights to which an Indemnitee seeking indemnification or advancement of expenses may be entitled under any law (common or statutory), agreement or vote of stockholders or disinterested directors or otherwise, both as to action in Indemnitee&#8217;s official capacity and as to action in any other capacity while holding office for the Corporation, and shall continue as to an Indemnitee who has ceased to be a director or officer, and shall inure to the benefit of the estate, heirs, executors and administrators of Indemnitee. Nothing contained in this Article EIGHTH shall be deemed to prohibit, and the Corporation is specifically authorized to enter into, agreements with officers and directors providing indemnification rights and procedures different from those set forth in this Article EIGHTH. In addition, the Corporation may, to the extent authorized from time to time by its Board of Directors, grant indemnification rights to other employees or agents of the Corporation or other persons serving the Corporation and such rights may be equivalent to, or greater or less than, those set forth in this Article EIGHTH.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">11. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Partial Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. If an Indemnitee is entitled under any provision of this Article EIGHTH to indemnification by the Corporation for some or a portion of the expenses (including attorneys&#8217; fees), liabilities, losses, judgments, fines (including excise taxes and penalties arising under the Employee Retirement Income Security Act of 1974) or amounts paid in settlement actually and reasonably incurred by or on behalf of Indemnitee in connection with any action, suit, proceeding or investigation and any appeal therefrom but not, however, for the total amount thereof, the Corporation shall nevertheless indemnify Indemnitee for the portion of such expenses (including attorneys&#8217; fees), liabilities, losses, judgments, fines (including excise taxes and penalties arising under the Employee Retirement Income Security Act of 1974) or amounts paid in settlement to which Indemnitee is entitled.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. The Corporation may purchase and maintain insurance, at its expense, to protect itself and any director, officer, employee or agent of the Corporation or another corporation, partnership, joint venture, trust or other enterprise (including any employee benefit plan) against any expense, liability or loss incurred by him or her in any such capacity, or arising out of his or her status as such, whether or not the Corporation would have the power to indemnify such person against such expense, liability or loss under the General Corporation Law of the State of Delaware.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">13. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Savings Clause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. If this Article EIGHTH or any portion hereof shall be invalidated on any ground by any court of competent jurisdiction, then the Corporation shall nevertheless indemnify each Indemnitee as to any expenses (including attorneys&#8217; fees), liabilities, losses, judgments, fines (including excise taxes and penalties arising under the Employee Retirement Income Security Act of 1974) and amounts paid in settlement in connection with any action, suit, proceeding or investigation, whether civil, criminal or administrative, including an action by or in the right of the Corporation, to the fullest extent permitted by any applicable portion of this Article EIGHTH that shall not have been invalidated and to the fullest extent permitted by applicable law.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">14. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Terms used herein and defined in Section 145(h) and Section 145(i) of the General Corporation Law of the State of Delaware shall have the respective meanings assigned to such terms in such Section 145(h) and Section 145(i).</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ninth&#58; This Article NINTH is inserted for the management of the business and for the conduct of the affairs of the Corporation.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">General Powers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Number of Directors&#59; Election of Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Subject to the rights of holders of any series of Preferred Stock to elect directors, the number of directors of the Corporation shall be established by the Board of Directors. Election of directors need not be by written ballot, except as and to the extent provided in the By-laws of the Corporation.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Classes of Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Subject to the rights of holders of any series of Preferred Stock to elect directors, the Board of Directors shall be and is divided into three classes, designated Class I, Class II and Class III. Each class shall consist, as nearly as may be possible, of one-third of the total number of directors constituting the entire Board of Directors. The Board of Directors is authorized to assign members of the Board of Directors already in office to Class I, Class II or Class III at the time such classification becomes effective.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Terms of Office</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Subject to the rights of holders of any series of Preferred Stock to elect directors, each director shall serve for a term ending on the date of the third annual meeting of stockholders following the annual meeting of stockholders at which such director was elected&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> that the term of each director shall continue until the election and qualification of his or her successor and be subject to his or her earlier death, resignation or removal. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Quorum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. The greater of (a) a majority of the directors at any time in office and (b) one-third of the number of directors fixed pursuant to Section 2 of this Article NINTH shall constitute a quorum of the Board of Directors. If at any meeting of the Board of Directors there shall be less than such a quorum, a majority of the directors present may adjourn the meeting from time to time without further notice other than announcement at the meeting, until a quorum shall be present.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Action at Meeting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Every act or decision done or made by a majority of the directors present at a meeting duly held at which a quorum is present shall be regarded as the act of the Board of Directors unless a greater number is required by law or by this Certificate of Incorporation.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">7. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Removal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Subject to the rights of holders of any series of Preferred Stock, directors of the Corporation may be removed only for cause and only by the affirmative vote of the holders of at least seventy-five percent (75%) of the votes which all the stockholders would be entitled to cast in any annual election of directors or class of directors.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Vacancies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Subject to the rights of holders of any series of Preferred Stock, any vacancy or newly created directorship in the Board of Directors, however occurring, shall be filled only by vote of a majority of the directors then in office, although less than a quorum, or by a sole remaining director and shall not be filled by the stockholders. A director elected to fill a vacancy shall hold office until the next election of the class for which such director shall have been chosen, subject to the election and qualification of a successor and to such director&#8217;s earlier death, resignation or removal.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Stockholder Nominations and Introduction of Business, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Advance notice of stockholder nominations for election of directors and other business to be brought by stockholders before a meeting of stockholders shall be given in the manner provided by the By-laws of the Corporation.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Amendments to Article</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Notwithstanding any other provisions of law, this Certificate of Incorporation or the By-laws of the Corporation, and notwithstanding the fact that a lesser percentage may be specified by law, the affirmative vote of the holders of at least seventy-five percent (75%) of the votes which all the stockholders would be entitled to cast in any annual election of directors or class of directors shall be required to amend or repeal, or to adopt any provision inconsistent with, this Article NINTH.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Tenth&#58; Stockholders of the Corporation may not take any action by written consent in lieu of a meeting. Notwithstanding any other provisions of law, this Certificate of Incorporation or the By-laws of the Corporation, and notwithstanding the fact that a lesser percentage may be specified by law, the affirmative vote of the holders of at least seventy-five percent (75%) of the votes which all the stockholders would be entitled to cast in any annual election of directors or class of directors shall be required to amend or repeal, or to adopt any provision inconsistent with, this Article TENTH.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Eleventh&#58; Special meetings of stockholders for any purpose or purposes may be called at any time by only the Board of Directors, the Chairman of the Board or the Chief Executive Officer, and may not be called by any other person or persons. Business transacted at any special meeting of stockholders shall be limited to matters relating to the purpose or purposes stated in the notice of meeting. Notwithstanding any other provisions of law, this Certificate of Incorporation or the By-laws of the Corporation, and notwithstanding the fact that a lesser percentage may be specified by law, the affirmative vote of the holders of at least seventy-five percent (75%) of the votes which all the stockholders would be entitled to cast in any annual election of directors or class of directors shall be required to amend or repeal, or to adopt any provision inconsistent with, this Article ELEVENTH.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">* * * </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">IN WITNESS WHEREOF, this Restated Certificate of Incorporation has been executed by a duly authorized officer of the Corporation on this seventh day of March, 2023.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#47;s&#47; Steven Kelly</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Steven Kelly</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">President and Chief Executive Officer</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>carm-exx41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i7c4fd4809a664184934719b79b5188a7_36"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 4.1</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">The following description of the securities of Carisma Therapeutics Inc. (&#8220;us,&#8221; &#8220;our,&#8221; &#8220;we&#8221; or the &#8220;Company&#8221;) registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), is intended as a summary only and therefore is not a complete description. This description is based upon, and is qualified by reference to, our certificate of incorporation, our by-laws, and applicable provisions of the Delaware General Corporation Law (the &#8220;DGCL&#8221;). You should read our certificate of incorporation and by-laws, which are incorporated by reference as Exhibit 3.1 and Exhibit 3.2, respectively, to the Annual Report on Form 10-K of which this Exhibit 4.1 is a part, for the provisions that are important to you.</font></div><div><font><br></font></div><div><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">Authorized Capital Stock</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Our authorized capital stock consists of 350,000,000 shares of common stock, par value $0.001 per share, and 5,000,000 shares of preferred stock, par value $0.001 per share, all of which is undesignated. Our common stock is registered under Section 12(b) of the Exchange Act.</font></div><div><font><br></font></div><div><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Common Stock</font></div><div style="text-indent:36pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:105%">Voting Rights</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">. Each holder of common stock is entitled to one vote for each share held of record on all matters to be voted upon by stockholders, including the election of directors. Our certificate of incorporation and by-laws do not provide for cumulative voting rights. Except as otherwise provided by law, our certificate of incorporation and by-laws, all matters other than the election of directors, shall be decided by the vote of the holders of shares of stock having a majority in voting power of the votes cast by the holders of all of the shares of stock present or represented by proxy at the meeting at which a quorum is present and voting affirmatively or negatively on such matter.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"> </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Directors shall be elected by a plurality of the shares present in person or represented by proxy at a meeting at which a quorum is present and entitled to vote on the election of directors.</font></div><div style="text-indent:36pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:105%">Dividends</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">. Subject to the rights, powers and preferences of any outstanding preferred stock, and except as provided by law or in our certificate of incorporation, dividends may be declared and paid or set aside for payment on the common stock out of legally available assets or funds when and as declared by the board of directors.</font></div><div style="text-indent:36pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:105%">Liquidation or Dissolution</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">. Subject to the rights, powers and preferences of any outstanding preferred stock, in the event of our liquidation or dissolution, our net assets will be distributed pro rata to the holders of our common stock.</font></div><div style="text-indent:36pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Other Rights</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Holders of the common stock have no right to convert the stock into any other security, have the stock redeemed, purchase additional stock, or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">maintain their proportionate ownership interest. Holders of shares of the common stock are not required to make additional capital contributions.</font></div><div><font><br></font></div><div><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">Preferred Stock</font></div><div style="text-indent:36pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">We are authorized to issue &#8220;blank check&#8221; preferred stock, which may be issued in one or more series upon authorization of our board of directors. Our board of directors is authorized to fix the designations, powers, preferences and the relative, participating, optional or other special rights and any qualifications, limitations and restrictions of the shares of each series of preferred stock. The authorized shares of our preferred stock are available for issuance without further action by our stockholders, unless such action is required by applicable law or the rules of any stock exchange on which our securities may be listed. If the approval of our stockholders is not required for the issuance of shares of our preferred stock, our board may determine not to seek stockholder approval. </font></div><div><font><br></font></div><div><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">Provisions of Our Certificate of Incorporation and By-Laws and Delaware Law That May Have Anti-Takeover Effects</font></div><div><font><br></font></div><div style="text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">No Cumulative Voting.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   The DGCL provides that stockholders are not entitled to the right to accumulate votes in the election of directors unless our certificate of incorporation provides otherwise. Our certificate of incorporation does not provide for cumulative voting.</font></div><div><font><br></font></div><div style="text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Board of Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.   Our certificate of incorporation and by-laws provide for a board of directors divided as nearly equally as possible into three classes. Each class is elected to a term expiring at the annual meeting of stockholders held in the third year following the year of such election. The number of directors comprising our board of directors is fixed from time to time by the board of directors.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Removal of Directors by Stockholders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.   Our certificate of incorporation provides that members of our board of directors may only be removed for cause by the affirmative vote of the holders of at least seventy-five percent (75%) of the outstanding shares entitled to vote on the election of the directors.</font></div><div><font><br></font></div><div style="text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Board Vacancies Filled Only by Majority of Directors Then in Office</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.   Vacancies and newly created seats on our board may be filled only by a vote of a majority of our board of directors. Further, only our board of directors may determine the number of directors on our board. The inability of stockholders to determine the number of directors or to fill vacancies or newly created seats on the board makes it more difficult to change the composition of our board of directors.</font></div><div><font><br></font></div><div style="text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Stockholder Nomination of Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.   Our by-laws provide that a stockholder must notify us in writing of any stockholder nomination of a director not earlier than the 120th day and not later than on the 90th day prior to the first anniversary of the preceding year&#8217;s annual meeting&#59; provided, that if the date of the annual meeting is advanced by more than 30 days or delayed by more than 60 days from such anniversary date, notice by the stockholder to be timely must be so delivered not earlier than the 120th day prior to the date of such annual meeting and not later than on the later of (x) the 90th day prior to the date of such annual meeting and (y) the 10th day following the day on which notice of the date of such annual meeting was given or public disclosure of the date of such annual meeting was made, whichever occurs first.</font></div><div><font><br></font></div><div style="text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">No Action By Written Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.   Our certificate of incorporation provides that our stockholders may not act by written consent and may only act at duly called meetings of stockholders.</font></div><div><font><br></font></div><div style="text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Super-Majority Voting.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">   The Delaware law provides generally that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a corporation&#8217;s certificate of incorporation or bylaws unless a corporation&#8217;s certificate of incorporation or bylaws, as the case may be, requires a greater percentage. Our by-laws may be amended or repealed by a majority vote of our board of directors or the affirmative vote of the holders of at least seventy-five percent (75%) of the votes that all our stockholders would be entitled to cast in any annual election of directors. In addition, the affirmative vote of the holders of at least seventy-five percent (75%) of the votes that all our stockholders would be entitled to cast in any annual election of directors is required to amend or repeal or to adopt any provisions inconsistent with any of the provisions of our certificate of incorporation described above.</font></div><div><font><br></font></div><div style="text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Delaware Business Combination Statute.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">   We are subject to Section 203 of the DGCL (&#8220;Section 203&#8221;), which prohibits a Delaware corporation from engaging in business combinations with an interested stockholder. An interested stockholder is generally defined as an entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation or any entity or person affiliated with or controlling or controlled by such entity or person, or interested stockholder. Section 203 provides that an interested stockholder may not engage in business combinations with the corporation for a period of three years after the date that such stockholder became an interested stockholder, with the following exceptions&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">before such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned (i) by persons who are directors and also officers and (ii) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer&#59; or</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">on or after such date, the business combination is approved by the board of directors and authorized at an annual or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66 2&#47;3% of the outstanding voting stock that is not owned by the interested stockholder.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, Section 203 defines business combinations to include the following&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any merger or consolidation involving the corporation and the interested stockholder&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any sale, lease, transfer, pledge or other disposition of 10% or more of the assets of the corporation to or with the interested stockholder&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder&#59; or</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the receipt by the interested stockholder of the benefit of any loss, advances, guarantees, pledges or other financial benefits by or through the corporation.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.17
<SEQUENCE>4
<FILENAME>carm-20241231xexx1017.htm
<DESCRIPTION>EX-10.17
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="iab7fbff941924218963b486a8e4d3be2_1"></div><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.17</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Carisma Therapeutics Inc.<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">STOCK OPTION AGREEMENT</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Carisma Therapeutics Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) hereby grants the following stock option pursuant to its Amended and Restated 2014 Stock Incentive Plan.  The terms and conditions attached hereto are also a part hereof.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice of Grant</font></div><div style="padding-left:5.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"></td><td style="width:48.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.819%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name of optionee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#58;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Grant Date&#58;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Incentive Stock Option or Nonstatutory Stock Option&#58;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Number of shares of the Company&#8217;s Common Stock subject to this option (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#58;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Option exercise price per Share&#58;<font style="font-size:7.8pt;position:relative;top:-4.2pt;vertical-align:baseline">1</font></font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Vesting Start Date&#58;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Final Exercise Date&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline"> 2</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Vesting Schedule&#58;</font></div><div style="padding-left:5.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"></td><td style="width:48.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.982%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Vesting Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Number of Options that Vest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All vesting is dependent on the Participant remaining an Eligible Participant, as provided herein.</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This option satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CARISMA THERAPEUTICS INC. </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br>Signature of Participant</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:27pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br>Street Address</font></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:19.85pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name of Officer</font></div><div style="padding-left:19.85pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></div></td></tr><tr style="height:27pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br>City&#47;State&#47;Zip Code</font></div></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font><br></font></div><div style="border-bottom:1pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:150pt"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;This must be at least 100% of the Grant Date Fair Market Value (as defined in the Plan) of the Common Stock on the date of grant (110% in the case of a Participant that owns more than 10% of the total combined voting power of all classes of stock of the Company or its parent or subsidiary (a &#8220;10% Shareholder&#8221;)) for the option to qualify as an incentive stock option (an &#8220;ISO&#8221;) under Section 422 of the Internal Revenue Code.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;The Final Exercise Date must be no more than 10 years (5 years in the case of a 10% Shareholder) from the date of grant for the option to qualify as an ISO.  The correct approach to calculate the final exercise date is to use the day immediately prior to the date ten years out from the date of the stock option award grant (5 years in the case of a 10% stockholder).  </font></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ActiveUS 167816198v.2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Carisma Therapeutics Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Stock Option Agreement</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Incorporated Terms and Conditions</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Grant of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This agreement evidences the grant by the Company, on the grant date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) set forth in the Notice of Grant that forms part of this agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), to the Participant of an option to purchase, in whole or in part, on the terms provided herein and in the Company&#8217;s Amended and Restated 2014 Stock Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the number of Shares set forth in the Notice of Grant of common stock, $0.001 par value per share, of the Company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), at the exercise price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">per Share set forth in the Notice of Grant.  Unless earlier terminated, this option shall expire at 5&#58;00 p.m., Eastern time, on the Final Exercise Date set forth in the Notice of Grant (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Final Exercise Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The option evidenced by this agreement is intended to be an incentive stock option as defined in Section 422 of the Internal Revenue Code of 1986, as amended, and any regulations promulgated thereunder (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) to the maximum extent permitted by law, solely to the extent designated as an incentive stock option in the Notice of Grant.  To the extent not designated as an incentive stock option, or to the extent that the option does not qualify as an incentive stock option, the option shall be a nonstatutory stock option.  Except as otherwise indicated by the context, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;, as used in this option, shall be deemed to include any person who acquires the right to exercise this option validly under its terms.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Vesting Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This option will become exercisable (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">vest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) in accordance with the vesting schedule set forth in the Notice of Grant.  For a grant to a newly hired Participant, options will vest and become exercisable, subject to the Participant&#8217;s continued service to the Company on each applicable vesting date, with respect to 25% of the shares of common stock subject to the Option on the first anniversary of the Participant&#8217;s start date with the Company and 1&#47;36 of the shares of common stock subject to the option each month thereafter until the option is fully vested on the fourth anniversary.  For each subsequent annual grant to a Participant, options will vest and become exercisable, subject to the Participant&#8217;s continued service to the Company, on each applicable vesting date, with respect to 1&#47;48 of the shares of common stock subject to the Option each month following the grant date until the option is fully vested on the fourth anniversary.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The right of exercise shall be cumulative so that to the extent the option is not exercised in any period to the maximum extent permissible it shall continue to be exercisable, in whole or in part, with respect to all Shares for which it is vested until the earlier of the Final Exercise Date or the termination of this option under Section&#160;3 hereof or the Plan.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Exercise of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Form of Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each election to exercise this option shall be in writing, in the form of the Stock Option Exercise Notice attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Annex A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, signed by the Participant, and received by the Company at its principal office, accompanied by this agreement, or in such other form (which may be electronic) as is approved by the Company, together with payment in full in the manner provided in the Plan.  The Participant may purchase less than the number of shares covered hereby, provided that no partial exercise of this option may be for any fractional share.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Continuous Relationship with the Company Required</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as otherwise provided in this Section&#160;3, this option may not be exercised unless the Participant, at the time he or she exercises this option, is, and has been at all times since the Grant Date, an employee, </font></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;- 2 -</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ActiveUS 167816198v.2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">director or officer of, or consultant or advisor to, the Company or any other entity the employees, officers, directors, consultants, or advisors of which are eligible to receive option grants under the Plan (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eligible Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Termination of Relationship with the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If the Participant ceases to be an Eligible Participant for any reason, including the Participant&#8217;s death or disability (within the meaning of Section 22(e)(3) of the Code) prior to the Final Exercise Date, then, except as provided in paragraph (d) below, the right to exercise this option shall terminate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">twelve months after such cessation (but in no event after the Final Exercise Date), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> this option shall be exercisable only to the extent that the Participant was entitled to exercise this option on the date of such cessation.  Notwithstanding the foregoing, if the Participant, prior to the Final Exercise Date, violates the restrictive covenants (including, without limitation, the non-competition, non-solicitation, or confidentiality provisions) of any employment contract, any non-competition, non-solicitation, confidentiality or assignment agreement to which the Participant is a party, or any other agreement between the Participant and the Company, the right to exercise this option shall terminate immediately upon such violation.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Termination for Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If, prior to the Final Exercise Date, the Participant&#8217;s employment or other relationship with the Company is terminated by the Company for Cause (as defined below), the right to exercise this option shall terminate immediately upon the effective date of such termination of employment or other service relationship.  If, prior to the Final Exercise Date, the Participant is given notice by the Company of the termination of his or her employment or other relationship by the Company for Cause, and the effective date of such employment or other termination is subsequent to the date of delivery of such notice, the right to exercise this option shall be suspended from the time of the delivery of such notice until the earlier of (i) such time as it is determined or otherwise agreed that the Participant&#8217;s employment or other relationship shall not be terminated for Cause as provided in such notice or (ii) the effective date of such termination of employment or other relationship (in which case the right to exercise this option shall, pursuant to the preceding sentence, terminate immediately upon the effective date of such termination of employment or other relationship).  If the Participant is subject to an individual employment or consulting agreement with the Company or eligible to participate in a Company severance plan or arrangement, in any case which agreement, plan or arrangement contains a definition of &#8220;cause&#8221; for termination of employment or other relationship, &#8220;Cause&#8221; shall have the meaning ascribed to such term in such agreement, plan or arrangement.  Otherwise, &#8220;Cause&#8221; shall mean willful misconduct by the Participant or willful failure by the Participant to perform his or her responsibilities to the Company (including, without limitation, breach by the Participant of any provision of any employment, consulting, advisory, nondisclosure, non-competition or other similar agreement between the Participant and the Company), as determined by the Company, which determination shall be conclusive.  The Participant&#8217;s employment or other relationship shall be considered to have been terminated for Cause if the Company determines, within 30 days after the Participant&#8217;s resignation, that termination for Cause was warranted.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Tax Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No Shares will be issued pursuant to the exercise of this option unless and until the Participant pays to the Company, or makes provision satisfactory to the Company for payment of, any federal, state or local withholding taxes required by law to be withheld in respect of this option.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Disqualifying Disposition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If this option is an incentive stock option and the Participant disposes of Shares acquired upon exercise of this option within two years from the Grant Date or one year after such Shares were acquired pursuant to exercise of this option, the Participant shall notify the Company in writing of such disposition.</font></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;- 3 -</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ActiveUS 167816198v.2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Transfer Restrictions&#59; Clawback.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">This option may not be sold, assigned, transferred, pledged, encumbered or otherwise disposed of by the Participant, either voluntarily or by operation of law, except by will or the laws of descent and distribution, and, during the lifetime of the Participant, this option shall be exercisable only by the Participant.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">In accepting this option, the Participant agrees to be bound by any clawback policy that the Company has in place or may adopt in the future.</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Provisions of the Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This option is subject to the provisions of the Plan (including the provisions relating to amendments to the Plan), a copy of which is furnished to the Participant with this option.</font></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;- 4 -</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ActiveUS 167816198v.2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ANNEX A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Carisma Therapeutics</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Stock Option Exercise Notice</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Carisma Therapeutics Inc. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3675 Market Street, Suite 200</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Philadelphia, PA 19104</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dear Sir or Madam&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">   (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), hereby irrevocably exercise the right to purchase </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shares of the Common Stock, $0.001 par value per share (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), of Carisma Therapeutics Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) at $</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;      </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> per share pursuant to the Company&#8217;s Amended and Restated 2014 Stock Incentive Plan and a stock option agreement with the Company dated </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Option Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Enclosed herewith is a payment of $</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the aggregate purchase price for the Shares.  The certificate for the Shares should be registered in my name as it appears below or, if so indicated below, jointly in my name and the name of the person designated below, with right of survivorship.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dated&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature <br>Print Name&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Address&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name and address of persons in whose name the Shares are to be jointly registered (if applicable)&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;- 5 -</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ActiveUS 167816198v.2</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>5
<FILENAME>carm-exx191.htm
<DESCRIPTION>EX-19.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i85ef1e38d1174d6fac06366c21d2b428_36"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 19.1</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">CARISMA THERAPEUTICS INC.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">INSIDER TRADING POLICY</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9pt">Background and purpose</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">1.1 Why Have We Adopted This Policy&#63;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The federal securities laws prohibit any member of the Board of Directors (a &#8220;Director&#8221;), officer (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;), an &#8220;executive officer&#8221;) or employee of Carisma Therapeutics Inc. (together with its subsidiaries, the &#8220;Company&#8221;) from purchasing or selling Company securities on the basis of material nonpublic information concerning the Company, or from tipping material nonpublic information to others.  These laws impose severe sanctions on individuals who violate them.  In addition, the Securities and Exchange Commission (the &#8220;SEC&#8221;) has the authority to impose large fines on the Company and on the Company&#8217;s Directors, executive officers and controlling stockholders if the Company&#8217;s employees engage in insider trading and the Company has failed to take appropriate steps to prevent it (so-called &#8220;controlling person&#8221; liability).</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">This insider trading policy is being adopted in light of these legal requirements, and with the goal of helping&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:14.49pt">prevent inadvertent violations of the insider trading laws&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">avoid embarrassing proxy disclosure of reporting violations by persons subject to Section 16 of the Exchange Act&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">promote compliance with the Company&#8217;s obligation to publicly disclose information related to its insider trading policies and procedures and the use of certain trading arrangements by Company insiders&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">avoid the appearance of impropriety on the part of those employed by, or associated with, the Company&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">protect the Company from controlling person liability&#59; and</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">protect the reputation of the Company, its Directors and its employees.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">As detailed below, this policy applies to family members and certain other persons and entities with whom Directors and employees have relationships.  While the provisions in Sections 2 and 3 of this policy are not applicable to transactions by the Company itself, transactions by the Company will only be made in accordance with applicable U.S. federal securities laws, including those relating to insider trading.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">1.2 What Type of Information is &#8220;Material&#8221;&#63;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Information concerning the Company is considered material if there is a substantial likelihood that a reasonable shareholder would consider the information important in making an investment decision with respect to the Company&#8217;s securities.  Stated another way, there must be a substantial likelihood that a reasonable shareholder would view the information as having significantly altered the &#8220;total mix&#8221; of information available about the Company.  Material information can include positive or negative information about the Company.  Information </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">concerning any of the following subjects, or the Company&#8217;s plans with respect to any of these subjects, would often be considered material&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:14.49pt">the Company&#8217;s liquidity, cash burn rate, revenues or earnings&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">a significant merger or acquisition involving the Company&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">a significant licensing or collaboration agreement or serious discussions regarding such an agreement&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">a change in control of the Company&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">a significant change in the management or the Board of Directors of the Company&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">the public or private sale of a significant amount of securities of the Company&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">the Company&#8217;s decision to commence or terminate the payment of cash dividends&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">the establishment of a program to repurchase securities of the Company&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">a stock split&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">a default on outstanding debt or preferred stock of the Company or a bankruptcy filing&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">a new product release or a significant development, invention or discovery&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">information concerning FDA actions or other significant regulatory developments, including a significant product recall&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">information concerning significant clinical trials or non-clinical studies, including the timing of and findings and data from such trials and studies&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">the loss, delay or gain of a significant contract, sale or order or other important development regarding customers, collaborators or suppliers&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">a significant operational issue or investigation of a potential such issue, including cybersecurity incidents and product defects&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">any litigation or disputes to which the Company may be a party&#59; </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">a conclusion by the Company or a notification from its independent auditor that any of the Company&#8217;s previously issued financial statements should no longer be relied upon&#59; or</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">a change in or disagreement (within the meaning of Item 304 of Regulation S-K) with the Company&#8217;s independent auditor.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">This list is illustrative only and is not intended to provide a comprehensive list of circumstances that could give rise to material information.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">1.3 When is Information &#8220;Nonpublic&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#63;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Information concerning the Company is considered nonpublic if it has not been disseminated in a manner making it available to investors generally.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Information will generally be considered nonpublic unless (1) the information has been disclosed in a press release, in a public filing made with the SEC (such as a Report on Form 10-K, Form 10-Q or Form 8-K), or through a news wire service or daily newspaper of wide circulation, and (2) a sufficient amount of time has passed so that the information has had an opportunity to be digested by the marketplace.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">2. PROHIBITIONS RELATING TO TRANSACTIONS IN THE COMPANY&#8217;S SECURITIES</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">2.1 Covered Persons</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  This Section 2 applies to the following individuals and entities (collectively, the &#8220;Covered Persons&#8221;)&#58;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:14.49pt">all Directors&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">all employees&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">all family members of Directors and employees who share the same address as, or are financially dependent on, the Director or employee and any other person who shares the same address as the Director or employee (other than (x) an employee or tenant of the Director or employee or (y) another unrelated person whom the Chief Executive Officer, the Principal Financial Officer or the General Counsel determines should not be covered by this policy)&#59; and</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">all corporations, limited liability companies, partnerships, trusts or other entities controlled by any of the above Covered Persons, unless the entity has implemented policies or procedures designed to ensure that such Covered Person cannot influence transactions by the entity involving Company securities.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">2.2 Prohibition on Trading While Aware of Material Nonpublic Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">(a) Prohibited Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. Except as provided in Section 2.2(b), no Covered Person may&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:14.49pt">purchase, sell or gift (which term, as used in this policy, includes charitable donations) any securities of the Company while such Covered Person is aware of any material nonpublic information concerning the Company or recommend doing so to someone else&#59; or</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">tip or otherwise disclose to someone else any material nonpublic information concerning the Company if the recipient may use that information to purchase, sell or gift Company securities or tip that information to others.</font></div><div style="text-indent:76.5pt"><font><br></font></div><div style="text-indent:76.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">In addition, no Covered Person who, in the course of service to the Company, learns of material nonpublic information about another company (1) with which the Company does business, such as the Company&#8217;s distributors, vendors, customers and suppliers, or (2) that is involved in a potential transaction or business relationship with Company, may engage in transactions in that other company&#8217;s securities until the information becomes public or is no longer material.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">(b) Exceptions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  The prohibitions in Sections 2.2(a) and 2.3 on purchases, sales and gifts of Company securities do not apply to&#58;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:14.49pt">exercises of stock options or other equity awards or the surrender of shares to the Company in payment of the exercise price or in satisfaction of any tax withholding obligations, in each case in a manner permitted by the applicable equity award agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, that the securities so acquired may not be sold (either outright or in connection with a &#8220;cashless&#8221; exercise transaction through a broker) while the Covered Person is aware of material nonpublic information or during an applicable blackout period (as defined in Section 2.3(b))&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">acquisitions or dispositions of Company common stock under the Company&#8217;s 401(k) or other individual account plan that are made pursuant to standing instructions, in a form approved by the Company, not entered into or modified while the Covered Person is aware of material nonpublic information or during an applicable blackout period&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">other purchases of securities from the Company (including purchases under the Company&#8217;s employee stock purchase plan pursuant to standing instructions, in a form approved by the Company) or sales of securities to the Company&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, that if the transaction involves the exercise of stock options or other equity awards, the transaction must be permitted by the first bullet above&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">bona fide gifts that are approved in advance by the Company&#59; </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">purchases, sales or gifts made pursuant to a binding contract, written plan or specific instruction which satisfies the applicable affirmative defense conditions of Rule 10b5-1(c), including as applicable the requirements applicable to an eligible sell-to-cover transaction as defined in Rule 10b5-1(c)(1)(ii)(D)(3) (a &#8220;trading plan&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> such trading plan&#58; (1) is in writing and (2) was submitted to the Company for review prior to its adoption&#59; and</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">purchases, sales or gifts made pursuant to a binding contract, written plan or specific instruction which satisfies the definition of a &#8220;non-Rule 10b5-1 trading arrangement&#8221; as such term is defined in Item 408(c) of Regulation S-K, provided such non-Rule 10b5-1 trading arrangement&#58; (1) is in writing and (2) was submitted to the Company for review prior to its adoption.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">(c)Application of Policy After Cessation of Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  If a person or entity ceases to be a Covered Person at a time when such person or entity is aware of material nonpublic information concerning the Company, the prohibitions on purchases, sales or gifts of securities in Section 2.2(a) shall continue to apply until that information has become public or is no longer material.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">2.3 Blackout Periods</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">(a) Regular Blackout Periods</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. Except as provided in Section 2.2(b), no Covered Person may purchase, sell or gift any securities of the Company during the period beginning three weeks prior to the scheduled release date of the Company&#8217;s press release to announce results of the most recently ended fiscal quarter and ending upon the completion of the second full trading day after the periodic report for such fiscal quarter is filed (a &#8220;regular blackout period&#8221;).</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">(b) Corporate News Blackout Periods</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  The Company may from time to time notify Directors, executive officers and other specified employees that an additional blackout period (a &#8220;corporate news blackout period&#8221;) is in effect in view of significant events or developments involving the Company.  In such event, except as provided in Section 2.2(b), no such individual who is notified of a corporate news blackout period may purchase, sell or gift any securities of the Company during such corporate news blackout period or inform anyone else that a corporate news blackout period is in effect.  (In this policy, regular blackout periods and corporate news blackout periods are each referred to as a &#8220;blackout period.&#8221;)</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">(c)Awareness of Material Non-Public Information when a Blackout Period is Not in Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Even if no blackout period is then in effect, if a Covered Person is aware of material nonpublic information the prohibitions contained in Section 2.2(a) apply.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">2.4 Prohibition on Pledges</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  No Covered Person may purchase Company securities on margin, borrow against Company securities held in a margin account, or pledge Company securities as collateral for a loan.  However, an exception may be granted in extraordinary situations where a Covered Person wishes to pledge Company securities as collateral for a loan (other than a margin loan) and clearly demonstrates the financial capacity to repay </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">the loan without resort to the pledged securities.  Any Covered Person who wishes to pledge Company securities as collateral for a loan must submit a request for approval to the Principal Financial Officer or the General Counsel. In addition, any such request by a Director or executive officer of the Company must also be reviewed and approved by the Audit Committee of the Board of Directors.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">2.5 Prohibition on Short Sales, Derivative Transactions and Hedging Transactions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  No Covered Person may engage in any of the following types of transactions with respect to Company securities&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:14.49pt">short sales, including short sales &#8220;against the box&#8221;&#59; or</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">purchases or sales of puts, calls or other derivative securities&#59; or</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">purchases of financial instruments (including prepaid variable forward contracts, equity swaps, collars and exchange funds) or other transactions that hedge or offset, or are designed to hedge or offset, any decrease in the market value of Company securities.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">2.6 Partnership Distributions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Nothing in this policy is intended to limit the ability of a venture capital partnership or other similar entity with which a Director is affiliated to distribute Company securities to its partners, members or other similar persons.  It is the responsibility of each affected Director and the affiliated entity, in consultation with their own counsel (as appropriate), to determine the timing of any distributions, based on all relevant facts and circumstances and applicable securities laws.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">2.7 Underwritten Public Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Nothing in this policy is intended to limit the ability of any Covered Person to sell Company securities as a selling stockholder in an underwritten public offering pursuant to an effective registration statement in accordance with applicable securities law.</font></div><div style="padding-left:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">3. ADDITIONAL PROHIBITIONS APPLICABLE TO DIRECTORS, EXECUTIVE OFFICERS AND DESIGNATED EMPLOYEES</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">3.1 Further Restricted Insiders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  This Section 3 applies to the following Covered Persons, who are subject to certain additional restrictions as set forth herein (collectively, the &#8220;Further Restricted Insiders&#8221;)&#58;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:14.49pt">all Directors&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">all executive officers&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">such other employees as are designated from time to time by the Board of Directors, the Chief Executive Officer, the Principal Financial Officer or the General Counsel as being subject to this Section 3 (the &#8220;Designated Employees&#8221;)&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">all family members of Directors, executive officers and Designated Employees who share the same address as, or are financially dependent on, the Director, executive officer or Designated Employee and any other person who shares the same address as the Director, executive officer or Designated Employee (other than (x) an employee or tenant of the Director, executive officer or Designated Employee or (y) another unrelated person whom the Chief Executive Officer, the Principal Financial Officer or the General Counsel determines should not be covered by this policy)&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">all corporations, limited liability companies, partnerships, trusts or other entities controlled by any of the above Further Restricted Insiders, unless the entity has implemented policies or procedures designed to ensure that such Further Restricted Insider cannot influence transactions by the entity involving Company securities.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">3.2 Notice and Pre-Clearance of Transactions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. </font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">(a) Pre-Transaction Clearance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  No Further Restricted Insider may purchase, sell, gift, transfer or otherwise acquire or dispose of securities of the Company, either directly or indirectly, other than in a transaction permitted under Section 2.2(b), unless such Further Restricted Insider pre-clears the transaction with any of the Chief Executive Officer, the Principal Financial Officer or the General Counsel.  A request for pre-clearance shall be made in accordance with the procedures established by the Chief Executive Officer, the Principal Financial Officer or the General Counsel. The Chief Executive Officer, the Principal Financial Officer and the General Counsel shall have sole discretion to decide whether to clear any contemplated transaction.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The General Counsel and the Chief Executive Officer shall have sole discretion to decide whether to clear transactions by the Principal Financial Officer or by Further Restricted Insiders as a result of their relationship with the Principal Financial Officer, and the Principal Financial Officer shall have sole discretion to decide whether to clear transactions by the General Counsel or Further Restricted Insiders as a result of their relationship with the General Counsel. All transactions that are pre-cleared must be effected within three business days of receipt of the pre-clearance unless a longer or shorter period has been specified by the Chief Executive Officer, the Principal Financial Officer or the General Counsel. A pre-cleared transaction (or any portion of a pre-cleared transaction) that has not been effected during the three business day period must be pre-cleared again prior to execution.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Notwithstanding receipt of pre-clearance, if the Further Restricted Insider becomes aware of material non-public information or becomes subject to a blackout period before the transaction is effected, the transaction may not be completed.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">(b) Post-Transaction Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Each Further Restricted Insider who is subject to reporting obligations under Section 16 of the Exchange Act shall also notify the Principal Financial Officer or the General Counsel (or such person&#8217;s designee) of the occurrence of any purchase, sale, gift, transfer, or other acquisition or disposition of securities of the Company as soon as possible following the transaction, but in any event within one business day after the transaction. Such notification may be oral or in writing (including by e-mail) and should include the identity of the Further Restricted Insider, the type of transaction, the date of the transaction, the number of shares involved, the purchase or sale price, and whether the transaction was effected pursuant to a contract, instruction or written plan that is intended either to satisfy the affirmative defense conditions of Rule 10b5-1(c) (and if so, the date of adoption of such contract, instruction or written plan) or to constitute a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K).</font></div><div style="padding-left:72pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">(c)Deemed Time of a Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  For purposes of this Section 3.2, a purchase, sale, gift, transfer, or other acquisition or disposition shall be deemed to occur at the time the person becomes irrevocably committed to it (for example, in the case of an open market purchase or sale, this occurs when the trade is executed, not when it settles).</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">4. REGULATION BTR</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">If the Company is required to impose a &#8220;pension fund blackout period&#8221; under Regulation BTR, each Director and executive officer shall not, directly or indirectly sell, purchase or otherwise transfer during such blackout period any equity securities of the Company acquired in connection with such person&#8217;s service as a Director or officer of the Company, except as permitted by Regulation BTR.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">5. PENALTIES FOR VIOLATION</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Violation of any of the foregoing rules is grounds for disciplinary action by the Company, including termination of employment.  In addition to any disciplinary actions the Company may take, insider trading can also result in administrative, civil or criminal proceedings which can result in significant fines and civil penalties, being barred from service as an officer or director of a public company, or imprisonment.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">6. COMPANY ASSISTANCE AND EDUCATION</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">6.1 Education</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  The Company shall take reasonable steps designed to ensure that all Directors and employees of the Company are educated about, and periodically reminded of, the federal securities law restrictions and Company policies regarding insider trading.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">6.2 Assistance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  The Company shall provide reasonable assistance to all Directors and executive officers, as requested by such Directors and executive officers, in connection with the filing of Forms 3, 4 and 5 under Section 16 of the Exchange Act.  However, the ultimate responsibility, and liability, for timely filing remains with the Directors and executive officers.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">6.3 Limitation on Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  None of the Company, the Chief Executive Officer, the Principal Financial Officer, the General Counsel or the Company&#8217;s other employees will have any liability for any delay in reviewing, or refusal of, a trading plan submitted pursuant to Section 2.2(b), a request for pre-clearance submitted pursuant to Section 3.2(a) or a request to allow a pledge submitted pursuant to Section 2.4.  Notwithstanding any review of a trading plan pursuant to Section 2.2(b) or pre-clearance of a transaction pursuant to Section 3.2(a), none of the Company, the Chief Executive Officer, the Principal Financial Officer, the General Counsel or the Company&#8217;s other employees assumes any liability for the legality or consequences of such trading plan or transaction to the person engaging in or adopting such trading plan or transaction. </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">CARISMA THERAPEUTICS INC.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">INSIDER TRADING POLICY</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">CERTIFICATION</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:200%">I have received and read the Insider Trading Policy for Carisma Therapeutics Inc. regarding trading in the Company&#8217;s securities and in other company&#8217;s securities.  I agree that it is my responsibility to adhere to the laws and requirements described in the policy.   I further acknowledge that it is my responsibility to contact the Chief Executive Officer, the Principal Financial Officer or the General Counsel with any questions or issues.</font></div><div style="padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:200%">________________________</font></div><div style="padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:200%">(Signature)</font></div><div style="padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:200%">Name&#58; ___________________</font></div><div style="padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:200%">Date&#58; ____________________</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>6
<FILENAME>carm-20241231xexx211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ie619a5bb58ec4aa083191446ad4d2f79_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subsidiaries of the Registrant</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name of Subsidiary</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Jurisdiction of Incorporation</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CTx Operations, Inc.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Delaware, U.S.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CARISMA Therapeutics S.&#224; r.l.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Luxembourg</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>7
<FILENAME>carm-20241231xexx231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i100e9f055fdd4ecd9b1a683b510bb497_1"></div><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Consent of Independent Registered Public Accounting Firm</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We consent to the incorporation by reference in the registration statements (Nos. 333-195170, 333-202677, 333-210523, 333-217686, 333-217687, 333-231644, 333-234697, 333-254264, 333-255941, 333-263070 and 333-271103) on Form S-8 and (Nos. 333-201176, 333-224682, 333-271295 and 333-271296) on Form S-3 of our report dated April 1, 2024, with respect to the consolidated financial statements of Carisma Therapeutics Inc. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; KPMG LLP </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Philadelphia, Pennsylvania</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">March&#160;31, 2025</font></div><div><font><br></font></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>8
<FILENAME>carm-20241231xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i9c09df282802449fb49e799d73094b66_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Steven Kelly, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Annual Report on Form 10-K of Carisma Therapeutics Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March&#160;31, 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Steven Kelly</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Steven Kelly</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>9
<FILENAME>carm-20241231xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i86c460544ef347bb94ce4193e69045f1_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Natalie McAndrew, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Annual Report on Form 10-K of Carisma Therapeutics Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March&#160;31, 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Natalie McAndrew</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Natalie McAndrew</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vice President of Finance<br>(Principal Financial Officer)</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>10
<FILENAME>carm-20241231xexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ib938c54e3e6d41c081938d070a70b42e_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Carisma Therapeutics Inc. (the &#8220;Company&#8221;) on Form 10-K for the year ended December&#160;31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March&#160;31, 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Steven Kelly</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Steven Kelly</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>11
<FILENAME>carm-20241231xexx322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i66a61678cf884aefb81b0c0eb3edcb65_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Carisma Therapeutics Inc. (the &#8220;Company&#8221;) on Form 10-K for the year ended December&#160;31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March&#160;31, 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Natalie McAndrew</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Natalie McAndrew</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vice President of Finance<br>(Principal Financial Officer)</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97
<SEQUENCE>12
<FILENAME>carm-20241231xexx97.htm
<DESCRIPTION>EX-97
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ided704b143e64f809eb18644e00245bd_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 97</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Dodd-Frank Compensation Recovery Policy</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This Compensation Recovery Policy (this &#8220;Policy&#8221;) is adopted by Carisma Therapeutics Inc. (the &#8220;Company&#8221;) in accordance with Nasdaq Listing Rule 5608 (&#8220;Rule 5608&#8221;), which implements Rule 10D-1 under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) (as promulgated pursuant to Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010). This Policy is effective as of October 2, 2023 (the &#8220;Effective Date&#8221;).</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:10.5pt;text-decoration:underline">Definitions</font></div><div><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:11.07pt">&#8220;Accounting Restatement&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> means a requirement that the Company prepare an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the U.S. federal securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period. Changes to the Company&#8217;s financial statements that do not represent error corrections are not an Accounting Restatement, including&#58; (A) retrospective application of a change in accounting principle&#59; (B) retrospective revision to reportable segment information due to a change in the structure of the Company&#8217;s internal organization&#59; (C) retrospective reclassification due to a discontinued operation&#59; (D) retrospective application of a change in reporting entity, such as from a reorganization of entities under common control&#59; and (E) retrospective revision for stock splits, reverse stock splits, stock dividends or other changes in capital structure.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:10.5pt">&#8220;Committee&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">means the Compensation Committee of the Company&#8217;s Board of Directors (the &#8220;Board&#8221;).</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:11.07pt">&#8220;Covered Person&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">means a person who served as an Executive Officer at any time during the performance period for the applicable Incentive-Based Compensation.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:10.5pt">&#8220;Erroneously Awarded Compensation&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">means the amount of Incentive-Based Compensation that was Received that exceeds the amount of Incentive-Based Compensation that otherwise would have been Received had the amount of Incentive-Based Compensation been determined based on the restated amounts, computed without regard to any taxes paid by the Covered Person or by the Company on the Covered Person&#8217;s behalf. For Incentive-Based Compensation based on stock price or total shareholder return, where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in an Accounting Restatement, the amount of Erroneously Awarded Compensation will be based on a reasonable estimate by the Committee of the effect of the Accounting Restatement on the stock price or total shareholder return upon which the Incentive-Based Compensation was Received. The Company will maintain documentation of the determination of that reasonable estimate and provide such documentation to Nasdaq.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:11.07pt">&#8220;Executive Officer&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">means</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the Company&#8217;s officers as defined in Rule 16a-1(f) under the Exchange Act. </font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:12.17pt">&#8220;Financial Reporting Measures&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">means (A) measures that are determined and presented in accordance with the accounting principles used in preparing the Company&#8217;s financial statements, and any measures that are derived wholly or in part from such measures (whether or not such measures are presented within the Company&#8217;s financial statements or included in a filing made with the U.S. Securities and Exchange Commission), (B) stock price and (C) total shareholder return.  </font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:10.5pt">&#8220;Incentive-Based Compensation&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">means any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a Financial Reporting Measure.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">h.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Incentive-Based Compensation is deemed to be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#8220;Received&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">in the Company&#8217;s fiscal period during which the Financial Reporting Measure specified in the applicable Incentive-Based Compensation award is attained, even if the payment or grant of the Incentive-Based Compensation occurs after the end of that period or is subject to additional time-based vesting requirements.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:12.73pt">&#8220;Recovery Period&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> means the three completed fiscal years immediately preceding the earlier of&#58; (A) the date the Board, a committee of the Board, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement&#59; or (B) the date a court, regulator, or other legally authorized body directs the Company to </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">prepare an Accounting Restatement. In addition, if there is a change in the Company&#8217;s fiscal year end, the Recovery Period will also include any transition period to the extent required by Rule 5608.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:10.5pt;text-decoration:underline">Recovery of Erroneously Awarded Compensation</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Subject to the terms of this Policy and the requirements of Rule 5608, if the Company is required to prepare an Accounting Restatement, the Company will attempt to recover, reasonably promptly from each Covered Person, any Erroneously Awarded Compensation that was Received by such Covered Person during the Recovery Period pursuant to Incentive-Based Compensation that is subject to this Policy.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:10.5pt;text-decoration:underline">Interpretation and Administration</font></div><div><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.07pt">Role of the Committee. This Policy will be interpreted by the Committee in a manner that is consistent with Rule 5608 and any other applicable law and will otherwise be interpreted in the business judgment of the Committee. All decisions and interpretations of the Committee that are consistent with Rule 5608 will be final and binding. </font></div><div style="text-indent:18pt"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Compensation Not Subject to this Policy. This Policy does not apply to Incentive-Based Compensation that was Received before the Effective Date. With respect to any Covered Person, this Policy does not apply to Incentive-Based Compensation that was Received by such Covered Person before beginning service as an Executive Officer.</font></div><div style="text-indent:18pt"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.07pt">Determination of Means of Recovery. Subject to the requirement that recovery be made reasonably promptly, the Committee will determine the appropriate means of recovery, which may vary between Covered Persons or based on the nature of the applicable Incentive-Based Compensation, and which may involve, without limitation, establishing a deferred repayment plan or setting off against current or future compensation otherwise payable to the Covered Person. Recovery of Erroneously Awarded Compensation will be made without regard to income taxes paid by the Covered Person or by the Company on the Covered Person&#8217;s behalf in connection with such Erroneously Awarded Compensation.</font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Determination That Recovery is Impracticable. The Company is not required to recover Erroneously Awarded Compensation if a determination is made by the Committee that either (A) after the Company has made and documented a reasonable attempt to recover such Erroneously Awarded Compensation, the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount to be recovered or (B) recovery of such Erroneously Awarded Compensation would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Section 401(a)(13) or 411(a) of the Internal Revenue Code and regulations thereunder.</font></div><div style="text-indent:18pt"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.07pt">No Indemnification or Company-Paid Insurance. The Company will not indemnify any Covered Person against the loss of Erroneously Awarded Compensation and will not pay or reimburse any Covered Person for the purchase of a third-party insurance policy to fund potential recovery obligations.</font></div><div style="text-indent:18pt"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12.17pt">Interaction with Other Clawback Provisions. The Company will be deemed to have recovered Erroneously Awarded Compensation in accordance with this Policy to the extent the Company actually receives such amounts pursuant to any other Company policy, program or agreement, pursuant to Section 304 of the Sarbanes-Oxley Act or otherwise.</font></div><div style="text-indent:18pt"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">No Limitation on Other Remedies. Nothing in this Policy will be deemed to limit the Company&#8217;s right to terminate employment of any Covered Person, to seek recovery of other compensation paid to a Covered Person, or to pursue other rights or remedies available to the Company under applicable law.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Adopted by the Board on November 6, 2023.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>carm-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:1dec34d0-de78-478e-a130-81bf7fce6e30,g:762837ba-4cc2-4d5a-8343-3052f0231779-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:carm="http://carismatx.com/20241231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://carismatx.com/20241231">
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/cyd-af-sub/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="carm-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="carm-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="carm-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="carm-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://carismatx.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://carismatx.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://carismatx.com/role/ConsolidatedBalanceSheets">
        <link:definition>9952151 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://carismatx.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>9952152 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>9952153 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity" roleURI="http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity">
        <link:definition>9952154 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; (Deficit) Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://carismatx.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>9952155 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Background" roleURI="http://carismatx.com/role/Background">
        <link:definition>9952156 - Disclosure - Background</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DevelopmentStageRisksandLiquidity" roleURI="http://carismatx.com/role/DevelopmentStageRisksandLiquidity">
        <link:definition>9952157 - Disclosure - Development-Stage Risks and Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://carismatx.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>9952158 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergerwithSesenBio" roleURI="http://carismatx.com/role/MergerwithSesenBio">
        <link:definition>9952159 - Disclosure - Merger with Sesen Bio</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesandOtherAssets" roleURI="http://carismatx.com/role/PrepaidExpensesandOtherAssets">
        <link:definition>9952160 - Disclosure - Prepaid Expenses and Other Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentnet" roleURI="http://carismatx.com/role/PropertyandEquipmentnet">
        <link:definition>9952161 - Disclosure - Property and Equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpenses" roleURI="http://carismatx.com/role/AccruedExpenses">
        <link:definition>9952162 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://carismatx.com/role/CommitmentsandContingencies">
        <link:definition>9952163 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersDeficitEquity" roleURI="http://carismatx.com/role/StockholdersDeficitEquity">
        <link:definition>9952164 - Disclosure - Stockholders&#8217; (Deficit) Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensation" roleURI="http://carismatx.com/role/StockbasedCompensation">
        <link:definition>9952165 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://carismatx.com/role/IncomeTaxes">
        <link:definition>9952166 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://carismatx.com/role/RelatedPartyTransactions">
        <link:definition>9952167 - Disclosure - Related-Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ModernaCollaborationandLicenseAgreement" roleURI="http://carismatx.com/role/ModernaCollaborationandLicenseAgreement">
        <link:definition>9952168 - Disclosure - Moderna Collaboration and License Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://carismatx.com/role/SubsequentEvents">
        <link:definition>9952169 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergerwithSesenBioTables" roleURI="http://carismatx.com/role/MergerwithSesenBioTables">
        <link:definition>9955513 - Disclosure - Merger with Sesen Bio (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesandOtherAssetsTables" roleURI="http://carismatx.com/role/PrepaidExpensesandOtherAssetsTables">
        <link:definition>9955514 - Disclosure - Prepaid Expenses and Other Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentnetTables" roleURI="http://carismatx.com/role/PropertyandEquipmentnetTables">
        <link:definition>9955515 - Disclosure - Property and Equipment, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTables" roleURI="http://carismatx.com/role/AccruedExpensesTables">
        <link:definition>9955516 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://carismatx.com/role/CommitmentsandContingenciesTables">
        <link:definition>9955517 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationTables" roleURI="http://carismatx.com/role/StockbasedCompensationTables">
        <link:definition>9955518 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://carismatx.com/role/IncomeTaxesTables">
        <link:definition>9955519 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ModernaCollaborationandLicenseAgreementTables" roleURI="http://carismatx.com/role/ModernaCollaborationandLicenseAgreementTables">
        <link:definition>9955520 - Disclosure - Moderna Collaboration and License Agreement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BackgroundDetails" roleURI="http://carismatx.com/role/BackgroundDetails">
        <link:definition>9955521 - Disclosure - Background (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DevelopmentStageRisksandLiquidityDetails" roleURI="http://carismatx.com/role/DevelopmentStageRisksandLiquidityDetails">
        <link:definition>9955522 - Disclosure - Development-Stage Risks and Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsMeasuredonRecurringBasisDetails" roleURI="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsMeasuredonRecurringBasisDetails">
        <link:definition>9955523 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value Hierarchy of Assets Measured on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>9955524 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofSignificantExpenseCategoriesbySegmentDetails" roleURI="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofSignificantExpenseCategoriesbySegmentDetails">
        <link:definition>9955525 - Disclosure - Summary of Significant Accounting Policies - Schedule of Significant Expense Categories by Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofDilutiveSecuritiesDetails" roleURI="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofDilutiveSecuritiesDetails">
        <link:definition>9955526 - Disclosure - Summary of Significant Accounting Policies - Schedule of Dilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails" roleURI="http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails">
        <link:definition>9955527 - Disclosure - Merger with Sesen Bio - Schedule of Net Assets Acquired in the Merger (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails_1" roleURI="http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails_1">
        <link:definition>9955527 - Disclosure - Merger with Sesen Bio - Schedule of Net Assets Acquired in the Merger (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesandOtherAssetsDetails" roleURI="http://carismatx.com/role/PrepaidExpensesandOtherAssetsDetails">
        <link:definition>9955528 - Disclosure - Prepaid Expenses and Other Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails" roleURI="http://carismatx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails">
        <link:definition>9955529 - Disclosure - Property and Equipment, net - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentnetNarrativeDetails" roleURI="http://carismatx.com/role/PropertyandEquipmentnetNarrativeDetails">
        <link:definition>9955530 - Disclosure - Property and Equipment, net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesDetails" roleURI="http://carismatx.com/role/AccruedExpensesDetails">
        <link:definition>9955531 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativeDetails" roleURI="http://carismatx.com/role/CommitmentsandContingenciesNarrativeDetails">
        <link:definition>9955532 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleofLeaseCostsDetails" roleURI="http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails">
        <link:definition>9955533 - Disclosure - Commitments and Contingencies - Schedule of Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleofLeaseTermandDiscountRateInformationDetails" roleURI="http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseTermandDiscountRateInformationDetails">
        <link:definition>9955534 - Disclosure - Commitments and Contingencies - Schedule of Lease Term and Discount Rate Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleofSupplementalCashFlowInformationDetails" roleURI="http://carismatx.com/role/CommitmentsandContingenciesScheduleofSupplementalCashFlowInformationDetails">
        <link:definition>9955535 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails" roleURI="http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails">
        <link:definition>9955536 - Disclosure - Commitments and Contingencies - Schedule of Future Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails_1" roleURI="http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails_1">
        <link:definition>9955536 - Disclosure - Commitments and Contingencies - Schedule of Future Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersDeficitEquityDetails" roleURI="http://carismatx.com/role/StockholdersDeficitEquityDetails">
        <link:definition>9955537 - Disclosure - Stockholders&#8217; (Deficit) Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationNarrativeDetails" roleURI="http://carismatx.com/role/StockbasedCompensationNarrativeDetails">
        <link:definition>9955538 - Disclosure - Stock-based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationScheduleofStockOptionActivityDetails" roleURI="http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails">
        <link:definition>9955539 - Disclosure - Stock-based Compensation - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationScheduleofEstimatedUsingTheBlackScholesOptionPricingModelDetails" roleURI="http://carismatx.com/role/StockbasedCompensationScheduleofEstimatedUsingTheBlackScholesOptionPricingModelDetails">
        <link:definition>9955540 - Disclosure - Stock-based Compensation - Schedule of Estimated Using The Black-Scholes Option-Pricing Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails" roleURI="http://carismatx.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails">
        <link:definition>9955541 - Disclosure - Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://carismatx.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>9955542 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails" roleURI="http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails">
        <link:definition>9955543 - Disclosure - Income Taxes- Schedule of Deferred Tax Assets for Federal Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://carismatx.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>9955544 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ModernaCollaborationandLicenseAgreementNarrativeDetails" roleURI="http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails">
        <link:definition>9955545 - Disclosure - Moderna Collaboration and License Agreement - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ModernaCollaborationandLicenseAgreementScheduleofEstimatedRevenueExpectedtobeRecognizedinTheFutureRelatedtoPerformanceObligationsDetails" roleURI="http://carismatx.com/role/ModernaCollaborationandLicenseAgreementScheduleofEstimatedRevenueExpectedtobeRecognizedinTheFutureRelatedtoPerformanceObligationsDetails">
        <link:definition>9955546 - Disclosure - Moderna Collaboration and License Agreement - Schedule of Estimated Revenue Expected to be Recognized in The Future Related to Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ModernaCollaborationandLicenseAgreementScheduleofChangesinDeferredRevenueDetails" roleURI="http://carismatx.com/role/ModernaCollaborationandLicenseAgreementScheduleofChangesinDeferredRevenueDetails">
        <link:definition>9955547 - Disclosure - Moderna Collaboration and License Agreement - Schedule of Changes in Deferred Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://carismatx.com/role/SubsequentEventsDetails">
        <link:definition>9955548 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="carm_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="carm_DeferredFinancingCostsNoncurrent" abstract="false" name="DeferredFinancingCostsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_ReclassificationsOfTemporaryToPermanentEquityShares" abstract="false" name="ReclassificationsOfTemporaryToPermanentEquityShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction" abstract="false" name="StockIssuedDuringPeriodSharesPreclosureFinancingTransaction" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction" abstract="false" name="StockIssuedDuringPeriodValuesPreclosureFinancingTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" abstract="false" name="StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" abstract="false" name="StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_AccretionOnMarketableSecurities" abstract="false" name="AccretionOnMarketableSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_WriteOffOfPropertyAndEquipment" abstract="false" name="WriteOffOfPropertyAndEquipment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_NoncashInterestExpense" abstract="false" name="NoncashInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_GainLossOnSaleOfEquipment" abstract="false" name="GainLossOnSaleOfEquipment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_PaymentsForProceedsFromMarketableSecurities" abstract="false" name="PaymentsForProceedsFromMarketableSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities" abstract="false" name="CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities" abstract="false" name="PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing" abstract="false" name="ProceedsFromIssuanceOfCommonStockPreClosingFinancing" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_ProceedsFromFailedSaleLeasebackTransaction" abstract="false" name="ProceedsFromFailedSaleLeasebackTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction" abstract="false" name="PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_NoncashOrPartNoncashAcquisitionEquityAssumed" abstract="false" name="NoncashOrPartNoncashAcquisitionEquityAssumed" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities" abstract="false" name="NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts" abstract="false" name="NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_NonCashEffectOfModificationOfOperatingLeaseRightOfUseAssetsOperatingLeaseLiabilities" abstract="false" name="NonCashEffectOfModificationOfOperatingLeaseRightOfUseAssetsOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability" abstract="false" name="DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_DevelopmentStageRisksAndLiquidityAbstract" abstract="true" name="DevelopmentStageRisksAndLiquidityAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="carm_DevelopmentStageRisksAndLiquidityTextBlock" abstract="false" name="DevelopmentStageRisksAndLiquidityTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="carm_DeferredFinancingCostsPolicyPolicyTextBlock" abstract="false" name="DeferredFinancingCostsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock" abstract="false" name="LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock" abstract="false" name="LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="carm_LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock" abstract="false" name="LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="carm_ScheduleOfChangesInDeferredRevenueTableTextBlock" abstract="false" name="ScheduleOfChangesInDeferredRevenueTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="carm_ReportingSegmentMember" abstract="true" name="ReportingSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses" abstract="false" name="ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses" abstract="false" name="GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_FacilitiesExpense" abstract="false" name="FacilitiesExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities" abstract="false" name="DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_CarismaTherapeuticsIncLegacyStockholdersMember" abstract="true" name="CarismaTherapeuticsIncLegacyStockholdersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="carm_CarismaTherapeuticsInc.Member" abstract="true" name="CarismaTherapeuticsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="carm_NumberOfBoardMembers" abstract="false" name="NumberOfBoardMembers" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash" abstract="false" name="Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_PrepaidResearchAndDevelopmentCurrent" abstract="false" name="PrepaidResearchAndDevelopmentCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_ReceivableDueFromCollaborativeArrangementCurrent" abstract="false" name="ReceivableDueFromCollaborativeArrangementCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_AccruedResearchAndDevelopmentExpenseCurrent" abstract="false" name="AccruedResearchAndDevelopmentExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_PennLicenseAgreementMember" abstract="true" name="PennLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember" abstract="true" name="ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="carm_TrusteesOfUniversityOfPennsylvaniaMember" abstract="true" name="TrusteesOfUniversityOfPennsylvaniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="carm_IncreaseDecreaseInFinanceLeaseRightOfUseAssetLeaseModification" abstract="false" name="IncreaseDecreaseInFinanceLeaseRightOfUseAssetLeaseModification" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification" abstract="false" name="IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_CommitmentsAnnualPaymentsRequiredToBePaid" abstract="false" name="CommitmentsAnnualPaymentsRequiredToBePaid" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents" abstract="false" name="AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_AdditionalMilestonePaymentsRequiredToBePaid" abstract="false" name="AdditionalMilestonePaymentsRequiredToBePaid" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_AdditionalMilestonePaymentsForFirstCarMProduct" abstract="false" name="AdditionalMilestonePaymentsForFirstCarMProduct" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_AgreementTerm" abstract="false" name="AgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="carm_FinanceLeaseCostAbstract" abstract="true" name="FinanceLeaseCostAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="carm_FinanceLeaseCost" abstract="false" name="FinanceLeaseCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_LeasesWeightedAverageRemainingLeaseTermAbstract" abstract="true" name="LeasesWeightedAverageRemainingLeaseTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="carm_LeasesWeightedAverageDiscountRateAbstract" abstract="true" name="LeasesWeightedAverageDiscountRateAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" abstract="true" name="CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="carm_FinancingCashUsedInFinanceLeases" abstract="false" name="FinancingCashUsedInFinanceLeases" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_AtTheMarketMember" abstract="true" name="AtTheMarketMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests" abstract="false" name="StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="carm_SaleOfStockStockOfferingAmount" abstract="false" name="SaleOfStockStockOfferingAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_SaleOfStockMaximumOfferingAmount" abstract="false" name="SaleOfStockMaximumOfferingAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_TwoThousandSeventeenStockIncentivePlanMember" abstract="true" name="TwoThousandSeventeenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="carm_TwoThousandFourteenStockIncentivePlanMember" abstract="true" name="TwoThousandFourteenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="carm_TwoThousandFourteenEmployeeStockPurchasePlanMember" abstract="true" name="TwoThousandFourteenEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="carm_SesenBioIncMember" abstract="true" name="SesenBioIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="carm_RevisedOperatingPlanMember" abstract="true" name="RevisedOperatingPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences" abstract="false" name="EffectiveIncomeTaxRateReconciliationPermanentDifferences" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization" abstract="false" name="DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_DeferredTaxAssetsStartUpCosts" abstract="false" name="DeferredTaxAssetsStartUpCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_DeferredTaxAssetsLeaseLiability" abstract="false" name="DeferredTaxAssetsLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_DeferredTaxAssetsAmortizableAssetsAndOther" abstract="false" name="DeferredTaxAssetsAmortizableAssetsAndOther" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_DeferredTaxAssetsEquityCompensation" abstract="false" name="DeferredTaxAssetsEquityCompensation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_DeferredTaxLiabilitiesRightOfUseAsset" abstract="false" name="DeferredTaxLiabilitiesRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_Pre2018Member" abstract="true" name="Pre2018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="carm_Post2017Member" abstract="true" name="Post2017Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="carm_StateJurisdictionMember" abstract="true" name="StateJurisdictionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="carm_LocalJurisdictionMember" abstract="true" name="LocalJurisdictionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="carm_CollaborationAndLicenseAgreementMember" abstract="true" name="CollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="carm_ModernaLicenseAgreementMember" abstract="true" name="ModernaLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="carm_ModernaMember" abstract="true" name="ModernaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="carm_ResearchAndDevelopmentServicesMember" abstract="true" name="ResearchAndDevelopmentServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="carm_OptionRightCollaborationRevenuesMember" abstract="true" name="OptionRightCollaborationRevenuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="carm_MilestonesMember" abstract="true" name="MilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="carm_MaximumNumberOfResearchTargets" abstract="false" name="MaximumNumberOfResearchTargets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="carm_NumberOfResearchTargetsNominatedAutoimmune" abstract="false" name="NumberOfResearchTargetsNominatedAutoimmune" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="carm_NumberOfResearchTargetsGrossOncology" abstract="false" name="NumberOfResearchTargetsGrossOncology" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="carm_UpfrontNonRefundablePaymentReceived" abstract="false" name="UpfrontNonRefundablePaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_NumberOfPotentialProductsToDevelopAndCommercialize" abstract="false" name="NumberOfPotentialProductsToDevelopAndCommercialize" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments" abstract="false" name="AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts" abstract="false" name="MinimumCommitmentToReimburseResearchAndDevelopmentCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts" abstract="false" name="PeriodOfReimbursementOfResearchAndDevelopmentCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="carm_NumberOfPerformanceObligations" abstract="false" name="NumberOfPerformanceObligations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="carm_CollaborativeArrangementRightsAndObligationsMilestonePayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_NumberOfPotentialResearchTargetDesignations" abstract="false" name="NumberOfPotentialResearchTargetDesignations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="carm_VariableConsideration" abstract="false" name="VariableConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_ContractTerm" abstract="false" name="ContractTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount" abstract="false" name="RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_RevenueRemainingPerformanceObligationOptionRightsAmount" abstract="false" name="RevenueRemainingPerformanceObligationOptionRightsAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_ContractWithCustomerLiabilityDeferralOfRevenue" abstract="false" name="ContractWithCustomerLiabilityDeferralOfRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_CashPreservationPlan2025Member" abstract="true" name="CashPreservationPlan2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="carm_NumberOfResearchTargetsNominatedOncology" abstract="false" name="NumberOfResearchTargetsNominatedOncology" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="carm_NumberOfResearchTargetsNominatedReplacements" abstract="false" name="NumberOfResearchTargetsNominatedReplacements" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="carm_NumberOfResearchTargetsTerminatedOncology" abstract="false" name="NumberOfResearchTargetsTerminatedOncology" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="carm_NumberOfResearchTargetsTerminatedAutoimmune" abstract="false" name="NumberOfResearchTargetsTerminatedAutoimmune" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>14
<FILENAME>carm-20241231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:1dec34d0-de78-478e-a130-81bf7fce6e30,g:762837ba-4cc2-4d5a-8343-3052f0231779-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://carismatx.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="carm-20241231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://carismatx.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_61fa7bbd-5a5a-4786-b49c-7f8f3a096edd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_262747c9-704d-434f-ba37-c367f9a6a1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_61fa7bbd-5a5a-4786-b49c-7f8f3a096edd" xlink:to="loc_us-gaap_Liabilities_262747c9-704d-434f-ba37-c367f9a6a1e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_41249dfa-d802-4b8b-8528-6e43be1e7b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_61fa7bbd-5a5a-4786-b49c-7f8f3a096edd" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_41249dfa-d802-4b8b-8528-6e43be1e7b4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_363e6786-8382-491e-9f1f-33718654862c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_61fa7bbd-5a5a-4786-b49c-7f8f3a096edd" xlink:to="loc_us-gaap_CommitmentsAndContingencies_363e6786-8382-491e-9f1f-33718654862c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_540d7248-d1c2-4b41-b285-512a3c41f131" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_aa91d977-19df-45f1-bd38-939124896200" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_540d7248-d1c2-4b41-b285-512a3c41f131" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_aa91d977-19df-45f1-bd38-939124896200" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_026d4e92-61a8-4f05-a523-abfa2244ff68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_540d7248-d1c2-4b41-b285-512a3c41f131" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_026d4e92-61a8-4f05-a523-abfa2244ff68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_9585f487-3678-4e21-871b-869d85006811" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_540d7248-d1c2-4b41-b285-512a3c41f131" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_9585f487-3678-4e21-871b-869d85006811" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_39d9eb30-2062-4ebf-bef1-f618769d8158" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_540d7248-d1c2-4b41-b285-512a3c41f131" xlink:to="loc_us-gaap_DeferredRevenueCurrent_39d9eb30-2062-4ebf-bef1-f618769d8158" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b942578c-f937-4134-ab79-052cd05ad3eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_540d7248-d1c2-4b41-b285-512a3c41f131" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_b942578c-f937-4134-ab79-052cd05ad3eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_9ce3cfdf-00d5-4652-a873-50a54407ef0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_540d7248-d1c2-4b41-b285-512a3c41f131" xlink:to="loc_us-gaap_AccountsPayableCurrent_9ce3cfdf-00d5-4652-a873-50a54407ef0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_33a90431-656b-42b3-939f-12f29729cba9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e8669456-fba0-4637-8116-f4456021f0a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_33a90431-656b-42b3-939f-12f29729cba9" xlink:to="loc_us-gaap_AssetsCurrent_e8669456-fba0-4637-8116-f4456021f0a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_fdcf57a3-b669-474f-b3ed-80bedc3489eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_33a90431-656b-42b3-939f-12f29729cba9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_fdcf57a3-b669-474f-b3ed-80bedc3489eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b8a1ba60-824a-4d0d-afd8-517c2c278c13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_33a90431-656b-42b3-939f-12f29729cba9" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b8a1ba60-824a-4d0d-afd8-517c2c278c13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DeferredFinancingCostsNoncurrent_84457e5a-0b55-440c-a632-f38feace5cdb" xlink:href="carm-20241231.xsd#carm_DeferredFinancingCostsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_33a90431-656b-42b3-939f-12f29729cba9" xlink:to="loc_carm_DeferredFinancingCostsNoncurrent_84457e5a-0b55-440c-a632-f38feace5cdb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6ded77cd-c7ca-43a8-9a81-6ab6f17d6164" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_154e7aec-4513-41f6-bf85-648d0ed52f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6ded77cd-c7ca-43a8-9a81-6ab6f17d6164" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_154e7aec-4513-41f6-bf85-648d0ed52f9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_e4952834-c6c9-4942-8b5f-377dd96bcf0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6ded77cd-c7ca-43a8-9a81-6ab6f17d6164" xlink:to="loc_us-gaap_CommonStockValue_e4952834-c6c9-4942-8b5f-377dd96bcf0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_21ec3940-0c46-440e-ada1-9ef3b3ed53a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6ded77cd-c7ca-43a8-9a81-6ab6f17d6164" xlink:to="loc_us-gaap_PreferredStockValue_21ec3940-0c46-440e-ada1-9ef3b3ed53a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_1d777151-fee6-4fe3-bd6f-c9dd18883f36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6ded77cd-c7ca-43a8-9a81-6ab6f17d6164" xlink:to="loc_us-gaap_AdditionalPaidInCapital_1d777151-fee6-4fe3-bd6f-c9dd18883f36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_4302a09b-33b0-401d-b865-9b00e77b8a12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_dd5f8165-bc7f-4cd2-b4b3-00f0b94d2aef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4302a09b-33b0-401d-b865-9b00e77b8a12" xlink:to="loc_us-gaap_LiabilitiesCurrent_dd5f8165-bc7f-4cd2-b4b3-00f0b94d2aef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_8c6d2f80-5290-4202-b869-7b2042bb7458" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4302a09b-33b0-401d-b865-9b00e77b8a12" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_8c6d2f80-5290-4202-b869-7b2042bb7458" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_74343aa6-ca4d-48cd-af28-9c086cbc9f28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4302a09b-33b0-401d-b865-9b00e77b8a12" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_74343aa6-ca4d-48cd-af28-9c086cbc9f28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_6992ebac-a429-4196-baed-d7b904407956" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4302a09b-33b0-401d-b865-9b00e77b8a12" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_6992ebac-a429-4196-baed-d7b904407956" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_9d8dc26c-ce28-440b-be8e-c297b6ea3918" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4302a09b-33b0-401d-b865-9b00e77b8a12" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_9d8dc26c-ce28-440b-be8e-c297b6ea3918" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_85105409-43f2-4552-b5ae-521406cc905a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3b3a4c49-74fb-4aa8-b219-1c6f1a1e9770" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_85105409-43f2-4552-b5ae-521406cc905a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3b3a4c49-74fb-4aa8-b219-1c6f1a1e9770" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7ae05360-b942-45a0-96d9-26ebf411af48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_85105409-43f2-4552-b5ae-521406cc905a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7ae05360-b942-45a0-96d9-26ebf411af48" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="carm-20241231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_c388b793-caff-4143-b64f-1a8e11611491" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_16ee0ca7-0c9e-47f8-83b3-9299c2739bde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_c388b793-caff-4143-b64f-1a8e11611491" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_16ee0ca7-0c9e-47f8-83b3-9299c2739bde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_602d7e8b-2ddb-4aec-afce-9534deac2f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_c388b793-caff-4143-b64f-1a8e11611491" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_602d7e8b-2ddb-4aec-afce-9534deac2f1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_13ff150d-9998-47e9-9267-e96681a0f75f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_53a65097-f4c1-4e72-9294-3a5f45f6620d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_13ff150d-9998-47e9-9267-e96681a0f75f" xlink:to="loc_us-gaap_OperatingExpenses_53a65097-f4c1-4e72-9294-3a5f45f6620d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_1658ee66-5627-487a-9d7c-b016c1b464ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_13ff150d-9998-47e9-9267-e96681a0f75f" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_1658ee66-5627-487a-9d7c-b016c1b464ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_beb90896-38d2-49b1-926d-ed85a0b7e9e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_b4ccc4c1-e600-49b4-a671-f240de05e767" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_beb90896-38d2-49b1-926d-ed85a0b7e9e4" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_b4ccc4c1-e600-49b4-a671-f240de05e767" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_86546869-cba3-4923-802f-903977b172ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_beb90896-38d2-49b1-926d-ed85a0b7e9e4" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_86546869-cba3-4923-802f-903977b172ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_342300b8-638b-46c1-a8a0-7c955f1239c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_beb90896-38d2-49b1-926d-ed85a0b7e9e4" xlink:to="loc_us-gaap_OperatingIncomeLoss_342300b8-638b-46c1-a8a0-7c955f1239c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_472cc8d9-d4c5-47bd-b4b4-1de46d8ea30d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_1ff7e488-7431-470e-8a61-406a169b32ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_472cc8d9-d4c5-47bd-b4b4-1de46d8ea30d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_1ff7e488-7431-470e-8a61-406a169b32ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_b9b53318-df23-4e25-b92f-a7de5b84a689" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_472cc8d9-d4c5-47bd-b4b4-1de46d8ea30d" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_b9b53318-df23-4e25-b92f-a7de5b84a689" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ebe0801c-3699-41cf-8344-4d2647df3d71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_472cc8d9-d4c5-47bd-b4b4-1de46d8ea30d" xlink:to="loc_us-gaap_NetIncomeLoss_ebe0801c-3699-41cf-8344-4d2647df3d71" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://carismatx.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="carm-20241231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://carismatx.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_02d51cf9-3f22-4808-9b06-478f79253906" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a4f03d08-e1f9-4845-9207-79982a5bf273" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_02d51cf9-3f22-4808-9b06-478f79253906" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a4f03d08-e1f9-4845-9207-79982a5bf273" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_PaymentsForProceedsFromMarketableSecurities_eb0a448f-538b-412e-aced-419f4391723d" xlink:href="carm-20241231.xsd#carm_PaymentsForProceedsFromMarketableSecurities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_02d51cf9-3f22-4808-9b06-478f79253906" xlink:to="loc_carm_PaymentsForProceedsFromMarketableSecurities_eb0a448f-538b-412e-aced-419f4391723d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_32f6dbc3-1cef-4785-ba4d-9487552a6f31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_02d51cf9-3f22-4808-9b06-478f79253906" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_32f6dbc3-1cef-4785-ba4d-9487552a6f31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_18b1bf29-cdab-410f-bb6f-673c37ba2f98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_92056b45-3e68-4c5e-8998-b787befce718" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_18b1bf29-cdab-410f-bb6f-673c37ba2f98" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_92056b45-3e68-4c5e-8998-b787befce718" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_feae1453-0cc5-4a57-8c5b-ffbb46b5f14d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_18b1bf29-cdab-410f-bb6f-673c37ba2f98" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_feae1453-0cc5-4a57-8c5b-ffbb46b5f14d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b2c51c08-23b0-47de-b4cb-5942da8aba55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_18b1bf29-cdab-410f-bb6f-673c37ba2f98" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b2c51c08-23b0-47de-b4cb-5942da8aba55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9d3a3bd1-470e-44e6-8c1f-a88c85f1adee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_GainLossOnSaleOfEquipment_1608d9ff-fb96-4441-935b-c465f963d894" xlink:href="carm-20241231.xsd#carm_GainLossOnSaleOfEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9d3a3bd1-470e-44e6-8c1f-a88c85f1adee" xlink:to="loc_carm_GainLossOnSaleOfEquipment_1608d9ff-fb96-4441-935b-c465f963d894" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_de2950a0-42d7-4d97-9044-e4afc3bce07a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9d3a3bd1-470e-44e6-8c1f-a88c85f1adee" xlink:to="loc_us-gaap_NetIncomeLoss_de2950a0-42d7-4d97-9044-e4afc3bce07a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_650b4c0c-6dc2-4fe7-98e8-0bd7f3c6fec6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9d3a3bd1-470e-44e6-8c1f-a88c85f1adee" xlink:to="loc_us-gaap_DepreciationAndAmortization_650b4c0c-6dc2-4fe7-98e8-0bd7f3c6fec6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_c7e131bd-9433-4f68-85d7-15e47d4170a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9d3a3bd1-470e-44e6-8c1f-a88c85f1adee" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_c7e131bd-9433-4f68-85d7-15e47d4170a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AccretionOnMarketableSecurities_6abc1801-e728-4f69-8f3d-b7c1d6c9f255" xlink:href="carm-20241231.xsd#carm_AccretionOnMarketableSecurities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9d3a3bd1-470e-44e6-8c1f-a88c85f1adee" xlink:to="loc_carm_AccretionOnMarketableSecurities_6abc1801-e728-4f69-8f3d-b7c1d6c9f255" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_WriteOffOfPropertyAndEquipment_bbe5e5fb-3699-4700-800b-1647b8946acd" xlink:href="carm-20241231.xsd#carm_WriteOffOfPropertyAndEquipment"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9d3a3bd1-470e-44e6-8c1f-a88c85f1adee" xlink:to="loc_carm_WriteOffOfPropertyAndEquipment_bbe5e5fb-3699-4700-800b-1647b8946acd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NoncashInterestExpense_4c6dc8d8-3d9e-436c-8530-6dcaf56ba5c1" xlink:href="carm-20241231.xsd#carm_NoncashInterestExpense"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9d3a3bd1-470e-44e6-8c1f-a88c85f1adee" xlink:to="loc_carm_NoncashInterestExpense_4c6dc8d8-3d9e-436c-8530-6dcaf56ba5c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_036603dd-de03-46af-82c2-57abdfb58136" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9d3a3bd1-470e-44e6-8c1f-a88c85f1adee" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_036603dd-de03-46af-82c2-57abdfb58136" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_9c971e98-67e1-4037-932c-2b6d70789501" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9d3a3bd1-470e-44e6-8c1f-a88c85f1adee" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_9c971e98-67e1-4037-932c-2b6d70789501" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8d952713-7073-4f04-bd94-a47f0642b413" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9d3a3bd1-470e-44e6-8c1f-a88c85f1adee" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8d952713-7073-4f04-bd94-a47f0642b413" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_3e77e698-dbfa-4e7f-8227-52ddfad7e715" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9d3a3bd1-470e-44e6-8c1f-a88c85f1adee" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_3e77e698-dbfa-4e7f-8227-52ddfad7e715" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_4ce7c006-2f1f-4343-929f-b569ddeb7ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9d3a3bd1-470e-44e6-8c1f-a88c85f1adee" xlink:to="loc_us-gaap_ShareBasedCompensation_4ce7c006-2f1f-4343-929f-b569ddeb7ae0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b62684bb-4268-4444-abf1-3b394a72f9d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9d3a3bd1-470e-44e6-8c1f-a88c85f1adee" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b62684bb-4268-4444-abf1-3b394a72f9d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_dfc77719-19ca-4971-996a-bacf080ed91a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9d3a3bd1-470e-44e6-8c1f-a88c85f1adee" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_dfc77719-19ca-4971-996a-bacf080ed91a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_c26746fe-c371-49ae-8fc2-89c5fd8585aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9d3a3bd1-470e-44e6-8c1f-a88c85f1adee" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_c26746fe-c371-49ae-8fc2-89c5fd8585aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_ed0567bc-e871-4cae-b470-da7503729c20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9d3a3bd1-470e-44e6-8c1f-a88c85f1adee" xlink:to="loc_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_ed0567bc-e871-4cae-b470-da7503729c20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleAndLeasebackTransactionGainLossNet_9e9fc63c-86eb-488b-96df-a93a8b636f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleAndLeasebackTransactionGainLossNet"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9d3a3bd1-470e-44e6-8c1f-a88c85f1adee" xlink:to="loc_us-gaap_SaleAndLeasebackTransactionGainLossNet_9e9fc63c-86eb-488b-96df-a93a8b636f7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_fe5b23e1-ec8f-4ae2-838b-fb9ca2397d61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9d3a3bd1-470e-44e6-8c1f-a88c85f1adee" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_fe5b23e1-ec8f-4ae2-838b-fb9ca2397d61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_274e9491-4bb0-4ef7-ad93-acd998d04330" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="19" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9d3a3bd1-470e-44e6-8c1f-a88c85f1adee" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_274e9491-4bb0-4ef7-ad93-acd998d04330" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9033b305-3439-49fa-8b23-bfe0b985fc38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing_285b0a04-c544-4b14-80a2-50b1af6d4165" xlink:href="carm-20241231.xsd#carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9033b305-3439-49fa-8b23-bfe0b985fc38" xlink:to="loc_carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing_285b0a04-c544-4b14-80a2-50b1af6d4165" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_aa0cd74b-d348-4daa-a1d9-ff8c6d3d1dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9033b305-3439-49fa-8b23-bfe0b985fc38" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_aa0cd74b-d348-4daa-a1d9-ff8c6d3d1dcb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1395af7a-d8b5-4e07-a27f-cff683ab613c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9033b305-3439-49fa-8b23-bfe0b985fc38" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1395af7a-d8b5-4e07-a27f-cff683ab613c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_1d87b019-3896-4ebd-8502-f8d8c30d911c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9033b305-3439-49fa-8b23-bfe0b985fc38" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_1d87b019-3896-4ebd-8502-f8d8c30d911c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction_0934f0fb-25f1-4e81-b4c3-b4bdbd540202" xlink:href="carm-20241231.xsd#carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9033b305-3439-49fa-8b23-bfe0b985fc38" xlink:to="loc_carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction_0934f0fb-25f1-4e81-b4c3-b4bdbd540202" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_3d8a9267-f630-4306-a1de-e72435736867" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9033b305-3439-49fa-8b23-bfe0b985fc38" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_3d8a9267-f630-4306-a1de-e72435736867" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ProceedsFromFailedSaleLeasebackTransaction_b5e5a668-1cac-46d3-ad91-3e15e10b99f5" xlink:href="carm-20241231.xsd#carm_ProceedsFromFailedSaleLeasebackTransaction"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9033b305-3439-49fa-8b23-bfe0b985fc38" xlink:to="loc_carm_ProceedsFromFailedSaleLeasebackTransaction_b5e5a668-1cac-46d3-ad91-3e15e10b99f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities_991d7d8f-adc0-4851-bbb9-572c1dd9ad6b" xlink:href="carm-20241231.xsd#carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9033b305-3439-49fa-8b23-bfe0b985fc38" xlink:to="loc_carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities_991d7d8f-adc0-4851-bbb9-572c1dd9ad6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities_41838f30-b77e-4152-9a55-0ea9cf07df68" xlink:href="carm-20241231.xsd#carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9033b305-3439-49fa-8b23-bfe0b985fc38" xlink:to="loc_carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities_41838f30-b77e-4152-9a55-0ea9cf07df68" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofSignificantExpenseCategoriesbySegmentDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#SummaryofSignificantAccountingPoliciesScheduleofSignificantExpenseCategoriesbySegmentDetails"/>
  <link:calculationLink xlink:role="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofSignificantExpenseCategoriesbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_46c895e4-22a1-4363-a99f-6de845c92566" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities_8ca6e7b2-5660-45e4-9464-5e5156fcf3af" xlink:href="carm-20241231.xsd#carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_46c895e4-22a1-4363-a99f-6de845c92566" xlink:to="loc_carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities_8ca6e7b2-5660-45e4-9464-5e5156fcf3af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses_cb93daf9-6b11-47ce-8254-26d1e135e230" xlink:href="carm-20241231.xsd#carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_46c895e4-22a1-4363-a99f-6de845c92566" xlink:to="loc_carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses_cb93daf9-6b11-47ce-8254-26d1e135e230" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_a1cc7eb0-3ec1-428a-b59a-784a991eb482" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_46c895e4-22a1-4363-a99f-6de845c92566" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_a1cc7eb0-3ec1-428a-b59a-784a991eb482" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_6667d72d-ed0d-4760-a53b-5f653aeba3b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_46c895e4-22a1-4363-a99f-6de845c92566" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_6667d72d-ed0d-4760-a53b-5f653aeba3b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_0205c229-81f8-44ba-a059-4f779f914680" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_46c895e4-22a1-4363-a99f-6de845c92566" xlink:to="loc_us-gaap_LaborAndRelatedExpense_0205c229-81f8-44ba-a059-4f779f914680" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses_bd417c1b-f00f-4fe3-b9c7-066a88fd53cc" xlink:href="carm-20241231.xsd#carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_46c895e4-22a1-4363-a99f-6de845c92566" xlink:to="loc_carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses_bd417c1b-f00f-4fe3-b9c7-066a88fd53cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_FacilitiesExpense_7dd8f037-6c0c-479f-a292-d27baaa377be" xlink:href="carm-20241231.xsd#carm_FacilitiesExpense"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_46c895e4-22a1-4363-a99f-6de845c92566" xlink:to="loc_carm_FacilitiesExpense_7dd8f037-6c0c-479f-a292-d27baaa377be" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails"/>
  <link:calculationLink xlink:role="http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_7e6b9bcc-c6b4-4ad3-98c7-91e05ed2a10f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_c34f9056-1f63-4dcc-8c98-eb88878a7adf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_7e6b9bcc-c6b4-4ad3-98c7-91e05ed2a10f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_c34f9056-1f63-4dcc-8c98-eb88878a7adf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_a56558e3-d504-4b23-b31e-24bf42784060" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_7e6b9bcc-c6b4-4ad3-98c7-91e05ed2a10f" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_a56558e3-d504-4b23-b31e-24bf42784060" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails_1" xlink:type="simple" xlink:href="carm-20241231.xsd#MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails_1"/>
  <link:calculationLink xlink:role="http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_ce2084bf-e7f8-4e71-ace3-32c0a4f095c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash_01b686ca-045c-4e82-b328-a730e4f33985" xlink:href="carm-20241231.xsd#carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_ce2084bf-e7f8-4e71-ace3-32c0a4f095c3" xlink:to="loc_carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash_01b686ca-045c-4e82-b328-a730e4f33985" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_37c2ba38-34f5-4558-b2d9-27d5e62ea71f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_ce2084bf-e7f8-4e71-ace3-32c0a4f095c3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_37c2ba38-34f5-4558-b2d9-27d5e62ea71f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6ef35b32-00bc-466a-a261-d3a0bd3c5b26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_ce2084bf-e7f8-4e71-ace3-32c0a4f095c3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6ef35b32-00bc-466a-a261-d3a0bd3c5b26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_b76bb7e8-9cb8-4a8b-b461-4a4938c19c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_ce2084bf-e7f8-4e71-ace3-32c0a4f095c3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_b76bb7e8-9cb8-4a8b-b461-4a4938c19c9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_fe553ff9-2459-406c-b0bc-2054dc8be043" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_ce2084bf-e7f8-4e71-ace3-32c0a4f095c3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_fe553ff9-2459-406c-b0bc-2054dc8be043" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://carismatx.com/role/PrepaidExpensesandOtherAssetsDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#PrepaidExpensesandOtherAssetsDetails"/>
  <link:calculationLink xlink:role="http://carismatx.com/role/PrepaidExpensesandOtherAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d7cc48a9-b2da-4569-9ee5-6fd2dd6bfe38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_5a8a1ffe-2cae-4263-9cef-456667e50ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d7cc48a9-b2da-4569-9ee5-6fd2dd6bfe38" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_5a8a1ffe-2cae-4263-9cef-456667e50ba2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_PrepaidResearchAndDevelopmentCurrent_5645ccb5-cfab-49c2-96fd-e103c7718763" xlink:href="carm-20241231.xsd#carm_PrepaidResearchAndDevelopmentCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d7cc48a9-b2da-4569-9ee5-6fd2dd6bfe38" xlink:to="loc_carm_PrepaidResearchAndDevelopmentCurrent_5645ccb5-cfab-49c2-96fd-e103c7718763" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ReceivableDueFromCollaborativeArrangementCurrent_5122b4f1-9933-4356-8ddc-da123b8486fe" xlink:href="carm-20241231.xsd#carm_ReceivableDueFromCollaborativeArrangementCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d7cc48a9-b2da-4569-9ee5-6fd2dd6bfe38" xlink:to="loc_carm_ReceivableDueFromCollaborativeArrangementCurrent_5122b4f1-9933-4356-8ddc-da123b8486fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsCurrent_80c16abf-315d-4a61-b03e-3c60afed83a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d7cc48a9-b2da-4569-9ee5-6fd2dd6bfe38" xlink:to="loc_us-gaap_DepositsAssetsCurrent_80c16abf-315d-4a61-b03e-3c60afed83a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_8a189de0-17f8-41be-834d-814eb1d091f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d7cc48a9-b2da-4569-9ee5-6fd2dd6bfe38" xlink:to="loc_us-gaap_PrepaidInsurance_8a189de0-17f8-41be-834d-814eb1d091f2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://carismatx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://carismatx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_eb4a417f-91a2-48f9-a021-9ef3a4e2934c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_faf88162-a422-40af-a1ac-a8286b3f1eac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_eb4a417f-91a2-48f9-a021-9ef3a4e2934c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_faf88162-a422-40af-a1ac-a8286b3f1eac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_0f5ae3d7-c869-4d2b-b8b8-cd833577e88e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_eb4a417f-91a2-48f9-a021-9ef3a4e2934c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_0f5ae3d7-c869-4d2b-b8b8-cd833577e88e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://carismatx.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#AccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://carismatx.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4e37e4df-722b-4d39-b965-d106bad96542" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_3f98c300-f2cb-4ed4-9817-e7701006d4fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4e37e4df-722b-4d39-b965-d106bad96542" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_3f98c300-f2cb-4ed4-9817-e7701006d4fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_bc23b0cd-346a-4055-8fa5-71d75130bfe4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4e37e4df-722b-4d39-b965-d106bad96542" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_bc23b0cd-346a-4055-8fa5-71d75130bfe4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AccruedResearchAndDevelopmentExpenseCurrent_bfad06c4-8770-42e8-b114-0913a78c5c63" xlink:href="carm-20241231.xsd#carm_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4e37e4df-722b-4d39-b965-d106bad96542" xlink:to="loc_carm_AccruedResearchAndDevelopmentExpenseCurrent_bfad06c4-8770-42e8-b114-0913a78c5c63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e081afee-8847-48e4-971d-01c6f3549126" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4e37e4df-722b-4d39-b965-d106bad96542" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e081afee-8847-48e4-971d-01c6f3549126" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#CommitmentsandContingenciesScheduleofLeaseCostsDetails"/>
  <link:calculationLink xlink:role="http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_57f11979-8ee5-4ae4-b882-49b4e53f4fad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_a0ae9738-0137-4719-8c5f-04cc197bd80e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_57f11979-8ee5-4ae4-b882-49b4e53f4fad" xlink:to="loc_us-gaap_VariableLeaseCost_a0ae9738-0137-4719-8c5f-04cc197bd80e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_FinanceLeaseCost_99937517-7455-422a-b473-99890d15a9f2" xlink:href="carm-20241231.xsd#carm_FinanceLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_57f11979-8ee5-4ae4-b882-49b4e53f4fad" xlink:to="loc_carm_FinanceLeaseCost_99937517-7455-422a-b473-99890d15a9f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_d3eb405e-eff6-4cbe-8a0e-760475ea7715" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_57f11979-8ee5-4ae4-b882-49b4e53f4fad" xlink:to="loc_us-gaap_OperatingLeaseCost_d3eb405e-eff6-4cbe-8a0e-760475ea7715" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_3d4fcb3a-f6f5-4841-971f-9af8642293bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_57f11979-8ee5-4ae4-b882-49b4e53f4fad" xlink:to="loc_us-gaap_ShortTermLeaseCost_3d4fcb3a-f6f5-4841-971f-9af8642293bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_FinanceLeaseCost_a075d77d-2d35-4136-9356-1eeeac7fa493" xlink:href="carm-20241231.xsd#carm_FinanceLeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_2b760394-de47-4be4-8cd5-f6475027b1fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_carm_FinanceLeaseCost_a075d77d-2d35-4136-9356-1eeeac7fa493" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_2b760394-de47-4be4-8cd5-f6475027b1fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_91a8abbb-57aa-4b51-a757-d28a1ab92488" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_carm_FinanceLeaseCost_a075d77d-2d35-4136-9356-1eeeac7fa493" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_91a8abbb-57aa-4b51-a757-d28a1ab92488" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_575c0cc0-a4c1-48ff-9e1a-fffbf44ea103" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_f3fc8a09-6173-4a61-b17a-dc3ee9ae9ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_575c0cc0-a4c1-48ff-9e1a-fffbf44ea103" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_f3fc8a09-6173-4a61-b17a-dc3ee9ae9ae1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_7b798bb4-7895-4652-aed0-17f3b52fa7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_575c0cc0-a4c1-48ff-9e1a-fffbf44ea103" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_7b798bb4-7895-4652-aed0-17f3b52fa7cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_904a39b5-ee18-4f6f-abc2-a167038eabbb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_575c0cc0-a4c1-48ff-9e1a-fffbf44ea103" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_904a39b5-ee18-4f6f-abc2-a167038eabbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_4a433d70-de0f-4fe3-aa8f-bf739108bbd7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_575c0cc0-a4c1-48ff-9e1a-fffbf44ea103" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_4a433d70-de0f-4fe3-aa8f-bf739108bbd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_5488959b-f77b-4938-95a4-64609fbcc5d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_575c0cc0-a4c1-48ff-9e1a-fffbf44ea103" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_5488959b-f77b-4938-95a4-64609fbcc5d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_f79108da-bba6-40e7-8a08-877008fab275" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_575c0cc0-a4c1-48ff-9e1a-fffbf44ea103" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_f79108da-bba6-40e7-8a08-877008fab275" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b47f24b0-27d5-48d8-9ecc-92ffddace65a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_411f534e-c57d-4d73-bb4a-a093de081527" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b47f24b0-27d5-48d8-9ecc-92ffddace65a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_411f534e-c57d-4d73-bb4a-a093de081527" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f4c5b2c9-967d-45e1-903c-fb7f7daa7bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b47f24b0-27d5-48d8-9ecc-92ffddace65a" xlink:to="loc_us-gaap_OperatingLeaseLiability_f4c5b2c9-967d-45e1-903c-fb7f7daa7bdc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="carm-20241231.xsd#CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_f829c429-5398-4aa5-b065-e002f515d502" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_c9a1ab7b-7239-47b7-8f8f-261938f10598" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_f829c429-5398-4aa5-b065-e002f515d502" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_c9a1ab7b-7239-47b7-8f8f-261938f10598" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_d8ce5589-debe-47b9-a758-1a836b01b261" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_f829c429-5398-4aa5-b065-e002f515d502" xlink:to="loc_us-gaap_FinanceLeaseLiability_d8ce5589-debe-47b9-a758-1a836b01b261" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e021098f-0c72-4718-ba4f-ccbb9f4b04e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0e8e7c7e-c8aa-4458-9774-b8b8d14e264d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e021098f-0c72-4718-ba4f-ccbb9f4b04e2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0e8e7c7e-c8aa-4458-9774-b8b8d14e264d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_fcbc0b60-e6bf-4939-949f-12a3db58530b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e021098f-0c72-4718-ba4f-ccbb9f4b04e2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_fcbc0b60-e6bf-4939-949f-12a3db58530b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_10f9e33d-9637-4640-a7cf-ab299bee5312" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e021098f-0c72-4718-ba4f-ccbb9f4b04e2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_10f9e33d-9637-4640-a7cf-ab299bee5312" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_74f14650-948f-489b-b7f7-8b871354c2a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e021098f-0c72-4718-ba4f-ccbb9f4b04e2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_74f14650-948f-489b-b7f7-8b871354c2a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e27e5e37-035b-469e-9dfd-11651a5e6747" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e021098f-0c72-4718-ba4f-ccbb9f4b04e2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e27e5e37-035b-469e-9dfd-11651a5e6747" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1a44e055-02d2-4492-8549-aebf30441ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e021098f-0c72-4718-ba4f-ccbb9f4b04e2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1a44e055-02d2-4492-8549-aebf30441ec9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://carismatx.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:calculationLink xlink:role="http://carismatx.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_59570277-7da6-4f00-ac1d-d626a354defb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_10b4b5c7-bebd-4717-9a8e-14e26c1302dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_59570277-7da6-4f00-ac1d-d626a354defb" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_10b4b5c7-bebd-4717-9a8e-14e26c1302dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_19331157-cef9-4295-9492-773b49e00baf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_59570277-7da6-4f00-ac1d-d626a354defb" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_19331157-cef9-4295-9492-773b49e00baf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9fc641e3-0b82-4491-b8da-a708c39285c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_59570277-7da6-4f00-ac1d-d626a354defb" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9fc641e3-0b82-4491-b8da-a708c39285c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences_4af04629-17e6-4377-9145-ec17585fa7f3" xlink:href="carm-20241231.xsd#carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_59570277-7da6-4f00-ac1d-d626a354defb" xlink:to="loc_carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences_4af04629-17e6-4377-9145-ec17585fa7f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_117bdf51-ea40-4f5f-8ae3-ef4bdf2f9882" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_59570277-7da6-4f00-ac1d-d626a354defb" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_117bdf51-ea40-4f5f-8ae3-ef4bdf2f9882" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal_27c07c94-cbd1-469d-b594-77b5aed59d21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_59570277-7da6-4f00-ac1d-d626a354defb" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal_27c07c94-cbd1-469d-b594-77b5aed59d21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_17a066d8-c35c-474d-9919-f502c5dbac16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_59570277-7da6-4f00-ac1d-d626a354defb" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_17a066d8-c35c-474d-9919-f502c5dbac16" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_eea7ca16-8d86-453f-8fba-b1d8d8164876" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1e33b462-91f2-4c60-9ddd-5ab0d6884df1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_eea7ca16-8d86-453f-8fba-b1d8d8164876" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1e33b462-91f2-4c60-9ddd-5ab0d6884df1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_288d0ab9-12ff-48dc-92ac-1ea8a6ad4b09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_eea7ca16-8d86-453f-8fba-b1d8d8164876" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_288d0ab9-12ff-48dc-92ac-1ea8a6ad4b09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_f8e39289-698d-42c8-a13e-a6dd61343dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_4e6b291f-4bda-46d3-8f23-ce040f3904eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_f8e39289-698d-42c8-a13e-a6dd61343dfe" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_4e6b291f-4bda-46d3-8f23-ce040f3904eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DeferredTaxLiabilitiesRightOfUseAsset_a31bfd70-a6fb-4323-81ee-90f6f6e958be" xlink:href="carm-20241231.xsd#carm_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_f8e39289-698d-42c8-a13e-a6dd61343dfe" xlink:to="loc_carm_DeferredTaxLiabilitiesRightOfUseAsset_a31bfd70-a6fb-4323-81ee-90f6f6e958be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_e5735eca-74e5-4861-b53c-82353f9f2e87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DeferredTaxAssetsStartUpCosts_f56e980b-6d3a-465a-b123-54c91b3b0b14" xlink:href="carm-20241231.xsd#carm_DeferredTaxAssetsStartUpCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e5735eca-74e5-4861-b53c-82353f9f2e87" xlink:to="loc_carm_DeferredTaxAssetsStartUpCosts_f56e980b-6d3a-465a-b123-54c91b3b0b14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_ac9a8884-fb00-49a5-8f57-e394bdb671db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e5735eca-74e5-4861-b53c-82353f9f2e87" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_ac9a8884-fb00-49a5-8f57-e394bdb671db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_bd8ccb2e-1600-45a3-9f4a-8eba547e3ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e5735eca-74e5-4861-b53c-82353f9f2e87" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_bd8ccb2e-1600-45a3-9f4a-8eba547e3ce4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization_79642b9f-f38f-4ca7-8c7c-e8dc7d7dfd90" xlink:href="carm-20241231.xsd#carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e5735eca-74e5-4861-b53c-82353f9f2e87" xlink:to="loc_carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization_79642b9f-f38f-4ca7-8c7c-e8dc7d7dfd90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DeferredTaxAssetsEquityCompensation_1a56c62e-d3e7-41aa-92dc-ac34da6d979d" xlink:href="carm-20241231.xsd#carm_DeferredTaxAssetsEquityCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e5735eca-74e5-4861-b53c-82353f9f2e87" xlink:to="loc_carm_DeferredTaxAssetsEquityCompensation_1a56c62e-d3e7-41aa-92dc-ac34da6d979d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DeferredTaxAssetsAmortizableAssetsAndOther_449353fb-1998-41ed-b8e8-a00747d65458" xlink:href="carm-20241231.xsd#carm_DeferredTaxAssetsAmortizableAssetsAndOther"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e5735eca-74e5-4861-b53c-82353f9f2e87" xlink:to="loc_carm_DeferredTaxAssetsAmortizableAssetsAndOther_449353fb-1998-41ed-b8e8-a00747d65458" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DeferredTaxAssetsLeaseLiability_f2ddb139-4b44-4f31-b46b-429dd717af85" xlink:href="carm-20241231.xsd#carm_DeferredTaxAssetsLeaseLiability"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e5735eca-74e5-4861-b53c-82353f9f2e87" xlink:to="loc_carm_DeferredTaxAssetsLeaseLiability_f2ddb139-4b44-4f31-b46b-429dd717af85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_ddb327f2-cd05-4f55-aa81-1610ba449c99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e5735eca-74e5-4861-b53c-82353f9f2e87" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_ddb327f2-cd05-4f55-aa81-1610ba449c99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_c6119e6e-d201-49ab-874b-e24656d62c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e5735eca-74e5-4861-b53c-82353f9f2e87" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_c6119e6e-d201-49ab-874b-e24656d62c4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_787ff921-351c-4052-a2b1-f404e71501d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_b8d86e80-4947-45d9-8d10-036da8508692" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_787ff921-351c-4052-a2b1-f404e71501d6" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_b8d86e80-4947-45d9-8d10-036da8508692" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_20222341-f0cf-4e7e-a7e8-7fa0d7160c17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_787ff921-351c-4052-a2b1-f404e71501d6" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_20222341-f0cf-4e7e-a7e8-7fa0d7160c17" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://carismatx.com/role/ModernaCollaborationandLicenseAgreementScheduleofEstimatedRevenueExpectedtobeRecognizedinTheFutureRelatedtoPerformanceObligationsDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#ModernaCollaborationandLicenseAgreementScheduleofEstimatedRevenueExpectedtobeRecognizedinTheFutureRelatedtoPerformanceObligationsDetails"/>
  <link:calculationLink xlink:role="http://carismatx.com/role/ModernaCollaborationandLicenseAgreementScheduleofEstimatedRevenueExpectedtobeRecognizedinTheFutureRelatedtoPerformanceObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_f657fb5a-5c35-4e9c-b2bc-c03a0312dd7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_RevenueRemainingPerformanceObligationOptionRightsAmount_812ebd97-ea6e-416f-bb55-3d7da2352fdf" xlink:href="carm-20241231.xsd#carm_RevenueRemainingPerformanceObligationOptionRightsAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation_f657fb5a-5c35-4e9c-b2bc-c03a0312dd7f" xlink:to="loc_carm_RevenueRemainingPerformanceObligationOptionRightsAmount_812ebd97-ea6e-416f-bb55-3d7da2352fdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount_d020b450-3136-4445-81f6-d60cd3286a2c" xlink:href="carm-20241231.xsd#carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation_f657fb5a-5c35-4e9c-b2bc-c03a0312dd7f" xlink:to="loc_carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount_d020b450-3136-4445-81f6-d60cd3286a2c" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>15
<FILENAME>carm-20241231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:1dec34d0-de78-478e-a130-81bf7fce6e30,g:762837ba-4cc2-4d5a-8343-3052f0231779-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity" xlink:type="simple" xlink:href="carm-20241231.xsd#ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"/>
  <link:definitionLink xlink:role="http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8cbe27f4-cdc0-40c0-8d92-5c98b3ea43eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_41601b7e-5934-4625-81df-48033a9d1d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_8cbe27f4-cdc0-40c0-8d92-5c98b3ea43eb" xlink:to="loc_us-gaap_StatementTable_41601b7e-5934-4625-81df-48033a9d1d1b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1c2fe158-3dd0-4237-9e1a-cd2f6c723d62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_41601b7e-5934-4625-81df-48033a9d1d1b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1c2fe158-3dd0-4237-9e1a-cd2f6c723d62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1c2fe158-3dd0-4237-9e1a-cd2f6c723d62_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1c2fe158-3dd0-4237-9e1a-cd2f6c723d62" xlink:to="loc_us-gaap_EquityComponentDomain_1c2fe158-3dd0-4237-9e1a-cd2f6c723d62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_94930cba-7d08-4976-86a4-64c028dfedbd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1c2fe158-3dd0-4237-9e1a-cd2f6c723d62" xlink:to="loc_us-gaap_EquityComponentDomain_94930cba-7d08-4976-86a4-64c028dfedbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_65e445b7-19d4-44ca-bb5e-dbbadaf42efd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_94930cba-7d08-4976-86a4-64c028dfedbd" xlink:to="loc_us-gaap_CommonStockMember_65e445b7-19d4-44ca-bb5e-dbbadaf42efd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_257edca9-e155-4601-9bb9-2b0355063d55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_94930cba-7d08-4976-86a4-64c028dfedbd" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_257edca9-e155-4601-9bb9-2b0355063d55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4c12ceb7-ea31-47f5-b00e-6ddd5a1909de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_94930cba-7d08-4976-86a4-64c028dfedbd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4c12ceb7-ea31-47f5-b00e-6ddd5a1909de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_af202bdc-9a0a-44c2-89b4-b26215b5a674" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_94930cba-7d08-4976-86a4-64c028dfedbd" xlink:to="loc_us-gaap_RetainedEarningsMember_af202bdc-9a0a-44c2-89b4-b26215b5a674" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_8b82ba48-982f-4cf6-8187-f8d8c7326c82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_94930cba-7d08-4976-86a4-64c028dfedbd" xlink:to="loc_us-gaap_NoncontrollingInterestMember_8b82ba48-982f-4cf6-8187-f8d8c7326c82" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_32ee9fff-61b7-4516-be0d-9be9d1d2fa1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8cbe27f4-cdc0-40c0-8d92-5c98b3ea43eb" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_32ee9fff-61b7-4516-be0d-9be9d1d2fa1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_d9fac99a-693b-466a-b999-7b46620b42f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_32ee9fff-61b7-4516-be0d-9be9d1d2fa1b" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_d9fac99a-693b-466a-b999-7b46620b42f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_202d230c-e9b7-470a-9641-ccd62f6e6217" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_32ee9fff-61b7-4516-be0d-9be9d1d2fa1b" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_202d230c-e9b7-470a-9641-ccd62f6e6217" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ReclassificationsOfTemporaryToPermanentEquityShares_5b69cf1e-6642-44b8-a039-393ee722b8c8" xlink:href="carm-20241231.xsd#carm_ReclassificationsOfTemporaryToPermanentEquityShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_32ee9fff-61b7-4516-be0d-9be9d1d2fa1b" xlink:to="loc_carm_ReclassificationsOfTemporaryToPermanentEquityShares_5b69cf1e-6642-44b8-a039-393ee722b8c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_ce3bd4a6-083f-48c9-97df-6970ae68e206" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_32ee9fff-61b7-4516-be0d-9be9d1d2fa1b" xlink:to="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_ce3bd4a6-083f-48c9-97df-6970ae68e206" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_e3d8971f-4dfa-42ae-a59b-6fffea580d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_21df95b1-db54-4f06-9f20-547fe89b068f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_340d78da-0560-4daa-a767-04921b9f291d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8cbe27f4-cdc0-40c0-8d92-5c98b3ea43eb" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_340d78da-0560-4daa-a767-04921b9f291d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_5f450143-0dd8-4674-9120-8b095d17aaf9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_340d78da-0560-4daa-a767-04921b9f291d" xlink:to="loc_us-gaap_SharesIssued_5f450143-0dd8-4674-9120-8b095d17aaf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_aa7fdc3e-ec42-4e19-b180-9bde0cb8bebf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_340d78da-0560-4daa-a767-04921b9f291d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_aa7fdc3e-ec42-4e19-b180-9bde0cb8bebf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_deebe50c-9ae6-40b9-a5a1-af0db218a57e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_340d78da-0560-4daa-a767-04921b9f291d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_deebe50c-9ae6-40b9-a5a1-af0db218a57e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_65df0b93-1470-4fd8-88ed-bbe23ffd4d52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_340d78da-0560-4daa-a767-04921b9f291d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_65df0b93-1470-4fd8-88ed-bbe23ffd4d52" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_07aff1f8-95d2-4d81-bd17-c26ee2fe5d61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_340d78da-0560-4daa-a767-04921b9f291d" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_07aff1f8-95d2-4d81-bd17-c26ee2fe5d61" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_434e16a2-b653-4ba1-a11b-62c1d8dab427" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_340d78da-0560-4daa-a767-04921b9f291d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_434e16a2-b653-4ba1-a11b-62c1d8dab427" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_47bc7a91-d7db-46bf-a2fe-d3c5a20e7ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_340d78da-0560-4daa-a767-04921b9f291d" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_47bc7a91-d7db-46bf-a2fe-d3c5a20e7ba7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction_703cafb3-1077-45d5-8266-5fe5defbd13d" xlink:href="carm-20241231.xsd#carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_340d78da-0560-4daa-a767-04921b9f291d" xlink:to="loc_carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction_703cafb3-1077-45d5-8266-5fe5defbd13d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction_b4464df1-7403-4346-8d59-af978f306706" xlink:href="carm-20241231.xsd#carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_340d78da-0560-4daa-a767-04921b9f291d" xlink:to="loc_carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction_b4464df1-7403-4346-8d59-af978f306706" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_eeb71094-800c-4c68-b346-33c649af4e13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_340d78da-0560-4daa-a767-04921b9f291d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_eeb71094-800c-4c68-b346-33c649af4e13" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_f0ed2ebe-49a3-426a-b97d-600380b4845d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_340d78da-0560-4daa-a767-04921b9f291d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_f0ed2ebe-49a3-426a-b97d-600380b4845d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_abd86d17-e671-4e68-9e46-1a071c368fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_340d78da-0560-4daa-a767-04921b9f291d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_abd86d17-e671-4e68-9e46-1a071c368fe0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_b133f91b-c7b5-4541-86b7-42b4beca9d35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_340d78da-0560-4daa-a767-04921b9f291d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_b133f91b-c7b5-4541-86b7-42b4beca9d35" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger_cbcdf767-6116-4ce9-844c-5d87db1c1d09" xlink:href="carm-20241231.xsd#carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_340d78da-0560-4daa-a767-04921b9f291d" xlink:to="loc_carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger_cbcdf767-6116-4ce9-844c-5d87db1c1d09" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger_bdb6d7f4-85aa-43fc-8dbf-ea323d810bc8" xlink:href="carm-20241231.xsd#carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_340d78da-0560-4daa-a767-04921b9f291d" xlink:to="loc_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger_bdb6d7f4-85aa-43fc-8dbf-ea323d810bc8" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d8522552-3c21-449c-8d30-91fcf342d288" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_340d78da-0560-4daa-a767-04921b9f291d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d8522552-3c21-449c-8d30-91fcf342d288" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7bdc9b90-ff88-40a4-b5eb-1567e0bdf16a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_340d78da-0560-4daa-a767-04921b9f291d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7bdc9b90-ff88-40a4-b5eb-1567e0bdf16a" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cab1cc29-c6b7-484e-8bdc-5fd1b4b906a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_340d78da-0560-4daa-a767-04921b9f291d" xlink:to="loc_us-gaap_NetIncomeLoss_cab1cc29-c6b7-484e-8bdc-5fd1b4b906a2" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_e36c5e29-eb82-4696-8796-848b429e3571" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e6693d03-a51a-4b10-a88c-58751b942ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://carismatx.com/role/BackgroundDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#BackgroundDetails"/>
  <link:definitionLink xlink:role="http://carismatx.com/role/BackgroundDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_ceb54b29-c6e3-416b-a632-33b958c8b73e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationSegmentAllocationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_34d4825f-9e34-4019-86cc-589037593193" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_ceb54b29-c6e3-416b-a632-33b958c8b73e" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_34d4825f-9e34-4019-86cc-589037593193" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_99e0390e-8101-4b02-b154-22e0901eb008" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_34d4825f-9e34-4019-86cc-589037593193" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_99e0390e-8101-4b02-b154-22e0901eb008" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_99e0390e-8101-4b02-b154-22e0901eb008_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_99e0390e-8101-4b02-b154-22e0901eb008" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_99e0390e-8101-4b02-b154-22e0901eb008_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_11b26c3a-3ba1-40b8-ab35-374f787b4978" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_99e0390e-8101-4b02-b154-22e0901eb008" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_11b26c3a-3ba1-40b8-ab35-374f787b4978" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_34ca35a8-d70b-4b09-b83b-5f4382d3ca3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_11b26c3a-3ba1-40b8-ab35-374f787b4978" xlink:to="loc_us-gaap_EmployeeSeveranceMember_34ca35a8-d70b-4b09-b83b-5f4382d3ca3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2c131f4b-7a2c-41aa-bf08-a4922c7c0a80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_34d4825f-9e34-4019-86cc-589037593193" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2c131f4b-7a2c-41aa-bf08-a4922c7c0a80" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2c131f4b-7a2c-41aa-bf08-a4922c7c0a80_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2c131f4b-7a2c-41aa-bf08-a4922c7c0a80" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2c131f4b-7a2c-41aa-bf08-a4922c7c0a80_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c29c836e-6177-4edc-9c10-2ee6aeae7440" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2c131f4b-7a2c-41aa-bf08-a4922c7c0a80" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c29c836e-6177-4edc-9c10-2ee6aeae7440" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_890c44df-89c2-4bc7-8059-bda12e86ff03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c29c836e-6177-4edc-9c10-2ee6aeae7440" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_890c44df-89c2-4bc7-8059-bda12e86ff03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_361e3d3d-12af-441c-9263-6a6cf1296d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c29c836e-6177-4edc-9c10-2ee6aeae7440" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_361e3d3d-12af-441c-9263-6a6cf1296d2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_b2f54b43-3f5a-443e-84c2-d87cd09375e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_ceb54b29-c6e3-416b-a632-33b958c8b73e" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_b2f54b43-3f5a-443e-84c2-d87cd09375e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_501c0ec8-076c-49b9-8bfd-8e9c303ec2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_ceb54b29-c6e3-416b-a632-33b958c8b73e" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_501c0ec8-076c-49b9-8bfd-8e9c303ec2a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_b20de058-5961-46c5-9d26-9bbc7e95794a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_ceb54b29-c6e3-416b-a632-33b958c8b73e" xlink:to="loc_us-gaap_RestructuringCharges_b20de058-5961-46c5-9d26-9bbc7e95794a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_f0fff15d-2cdd-463e-ab11-ad1a7de143d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCharges_b20de058-5961-46c5-9d26-9bbc7e95794a" xlink:to="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_f0fff15d-2cdd-463e-ab11-ad1a7de143d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_beb75f5b-9523-44bc-b7be-cea0579a1202" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_ceb54b29-c6e3-416b-a632-33b958c8b73e" xlink:to="loc_us-gaap_RestructuringReserve_beb75f5b-9523-44bc-b7be-cea0579a1202" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsMeasuredonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf2bb7e8-6f57-4f61-9535-5d6fba6f205c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_868228f5-a5d5-47a0-bdd9-6efdcfb39374" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf2bb7e8-6f57-4f61-9535-5d6fba6f205c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_868228f5-a5d5-47a0-bdd9-6efdcfb39374" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_444f646d-6fe7-4f09-88c0-c33326af937a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_868228f5-a5d5-47a0-bdd9-6efdcfb39374" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_444f646d-6fe7-4f09-88c0-c33326af937a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_444f646d-6fe7-4f09-88c0-c33326af937a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_444f646d-6fe7-4f09-88c0-c33326af937a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_444f646d-6fe7-4f09-88c0-c33326af937a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_398777b6-1c4c-459e-802f-9b5853961369" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_444f646d-6fe7-4f09-88c0-c33326af937a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_398777b6-1c4c-459e-802f-9b5853961369" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_269cea04-494b-4646-b44c-ada9614c5b38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_398777b6-1c4c-459e-802f-9b5853961369" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_269cea04-494b-4646-b44c-ada9614c5b38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_aaec4540-0e57-4508-acfb-53841a07a713" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_868228f5-a5d5-47a0-bdd9-6efdcfb39374" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_aaec4540-0e57-4508-acfb-53841a07a713" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_aaec4540-0e57-4508-acfb-53841a07a713_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_aaec4540-0e57-4508-acfb-53841a07a713" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_aaec4540-0e57-4508-acfb-53841a07a713_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c73a1d12-dc80-4979-83d1-8dc13bbc20f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_aaec4540-0e57-4508-acfb-53841a07a713" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c73a1d12-dc80-4979-83d1-8dc13bbc20f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_660a838d-2467-43cd-9a56-bdf58c168576" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c73a1d12-dc80-4979-83d1-8dc13bbc20f4" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_660a838d-2467-43cd-9a56-bdf58c168576" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_142c482a-d26f-4ef6-8db3-410518c890e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c73a1d12-dc80-4979-83d1-8dc13bbc20f4" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_142c482a-d26f-4ef6-8db3-410518c890e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_fdab007d-bcad-46a4-9d61-2f6ce1ce130e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c73a1d12-dc80-4979-83d1-8dc13bbc20f4" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_fdab007d-bcad-46a4-9d61-2f6ce1ce130e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_2c5af930-d595-48cc-af70-7c02bb237fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf2bb7e8-6f57-4f61-9535-5d6fba6f205c" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_2c5af930-d595-48cc-af70-7c02bb237fa1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c0bad2a5-3213-4ac5-bcad-43cea40cdda9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_2c5af930-d595-48cc-af70-7c02bb237fa1" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c0bad2a5-3213-4ac5-bcad-43cea40cdda9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_17768fca-6f74-4704-a5da-d82d0d19d5b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_98416266-d2fb-40ac-b8a1-5fea19c3b112" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_17768fca-6f74-4704-a5da-d82d0d19d5b1" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_98416266-d2fb-40ac-b8a1-5fea19c3b112" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_70a37896-2386-4045-b487-49e2fc9663ea" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_98416266-d2fb-40ac-b8a1-5fea19c3b112" xlink:to="loc_srt_RangeAxis_70a37896-2386-4045-b487-49e2fc9663ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_70a37896-2386-4045-b487-49e2fc9663ea_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_70a37896-2386-4045-b487-49e2fc9663ea" xlink:to="loc_srt_RangeMember_70a37896-2386-4045-b487-49e2fc9663ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fd2ceff3-4220-4198-b704-9c7cd8ced2ab" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_70a37896-2386-4045-b487-49e2fc9663ea" xlink:to="loc_srt_RangeMember_fd2ceff3-4220-4198-b704-9c7cd8ced2ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c5ac7d63-7112-40bf-99a1-6407e5b7378e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fd2ceff3-4220-4198-b704-9c7cd8ced2ab" xlink:to="loc_srt_MinimumMember_c5ac7d63-7112-40bf-99a1-6407e5b7378e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_58e1120b-c23a-4588-8b6b-495588377083" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fd2ceff3-4220-4198-b704-9c7cd8ced2ab" xlink:to="loc_srt_MaximumMember_58e1120b-c23a-4588-8b6b-495588377083" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_f1c42455-d542-4866-865b-be649041b0b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_17768fca-6f74-4704-a5da-d82d0d19d5b1" xlink:to="loc_us-gaap_NumberOfOperatingSegments_f1c42455-d542-4866-865b-be649041b0b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_65e4fbb5-8312-4684-b59e-60580573f60d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_17768fca-6f74-4704-a5da-d82d0d19d5b1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_65e4fbb5-8312-4684-b59e-60580573f60d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_ac8c9f71-bde9-471b-80dd-08e5c729ba3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_17768fca-6f74-4704-a5da-d82d0d19d5b1" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_ac8c9f71-bde9-471b-80dd-08e5c729ba3b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofSignificantExpenseCategoriesbySegmentDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#SummaryofSignificantAccountingPoliciesScheduleofSignificantExpenseCategoriesbySegmentDetails"/>
  <link:definitionLink xlink:role="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofSignificantExpenseCategoriesbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_51597a67-8a7b-4c43-86b8-f55b6e85cc8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_98410630-0f38-4c3b-9650-40c71008537a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_51597a67-8a7b-4c43-86b8-f55b6e85cc8f" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_98410630-0f38-4c3b-9650-40c71008537a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_42248d94-a037-40a0-af20-6bfd78dc5874" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_98410630-0f38-4c3b-9650-40c71008537a" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_42248d94-a037-40a0-af20-6bfd78dc5874" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_42248d94-a037-40a0-af20-6bfd78dc5874_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_42248d94-a037-40a0-af20-6bfd78dc5874" xlink:to="loc_us-gaap_SegmentDomain_42248d94-a037-40a0-af20-6bfd78dc5874_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1bbf4d7c-e4ec-4d19-ac7c-87c0edcdcd06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_42248d94-a037-40a0-af20-6bfd78dc5874" xlink:to="loc_us-gaap_SegmentDomain_1bbf4d7c-e4ec-4d19-ac7c-87c0edcdcd06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ReportingSegmentMember_792afa3e-8a59-41e4-b88e-627108ca27ab" xlink:href="carm-20241231.xsd#carm_ReportingSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1bbf4d7c-e4ec-4d19-ac7c-87c0edcdcd06" xlink:to="loc_carm_ReportingSegmentMember_792afa3e-8a59-41e4-b88e-627108ca27ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_8eb88a62-e4ac-4f83-9e63-0cfb93858463" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_51597a67-8a7b-4c43-86b8-f55b6e85cc8f" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_8eb88a62-e4ac-4f83-9e63-0cfb93858463" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationAdditionalInformationAbstract_37ea93e6-28b7-45ac-b615-7f07eb0d2cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationAdditionalInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_51597a67-8a7b-4c43-86b8-f55b6e85cc8f" xlink:to="loc_us-gaap_SegmentReportingInformationAdditionalInformationAbstract_37ea93e6-28b7-45ac-b615-7f07eb0d2cf1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses_8d7c5bf8-8afa-4cad-bfbc-d6cbf622d53a" xlink:href="carm-20241231.xsd#carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationAdditionalInformationAbstract_37ea93e6-28b7-45ac-b615-7f07eb0d2cf1" xlink:to="loc_carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses_8d7c5bf8-8afa-4cad-bfbc-d6cbf622d53a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses_6ad543a2-8ef6-4c5f-ba06-a088bf8ba799" xlink:href="carm-20241231.xsd#carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationAdditionalInformationAbstract_37ea93e6-28b7-45ac-b615-7f07eb0d2cf1" xlink:to="loc_carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses_6ad543a2-8ef6-4c5f-ba06-a088bf8ba799" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_FacilitiesExpense_d7c7228b-d9b4-4769-bc60-e1c9eccd5ef5" xlink:href="carm-20241231.xsd#carm_FacilitiesExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationAdditionalInformationAbstract_37ea93e6-28b7-45ac-b615-7f07eb0d2cf1" xlink:to="loc_carm_FacilitiesExpense_d7c7228b-d9b4-4769-bc60-e1c9eccd5ef5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_c10f7a2e-58b2-496c-a2ec-63a0f6a8da61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationAdditionalInformationAbstract_37ea93e6-28b7-45ac-b615-7f07eb0d2cf1" xlink:to="loc_us-gaap_LaborAndRelatedExpense_c10f7a2e-58b2-496c-a2ec-63a0f6a8da61" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities_ac88773a-3594-47f9-91be-5612ae9944db" xlink:href="carm-20241231.xsd#carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationAdditionalInformationAbstract_37ea93e6-28b7-45ac-b615-7f07eb0d2cf1" xlink:to="loc_carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities_ac88773a-3594-47f9-91be-5612ae9944db" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_ca01220d-b511-4843-b97d-5fea23f6b136" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationAdditionalInformationAbstract_37ea93e6-28b7-45ac-b615-7f07eb0d2cf1" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_ca01220d-b511-4843-b97d-5fea23f6b136" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ff305e02-1209-4e61-91c8-b3027062d44b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_51597a67-8a7b-4c43-86b8-f55b6e85cc8f" xlink:to="loc_us-gaap_NetIncomeLoss_ff305e02-1209-4e61-91c8-b3027062d44b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofDilutiveSecuritiesDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#SummaryofSignificantAccountingPoliciesScheduleofDilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofDilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3facfb1c-af12-4aae-a16a-00e758a51651" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_561b85d0-51f9-4841-a730-d5f9bdef1f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3facfb1c-af12-4aae-a16a-00e758a51651" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_561b85d0-51f9-4841-a730-d5f9bdef1f2c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_eecabe1e-2a64-4847-8c34-37850ba11317" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_561b85d0-51f9-4841-a730-d5f9bdef1f2c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_eecabe1e-2a64-4847-8c34-37850ba11317" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_eecabe1e-2a64-4847-8c34-37850ba11317_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_eecabe1e-2a64-4847-8c34-37850ba11317" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_eecabe1e-2a64-4847-8c34-37850ba11317_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1be956a4-2d55-4569-a3c2-ba5fdc90768d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_eecabe1e-2a64-4847-8c34-37850ba11317" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1be956a4-2d55-4569-a3c2-ba5fdc90768d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_615e3c35-b57d-49b5-a12c-324e8642639d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1be956a4-2d55-4569-a3c2-ba5fdc90768d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_615e3c35-b57d-49b5-a12c-324e8642639d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2773a8ff-41da-4df3-9658-f969e17b87ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3facfb1c-af12-4aae-a16a-00e758a51651" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2773a8ff-41da-4df3-9658-f969e17b87ec" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails"/>
  <link:definitionLink xlink:role="http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_e5d3ce1e-9099-4bcf-ab9f-374223ce49b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2f4dbaa5-7faa-4a1b-8e2c-974c40088cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5d3ce1e-9099-4bcf-ab9f-374223ce49b7" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2f4dbaa5-7faa-4a1b-8e2c-974c40088cbb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_85b6bfc6-3a71-4c6a-8e4c-7c57c331f2f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2f4dbaa5-7faa-4a1b-8e2c-974c40088cbb" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_85b6bfc6-3a71-4c6a-8e4c-7c57c331f2f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_85b6bfc6-3a71-4c6a-8e4c-7c57c331f2f3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_85b6bfc6-3a71-4c6a-8e4c-7c57c331f2f3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_85b6bfc6-3a71-4c6a-8e4c-7c57c331f2f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dfbf2feb-329e-4c52-9edd-ded3a5b5f1a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_85b6bfc6-3a71-4c6a-8e4c-7c57c331f2f3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dfbf2feb-329e-4c52-9edd-ded3a5b5f1a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CarismaTherapeuticsIncLegacyStockholdersMember_febbeb79-40c1-4600-abfd-d764c242d5a7" xlink:href="carm-20241231.xsd#carm_CarismaTherapeuticsIncLegacyStockholdersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dfbf2feb-329e-4c52-9edd-ded3a5b5f1a0" xlink:to="loc_carm_CarismaTherapeuticsIncLegacyStockholdersMember_febbeb79-40c1-4600-abfd-d764c242d5a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_a4bd0950-bf14-40f7-9e26-fec8912a9bc4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2f4dbaa5-7faa-4a1b-8e2c-974c40088cbb" xlink:to="loc_dei_LegalEntityAxis_a4bd0950-bf14-40f7-9e26-fec8912a9bc4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a4bd0950-bf14-40f7-9e26-fec8912a9bc4_default" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_a4bd0950-bf14-40f7-9e26-fec8912a9bc4" xlink:to="loc_dei_EntityDomain_a4bd0950-bf14-40f7-9e26-fec8912a9bc4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_8bfdeeb1-21e2-4fcc-b149-eb105ac06346" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_a4bd0950-bf14-40f7-9e26-fec8912a9bc4" xlink:to="loc_dei_EntityDomain_8bfdeeb1-21e2-4fcc-b149-eb105ac06346" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CarismaTherapeuticsInc.Member_ae432bdd-9b32-4d0a-96c9-7e91e41a29c2" xlink:href="carm-20241231.xsd#carm_CarismaTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_8bfdeeb1-21e2-4fcc-b149-eb105ac06346" xlink:to="loc_carm_CarismaTherapeuticsInc.Member_ae432bdd-9b32-4d0a-96c9-7e91e41a29c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_a640f68b-caaf-46d5-8afe-843436492958" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5d3ce1e-9099-4bcf-ab9f-374223ce49b7" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_a640f68b-caaf-46d5-8afe-843436492958" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NumberOfBoardMembers_cf50136c-f088-4121-acfe-7d4b840cc9cb" xlink:href="carm-20241231.xsd#carm_NumberOfBoardMembers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5d3ce1e-9099-4bcf-ab9f-374223ce49b7" xlink:to="loc_carm_NumberOfBoardMembers_cf50136c-f088-4121-acfe-7d4b840cc9cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_357c2051-ef40-4873-80eb-c83756e154a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5d3ce1e-9099-4bcf-ab9f-374223ce49b7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_357c2051-ef40-4873-80eb-c83756e154a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_f2c35b0c-cba5-420f-8788-ab8574bee570" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5d3ce1e-9099-4bcf-ab9f-374223ce49b7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_f2c35b0c-cba5-420f-8788-ab8574bee570" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_bbb2e453-c634-42af-b222-eb0a5a827b07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5d3ce1e-9099-4bcf-ab9f-374223ce49b7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_bbb2e453-c634-42af-b222-eb0a5a827b07" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_892e7cfa-d1eb-4e6b-a4f0-4eec90aedfef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5d3ce1e-9099-4bcf-ab9f-374223ce49b7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_892e7cfa-d1eb-4e6b-a4f0-4eec90aedfef" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash_4c5c11a6-3ab5-42dd-9b84-e8ecd90f131d" xlink:href="carm-20241231.xsd#carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5d3ce1e-9099-4bcf-ab9f-374223ce49b7" xlink:to="loc_carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash_4c5c11a6-3ab5-42dd-9b84-e8ecd90f131d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_ae3b5286-dcc8-4066-b1f7-47917e53be0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5d3ce1e-9099-4bcf-ab9f-374223ce49b7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_ae3b5286-dcc8-4066-b1f7-47917e53be0a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_168b8fc0-4e63-42ca-ac4a-4a87501b6ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5d3ce1e-9099-4bcf-ab9f-374223ce49b7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_168b8fc0-4e63-42ca-ac4a-4a87501b6ca8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_b2ccac5d-69e2-49f8-ae04-185536919ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5d3ce1e-9099-4bcf-ab9f-374223ce49b7" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_b2ccac5d-69e2-49f8-ae04-185536919ae0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_debf8bd0-fc05-4085-a32b-55d0a08244c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5d3ce1e-9099-4bcf-ab9f-374223ce49b7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_debf8bd0-fc05-4085-a32b-55d0a08244c1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_4a2328e6-4c60-47b7-a1af-d2b5fb643840" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5d3ce1e-9099-4bcf-ab9f-374223ce49b7" xlink:to="loc_us-gaap_SeveranceCosts1_4a2328e6-4c60-47b7-a1af-d2b5fb643840" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://carismatx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://carismatx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2de96b28-03b4-4e20-ab6e-b1290ed5aea1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8912e74f-fa7c-4ccb-8563-78a9df056d80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2de96b28-03b4-4e20-ab6e-b1290ed5aea1" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8912e74f-fa7c-4ccb-8563-78a9df056d80" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_91a541a2-7a7a-436a-bc29-205c01d29c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8912e74f-fa7c-4ccb-8563-78a9df056d80" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_91a541a2-7a7a-436a-bc29-205c01d29c5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_91a541a2-7a7a-436a-bc29-205c01d29c5f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_91a541a2-7a7a-436a-bc29-205c01d29c5f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_91a541a2-7a7a-436a-bc29-205c01d29c5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_337c9009-563d-44e4-ad0d-e70731b3f586" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_91a541a2-7a7a-436a-bc29-205c01d29c5f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_337c9009-563d-44e4-ad0d-e70731b3f586" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_eddc4f51-43b4-4994-a323-f32a31a59490" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_337c9009-563d-44e4-ad0d-e70731b3f586" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_eddc4f51-43b4-4994-a323-f32a31a59490" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_628d09dd-7de5-4721-be03-da69d048db13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_337c9009-563d-44e4-ad0d-e70731b3f586" xlink:to="loc_us-gaap_EquipmentMember_628d09dd-7de5-4721-be03-da69d048db13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_c1712997-470a-45d9-8e94-499f15f095f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_337c9009-563d-44e4-ad0d-e70731b3f586" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_c1712997-470a-45d9-8e94-499f15f095f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_8f5396dc-39fa-4c7d-a5ef-e06eee357adf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_337c9009-563d-44e4-ad0d-e70731b3f586" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_8f5396dc-39fa-4c7d-a5ef-e06eee357adf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_076b9230-5ec8-4ca2-8b8e-3a7caf9c6e04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_337c9009-563d-44e4-ad0d-e70731b3f586" xlink:to="loc_us-gaap_ConstructionInProgressMember_076b9230-5ec8-4ca2-8b8e-3a7caf9c6e04" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_99c706a8-7f33-4443-ac28-0b28022cdc75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2de96b28-03b4-4e20-ab6e-b1290ed5aea1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_99c706a8-7f33-4443-ac28-0b28022cdc75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_09d81eba-5c1f-411e-815d-6b2bc5afdd46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2de96b28-03b4-4e20-ab6e-b1290ed5aea1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_09d81eba-5c1f-411e-815d-6b2bc5afdd46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_df0d248e-be48-41e8-9f10-ecb661e7cf95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2de96b28-03b4-4e20-ab6e-b1290ed5aea1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_df0d248e-be48-41e8-9f10-ecb661e7cf95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleLeasebackTransactionNetBookValue_6fa88399-5cd4-41a4-a6d1-ad4380356630" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleLeasebackTransactionNetBookValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2de96b28-03b4-4e20-ab6e-b1290ed5aea1" xlink:to="loc_us-gaap_SaleLeasebackTransactionNetBookValue_6fa88399-5cd4-41a4-a6d1-ad4380356630" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_86c9dbf8-e9e1-4aba-9d7f-b911a2f62afd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2de96b28-03b4-4e20-ab6e-b1290ed5aea1" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_86c9dbf8-e9e1-4aba-9d7f-b911a2f62afd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleLeasebackTransactionAccumulatedDepreciation_e66811c3-9db9-40ec-9476-850167eb3e46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleLeasebackTransactionAccumulatedDepreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2de96b28-03b4-4e20-ab6e-b1290ed5aea1" xlink:to="loc_us-gaap_SaleLeasebackTransactionAccumulatedDepreciation_e66811c3-9db9-40ec-9476-850167eb3e46" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_afaf24e6-a273-4608-a770-fa02d2a5af60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2de96b28-03b4-4e20-ab6e-b1290ed5aea1" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_afaf24e6-a273-4608-a770-fa02d2a5af60" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://carismatx.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://carismatx.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_dc523eb2-4c7f-4307-a13f-9392fdb81108" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_0cbda257-b2bc-465d-9112-14964ab424fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_dc523eb2-4c7f-4307-a13f-9392fdb81108" xlink:to="loc_us-gaap_LossContingenciesTable_0cbda257-b2bc-465d-9112-14964ab424fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e5aa3f73-78a4-459b-b840-20c541933a50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_0cbda257-b2bc-465d-9112-14964ab424fe" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e5aa3f73-78a4-459b-b840-20c541933a50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e5aa3f73-78a4-459b-b840-20c541933a50_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e5aa3f73-78a4-459b-b840-20c541933a50" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e5aa3f73-78a4-459b-b840-20c541933a50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b70b3d53-ff92-4fe5-8f5b-91d26ba664d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e5aa3f73-78a4-459b-b840-20c541933a50" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b70b3d53-ff92-4fe5-8f5b-91d26ba664d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_PennLicenseAgreementMember_f7c7ce0c-03bc-4546-8d38-9ab37d2e00d6" xlink:href="carm-20241231.xsd#carm_PennLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b70b3d53-ff92-4fe5-8f5b-91d26ba664d9" xlink:to="loc_carm_PennLicenseAgreementMember_f7c7ce0c-03bc-4546-8d38-9ab37d2e00d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember_350fc086-5162-44a0-94f4-b7afe9d6b8e8" xlink:href="carm-20241231.xsd#carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b70b3d53-ff92-4fe5-8f5b-91d26ba664d9" xlink:to="loc_carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember_350fc086-5162-44a0-94f4-b7afe9d6b8e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3ca1c9ee-817d-41b4-9763-ec55d960238c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_0cbda257-b2bc-465d-9112-14964ab424fe" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3ca1c9ee-817d-41b4-9763-ec55d960238c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ca1c9ee-817d-41b4-9763-ec55d960238c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3ca1c9ee-817d-41b4-9763-ec55d960238c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ca1c9ee-817d-41b4-9763-ec55d960238c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_311a7194-5f9b-47cd-bd4e-2abf4b4ede52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3ca1c9ee-817d-41b4-9763-ec55d960238c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_311a7194-5f9b-47cd-bd4e-2abf4b4ede52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_2d698631-4288-46f2-a5ae-e883f7fb971e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_311a7194-5f9b-47cd-bd4e-2abf4b4ede52" xlink:to="loc_us-gaap_EquipmentMember_2d698631-4288-46f2-a5ae-e883f7fb971e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_813be22a-ddeb-46e4-b1cd-099e59ec72f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_0cbda257-b2bc-465d-9112-14964ab424fe" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_813be22a-ddeb-46e4-b1cd-099e59ec72f6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_813be22a-ddeb-46e4-b1cd-099e59ec72f6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_813be22a-ddeb-46e4-b1cd-099e59ec72f6" xlink:to="loc_us-gaap_RelatedPartyDomain_813be22a-ddeb-46e4-b1cd-099e59ec72f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_55181dda-ff45-47c6-afe5-41f9a56cc669" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_813be22a-ddeb-46e4-b1cd-099e59ec72f6" xlink:to="loc_us-gaap_RelatedPartyDomain_55181dda-ff45-47c6-afe5-41f9a56cc669" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_TrusteesOfUniversityOfPennsylvaniaMember_4804009b-916e-4be3-8aaf-1afdf1d87592" xlink:href="carm-20241231.xsd#carm_TrusteesOfUniversityOfPennsylvaniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_55181dda-ff45-47c6-afe5-41f9a56cc669" xlink:to="loc_carm_TrusteesOfUniversityOfPennsylvaniaMember_4804009b-916e-4be3-8aaf-1afdf1d87592" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e37a6f69-c2af-4083-bf01-9181559600c5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_0cbda257-b2bc-465d-9112-14964ab424fe" xlink:to="loc_srt_RangeAxis_e37a6f69-c2af-4083-bf01-9181559600c5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e37a6f69-c2af-4083-bf01-9181559600c5_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e37a6f69-c2af-4083-bf01-9181559600c5" xlink:to="loc_srt_RangeMember_e37a6f69-c2af-4083-bf01-9181559600c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0e636db0-0128-47e6-a91a-6c0838c32d3b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e37a6f69-c2af-4083-bf01-9181559600c5" xlink:to="loc_srt_RangeMember_0e636db0-0128-47e6-a91a-6c0838c32d3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b9822db4-3743-454c-9e91-1a7ef2d60aef" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0e636db0-0128-47e6-a91a-6c0838c32d3b" xlink:to="loc_srt_MaximumMember_b9822db4-3743-454c-9e91-1a7ef2d60aef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_IncreaseDecreaseInFinanceLeaseRightOfUseAssetLeaseModification_2568dbb7-2b47-4b7d-ba48-fee232798038" xlink:href="carm-20241231.xsd#carm_IncreaseDecreaseInFinanceLeaseRightOfUseAssetLeaseModification"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_dc523eb2-4c7f-4307-a13f-9392fdb81108" xlink:to="loc_carm_IncreaseDecreaseInFinanceLeaseRightOfUseAssetLeaseModification_2568dbb7-2b47-4b7d-ba48-fee232798038" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification_423f2c47-33d7-4d35-9549-7171415965bb" xlink:href="carm-20241231.xsd#carm_IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_dc523eb2-4c7f-4307-a13f-9392fdb81108" xlink:to="loc_carm_IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification_423f2c47-33d7-4d35-9549-7171415965bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleAndLeasebackTransactionGainLossNet_9b4b7b33-5f35-49f8-85fc-bf42408605b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleAndLeasebackTransactionGainLossNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_dc523eb2-4c7f-4307-a13f-9392fdb81108" xlink:to="loc_us-gaap_SaleAndLeasebackTransactionGainLossNet_9b4b7b33-5f35-49f8-85fc-bf42408605b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_f220801d-a715-4acc-8883-79d6486e9020" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_dc523eb2-4c7f-4307-a13f-9392fdb81108" xlink:to="loc_us-gaap_FinanceLeaseLiability_f220801d-a715-4acc-8883-79d6486e9020" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CommitmentsAnnualPaymentsRequiredToBePaid_14cbc0d3-5d7c-4261-aacd-2d14968ebb34" xlink:href="carm-20241231.xsd#carm_CommitmentsAnnualPaymentsRequiredToBePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_dc523eb2-4c7f-4307-a13f-9392fdb81108" xlink:to="loc_carm_CommitmentsAnnualPaymentsRequiredToBePaid_14cbc0d3-5d7c-4261-aacd-2d14968ebb34" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents_2188b13d-b29d-4dd7-9666-3b74692c907e" xlink:href="carm-20241231.xsd#carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_dc523eb2-4c7f-4307-a13f-9392fdb81108" xlink:to="loc_carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents_2188b13d-b29d-4dd7-9666-3b74692c907e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AdditionalMilestonePaymentsRequiredToBePaid_c87e36f2-399c-4f52-8735-c7472cb4740a" xlink:href="carm-20241231.xsd#carm_AdditionalMilestonePaymentsRequiredToBePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_dc523eb2-4c7f-4307-a13f-9392fdb81108" xlink:to="loc_carm_AdditionalMilestonePaymentsRequiredToBePaid_c87e36f2-399c-4f52-8735-c7472cb4740a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AdditionalMilestonePaymentsForFirstCarMProduct_f2df98db-8244-4520-8306-dc9840d9f6c6" xlink:href="carm-20241231.xsd#carm_AdditionalMilestonePaymentsForFirstCarMProduct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_dc523eb2-4c7f-4307-a13f-9392fdb81108" xlink:to="loc_carm_AdditionalMilestonePaymentsForFirstCarMProduct_f2df98db-8244-4520-8306-dc9840d9f6c6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AgreementTerm_fbf224a8-732e-479c-9d9f-10c907dfa011" xlink:href="carm-20241231.xsd#carm_AgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_dc523eb2-4c7f-4307-a13f-9392fdb81108" xlink:to="loc_carm_AgreementTerm_fbf224a8-732e-479c-9d9f-10c907dfa011" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContractTermination_0dc5f7f9-f8c8-4d75-9865-9b399691eb5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossOnContractTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_dc523eb2-4c7f-4307-a13f-9392fdb81108" xlink:to="loc_us-gaap_LossOnContractTermination_0dc5f7f9-f8c8-4d75-9865-9b399691eb5d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_535ff31f-4eff-4e1e-a495-dac8d0ead610" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_dc523eb2-4c7f-4307-a13f-9392fdb81108" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_535ff31f-4eff-4e1e-a495-dac8d0ead610" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_e9e815a1-617a-470c-8808-20ed1b96b707" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_dc523eb2-4c7f-4307-a13f-9392fdb81108" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_e9e815a1-617a-470c-8808-20ed1b96b707" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://carismatx.com/role/StockholdersDeficitEquityDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#StockholdersDeficitEquityDetails"/>
  <link:definitionLink xlink:role="http://carismatx.com/role/StockholdersDeficitEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_7ca98b39-32e9-4e4e-87d9-d6690f8f4724" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_e7976733-42b0-411b-907e-8e12fe116483" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ca98b39-32e9-4e4e-87d9-d6690f8f4724" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_e7976733-42b0-411b-907e-8e12fe116483" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_d3872a91-7d93-40a6-b792-d95d570a5e56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e7976733-42b0-411b-907e-8e12fe116483" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_d3872a91-7d93-40a6-b792-d95d570a5e56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d3872a91-7d93-40a6-b792-d95d570a5e56_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d3872a91-7d93-40a6-b792-d95d570a5e56" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d3872a91-7d93-40a6-b792-d95d570a5e56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5eafc63d-c921-4465-8c86-7e0208890b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d3872a91-7d93-40a6-b792-d95d570a5e56" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5eafc63d-c921-4465-8c86-7e0208890b7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AtTheMarketMember_320612e6-7ede-44c6-b45e-a0ab320588ec" xlink:href="carm-20241231.xsd#carm_AtTheMarketMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5eafc63d-c921-4465-8c86-7e0208890b7b" xlink:to="loc_carm_AtTheMarketMember_320612e6-7ede-44c6-b45e-a0ab320588ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ddffb9e2-7f77-427c-aa9a-647477ecc457" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ca98b39-32e9-4e4e-87d9-d6690f8f4724" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ddffb9e2-7f77-427c-aa9a-647477ecc457" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_07eea54a-47ae-44a1-af4f-89070c11770d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ca98b39-32e9-4e4e-87d9-d6690f8f4724" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_07eea54a-47ae-44a1-af4f-89070c11770d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_98a531c4-57a3-456b-ab12-76f0c783f5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ca98b39-32e9-4e4e-87d9-d6690f8f4724" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_98a531c4-57a3-456b-ab12-76f0c783f5f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_9c9b2521-aa5e-492d-a814-eac5b5c1ceb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ca98b39-32e9-4e4e-87d9-d6690f8f4724" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_9c9b2521-aa5e-492d-a814-eac5b5c1ceb0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_34fd42c9-eb9f-4e40-af1d-a76aaf297b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ca98b39-32e9-4e4e-87d9-d6690f8f4724" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_34fd42c9-eb9f-4e40-af1d-a76aaf297b9c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests_af9b8c13-0fef-4d5e-8d62-5a3b6339e6e4" xlink:href="carm-20241231.xsd#carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ca98b39-32e9-4e4e-87d9-d6690f8f4724" xlink:to="loc_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests_af9b8c13-0fef-4d5e-8d62-5a3b6339e6e4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2320e084-643a-4277-8505-d1af8cc26a57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ca98b39-32e9-4e4e-87d9-d6690f8f4724" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2320e084-643a-4277-8505-d1af8cc26a57" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_SaleOfStockStockOfferingAmount_971c5910-087d-4221-9dd4-6e6a60f4a966" xlink:href="carm-20241231.xsd#carm_SaleOfStockStockOfferingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ca98b39-32e9-4e4e-87d9-d6690f8f4724" xlink:to="loc_carm_SaleOfStockStockOfferingAmount_971c5910-087d-4221-9dd4-6e6a60f4a966" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_SaleOfStockMaximumOfferingAmount_bb4048be-6916-4483-87d2-eb758893242c" xlink:href="carm-20241231.xsd#carm_SaleOfStockMaximumOfferingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ca98b39-32e9-4e4e-87d9-d6690f8f4724" xlink:to="loc_carm_SaleOfStockMaximumOfferingAmount_bb4048be-6916-4483-87d2-eb758893242c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_c56d042b-63ad-412f-a6f7-ad822e7b01db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ca98b39-32e9-4e4e-87d9-d6690f8f4724" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_c56d042b-63ad-412f-a6f7-ad822e7b01db" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_f6ddb10c-582e-4a54-b783-ec6079d1884b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ca98b39-32e9-4e4e-87d9-d6690f8f4724" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_f6ddb10c-582e-4a54-b783-ec6079d1884b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_07d9a1ef-4905-4bed-9c55-9266f8998d79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ca98b39-32e9-4e4e-87d9-d6690f8f4724" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_07d9a1ef-4905-4bed-9c55-9266f8998d79" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_3db0916e-d298-40e7-88ba-4d8bf4fda666" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ca98b39-32e9-4e4e-87d9-d6690f8f4724" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_3db0916e-d298-40e7-88ba-4d8bf4fda666" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_5998b4ab-f3d5-4ab2-a072-f7702670c416" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ca98b39-32e9-4e4e-87d9-d6690f8f4724" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_5998b4ab-f3d5-4ab2-a072-f7702670c416" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_463a429c-b04c-4146-91c4-5e47e0de8f13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ca98b39-32e9-4e4e-87d9-d6690f8f4724" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_463a429c-b04c-4146-91c4-5e47e0de8f13" xlink:type="arc" order="14"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://carismatx.com/role/StockbasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#StockbasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://carismatx.com/role/StockbasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23daa344-1f77-4169-8a72-10653306c7bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18e2a80e-049a-43f1-b113-0bfd7393878e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23daa344-1f77-4169-8a72-10653306c7bc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18e2a80e-049a-43f1-b113-0bfd7393878e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_760193ce-bc00-4aab-be65-79ebb6e3c5be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18e2a80e-049a-43f1-b113-0bfd7393878e" xlink:to="loc_us-gaap_PlanNameAxis_760193ce-bc00-4aab-be65-79ebb6e3c5be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_760193ce-bc00-4aab-be65-79ebb6e3c5be_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_760193ce-bc00-4aab-be65-79ebb6e3c5be" xlink:to="loc_us-gaap_PlanNameDomain_760193ce-bc00-4aab-be65-79ebb6e3c5be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f9db7c16-6a40-4e29-ad78-bada03b4ba29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_760193ce-bc00-4aab-be65-79ebb6e3c5be" xlink:to="loc_us-gaap_PlanNameDomain_f9db7c16-6a40-4e29-ad78-bada03b4ba29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_TwoThousandSeventeenStockIncentivePlanMember_fe29aa8d-c470-4fe8-9c23-f6ca471bdf21" xlink:href="carm-20241231.xsd#carm_TwoThousandSeventeenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_f9db7c16-6a40-4e29-ad78-bada03b4ba29" xlink:to="loc_carm_TwoThousandSeventeenStockIncentivePlanMember_fe29aa8d-c470-4fe8-9c23-f6ca471bdf21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_TwoThousandFourteenStockIncentivePlanMember_f02c3760-bffd-4c6a-b63a-4783677afc46" xlink:href="carm-20241231.xsd#carm_TwoThousandFourteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_f9db7c16-6a40-4e29-ad78-bada03b4ba29" xlink:to="loc_carm_TwoThousandFourteenStockIncentivePlanMember_f02c3760-bffd-4c6a-b63a-4783677afc46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_TwoThousandFourteenEmployeeStockPurchasePlanMember_edb38e18-2812-47c5-9b3d-9e84f7274369" xlink:href="carm-20241231.xsd#carm_TwoThousandFourteenEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_f9db7c16-6a40-4e29-ad78-bada03b4ba29" xlink:to="loc_carm_TwoThousandFourteenEmployeeStockPurchasePlanMember_edb38e18-2812-47c5-9b3d-9e84f7274369" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f3ef73fb-963a-4435-b808-e69449d25a44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18e2a80e-049a-43f1-b113-0bfd7393878e" xlink:to="loc_us-gaap_AwardTypeAxis_f3ef73fb-963a-4435-b808-e69449d25a44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f3ef73fb-963a-4435-b808-e69449d25a44_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f3ef73fb-963a-4435-b808-e69449d25a44" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f3ef73fb-963a-4435-b808-e69449d25a44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_462cb4e8-8f83-4b42-a845-614dc535049d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f3ef73fb-963a-4435-b808-e69449d25a44" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_462cb4e8-8f83-4b42-a845-614dc535049d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0efba25d-3c59-4489-af79-5a69994a29e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_462cb4e8-8f83-4b42-a845-614dc535049d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0efba25d-3c59-4489-af79-5a69994a29e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_e1d87c43-8e57-4b47-846d-0d9842c6b2c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23daa344-1f77-4169-8a72-10653306c7bc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_e1d87c43-8e57-4b47-846d-0d9842c6b2c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_190add08-281c-405d-8f13-6998efac17b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23daa344-1f77-4169-8a72-10653306c7bc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_190add08-281c-405d-8f13-6998efac17b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_735f81e1-f543-4d53-888c-d26552d6b895" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23daa344-1f77-4169-8a72-10653306c7bc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_735f81e1-f543-4d53-888c-d26552d6b895" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_a2dfccb3-4667-49c7-b0d6-be2482cc2440" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23daa344-1f77-4169-8a72-10653306c7bc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_a2dfccb3-4667-49c7-b0d6-be2482cc2440" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://carismatx.com/role/StockbasedCompensationScheduleofEstimatedUsingTheBlackScholesOptionPricingModelDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#StockbasedCompensationScheduleofEstimatedUsingTheBlackScholesOptionPricingModelDetails"/>
  <link:definitionLink xlink:role="http://carismatx.com/role/StockbasedCompensationScheduleofEstimatedUsingTheBlackScholesOptionPricingModelDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_958767af-1abc-4e88-a63d-2d44937d62e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2be9d12c-a493-4028-a2d1-470fc96b1088" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_958767af-1abc-4e88-a63d-2d44937d62e6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2be9d12c-a493-4028-a2d1-470fc96b1088" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_15d3c181-f618-444d-8dd9-e6b89e244fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2be9d12c-a493-4028-a2d1-470fc96b1088" xlink:to="loc_us-gaap_AwardTypeAxis_15d3c181-f618-444d-8dd9-e6b89e244fa5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15d3c181-f618-444d-8dd9-e6b89e244fa5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_15d3c181-f618-444d-8dd9-e6b89e244fa5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15d3c181-f618-444d-8dd9-e6b89e244fa5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a3c8cbf9-d135-46b2-ac0d-851f0800993d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_15d3c181-f618-444d-8dd9-e6b89e244fa5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a3c8cbf9-d135-46b2-ac0d-851f0800993d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9c51efae-6ffe-4f32-8155-3eab2cbf7a35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a3c8cbf9-d135-46b2-ac0d-851f0800993d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9c51efae-6ffe-4f32-8155-3eab2cbf7a35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a484cfc2-4e5f-43d4-b80e-0fa4f4ba24a0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2be9d12c-a493-4028-a2d1-470fc96b1088" xlink:to="loc_srt_RangeAxis_a484cfc2-4e5f-43d4-b80e-0fa4f4ba24a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a484cfc2-4e5f-43d4-b80e-0fa4f4ba24a0_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a484cfc2-4e5f-43d4-b80e-0fa4f4ba24a0" xlink:to="loc_srt_RangeMember_a484cfc2-4e5f-43d4-b80e-0fa4f4ba24a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a029f103-4ec1-4c08-a5e8-f61837ef7051" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a484cfc2-4e5f-43d4-b80e-0fa4f4ba24a0" xlink:to="loc_srt_RangeMember_a029f103-4ec1-4c08-a5e8-f61837ef7051" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8aafae29-d275-40c9-bca5-9492599967b3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a029f103-4ec1-4c08-a5e8-f61837ef7051" xlink:to="loc_srt_MinimumMember_8aafae29-d275-40c9-bca5-9492599967b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3497c1d1-b217-493f-9fd5-0cad92b49df2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a029f103-4ec1-4c08-a5e8-f61837ef7051" xlink:to="loc_srt_MaximumMember_3497c1d1-b217-493f-9fd5-0cad92b49df2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1c128f16-a503-4c83-91ea-e92ba3d361ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_958767af-1abc-4e88-a63d-2d44937d62e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1c128f16-a503-4c83-91ea-e92ba3d361ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e0738d6f-cf15-4a5f-9c4b-775a7c616d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_958767af-1abc-4e88-a63d-2d44937d62e6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e0738d6f-cf15-4a5f-9c4b-775a7c616d5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8a2652c3-8aef-45d8-8a56-aef28a017741" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_958767af-1abc-4e88-a63d-2d44937d62e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8a2652c3-8aef-45d8-8a56-aef28a017741" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4365210e-8a8c-47d3-b5f0-c043b3181a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_958767af-1abc-4e88-a63d-2d44937d62e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4365210e-8a8c-47d3-b5f0-c043b3181a2d" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://carismatx.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://carismatx.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_001f0c9f-b155-41b0-bf9f-8295f443b01b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_170da086-bdfa-41cb-bea2-d98f240d79c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_001f0c9f-b155-41b0-bf9f-8295f443b01b" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_170da086-bdfa-41cb-bea2-d98f240d79c7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e15b0b8b-db88-423e-aee6-99b8c034cee2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_170da086-bdfa-41cb-bea2-d98f240d79c7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e15b0b8b-db88-423e-aee6-99b8c034cee2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e15b0b8b-db88-423e-aee6-99b8c034cee2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e15b0b8b-db88-423e-aee6-99b8c034cee2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e15b0b8b-db88-423e-aee6-99b8c034cee2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_67402467-deb2-43aa-a4f5-cf31753ed1cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e15b0b8b-db88-423e-aee6-99b8c034cee2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_67402467-deb2-43aa-a4f5-cf31753ed1cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ecad4037-256e-48ca-8b9d-c1aa23285d73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_67402467-deb2-43aa-a4f5-cf31753ed1cb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ecad4037-256e-48ca-8b9d-c1aa23285d73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_38843da7-8578-4f22-920a-fb8c7b9c0f19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_67402467-deb2-43aa-a4f5-cf31753ed1cb" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_38843da7-8578-4f22-920a-fb8c7b9c0f19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_278d0603-dfbd-4818-adb6-2de0d8c944ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_170da086-bdfa-41cb-bea2-d98f240d79c7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_278d0603-dfbd-4818-adb6-2de0d8c944ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_278d0603-dfbd-4818-adb6-2de0d8c944ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_278d0603-dfbd-4818-adb6-2de0d8c944ab" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_278d0603-dfbd-4818-adb6-2de0d8c944ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b61440a8-3e90-49f4-af41-3534ac18b1a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_278d0603-dfbd-4818-adb6-2de0d8c944ab" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b61440a8-3e90-49f4-af41-3534ac18b1a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_SesenBioIncMember_e0bd238c-e00b-4ac8-b48d-b144519532be" xlink:href="carm-20241231.xsd#carm_SesenBioIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b61440a8-3e90-49f4-af41-3534ac18b1a1" xlink:to="loc_carm_SesenBioIncMember_e0bd238c-e00b-4ac8-b48d-b144519532be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_c2a92ca7-5a94-441a-a96c-44b12ed114e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_170da086-bdfa-41cb-bea2-d98f240d79c7" xlink:to="loc_us-gaap_PlanNameAxis_c2a92ca7-5a94-441a-a96c-44b12ed114e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c2a92ca7-5a94-441a-a96c-44b12ed114e7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_c2a92ca7-5a94-441a-a96c-44b12ed114e7" xlink:to="loc_us-gaap_PlanNameDomain_c2a92ca7-5a94-441a-a96c-44b12ed114e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9e0afe86-0a56-4a3a-9753-2038509804d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_c2a92ca7-5a94-441a-a96c-44b12ed114e7" xlink:to="loc_us-gaap_PlanNameDomain_9e0afe86-0a56-4a3a-9753-2038509804d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_RevisedOperatingPlanMember_a76c5c06-b42c-4650-ad84-96eb58bcdd90" xlink:href="carm-20241231.xsd#carm_RevisedOperatingPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_9e0afe86-0a56-4a3a-9753-2038509804d1" xlink:to="loc_carm_RevisedOperatingPlanMember_a76c5c06-b42c-4650-ad84-96eb58bcdd90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_c69e6100-ab06-40c7-96ba-6c022e02da69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_001f0c9f-b155-41b0-bf9f-8295f443b01b" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_c69e6100-ab06-40c7-96ba-6c022e02da69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6b6162db-1821-40b8-80c8-ac9d064dab07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_001f0c9f-b155-41b0-bf9f-8295f443b01b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6b6162db-1821-40b8-80c8-ac9d064dab07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c20ffd70-cd89-45fe-8651-95b12fd73fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_001f0c9f-b155-41b0-bf9f-8295f443b01b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c20ffd70-cd89-45fe-8651-95b12fd73fb1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_67825f37-998c-4d04-b724-95cd682c8c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_001f0c9f-b155-41b0-bf9f-8295f443b01b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_67825f37-998c-4d04-b724-95cd682c8c5d" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://carismatx.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://carismatx.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_12c11eea-7038-40e7-9b7b-bd0cd5a254af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_958a53a0-f1b1-4de8-81c7-991215096b61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_12c11eea-7038-40e7-9b7b-bd0cd5a254af" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_958a53a0-f1b1-4de8-81c7-991215096b61" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_19af8878-9140-4d75-a4ea-a4d76a9b9681" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_958a53a0-f1b1-4de8-81c7-991215096b61" xlink:to="loc_us-gaap_TaxPeriodAxis_19af8878-9140-4d75-a4ea-a4d76a9b9681" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_19af8878-9140-4d75-a4ea-a4d76a9b9681_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_19af8878-9140-4d75-a4ea-a4d76a9b9681" xlink:to="loc_us-gaap_TaxPeriodDomain_19af8878-9140-4d75-a4ea-a4d76a9b9681_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_1a46ec2a-220b-415f-9804-cc6adbb7bb94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_19af8878-9140-4d75-a4ea-a4d76a9b9681" xlink:to="loc_us-gaap_TaxPeriodDomain_1a46ec2a-220b-415f-9804-cc6adbb7bb94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_Pre2018Member_04df5146-535a-4fca-8849-d91c7bfec8d9" xlink:href="carm-20241231.xsd#carm_Pre2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_1a46ec2a-220b-415f-9804-cc6adbb7bb94" xlink:to="loc_carm_Pre2018Member_04df5146-535a-4fca-8849-d91c7bfec8d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_Post2017Member_a6a2a6b1-5599-4b87-ad64-3ea5fa6f91bb" xlink:href="carm-20241231.xsd#carm_Post2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_1a46ec2a-220b-415f-9804-cc6adbb7bb94" xlink:to="loc_carm_Post2017Member_a6a2a6b1-5599-4b87-ad64-3ea5fa6f91bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_59905786-a4fe-43ce-a3ce-f0a8a0931670" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_958a53a0-f1b1-4de8-81c7-991215096b61" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_59905786-a4fe-43ce-a3ce-f0a8a0931670" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_59905786-a4fe-43ce-a3ce-f0a8a0931670_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_59905786-a4fe-43ce-a3ce-f0a8a0931670" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_59905786-a4fe-43ce-a3ce-f0a8a0931670_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_a4e76c2f-02f2-425f-a05f-c67ef86f628a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_59905786-a4fe-43ce-a3ce-f0a8a0931670" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_a4e76c2f-02f2-425f-a05f-c67ef86f628a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_6470b18a-eb2f-48b5-ad79-d23ae637cd77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_a4e76c2f-02f2-425f-a05f-c67ef86f628a" xlink:to="loc_us-gaap_DomesticCountryMember_6470b18a-eb2f-48b5-ad79-d23ae637cd77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_StateJurisdictionMember_695b63ff-5ec8-4319-8200-295d6591517e" xlink:href="carm-20241231.xsd#carm_StateJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_a4e76c2f-02f2-425f-a05f-c67ef86f628a" xlink:to="loc_carm_StateJurisdictionMember_695b63ff-5ec8-4319-8200-295d6591517e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_LocalJurisdictionMember_1a027239-9d58-4fd8-a14b-e24a582e11db" xlink:href="carm-20241231.xsd#carm_LocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_a4e76c2f-02f2-425f-a05f-c67ef86f628a" xlink:to="loc_carm_LocalJurisdictionMember_1a027239-9d58-4fd8-a14b-e24a582e11db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_bf72cc91-52a4-479d-b1ee-94c3ed128ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_958a53a0-f1b1-4de8-81c7-991215096b61" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_bf72cc91-52a4-479d-b1ee-94c3ed128ac1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_bf72cc91-52a4-479d-b1ee-94c3ed128ac1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_bf72cc91-52a4-479d-b1ee-94c3ed128ac1" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_bf72cc91-52a4-479d-b1ee-94c3ed128ac1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_1eb4ff29-3170-4cff-875e-dec2c0d97087" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_bf72cc91-52a4-479d-b1ee-94c3ed128ac1" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_1eb4ff29-3170-4cff-875e-dec2c0d97087" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_04c0def1-be17-4335-82b8-17654cec824e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_1eb4ff29-3170-4cff-875e-dec2c0d97087" xlink:to="loc_us-gaap_ResearchMember_04c0def1-be17-4335-82b8-17654cec824e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_a250cc9b-76aa-4b26-a1aa-a68a5cbf95c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_12c11eea-7038-40e7-9b7b-bd0cd5a254af" xlink:to="loc_us-gaap_OperatingLossCarryforwards_a250cc9b-76aa-4b26-a1aa-a68a5cbf95c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_8642801c-cd75-41f3-8436-7fb414af9491" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_12c11eea-7038-40e7-9b7b-bd0cd5a254af" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_8642801c-cd75-41f3-8436-7fb414af9491" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_2553f407-bf06-44db-a81b-232e03e5b09f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_12c11eea-7038-40e7-9b7b-bd0cd5a254af" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_2553f407-bf06-44db-a81b-232e03e5b09f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#ModernaCollaborationandLicenseAgreementNarrativeDetails"/>
  <link:definitionLink xlink:role="http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c95218be-bf3f-4f45-9533-a4b74e97b00b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f16071d2-8f30-44af-bf3f-40ea5ab1179f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c95218be-bf3f-4f45-9533-a4b74e97b00b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f16071d2-8f30-44af-bf3f-40ea5ab1179f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_62b23f3b-7641-4421-b877-b9c57e372bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f16071d2-8f30-44af-bf3f-40ea5ab1179f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_62b23f3b-7641-4421-b877-b9c57e372bd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_62b23f3b-7641-4421-b877-b9c57e372bd9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_62b23f3b-7641-4421-b877-b9c57e372bd9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_62b23f3b-7641-4421-b877-b9c57e372bd9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_24d70e49-32ff-471d-a6e1-bfcea1641b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_62b23f3b-7641-4421-b877-b9c57e372bd9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_24d70e49-32ff-471d-a6e1-bfcea1641b0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CollaborationAndLicenseAgreementMember_be41c533-966b-4671-8f50-a061e223a223" xlink:href="carm-20241231.xsd#carm_CollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_24d70e49-32ff-471d-a6e1-bfcea1641b0d" xlink:to="loc_carm_CollaborationAndLicenseAgreementMember_be41c533-966b-4671-8f50-a061e223a223" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ModernaLicenseAgreementMember_a4dc61d7-0d15-413b-9265-3ab4e5beb874" xlink:href="carm-20241231.xsd#carm_ModernaLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_24d70e49-32ff-471d-a6e1-bfcea1641b0d" xlink:to="loc_carm_ModernaLicenseAgreementMember_a4dc61d7-0d15-413b-9265-3ab4e5beb874" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d5728c66-3d9d-4110-963c-18a66403fade" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f16071d2-8f30-44af-bf3f-40ea5ab1179f" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d5728c66-3d9d-4110-963c-18a66403fade" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d5728c66-3d9d-4110-963c-18a66403fade_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d5728c66-3d9d-4110-963c-18a66403fade" xlink:to="loc_us-gaap_RelatedPartyDomain_d5728c66-3d9d-4110-963c-18a66403fade_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_0ddd3919-c316-49b9-b99c-0491783ee0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d5728c66-3d9d-4110-963c-18a66403fade" xlink:to="loc_us-gaap_RelatedPartyDomain_0ddd3919-c316-49b9-b99c-0491783ee0d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ModernaMember_39d6688a-84c9-4bee-ab0e-4bce5db58b7b" xlink:href="carm-20241231.xsd#carm_ModernaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_0ddd3919-c316-49b9-b99c-0491783ee0d0" xlink:to="loc_carm_ModernaMember_39d6688a-84c9-4bee-ab0e-4bce5db58b7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c5b61ad9-3bcc-42cb-93e1-9bbc9943e2a9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f16071d2-8f30-44af-bf3f-40ea5ab1179f" xlink:to="loc_srt_RangeAxis_c5b61ad9-3bcc-42cb-93e1-9bbc9943e2a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c5b61ad9-3bcc-42cb-93e1-9bbc9943e2a9_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c5b61ad9-3bcc-42cb-93e1-9bbc9943e2a9" xlink:to="loc_srt_RangeMember_c5b61ad9-3bcc-42cb-93e1-9bbc9943e2a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f0dc3dfc-d614-4277-944a-f0d338341971" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c5b61ad9-3bcc-42cb-93e1-9bbc9943e2a9" xlink:to="loc_srt_RangeMember_f0dc3dfc-d614-4277-944a-f0d338341971" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_df138fbd-cd7f-4761-b4e9-978536c0ecbd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f0dc3dfc-d614-4277-944a-f0d338341971" xlink:to="loc_srt_MinimumMember_df138fbd-cd7f-4761-b4e9-978536c0ecbd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_99e9a9c4-b267-4046-a7a3-52f30f1f1ce6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f0dc3dfc-d614-4277-944a-f0d338341971" xlink:to="loc_srt_MaximumMember_99e9a9c4-b267-4046-a7a3-52f30f1f1ce6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3358ba7d-ae20-46ec-be78-3547b5352a26" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f16071d2-8f30-44af-bf3f-40ea5ab1179f" xlink:to="loc_srt_ProductOrServiceAxis_3358ba7d-ae20-46ec-be78-3547b5352a26" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3358ba7d-ae20-46ec-be78-3547b5352a26_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_3358ba7d-ae20-46ec-be78-3547b5352a26" xlink:to="loc_srt_ProductsAndServicesDomain_3358ba7d-ae20-46ec-be78-3547b5352a26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_56395771-9fe5-4aa4-8d93-55d3efa5dccd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_3358ba7d-ae20-46ec-be78-3547b5352a26" xlink:to="loc_srt_ProductsAndServicesDomain_56395771-9fe5-4aa4-8d93-55d3efa5dccd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ResearchAndDevelopmentServicesMember_d37d046e-bded-4078-9bb2-350ddd73a4e4" xlink:href="carm-20241231.xsd#carm_ResearchAndDevelopmentServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_56395771-9fe5-4aa4-8d93-55d3efa5dccd" xlink:to="loc_carm_ResearchAndDevelopmentServicesMember_d37d046e-bded-4078-9bb2-350ddd73a4e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_OptionRightCollaborationRevenuesMember_d590bb24-abb6-4818-8786-d576b3d6ece6" xlink:href="carm-20241231.xsd#carm_OptionRightCollaborationRevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_56395771-9fe5-4aa4-8d93-55d3efa5dccd" xlink:to="loc_carm_OptionRightCollaborationRevenuesMember_d590bb24-abb6-4818-8786-d576b3d6ece6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_MilestonesMember_d3723a28-3625-4e03-9934-62dd91bc23e9" xlink:href="carm-20241231.xsd#carm_MilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_56395771-9fe5-4aa4-8d93-55d3efa5dccd" xlink:to="loc_carm_MilestonesMember_d3723a28-3625-4e03-9934-62dd91bc23e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_27cc0199-44d1-4846-b5c1-02a3d5551673" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f16071d2-8f30-44af-bf3f-40ea5ab1179f" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_27cc0199-44d1-4846-b5c1-02a3d5551673" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_27cc0199-44d1-4846-b5c1-02a3d5551673_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_27cc0199-44d1-4846-b5c1-02a3d5551673" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_27cc0199-44d1-4846-b5c1-02a3d5551673_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3539960c-ec84-450d-ba26-c8ea9d74390c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_27cc0199-44d1-4846-b5c1-02a3d5551673" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3539960c-ec84-450d-ba26-c8ea9d74390c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_0813b886-3a18-4f44-aadb-71814cb44a23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3539960c-ec84-450d-ba26-c8ea9d74390c" xlink:to="loc_us-gaap_SubsequentEventMember_0813b886-3a18-4f44-aadb-71814cb44a23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_MaximumNumberOfResearchTargets_4a747f11-40c9-4f89-8570-d6deebbec791" xlink:href="carm-20241231.xsd#carm_MaximumNumberOfResearchTargets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c95218be-bf3f-4f45-9533-a4b74e97b00b" xlink:to="loc_carm_MaximumNumberOfResearchTargets_4a747f11-40c9-4f89-8570-d6deebbec791" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NumberOfResearchTargetsNominatedAutoimmune_1ef04c71-1ce2-490d-a759-ffde85625d33" xlink:href="carm-20241231.xsd#carm_NumberOfResearchTargetsNominatedAutoimmune"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c95218be-bf3f-4f45-9533-a4b74e97b00b" xlink:to="loc_carm_NumberOfResearchTargetsNominatedAutoimmune_1ef04c71-1ce2-490d-a759-ffde85625d33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NumberOfResearchTargetsGrossOncology_ad6e3ad2-06e5-4ba2-b52a-e685c4505ea1" xlink:href="carm-20241231.xsd#carm_NumberOfResearchTargetsGrossOncology"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c95218be-bf3f-4f45-9533-a4b74e97b00b" xlink:to="loc_carm_NumberOfResearchTargetsGrossOncology_ad6e3ad2-06e5-4ba2-b52a-e685c4505ea1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_UpfrontNonRefundablePaymentReceived_d9390baf-9d58-4873-9a59-331c2d3016cb" xlink:href="carm-20241231.xsd#carm_UpfrontNonRefundablePaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c95218be-bf3f-4f45-9533-a4b74e97b00b" xlink:to="loc_carm_UpfrontNonRefundablePaymentReceived_d9390baf-9d58-4873-9a59-331c2d3016cb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NumberOfPotentialProductsToDevelopAndCommercialize_7f3ffdad-34ab-48b0-bdf2-581d66cee5c5" xlink:href="carm-20241231.xsd#carm_NumberOfPotentialProductsToDevelopAndCommercialize"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c95218be-bf3f-4f45-9533-a4b74e97b00b" xlink:to="loc_carm_NumberOfPotentialProductsToDevelopAndCommercialize_7f3ffdad-34ab-48b0-bdf2-581d66cee5c5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments_66e0dc53-1196-4f2e-8fb5-debcc4d0f439" xlink:href="carm-20241231.xsd#carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c95218be-bf3f-4f45-9533-a4b74e97b00b" xlink:to="loc_carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments_66e0dc53-1196-4f2e-8fb5-debcc4d0f439" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts_8c42977a-55f7-4e89-8143-0d0c6d8ec48b" xlink:href="carm-20241231.xsd#carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c95218be-bf3f-4f45-9533-a4b74e97b00b" xlink:to="loc_carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts_8c42977a-55f7-4e89-8143-0d0c6d8ec48b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts_ba56b93b-6e6a-4877-92d6-d7c19aee2613" xlink:href="carm-20241231.xsd#carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c95218be-bf3f-4f45-9533-a4b74e97b00b" xlink:to="loc_carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts_ba56b93b-6e6a-4877-92d6-d7c19aee2613" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NumberOfPerformanceObligations_b000d61c-e749-4467-968e-82ec881a3ae1" xlink:href="carm-20241231.xsd#carm_NumberOfPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c95218be-bf3f-4f45-9533-a4b74e97b00b" xlink:to="loc_carm_NumberOfPerformanceObligations_b000d61c-e749-4467-968e-82ec881a3ae1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CollaborativeArrangementRightsAndObligationsMilestonePayments_6414a404-9f24-4ecd-82f6-c41efd45f2c0" xlink:href="carm-20241231.xsd#carm_CollaborativeArrangementRightsAndObligationsMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c95218be-bf3f-4f45-9533-a4b74e97b00b" xlink:to="loc_carm_CollaborativeArrangementRightsAndObligationsMilestonePayments_6414a404-9f24-4ecd-82f6-c41efd45f2c0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_10c869fa-7f66-40b0-9d78-32b7ba79f325" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c95218be-bf3f-4f45-9533-a4b74e97b00b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_10c869fa-7f66-40b0-9d78-32b7ba79f325" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_eacd79a3-c085-4ee2-9f39-797d4d3c4c84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c95218be-bf3f-4f45-9533-a4b74e97b00b" xlink:to="loc_us-gaap_ContractWithCustomerLiability_eacd79a3-c085-4ee2-9f39-797d4d3c4c84" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_4690b143-9665-486d-ae24-2c46c783e268" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c95218be-bf3f-4f45-9533-a4b74e97b00b" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_4690b143-9665-486d-ae24-2c46c783e268" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NumberOfPotentialResearchTargetDesignations_8cae9129-b302-4e51-8cda-c8daa44efbc8" xlink:href="carm-20241231.xsd#carm_NumberOfPotentialResearchTargetDesignations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c95218be-bf3f-4f45-9533-a4b74e97b00b" xlink:to="loc_carm_NumberOfPotentialResearchTargetDesignations_8cae9129-b302-4e51-8cda-c8daa44efbc8" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_f511cbae-777d-47e2-b13a-5ab2b7539eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c95218be-bf3f-4f45-9533-a4b74e97b00b" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_f511cbae-777d-47e2-b13a-5ab2b7539eb2" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfOtherReceivables_c1bf981f-6039-4bda-945e-5b1fc21bcb5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromCollectionOfOtherReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c95218be-bf3f-4f45-9533-a4b74e97b00b" xlink:to="loc_us-gaap_ProceedsFromCollectionOfOtherReceivables_c1bf981f-6039-4bda-945e-5b1fc21bcb5a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_VariableConsideration_0f1fdbaf-bcca-4b06-97d5-cbabed537839" xlink:href="carm-20241231.xsd#carm_VariableConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c95218be-bf3f-4f45-9533-a4b74e97b00b" xlink:to="loc_carm_VariableConsideration_0f1fdbaf-bcca-4b06-97d5-cbabed537839" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ContractTerm_773d01e3-07af-45d5-a913-d18c96140497" xlink:href="carm-20241231.xsd#carm_ContractTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c95218be-bf3f-4f45-9533-a4b74e97b00b" xlink:to="loc_carm_ContractTerm_773d01e3-07af-45d5-a913-d18c96140497" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_ce99e64f-94bf-4598-8099-76118b21b7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c95218be-bf3f-4f45-9533-a4b74e97b00b" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_ce99e64f-94bf-4598-8099-76118b21b7dd" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_fd5f718a-247b-4371-b4bb-3c3e709b1c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c95218be-bf3f-4f45-9533-a4b74e97b00b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_fd5f718a-247b-4371-b4bb-3c3e709b1c7d" xlink:type="arc" order="19"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://carismatx.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://carismatx.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_a1125499-e07c-4910-93b3-870f04d35cee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_2637f56a-9e4a-4974-89b3-8e51ac2e7a24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_a1125499-e07c-4910-93b3-870f04d35cee" xlink:to="loc_us-gaap_SubsequentEventTable_2637f56a-9e4a-4974-89b3-8e51ac2e7a24" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_282904be-9bae-4356-8ab4-536da4115bea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_2637f56a-9e4a-4974-89b3-8e51ac2e7a24" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_282904be-9bae-4356-8ab4-536da4115bea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_282904be-9bae-4356-8ab4-536da4115bea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_282904be-9bae-4356-8ab4-536da4115bea" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_282904be-9bae-4356-8ab4-536da4115bea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c4d9b522-6bb8-4e1b-a919-016fc243d05f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_282904be-9bae-4356-8ab4-536da4115bea" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c4d9b522-6bb8-4e1b-a919-016fc243d05f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_f7fc66df-0085-4142-91ef-5d3ddb6c446f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c4d9b522-6bb8-4e1b-a919-016fc243d05f" xlink:to="loc_us-gaap_SubsequentEventMember_f7fc66df-0085-4142-91ef-5d3ddb6c446f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_94009c41-a7d5-4244-95ad-9aae46dacb3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_2637f56a-9e4a-4974-89b3-8e51ac2e7a24" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_94009c41-a7d5-4244-95ad-9aae46dacb3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_94009c41-a7d5-4244-95ad-9aae46dacb3e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_94009c41-a7d5-4244-95ad-9aae46dacb3e" xlink:to="loc_us-gaap_RelatedPartyDomain_94009c41-a7d5-4244-95ad-9aae46dacb3e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_4f862777-0fa6-4cd1-bc5b-3fe16778d37b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_94009c41-a7d5-4244-95ad-9aae46dacb3e" xlink:to="loc_us-gaap_RelatedPartyDomain_4f862777-0fa6-4cd1-bc5b-3fe16778d37b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ModernaMember_16eeabb2-510f-42cf-8cbe-8aea785d59ca" xlink:href="carm-20241231.xsd#carm_ModernaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_4f862777-0fa6-4cd1-bc5b-3fe16778d37b" xlink:to="loc_carm_ModernaMember_16eeabb2-510f-42cf-8cbe-8aea785d59ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5d37bbcb-440b-4bc2-bc77-447deb5967dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_2637f56a-9e4a-4974-89b3-8e51ac2e7a24" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5d37bbcb-440b-4bc2-bc77-447deb5967dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5d37bbcb-440b-4bc2-bc77-447deb5967dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5d37bbcb-440b-4bc2-bc77-447deb5967dd" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5d37bbcb-440b-4bc2-bc77-447deb5967dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3d46464f-b738-4b2b-9303-eeb4ab65ade9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5d37bbcb-440b-4bc2-bc77-447deb5967dd" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3d46464f-b738-4b2b-9303-eeb4ab65ade9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CollaborationAndLicenseAgreementMember_356f1225-1e14-4484-9181-1202579dd48e" xlink:href="carm-20241231.xsd#carm_CollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3d46464f-b738-4b2b-9303-eeb4ab65ade9" xlink:to="loc_carm_CollaborationAndLicenseAgreementMember_356f1225-1e14-4484-9181-1202579dd48e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_6078e9a3-adaa-4ab7-9759-a206f94a775a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_2637f56a-9e4a-4974-89b3-8e51ac2e7a24" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_6078e9a3-adaa-4ab7-9759-a206f94a775a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_6078e9a3-adaa-4ab7-9759-a206f94a775a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_6078e9a3-adaa-4ab7-9759-a206f94a775a" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_6078e9a3-adaa-4ab7-9759-a206f94a775a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_954ec184-a35f-419a-a84d-6d027924e8a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_6078e9a3-adaa-4ab7-9759-a206f94a775a" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_954ec184-a35f-419a-a84d-6d027924e8a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_7b8bc9d8-95a5-44f2-bf32-6d071e756d80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_954ec184-a35f-419a-a84d-6d027924e8a1" xlink:to="loc_us-gaap_EmployeeSeveranceMember_7b8bc9d8-95a5-44f2-bf32-6d071e756d80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_6004a414-aa96-4e20-ae32-af808ab9fcd2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_2637f56a-9e4a-4974-89b3-8e51ac2e7a24" xlink:to="loc_us-gaap_RestructuringPlanAxis_6004a414-aa96-4e20-ae32-af808ab9fcd2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_6004a414-aa96-4e20-ae32-af808ab9fcd2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_6004a414-aa96-4e20-ae32-af808ab9fcd2" xlink:to="loc_us-gaap_RestructuringPlanDomain_6004a414-aa96-4e20-ae32-af808ab9fcd2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_b599aec7-98e3-448d-aa71-acbb8b59d15b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_6004a414-aa96-4e20-ae32-af808ab9fcd2" xlink:to="loc_us-gaap_RestructuringPlanDomain_b599aec7-98e3-448d-aa71-acbb8b59d15b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CashPreservationPlan2025Member_59a4c346-9bb4-4b79-9ff5-614545e07462" xlink:href="carm-20241231.xsd#carm_CashPreservationPlan2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_b599aec7-98e3-448d-aa71-acbb8b59d15b" xlink:to="loc_carm_CashPreservationPlan2025Member_59a4c346-9bb4-4b79-9ff5-614545e07462" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NumberOfResearchTargetsNominatedOncology_50b497fb-cd19-429b-af2e-c022264dfd35" xlink:href="carm-20241231.xsd#carm_NumberOfResearchTargetsNominatedOncology"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_a1125499-e07c-4910-93b3-870f04d35cee" xlink:to="loc_carm_NumberOfResearchTargetsNominatedOncology_50b497fb-cd19-429b-af2e-c022264dfd35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NumberOfResearchTargetsNominatedReplacements_25ba2343-18ca-4542-9db1-88ac9e121d24" xlink:href="carm-20241231.xsd#carm_NumberOfResearchTargetsNominatedReplacements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_a1125499-e07c-4910-93b3-870f04d35cee" xlink:to="loc_carm_NumberOfResearchTargetsNominatedReplacements_25ba2343-18ca-4542-9db1-88ac9e121d24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NumberOfResearchTargetsTerminatedOncology_6ae5736f-174c-4dda-9692-74bc31e35002" xlink:href="carm-20241231.xsd#carm_NumberOfResearchTargetsTerminatedOncology"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_a1125499-e07c-4910-93b3-870f04d35cee" xlink:to="loc_carm_NumberOfResearchTargetsTerminatedOncology_6ae5736f-174c-4dda-9692-74bc31e35002" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NumberOfResearchTargetsTerminatedAutoimmune_e222e840-0b8a-4b46-8bd0-f831c058b06e" xlink:href="carm-20241231.xsd#carm_NumberOfResearchTargetsTerminatedAutoimmune"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_a1125499-e07c-4910-93b3-870f04d35cee" xlink:to="loc_carm_NumberOfResearchTargetsTerminatedAutoimmune_e222e840-0b8a-4b46-8bd0-f831c058b06e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NumberOfResearchTargetsGrossOncology_72bb5258-c272-453f-8255-24290d988a7e" xlink:href="carm-20241231.xsd#carm_NumberOfResearchTargetsGrossOncology"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_a1125499-e07c-4910-93b3-870f04d35cee" xlink:to="loc_carm_NumberOfResearchTargetsGrossOncology_72bb5258-c272-453f-8255-24290d988a7e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfOtherReceivables_398ac84f-60e3-432a-9efa-c0d55d2cb50b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromCollectionOfOtherReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_a1125499-e07c-4910-93b3-870f04d35cee" xlink:to="loc_us-gaap_ProceedsFromCollectionOfOtherReceivables_398ac84f-60e3-432a-9efa-c0d55d2cb50b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_8df68323-7994-47a4-a4b2-cca5cfc58743" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_a1125499-e07c-4910-93b3-870f04d35cee" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_8df68323-7994-47a4-a4b2-cca5cfc58743" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_971ac957-16d7-4a93-b497-72bfc5b433d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_a1125499-e07c-4910-93b3-870f04d35cee" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_971ac957-16d7-4a93-b497-72bfc5b433d7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_6f9bc0a7-f7fc-41d9-a088-5075e8063ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_a1125499-e07c-4910-93b3-870f04d35cee" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_6f9bc0a7-f7fc-41d9-a088-5075e8063ee9" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="691"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>16
<FILENAME>carm-20241231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:1dec34d0-de78-478e-a130-81bf7fce6e30,g:762837ba-4cc2-4d5a-8343-3052f0231779-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d8dec588-4497-4e34-bc41-8c5c13218368_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_0cd20695-91f1-443e-b15b-501544f5afc7_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of convertible preferred stock and non-controlling interests to common stock</link:label>
    <link:label id="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_label_en-US" xlink:label="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassifications of Temporary to Permanent Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:to="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger_1711c0e3-3378-4f4a-8327-f239fe787baa_terseLabel_en-US" xlink:label="lab_carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of convertible preferred stock and non-controlling interests to common stock (in shares)</link:label>
    <link:label id="lab_carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger_label_en-US" xlink:label="lab_carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Preferred Stock and Non-controlling Interests Upon Merger</link:label>
    <link:label id="lab_carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger_documentation_en-US" xlink:label="lab_carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of stock issued during the period upon the conversion of convertible preferred stock and noncontrolling interests upon merger.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" xlink:href="carm-20241231.xsd#carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" xlink:to="lab_carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1d326085-7728-41d7-b243-64c8f9c46fe7_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_863b0b41-b97e-4100-9f27-185c0ba29477_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_55ad6db2-26e6-4d83-a642-4760386c3129_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related-Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_1477843c-55cd-42fd-8b46-a73383ce72e7_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Lease Costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_94ebfd9b-0e9e-4efd-8148-f5e0f0e7238c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Prepaid Expenses and Other Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_49b98cbb-d02d-474a-82af-0f78d55281a6_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_028a24bb-f455-4f62-ab36-ff7e4187c62f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_AdditionalMilestonePaymentsForFirstCarMProduct_009bfab4-8aab-4a7c-a01b-de8d63d46fb1_terseLabel_en-US" xlink:label="lab_carm_AdditionalMilestonePaymentsForFirstCarMProduct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional milestone payments for first CAR-M product</link:label>
    <link:label id="lab_carm_AdditionalMilestonePaymentsForFirstCarMProduct_label_en-US" xlink:label="lab_carm_AdditionalMilestonePaymentsForFirstCarMProduct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Milestone Payments for the First CAR-M Product</link:label>
    <link:label id="lab_carm_AdditionalMilestonePaymentsForFirstCarMProduct_documentation_en-US" xlink:label="lab_carm_AdditionalMilestonePaymentsForFirstCarMProduct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional amount required to be paid in development and regulatory milestone payments for the first CAR-M product directed to mesothelin.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AdditionalMilestonePaymentsForFirstCarMProduct" xlink:href="carm-20241231.xsd#carm_AdditionalMilestonePaymentsForFirstCarMProduct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_AdditionalMilestonePaymentsForFirstCarMProduct" xlink:to="lab_carm_AdditionalMilestonePaymentsForFirstCarMProduct" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_NumberOfPotentialProductsToDevelopAndCommercialize_42d3e93a-88aa-4313-9874-2585ef2b4766_terseLabel_en-US" xlink:label="lab_carm_NumberOfPotentialProductsToDevelopAndCommercialize" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of potential products to develop and commercialize</link:label>
    <link:label id="lab_carm_NumberOfPotentialProductsToDevelopAndCommercialize_label_en-US" xlink:label="lab_carm_NumberOfPotentialProductsToDevelopAndCommercialize" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Potential Products to Develop and Commercialize</link:label>
    <link:label id="lab_carm_NumberOfPotentialProductsToDevelopAndCommercialize_documentation_en-US" xlink:label="lab_carm_NumberOfPotentialProductsToDevelopAndCommercialize" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of potential products to develop and commercialize</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NumberOfPotentialProductsToDevelopAndCommercialize" xlink:href="carm-20241231.xsd#carm_NumberOfPotentialProductsToDevelopAndCommercialize"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_NumberOfPotentialProductsToDevelopAndCommercialize" xlink:to="lab_carm_NumberOfPotentialProductsToDevelopAndCommercialize" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_AdditionalMilestonePaymentsRequiredToBePaid_5cbd98a4-0e6d-4325-95c0-2ecafdf0996f_terseLabel_en-US" xlink:label="lab_carm_AdditionalMilestonePaymentsRequiredToBePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional milestone payments</link:label>
    <link:label id="lab_carm_AdditionalMilestonePaymentsRequiredToBePaid_label_en-US" xlink:label="lab_carm_AdditionalMilestonePaymentsRequiredToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Milestone Payments Required to be Paid</link:label>
    <link:label id="lab_carm_AdditionalMilestonePaymentsRequiredToBePaid_documentation_en-US" xlink:label="lab_carm_AdditionalMilestonePaymentsRequiredToBePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of additional milestone payments required to be paid per product in commercial milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AdditionalMilestonePaymentsRequiredToBePaid" xlink:href="carm-20241231.xsd#carm_AdditionalMilestonePaymentsRequiredToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_AdditionalMilestonePaymentsRequiredToBePaid" xlink:to="lab_carm_AdditionalMilestonePaymentsRequiredToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_d72de88a-f75a-4cf2-9a83-61315602cd21_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_88e65fbd-ca1c-4a6a-9196-d3f6f3e2782b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_a8196ff7-b122-4eba-8a4a-cc8e99630c20_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business acquisition percentage of voting interests acquired (as a percent)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities_6cec113d-0e89-4f9d-ae9c-6e4fb5b4e198_terseLabel_en-US" xlink:label="lab_carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation, amortization and interest on finance and sale-leaseback lease liabilities</link:label>
    <link:label id="lab_carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities_label_en-US" xlink:label="lab_carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Amortization And Interest On Finance And Sale-Leaseback Lease Liabilities</link:label>
    <link:label id="lab_carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities_documentation_en-US" xlink:label="lab_carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Depreciation, Amortization And Interest On Finance And Sale-Leaseback Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities" xlink:href="carm-20241231.xsd#carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities" xlink:to="lab_carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction_1110e356-6ab5-49c3-aa56-9c74a9f43466_negatedLabel_en-US" xlink:label="lab_carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payment of finance liability from failed sale-leaseback arrangements</link:label>
    <link:label id="lab_carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction_label_en-US" xlink:label="lab_carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment of Finance Liability, Failed Sale Leaseback Transaction</link:label>
    <link:label id="lab_carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction_documentation_en-US" xlink:label="lab_carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of cash outflow in a failed sale-leaseback recognized in financing activities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction" xlink:href="carm-20241231.xsd#carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction" xlink:to="lab_carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_e1bdbd83-f5e6-4e70-9846-7d2dc2cc0894_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_1b853efa-6d91-4452-8961-c5e9c143b360_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_a1dad681-7983-4925-ad68-6f1b9da9646e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_5cebec07-3c39-444a-90e4-edd426ab2eb0_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credit carryforward</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_LeasesWeightedAverageRemainingLeaseTermAbstract_2e02ecae-2961-46f3-9efa-e1dc2703e27b_terseLabel_en-US" xlink:label="lab_carm_LeasesWeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining lease term (in years)</link:label>
    <link:label id="lab_carm_LeasesWeightedAverageRemainingLeaseTermAbstract_label_en-US" xlink:label="lab_carm_LeasesWeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases, Weighted Average Remaining Lease Term [Abstract]</link:label>
    <link:label id="lab_carm_LeasesWeightedAverageRemainingLeaseTermAbstract_documentation_en-US" xlink:label="lab_carm_LeasesWeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">No definition available.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_LeasesWeightedAverageRemainingLeaseTermAbstract" xlink:href="carm-20241231.xsd#carm_LeasesWeightedAverageRemainingLeaseTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_LeasesWeightedAverageRemainingLeaseTermAbstract" xlink:to="lab_carm_LeasesWeightedAverageRemainingLeaseTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_DeferredFinancingCostsPolicyPolicyTextBlock_57ed7d2c-0a40-487d-85ae-b5c246f30748_terseLabel_en-US" xlink:label="lab_carm_DeferredFinancingCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Financing Costs</link:label>
    <link:label id="lab_carm_DeferredFinancingCostsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_carm_DeferredFinancingCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Financing Costs, Policy [Policy Text Block]</link:label>
    <link:label id="lab_carm_DeferredFinancingCostsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_carm_DeferredFinancingCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Financing Costs, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DeferredFinancingCostsPolicyPolicyTextBlock" xlink:href="carm-20241231.xsd#carm_DeferredFinancingCostsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_DeferredFinancingCostsPolicyPolicyTextBlock" xlink:to="lab_carm_DeferredFinancingCostsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2d28a06c-1a28-4067-8f29-6b40bb17fc56_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon settlement of convertible promissory note, accrued interest, and related derivative liability (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationAdditionalInformationAbstract_67a0807d-b88a-477e-b5ab-2e741a95d0a5_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationAdditionalInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less:</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationAdditionalInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationAdditionalInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information, Additional Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationAdditionalInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationAdditionalInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationAdditionalInformationAbstract" xlink:to="lab_us-gaap_SegmentReportingInformationAdditionalInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts_98171320-bc06-442c-8f05-6b2c1ffbff1d_terseLabel_en-US" xlink:label="lab_carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum commitment to reimburse research and development costs</link:label>
    <link:label id="lab_carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts_label_en-US" xlink:label="lab_carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum Commitment to Reimburse Research and Development Costs</link:label>
    <link:label id="lab_carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts_documentation_en-US" xlink:label="lab_carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Minimum commitment to reimburse research and development costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts" xlink:href="carm-20241231.xsd#carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts" xlink:to="lab_carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_a07f33dd-47f0-4fef-a98d-7fb0a2593da3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_d0bd706f-d09e-4f46-87a2-671d544a1d26_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Background</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_606bcbc1-0def-4a47-a56d-e29bda374fdf_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuePerformanceObligationAbstract_c49db966-c002-43a6-aedd-bdcd2b7c778b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuePerformanceObligationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance obligations:</link:label>
    <link:label id="lab_us-gaap_RevenuePerformanceObligationAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuePerformanceObligationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Performance Obligation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuePerformanceObligationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuePerformanceObligationAbstract" xlink:to="lab_us-gaap_RevenuePerformanceObligationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_LeasesWeightedAverageDiscountRateAbstract_2998dc1f-72e5-4840-a364-008426564904_terseLabel_en-US" xlink:label="lab_carm_LeasesWeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_carm_LeasesWeightedAverageDiscountRateAbstract_label_en-US" xlink:label="lab_carm_LeasesWeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases, Weighted Average Discount Rate [Abstract]</link:label>
    <link:label id="lab_carm_LeasesWeightedAverageDiscountRateAbstract_documentation_en-US" xlink:label="lab_carm_LeasesWeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">No definition available.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_LeasesWeightedAverageDiscountRateAbstract" xlink:href="carm-20241231.xsd#carm_LeasesWeightedAverageDiscountRateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_LeasesWeightedAverageDiscountRateAbstract" xlink:to="lab_carm_LeasesWeightedAverageDiscountRateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_8f269120-0c2e-4f0e-ab43-1e96bb32db5f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_a95a6c78-609c-47be-ad7d-2ae9fb2db9a1_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_80b4a4f1-723d-4c6e-9fe1-b8a98fed2c16_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_709f5158-c5b8-491c-a4ce-2ed2e3046002_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Entity common stock, shares outstanding immediately after merger (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_e41398af-d60c-4069-891e-e510e8bddec7_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_bf98487c-935a-4750-a946-82726cc19938_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration receivable</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_5a71ac8d-e9f8-457d-9357-a698dcdea3fd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_ReceivableDueFromCollaborativeArrangementCurrent_5dee4c23-620a-4ef9-a0e8-62ee95d65b9a_terseLabel_en-US" xlink:label="lab_carm_ReceivableDueFromCollaborativeArrangementCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration receivable</link:label>
    <link:label id="lab_carm_ReceivableDueFromCollaborativeArrangementCurrent_label_en-US" xlink:label="lab_carm_ReceivableDueFromCollaborativeArrangementCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivable Due From Collaborative Arrangement, Current</link:label>
    <link:label id="lab_carm_ReceivableDueFromCollaborativeArrangementCurrent_documentation_en-US" xlink:label="lab_carm_ReceivableDueFromCollaborativeArrangementCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Receivable Due From Collaborative Arrangement, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ReceivableDueFromCollaborativeArrangementCurrent" xlink:href="carm-20241231.xsd#carm_ReceivableDueFromCollaborativeArrangementCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_ReceivableDueFromCollaborativeArrangementCurrent" xlink:to="lab_carm_ReceivableDueFromCollaborativeArrangementCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_a8461d26-23a4-4d89-8b4b-74e4348acf41_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease, ROU assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, before Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2e98ed38-e29e-42b0-bd2f-00a5a91407ea_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_723a2582-08a6-4210-9a68-c0f8aa03a950_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction in workforce, number of employees</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_025aa952-9b1e-4d30-8114-72c841bb67c4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_DevelopmentStageRisksAndLiquidityAbstract_2bf4731a-0ddd-44d1-9172-d7c6297dc8e9_terseLabel_en-US" xlink:label="lab_carm_DevelopmentStageRisksAndLiquidityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development-Stage Risks and Liquidity</link:label>
    <link:label id="lab_carm_DevelopmentStageRisksAndLiquidityAbstract_label_en-US" xlink:label="lab_carm_DevelopmentStageRisksAndLiquidityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development-Stage Risks and Liquidity</link:label>
    <link:label id="lab_carm_DevelopmentStageRisksAndLiquidityAbstract_documentation_en-US" xlink:label="lab_carm_DevelopmentStageRisksAndLiquidityAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">No definition available.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DevelopmentStageRisksAndLiquidityAbstract" xlink:href="carm-20241231.xsd#carm_DevelopmentStageRisksAndLiquidityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_DevelopmentStageRisksAndLiquidityAbstract" xlink:to="lab_carm_DevelopmentStageRisksAndLiquidityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_92f78936-c53d-4d39-9058-6328d8b8878f_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Moderna Collaboration and License Agreement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_4c577dcc-c419-414e-b555-2eea50f84d0b_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_71bc773d-db37-47de-9ec4-d8bcbfa64424_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_f915a46a-eb07-497e-a99d-19eeddae6d23_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_71d14551-0eaf-410b-8cff-01c0ce2b0a09_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_e9174cf8-6859-43c9-8b5f-a6d92fbe7832_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_TwoThousandFourteenStockIncentivePlanMember_367350c6-2632-4de4-85ae-72f1554ade6e_terseLabel_en-US" xlink:label="lab_carm_TwoThousandFourteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2014 Stock Incentive Plan</link:label>
    <link:label id="lab_carm_TwoThousandFourteenStockIncentivePlanMember_label_en-US" xlink:label="lab_carm_TwoThousandFourteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Fourteen Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_carm_TwoThousandFourteenStockIncentivePlanMember_documentation_en-US" xlink:label="lab_carm_TwoThousandFourteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Two Thousand Fourteen Stock Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_TwoThousandFourteenStockIncentivePlanMember" xlink:href="carm-20241231.xsd#carm_TwoThousandFourteenStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_TwoThousandFourteenStockIncentivePlanMember" xlink:to="lab_carm_TwoThousandFourteenStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_fc5900d6-91fa-4fbd-9fa7-46012ef40ad1_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_f1828bcc-d062-4626-bb40-bfffa7b3097f_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesIssued" xlink:to="lab_us-gaap_TemporaryEquitySharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_f11afa99-6e99-4056-a12d-62b359dc682e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_31a68050-2fe4-4eb3-8782-125df0fe0d14_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_GainLossOnSaleOfEquipment_5b564f20-2be6-4db5-93ba-90ea5b6f8908_negatedTerseLabel_en-US" xlink:label="lab_carm_GainLossOnSaleOfEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on sale of equipment</link:label>
    <link:label id="lab_carm_GainLossOnSaleOfEquipment_label_en-US" xlink:label="lab_carm_GainLossOnSaleOfEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Sale of Equipment</link:label>
    <link:label id="lab_carm_GainLossOnSaleOfEquipment_documentation_en-US" xlink:label="lab_carm_GainLossOnSaleOfEquipment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Sale of Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_GainLossOnSaleOfEquipment" xlink:href="carm-20241231.xsd#carm_GainLossOnSaleOfEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_GainLossOnSaleOfEquipment" xlink:to="lab_carm_GainLossOnSaleOfEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_0dab68ed-0140-4d42-8a48-584a72afb20e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_e8977a7a-c99d-4a7c-98f3-0dc0ab1802f8_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_CommitmentsAnnualPaymentsRequiredToBePaid_a4ec078d-7f10-4132-aef2-9d7c92d58814_terseLabel_en-US" xlink:label="lab_carm_CommitmentsAnnualPaymentsRequiredToBePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual payments to be made</link:label>
    <link:label id="lab_carm_CommitmentsAnnualPaymentsRequiredToBePaid_label_en-US" xlink:label="lab_carm_CommitmentsAnnualPaymentsRequiredToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments, Annual Payments Required to be Paid</link:label>
    <link:label id="lab_carm_CommitmentsAnnualPaymentsRequiredToBePaid_documentation_en-US" xlink:label="lab_carm_CommitmentsAnnualPaymentsRequiredToBePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of annual payments required to be paid.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CommitmentsAnnualPaymentsRequiredToBePaid" xlink:href="carm-20241231.xsd#carm_CommitmentsAnnualPaymentsRequiredToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_CommitmentsAnnualPaymentsRequiredToBePaid" xlink:to="lab_carm_CommitmentsAnnualPaymentsRequiredToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4990cc6a-e500-4b41-83b5-f4f141e001d2_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities_bd6cc61f-0f8e-43f4-a3fe-6ad484fc9a0e_terseLabel_en-US" xlink:label="lab_carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash acquired in connection with the reverse recapitalization</link:label>
    <link:label id="lab_carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities_label_en-US" xlink:label="lab_carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash Acquired in Reverse Recapitalization, Financing Activities</link:label>
    <link:label id="lab_carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities_documentation_en-US" xlink:label="lab_carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of cash, cash equivalents and restricted cash acquired associated with the reverse capitalization during the period .</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities" xlink:href="carm-20241231.xsd#carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities" xlink:to="lab_carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_5b84aeec-326c-4c11-8234-aee91e2a31f7_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_32e8a08d-48fc-49df-be5c-62f1c09baaf7_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_8a8bbfa4-5a77-4a56-90be-ab90dc2f8ac3_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid asset</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_1cfad1ff-28b2-475a-8f45-bcc9fac79a4c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInDeferredRevenueRollForward_84026f27-1b07-4b1f-a155-8e2c76207d5f_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInDeferredRevenueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Movement in Deferred Revenue [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInDeferredRevenueRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInDeferredRevenueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Movement in Deferred Revenue [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInDeferredRevenueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MovementInDeferredRevenueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInDeferredRevenueRollForward" xlink:to="lab_us-gaap_MovementInDeferredRevenueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_e12608a8-eb1d-4c92-af18-77e0bab1c6b5_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total future minimum payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ea15f8fd-2a47-4ac0-89cf-6df46899e315_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_5c50db3a-919d-46f5-b7a9-bec901475107_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_b17dd9b6-b17f-45cf-81c6-1e9939f687f8_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_4bc180fd-6286-49f6-bb40-336dd5262a00_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_e031594d-27a4-4564-9285-2e25db654391_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_d791d0a4-0a4e-4d18-ab39-7339aa25d43e_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_d6309d9f-9473-47cf-ab4d-c9563844a9e4_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_5bc83fb2-7cf4-44bb-bf28-a4aa764af749_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_e4a4478f-725a-480d-adbb-1a9adbbf43aa_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleLeasebackTransactionAccumulatedDepreciation_dc52ed6f-2352-45c8-80f1-80927ed5a0ba_terseLabel_en-US" xlink:label="lab_us-gaap_SaleLeasebackTransactionAccumulatedDepreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale leaseback transaction, accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_SaleLeasebackTransactionAccumulatedDepreciation_label_en-US" xlink:label="lab_us-gaap_SaleLeasebackTransactionAccumulatedDepreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Leaseback Transaction, Accumulated Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleLeasebackTransactionAccumulatedDepreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleLeasebackTransactionAccumulatedDepreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleLeasebackTransactionAccumulatedDepreciation" xlink:to="lab_us-gaap_SaleLeasebackTransactionAccumulatedDepreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_c6af50c9-4ac5-4552-9591-1ab69e9a1d47_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_VariableConsideration_5f6142c3-bf35-4e4c-ad96-c03faa29377c_terseLabel_en-US" xlink:label="lab_carm_VariableConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable consideration</link:label>
    <link:label id="lab_carm_VariableConsideration_label_en-US" xlink:label="lab_carm_VariableConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Consideration</link:label>
    <link:label id="lab_carm_VariableConsideration_documentation_en-US" xlink:label="lab_carm_VariableConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of variable consideration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_VariableConsideration" xlink:href="carm-20241231.xsd#carm_VariableConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_VariableConsideration" xlink:to="lab_carm_VariableConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_fbde5b5f-2f5a-41de-accb-6ef07a03b2c1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding as of December 31, 2024</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction_c794e48f-2114-4217-bc40-729b6ac041b7_terseLabel_en-US" xlink:label="lab_carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for cash in pre-closing financing</link:label>
    <link:label id="lab_carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction_label_en-US" xlink:label="lab_carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Values, Pre-closing Financing Transaction</link:label>
    <link:label id="lab_carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction_documentation_en-US" xlink:label="lab_carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of stock issued pursuant to preclosing financing during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction" xlink:href="carm-20241231.xsd#carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction" xlink:to="lab_carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3db50ab4-81a6-4ac0-acbc-f7d23239ddd7_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of non-cash financing and investing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities_9477cca1-feb9-48bd-9e05-529f0c00abb5_negatedLabel_en-US" xlink:label="lab_carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payment of reverse recapitalization finance costs</link:label>
    <link:label id="lab_carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities_label_en-US" xlink:label="lab_carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment of Finance Costs, Reverse Recapitalization, Financing Activities</link:label>
    <link:label id="lab_carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities_documentation_en-US" xlink:label="lab_carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of cash outflow for payment of reverse recapitalization finance costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities" xlink:href="carm-20241231.xsd#carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities" xlink:to="lab_carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_AccruedResearchAndDevelopmentExpenseCurrent_2ebf41cd-84b0-48e2-a8ed-2ff9fefd360c_terseLabel_en-US" xlink:label="lab_carm_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_carm_AccruedResearchAndDevelopmentExpenseCurrent_label_en-US" xlink:label="lab_carm_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Research and Development Expense, Current</link:label>
    <link:label id="lab_carm_AccruedResearchAndDevelopmentExpenseCurrent_documentation_en-US" xlink:label="lab_carm_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Research and Development Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AccruedResearchAndDevelopmentExpenseCurrent" xlink:href="carm-20241231.xsd#carm_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_AccruedResearchAndDevelopmentExpenseCurrent" xlink:to="lab_carm_AccruedResearchAndDevelopmentExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_7ee80ae6-7ac4-4a2e-841d-c22bdf215b4e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_3466f38c-bb21-47e7-8a79-d5db203af755_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_eef136b4-aab8-4e7f-8e92-82316dad14cb_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_fe2e011f-e606-4178-802f-072f84d1c52f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_ReclassificationsOfTemporaryToPermanentEquityShares_9dcd8b00-5964-4a72-b6d8-31274db58460_terseLabel_en-US" xlink:label="lab_carm_ReclassificationsOfTemporaryToPermanentEquityShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of convertible preferred stock and non-controlling interests to common stock (in shares)</link:label>
    <link:label id="lab_carm_ReclassificationsOfTemporaryToPermanentEquityShares_label_en-US" xlink:label="lab_carm_ReclassificationsOfTemporaryToPermanentEquityShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassifications of Temporary to Permanent Equity, Shares</link:label>
    <link:label id="lab_carm_ReclassificationsOfTemporaryToPermanentEquityShares_documentation_en-US" xlink:label="lab_carm_ReclassificationsOfTemporaryToPermanentEquityShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of stock classified as temporary equity reclassified or converted to permanent equity during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ReclassificationsOfTemporaryToPermanentEquityShares" xlink:href="carm-20241231.xsd#carm_ReclassificationsOfTemporaryToPermanentEquityShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_ReclassificationsOfTemporaryToPermanentEquityShares" xlink:to="lab_carm_ReclassificationsOfTemporaryToPermanentEquityShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_157830db-ad07-48af-9379-5bab32770b58_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5902d500-2cac-4d8f-9a32-49c174bcb91f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_64ff69ef-487a-4152-be64-8cb5ee35209c_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_2e9515bc-83fb-434d-834b-3476d8b8e45b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0d8f026c-d30d-4e43-9e2b-0bb64f57a913_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts_877b61eb-b5aa-4524-b74e-9e287f9c90ef_terseLabel_en-US" xlink:label="lab_carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period of reimbursement of research and development costs (in years)</link:label>
    <link:label id="lab_carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts_label_en-US" xlink:label="lab_carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period of Reimbursement of Research and Development Costs</link:label>
    <link:label id="lab_carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts_documentation_en-US" xlink:label="lab_carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period of reimbursement of research and development costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts" xlink:href="carm-20241231.xsd#carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts" xlink:to="lab_carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability_d0f31b6e-93c5-4fe0-a67c-2473e962588b_terseLabel_en-US" xlink:label="lab_carm_DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal of property and equipment in exchange for reduction in financing lease liability</link:label>
    <link:label id="lab_carm_DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability_label_en-US" xlink:label="lab_carm_DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Of Property, Plant And Equipment In Exchange For Reduction Of Capital Lease Liability</link:label>
    <link:label id="lab_carm_DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability_documentation_en-US" xlink:label="lab_carm_DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Of Property, Plant And Equipment In Exchange For Reduction Of Capital Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability" xlink:href="carm-20241231.xsd#carm_DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability" xlink:to="lab_carm_DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_befb7580-39ef-4543-a17a-1a04075c776f_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_8ae9dcb3-30ba-41fd-90ce-57e08d7b89ce_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_143ab998-0656-4c9b-9b9f-8181858998c5_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anti-dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_88899099-77d4-46d5-b01d-ba4e3a8ba0ba_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_3df6e447-01dd-4f15-8729-1e948dc8936e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Estimated Revenue Expected to be Recognized in The Future Related to Performance Obligations</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_cc10ee0a-3acd-430b-b499-87691e73fa51_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_838014d9-8b6b-4824-8d84-d84089f1afdb_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of the year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_35f4ea41-bead-4041-bc98-59795ef54bff_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of the year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_OptionRightCollaborationRevenuesMember_6a3a7a57-8868-4dcf-93cd-759e9ebc4360_terseLabel_en-US" xlink:label="lab_carm_OptionRightCollaborationRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Right Collaboration Revenues</link:label>
    <link:label id="lab_carm_OptionRightCollaborationRevenuesMember_label_en-US" xlink:label="lab_carm_OptionRightCollaborationRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Right Collaboration Revenues [Member]</link:label>
    <link:label id="lab_carm_OptionRightCollaborationRevenuesMember_documentation_en-US" xlink:label="lab_carm_OptionRightCollaborationRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Right Collaboration Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_OptionRightCollaborationRevenuesMember" xlink:href="carm-20241231.xsd#carm_OptionRightCollaborationRevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_OptionRightCollaborationRevenuesMember" xlink:to="lab_carm_OptionRightCollaborationRevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_480c03fb-e340-4d8e-a001-3c3ecf344d1b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future compensation cost for awards not vested</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_d7d72df9-e862-4bad-8677-348278e4c179_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_9267d528-aff7-4961-b66d-d5cb28c0a3dd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_b7ce86f3-5db7-4fec-a5e5-5408c0a95df1_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_83da54ed-a0f4-4e6d-ae9f-543d6a27e582_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short term lease cost</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_b0296d43-2cd6-4ba1-82ad-8a9534ad3a52_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2f923a36-3506-4524-bc06-768201b109a7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_628e5fc2-433d-44a6-b800-2b9ee6fcfe83_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_3901414d-9fea-4339-801d-fc1df10546ad_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_06338edf-4ff8-4edf-9467-1cc68c93c1a1_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_aacc17ca-2b85-4bd7-b594-ce7080b44b9c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_IncreaseDecreaseInFinanceLeaseRightOfUseAssetLeaseModification_9ec15b45-c254-44b5-9243-de9fe5e3134f_negatedTerseLabel_en-US" xlink:label="lab_carm_IncreaseDecreaseInFinanceLeaseRightOfUseAssetLeaseModification" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Decrease in finance lease, right-of-use asset, lease modification</link:label>
    <link:label id="lab_carm_IncreaseDecreaseInFinanceLeaseRightOfUseAssetLeaseModification_label_en-US" xlink:label="lab_carm_IncreaseDecreaseInFinanceLeaseRightOfUseAssetLeaseModification" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Finance Lease, Right-of-Use Asset, Lease Modification</link:label>
    <link:label id="lab_carm_IncreaseDecreaseInFinanceLeaseRightOfUseAssetLeaseModification_documentation_en-US" xlink:label="lab_carm_IncreaseDecreaseInFinanceLeaseRightOfUseAssetLeaseModification" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Finance Lease, Right-of-Use Asset, Lease Modification</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_IncreaseDecreaseInFinanceLeaseRightOfUseAssetLeaseModification" xlink:href="carm-20241231.xsd#carm_IncreaseDecreaseInFinanceLeaseRightOfUseAssetLeaseModification"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_IncreaseDecreaseInFinanceLeaseRightOfUseAssetLeaseModification" xlink:to="lab_carm_IncreaseDecreaseInFinanceLeaseRightOfUseAssetLeaseModification" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_49cd83ce-4d22-4ff6-bf34-19b09838bbd0_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_e7925904-ce57-461d-aaf6-7778727c150d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_46378cc9-5ea1-4882-b36a-928892d8893b_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b23403c9-9bc3-4e71-a37e-3b5ea7e88cff_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_StateJurisdictionMember_a89dd783-b76c-4909-82aa-048e36a586ff_terseLabel_en-US" xlink:label="lab_carm_StateJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_carm_StateJurisdictionMember_label_en-US" xlink:label="lab_carm_StateJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State Jurisdiction [Member]</link:label>
    <link:label id="lab_carm_StateJurisdictionMember_documentation_en-US" xlink:label="lab_carm_StateJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">State Jurisdiction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_StateJurisdictionMember" xlink:href="carm-20241231.xsd#carm_StateJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_StateJurisdictionMember" xlink:to="lab_carm_StateJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_915badd8-6a69-4615-a531-0248716e845b_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_d0f6c4c1-ebd0-4edf-a4a2-e103d783dee8_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_ModernaLicenseAgreementMember_1fee4631-26fa-46d7-9f98-269c70b0e09b_terseLabel_en-US" xlink:label="lab_carm_ModernaLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Moderna License Agreement</link:label>
    <link:label id="lab_carm_ModernaLicenseAgreementMember_label_en-US" xlink:label="lab_carm_ModernaLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Moderna License Agreement [Member]</link:label>
    <link:label id="lab_carm_ModernaLicenseAgreementMember_documentation_en-US" xlink:label="lab_carm_ModernaLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to moderna license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ModernaLicenseAgreementMember" xlink:href="carm-20241231.xsd#carm_ModernaLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_ModernaLicenseAgreementMember" xlink:to="lab_carm_ModernaLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_43b1238a-fe5e-47fb-b3d9-c0d680a27a1f_terseLabel_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Personnel expense</link:label>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_label_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Labor and Related Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LaborAndRelatedExpense" xlink:to="lab_us-gaap_LaborAndRelatedExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9bf2ced2-308e-4a7d-887d-8a079873c35c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable as of December 31, 2024 (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses_8edbc1b3-4800-4af9-90d9-58fd0672d21b_terseLabel_en-US" xlink:label="lab_carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative, excluding facilities and personnel expenses, depreciation and amortization expenses</link:label>
    <link:label id="lab_carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses_label_en-US" xlink:label="lab_carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General And Administrative, Excluding Facilities And Personnel Expenses, Depreciation And Amortization Expenses</link:label>
    <link:label id="lab_carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses_documentation_en-US" xlink:label="lab_carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">General And Administrative, Excluding Facilities And Personnel Expenses, Depreciation And Amortization Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses" xlink:href="carm-20241231.xsd#carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses" xlink:to="lab_carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_233da403-a919-4685-9355-e7dbed230e16_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_f75be94a-476e-4c21-b96d-947cbd99cd5c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d4b61037-ace8-413e-ba81-f28ffd972d5a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_5f0aa81e-ad68-4041-affe-7d7b3701df87_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets obtained in exchange for new financing lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_82b694ea-ab7f-42db-9c84-1a638b194db9_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_NumberOfResearchTargetsNominatedReplacements_5e86d8f4-8c60-4b52-8962-b6bc2f0249e5_terseLabel_en-US" xlink:label="lab_carm_NumberOfResearchTargetsNominatedReplacements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of research targets, replacement nominations</link:label>
    <link:label id="lab_carm_NumberOfResearchTargetsNominatedReplacements_label_en-US" xlink:label="lab_carm_NumberOfResearchTargetsNominatedReplacements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Research Targets Nominated, Replacements</link:label>
    <link:label id="lab_carm_NumberOfResearchTargetsNominatedReplacements_documentation_en-US" xlink:label="lab_carm_NumberOfResearchTargetsNominatedReplacements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Research Targets Nominated, Replacements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NumberOfResearchTargetsNominatedReplacements" xlink:href="carm-20241231.xsd#carm_NumberOfResearchTargetsNominatedReplacements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_NumberOfResearchTargetsNominatedReplacements" xlink:to="lab_carm_NumberOfResearchTargetsNominatedReplacements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_ed7a23c9-97f1-4a73-b4a0-751e56283521_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_dd97dc99-4648-48bc-8ff8-aad38c6137ac_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_LocalJurisdictionMember_1ee10daf-9f48-40d7-b055-0033f308bcb3_terseLabel_en-US" xlink:label="lab_carm_LocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local</link:label>
    <link:label id="lab_carm_LocalJurisdictionMember_label_en-US" xlink:label="lab_carm_LocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Jurisdiction [Member]</link:label>
    <link:label id="lab_carm_LocalJurisdictionMember_documentation_en-US" xlink:label="lab_carm_LocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Local Jurisdiction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_LocalJurisdictionMember" xlink:href="carm-20241231.xsd#carm_LocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_LocalJurisdictionMember" xlink:to="lab_carm_LocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_80728f33-e6cc-4c49-81c1-97a07d15baff_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_db81383a-674a-4904-ab94-d500765e372d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating losses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_1ab7953f-41aa-40bb-bd6a-5ff76847523c_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lab equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_c861df61-eed6-494e-96aa-f5a7e58705b9_verboseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Laboratory Equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_0716e1e5-55ad-4c06-8929-e68d7a2f3403_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses_cd420b6e-1f33-473a-a8d5-6ea566e68231_terseLabel_en-US" xlink:label="lab_carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development, excluding facilities, personnel, depreciation and amortization expenses</link:label>
    <link:label id="lab_carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses_label_en-US" xlink:label="lab_carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development, Excluding Facilities, Personnel, Depreciation and Amortization Expenses</link:label>
    <link:label id="lab_carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses_documentation_en-US" xlink:label="lab_carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and Development, Excluding Facilities, Personnel, Depreciation and Amortization Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses" xlink:href="carm-20241231.xsd#carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses" xlink:to="lab_carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidInsurance_90f5a7bd-9ab9-4059-bc76-59d1e4cffcaf_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insurance</link:label>
    <link:label id="lab_us-gaap_PrepaidInsurance_label_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_20e967f2-9c0c-4385-ba48-f9c1df713866_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_23a53ccb-202d-4b01-b232-7fe00310cde4_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_65995147-db55-4464-90bd-736b7d5e8110_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_11c1f2d7-389a-4b8f-9db0-e065b8a0dfa0_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_f0069683-40c1-4d8f-879f-e60b435b597d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_39d124fe-3b0f-4896-8e86-3adb739f6f52_negatedLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_4802e91e-d8a9-43d7-af17-34331c51e1f6_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_58b9e75f-3c1c-449c-80db-fa68e2677f75_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares of common stock outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_c05ac6ed-afb5-4978-964f-ca915050f838_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected cost with the reduction in workforce</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_9aefee5a-54af-4389-8ed0-fea1966ec5d4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_c07f1cad-ceea-44b7-a606-ed4af04005dd_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_e547f287-ccbe-4858-8d3f-3a4fa4dcb582_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_DevelopmentStageRisksAndLiquidityTextBlock_6954b80c-121b-4361-8d17-f053e9fcf1a7_terseLabel_en-US" xlink:label="lab_carm_DevelopmentStageRisksAndLiquidityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development-Stage Risks and Liquidity</link:label>
    <link:label id="lab_carm_DevelopmentStageRisksAndLiquidityTextBlock_label_en-US" xlink:label="lab_carm_DevelopmentStageRisksAndLiquidityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development-Stage Risks and Liquidity [Text Block]</link:label>
    <link:label id="lab_carm_DevelopmentStageRisksAndLiquidityTextBlock_documentation_en-US" xlink:label="lab_carm_DevelopmentStageRisksAndLiquidityTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development-Stage Risks and Liquidity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DevelopmentStageRisksAndLiquidityTextBlock" xlink:href="carm-20241231.xsd#carm_DevelopmentStageRisksAndLiquidityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_DevelopmentStageRisksAndLiquidityTextBlock" xlink:to="lab_carm_DevelopmentStageRisksAndLiquidityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_f9245219-2e7f-41d4-9e76-2eab1d548d21_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_25326fd5-43bf-44f1-8465-bdcf4fde1b30_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_fcb3287d-94d1-409b-8fc8-c8e8076086f5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock_0cc0689f-c8ff-498a-8e7a-dcffd89ddd87_terseLabel_en-US" xlink:label="lab_carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Lease Term and Discount Rate Information</link:label>
    <link:label id="lab_carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock_label_en-US" xlink:label="lab_carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating and Finance Lease, Lease term and Discount Rate Information [Table Text Block]</link:label>
    <link:label id="lab_carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock_documentation_en-US" xlink:label="lab_carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The tabular disclosure of ease term and discount rate information relating to operating and finance leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock" xlink:href="carm-20241231.xsd#carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock" xlink:to="lab_carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_AgreementTerm_3ccc3b41-aa2e-4114-a74b-cd41e4523a3c_terseLabel_en-US" xlink:label="lab_carm_AgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement term (in years)</link:label>
    <link:label id="lab_carm_AgreementTerm_label_en-US" xlink:label="lab_carm_AgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreement term</link:label>
    <link:label id="lab_carm_AgreementTerm_documentation_en-US" xlink:label="lab_carm_AgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The period of agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AgreementTerm" xlink:href="carm-20241231.xsd#carm_AgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_AgreementTerm" xlink:to="lab_carm_AgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_1282f63f-d306-4407-860e-5fcd4d426e8b_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3add4b5e-75f0-4687-a96c-358dd6f92806_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_67cb1a49-24c3-4b06-a914-97d826dce05e_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0a86dc88-34ec-4aa2-bcb1-b7120e8705cb_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding as of December 31, 2024</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_a8606822-099a-4799-855b-1c67a483c0b6_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a8e372b1-c5a5-4aec-9628-a9081b46ad58_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_1539dddc-92c9-49a5-9f77-c383c02f91bd_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_adebc48b-8c79-45bd-ae41-ac7ffff44fb1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Significant Expense Categories by Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_Pre2018Member_c32bf820-fac4-47a7-bcf5-33b71de27533_terseLabel_en-US" xlink:label="lab_carm_Pre2018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-2018</link:label>
    <link:label id="lab_carm_Pre2018Member_label_en-US" xlink:label="lab_carm_Pre2018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-2018 [Member]</link:label>
    <link:label id="lab_carm_Pre2018Member_documentation_en-US" xlink:label="lab_carm_Pre2018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre-2018</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_Pre2018Member" xlink:href="carm-20241231.xsd#carm_Pre2018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_Pre2018Member" xlink:to="lab_carm_Pre2018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_5fe72930-6003-4d37-aa05-753eee372bfb_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_15c72d2c-40b1-492d-920d-914a5e9c295d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_dbf0ba98-3a6b-47ff-bcd0-1a025ee313a3_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a7d03fd4-bfd6-4f4d-8127-40d23002752d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable as of December 31, 2024</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_DeferredTaxAssetsEquityCompensation_311ade6f-881e-45a5-935f-bb3dd1b05b7f_terseLabel_en-US" xlink:label="lab_carm_DeferredTaxAssetsEquityCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity compensation</link:label>
    <link:label id="lab_carm_DeferredTaxAssetsEquityCompensation_label_en-US" xlink:label="lab_carm_DeferredTaxAssetsEquityCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Equity Compensation</link:label>
    <link:label id="lab_carm_DeferredTaxAssetsEquityCompensation_documentation_en-US" xlink:label="lab_carm_DeferredTaxAssetsEquityCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Equity Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DeferredTaxAssetsEquityCompensation" xlink:href="carm-20241231.xsd#carm_DeferredTaxAssetsEquityCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_DeferredTaxAssetsEquityCompensation" xlink:to="lab_carm_DeferredTaxAssetsEquityCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_RevenueRemainingPerformanceObligationOptionRightsAmount_e37e3112-7715-4603-878f-86267dbf15c8_terseLabel_en-US" xlink:label="lab_carm_RevenueRemainingPerformanceObligationOptionRightsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option rights</link:label>
    <link:label id="lab_carm_RevenueRemainingPerformanceObligationOptionRightsAmount_label_en-US" xlink:label="lab_carm_RevenueRemainingPerformanceObligationOptionRightsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Option Rights, Amount</link:label>
    <link:label id="lab_carm_RevenueRemainingPerformanceObligationOptionRightsAmount_documentation_en-US" xlink:label="lab_carm_RevenueRemainingPerformanceObligationOptionRightsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of transaction price allocated to option rights performance obligation that has not been recognized as revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_RevenueRemainingPerformanceObligationOptionRightsAmount" xlink:href="carm-20241231.xsd#carm_RevenueRemainingPerformanceObligationOptionRightsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_RevenueRemainingPerformanceObligationOptionRightsAmount" xlink:to="lab_carm_RevenueRemainingPerformanceObligationOptionRightsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_29b8f773-151a-4d73-994a-22be57fe9371_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_873e7a62-b296-4ae2-ad07-42af69079cde_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_c3a15721-1844-4347-be9f-7d918cb14185_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_SaleOfStockMaximumOfferingAmount_d4d54bd5-2b59-4da9-8a87-e688e4fa204a_terseLabel_en-US" xlink:label="lab_carm_SaleOfStockMaximumOfferingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, maximum aggregate offering price</link:label>
    <link:label id="lab_carm_SaleOfStockMaximumOfferingAmount_label_en-US" xlink:label="lab_carm_SaleOfStockMaximumOfferingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Maximum Offering Amount</link:label>
    <link:label id="lab_carm_SaleOfStockMaximumOfferingAmount_documentation_en-US" xlink:label="lab_carm_SaleOfStockMaximumOfferingAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Maximum Offering Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_SaleOfStockMaximumOfferingAmount" xlink:href="carm-20241231.xsd#carm_SaleOfStockMaximumOfferingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_SaleOfStockMaximumOfferingAmount" xlink:to="lab_carm_SaleOfStockMaximumOfferingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_7b663ec2-ff48-41b4-b075-433cadbaadc2_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_35552021-101a-494d-8067-4fcdd950e073_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_d6a6a241-6544-4280-be2b-ee6ed0cbe730_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at the end of the period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_4fff9bb5-782e-4a30-9a6d-11610911573d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of deferred financing costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Financing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_536368da-baee-4c52-a05d-bf01aa6bd905_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office furniture</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ec2b0202-2cbb-4b96-bccb-e43549dfb9d3_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_f168462f-2b96-4c2d-97a4-0f7b1c746aee_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_ContractWithCustomerLiabilityDeferralOfRevenue_920f5075-2c87-485e-a278-9f53e9c7eebe_terseLabel_en-US" xlink:label="lab_carm_ContractWithCustomerLiabilityDeferralOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferral of revenue</link:label>
    <link:label id="lab_carm_ContractWithCustomerLiabilityDeferralOfRevenue_label_en-US" xlink:label="lab_carm_ContractWithCustomerLiabilityDeferralOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer Liability, Deferral of Revenue</link:label>
    <link:label id="lab_carm_ContractWithCustomerLiabilityDeferralOfRevenue_documentation_en-US" xlink:label="lab_carm_ContractWithCustomerLiabilityDeferralOfRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of revenue deferred.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ContractWithCustomerLiabilityDeferralOfRevenue" xlink:href="carm-20241231.xsd#carm_ContractWithCustomerLiabilityDeferralOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_ContractWithCustomerLiabilityDeferralOfRevenue" xlink:to="lab_carm_ContractWithCustomerLiabilityDeferralOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_3bfbb0de-6e3a-4593-ab0a-d573d941021d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_840b101d-864d-4c0c-9969-d9a638aa668e_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issue price per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_c0167b27-223c-4234-b9c9-454ba87058c0_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_813e7f17-0f30-4b94-b060-1dcddc0c2763_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Estimated Using The Black-Scholes Option-Pricing Model</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_ad4f6c06-8345-4534-ae25-ac6267aeb583_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_f49553c6-e2dc-4f6a-b38a-004f19dde7f6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Merger with Sesen Bio</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_98d01040-ebf4-4519-ac07-99317bae4421_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d287b3ed-e09c-47eb-8d3a-75786bb7a9e2_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_9c0fb8ee-9600-4088-a73c-036c75ccbe1d_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_ae6502a9-723b-4fb6-a136-5446cd6a78ed_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount to the market price (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_0d07a256-2b0b-4e96-a4e2-dfbc8e07e9ea_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_a411673f-648e-4bd7-bb9f-6d933dd7f501_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease, accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_ProceedsFromFailedSaleLeasebackTransaction_78a2ba68-3216-4bae-99a9-0e20abcf3d17_terseLabel_en-US" xlink:label="lab_carm_ProceedsFromFailedSaleLeasebackTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from failed sale-leaseback arrangement</link:label>
    <link:label id="lab_carm_ProceedsFromFailedSaleLeasebackTransaction_label_en-US" xlink:label="lab_carm_ProceedsFromFailedSaleLeasebackTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Failed Sale Leaseback Transaction</link:label>
    <link:label id="lab_carm_ProceedsFromFailedSaleLeasebackTransaction_documentation_en-US" xlink:label="lab_carm_ProceedsFromFailedSaleLeasebackTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of cash inflow received by a seller-lessee in a failed sale-leaseback recognized in financing activities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ProceedsFromFailedSaleLeasebackTransaction" xlink:href="carm-20241231.xsd#carm_ProceedsFromFailedSaleLeasebackTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_ProceedsFromFailedSaleLeasebackTransaction" xlink:to="lab_carm_ProceedsFromFailedSaleLeasebackTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_25e48c73-e877-4e8c-b739-67fba3e629fb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_d3d31aa5-d458-4350-9329-f05f75af9655_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_032014fc-ef66-41de-8909-2fd59fe7905b_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_ed5e71b5-2a72-4586-b22a-906ac05ced51_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_ba918ad2-fe17-4c29-9b46-3c51718fc931_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8e739a27-9ac2-43de-9b0d-595777cbfc36_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Dilutive Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_30124a67-86f3-4415-9fb6-b5dad4a768e7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total net assets acquired less transaction costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_016b0cc1-044b-4bc9-b58a-3e3db415a0f2_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total net assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_NonCashEffectOfModificationOfOperatingLeaseRightOfUseAssetsOperatingLeaseLiabilities_e51a896d-fe52-40fa-9aa7-2a7c94bd69bd_terseLabel_en-US" xlink:label="lab_carm_NonCashEffectOfModificationOfOperatingLeaseRightOfUseAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Modification of operating lease right-of-use asset and operating lease liabilities</link:label>
    <link:label id="lab_carm_NonCashEffectOfModificationOfOperatingLeaseRightOfUseAssetsOperatingLeaseLiabilities_label_en-US" xlink:label="lab_carm_NonCashEffectOfModificationOfOperatingLeaseRightOfUseAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Cash Effect of Modification of Operating Lease Right-of-Use Assets Operating Lease Liabilities</link:label>
    <link:label id="lab_carm_NonCashEffectOfModificationOfOperatingLeaseRightOfUseAssetsOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_carm_NonCashEffectOfModificationOfOperatingLeaseRightOfUseAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Cash Effect of Modification of Operating Lease Right-of-Use Assets Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NonCashEffectOfModificationOfOperatingLeaseRightOfUseAssetsOperatingLeaseLiabilities" xlink:href="carm-20241231.xsd#carm_NonCashEffectOfModificationOfOperatingLeaseRightOfUseAssetsOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_NonCashEffectOfModificationOfOperatingLeaseRightOfUseAssetsOperatingLeaseLiabilities" xlink:to="lab_carm_NonCashEffectOfModificationOfOperatingLeaseRightOfUseAssetsOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_ffbe633c-16be-49b3-94f2-1517458b44d5_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (decrease) increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_d1f3688f-3d29-4087-a4b7-7a628b3d4a65_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_CarismaTherapeuticsIncLegacyStockholdersMember_53679e1d-6d43-418f-b1e3-ca683170ddea_terseLabel_en-US" xlink:label="lab_carm_CarismaTherapeuticsIncLegacyStockholdersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CARISMA Therapeutics Inc, Legacy, Stockholders</link:label>
    <link:label id="lab_carm_CarismaTherapeuticsIncLegacyStockholdersMember_label_en-US" xlink:label="lab_carm_CarismaTherapeuticsIncLegacyStockholdersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CARISMA Therapeutics Inc, Legacy, Stockholders [Member]</link:label>
    <link:label id="lab_carm_CarismaTherapeuticsIncLegacyStockholdersMember_documentation_en-US" xlink:label="lab_carm_CarismaTherapeuticsIncLegacyStockholdersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the stockholders of legacy CARISMA Therapeutics, prior to the merger.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CarismaTherapeuticsIncLegacyStockholdersMember" xlink:href="carm-20241231.xsd#carm_CarismaTherapeuticsIncLegacyStockholdersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_CarismaTherapeuticsIncLegacyStockholdersMember" xlink:to="lab_carm_CarismaTherapeuticsIncLegacyStockholdersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_416c0bc6-f961-401d-98da-cfe38d001865_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_ContractTerm_dfa7843e-cd89-4d12-9c46-fd20fa51b7ab_terseLabel_en-US" xlink:label="lab_carm_ContractTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of contract (in years)</link:label>
    <link:label id="lab_carm_ContractTerm_label_en-US" xlink:label="lab_carm_ContractTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Term</link:label>
    <link:label id="lab_carm_ContractTerm_documentation_en-US" xlink:label="lab_carm_ContractTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period of contract.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ContractTerm" xlink:href="carm-20241231.xsd#carm_ContractTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_ContractTerm" xlink:to="lab_carm_ContractTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_ResearchAndDevelopmentServicesMember_83600699-5775-4e50-bbfa-f3bf013c1dcb_terseLabel_en-US" xlink:label="lab_carm_ResearchAndDevelopmentServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Services</link:label>
    <link:label id="lab_carm_ResearchAndDevelopmentServicesMember_label_en-US" xlink:label="lab_carm_ResearchAndDevelopmentServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Services [Member]</link:label>
    <link:label id="lab_carm_ResearchAndDevelopmentServicesMember_documentation_en-US" xlink:label="lab_carm_ResearchAndDevelopmentServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to research and development services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ResearchAndDevelopmentServicesMember" xlink:href="carm-20241231.xsd#carm_ResearchAndDevelopmentServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_ResearchAndDevelopmentServicesMember" xlink:to="lab_carm_ResearchAndDevelopmentServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_60a50147-debb-4ec7-a6d1-2056c7af74e6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_150ff73d-66f5-4d94-972a-44aa43cf396e_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_bf63f017-8138-410e-a74c-5ad4c5d23550_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently adopted accounting pronouncements and Recently issued but not yet adopted accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_b8e6e9ff-fcdb-4a46-9143-4c935986b075_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share of common stock, diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments_e267868e-fa59-42aa-8bfc-3b3eb14dccb4_terseLabel_en-US" xlink:label="lab_carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount receivable per product</link:label>
    <link:label id="lab_carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments_label_en-US" xlink:label="lab_carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount Receivable Per Product in Development Target Designation, Development, Regulatory and Commercial Milestone Payments</link:label>
    <link:label id="lab_carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments_documentation_en-US" xlink:label="lab_carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount receivable per product in development target designation, development, regulatory and commercial milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments" xlink:href="carm-20241231.xsd#carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments" xlink:to="lab_carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_fe850d3d-ccb4-4f15-b5e7-30effeb7e0e7_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember_e4281145-31f9-4731-9577-0b392ef69adc_terseLabel_en-US" xlink:label="lab_carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Novartis Agreement</link:label>
    <link:label id="lab_carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember_label_en-US" xlink:label="lab_carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Manufacturing and Supply Agreement with Novartis Pharmaceuticals Corporation [Member]</link:label>
    <link:label id="lab_carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember_documentation_en-US" xlink:label="lab_carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to manufacturing and supply agreement with Novartis Pharmaceuticals Corporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember" xlink:href="carm-20241231.xsd#carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember" xlink:to="lab_carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_ed02c046-3bdf-4347-aa1c-55de6aea1239_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_71ad564d-d3c4-47b0-971d-71a024d8125e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction in the operating right of use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_5bd8d05e-893c-4712-a858-76969853c290_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_39aeb1e9-a98e-4ac3-b5b7-51209e2cf38a_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_8a3d611c-7b33-4d11-b96d-690d5ab2e701_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease in contract with customer, liability</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_198fa771-14dc-44ea-9a7e-0ea961e169f2_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and marketable securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_f8ebdfc4-172c-41a8-a83b-2aacc663c3cc_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_66cf7abe-851f-4aa7-b39e-c779222864e8_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction in workforce (as a percent)</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_3dc91bfa-79e9-4032-8879-a62dca9603a9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_b08cbd7e-f6c4-4e2a-898a-a14c90a90a19_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_2f5e1351-b698-4044-96d3-5f8a521f82d7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value Hierarchy of Assets Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_ff25340e-829a-4dab-824b-4ffce3cfacb3_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross proceeds</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received Per Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_3ddd128d-61de-4385-8c87-bd9620f5f5a0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Severance</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_078b2742-2f1c-4c0a-bab4-dc435fba3354_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests_e0479f3a-d198-4c79-83e7-8501b46f20a7_terseLabel_en-US" xlink:label="lab_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued upon conversion of convertible preferred stock and exchangeable shares previously presented as noncontrolling interests (in shares)</link:label>
    <link:label id="lab_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests_label_en-US" xlink:label="lab_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Preferred Stock and Non-Controlling Interests</link:label>
    <link:label id="lab_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests_documentation_en-US" xlink:label="lab_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of stock issued during the period upon the conversion of convertible preferred stock and noncontrolling interests.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests" xlink:href="carm-20241231.xsd#carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests" xlink:to="lab_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_AtTheMarketMember_b4312433-050f-4ff9-bea6-5f8f822e4d63_terseLabel_en-US" xlink:label="lab_carm_AtTheMarketMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At-the-Market</link:label>
    <link:label id="lab_carm_AtTheMarketMember_label_en-US" xlink:label="lab_carm_AtTheMarketMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At-the-Market [Member]</link:label>
    <link:label id="lab_carm_AtTheMarketMember_documentation_en-US" xlink:label="lab_carm_AtTheMarketMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At-the-Market</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AtTheMarketMember" xlink:href="carm-20241231.xsd#carm_AtTheMarketMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_AtTheMarketMember" xlink:to="lab_carm_AtTheMarketMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_b53e8917-4507-471d-95f7-e62a5a5e457d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_d9670753-3669-4384-9228-ca6b6140dcff_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets, net of valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepositsAssetsCurrent_6b4b2b17-114b-4380-b955-7b48e8e58e13_terseLabel_en-US" xlink:label="lab_us-gaap_DepositsAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deposits</link:label>
    <link:label id="lab_us-gaap_DepositsAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DepositsAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deposits Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositsAssetsCurrent" xlink:to="lab_us-gaap_DepositsAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_498262ca-bd0a-4365-9771-0d273465f80a_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosures of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8807f982-36c4-43d0-859e-8a0eb0dd425c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average period compensation cost of unvested awards to be expensed (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_TrusteesOfUniversityOfPennsylvaniaMember_2f824207-f41d-40a3-a9c3-0c8ac4e901a7_terseLabel_en-US" xlink:label="lab_carm_TrusteesOfUniversityOfPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Penn</link:label>
    <link:label id="lab_carm_TrusteesOfUniversityOfPennsylvaniaMember_label_en-US" xlink:label="lab_carm_TrusteesOfUniversityOfPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trustees of the University of Pennsylvania [Member]</link:label>
    <link:label id="lab_carm_TrusteesOfUniversityOfPennsylvaniaMember_documentation_en-US" xlink:label="lab_carm_TrusteesOfUniversityOfPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to Trustees of the University of Pennsylvania .</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_TrusteesOfUniversityOfPennsylvaniaMember" xlink:href="carm-20241231.xsd#carm_TrusteesOfUniversityOfPennsylvaniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_TrusteesOfUniversityOfPennsylvaniaMember" xlink:to="lab_carm_TrusteesOfUniversityOfPennsylvaniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9eeeb243-4aa9-43cf-8b1b-4df1254173e9_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaboration revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_TwoThousandSeventeenStockIncentivePlanMember_2ab0a01f-29f9-4bce-8d23-7810653d2302_terseLabel_en-US" xlink:label="lab_carm_TwoThousandSeventeenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 Stock Incentive Plan</link:label>
    <link:label id="lab_carm_TwoThousandSeventeenStockIncentivePlanMember_label_en-US" xlink:label="lab_carm_TwoThousandSeventeenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Seventeen Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_carm_TwoThousandSeventeenStockIncentivePlanMember_documentation_en-US" xlink:label="lab_carm_TwoThousandSeventeenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Two Thousand Seventeen Stock Incentive, a Legacy Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_TwoThousandSeventeenStockIncentivePlanMember" xlink:href="carm-20241231.xsd#carm_TwoThousandSeventeenStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_TwoThousandSeventeenStockIncentivePlanMember" xlink:to="lab_carm_TwoThousandSeventeenStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_29c4306f-a231-4f6e-8c09-2d8813168875_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_08e0aac0-b634-477e-95f3-bf45dd899ddb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_0808e0a2-b677-462e-b7d1-6e9cc4a09016_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d04ea7eb-440d-4419-aa39-0ed90c36a97c_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total provision</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_ef3d6594-6e52-496e-9879-1a305a4db18a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_2de716ae-a59b-4a74-a25c-affb45c28f14_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_62f2851c-610e-4e4b-b6ac-c16d14d35321_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_311010d2-2501-41c0-9d6b-c7ace36a0a08_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_90629295-a0cb-4f47-a63e-403a1e0b5076_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Merger with Sesen Bio</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_755c1172-4065-47a1-bdb2-58832ae72015_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; (deficit) equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_a326bff2-ea33-4bf7-9f22-143160e56a03_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities_8d199139-9886-4fe9-b948-a6087823523a_terseLabel_en-US" xlink:label="lab_carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain on marketable securities</link:label>
    <link:label id="lab_carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities_label_en-US" xlink:label="lab_carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash or Part Noncash, Unrealized Gain (Loss) on Marketable Securities</link:label>
    <link:label id="lab_carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities_documentation_en-US" xlink:label="lab_carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of unrealized gain (loss) on marketable securities in a noncash (or part noncash) transaction.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities" xlink:href="carm-20241231.xsd#carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities" xlink:to="lab_carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_323d7bbe-d1ca-40ba-9ff9-db1d92844f1d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation and related expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_a786a724-0c5d-4761-840e-d1be640876d6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_FinanceLeaseCost_4bae9f61-f797-4cbc-a5a6-46891194298c_totalLabel_en-US" xlink:label="lab_carm_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total finance lease cost</link:label>
    <link:label id="lab_carm_FinanceLeaseCost_label_en-US" xlink:label="lab_carm_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease Cost</link:label>
    <link:label id="lab_carm_FinanceLeaseCost_documentation_en-US" xlink:label="lab_carm_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of finance lease cost expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_FinanceLeaseCost" xlink:href="carm-20241231.xsd#carm_FinanceLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_FinanceLeaseCost" xlink:to="lab_carm_FinanceLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2e854e91-9517-4a41-817b-2441750b2dc9_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_bc216cb2-ec13-4356-a17a-940a57eb4bad_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_21a1b8c4-119e-406f-8735-2bd4bbc551b2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_d1c43ea9-50c8-4025-aabf-30eed5567897_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_1395cd08-0a44-4e29-9c17-6fbad1a4a017_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_2300dc48-f950-4848-b6f4-76ed137ac4c6_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b9b320ec-5f6c-4812-bd5c-d7acd1c7cf30_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_1df8ebbc-f9eb-4df6-ab4f-68a85e0451cc_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_64e39a19-5da5-4185-ad68-9f28ab5f7432_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal_cbeb827a-bde5-483d-916b-d65c93fa06c1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">State and local tax rate change</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, State and Local, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_NumberOfResearchTargetsTerminatedAutoimmune_ad0a539e-ade0-4dc2-beae-f281250ede63_terseLabel_en-US" xlink:label="lab_carm_NumberOfResearchTargetsTerminatedAutoimmune" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of autoimmune research targets, ceased development</link:label>
    <link:label id="lab_carm_NumberOfResearchTargetsTerminatedAutoimmune_label_en-US" xlink:label="lab_carm_NumberOfResearchTargetsTerminatedAutoimmune" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Research Targets, Terminated, Autoimmune</link:label>
    <link:label id="lab_carm_NumberOfResearchTargetsTerminatedAutoimmune_documentation_en-US" xlink:label="lab_carm_NumberOfResearchTargetsTerminatedAutoimmune" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Research Targets, Terminated, Autoimmune</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NumberOfResearchTargetsTerminatedAutoimmune" xlink:href="carm-20241231.xsd#carm_NumberOfResearchTargetsTerminatedAutoimmune"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_NumberOfResearchTargetsTerminatedAutoimmune" xlink:to="lab_carm_NumberOfResearchTargetsTerminatedAutoimmune" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_1085b0a8-8cfb-4e4c-9a5a-ef335063955e_terseLabel_en-US" xlink:label="lab_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">No definition available.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:href="carm-20241231.xsd#carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="lab_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_04449175-c6a4-46cc-8e44-dae11e2d5de8_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets obtained in exchange for new operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_83393001-13b5-4358-b293-9f20eb7dc1b5_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cae616f0-5cd9-4628-a4d6-c44982030238_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9e038c17-355e-4bdb-8c30-5576a8793611_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_69c099e5-cb2a-4179-b06a-573bc23e6ac2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_6166eeee-98e2-44c4-8c6b-4202905d498d_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_81137eae-6f34-42ae-ae33-90eb9a86908f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_7b09d2c6-b2f6-4b32-97af-bd64fe38c794_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_d91f0e29-96af-4827-b04b-9f129ea45f89_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_c9e332ca-0d24-414f-a9c0-c62dc954111c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Compensated Absences</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_ad49954f-a0e9-4d7c-b5ff-5d49c5fb5071_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_d9bd783b-db6b-433a-9b6c-5dc8ea71e734_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_54effcea-0406-4a73-9776-0b14a179be25_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and Stockholders' (Deficit) Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_Post2017Member_2f6b10d8-0299-44cb-9573-12dd676c782e_terseLabel_en-US" xlink:label="lab_carm_Post2017Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Post-2017</link:label>
    <link:label id="lab_carm_Post2017Member_label_en-US" xlink:label="lab_carm_Post2017Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Post-2017 [Member]</link:label>
    <link:label id="lab_carm_Post2017Member_documentation_en-US" xlink:label="lab_carm_Post2017Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Post-2017</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_Post2017Member" xlink:href="carm-20241231.xsd#carm_Post2017Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_Post2017Member" xlink:to="lab_carm_Post2017Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_1241788c-0a7c-4666-ba29-4beec9aeaa94_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer software</link:label>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Software Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember" xlink:to="lab_us-gaap_SoftwareDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_424983cf-391d-48aa-9f78-37d8a0edd25b_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss contingency, estimate of possible loss</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_85bcb2bd-3fe6-425d-9ec9-34bc2601b6d3_terseLabel_en-US" xlink:label="lab_carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label id="lab_carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_label_en-US" xlink:label="lab_carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Paid for Amounts Included in the Measurement of Lease Liabilities [Abstract]</link:label>
    <link:label id="lab_carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_documentation_en-US" xlink:label="lab_carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">No definition available.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:href="carm-20241231.xsd#carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="lab_carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_93482c16-62e5-45e3-8410-a6641579309c_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_68da1aae-5ef1-4d1e-8ba1-a3ecf54ebe2a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncurrent portion of deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_1a0000e9-69a9-455a-bd31-a1d518b67625_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_30009e0f-e75c-42af-b3d7-9d087ed8c653_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction_88a7751c-8920-4f7b-85fa-07f1d5d3b5dc_terseLabel_en-US" xlink:label="lab_carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for cash in pre-closing financing (in shares)</link:label>
    <link:label id="lab_carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction_label_en-US" xlink:label="lab_carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Pre-closing, Financing Transaction</link:label>
    <link:label id="lab_carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction_documentation_en-US" xlink:label="lab_carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares of stock issued during the period pursuant to pre-closing financing.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction" xlink:href="carm-20241231.xsd#carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction" xlink:to="lab_carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_30fa058a-f74d-49a3-9468-66fca30b0eb8_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding as of December 31, 2023 (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8295c1e6-af3d-49c4-99e1-80cf22d9fbe9_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding as of December 31, 2024 (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_UpfrontNonRefundablePaymentReceived_4a84d458-a715-4aed-8f12-e34e1def6b6f_terseLabel_en-US" xlink:label="lab_carm_UpfrontNonRefundablePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront non-refundable payment received</link:label>
    <link:label id="lab_carm_UpfrontNonRefundablePaymentReceived_label_en-US" xlink:label="lab_carm_UpfrontNonRefundablePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront Non-Refundable Payment Received</link:label>
    <link:label id="lab_carm_UpfrontNonRefundablePaymentReceived_documentation_en-US" xlink:label="lab_carm_UpfrontNonRefundablePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront non-refundable payment received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_UpfrontNonRefundablePaymentReceived" xlink:href="carm-20241231.xsd#carm_UpfrontNonRefundablePaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_UpfrontNonRefundablePaymentReceived" xlink:to="lab_carm_UpfrontNonRefundablePaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_42c26e6e-7185-459b-975c-f580f9280094_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right of use assets &#8211; operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_ModernaMember_02086ee5-53c4-44f4-9e2d-dbd93be69d8d_terseLabel_en-US" xlink:label="lab_carm_ModernaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Moderna</link:label>
    <link:label id="lab_carm_ModernaMember_label_en-US" xlink:label="lab_carm_ModernaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Moderna [Member]</link:label>
    <link:label id="lab_carm_ModernaMember_documentation_en-US" xlink:label="lab_carm_ModernaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to Moderna, a significant shareholder.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ModernaMember" xlink:href="carm-20241231.xsd#carm_ModernaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_ModernaMember" xlink:to="lab_carm_ModernaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5fcd3bd5-6e1c-46f1-bb72-005b15293bce_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding as of December 31, 2023 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1a6d78c8-2fa6-416c-92d0-71e45305b54a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding as of December 31, 2024 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_41cfef6d-01b6-4f8f-8791-cc3636fbac6a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodAxis_0011d0cc-c7b8-4c00-ad77-32510ea75e90_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodAxis_label_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_04012087-fe6a-4614-9be5-4ee0dbeee28b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Federal tax benefit at statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleLeasebackTransactionNetBookValue_6b73ebe2-b803-4142-b29d-b5c0ca066d1a_terseLabel_en-US" xlink:label="lab_us-gaap_SaleLeasebackTransactionNetBookValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale lease-back asset</link:label>
    <link:label id="lab_us-gaap_SaleLeasebackTransactionNetBookValue_label_en-US" xlink:label="lab_us-gaap_SaleLeasebackTransactionNetBookValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Leaseback Transaction, Net Book Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleLeasebackTransactionNetBookValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleLeasebackTransactionNetBookValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleLeasebackTransactionNetBookValue" xlink:to="lab_us-gaap_SaleLeasebackTransactionNetBookValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_SesenBioIncMember_bbfc1f0f-afc6-4aba-9b43-a22223f7d6a3_terseLabel_en-US" xlink:label="lab_carm_SesenBioIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sesen Bio, Inc.</link:label>
    <link:label id="lab_carm_SesenBioIncMember_label_en-US" xlink:label="lab_carm_SesenBioIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sesen Bio, Inc [Member]</link:label>
    <link:label id="lab_carm_SesenBioIncMember_documentation_en-US" xlink:label="lab_carm_SesenBioIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the entity Sesen Bio, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_SesenBioIncMember" xlink:href="carm-20241231.xsd#carm_SesenBioIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_SesenBioIncMember" xlink:to="lab_carm_SesenBioIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_AccretionOnMarketableSecurities_fa67e740-27cf-461a-b44b-3c77ce3ef121_negatedLabel_en-US" xlink:label="lab_carm_AccretionOnMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accretion on marketable securities</link:label>
    <link:label id="lab_carm_AccretionOnMarketableSecurities_label_en-US" xlink:label="lab_carm_AccretionOnMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion on Marketable Securities</link:label>
    <link:label id="lab_carm_AccretionOnMarketableSecurities_documentation_en-US" xlink:label="lab_carm_AccretionOnMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of accretion on marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AccretionOnMarketableSecurities" xlink:href="carm-20241231.xsd#carm_AccretionOnMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_AccretionOnMarketableSecurities" xlink:to="lab_carm_AccretionOnMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_8b92c64f-383d-4adf-b434-de9ebccda418_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets for Federal Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_e4f2ff9c-3be6-4f86-8a15-fcc0c1a588e1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_44a26d73-0dc3-40f8-bd75-182ae6e6a2c9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NOL carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_39fce924-07eb-4dea-89b2-f443146be354_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_8220f81d-3cd2-4a37-812e-5bc7cec1b7e6_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_c409953c-8b72-484f-91f5-0923b6fa66ee_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization_d2ec880c-e36f-4eb0-93d6-0dccf9f16af9_terseLabel_en-US" xlink:label="lab_carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized research and development costs, net of amortization</link:label>
    <link:label id="lab_carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization_label_en-US" xlink:label="lab_carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Capitalized Research and Development Costs, Net Of Amortization</link:label>
    <link:label id="lab_carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization_documentation_en-US" xlink:label="lab_carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Capitalized Research and Development Costs, Net Of Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization" xlink:href="carm-20241231.xsd#carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization" xlink:to="lab_carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_MilestonesMember_08bbbded-e176-4a7e-8c16-46f2af5d7f40_terseLabel_en-US" xlink:label="lab_carm_MilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestones</link:label>
    <link:label id="lab_carm_MilestonesMember_label_en-US" xlink:label="lab_carm_MilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestones [Member]</link:label>
    <link:label id="lab_carm_MilestonesMember_documentation_en-US" xlink:label="lab_carm_MilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_MilestonesMember" xlink:href="carm-20241231.xsd#carm_MilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_MilestonesMember" xlink:to="lab_carm_MilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_cbf9f5ba-0a63-42a4-bae5-5269fd1c26d1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_AuditInformationAbstract_label_en-US" xlink:label="lab_carm_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_carm_AuditInformationAbstract_documentation_en-US" xlink:label="lab_carm_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AuditInformationAbstract" xlink:href="carm-20241231.xsd#carm_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_AuditInformationAbstract" xlink:to="lab_carm_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_65f98ac6-951e-4042-8213-ec24eb144a1b_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash_2a627c59-45cf-4fdc-b5ce-ff52e5da72db_terseLabel_en-US" xlink:label="lab_carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash_label_en-US" xlink:label="lab_carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BusinessCombinationRecognizedIdentifiableAssetsAcquiredRestrictedCash</link:label>
    <link:label id="lab_carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash_documentation_en-US" xlink:label="lab_carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of restricted cash from business combination.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash" xlink:href="carm-20241231.xsd#carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash" xlink:to="lab_carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_7d7a376f-e32a-48c2-8a80-0c797d13ac57_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_CollaborationAndLicenseAgreementMember_947d091b-9903-4226-a1c3-d4acde0127bc_terseLabel_en-US" xlink:label="lab_carm_CollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration and License Agreement</link:label>
    <link:label id="lab_carm_CollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_carm_CollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration and License Agreement [Member]</link:label>
    <link:label id="lab_carm_CollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_carm_CollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to collaboration and license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CollaborationAndLicenseAgreementMember" xlink:href="carm-20241231.xsd#carm_CollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_CollaborationAndLicenseAgreementMember" xlink:to="lab_carm_CollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_faf86174-4b98-4ec3-b797-1d78eaa74c0f_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing liability</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_4c00c20e-cf57-4d9e-bf84-3a547f008cbb_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_173a47a1-6a5c-4cc5-9c6b-152f31d4bf5f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_7a8694f1-5b22-499d-88e2-1aee29181e61_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossOnContractTermination_e96de6de-dddd-4dcd-a28d-d4c13f31d8cd_terseLabel_en-US" xlink:label="lab_us-gaap_LossOnContractTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract termination fee</link:label>
    <link:label id="lab_us-gaap_LossOnContractTermination_label_en-US" xlink:label="lab_us-gaap_LossOnContractTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss on Contract Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContractTermination" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossOnContractTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossOnContractTermination" xlink:to="lab_us-gaap_LossOnContractTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_DeferredTaxAssetsLeaseLiability_66f82f2b-babe-487a-81a4-163fe05f773a_terseLabel_en-US" xlink:label="lab_carm_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_carm_DeferredTaxAssetsLeaseLiability_label_en-US" xlink:label="lab_carm_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Lease Liability</link:label>
    <link:label id="lab_carm_DeferredTaxAssetsLeaseLiability_documentation_en-US" xlink:label="lab_carm_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DeferredTaxAssetsLeaseLiability" xlink:href="carm-20241231.xsd#carm_DeferredTaxAssetsLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_DeferredTaxAssetsLeaseLiability" xlink:to="lab_carm_DeferredTaxAssetsLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a3212c93-580c-48ca-961b-6945546871a8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_e9dc75e0-16a8-44ee-bb9d-1af4714b81c2_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_DeferredFinancingCostsNoncurrent_cfbcf155-9dc8-4225-b1f9-6958ebb25a59_terseLabel_en-US" xlink:label="lab_carm_DeferredFinancingCostsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred financing costs</link:label>
    <link:label id="lab_carm_DeferredFinancingCostsNoncurrent_label_en-US" xlink:label="lab_carm_DeferredFinancingCostsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Financing Costs, Noncurrent</link:label>
    <link:label id="lab_carm_DeferredFinancingCostsNoncurrent_documentation_en-US" xlink:label="lab_carm_DeferredFinancingCostsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Financing Costs, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DeferredFinancingCostsNoncurrent" xlink:href="carm-20241231.xsd#carm_DeferredFinancingCostsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_DeferredFinancingCostsNoncurrent" xlink:to="lab_carm_DeferredFinancingCostsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_FinancingCashUsedInFinanceLeases_05768ed8-af53-4c85-8f29-ef8655796249_terseLabel_en-US" xlink:label="lab_carm_FinancingCashUsedInFinanceLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing cash used in finance leases</link:label>
    <link:label id="lab_carm_FinancingCashUsedInFinanceLeases_label_en-US" xlink:label="lab_carm_FinancingCashUsedInFinanceLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing cash used in finance leases</link:label>
    <link:label id="lab_carm_FinancingCashUsedInFinanceLeases_documentation_en-US" xlink:label="lab_carm_FinancingCashUsedInFinanceLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of cash outflow for payment on finance lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_FinancingCashUsedInFinanceLeases" xlink:href="carm-20241231.xsd#carm_FinancingCashUsedInFinanceLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_FinancingCashUsedInFinanceLeases" xlink:to="lab_carm_FinancingCashUsedInFinanceLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_b4edc968-0057-4801-b98d-5695dd057d1c_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: Transaction costs</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_cb195a7a-22c1-4e4b-b68a-d46ad489164e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ecbc49da-1435-4e15-8f98-19dd2eb84fb0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_NumberOfPotentialResearchTargetDesignations_276d93de-bc90-4981-a427-076f40a84c3e_terseLabel_en-US" xlink:label="lab_carm_NumberOfPotentialResearchTargetDesignations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of potential research target designations</link:label>
    <link:label id="lab_carm_NumberOfPotentialResearchTargetDesignations_label_en-US" xlink:label="lab_carm_NumberOfPotentialResearchTargetDesignations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Potential Research Target Designations</link:label>
    <link:label id="lab_carm_NumberOfPotentialResearchTargetDesignations_documentation_en-US" xlink:label="lab_carm_NumberOfPotentialResearchTargetDesignations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Potential Research Target Designations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NumberOfPotentialResearchTargetDesignations" xlink:href="carm-20241231.xsd#carm_NumberOfPotentialResearchTargetDesignations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_NumberOfPotentialResearchTargetDesignations" xlink:to="lab_carm_NumberOfPotentialResearchTargetDesignations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_3d9cb3fd-7e92-4db5-b923-0faaea9bea1d_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3b359c89-d2e5-4cc6-b983-c3e4336bd451_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents &#8211; money markets accounts</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReduction_df74340b-1159-4da7-8e2c-2fa376826539_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReduction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of convertible promissory note, accrued interest and derivative liability upon Merger</link:label>
    <link:label id="lab_us-gaap_NotesReduction_label_en-US" xlink:label="lab_us-gaap_NotesReduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReduction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesReduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReduction" xlink:to="lab_us-gaap_NotesReduction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleAndLeasebackTransactionGainLossNet_9457a101-0120-4ccf-88f2-c07810110335_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SaleAndLeasebackTransactionGainLossNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gain on sale of sale-leaseback</link:label>
    <link:label id="lab_us-gaap_SaleAndLeasebackTransactionGainLossNet_e1058ab1-0aae-4bbd-a172-c69f29a44018_terseLabel_en-US" xlink:label="lab_us-gaap_SaleAndLeasebackTransactionGainLossNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on sale of sale-leaseback</link:label>
    <link:label id="lab_us-gaap_SaleAndLeasebackTransactionGainLossNet_label_en-US" xlink:label="lab_us-gaap_SaleAndLeasebackTransactionGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale and Leaseback Transaction, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleAndLeasebackTransactionGainLossNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleAndLeasebackTransactionGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleAndLeasebackTransactionGainLossNet" xlink:to="lab_us-gaap_SaleAndLeasebackTransactionGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_PennLicenseAgreementMember_65f530da-f04b-49c4-820c-0c2afae298d4_terseLabel_en-US" xlink:label="lab_carm_PennLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Penn License Agreement</link:label>
    <link:label id="lab_carm_PennLicenseAgreementMember_label_en-US" xlink:label="lab_carm_PennLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Penn License Agreement [Member]</link:label>
    <link:label id="lab_carm_PennLicenseAgreementMember_documentation_en-US" xlink:label="lab_carm_PennLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to Penn License Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_PennLicenseAgreementMember" xlink:href="carm-20241231.xsd#carm_PennLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_PennLicenseAgreementMember" xlink:to="lab_carm_PennLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_c9e8c8e6-e90e-4f5f-82a7-399b040d6960_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_ab11b5f7-c45a-453c-add9-f6d4fe5b3cf1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification_b2b42bc8-8321-4bcb-ac8c-19af9e9bfc02_negatedTerseLabel_en-US" xlink:label="lab_carm_IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Decrease in finance lease, liability, lease modification</link:label>
    <link:label id="lab_carm_IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification_label_en-US" xlink:label="lab_carm_IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Finance Lease, Liability, Lease Modification</link:label>
    <link:label id="lab_carm_IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification_documentation_en-US" xlink:label="lab_carm_IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Finance Lease, Liability, Lease Modification</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification" xlink:href="carm-20241231.xsd#carm_IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification" xlink:to="lab_carm_IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsDisclosureTextBlock_982d3ed8-9e73-41e0-b8a8-5157e9f89311_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid Expenses and Other Assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_OtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_dac4c650-fb96-479a-b98a-4c4d374cfb1d_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_4caa31d7-d940-4e26-8082-2017d027800d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c30eec4c-4eab-42b1-a417-f10362770a23_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual term (years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cdb02c23-76e0-4d15-ac55-830dd312075d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_4026b956-dc55-4233-b508-698dbef2ecfd_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_401307cb-3ab0-4407-8053-a39fe75a48c9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_b7f17793-85fe-4600-85b0-f9543b8a0b7c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_7a8c6303-22a7-42e5-a702-d5edd0ae950c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8265b81c-cb0e-4092-8a86-ef96197c0844_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_DeferredTaxAssetsAmortizableAssetsAndOther_816520a2-43fc-48ce-ab6e-851c481bc0d3_terseLabel_en-US" xlink:label="lab_carm_DeferredTaxAssetsAmortizableAssetsAndOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortizable assets and other</link:label>
    <link:label id="lab_carm_DeferredTaxAssetsAmortizableAssetsAndOther_label_en-US" xlink:label="lab_carm_DeferredTaxAssetsAmortizableAssetsAndOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Amortizable Assets And Other</link:label>
    <link:label id="lab_carm_DeferredTaxAssetsAmortizableAssetsAndOther_documentation_en-US" xlink:label="lab_carm_DeferredTaxAssetsAmortizableAssetsAndOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Amortizable Assets And Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DeferredTaxAssetsAmortizableAssetsAndOther" xlink:href="carm-20241231.xsd#carm_DeferredTaxAssetsAmortizableAssetsAndOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_DeferredTaxAssetsAmortizableAssetsAndOther" xlink:to="lab_carm_DeferredTaxAssetsAmortizableAssetsAndOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_d6947f82-8871-4498-ac7a-6ebd261cf026_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_25e5872e-7ed1-4914-8bb7-578c712c0c4f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_429eeee2-390c-4e33-a85b-558afd0e7702_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_3f28398e-2536-4d04-94ef-e44cd5d7abe7_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ed1f7735-b1b2-4a97-8476-2142d897ee80_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6b57208f-5229-4bdb-b248-05488171ea77_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Sale of common stock under Open Market Sales Agreement, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9988f38c-d3fe-44d6-a34b-932e4d34184e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued in a pre-closing funding (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_2270d307-fa18-4288-9600-404531a4187c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_7dcd6efd-11d3-43dc-be58-c6cd08c02088_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_PaymentsForProceedsFromMarketableSecurities_bd538490-fef0-4a31-948c-2e80f2d9fbb1_negatedLabel_en-US" xlink:label="lab_carm_PaymentsForProceedsFromMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the sale of marketable securities</link:label>
    <link:label id="lab_carm_PaymentsForProceedsFromMarketableSecurities_label_en-US" xlink:label="lab_carm_PaymentsForProceedsFromMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for (Proceeds from) Marketable Securities</link:label>
    <link:label id="lab_carm_PaymentsForProceedsFromMarketableSecurities_documentation_en-US" xlink:label="lab_carm_PaymentsForProceedsFromMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The net cash paid (received) associated with the acquisition or disposal of all investments, including marketable securities and other assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_PaymentsForProceedsFromMarketableSecurities" xlink:href="carm-20241231.xsd#carm_PaymentsForProceedsFromMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_PaymentsForProceedsFromMarketableSecurities" xlink:to="lab_carm_PaymentsForProceedsFromMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_c7d72165-fee1-4cbc-8826-10f3d572ad05_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_NoncashInterestExpense_5d91f52b-6bb0-4147-9bdb-95de7201f0ba_terseLabel_en-US" xlink:label="lab_carm_NoncashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_carm_NoncashInterestExpense_label_en-US" xlink:label="lab_carm_NoncashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Interest Expense</link:label>
    <link:label id="lab_carm_NoncashInterestExpense_documentation_en-US" xlink:label="lab_carm_NoncashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of expense (income) related to the increase (decrease) in interest expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NoncashInterestExpense" xlink:href="carm-20241231.xsd#carm_NoncashInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_NoncashInterestExpense" xlink:to="lab_carm_NoncashInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_f64bdbdb-ee49-41a9-b071-acb62eb8a814_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other segment items(a)</link:label>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_label_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Other Segment Item, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:to="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_fa136886-b194-4da8-be11-671f5200e5ca_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_NumberOfPerformanceObligations_c634ab4d-604e-402e-8493-3034d2f3a54d_terseLabel_en-US" xlink:label="lab_carm_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of performance obligations</link:label>
    <link:label id="lab_carm_NumberOfPerformanceObligations_label_en-US" xlink:label="lab_carm_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Performance Obligations</link:label>
    <link:label id="lab_carm_NumberOfPerformanceObligations_documentation_en-US" xlink:label="lab_carm_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Performance Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NumberOfPerformanceObligations" xlink:href="carm-20241231.xsd#carm_NumberOfPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_NumberOfPerformanceObligations" xlink:to="lab_carm_NumberOfPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_bee5a40c-1ce1-4723-9104-e856f2c7de7e_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; (Deficit) Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_3a2d8f40-d6a1-40b6-ad9d-c8bc5d5fad22_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_1e33cf40-34f3-440d-9fad-e160e3540981_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_ReportingSegmentMember_43013c64-c0fa-4985-b5fd-c6c3da7130de_terseLabel_en-US" xlink:label="lab_carm_ReportingSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reporting Segment</link:label>
    <link:label id="lab_carm_ReportingSegmentMember_label_en-US" xlink:label="lab_carm_ReportingSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reporting Segment [Member]</link:label>
    <link:label id="lab_carm_ReportingSegmentMember_documentation_en-US" xlink:label="lab_carm_ReportingSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reporting Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ReportingSegmentMember" xlink:href="carm-20241231.xsd#carm_ReportingSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_ReportingSegmentMember" xlink:to="lab_carm_ReportingSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8c167bac-0228-4e23-89c4-28813c9307b0_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_5a43c062-c270-4b54-8e49-8974ef5f9ed7_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_cc62928b-4df0-45ab-b8f4-4ac1e47f224e_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_CashPreservationPlan2025Member_1bc726e7-ebe4-4172-af76-760ce2b74869_terseLabel_en-US" xlink:label="lab_carm_CashPreservationPlan2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025 Cash Preservation Plan</link:label>
    <link:label id="lab_carm_CashPreservationPlan2025Member_label_en-US" xlink:label="lab_carm_CashPreservationPlan2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Preservation Plan, 2025 [Member]</link:label>
    <link:label id="lab_carm_CashPreservationPlan2025Member_documentation_en-US" xlink:label="lab_carm_CashPreservationPlan2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Preservation Plan, 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CashPreservationPlan2025Member" xlink:href="carm-20241231.xsd#carm_CashPreservationPlan2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_CashPreservationPlan2025Member" xlink:to="lab_carm_CashPreservationPlan2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_dcd587a8-9284-42d3-b3f2-3e0fbb164759_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_27ba2cf6-99fb-4574-aaa2-a134da64730a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock_507b6b9b-0ef3-4adf-969b-83ae45dedac3_terseLabel_en-US" xlink:label="lab_carm_LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Maturities of Lease Liabilities</link:label>
    <link:label id="lab_carm_LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock_label_en-US" xlink:label="lab_carm_LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating and Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:label id="lab_carm_LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock_documentation_en-US" xlink:label="lab_carm_LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of undiscounted cash flows of lessee's operating lease liability and finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock" xlink:href="carm-20241231.xsd#carm_LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock" xlink:to="lab_carm_LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_PrepaidResearchAndDevelopmentCurrent_5a891ecc-e20b-4385-bdbf-07bd5a3bf6fe_terseLabel_en-US" xlink:label="lab_carm_PrepaidResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_carm_PrepaidResearchAndDevelopmentCurrent_label_en-US" xlink:label="lab_carm_PrepaidResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Research and Development, Current</link:label>
    <link:label id="lab_carm_PrepaidResearchAndDevelopmentCurrent_documentation_en-US" xlink:label="lab_carm_PrepaidResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepaid Research and Development, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_PrepaidResearchAndDevelopmentCurrent" xlink:href="carm-20241231.xsd#carm_PrepaidResearchAndDevelopmentCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_PrepaidResearchAndDevelopmentCurrent" xlink:to="lab_carm_PrepaidResearchAndDevelopmentCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_TwoThousandFourteenEmployeeStockPurchasePlanMember_3f2d1ea7-e023-4d6e-918a-bafbe9a75fb2_terseLabel_en-US" xlink:label="lab_carm_TwoThousandFourteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2014 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_carm_TwoThousandFourteenEmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_carm_TwoThousandFourteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Fourteen Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_carm_TwoThousandFourteenEmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_carm_TwoThousandFourteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Two Thousand Fourteen Employee Stock Purchase Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_TwoThousandFourteenEmployeeStockPurchasePlanMember" xlink:href="carm-20241231.xsd#carm_TwoThousandFourteenEmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_TwoThousandFourteenEmployeeStockPurchasePlanMember" xlink:to="lab_carm_TwoThousandFourteenEmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_9049ffc7-7245-4764-b5cb-a4282b42855e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_de0a9dc6-425b-40d1-82b4-b19ea3bb56f2_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_bbfc06b7-fdaf-4bd8-8cf8-70e51c059dcd_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences_aaa28929-b2af-4677-84e1-136ca6aca252_negatedTerseLabel_en-US" xlink:label="lab_carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Permanent differences</link:label>
    <link:label id="lab_carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences_label_en-US" xlink:label="lab_carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation Permanent Differences</link:label>
    <link:label id="lab_carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences_documentation_en-US" xlink:label="lab_carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation Permanent Differences</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:href="carm-20241231.xsd#carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:to="lab_carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_SaleOfStockStockOfferingAmount_9f61cddb-57ba-43b3-a2da-f91911645262_terseLabel_en-US" xlink:label="lab_carm_SaleOfStockStockOfferingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock offering, amount</link:label>
    <link:label id="lab_carm_SaleOfStockStockOfferingAmount_label_en-US" xlink:label="lab_carm_SaleOfStockStockOfferingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Stock Offering, Amount</link:label>
    <link:label id="lab_carm_SaleOfStockStockOfferingAmount_documentation_en-US" xlink:label="lab_carm_SaleOfStockStockOfferingAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Stock Offering, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_SaleOfStockStockOfferingAmount" xlink:href="carm-20241231.xsd#carm_SaleOfStockStockOfferingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_SaleOfStockStockOfferingAmount" xlink:to="lab_carm_SaleOfStockStockOfferingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_c65128db-2688-4550-98cb-12ebf4035a97_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_cc09205a-5bff-4818-822c-ee8c2c5c5c5b_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dc107bda-44ca-4888-b4e0-db04caae507c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_6c2c93f3-f95b-42de-be39-93cdc8df74c9_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_8bda9e32-6d98-4f2c-844d-6949bdb14c2b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_ab26043f-5e5f-4ac4-bc83-73861fcb80cc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_4e205004-812c-4af2-abfb-08ae47eb2e75_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_24928fb6-1c98-4b0e-878f-1c43f704261d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_335cad84-d216-4573-9c7c-450aae2062ba_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_FacilitiesExpense_3c62c988-f46a-462a-8a23-35597bf3ee02_terseLabel_en-US" xlink:label="lab_carm_FacilitiesExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facilities expense</link:label>
    <link:label id="lab_carm_FacilitiesExpense_label_en-US" xlink:label="lab_carm_FacilitiesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facilities Expense</link:label>
    <link:label id="lab_carm_FacilitiesExpense_documentation_en-US" xlink:label="lab_carm_FacilitiesExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Facilities Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_FacilitiesExpense" xlink:href="carm-20241231.xsd#carm_FacilitiesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_FacilitiesExpense" xlink:to="lab_carm_FacilitiesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_c8705748-b0ff-4736-b8c4-677f01e20df6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_RevisedOperatingPlanMember_10cbff2f-c77b-4502-9998-1583a99052f5_terseLabel_en-US" xlink:label="lab_carm_RevisedOperatingPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revised Operating Plan</link:label>
    <link:label id="lab_carm_RevisedOperatingPlanMember_label_en-US" xlink:label="lab_carm_RevisedOperatingPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revised Operating Plan [Member]</link:label>
    <link:label id="lab_carm_RevisedOperatingPlanMember_documentation_en-US" xlink:label="lab_carm_RevisedOperatingPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revised Operating Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_RevisedOperatingPlanMember" xlink:href="carm-20241231.xsd#carm_RevisedOperatingPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_RevisedOperatingPlanMember" xlink:to="lab_carm_RevisedOperatingPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodDomain_b420d901-efa7-421d-bba4-8b7c179d919f_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodDomain_label_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_548edca4-d98b-483d-b5e1-807b7a65c50e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable as of December 31, 2024 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8ce26ba8-1114-4dac-832e-832d36f99251_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_806e7198-b63a-4eb5-82b7-c9303d783149_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_0268ef04-52c6-4c2d-bc87-330e7eb5d73a_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_04e7b6da-9768-4ed2-8ce0-b2389994186f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_633c2c5a-a0be-4a47-882e-710457632b91_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c1460cd6-e655-483c-b37a-ee46671d8996_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_3073e97f-c8fc-47b6-ab7c-4cd386eeb586_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share information:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_DeferredTaxLiabilitiesRightOfUseAsset_76a25026-349d-441b-a948-f0ae5c040ad9_negatedTerseLabel_en-US" xlink:label="lab_carm_DeferredTaxLiabilitiesRightOfUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Right of use asset</link:label>
    <link:label id="lab_carm_DeferredTaxLiabilitiesRightOfUseAsset_label_en-US" xlink:label="lab_carm_DeferredTaxLiabilitiesRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Right Of Use Asset</link:label>
    <link:label id="lab_carm_DeferredTaxLiabilitiesRightOfUseAsset_documentation_en-US" xlink:label="lab_carm_DeferredTaxLiabilitiesRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Right Of Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DeferredTaxLiabilitiesRightOfUseAsset" xlink:href="carm-20241231.xsd#carm_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="lab_carm_DeferredTaxLiabilitiesRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_14bdced3-18fe-44e9-9193-bef59de0c597_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_f0fad089-437c-4091-9ec7-1111e4a679c6_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_512bf1bc-d03f-4cf7-8664-099a3f35d6dd_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount_77800205-2aa0-4603-9123-aba7d7cebc4c_terseLabel_en-US" xlink:label="lab_carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount_label_en-US" xlink:label="lab_carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Research and Development, Amount</link:label>
    <link:label id="lab_carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount_documentation_en-US" xlink:label="lab_carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of transaction price allocated to research and development performance obligation that has not been recognized as revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount" xlink:href="carm-20241231.xsd#carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount" xlink:to="lab_carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_94543289-05f3-4984-aa69-96850a60b1b0_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_0e1751d7-8d7b-4d0e-9753-65d51e2545c7_terseLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of derivative liability</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_dd45b678-5a2f-4466-8b9c-e245f800bbc7_negatedLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of derivative liability</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_label_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Embedded Derivative, Gain (Loss) on Embedded Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:to="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f6cd9df1-cc84-41e3-bebf-c6f266c56974_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_c66b8f77-1066-428e-b0b5-e8a952d07b87_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_6b3b2514-a641-4f49-ba3f-ca0ec0cf6e27_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents_3b2da8c6-610f-43b5-9d2c-79a6499b4885_terseLabel_en-US" xlink:label="lab_carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payments</link:label>
    <link:label id="lab_carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents_label_en-US" xlink:label="lab_carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount Payable upon Achievement of Certain Clinical, Regulatory and Commercial Milestone Events</link:label>
    <link:label id="lab_carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents_documentation_en-US" xlink:label="lab_carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount required to pay per product in development upon the achievement of certain clinical, regulatory and commercial milestone events.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents" xlink:href="carm-20241231.xsd#carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents" xlink:to="lab_carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_2dc32757-b247-4c14-b739-41333903ec17_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent" xlink:to="lab_us-gaap_DeferredRevenueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationSegmentAllocationLineItems_147ec0e2-7b1a-4bd0-b718-8e799bc2d2a3_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSegmentAllocationLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Background</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSegmentAllocationLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSegmentAllocationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Segment Allocation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationSegmentAllocationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems" xlink:to="lab_us-gaap_BusinessCombinationSegmentAllocationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_f4914767-8429-491a-b048-6bbf7160522e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_a734e042-2c7d-442f-97dc-c488f28bd54f_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_cab56740-b56d-4bab-a744-bc6a41bf2c78_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_bae90176-aebe-4d75-ba28-1154585fd624_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock_aad7464f-df05-427c-a69b-117023349192_terseLabel_en-US" xlink:label="lab_carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Supplemental Cash Flow Information</link:label>
    <link:label id="lab_carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock_label_en-US" xlink:label="lab_carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating and Finance Lease, Supplemental Cash flow Information [Table Text Block]</link:label>
    <link:label id="lab_carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock_documentation_en-US" xlink:label="lab_carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The tabular disclosure of supplemental cash flow information relating to operating and finance leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock" xlink:href="carm-20241231.xsd#carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock" xlink:to="lab_carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_de677871-b949-43f3-958b-21b56dd43aa9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_NumberOfResearchTargetsNominatedOncology_ccbc3d42-3b35-4fd8-81ee-4dee19e9c00e_terseLabel_en-US" xlink:label="lab_carm_NumberOfResearchTargetsNominatedOncology" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of oncology research targets, nominated</link:label>
    <link:label id="lab_carm_NumberOfResearchTargetsNominatedOncology_label_en-US" xlink:label="lab_carm_NumberOfResearchTargetsNominatedOncology" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Research Targets Nominated, Oncology</link:label>
    <link:label id="lab_carm_NumberOfResearchTargetsNominatedOncology_documentation_en-US" xlink:label="lab_carm_NumberOfResearchTargetsNominatedOncology" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Research Targets Nominated, Oncology</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NumberOfResearchTargetsNominatedOncology" xlink:href="carm-20241231.xsd#carm_NumberOfResearchTargetsNominatedOncology"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_NumberOfResearchTargetsNominatedOncology" xlink:to="lab_carm_NumberOfResearchTargetsNominatedOncology" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9a9e3511-438d-4c4c-a3af-cc04c7b19ce2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_d58a02db-031d-45a6-8e60-3c88cb33bdae_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of lease assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_d3e4efb9-5dd6-4f97-90a7-5a05bc479542_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_eb682ef6-1538-4c95-8f95-4ad61d6e6b30_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_01d98c04-1586-464a-a072-4b388d3fbeb8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_62de01cf-1d03-4f96-912c-388012685713_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0f0c9f77-bb49-475b-bbbf-24ac8bc34568_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; (deficit) equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_CollaborativeArrangementRightsAndObligationsMilestonePayments_35ad0e8d-8723-4a5b-b516-d01f83cf4bec_terseLabel_en-US" xlink:label="lab_carm_CollaborativeArrangementRightsAndObligationsMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment</link:label>
    <link:label id="lab_carm_CollaborativeArrangementRightsAndObligationsMilestonePayments_label_en-US" xlink:label="lab_carm_CollaborativeArrangementRightsAndObligationsMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Milestone Payments</link:label>
    <link:label id="lab_carm_CollaborativeArrangementRightsAndObligationsMilestonePayments_documentation_en-US" xlink:label="lab_carm_CollaborativeArrangementRightsAndObligationsMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CollaborativeArrangementRightsAndObligationsMilestonePayments" xlink:href="carm-20241231.xsd#carm_CollaborativeArrangementRightsAndObligationsMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_CollaborativeArrangementRightsAndObligationsMilestonePayments" xlink:to="lab_carm_CollaborativeArrangementRightsAndObligationsMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_3b094731-2f46-481f-9b00-74909b122a74_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of common stock under Open Market Sales Agreement, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_9ac66c58-c458-4c59-aa67-302ce2101dc2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_1c0287cd-c9e2-46e0-834b-8b23aec3b734_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_a47ce044-67b4-4c96-b747-876c6ad47cef_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e4ba8f16-241a-4762-b4e5-2887a99451e5_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_16b58002-9948-42e4-b890-a4222b6c11bf_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_9644a4a3-a654-4b8a-bf24-beebd8f32902_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock $0.001 par value, 350,000,000 shares authorized, 41,750,109 and 40,609,915 shares issued and outstanding at December&#160;31, 2024 and 2023, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_28fd9acc-b720-4770-8668-3f8df2f7bdeb_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_97b3e3ed-a5cc-49d9-8629-a74faadd7738_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_a1ef8d79-f416-420f-a669-eb8c76bda8d4_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating cash used in finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fbc27c60-7733-42e6-8f88-70ec51b48190_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger_77bfd082-df7a-4b89-95eb-5d1f0fba8a9f_terseLabel_en-US" xlink:label="lab_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of convertible preferred stock and non-controlling interests to common stock</link:label>
    <link:label id="lab_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger_label_en-US" xlink:label="lab_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Preferred Stock and Non-controlling Interests Upon Merger</link:label>
    <link:label id="lab_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger_documentation_en-US" xlink:label="lab_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of stock issued during the period upon the conversion of convertible preferred stock and noncontrolling interests upon merger.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" xlink:href="carm-20241231.xsd#carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" xlink:to="lab_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_ae57f93f-5c38-485d-8add-98f95ccaef09_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock to Sesen Bio shareholders in reverse capitalization</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_6737e8bf-8afb-40bb-9a2f-adfa8112fd1d_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_70a20a54-9e73-4aa3-a18f-2465dd607f3d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock to Sesen Bio shareholders in reverse capitalization (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_4a0d27b9-656a-4ae8-bb7a-38903f9e018d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">State and local tax, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_482018e8-c4e3-4432-9649-a5155d923da7_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_CarismaTherapeuticsInc.Member_a4af348c-f80a-48bd-b377-678fd489a20f_terseLabel_en-US" xlink:label="lab_carm_CarismaTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carisma Therapeutics Inc.</link:label>
    <link:label id="lab_carm_CarismaTherapeuticsInc.Member_label_en-US" xlink:label="lab_carm_CarismaTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carisma Therapeutics Inc. [Member]</link:label>
    <link:label id="lab_carm_CarismaTherapeuticsInc.Member_documentation_en-US" xlink:label="lab_carm_CarismaTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Carisma Therapeutics Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CarismaTherapeuticsInc.Member" xlink:href="carm-20241231.xsd#carm_CarismaTherapeuticsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_CarismaTherapeuticsInc.Member" xlink:to="lab_carm_CarismaTherapeuticsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c6afd5ff-51f2-44aa-9a29-eaac1305c27e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_4cd897cf-f127-4c80-a807-1ccb07febffb_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock $0.001 par value, 5,000,000 shares authorized, none issued or outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_NumberOfResearchTargetsNominatedAutoimmune_00c773ae-43e2-4175-aeb2-26705ed58bf1_terseLabel_en-US" xlink:label="lab_carm_NumberOfResearchTargetsNominatedAutoimmune" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of nominated autoimmune target</link:label>
    <link:label id="lab_carm_NumberOfResearchTargetsNominatedAutoimmune_label_en-US" xlink:label="lab_carm_NumberOfResearchTargetsNominatedAutoimmune" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Research Targets Nominated, Autoimmune</link:label>
    <link:label id="lab_carm_NumberOfResearchTargetsNominatedAutoimmune_documentation_en-US" xlink:label="lab_carm_NumberOfResearchTargetsNominatedAutoimmune" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Research Targets Nominated, Autoimmune</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NumberOfResearchTargetsNominatedAutoimmune" xlink:href="carm-20241231.xsd#carm_NumberOfResearchTargetsNominatedAutoimmune"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_NumberOfResearchTargetsNominatedAutoimmune" xlink:to="lab_carm_NumberOfResearchTargetsNominatedAutoimmune" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_7b5b8240-1454-49a0-9e5c-a9902bed79c1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, estimated useful lives (in years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_a52965c6-8e73-401f-b7b9-379b04c76514_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_d5be3950-f203-4845-9714-f6f63979caf3_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_e72f78a7-fad5-4d6f-9f01-e709288cea7e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share of common stock, basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_65ea8ca7-3b5b-440a-adfa-f9ed2ee1ce05_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_b29a9e1d-c08c-46fa-bedd-c1c822a10578_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of common stock under Open Market Sales Agreement, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_1a0ce6df-b69e-44d9-af7c-46bc1844fef1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating cash used in operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_61b3fd1f-cdf5-42a9-a8e9-a9a0b1da05bd_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Terms (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_eca908a6-6f57-40be-b62a-ccd7cab5b1ff_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_2911667d-2aed-4d16-9289-e67f4a942f0d_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_08944394-a4b0-4ce0-badd-e754a40dfc92_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_f05a6087-7c1f-4e72-8776-ed5bae99a6e3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_58bec96e-c8d3-4306-94c1-4704c78f808e_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_NumberOfResearchTargetsGrossOncology_e2b4822d-6725-4f71-b2f3-81cc99fa9a1d_terseLabel_en-US" xlink:label="lab_carm_NumberOfResearchTargetsGrossOncology" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of oncology research targets</link:label>
    <link:label id="lab_carm_NumberOfResearchTargetsGrossOncology_label_en-US" xlink:label="lab_carm_NumberOfResearchTargetsGrossOncology" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Research Targets, Gross, Oncology</link:label>
    <link:label id="lab_carm_NumberOfResearchTargetsGrossOncology_documentation_en-US" xlink:label="lab_carm_NumberOfResearchTargetsGrossOncology" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Research Targets, Gross, Oncology</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NumberOfResearchTargetsGrossOncology" xlink:href="carm-20241231.xsd#carm_NumberOfResearchTargetsGrossOncology"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_NumberOfResearchTargetsGrossOncology" xlink:to="lab_carm_NumberOfResearchTargetsGrossOncology" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_ce99a5e5-962e-4db2-9f69-743db9e5265b_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payment of principal related to finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_ScheduleOfChangesInDeferredRevenueTableTextBlock_54e9f88a-8d00-4060-b12c-77c645a06186_terseLabel_en-US" xlink:label="lab_carm_ScheduleOfChangesInDeferredRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Changes in Deferred Revenue</link:label>
    <link:label id="lab_carm_ScheduleOfChangesInDeferredRevenueTableTextBlock_label_en-US" xlink:label="lab_carm_ScheduleOfChangesInDeferredRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Changes in Deferred Revenue [Table Text Block]</link:label>
    <link:label id="lab_carm_ScheduleOfChangesInDeferredRevenueTableTextBlock_documentation_en-US" xlink:label="lab_carm_ScheduleOfChangesInDeferredRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of changes in deferred revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ScheduleOfChangesInDeferredRevenueTableTextBlock" xlink:href="carm-20241231.xsd#carm_ScheduleOfChangesInDeferredRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_ScheduleOfChangesInDeferredRevenueTableTextBlock" xlink:to="lab_carm_ScheduleOfChangesInDeferredRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2afa3a41-b3d6-4aba-87e6-7365abc6c9b7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_46f585fd-1321-4c9a-ae5a-8c5f3481d4d1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_012435ce-8729-4430-a3fa-74cf28b7f2bf_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_a484bbb1-1129-47aa-9ce1-9535d31c2ce9_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_3a468412-4d80-460d-8ef7-9bd997624285_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of credit risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_DeferredTaxAssetsStartUpCosts_2377c15d-a877-4eda-8e99-97160237cadd_terseLabel_en-US" xlink:label="lab_carm_DeferredTaxAssetsStartUpCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Start-up costs</link:label>
    <link:label id="lab_carm_DeferredTaxAssetsStartUpCosts_label_en-US" xlink:label="lab_carm_DeferredTaxAssetsStartUpCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Start Up Costs</link:label>
    <link:label id="lab_carm_DeferredTaxAssetsStartUpCosts_documentation_en-US" xlink:label="lab_carm_DeferredTaxAssetsStartUpCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Start Up Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DeferredTaxAssetsStartUpCosts" xlink:href="carm-20241231.xsd#carm_DeferredTaxAssetsStartUpCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_DeferredTaxAssetsStartUpCosts" xlink:to="lab_carm_DeferredTaxAssetsStartUpCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_dcd58f9d-654a-4f43-afdc-4429717c2461_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_d73245a6-f607-4a26-8703-4108d93291e7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_69cdd1dc-0e6b-4da1-b135-0aeb4cde159c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 8)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_8ecc9116-91ed-4ccd-9504-8b7249b86951_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts_d853c468-19b1-4ed8-bcf4-0c2ed87ccc3b_terseLabel_en-US" xlink:label="lab_carm_NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification of deferred financing costs to additional paid-in-capital</link:label>
    <link:label id="lab_carm_NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts_label_en-US" xlink:label="lab_carm_NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash or Part Noncash Transaction, Reclassification of Debt Finance Costs</link:label>
    <link:label id="lab_carm_NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts_documentation_en-US" xlink:label="lab_carm_NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncash or Part Noncash Transaction, Reclassification of Debt Finance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts" xlink:href="carm-20241231.xsd#carm_NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts" xlink:to="lab_carm_NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_f5c7710a-8957-4f3b-ba63-26c9bcb6da24_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_75c29fa3-b99f-4245-84fa-1a31dae2b5eb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_296b206e-910f-43fb-9560-56266702e7db_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f9a9db16-da45-43f6-bb0a-0d071597b790_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_fdfec622-da9d-48bc-b8a9-443389d631bc_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_98eb314e-a6b8-4863-b99c-27991042183d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_9b59b442-ed34-4967-9783-3e06ad060716_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Net Assets Acquired in the Merger</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_3bec16aa-c1cb-4981-b84d-3ce4c308af34_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ee9cc15f-8ca3-4f81-b9a8-fa0341c853e5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_774d938d-1199-4228-b0de-f2d00aecdfb2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_9d8a5495-fce4-40f7-be4f-f236c5ffc605_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_e7ecf0a8-0252-4ac4-add8-989f91ff06e5_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_b9d6c292-3ab6-425e-97f1-a98d1e51dd16_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_8b920f73-6a4c-4d98-b829-6031cf7d4905_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_label_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:to="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_f7bbb887-eb9c-41b3-9a59-af11a26e94c3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon settlement of convertible promissory note, accrued interest, and related derivative liability</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_e6935197-2e8f-4ed5-af8f-9f9f0223ab3e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_5bb9650b-dea8-466b-bc68-248c7852fa34_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_24c943cf-52a4-45ea-9fd0-21fd84fa8058_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_51c155e7-ed1a-41fb-9b21-6fa76764c732_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_0516298a-6a5c-4bf9-8e2d-6d9b4da651e4_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_3163b7c3-2430-4464-8735-15c03e297454_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance Leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_d72f544a-053f-491c-bdc6-a9d97ba57131_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Realized gain on marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Security, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:to="lab_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_83931c41-bd5f-4ae3-a51d-f885ddbb6858_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Moderna Collaboration and License Agreement</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_6221ef76-1ca4-43d5-8908-3c4567442f7e_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_6756922f-ef24-402d-b27b-46f999a05cb6_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_13204972-614d-4b6e-88f5-89a6999ec0ed_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_54b58561-cb1c-4c96-b14d-4ad1919770ce_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_d7c3701f-add2-45fd-bb85-ff33323f87dc_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Severance and personnel costs paid</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_477bedf8-8060-4ed0-a78f-a86e2919b055_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_25aa29b5-f6e3-4a42-8da9-f41dcffdacb0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_412b2167-934e-47e9-b8be-8c5119ea604c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable as of December 31, 2024</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_be24fe6e-2dde-4aa9-9822-ac47d89f9551_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_cc72411a-ec4a-43cc-83f9-108da21f13eb_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_5341cbcf-9217-40b1-b6e0-8f3c78d0018f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_NoncashOrPartNoncashAcquisitionEquityAssumed_8124d301-591e-40ec-9dee-0fa8b34c6b3b_terseLabel_en-US" xlink:label="lab_carm_NoncashOrPartNoncashAcquisitionEquityAssumed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of convertible preferred stock and non-controlling interests upon Merger</link:label>
    <link:label id="lab_carm_NoncashOrPartNoncashAcquisitionEquityAssumed_label_en-US" xlink:label="lab_carm_NoncashOrPartNoncashAcquisitionEquityAssumed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash or Part Noncash Acquisition, Equity Assumed</link:label>
    <link:label id="lab_carm_NoncashOrPartNoncashAcquisitionEquityAssumed_documentation_en-US" xlink:label="lab_carm_NoncashOrPartNoncashAcquisitionEquityAssumed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of equity that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NoncashOrPartNoncashAcquisitionEquityAssumed" xlink:href="carm-20241231.xsd#carm_NoncashOrPartNoncashAcquisitionEquityAssumed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_NoncashOrPartNoncashAcquisitionEquityAssumed" xlink:to="lab_carm_NoncashOrPartNoncashAcquisitionEquityAssumed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_67dca5f3-bcda-4d70-90a9-d4ccf5eabf9a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueNoncurrent" xlink:to="lab_us-gaap_DeferredRevenueNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_NumberOfBoardMembers_1eb88a4d-38ca-4d22-b293-e2dfcc4540aa_terseLabel_en-US" xlink:label="lab_carm_NumberOfBoardMembers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of board seats</link:label>
    <link:label id="lab_carm_NumberOfBoardMembers_label_en-US" xlink:label="lab_carm_NumberOfBoardMembers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Board Members</link:label>
    <link:label id="lab_carm_NumberOfBoardMembers_documentation_en-US" xlink:label="lab_carm_NumberOfBoardMembers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Board Members</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NumberOfBoardMembers" xlink:href="carm-20241231.xsd#carm_NumberOfBoardMembers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_NumberOfBoardMembers" xlink:to="lab_carm_NumberOfBoardMembers" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_NumberOfResearchTargetsTerminatedOncology_25ce651c-2ee6-4cfa-a952-08bbdc29a38e_terseLabel_en-US" xlink:label="lab_carm_NumberOfResearchTargetsTerminatedOncology" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of oncology research targets, ceased development</link:label>
    <link:label id="lab_carm_NumberOfResearchTargetsTerminatedOncology_label_en-US" xlink:label="lab_carm_NumberOfResearchTargetsTerminatedOncology" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Research Targets, Terminated, Oncology</link:label>
    <link:label id="lab_carm_NumberOfResearchTargetsTerminatedOncology_documentation_en-US" xlink:label="lab_carm_NumberOfResearchTargetsTerminatedOncology" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Research Targets, Terminated, Oncology</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NumberOfResearchTargetsTerminatedOncology" xlink:href="carm-20241231.xsd#carm_NumberOfResearchTargetsTerminatedOncology"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_NumberOfResearchTargetsTerminatedOncology" xlink:to="lab_carm_NumberOfResearchTargetsTerminatedOncology" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_696484f2-4429-4fc1-9a9f-eca163d77a94_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e98cf446-f71c-4d6b-aac8-d81e07ae172e_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total future minimum payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_f7ded633-318e-4287-9e7a-f981fadd1102_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_69d70859-f9e9-47cb-98f4-984e8ec83250_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_2f4fa733-db19-45f2-8e1d-11145a4bca2f_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recognition of unearned revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9f7ef722-1c49-4e59-8ba6-8660d8256d83_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cf5b94c9-0da6-47b7-9881-7afedc417dac_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Prepaid expense and other assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_2652c25d-abf7-49bf-9608-eb2af575ed57_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_FinanceLeaseCostAbstract_23fc1490-a678-4574-9c5a-07a37d7bcd5b_terseLabel_en-US" xlink:label="lab_carm_FinanceLeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease cost:</link:label>
    <link:label id="lab_carm_FinanceLeaseCostAbstract_label_en-US" xlink:label="lab_carm_FinanceLeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease Cost [Abstract]</link:label>
    <link:label id="lab_carm_FinanceLeaseCostAbstract_documentation_en-US" xlink:label="lab_carm_FinanceLeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">No definition available.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_FinanceLeaseCostAbstract" xlink:href="carm-20241231.xsd#carm_FinanceLeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_FinanceLeaseCostAbstract" xlink:to="lab_carm_FinanceLeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0c38b0d5-8597-4095-8bf2-8b99be5117fd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_4cc2595b-f0a4-467b-9cd2-c024a0a2692b_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_85ed99c9-b3d0-4295-a08e-7584bd0047ba_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_WriteOffOfPropertyAndEquipment_5a441520-33f6-477a-884b-cd11196abe88_terseLabel_en-US" xlink:label="lab_carm_WriteOffOfPropertyAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Write-off of property and equipment</link:label>
    <link:label id="lab_carm_WriteOffOfPropertyAndEquipment_label_en-US" xlink:label="lab_carm_WriteOffOfPropertyAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Write-off of Property and Equipment</link:label>
    <link:label id="lab_carm_WriteOffOfPropertyAndEquipment_documentation_en-US" xlink:label="lab_carm_WriteOffOfPropertyAndEquipment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Write-off of Property and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_WriteOffOfPropertyAndEquipment" xlink:href="carm-20241231.xsd#carm_WriteOffOfPropertyAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_WriteOffOfPropertyAndEquipment" xlink:to="lab_carm_WriteOffOfPropertyAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCollectionOfOtherReceivables_2fc3360b-d38a-4150-bbfd-1834c8b2cb6e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollectionOfOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from collection of collaboration receivable</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollectionOfOtherReceivables_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollectionOfOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Collection of Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromCollectionOfOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollectionOfOtherReceivables" xlink:to="lab_us-gaap_ProceedsFromCollectionOfOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_MaximumNumberOfResearchTargets_64f8080f-1f7f-4780-ae9c-334e7089e82f_terseLabel_en-US" xlink:label="lab_carm_MaximumNumberOfResearchTargets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum of research targets</link:label>
    <link:label id="lab_carm_MaximumNumberOfResearchTargets_label_en-US" xlink:label="lab_carm_MaximumNumberOfResearchTargets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Number of Research Targets</link:label>
    <link:label id="lab_carm_MaximumNumberOfResearchTargets_documentation_en-US" xlink:label="lab_carm_MaximumNumberOfResearchTargets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum number of research targets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_MaximumNumberOfResearchTargets" xlink:href="carm-20241231.xsd#carm_MaximumNumberOfResearchTargets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_MaximumNumberOfResearchTargets" xlink:to="lab_carm_MaximumNumberOfResearchTargets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d7e30567-f268-40e4-a2a6-6402deb84e43_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a6c92b17-65e9-4ba8-8946-9838e5101412_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares of common stock outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing_ac6ad4c7-f668-4798-bbf5-e03da0e14731_terseLabel_en-US" xlink:label="lab_carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the issuance of common stock in pre-closing financing</link:label>
    <link:label id="lab_carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing_label_en-US" xlink:label="lab_carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock, Pre-Closing Financing</link:label>
    <link:label id="lab_carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing_documentation_en-US" xlink:label="lab_carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock, Pre-Closing Financing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing" xlink:href="carm-20241231.xsd#carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing" xlink:to="lab_carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_731d873d-5868-4eb3-8a87-eec0cf785d11_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; (deficit) equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_13a26d8f-dc66-40c0-991a-d188444602a1_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6e163e52-229c-4edf-af47-438c8b721c1e_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8581e156-06b4-4c62-835f-6210a40ac3c1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; (Deficit) Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_7dbadd46-02e3-4c6a-a30f-e8b860111321_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_75700dc0-4ce9-40a8-98e6-18806c5ab055_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c80d3781-3811-4681-8801-2ce6d73a9a98_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_763c2d9f-6cc1-4a67-b3f3-0b4f845de117_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based options forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_7bef5225-0d7e-420c-abb3-58b43a72c271_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_2e221b3c-2d20-4c44-837f-211626260d09_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring reserve</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_40bb693c-ad9f-4cac-b5c3-846ddbd980e8_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_baa414dd-8e00-4115-a629-2f04b4e6d19b_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_2443e1c5-fbfd-4fdd-807b-121d47214228_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: reclassification to net loss of previous unrealized gain on marketable securities</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_d4436e22-6d49-4c4a-8f87-36d6ce9529a7_negatedLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Reclassification to net loss of previous unrealized gain on marketable securities</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_8919b658-4e0b-435a-85d2-e20ea36eb355_totalLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total performance obligations</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_e43fad15-8b8c-4e81-9160-e817df80d37d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_c92a4211-3576-4f79-8716-4052a2eb8547_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>17
<FILENAME>carm-20241231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:1dec34d0-de78-478e-a130-81bf7fce6e30,g:762837ba-4cc2-4d5a-8343-3052f0231779-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://carismatx.com/role/CoverPage" xlink:type="simple" xlink:href="carm-20241231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_5919ac57-3636-47de-9e8e-b4518dd02213" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_6ef0a535-7c5f-4df2-9258-8d250f6027b5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5919ac57-3636-47de-9e8e-b4518dd02213" xlink:to="loc_dei_DocumentType_6ef0a535-7c5f-4df2-9258-8d250f6027b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_e5efa922-4a67-4454-9e3e-8fa20f635683" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5919ac57-3636-47de-9e8e-b4518dd02213" xlink:to="loc_dei_DocumentAnnualReport_e5efa922-4a67-4454-9e3e-8fa20f635683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_581e0958-05b6-41ea-aedc-8f52f687bd29" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5919ac57-3636-47de-9e8e-b4518dd02213" xlink:to="loc_dei_DocumentPeriodEndDate_581e0958-05b6-41ea-aedc-8f52f687bd29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_db00ac73-d40b-42cf-a83d-9f7d668b7880" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5919ac57-3636-47de-9e8e-b4518dd02213" xlink:to="loc_dei_CurrentFiscalYearEndDate_db00ac73-d40b-42cf-a83d-9f7d668b7880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_a28e22aa-802b-475e-84f2-b76374b70243" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5919ac57-3636-47de-9e8e-b4518dd02213" xlink:to="loc_dei_DocumentTransitionReport_a28e22aa-802b-475e-84f2-b76374b70243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_84a93613-cbd8-44c8-a8e4-8e9675f12e7a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5919ac57-3636-47de-9e8e-b4518dd02213" xlink:to="loc_dei_EntityFileNumber_84a93613-cbd8-44c8-a8e4-8e9675f12e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_4a0ecc06-92df-48db-99c9-4bb3472c6c47" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5919ac57-3636-47de-9e8e-b4518dd02213" xlink:to="loc_dei_EntityRegistrantName_4a0ecc06-92df-48db-99c9-4bb3472c6c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_c184e182-3512-45a5-be97-4555a85a117e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5919ac57-3636-47de-9e8e-b4518dd02213" xlink:to="loc_dei_EntityIncorporationStateCountryCode_c184e182-3512-45a5-be97-4555a85a117e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_308738f1-02e5-4f87-99ab-ad3e47a337dc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5919ac57-3636-47de-9e8e-b4518dd02213" xlink:to="loc_dei_EntityTaxIdentificationNumber_308738f1-02e5-4f87-99ab-ad3e47a337dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_372f0240-004e-4094-862f-5cb229d0877e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5919ac57-3636-47de-9e8e-b4518dd02213" xlink:to="loc_dei_EntityAddressAddressLine1_372f0240-004e-4094-862f-5cb229d0877e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_124315fc-0dac-45b4-928c-685c90808545" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5919ac57-3636-47de-9e8e-b4518dd02213" xlink:to="loc_dei_EntityAddressAddressLine2_124315fc-0dac-45b4-928c-685c90808545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_da32b459-f9e6-446f-abd8-4631f2e21da7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5919ac57-3636-47de-9e8e-b4518dd02213" xlink:to="loc_dei_EntityAddressCityOrTown_da32b459-f9e6-446f-abd8-4631f2e21da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_f4ab7d2e-e327-4000-8abc-89f2e1d0fd8d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5919ac57-3636-47de-9e8e-b4518dd02213" xlink:to="loc_dei_EntityAddressStateOrProvince_f4ab7d2e-e327-4000-8abc-89f2e1d0fd8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_b2a84720-331d-4551-ba11-9a3fe134e7a4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5919ac57-3636-47de-9e8e-b4518dd02213" xlink:to="loc_dei_EntityAddressPostalZipCode_b2a84720-331d-4551-ba11-9a3fe134e7a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_ab9439e6-8c51-4f29-b09b-1d3f417d57c2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5919ac57-3636-47de-9e8e-b4518dd02213" xlink:to="loc_dei_CityAreaCode_ab9439e6-8c51-4f29-b09b-1d3f417d57c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_3bc1bd41-e8cd-49c5-9f91-915dae5ba3c7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5919ac57-3636-47de-9e8e-b4518dd02213" xlink:to="loc_dei_LocalPhoneNumber_3bc1bd41-e8cd-49c5-9f91-915dae5ba3c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_df4d1332-99df-43fa-85c0-5cf152c61137" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5919ac57-3636-47de-9e8e-b4518dd02213" xlink:to="loc_dei_Security12bTitle_df4d1332-99df-43fa-85c0-5cf152c61137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_18c2dcd6-45c5-4e8c-aea9-9436e7c8a8ad" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5919ac57-3636-47de-9e8e-b4518dd02213" xlink:to="loc_dei_TradingSymbol_18c2dcd6-45c5-4e8c-aea9-9436e7c8a8ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_033ecc89-9971-4084-ab43-1ae04a25c445" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5919ac57-3636-47de-9e8e-b4518dd02213" xlink:to="loc_dei_SecurityExchangeName_033ecc89-9971-4084-ab43-1ae04a25c445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_22806039-8cb6-4077-a8fa-eff2afbc1979" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5919ac57-3636-47de-9e8e-b4518dd02213" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_22806039-8cb6-4077-a8fa-eff2afbc1979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_5ed48259-67d4-47bb-9eae-da4b6011282d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5919ac57-3636-47de-9e8e-b4518dd02213" xlink:to="loc_dei_EntityVoluntaryFilers_5ed48259-67d4-47bb-9eae-da4b6011282d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_6ffdb7ee-811d-4a36-836c-52aaf3cdf7d7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5919ac57-3636-47de-9e8e-b4518dd02213" xlink:to="loc_dei_EntityCurrentReportingStatus_6ffdb7ee-811d-4a36-836c-52aaf3cdf7d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_0e39a4d8-795f-492b-9799-1adbb2b813c5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5919ac57-3636-47de-9e8e-b4518dd02213" xlink:to="loc_dei_EntityInteractiveDataCurrent_0e39a4d8-795f-492b-9799-1adbb2b813c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_9ae43069-0169-4254-afef-8f15552049da" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5919ac57-3636-47de-9e8e-b4518dd02213" xlink:to="loc_dei_EntityFilerCategory_9ae43069-0169-4254-afef-8f15552049da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_ef4cd5e5-d523-4fbf-bc2b-fe9af1f7ee5f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5919ac57-3636-47de-9e8e-b4518dd02213" xlink:to="loc_dei_EntitySmallBusiness_ef4cd5e5-d523-4fbf-bc2b-fe9af1f7ee5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_28167e88-551f-45df-a4fa-5871571bdd93" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5919ac57-3636-47de-9e8e-b4518dd02213" xlink:to="loc_dei_EntityEmergingGrowthCompany_28167e88-551f-45df-a4fa-5871571bdd93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_097a387b-067d-43aa-8387-6b85c6c24784" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5919ac57-3636-47de-9e8e-b4518dd02213" xlink:to="loc_dei_IcfrAuditorAttestationFlag_097a387b-067d-43aa-8387-6b85c6c24784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_483e7abf-732b-4982-90e2-a88fb92e23f7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5919ac57-3636-47de-9e8e-b4518dd02213" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_483e7abf-732b-4982-90e2-a88fb92e23f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_a5763f47-fe10-4f93-ba7d-a67f3b36d748" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5919ac57-3636-47de-9e8e-b4518dd02213" xlink:to="loc_dei_EntityShellCompany_a5763f47-fe10-4f93-ba7d-a67f3b36d748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_dd4d531f-3d9f-4106-b44e-4295890c3944" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5919ac57-3636-47de-9e8e-b4518dd02213" xlink:to="loc_dei_EntityPublicFloat_dd4d531f-3d9f-4106-b44e-4295890c3944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_94a8d660-21de-404b-b65d-f1411a579306" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5919ac57-3636-47de-9e8e-b4518dd02213" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_94a8d660-21de-404b-b65d-f1411a579306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_a33730e9-3c9c-44cc-9e2b-bdb5824b0a91" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5919ac57-3636-47de-9e8e-b4518dd02213" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_a33730e9-3c9c-44cc-9e2b-bdb5824b0a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_60085102-0611-4c36-b3f4-d195563af493" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5919ac57-3636-47de-9e8e-b4518dd02213" xlink:to="loc_dei_EntityCentralIndexKey_60085102-0611-4c36-b3f4-d195563af493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_b21325f2-4fa0-439a-9102-706bd5ee31d0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5919ac57-3636-47de-9e8e-b4518dd02213" xlink:to="loc_dei_AmendmentFlag_b21325f2-4fa0-439a-9102-706bd5ee31d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_dd26b61b-a4d8-4d59-8f42-e8f8e3f88ef6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5919ac57-3636-47de-9e8e-b4518dd02213" xlink:to="loc_dei_DocumentFiscalYearFocus_dd26b61b-a4d8-4d59-8f42-e8f8e3f88ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_ef379608-c708-4182-aae0-0d584e5f9b2a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5919ac57-3636-47de-9e8e-b4518dd02213" xlink:to="loc_dei_DocumentFiscalPeriodFocus_ef379608-c708-4182-aae0-0d584e5f9b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/AuditInformation" xlink:type="simple" xlink:href="carm-20241231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_carm_AuditInformationAbstract_54bd394f-66f5-4cfc-9a99-da97828ab2f6" xlink:href="carm-20241231.xsd#carm_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_2f3964ab-7e19-4ee4-b2f8-40d0a1fd98a9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_carm_AuditInformationAbstract_54bd394f-66f5-4cfc-9a99-da97828ab2f6" xlink:to="loc_dei_AuditorFirmId_2f3964ab-7e19-4ee4-b2f8-40d0a1fd98a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_32fbcfbe-76ec-487d-812e-ff2a9369b3c0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_carm_AuditInformationAbstract_54bd394f-66f5-4cfc-9a99-da97828ab2f6" xlink:to="loc_dei_AuditorName_32fbcfbe-76ec-487d-812e-ff2a9369b3c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_26cf3833-fd58-4b6e-a3ef-f5611d9f9cb4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_carm_AuditInformationAbstract_54bd394f-66f5-4cfc-9a99-da97828ab2f6" xlink:to="loc_dei_AuditorLocation_26cf3833-fd58-4b6e-a3ef-f5611d9f9cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="carm-20241231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_bddc827c-f3b4-45f6-a914-aa3170e1b39e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_26e29813-9d34-4587-8454-96d7b783762e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bddc827c-f3b4-45f6-a914-aa3170e1b39e" xlink:to="loc_us-gaap_AssetsAbstract_26e29813-9d34-4587-8454-96d7b783762e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_b096cdb4-afe3-43a6-9d7b-5363d97fe774" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_26e29813-9d34-4587-8454-96d7b783762e" xlink:to="loc_us-gaap_AssetsCurrentAbstract_b096cdb4-afe3-43a6-9d7b-5363d97fe774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_51e1aa47-f27c-494a-9109-7805a039a4e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b096cdb4-afe3-43a6-9d7b-5363d97fe774" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_51e1aa47-f27c-494a-9109-7805a039a4e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3d440003-c56d-45db-8b22-9ab880e35b19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b096cdb4-afe3-43a6-9d7b-5363d97fe774" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3d440003-c56d-45db-8b22-9ab880e35b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_671788bc-06e8-47b8-8015-8ab8f63a5ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b096cdb4-afe3-43a6-9d7b-5363d97fe774" xlink:to="loc_us-gaap_AssetsCurrent_671788bc-06e8-47b8-8015-8ab8f63a5ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_9d93711a-bf91-4fc2-aa67-ace67011a51d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_26e29813-9d34-4587-8454-96d7b783762e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_9d93711a-bf91-4fc2-aa67-ace67011a51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_8f958f8c-aa05-49c7-800d-bbee0871b2f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_26e29813-9d34-4587-8454-96d7b783762e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_8f958f8c-aa05-49c7-800d-bbee0871b2f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DeferredFinancingCostsNoncurrent_0deac78e-ae0a-4172-8ce8-2f758e45bb5b" xlink:href="carm-20241231.xsd#carm_DeferredFinancingCostsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_26e29813-9d34-4587-8454-96d7b783762e" xlink:to="loc_carm_DeferredFinancingCostsNoncurrent_0deac78e-ae0a-4172-8ce8-2f758e45bb5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_343a4854-1c12-4ff6-8dab-ec63f1bad65e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_26e29813-9d34-4587-8454-96d7b783762e" xlink:to="loc_us-gaap_Assets_343a4854-1c12-4ff6-8dab-ec63f1bad65e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e78eb599-f651-4d12-9df5-6cc2603d077a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bddc827c-f3b4-45f6-a914-aa3170e1b39e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e78eb599-f651-4d12-9df5-6cc2603d077a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_896ab4ed-134c-4504-80df-fb8d590231a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e78eb599-f651-4d12-9df5-6cc2603d077a" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_896ab4ed-134c-4504-80df-fb8d590231a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a540e683-672d-4d6a-8693-3e61784899b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_896ab4ed-134c-4504-80df-fb8d590231a7" xlink:to="loc_us-gaap_AccountsPayableCurrent_a540e683-672d-4d6a-8693-3e61784899b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_48c9067d-b158-4f42-8710-bc29532cb9d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_896ab4ed-134c-4504-80df-fb8d590231a7" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_48c9067d-b158-4f42-8710-bc29532cb9d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_c85e5d86-58bb-471a-81e9-59ed77c3b795" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_896ab4ed-134c-4504-80df-fb8d590231a7" xlink:to="loc_us-gaap_DeferredRevenueCurrent_c85e5d86-58bb-471a-81e9-59ed77c3b795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_294bbacf-d571-405e-8ccb-f8fef51d736b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_896ab4ed-134c-4504-80df-fb8d590231a7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_294bbacf-d571-405e-8ccb-f8fef51d736b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_51d327f4-4a66-4043-9fde-fd1e9f646438" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_896ab4ed-134c-4504-80df-fb8d590231a7" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_51d327f4-4a66-4043-9fde-fd1e9f646438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_8b2a521e-a5f6-4e16-8ec7-374a72df082b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_896ab4ed-134c-4504-80df-fb8d590231a7" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_8b2a521e-a5f6-4e16-8ec7-374a72df082b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5727f066-27c5-4abd-8a9a-e4f5ef27092d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_896ab4ed-134c-4504-80df-fb8d590231a7" xlink:to="loc_us-gaap_LiabilitiesCurrent_5727f066-27c5-4abd-8a9a-e4f5ef27092d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_c547056d-f88f-4080-a2da-c3bb08a52e05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e78eb599-f651-4d12-9df5-6cc2603d077a" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_c547056d-f88f-4080-a2da-c3bb08a52e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f9dc4999-6b06-4562-a327-6e59c455d64f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e78eb599-f651-4d12-9df5-6cc2603d077a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f9dc4999-6b06-4562-a327-6e59c455d64f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_d1468bfb-6551-45b3-a8a5-428531b61181" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e78eb599-f651-4d12-9df5-6cc2603d077a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_d1468bfb-6551-45b3-a8a5-428531b61181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_09314809-0af9-42f9-a05f-0292c1cbf5eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e78eb599-f651-4d12-9df5-6cc2603d077a" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_09314809-0af9-42f9-a05f-0292c1cbf5eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ef2910e2-5e60-4bc3-ab64-d36e6e21fd9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e78eb599-f651-4d12-9df5-6cc2603d077a" xlink:to="loc_us-gaap_Liabilities_ef2910e2-5e60-4bc3-ab64-d36e6e21fd9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_e682db57-e9d0-4576-a7fe-798937d15583" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e78eb599-f651-4d12-9df5-6cc2603d077a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_e682db57-e9d0-4576-a7fe-798937d15583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a09a726c-ecc7-40f4-a857-38ff11a9dabf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e78eb599-f651-4d12-9df5-6cc2603d077a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a09a726c-ecc7-40f4-a857-38ff11a9dabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_8b9f56e0-f859-48ec-9b05-b8e0138f0c89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a09a726c-ecc7-40f4-a857-38ff11a9dabf" xlink:to="loc_us-gaap_PreferredStockValue_8b9f56e0-f859-48ec-9b05-b8e0138f0c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_409c9832-04d0-4eba-8706-51eaaeec8d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a09a726c-ecc7-40f4-a857-38ff11a9dabf" xlink:to="loc_us-gaap_CommonStockValue_409c9832-04d0-4eba-8706-51eaaeec8d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_ec65e6a8-8321-4120-9782-22b311937e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a09a726c-ecc7-40f4-a857-38ff11a9dabf" xlink:to="loc_us-gaap_AdditionalPaidInCapital_ec65e6a8-8321-4120-9782-22b311937e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_76511c70-0085-41f5-8641-d6eff2f60d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a09a726c-ecc7-40f4-a857-38ff11a9dabf" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_76511c70-0085-41f5-8641-d6eff2f60d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c96f81fa-ec1c-44dc-a3e2-77b46f8d9b47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a09a726c-ecc7-40f4-a857-38ff11a9dabf" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c96f81fa-ec1c-44dc-a3e2-77b46f8d9b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_645703a4-d294-4ab3-8b37-7a3e0557d9e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e78eb599-f651-4d12-9df5-6cc2603d077a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_645703a4-d294-4ab3-8b37-7a3e0557d9e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="carm-20241231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_26948370-b90d-4c71-88f3-0846e14ce4fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_d3418c12-4aa6-4786-a3ea-fe172b840ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_26948370-b90d-4c71-88f3-0846e14ce4fe" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_d3418c12-4aa6-4786-a3ea-fe172b840ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_a477793f-6778-4b52-a26f-a073edb28d38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_26948370-b90d-4c71-88f3-0846e14ce4fe" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_a477793f-6778-4b52-a26f-a073edb28d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_6108d6e3-5919-4bab-a0a8-8f0d060616b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_26948370-b90d-4c71-88f3-0846e14ce4fe" xlink:to="loc_us-gaap_PreferredStockSharesIssued_6108d6e3-5919-4bab-a0a8-8f0d060616b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_1dcbada2-024b-4a3f-89b0-6a37c03ec602" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_26948370-b90d-4c71-88f3-0846e14ce4fe" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_1dcbada2-024b-4a3f-89b0-6a37c03ec602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_65dd786a-0790-4450-afd7-44ca2722e232" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_26948370-b90d-4c71-88f3-0846e14ce4fe" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_65dd786a-0790-4450-afd7-44ca2722e232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_b2244104-54e6-434d-8e71-0551866da562" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_26948370-b90d-4c71-88f3-0846e14ce4fe" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_b2244104-54e6-434d-8e71-0551866da562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_d465b4de-9b5f-489c-9365-a1015d65b6a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_26948370-b90d-4c71-88f3-0846e14ce4fe" xlink:to="loc_us-gaap_CommonStockSharesIssued_d465b4de-9b5f-489c-9365-a1015d65b6a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0e400ba4-fdb6-4f5c-ab35-ae1447903874" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_26948370-b90d-4c71-88f3-0846e14ce4fe" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_0e400ba4-fdb6-4f5c-ab35-ae1447903874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="carm-20241231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_bd277fe5-baed-41ca-94cd-fe75c239c79b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_bfe129e6-344a-44c0-8479-8dff62b07a40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_bd277fe5-baed-41ca-94cd-fe75c239c79b" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_bfe129e6-344a-44c0-8479-8dff62b07a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_b2bf4473-4caf-4c88-97ff-22589a5931ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_bd277fe5-baed-41ca-94cd-fe75c239c79b" xlink:to="loc_us-gaap_OperatingExpensesAbstract_b2bf4473-4caf-4c88-97ff-22589a5931ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3397a3dc-8824-429a-a231-4588e5f57768" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b2bf4473-4caf-4c88-97ff-22589a5931ca" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3397a3dc-8824-429a-a231-4588e5f57768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_6863e38d-8ee4-4052-841d-e7425b9b154a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b2bf4473-4caf-4c88-97ff-22589a5931ca" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_6863e38d-8ee4-4052-841d-e7425b9b154a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_986111ac-4753-4984-bec7-d25f715d9b47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b2bf4473-4caf-4c88-97ff-22589a5931ca" xlink:to="loc_us-gaap_OperatingExpenses_986111ac-4753-4984-bec7-d25f715d9b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c8468806-a580-44db-b50d-d088078c158e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_bd277fe5-baed-41ca-94cd-fe75c239c79b" xlink:to="loc_us-gaap_OperatingIncomeLoss_c8468806-a580-44db-b50d-d088078c158e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_2b7ef0ce-9adc-492b-b7d5-2b1229058645" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_bd277fe5-baed-41ca-94cd-fe75c239c79b" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_2b7ef0ce-9adc-492b-b7d5-2b1229058645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_bce8a45c-dc3f-47ba-a4f1-063e9520f4d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_bd277fe5-baed-41ca-94cd-fe75c239c79b" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_bce8a45c-dc3f-47ba-a4f1-063e9520f4d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7b2bb508-9a49-4837-9db9-1247b4ca93ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_bd277fe5-baed-41ca-94cd-fe75c239c79b" xlink:to="loc_us-gaap_NetIncomeLoss_7b2bb508-9a49-4837-9db9-1247b4ca93ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6af5fd33-058e-4efd-a6c5-93683277ab26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_bd277fe5-baed-41ca-94cd-fe75c239c79b" xlink:to="loc_us-gaap_EarningsPerShareAbstract_6af5fd33-058e-4efd-a6c5-93683277ab26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e75aa3d8-9841-42c6-9dc0-da989159b35e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6af5fd33-058e-4efd-a6c5-93683277ab26" xlink:to="loc_us-gaap_EarningsPerShareBasic_e75aa3d8-9841-42c6-9dc0-da989159b35e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_8f44b205-5e1f-4b01-bdb5-ba93ba223312" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6af5fd33-058e-4efd-a6c5-93683277ab26" xlink:to="loc_us-gaap_EarningsPerShareDiluted_8f44b205-5e1f-4b01-bdb5-ba93ba223312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0474ac90-92fd-42a1-b207-d4462aee4e98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6af5fd33-058e-4efd-a6c5-93683277ab26" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0474ac90-92fd-42a1-b207-d4462aee4e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_283c37a2-09c0-4ed7-b0c0-0fb485a2624f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6af5fd33-058e-4efd-a6c5-93683277ab26" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_283c37a2-09c0-4ed7-b0c0-0fb485a2624f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_d3b0b159-b698-4fe7-847a-9c8d3cbb0d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_bd277fe5-baed-41ca-94cd-fe75c239c79b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_d3b0b159-b698-4fe7-847a-9c8d3cbb0d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b2807018-8207-484f-baa5-af18c50a46dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_d3b0b159-b698-4fe7-847a-9c8d3cbb0d2b" xlink:to="loc_us-gaap_NetIncomeLoss_b2807018-8207-484f-baa5-af18c50a46dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_dc6bc64d-99e7-4e62-b62e-1cab7084aa0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_d3b0b159-b698-4fe7-847a-9c8d3cbb0d2b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_dc6bc64d-99e7-4e62-b62e-1cab7084aa0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_7c6b18bc-c1a0-4dd1-bbe4-b6cae46aa066" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_d3b0b159-b698-4fe7-847a-9c8d3cbb0d2b" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_7c6b18bc-c1a0-4dd1-bbe4-b6cae46aa066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_c60011b2-a6cd-4a5d-a925-eea09304c0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_d3b0b159-b698-4fe7-847a-9c8d3cbb0d2b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_c60011b2-a6cd-4a5d-a925-eea09304c0c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity" xlink:type="simple" xlink:href="carm-20241231.xsd#ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_e7abcf6b-4824-432b-b351-dcf6e4c94c88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_41601b7e-5934-4625-81df-48033a9d1d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_e7abcf6b-4824-432b-b351-dcf6e4c94c88" xlink:to="loc_us-gaap_StatementTable_41601b7e-5934-4625-81df-48033a9d1d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1c2fe158-3dd0-4237-9e1a-cd2f6c723d62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_41601b7e-5934-4625-81df-48033a9d1d1b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1c2fe158-3dd0-4237-9e1a-cd2f6c723d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_94930cba-7d08-4976-86a4-64c028dfedbd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1c2fe158-3dd0-4237-9e1a-cd2f6c723d62" xlink:to="loc_us-gaap_EquityComponentDomain_94930cba-7d08-4976-86a4-64c028dfedbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_65e445b7-19d4-44ca-bb5e-dbbadaf42efd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_94930cba-7d08-4976-86a4-64c028dfedbd" xlink:to="loc_us-gaap_CommonStockMember_65e445b7-19d4-44ca-bb5e-dbbadaf42efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_257edca9-e155-4601-9bb9-2b0355063d55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_94930cba-7d08-4976-86a4-64c028dfedbd" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_257edca9-e155-4601-9bb9-2b0355063d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4c12ceb7-ea31-47f5-b00e-6ddd5a1909de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_94930cba-7d08-4976-86a4-64c028dfedbd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4c12ceb7-ea31-47f5-b00e-6ddd5a1909de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_af202bdc-9a0a-44c2-89b4-b26215b5a674" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_94930cba-7d08-4976-86a4-64c028dfedbd" xlink:to="loc_us-gaap_RetainedEarningsMember_af202bdc-9a0a-44c2-89b4-b26215b5a674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_8b82ba48-982f-4cf6-8187-f8d8c7326c82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_94930cba-7d08-4976-86a4-64c028dfedbd" xlink:to="loc_us-gaap_NoncontrollingInterestMember_8b82ba48-982f-4cf6-8187-f8d8c7326c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8cbe27f4-cdc0-40c0-8d92-5c98b3ea43eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_41601b7e-5934-4625-81df-48033a9d1d1b" xlink:to="loc_us-gaap_StatementLineItems_8cbe27f4-cdc0-40c0-8d92-5c98b3ea43eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_32ee9fff-61b7-4516-be0d-9be9d1d2fa1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8cbe27f4-cdc0-40c0-8d92-5c98b3ea43eb" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_32ee9fff-61b7-4516-be0d-9be9d1d2fa1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_d9fac99a-693b-466a-b999-7b46620b42f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_32ee9fff-61b7-4516-be0d-9be9d1d2fa1b" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_d9fac99a-693b-466a-b999-7b46620b42f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_202d230c-e9b7-470a-9641-ccd62f6e6217" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_32ee9fff-61b7-4516-be0d-9be9d1d2fa1b" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_202d230c-e9b7-470a-9641-ccd62f6e6217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ReclassificationsOfTemporaryToPermanentEquityShares_5b69cf1e-6642-44b8-a039-393ee722b8c8" xlink:href="carm-20241231.xsd#carm_ReclassificationsOfTemporaryToPermanentEquityShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_32ee9fff-61b7-4516-be0d-9be9d1d2fa1b" xlink:to="loc_carm_ReclassificationsOfTemporaryToPermanentEquityShares_5b69cf1e-6642-44b8-a039-393ee722b8c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_ce3bd4a6-083f-48c9-97df-6970ae68e206" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_32ee9fff-61b7-4516-be0d-9be9d1d2fa1b" xlink:to="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_ce3bd4a6-083f-48c9-97df-6970ae68e206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_e3d8971f-4dfa-42ae-a59b-6fffea580d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_32ee9fff-61b7-4516-be0d-9be9d1d2fa1b" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_e3d8971f-4dfa-42ae-a59b-6fffea580d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_21df95b1-db54-4f06-9f20-547fe89b068f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_32ee9fff-61b7-4516-be0d-9be9d1d2fa1b" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_21df95b1-db54-4f06-9f20-547fe89b068f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_340d78da-0560-4daa-a767-04921b9f291d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8cbe27f4-cdc0-40c0-8d92-5c98b3ea43eb" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_340d78da-0560-4daa-a767-04921b9f291d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_5f450143-0dd8-4674-9120-8b095d17aaf9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_340d78da-0560-4daa-a767-04921b9f291d" xlink:to="loc_us-gaap_SharesIssued_5f450143-0dd8-4674-9120-8b095d17aaf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_aa7fdc3e-ec42-4e19-b180-9bde0cb8bebf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_340d78da-0560-4daa-a767-04921b9f291d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_aa7fdc3e-ec42-4e19-b180-9bde0cb8bebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_deebe50c-9ae6-40b9-a5a1-af0db218a57e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_340d78da-0560-4daa-a767-04921b9f291d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_deebe50c-9ae6-40b9-a5a1-af0db218a57e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_65df0b93-1470-4fd8-88ed-bbe23ffd4d52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_340d78da-0560-4daa-a767-04921b9f291d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_65df0b93-1470-4fd8-88ed-bbe23ffd4d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_07aff1f8-95d2-4d81-bd17-c26ee2fe5d61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_340d78da-0560-4daa-a767-04921b9f291d" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_07aff1f8-95d2-4d81-bd17-c26ee2fe5d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_434e16a2-b653-4ba1-a11b-62c1d8dab427" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_340d78da-0560-4daa-a767-04921b9f291d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_434e16a2-b653-4ba1-a11b-62c1d8dab427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_47bc7a91-d7db-46bf-a2fe-d3c5a20e7ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_340d78da-0560-4daa-a767-04921b9f291d" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_47bc7a91-d7db-46bf-a2fe-d3c5a20e7ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction_703cafb3-1077-45d5-8266-5fe5defbd13d" xlink:href="carm-20241231.xsd#carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_340d78da-0560-4daa-a767-04921b9f291d" xlink:to="loc_carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction_703cafb3-1077-45d5-8266-5fe5defbd13d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction_b4464df1-7403-4346-8d59-af978f306706" xlink:href="carm-20241231.xsd#carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_340d78da-0560-4daa-a767-04921b9f291d" xlink:to="loc_carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction_b4464df1-7403-4346-8d59-af978f306706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_eeb71094-800c-4c68-b346-33c649af4e13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_340d78da-0560-4daa-a767-04921b9f291d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_eeb71094-800c-4c68-b346-33c649af4e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_f0ed2ebe-49a3-426a-b97d-600380b4845d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_340d78da-0560-4daa-a767-04921b9f291d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_f0ed2ebe-49a3-426a-b97d-600380b4845d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_abd86d17-e671-4e68-9e46-1a071c368fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_340d78da-0560-4daa-a767-04921b9f291d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_abd86d17-e671-4e68-9e46-1a071c368fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_b133f91b-c7b5-4541-86b7-42b4beca9d35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_340d78da-0560-4daa-a767-04921b9f291d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_b133f91b-c7b5-4541-86b7-42b4beca9d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger_cbcdf767-6116-4ce9-844c-5d87db1c1d09" xlink:href="carm-20241231.xsd#carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_340d78da-0560-4daa-a767-04921b9f291d" xlink:to="loc_carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger_cbcdf767-6116-4ce9-844c-5d87db1c1d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger_bdb6d7f4-85aa-43fc-8dbf-ea323d810bc8" xlink:href="carm-20241231.xsd#carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_340d78da-0560-4daa-a767-04921b9f291d" xlink:to="loc_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger_bdb6d7f4-85aa-43fc-8dbf-ea323d810bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d8522552-3c21-449c-8d30-91fcf342d288" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_340d78da-0560-4daa-a767-04921b9f291d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d8522552-3c21-449c-8d30-91fcf342d288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7bdc9b90-ff88-40a4-b5eb-1567e0bdf16a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_340d78da-0560-4daa-a767-04921b9f291d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7bdc9b90-ff88-40a4-b5eb-1567e0bdf16a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cab1cc29-c6b7-484e-8bdc-5fd1b4b906a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_340d78da-0560-4daa-a767-04921b9f291d" xlink:to="loc_us-gaap_NetIncomeLoss_cab1cc29-c6b7-484e-8bdc-5fd1b4b906a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_e36c5e29-eb82-4696-8796-848b429e3571" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_340d78da-0560-4daa-a767-04921b9f291d" xlink:to="loc_us-gaap_SharesIssued_e36c5e29-eb82-4696-8796-848b429e3571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e6693d03-a51a-4b10-a88c-58751b942ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_340d78da-0560-4daa-a767-04921b9f291d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e6693d03-a51a-4b10-a88c-58751b942ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="carm-20241231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_f5202579-4869-4148-8cf0-1dc38576a669" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_fd3cd546-6de4-4c59-816f-9e3188b22e58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f5202579-4869-4148-8cf0-1dc38576a669" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_fd3cd546-6de4-4c59-816f-9e3188b22e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b87f1de8-7a2f-4073-8d6a-73fe5775c429" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_fd3cd546-6de4-4c59-816f-9e3188b22e58" xlink:to="loc_us-gaap_NetIncomeLoss_b87f1de8-7a2f-4073-8d6a-73fe5775c429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6f95d904-880b-43f2-974b-28122de2dc7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_fd3cd546-6de4-4c59-816f-9e3188b22e58" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6f95d904-880b-43f2-974b-28122de2dc7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_c53549b1-2151-4ae2-b9e5-c0cfaf25bff6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6f95d904-880b-43f2-974b-28122de2dc7e" xlink:to="loc_us-gaap_DepreciationAndAmortization_c53549b1-2151-4ae2-b9e5-c0cfaf25bff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_c8296069-fc41-46f6-bab4-8c94256f5b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6f95d904-880b-43f2-974b-28122de2dc7e" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_c8296069-fc41-46f6-bab4-8c94256f5b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_247b8b91-4fa3-411f-aa52-bf3af4fd50eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6f95d904-880b-43f2-974b-28122de2dc7e" xlink:to="loc_us-gaap_ShareBasedCompensation_247b8b91-4fa3-411f-aa52-bf3af4fd50eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_63d75ac6-eb8f-4bd2-be84-57941c561c89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6f95d904-880b-43f2-974b-28122de2dc7e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_63d75ac6-eb8f-4bd2-be84-57941c561c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_8d3adc11-f0ad-4494-bc23-68c678776309" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6f95d904-880b-43f2-974b-28122de2dc7e" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_8d3adc11-f0ad-4494-bc23-68c678776309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_b5b93dba-4a6b-42c4-a782-96ad82c59eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6f95d904-880b-43f2-974b-28122de2dc7e" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_b5b93dba-4a6b-42c4-a782-96ad82c59eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AccretionOnMarketableSecurities_c465bf58-5ff1-4bc7-b0e5-df91e6b8d475" xlink:href="carm-20241231.xsd#carm_AccretionOnMarketableSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6f95d904-880b-43f2-974b-28122de2dc7e" xlink:to="loc_carm_AccretionOnMarketableSecurities_c465bf58-5ff1-4bc7-b0e5-df91e6b8d475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_WriteOffOfPropertyAndEquipment_d6465e70-b117-40d7-87b0-9c28a700af59" xlink:href="carm-20241231.xsd#carm_WriteOffOfPropertyAndEquipment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6f95d904-880b-43f2-974b-28122de2dc7e" xlink:to="loc_carm_WriteOffOfPropertyAndEquipment_d6465e70-b117-40d7-87b0-9c28a700af59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_7baa4798-d54b-4e64-8450-f9877f83aed4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6f95d904-880b-43f2-974b-28122de2dc7e" xlink:to="loc_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_7baa4798-d54b-4e64-8450-f9877f83aed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NoncashInterestExpense_786cf613-53c7-4864-a343-7a01bcb04995" xlink:href="carm-20241231.xsd#carm_NoncashInterestExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6f95d904-880b-43f2-974b-28122de2dc7e" xlink:to="loc_carm_NoncashInterestExpense_786cf613-53c7-4864-a343-7a01bcb04995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_GainLossOnSaleOfEquipment_f57c2caa-143c-41fa-a4dc-7175d97586a1" xlink:href="carm-20241231.xsd#carm_GainLossOnSaleOfEquipment"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6f95d904-880b-43f2-974b-28122de2dc7e" xlink:to="loc_carm_GainLossOnSaleOfEquipment_f57c2caa-143c-41fa-a4dc-7175d97586a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleAndLeasebackTransactionGainLossNet_0fb0eda5-ffdb-462d-8b38-a07af79fa583" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleAndLeasebackTransactionGainLossNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6f95d904-880b-43f2-974b-28122de2dc7e" xlink:to="loc_us-gaap_SaleAndLeasebackTransactionGainLossNet_0fb0eda5-ffdb-462d-8b38-a07af79fa583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_83a6edca-833e-4f06-951d-816c798a555e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6f95d904-880b-43f2-974b-28122de2dc7e" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_83a6edca-833e-4f06-951d-816c798a555e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_992be4f5-3b18-4c59-9ed2-130afeb550bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_83a6edca-833e-4f06-951d-816c798a555e" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_992be4f5-3b18-4c59-9ed2-130afeb550bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_24b67889-9b2d-48a2-8230-48952799f0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_83a6edca-833e-4f06-951d-816c798a555e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_24b67889-9b2d-48a2-8230-48952799f0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_23c1595b-1c79-4212-adad-17a991fa177b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_83a6edca-833e-4f06-951d-816c798a555e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_23c1595b-1c79-4212-adad-17a991fa177b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_9124de36-6d8a-4bf4-b3e3-f2ea64485c39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_83a6edca-833e-4f06-951d-816c798a555e" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_9124de36-6d8a-4bf4-b3e3-f2ea64485c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_bd219e19-7f10-4707-82e4-2c6fb55917fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_83a6edca-833e-4f06-951d-816c798a555e" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_bd219e19-7f10-4707-82e4-2c6fb55917fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_d366f84c-6a69-41df-98ca-77c04c849ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_83a6edca-833e-4f06-951d-816c798a555e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_d366f84c-6a69-41df-98ca-77c04c849ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2495833a-7e2a-4191-9b2b-992c49b660dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_fd3cd546-6de4-4c59-816f-9e3188b22e58" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2495833a-7e2a-4191-9b2b-992c49b660dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_740ed3c4-c8a9-4536-9545-1f6963e276c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f5202579-4869-4148-8cf0-1dc38576a669" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_740ed3c4-c8a9-4536-9545-1f6963e276c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_d0cdd509-2324-4b04-a6b6-da488c768283" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_740ed3c4-c8a9-4536-9545-1f6963e276c5" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_d0cdd509-2324-4b04-a6b6-da488c768283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_PaymentsForProceedsFromMarketableSecurities_fbc41468-974f-4e49-8c78-d46c1d14f8ab" xlink:href="carm-20241231.xsd#carm_PaymentsForProceedsFromMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_740ed3c4-c8a9-4536-9545-1f6963e276c5" xlink:to="loc_carm_PaymentsForProceedsFromMarketableSecurities_fbc41468-974f-4e49-8c78-d46c1d14f8ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d70c841a-19de-4ca9-8247-8b5d647d9456" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_740ed3c4-c8a9-4536-9545-1f6963e276c5" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d70c841a-19de-4ca9-8247-8b5d647d9456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_96a4d26e-78b4-45e6-8a2b-d986a86940dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_740ed3c4-c8a9-4536-9545-1f6963e276c5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_96a4d26e-78b4-45e6-8a2b-d986a86940dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ec667b58-276c-4d9c-93bb-28951328dc50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f5202579-4869-4148-8cf0-1dc38576a669" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ec667b58-276c-4d9c-93bb-28951328dc50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities_e4711eb9-e474-4a58-afcf-7ac8857c350e" xlink:href="carm-20241231.xsd#carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ec667b58-276c-4d9c-93bb-28951328dc50" xlink:to="loc_carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities_e4711eb9-e474-4a58-afcf-7ac8857c350e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities_42d7881d-3628-46e8-944c-5ac15b36e4e2" xlink:href="carm-20241231.xsd#carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ec667b58-276c-4d9c-93bb-28951328dc50" xlink:to="loc_carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities_42d7881d-3628-46e8-944c-5ac15b36e4e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing_a9153002-8aee-4d61-abed-6694b6afe7a1" xlink:href="carm-20241231.xsd#carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ec667b58-276c-4d9c-93bb-28951328dc50" xlink:to="loc_carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing_a9153002-8aee-4d61-abed-6694b6afe7a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_2ccc6084-4eb3-47e0-ab2b-9a34767d7a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ec667b58-276c-4d9c-93bb-28951328dc50" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_2ccc6084-4eb3-47e0-ab2b-9a34767d7a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ProceedsFromFailedSaleLeasebackTransaction_f3a8b915-a3ce-484e-9584-8e7a061adbcf" xlink:href="carm-20241231.xsd#carm_ProceedsFromFailedSaleLeasebackTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ec667b58-276c-4d9c-93bb-28951328dc50" xlink:to="loc_carm_ProceedsFromFailedSaleLeasebackTransaction_f3a8b915-a3ce-484e-9584-8e7a061adbcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction_2d1e594e-c0c7-4f1d-89ca-b653438bb2dc" xlink:href="carm-20241231.xsd#carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ec667b58-276c-4d9c-93bb-28951328dc50" xlink:to="loc_carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction_2d1e594e-c0c7-4f1d-89ca-b653438bb2dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_2d0195b5-0eb6-415f-a30d-67536e7be57d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ec667b58-276c-4d9c-93bb-28951328dc50" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_2d0195b5-0eb6-415f-a30d-67536e7be57d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_ec51b71f-1b6a-42ff-b0b7-5d48f817613e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ec667b58-276c-4d9c-93bb-28951328dc50" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_ec51b71f-1b6a-42ff-b0b7-5d48f817613e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_cd5cd37c-9b65-45b3-ad66-7192cb0cd401" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ec667b58-276c-4d9c-93bb-28951328dc50" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_cd5cd37c-9b65-45b3-ad66-7192cb0cd401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dce2ea9d-8828-4987-9d77-1c323d89bcf7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ec667b58-276c-4d9c-93bb-28951328dc50" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dce2ea9d-8828-4987-9d77-1c323d89bcf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_c71d7c4f-e8fb-4a47-a055-851109fc28e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f5202579-4869-4148-8cf0-1dc38576a669" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_c71d7c4f-e8fb-4a47-a055-851109fc28e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bd87cae2-8540-48ec-8299-c43ced894f90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f5202579-4869-4148-8cf0-1dc38576a669" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bd87cae2-8540-48ec-8299-c43ced894f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f207c8af-9183-4cc9-80c9-3b7b9dae1b16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f5202579-4869-4148-8cf0-1dc38576a669" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f207c8af-9183-4cc9-80c9-3b7b9dae1b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_f8d7dfd5-8549-4b5d-9037-4b96ba735182" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f5202579-4869-4148-8cf0-1dc38576a669" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_f8d7dfd5-8549-4b5d-9037-4b96ba735182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_afda5133-5fa9-411e-a747-6357223b7d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_f8d7dfd5-8549-4b5d-9037-4b96ba735182" xlink:to="loc_us-gaap_InterestPaidNet_afda5133-5fa9-411e-a747-6357223b7d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_c81ab2e5-9345-48ca-9adb-419199896f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f5202579-4869-4148-8cf0-1dc38576a669" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_c81ab2e5-9345-48ca-9adb-419199896f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NoncashOrPartNoncashAcquisitionEquityAssumed_bcc1589e-2f3f-4238-96b6-8344434a2d2a" xlink:href="carm-20241231.xsd#carm_NoncashOrPartNoncashAcquisitionEquityAssumed"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_c81ab2e5-9345-48ca-9adb-419199896f6d" xlink:to="loc_carm_NoncashOrPartNoncashAcquisitionEquityAssumed_bcc1589e-2f3f-4238-96b6-8344434a2d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReduction_99b05eea-538f-4faf-a07d-1f8b8de7d2ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesReduction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_c81ab2e5-9345-48ca-9adb-419199896f6d" xlink:to="loc_us-gaap_NotesReduction_99b05eea-538f-4faf-a07d-1f8b8de7d2ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities_9456d219-1819-48ca-a4dd-4c2e0d390538" xlink:href="carm-20241231.xsd#carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_c81ab2e5-9345-48ca-9adb-419199896f6d" xlink:to="loc_carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities_9456d219-1819-48ca-a4dd-4c2e0d390538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts_d9bd7756-d494-4bf2-881e-d9fffcfc6530" xlink:href="carm-20241231.xsd#carm_NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_c81ab2e5-9345-48ca-9adb-419199896f6d" xlink:to="loc_carm_NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts_d9bd7756-d494-4bf2-881e-d9fffcfc6530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_4679290e-e002-43ac-813f-f023e20cfa9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_c81ab2e5-9345-48ca-9adb-419199896f6d" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_4679290e-e002-43ac-813f-f023e20cfa9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_00a70a50-f0fa-46c8-8751-6b92582ed231" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_c81ab2e5-9345-48ca-9adb-419199896f6d" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_00a70a50-f0fa-46c8-8751-6b92582ed231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NonCashEffectOfModificationOfOperatingLeaseRightOfUseAssetsOperatingLeaseLiabilities_9e1c60aa-5d6f-440e-b6a9-3696b6f9f7d1" xlink:href="carm-20241231.xsd#carm_NonCashEffectOfModificationOfOperatingLeaseRightOfUseAssetsOperatingLeaseLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_c81ab2e5-9345-48ca-9adb-419199896f6d" xlink:to="loc_carm_NonCashEffectOfModificationOfOperatingLeaseRightOfUseAssetsOperatingLeaseLiabilities_9e1c60aa-5d6f-440e-b6a9-3696b6f9f7d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability_3aa0aa58-fe3a-4d45-a4a2-3f3d62386115" xlink:href="carm-20241231.xsd#carm_DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_c81ab2e5-9345-48ca-9adb-419199896f6d" xlink:to="loc_carm_DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability_3aa0aa58-fe3a-4d45-a4a2-3f3d62386115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/Background" xlink:type="simple" xlink:href="carm-20241231.xsd#Background"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/Background" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bc236a2d-fef6-4c3d-9379-637a6d8b1865" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_017e9685-174a-435d-a8f8-6c0b48235237" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bc236a2d-fef6-4c3d-9379-637a6d8b1865" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_017e9685-174a-435d-a8f8-6c0b48235237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/DevelopmentStageRisksandLiquidity" xlink:type="simple" xlink:href="carm-20241231.xsd#DevelopmentStageRisksandLiquidity"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/DevelopmentStageRisksandLiquidity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_carm_DevelopmentStageRisksAndLiquidityAbstract_07b2fac8-d147-49ea-ae4b-2b3f927922fd" xlink:href="carm-20241231.xsd#carm_DevelopmentStageRisksAndLiquidityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DevelopmentStageRisksAndLiquidityTextBlock_a3d33493-20e9-4ab8-8217-4b2f6c21e6e4" xlink:href="carm-20241231.xsd#carm_DevelopmentStageRisksAndLiquidityTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_carm_DevelopmentStageRisksAndLiquidityAbstract_07b2fac8-d147-49ea-ae4b-2b3f927922fd" xlink:to="loc_carm_DevelopmentStageRisksAndLiquidityTextBlock_a3d33493-20e9-4ab8-8217-4b2f6c21e6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="carm-20241231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e0e53fd5-30b8-4cb4-8f2c-2c6155aae430" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_b265a55f-eefd-447c-9388-5261f8f66998" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e0e53fd5-30b8-4cb4-8f2c-2c6155aae430" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_b265a55f-eefd-447c-9388-5261f8f66998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/MergerwithSesenBio" xlink:type="simple" xlink:href="carm-20241231.xsd#MergerwithSesenBio"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/MergerwithSesenBio" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_bb89979a-2007-407e-a851-bc75ce9ab7a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_19ebc7b2-7302-43a4-ba47-7ca53dbfa576" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_bb89979a-2007-407e-a851-bc75ce9ab7a6" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_19ebc7b2-7302-43a4-ba47-7ca53dbfa576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/PrepaidExpensesandOtherAssets" xlink:type="simple" xlink:href="carm-20241231.xsd#PrepaidExpensesandOtherAssets"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/PrepaidExpensesandOtherAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_e9494596-2864-49e2-815d-afcf7840401b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsDisclosureTextBlock_48c03291-fcaf-48fd-adbe-90f1bcb575ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_e9494596-2864-49e2-815d-afcf7840401b" xlink:to="loc_us-gaap_OtherAssetsDisclosureTextBlock_48c03291-fcaf-48fd-adbe-90f1bcb575ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/PropertyandEquipmentnet" xlink:type="simple" xlink:href="carm-20241231.xsd#PropertyandEquipmentnet"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/PropertyandEquipmentnet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_874dd359-2661-4f17-b2c9-39d39a822647" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_befb8218-0a23-4787-8c73-32b436c78247" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_874dd359-2661-4f17-b2c9-39d39a822647" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_befb8218-0a23-4787-8c73-32b436c78247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/AccruedExpenses" xlink:type="simple" xlink:href="carm-20241231.xsd#AccruedExpenses"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_5517a86e-aeac-4443-9b70-461dd2d46ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_d80ccc74-ba29-4377-b7df-5c3f38282ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5517a86e-aeac-4443-9b70-461dd2d46ea2" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_d80ccc74-ba29-4377-b7df-5c3f38282ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="carm-20241231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6a3a0a54-60b1-41f3-a114-85ffbd74ccf8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_228eb8a8-f6d3-419c-a6ab-de14cf95ec70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6a3a0a54-60b1-41f3-a114-85ffbd74ccf8" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_228eb8a8-f6d3-419c-a6ab-de14cf95ec70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/StockholdersDeficitEquity" xlink:type="simple" xlink:href="carm-20241231.xsd#StockholdersDeficitEquity"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/StockholdersDeficitEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_892b71c7-6a58-482d-9606-6c0d3d03e9fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_dd582c89-073f-41ff-bdf3-bc2996fcc99c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_892b71c7-6a58-482d-9606-6c0d3d03e9fe" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_dd582c89-073f-41ff-bdf3-bc2996fcc99c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="carm-20241231.xsd#StockbasedCompensation"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/StockbasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5bbb711d-dd11-490d-b47d-900015c86852" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1d6d63c6-d07e-4b76-81d6-722feea3e693" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5bbb711d-dd11-490d-b47d-900015c86852" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1d6d63c6-d07e-4b76-81d6-722feea3e693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/IncomeTaxes" xlink:type="simple" xlink:href="carm-20241231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7384be65-8e54-4c3f-9ae0-2a74c6c97dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_5076465b-c5a6-4321-bb21-6f2d77d0e27e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7384be65-8e54-4c3f-9ae0-2a74c6c97dc2" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_5076465b-c5a6-4321-bb21-6f2d77d0e27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="carm-20241231.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_6393f947-b81b-444b-a7e3-6f7ff14a0719" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_fccdd1b7-f343-44fa-877d-b9573c2917dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_6393f947-b81b-444b-a7e3-6f7ff14a0719" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_fccdd1b7-f343-44fa-877d-b9573c2917dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/ModernaCollaborationandLicenseAgreement" xlink:type="simple" xlink:href="carm-20241231.xsd#ModernaCollaborationandLicenseAgreement"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/ModernaCollaborationandLicenseAgreement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_bf7cb84f-8fd7-4cbc-821d-8cf32b2031af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_432605d0-a130-4953-ad8d-f5c968808f34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_bf7cb84f-8fd7-4cbc-821d-8cf32b2031af" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_432605d0-a130-4953-ad8d-f5c968808f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/SubsequentEvents" xlink:type="simple" xlink:href="carm-20241231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_aa8e9375-c102-415c-84e5-95d1039c2ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_2b4e5a84-a329-44dc-aab6-1ef3392240f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_aa8e9375-c102-415c-84e5-95d1039c2ed3" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_2b4e5a84-a329-44dc-aab6-1ef3392240f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="carm-20241231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4c16dcc4-b3f3-44b3-8f2b-ae79b2493094" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d272b529-756e-4ab7-ada4-7c7b835dc893" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4c16dcc4-b3f3-44b3-8f2b-ae79b2493094" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d272b529-756e-4ab7-ada4-7c7b835dc893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_4544b792-26e0-4c50-991a-d0e3de8f1809" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4c16dcc4-b3f3-44b3-8f2b-ae79b2493094" xlink:to="loc_us-gaap_UseOfEstimates_4544b792-26e0-4c50-991a-d0e3de8f1809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_1b62999e-4ba7-4c0b-a4c1-b0d51241db1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4c16dcc4-b3f3-44b3-8f2b-ae79b2493094" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_1b62999e-4ba7-4c0b-a4c1-b0d51241db1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_3c2c101f-62d6-472a-8263-2598e17e64d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4c16dcc4-b3f3-44b3-8f2b-ae79b2493094" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_3c2c101f-62d6-472a-8263-2598e17e64d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_fac05d90-a53e-4d7d-b142-37484f1fb1d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4c16dcc4-b3f3-44b3-8f2b-ae79b2493094" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_fac05d90-a53e-4d7d-b142-37484f1fb1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_bb144112-ec37-4b41-b7c5-711afab7e8a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4c16dcc4-b3f3-44b3-8f2b-ae79b2493094" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_bb144112-ec37-4b41-b7c5-711afab7e8a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_46968e87-08ab-4aa4-a004-e5ba1562a366" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4c16dcc4-b3f3-44b3-8f2b-ae79b2493094" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_46968e87-08ab-4aa4-a004-e5ba1562a366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_85c57f56-ef2b-41f4-91ac-f5367a0782b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4c16dcc4-b3f3-44b3-8f2b-ae79b2493094" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_85c57f56-ef2b-41f4-91ac-f5367a0782b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_cbb0e220-bc3a-4050-b881-e536677e14da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4c16dcc4-b3f3-44b3-8f2b-ae79b2493094" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_cbb0e220-bc3a-4050-b881-e536677e14da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_fb568ede-6cfe-445d-8810-dc1016773552" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4c16dcc4-b3f3-44b3-8f2b-ae79b2493094" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_fb568ede-6cfe-445d-8810-dc1016773552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DeferredFinancingCostsPolicyPolicyTextBlock_955a24b5-89b7-400c-a64d-8d85c5694c77" xlink:href="carm-20241231.xsd#carm_DeferredFinancingCostsPolicyPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4c16dcc4-b3f3-44b3-8f2b-ae79b2493094" xlink:to="loc_carm_DeferredFinancingCostsPolicyPolicyTextBlock_955a24b5-89b7-400c-a64d-8d85c5694c77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_ba1ff699-022f-4504-b1fb-ef16f35b482c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4c16dcc4-b3f3-44b3-8f2b-ae79b2493094" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_ba1ff699-022f-4504-b1fb-ef16f35b482c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_ca0eb499-381b-4fba-9357-cd101b99781c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4c16dcc4-b3f3-44b3-8f2b-ae79b2493094" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_ca0eb499-381b-4fba-9357-cd101b99781c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_398c6b84-3125-4b49-b3ac-3c613d2ba811" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4c16dcc4-b3f3-44b3-8f2b-ae79b2493094" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_398c6b84-3125-4b49-b3ac-3c613d2ba811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_9fa2288f-bd27-45db-95ab-924a36ccb7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4c16dcc4-b3f3-44b3-8f2b-ae79b2493094" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_9fa2288f-bd27-45db-95ab-924a36ccb7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_82c696ea-8a16-46b4-adc7-1aa30af8a942" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4c16dcc4-b3f3-44b3-8f2b-ae79b2493094" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_82c696ea-8a16-46b4-adc7-1aa30af8a942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_461bf603-fce0-4142-b077-2f37a90d352d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4c16dcc4-b3f3-44b3-8f2b-ae79b2493094" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_461bf603-fce0-4142-b077-2f37a90d352d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="carm-20241231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5e64191f-7ecb-4dfd-80b6-2ef0bbc142b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_ce5992b9-a0a3-4346-ad5f-c8748388deb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5e64191f-7ecb-4dfd-80b6-2ef0bbc142b3" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_ce5992b9-a0a3-4346-ad5f-c8748388deb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_8001e493-51c1-4b91-8b27-e7022f2c7bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5e64191f-7ecb-4dfd-80b6-2ef0bbc142b3" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_8001e493-51c1-4b91-8b27-e7022f2c7bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1b75eafc-144d-4c71-9e51-410f73dbe0eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5e64191f-7ecb-4dfd-80b6-2ef0bbc142b3" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1b75eafc-144d-4c71-9e51-410f73dbe0eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/MergerwithSesenBioTables" xlink:type="simple" xlink:href="carm-20241231.xsd#MergerwithSesenBioTables"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/MergerwithSesenBioTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_90f18f2c-5a7f-440a-b504-40d109efb189" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_56830224-f250-4bff-a9a8-a69312d25912" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_90f18f2c-5a7f-440a-b504-40d109efb189" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_56830224-f250-4bff-a9a8-a69312d25912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/PrepaidExpensesandOtherAssetsTables" xlink:type="simple" xlink:href="carm-20241231.xsd#PrepaidExpensesandOtherAssetsTables"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/PrepaidExpensesandOtherAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_8c4eada7-2233-40b4-805a-48f1876986e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_57943732-b929-4669-bb08-d7dd1b35aacc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_8c4eada7-2233-40b4-805a-48f1876986e6" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_57943732-b929-4669-bb08-d7dd1b35aacc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/PropertyandEquipmentnetTables" xlink:type="simple" xlink:href="carm-20241231.xsd#PropertyandEquipmentnetTables"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/PropertyandEquipmentnetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d32ab953-7a5d-4d1c-94f7-f0af46ecc9be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_bab0cb2c-0196-4208-8bc5-b53c33ca43ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d32ab953-7a5d-4d1c-94f7-f0af46ecc9be" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_bab0cb2c-0196-4208-8bc5-b53c33ca43ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="carm-20241231.xsd#AccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/AccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_89d0e5aa-7b77-46d6-b87f-c017f1bce78e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_bed453a0-1236-4fe9-9c43-2962ab4f0a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_89d0e5aa-7b77-46d6-b87f-c017f1bce78e" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_bed453a0-1236-4fe9-9c43-2962ab4f0a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="carm-20241231.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fc9730ef-4a67-44b5-a509-1c4e295a8bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_094a4f0a-7e71-4706-a7cb-29d4231354e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fc9730ef-4a67-44b5-a509-1c4e295a8bcf" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_094a4f0a-7e71-4706-a7cb-29d4231354e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock_7acf8314-f76a-4e0e-836c-b9f94fecfeea" xlink:href="carm-20241231.xsd#carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fc9730ef-4a67-44b5-a509-1c4e295a8bcf" xlink:to="loc_carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock_7acf8314-f76a-4e0e-836c-b9f94fecfeea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock_37d9573b-c014-4113-bcb8-5f7f2e0523b8" xlink:href="carm-20241231.xsd#carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fc9730ef-4a67-44b5-a509-1c4e295a8bcf" xlink:to="loc_carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock_37d9573b-c014-4113-bcb8-5f7f2e0523b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock_13c285c7-191b-4fe9-9ea9-53a748f778a0" xlink:href="carm-20241231.xsd#carm_LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fc9730ef-4a67-44b5-a509-1c4e295a8bcf" xlink:to="loc_carm_LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock_13c285c7-191b-4fe9-9ea9-53a748f778a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="carm-20241231.xsd#StockbasedCompensationTables"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/StockbasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5098a330-19bc-4cdc-82f8-76545436756c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_eb8b3c35-9688-4200-99b2-20e45b8499bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5098a330-19bc-4cdc-82f8-76545436756c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_eb8b3c35-9688-4200-99b2-20e45b8499bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8ab78029-f080-4c70-98ed-6db68fdb0e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5098a330-19bc-4cdc-82f8-76545436756c" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8ab78029-f080-4c70-98ed-6db68fdb0e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_8a3edbea-e456-4c0f-a4b9-1a07066d10f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5098a330-19bc-4cdc-82f8-76545436756c" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_8a3edbea-e456-4c0f-a4b9-1a07066d10f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="carm-20241231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5ff3d910-76ac-4d9b-ba7e-8299c5c11ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_8bda9fbb-9efd-4fb0-906a-32528b291f37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5ff3d910-76ac-4d9b-ba7e-8299c5c11ac5" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_8bda9fbb-9efd-4fb0-906a-32528b291f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_058ef38c-4ff1-42bf-86e5-5fa5addd99ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5ff3d910-76ac-4d9b-ba7e-8299c5c11ac5" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_058ef38c-4ff1-42bf-86e5-5fa5addd99ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/ModernaCollaborationandLicenseAgreementTables" xlink:type="simple" xlink:href="carm-20241231.xsd#ModernaCollaborationandLicenseAgreementTables"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/ModernaCollaborationandLicenseAgreementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4fa1b788-8aa4-445c-8f63-74fef7f98790" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_04dc9de6-4366-4b10-86b0-bed918d7f193" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4fa1b788-8aa4-445c-8f63-74fef7f98790" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_04dc9de6-4366-4b10-86b0-bed918d7f193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ScheduleOfChangesInDeferredRevenueTableTextBlock_ef6050fc-a4c4-4733-8078-f054c917bd1e" xlink:href="carm-20241231.xsd#carm_ScheduleOfChangesInDeferredRevenueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4fa1b788-8aa4-445c-8f63-74fef7f98790" xlink:to="loc_carm_ScheduleOfChangesInDeferredRevenueTableTextBlock_ef6050fc-a4c4-4733-8078-f054c917bd1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/BackgroundDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#BackgroundDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/BackgroundDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1535c807-848e-45fd-89c9-8d1419f0fe2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_34d4825f-9e34-4019-86cc-589037593193" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1535c807-848e-45fd-89c9-8d1419f0fe2b" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_34d4825f-9e34-4019-86cc-589037593193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_99e0390e-8101-4b02-b154-22e0901eb008" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_34d4825f-9e34-4019-86cc-589037593193" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_99e0390e-8101-4b02-b154-22e0901eb008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_11b26c3a-3ba1-40b8-ab35-374f787b4978" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_99e0390e-8101-4b02-b154-22e0901eb008" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_11b26c3a-3ba1-40b8-ab35-374f787b4978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_34ca35a8-d70b-4b09-b83b-5f4382d3ca3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_11b26c3a-3ba1-40b8-ab35-374f787b4978" xlink:to="loc_us-gaap_EmployeeSeveranceMember_34ca35a8-d70b-4b09-b83b-5f4382d3ca3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2c131f4b-7a2c-41aa-bf08-a4922c7c0a80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_34d4825f-9e34-4019-86cc-589037593193" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2c131f4b-7a2c-41aa-bf08-a4922c7c0a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c29c836e-6177-4edc-9c10-2ee6aeae7440" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2c131f4b-7a2c-41aa-bf08-a4922c7c0a80" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c29c836e-6177-4edc-9c10-2ee6aeae7440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_890c44df-89c2-4bc7-8059-bda12e86ff03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c29c836e-6177-4edc-9c10-2ee6aeae7440" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_890c44df-89c2-4bc7-8059-bda12e86ff03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_361e3d3d-12af-441c-9263-6a6cf1296d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c29c836e-6177-4edc-9c10-2ee6aeae7440" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_361e3d3d-12af-441c-9263-6a6cf1296d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_ceb54b29-c6e3-416b-a632-33b958c8b73e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationSegmentAllocationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_34d4825f-9e34-4019-86cc-589037593193" xlink:to="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_ceb54b29-c6e3-416b-a632-33b958c8b73e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_b2f54b43-3f5a-443e-84c2-d87cd09375e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_ceb54b29-c6e3-416b-a632-33b958c8b73e" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_b2f54b43-3f5a-443e-84c2-d87cd09375e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_501c0ec8-076c-49b9-8bfd-8e9c303ec2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_ceb54b29-c6e3-416b-a632-33b958c8b73e" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_501c0ec8-076c-49b9-8bfd-8e9c303ec2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_b20de058-5961-46c5-9d26-9bbc7e95794a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_ceb54b29-c6e3-416b-a632-33b958c8b73e" xlink:to="loc_us-gaap_RestructuringCharges_b20de058-5961-46c5-9d26-9bbc7e95794a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_f0fff15d-2cdd-463e-ab11-ad1a7de143d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCharges_b20de058-5961-46c5-9d26-9bbc7e95794a" xlink:to="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_f0fff15d-2cdd-463e-ab11-ad1a7de143d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_beb75f5b-9523-44bc-b7be-cea0579a1202" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_ceb54b29-c6e3-416b-a632-33b958c8b73e" xlink:to="loc_us-gaap_RestructuringReserve_beb75f5b-9523-44bc-b7be-cea0579a1202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/DevelopmentStageRisksandLiquidityDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#DevelopmentStageRisksandLiquidityDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/DevelopmentStageRisksandLiquidityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_carm_DevelopmentStageRisksAndLiquidityAbstract_ee958fee-cb3c-49fa-ae4f-e1079c68a2a8" xlink:href="carm-20241231.xsd#carm_DevelopmentStageRisksAndLiquidityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ad95ca02-ea04-4ec4-b906-6bab28d88dba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_carm_DevelopmentStageRisksAndLiquidityAbstract_ee958fee-cb3c-49fa-ae4f-e1079c68a2a8" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ad95ca02-ea04-4ec4-b906-6bab28d88dba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_8437bda4-47f2-4981-afa0-b0f1aa4c5e56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_carm_DevelopmentStageRisksAndLiquidityAbstract_ee958fee-cb3c-49fa-ae4f-e1079c68a2a8" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_8437bda4-47f2-4981-afa0-b0f1aa4c5e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsMeasuredonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_17a9d3ef-9ba9-4452-bde6-56e761cf662c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_868228f5-a5d5-47a0-bdd9-6efdcfb39374" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_17a9d3ef-9ba9-4452-bde6-56e761cf662c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_868228f5-a5d5-47a0-bdd9-6efdcfb39374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_444f646d-6fe7-4f09-88c0-c33326af937a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_868228f5-a5d5-47a0-bdd9-6efdcfb39374" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_444f646d-6fe7-4f09-88c0-c33326af937a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_398777b6-1c4c-459e-802f-9b5853961369" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_444f646d-6fe7-4f09-88c0-c33326af937a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_398777b6-1c4c-459e-802f-9b5853961369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_269cea04-494b-4646-b44c-ada9614c5b38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_398777b6-1c4c-459e-802f-9b5853961369" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_269cea04-494b-4646-b44c-ada9614c5b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_aaec4540-0e57-4508-acfb-53841a07a713" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_868228f5-a5d5-47a0-bdd9-6efdcfb39374" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_aaec4540-0e57-4508-acfb-53841a07a713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c73a1d12-dc80-4979-83d1-8dc13bbc20f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_aaec4540-0e57-4508-acfb-53841a07a713" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c73a1d12-dc80-4979-83d1-8dc13bbc20f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_660a838d-2467-43cd-9a56-bdf58c168576" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c73a1d12-dc80-4979-83d1-8dc13bbc20f4" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_660a838d-2467-43cd-9a56-bdf58c168576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_142c482a-d26f-4ef6-8db3-410518c890e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c73a1d12-dc80-4979-83d1-8dc13bbc20f4" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_142c482a-d26f-4ef6-8db3-410518c890e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_fdab007d-bcad-46a4-9d61-2f6ce1ce130e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c73a1d12-dc80-4979-83d1-8dc13bbc20f4" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_fdab007d-bcad-46a4-9d61-2f6ce1ce130e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf2bb7e8-6f57-4f61-9535-5d6fba6f205c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_868228f5-a5d5-47a0-bdd9-6efdcfb39374" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf2bb7e8-6f57-4f61-9535-5d6fba6f205c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_2c5af930-d595-48cc-af70-7c02bb237fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf2bb7e8-6f57-4f61-9535-5d6fba6f205c" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_2c5af930-d595-48cc-af70-7c02bb237fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c0bad2a5-3213-4ac5-bcad-43cea40cdda9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_2c5af930-d595-48cc-af70-7c02bb237fa1" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c0bad2a5-3213-4ac5-bcad-43cea40cdda9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_376bfab8-d4b3-43d6-a063-d4e5c992b463" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_98416266-d2fb-40ac-b8a1-5fea19c3b112" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_376bfab8-d4b3-43d6-a063-d4e5c992b463" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_98416266-d2fb-40ac-b8a1-5fea19c3b112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_70a37896-2386-4045-b487-49e2fc9663ea" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_98416266-d2fb-40ac-b8a1-5fea19c3b112" xlink:to="loc_srt_RangeAxis_70a37896-2386-4045-b487-49e2fc9663ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fd2ceff3-4220-4198-b704-9c7cd8ced2ab" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_70a37896-2386-4045-b487-49e2fc9663ea" xlink:to="loc_srt_RangeMember_fd2ceff3-4220-4198-b704-9c7cd8ced2ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c5ac7d63-7112-40bf-99a1-6407e5b7378e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fd2ceff3-4220-4198-b704-9c7cd8ced2ab" xlink:to="loc_srt_MinimumMember_c5ac7d63-7112-40bf-99a1-6407e5b7378e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_58e1120b-c23a-4588-8b6b-495588377083" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fd2ceff3-4220-4198-b704-9c7cd8ced2ab" xlink:to="loc_srt_MaximumMember_58e1120b-c23a-4588-8b6b-495588377083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_17768fca-6f74-4704-a5da-d82d0d19d5b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_98416266-d2fb-40ac-b8a1-5fea19c3b112" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_17768fca-6f74-4704-a5da-d82d0d19d5b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_f1c42455-d542-4866-865b-be649041b0b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_17768fca-6f74-4704-a5da-d82d0d19d5b1" xlink:to="loc_us-gaap_NumberOfOperatingSegments_f1c42455-d542-4866-865b-be649041b0b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_65e4fbb5-8312-4684-b59e-60580573f60d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_17768fca-6f74-4704-a5da-d82d0d19d5b1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_65e4fbb5-8312-4684-b59e-60580573f60d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_ac8c9f71-bde9-471b-80dd-08e5c729ba3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_17768fca-6f74-4704-a5da-d82d0d19d5b1" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_ac8c9f71-bde9-471b-80dd-08e5c729ba3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofSignificantExpenseCategoriesbySegmentDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#SummaryofSignificantAccountingPoliciesScheduleofSignificantExpenseCategoriesbySegmentDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofSignificantExpenseCategoriesbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d45c2f95-6d76-44b8-98ae-a7e770ff2871" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_98410630-0f38-4c3b-9650-40c71008537a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d45c2f95-6d76-44b8-98ae-a7e770ff2871" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_98410630-0f38-4c3b-9650-40c71008537a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_42248d94-a037-40a0-af20-6bfd78dc5874" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_98410630-0f38-4c3b-9650-40c71008537a" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_42248d94-a037-40a0-af20-6bfd78dc5874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1bbf4d7c-e4ec-4d19-ac7c-87c0edcdcd06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_42248d94-a037-40a0-af20-6bfd78dc5874" xlink:to="loc_us-gaap_SegmentDomain_1bbf4d7c-e4ec-4d19-ac7c-87c0edcdcd06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ReportingSegmentMember_792afa3e-8a59-41e4-b88e-627108ca27ab" xlink:href="carm-20241231.xsd#carm_ReportingSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1bbf4d7c-e4ec-4d19-ac7c-87c0edcdcd06" xlink:to="loc_carm_ReportingSegmentMember_792afa3e-8a59-41e4-b88e-627108ca27ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_51597a67-8a7b-4c43-86b8-f55b6e85cc8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_98410630-0f38-4c3b-9650-40c71008537a" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_51597a67-8a7b-4c43-86b8-f55b6e85cc8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_8eb88a62-e4ac-4f83-9e63-0cfb93858463" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_51597a67-8a7b-4c43-86b8-f55b6e85cc8f" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_8eb88a62-e4ac-4f83-9e63-0cfb93858463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationAdditionalInformationAbstract_37ea93e6-28b7-45ac-b615-7f07eb0d2cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationAdditionalInformationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_51597a67-8a7b-4c43-86b8-f55b6e85cc8f" xlink:to="loc_us-gaap_SegmentReportingInformationAdditionalInformationAbstract_37ea93e6-28b7-45ac-b615-7f07eb0d2cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses_8d7c5bf8-8afa-4cad-bfbc-d6cbf622d53a" xlink:href="carm-20241231.xsd#carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationAdditionalInformationAbstract_37ea93e6-28b7-45ac-b615-7f07eb0d2cf1" xlink:to="loc_carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses_8d7c5bf8-8afa-4cad-bfbc-d6cbf622d53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses_6ad543a2-8ef6-4c5f-ba06-a088bf8ba799" xlink:href="carm-20241231.xsd#carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationAdditionalInformationAbstract_37ea93e6-28b7-45ac-b615-7f07eb0d2cf1" xlink:to="loc_carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses_6ad543a2-8ef6-4c5f-ba06-a088bf8ba799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_FacilitiesExpense_d7c7228b-d9b4-4769-bc60-e1c9eccd5ef5" xlink:href="carm-20241231.xsd#carm_FacilitiesExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationAdditionalInformationAbstract_37ea93e6-28b7-45ac-b615-7f07eb0d2cf1" xlink:to="loc_carm_FacilitiesExpense_d7c7228b-d9b4-4769-bc60-e1c9eccd5ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_c10f7a2e-58b2-496c-a2ec-63a0f6a8da61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationAdditionalInformationAbstract_37ea93e6-28b7-45ac-b615-7f07eb0d2cf1" xlink:to="loc_us-gaap_LaborAndRelatedExpense_c10f7a2e-58b2-496c-a2ec-63a0f6a8da61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities_ac88773a-3594-47f9-91be-5612ae9944db" xlink:href="carm-20241231.xsd#carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationAdditionalInformationAbstract_37ea93e6-28b7-45ac-b615-7f07eb0d2cf1" xlink:to="loc_carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities_ac88773a-3594-47f9-91be-5612ae9944db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_ca01220d-b511-4843-b97d-5fea23f6b136" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationAdditionalInformationAbstract_37ea93e6-28b7-45ac-b615-7f07eb0d2cf1" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_ca01220d-b511-4843-b97d-5fea23f6b136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ff305e02-1209-4e61-91c8-b3027062d44b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_51597a67-8a7b-4c43-86b8-f55b6e85cc8f" xlink:to="loc_us-gaap_NetIncomeLoss_ff305e02-1209-4e61-91c8-b3027062d44b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofDilutiveSecuritiesDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#SummaryofSignificantAccountingPoliciesScheduleofDilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofDilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5277e3a9-fd20-4dd8-9b46-7b4ba9e4b8f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_561b85d0-51f9-4841-a730-d5f9bdef1f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5277e3a9-fd20-4dd8-9b46-7b4ba9e4b8f7" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_561b85d0-51f9-4841-a730-d5f9bdef1f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_eecabe1e-2a64-4847-8c34-37850ba11317" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_561b85d0-51f9-4841-a730-d5f9bdef1f2c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_eecabe1e-2a64-4847-8c34-37850ba11317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1be956a4-2d55-4569-a3c2-ba5fdc90768d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_eecabe1e-2a64-4847-8c34-37850ba11317" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1be956a4-2d55-4569-a3c2-ba5fdc90768d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_615e3c35-b57d-49b5-a12c-324e8642639d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1be956a4-2d55-4569-a3c2-ba5fdc90768d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_615e3c35-b57d-49b5-a12c-324e8642639d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3facfb1c-af12-4aae-a16a-00e758a51651" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_561b85d0-51f9-4841-a730-d5f9bdef1f2c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3facfb1c-af12-4aae-a16a-00e758a51651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2773a8ff-41da-4df3-9658-f969e17b87ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3facfb1c-af12-4aae-a16a-00e758a51651" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2773a8ff-41da-4df3-9658-f969e17b87ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_783e529b-77c0-45bb-9066-87531532fbf4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2f4dbaa5-7faa-4a1b-8e2c-974c40088cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_783e529b-77c0-45bb-9066-87531532fbf4" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2f4dbaa5-7faa-4a1b-8e2c-974c40088cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_85b6bfc6-3a71-4c6a-8e4c-7c57c331f2f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2f4dbaa5-7faa-4a1b-8e2c-974c40088cbb" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_85b6bfc6-3a71-4c6a-8e4c-7c57c331f2f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dfbf2feb-329e-4c52-9edd-ded3a5b5f1a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_85b6bfc6-3a71-4c6a-8e4c-7c57c331f2f3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dfbf2feb-329e-4c52-9edd-ded3a5b5f1a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CarismaTherapeuticsIncLegacyStockholdersMember_febbeb79-40c1-4600-abfd-d764c242d5a7" xlink:href="carm-20241231.xsd#carm_CarismaTherapeuticsIncLegacyStockholdersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dfbf2feb-329e-4c52-9edd-ded3a5b5f1a0" xlink:to="loc_carm_CarismaTherapeuticsIncLegacyStockholdersMember_febbeb79-40c1-4600-abfd-d764c242d5a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_a4bd0950-bf14-40f7-9e26-fec8912a9bc4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2f4dbaa5-7faa-4a1b-8e2c-974c40088cbb" xlink:to="loc_dei_LegalEntityAxis_a4bd0950-bf14-40f7-9e26-fec8912a9bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_8bfdeeb1-21e2-4fcc-b149-eb105ac06346" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_a4bd0950-bf14-40f7-9e26-fec8912a9bc4" xlink:to="loc_dei_EntityDomain_8bfdeeb1-21e2-4fcc-b149-eb105ac06346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CarismaTherapeuticsInc.Member_ae432bdd-9b32-4d0a-96c9-7e91e41a29c2" xlink:href="carm-20241231.xsd#carm_CarismaTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_8bfdeeb1-21e2-4fcc-b149-eb105ac06346" xlink:to="loc_carm_CarismaTherapeuticsInc.Member_ae432bdd-9b32-4d0a-96c9-7e91e41a29c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_e5d3ce1e-9099-4bcf-ab9f-374223ce49b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2f4dbaa5-7faa-4a1b-8e2c-974c40088cbb" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_e5d3ce1e-9099-4bcf-ab9f-374223ce49b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_a640f68b-caaf-46d5-8afe-843436492958" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5d3ce1e-9099-4bcf-ab9f-374223ce49b7" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_a640f68b-caaf-46d5-8afe-843436492958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NumberOfBoardMembers_cf50136c-f088-4121-acfe-7d4b840cc9cb" xlink:href="carm-20241231.xsd#carm_NumberOfBoardMembers"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5d3ce1e-9099-4bcf-ab9f-374223ce49b7" xlink:to="loc_carm_NumberOfBoardMembers_cf50136c-f088-4121-acfe-7d4b840cc9cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_357c2051-ef40-4873-80eb-c83756e154a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5d3ce1e-9099-4bcf-ab9f-374223ce49b7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_357c2051-ef40-4873-80eb-c83756e154a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_f2c35b0c-cba5-420f-8788-ab8574bee570" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5d3ce1e-9099-4bcf-ab9f-374223ce49b7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_f2c35b0c-cba5-420f-8788-ab8574bee570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_bbb2e453-c634-42af-b222-eb0a5a827b07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5d3ce1e-9099-4bcf-ab9f-374223ce49b7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_bbb2e453-c634-42af-b222-eb0a5a827b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_892e7cfa-d1eb-4e6b-a4f0-4eec90aedfef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5d3ce1e-9099-4bcf-ab9f-374223ce49b7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_892e7cfa-d1eb-4e6b-a4f0-4eec90aedfef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash_4c5c11a6-3ab5-42dd-9b84-e8ecd90f131d" xlink:href="carm-20241231.xsd#carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5d3ce1e-9099-4bcf-ab9f-374223ce49b7" xlink:to="loc_carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash_4c5c11a6-3ab5-42dd-9b84-e8ecd90f131d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_ae3b5286-dcc8-4066-b1f7-47917e53be0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5d3ce1e-9099-4bcf-ab9f-374223ce49b7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_ae3b5286-dcc8-4066-b1f7-47917e53be0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_168b8fc0-4e63-42ca-ac4a-4a87501b6ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5d3ce1e-9099-4bcf-ab9f-374223ce49b7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_168b8fc0-4e63-42ca-ac4a-4a87501b6ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_b2ccac5d-69e2-49f8-ae04-185536919ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5d3ce1e-9099-4bcf-ab9f-374223ce49b7" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_b2ccac5d-69e2-49f8-ae04-185536919ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_debf8bd0-fc05-4085-a32b-55d0a08244c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5d3ce1e-9099-4bcf-ab9f-374223ce49b7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_debf8bd0-fc05-4085-a32b-55d0a08244c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_4a2328e6-4c60-47b7-a1af-d2b5fb643840" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5d3ce1e-9099-4bcf-ab9f-374223ce49b7" xlink:to="loc_us-gaap_SeveranceCosts1_4a2328e6-4c60-47b7-a1af-d2b5fb643840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/PrepaidExpensesandOtherAssetsDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#PrepaidExpensesandOtherAssetsDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/PrepaidExpensesandOtherAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_67601360-5041-47f2-a010-228f77abbf61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_PrepaidResearchAndDevelopmentCurrent_7a9895f4-5549-4792-ad6c-93b508ddeeba" xlink:href="carm-20241231.xsd#carm_PrepaidResearchAndDevelopmentCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_67601360-5041-47f2-a010-228f77abbf61" xlink:to="loc_carm_PrepaidResearchAndDevelopmentCurrent_7a9895f4-5549-4792-ad6c-93b508ddeeba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ReceivableDueFromCollaborativeArrangementCurrent_40cf91a4-63c8-48d8-a83e-b28c96b290d3" xlink:href="carm-20241231.xsd#carm_ReceivableDueFromCollaborativeArrangementCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_67601360-5041-47f2-a010-228f77abbf61" xlink:to="loc_carm_ReceivableDueFromCollaborativeArrangementCurrent_40cf91a4-63c8-48d8-a83e-b28c96b290d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_699cc469-d4e9-43da-bdd1-3123c6164944" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_67601360-5041-47f2-a010-228f77abbf61" xlink:to="loc_us-gaap_PrepaidInsurance_699cc469-d4e9-43da-bdd1-3123c6164944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsCurrent_991b2e3b-e75b-4a40-99a1-ed489f389bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_67601360-5041-47f2-a010-228f77abbf61" xlink:to="loc_us-gaap_DepositsAssetsCurrent_991b2e3b-e75b-4a40-99a1-ed489f389bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_86c6ab5f-c523-421d-a185-f8b0723c659e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_67601360-5041-47f2-a010-228f77abbf61" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_86c6ab5f-c523-421d-a185-f8b0723c659e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3ef9ecd4-b4a1-4620-ad86-ca9fe66db4b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_67601360-5041-47f2-a010-228f77abbf61" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3ef9ecd4-b4a1-4620-ad86-ca9fe66db4b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7789cc2b-7192-45a2-8975-c5dbb9d1aa02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8912e74f-fa7c-4ccb-8563-78a9df056d80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7789cc2b-7192-45a2-8975-c5dbb9d1aa02" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8912e74f-fa7c-4ccb-8563-78a9df056d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_91a541a2-7a7a-436a-bc29-205c01d29c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8912e74f-fa7c-4ccb-8563-78a9df056d80" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_91a541a2-7a7a-436a-bc29-205c01d29c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_337c9009-563d-44e4-ad0d-e70731b3f586" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_91a541a2-7a7a-436a-bc29-205c01d29c5f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_337c9009-563d-44e4-ad0d-e70731b3f586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_eddc4f51-43b4-4994-a323-f32a31a59490" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_337c9009-563d-44e4-ad0d-e70731b3f586" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_eddc4f51-43b4-4994-a323-f32a31a59490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_628d09dd-7de5-4721-be03-da69d048db13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_337c9009-563d-44e4-ad0d-e70731b3f586" xlink:to="loc_us-gaap_EquipmentMember_628d09dd-7de5-4721-be03-da69d048db13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_c1712997-470a-45d9-8e94-499f15f095f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_337c9009-563d-44e4-ad0d-e70731b3f586" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_c1712997-470a-45d9-8e94-499f15f095f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_8f5396dc-39fa-4c7d-a5ef-e06eee357adf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_337c9009-563d-44e4-ad0d-e70731b3f586" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_8f5396dc-39fa-4c7d-a5ef-e06eee357adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_076b9230-5ec8-4ca2-8b8e-3a7caf9c6e04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_337c9009-563d-44e4-ad0d-e70731b3f586" xlink:to="loc_us-gaap_ConstructionInProgressMember_076b9230-5ec8-4ca2-8b8e-3a7caf9c6e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2de96b28-03b4-4e20-ab6e-b1290ed5aea1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8912e74f-fa7c-4ccb-8563-78a9df056d80" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2de96b28-03b4-4e20-ab6e-b1290ed5aea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_99c706a8-7f33-4443-ac28-0b28022cdc75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2de96b28-03b4-4e20-ab6e-b1290ed5aea1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_99c706a8-7f33-4443-ac28-0b28022cdc75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_09d81eba-5c1f-411e-815d-6b2bc5afdd46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2de96b28-03b4-4e20-ab6e-b1290ed5aea1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_09d81eba-5c1f-411e-815d-6b2bc5afdd46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_df0d248e-be48-41e8-9f10-ecb661e7cf95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2de96b28-03b4-4e20-ab6e-b1290ed5aea1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_df0d248e-be48-41e8-9f10-ecb661e7cf95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleLeasebackTransactionNetBookValue_6fa88399-5cd4-41a4-a6d1-ad4380356630" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleLeasebackTransactionNetBookValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2de96b28-03b4-4e20-ab6e-b1290ed5aea1" xlink:to="loc_us-gaap_SaleLeasebackTransactionNetBookValue_6fa88399-5cd4-41a4-a6d1-ad4380356630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_86c9dbf8-e9e1-4aba-9d7f-b911a2f62afd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2de96b28-03b4-4e20-ab6e-b1290ed5aea1" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_86c9dbf8-e9e1-4aba-9d7f-b911a2f62afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleLeasebackTransactionAccumulatedDepreciation_e66811c3-9db9-40ec-9476-850167eb3e46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleLeasebackTransactionAccumulatedDepreciation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2de96b28-03b4-4e20-ab6e-b1290ed5aea1" xlink:to="loc_us-gaap_SaleLeasebackTransactionAccumulatedDepreciation_e66811c3-9db9-40ec-9476-850167eb3e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_afaf24e6-a273-4608-a770-fa02d2a5af60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2de96b28-03b4-4e20-ab6e-b1290ed5aea1" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_afaf24e6-a273-4608-a770-fa02d2a5af60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/PropertyandEquipmentnetNarrativeDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#PropertyandEquipmentnetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/PropertyandEquipmentnetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c96c1c97-81e4-4e48-aac0-cc9b2f3caeaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_fc72f90a-fe3a-4701-ac0c-6633cfab7a86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c96c1c97-81e4-4e48-aac0-cc9b2f3caeaf" xlink:to="loc_us-gaap_DepreciationAndAmortization_fc72f90a-fe3a-4701-ac0c-6633cfab7a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#AccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_351b100d-fbc6-4896-a756-dd17c6e44d99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AccruedResearchAndDevelopmentExpenseCurrent_8db34089-4187-44a9-8b83-1cd75cd8674b" xlink:href="carm-20241231.xsd#carm_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_351b100d-fbc6-4896-a756-dd17c6e44d99" xlink:to="loc_carm_AccruedResearchAndDevelopmentExpenseCurrent_8db34089-4187-44a9-8b83-1cd75cd8674b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_efdf82d2-df01-4714-8314-fb82d4be5c60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_351b100d-fbc6-4896-a756-dd17c6e44d99" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_efdf82d2-df01-4714-8314-fb82d4be5c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ba428c8f-2c57-4719-89f8-99847a989d68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_351b100d-fbc6-4896-a756-dd17c6e44d99" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ba428c8f-2c57-4719-89f8-99847a989d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_51a8e13c-ccfd-4d88-b317-901ad93441d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_351b100d-fbc6-4896-a756-dd17c6e44d99" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_51a8e13c-ccfd-4d88-b317-901ad93441d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_49ef9627-ecc6-4a36-b3b5-9e82f235e3ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_351b100d-fbc6-4896-a756-dd17c6e44d99" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_49ef9627-ecc6-4a36-b3b5-9e82f235e3ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b35a4160-bb8a-4714-96e3-70012a90fe3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_0cbda257-b2bc-465d-9112-14964ab424fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b35a4160-bb8a-4714-96e3-70012a90fe3d" xlink:to="loc_us-gaap_LossContingenciesTable_0cbda257-b2bc-465d-9112-14964ab424fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e5aa3f73-78a4-459b-b840-20c541933a50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_0cbda257-b2bc-465d-9112-14964ab424fe" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e5aa3f73-78a4-459b-b840-20c541933a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b70b3d53-ff92-4fe5-8f5b-91d26ba664d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e5aa3f73-78a4-459b-b840-20c541933a50" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b70b3d53-ff92-4fe5-8f5b-91d26ba664d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_PennLicenseAgreementMember_f7c7ce0c-03bc-4546-8d38-9ab37d2e00d6" xlink:href="carm-20241231.xsd#carm_PennLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b70b3d53-ff92-4fe5-8f5b-91d26ba664d9" xlink:to="loc_carm_PennLicenseAgreementMember_f7c7ce0c-03bc-4546-8d38-9ab37d2e00d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember_350fc086-5162-44a0-94f4-b7afe9d6b8e8" xlink:href="carm-20241231.xsd#carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b70b3d53-ff92-4fe5-8f5b-91d26ba664d9" xlink:to="loc_carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember_350fc086-5162-44a0-94f4-b7afe9d6b8e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3ca1c9ee-817d-41b4-9763-ec55d960238c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_0cbda257-b2bc-465d-9112-14964ab424fe" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3ca1c9ee-817d-41b4-9763-ec55d960238c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_311a7194-5f9b-47cd-bd4e-2abf4b4ede52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3ca1c9ee-817d-41b4-9763-ec55d960238c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_311a7194-5f9b-47cd-bd4e-2abf4b4ede52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_2d698631-4288-46f2-a5ae-e883f7fb971e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_311a7194-5f9b-47cd-bd4e-2abf4b4ede52" xlink:to="loc_us-gaap_EquipmentMember_2d698631-4288-46f2-a5ae-e883f7fb971e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_813be22a-ddeb-46e4-b1cd-099e59ec72f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_0cbda257-b2bc-465d-9112-14964ab424fe" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_813be22a-ddeb-46e4-b1cd-099e59ec72f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_55181dda-ff45-47c6-afe5-41f9a56cc669" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_813be22a-ddeb-46e4-b1cd-099e59ec72f6" xlink:to="loc_us-gaap_RelatedPartyDomain_55181dda-ff45-47c6-afe5-41f9a56cc669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_TrusteesOfUniversityOfPennsylvaniaMember_4804009b-916e-4be3-8aaf-1afdf1d87592" xlink:href="carm-20241231.xsd#carm_TrusteesOfUniversityOfPennsylvaniaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_55181dda-ff45-47c6-afe5-41f9a56cc669" xlink:to="loc_carm_TrusteesOfUniversityOfPennsylvaniaMember_4804009b-916e-4be3-8aaf-1afdf1d87592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e37a6f69-c2af-4083-bf01-9181559600c5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_0cbda257-b2bc-465d-9112-14964ab424fe" xlink:to="loc_srt_RangeAxis_e37a6f69-c2af-4083-bf01-9181559600c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0e636db0-0128-47e6-a91a-6c0838c32d3b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e37a6f69-c2af-4083-bf01-9181559600c5" xlink:to="loc_srt_RangeMember_0e636db0-0128-47e6-a91a-6c0838c32d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b9822db4-3743-454c-9e91-1a7ef2d60aef" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0e636db0-0128-47e6-a91a-6c0838c32d3b" xlink:to="loc_srt_MaximumMember_b9822db4-3743-454c-9e91-1a7ef2d60aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_dc523eb2-4c7f-4307-a13f-9392fdb81108" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_0cbda257-b2bc-465d-9112-14964ab424fe" xlink:to="loc_us-gaap_LossContingenciesLineItems_dc523eb2-4c7f-4307-a13f-9392fdb81108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_IncreaseDecreaseInFinanceLeaseRightOfUseAssetLeaseModification_2568dbb7-2b47-4b7d-ba48-fee232798038" xlink:href="carm-20241231.xsd#carm_IncreaseDecreaseInFinanceLeaseRightOfUseAssetLeaseModification"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_dc523eb2-4c7f-4307-a13f-9392fdb81108" xlink:to="loc_carm_IncreaseDecreaseInFinanceLeaseRightOfUseAssetLeaseModification_2568dbb7-2b47-4b7d-ba48-fee232798038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification_423f2c47-33d7-4d35-9549-7171415965bb" xlink:href="carm-20241231.xsd#carm_IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_dc523eb2-4c7f-4307-a13f-9392fdb81108" xlink:to="loc_carm_IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification_423f2c47-33d7-4d35-9549-7171415965bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleAndLeasebackTransactionGainLossNet_9b4b7b33-5f35-49f8-85fc-bf42408605b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleAndLeasebackTransactionGainLossNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_dc523eb2-4c7f-4307-a13f-9392fdb81108" xlink:to="loc_us-gaap_SaleAndLeasebackTransactionGainLossNet_9b4b7b33-5f35-49f8-85fc-bf42408605b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_f220801d-a715-4acc-8883-79d6486e9020" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_dc523eb2-4c7f-4307-a13f-9392fdb81108" xlink:to="loc_us-gaap_FinanceLeaseLiability_f220801d-a715-4acc-8883-79d6486e9020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CommitmentsAnnualPaymentsRequiredToBePaid_14cbc0d3-5d7c-4261-aacd-2d14968ebb34" xlink:href="carm-20241231.xsd#carm_CommitmentsAnnualPaymentsRequiredToBePaid"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_dc523eb2-4c7f-4307-a13f-9392fdb81108" xlink:to="loc_carm_CommitmentsAnnualPaymentsRequiredToBePaid_14cbc0d3-5d7c-4261-aacd-2d14968ebb34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents_2188b13d-b29d-4dd7-9666-3b74692c907e" xlink:href="carm-20241231.xsd#carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_dc523eb2-4c7f-4307-a13f-9392fdb81108" xlink:to="loc_carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents_2188b13d-b29d-4dd7-9666-3b74692c907e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AdditionalMilestonePaymentsRequiredToBePaid_c87e36f2-399c-4f52-8735-c7472cb4740a" xlink:href="carm-20241231.xsd#carm_AdditionalMilestonePaymentsRequiredToBePaid"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_dc523eb2-4c7f-4307-a13f-9392fdb81108" xlink:to="loc_carm_AdditionalMilestonePaymentsRequiredToBePaid_c87e36f2-399c-4f52-8735-c7472cb4740a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AdditionalMilestonePaymentsForFirstCarMProduct_f2df98db-8244-4520-8306-dc9840d9f6c6" xlink:href="carm-20241231.xsd#carm_AdditionalMilestonePaymentsForFirstCarMProduct"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_dc523eb2-4c7f-4307-a13f-9392fdb81108" xlink:to="loc_carm_AdditionalMilestonePaymentsForFirstCarMProduct_f2df98db-8244-4520-8306-dc9840d9f6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AgreementTerm_fbf224a8-732e-479c-9d9f-10c907dfa011" xlink:href="carm-20241231.xsd#carm_AgreementTerm"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_dc523eb2-4c7f-4307-a13f-9392fdb81108" xlink:to="loc_carm_AgreementTerm_fbf224a8-732e-479c-9d9f-10c907dfa011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContractTermination_0dc5f7f9-f8c8-4d75-9865-9b399691eb5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossOnContractTermination"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_dc523eb2-4c7f-4307-a13f-9392fdb81108" xlink:to="loc_us-gaap_LossOnContractTermination_0dc5f7f9-f8c8-4d75-9865-9b399691eb5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_535ff31f-4eff-4e1e-a495-dac8d0ead610" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_dc523eb2-4c7f-4307-a13f-9392fdb81108" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_535ff31f-4eff-4e1e-a495-dac8d0ead610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_e9e815a1-617a-470c-8808-20ed1b96b707" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_dc523eb2-4c7f-4307-a13f-9392fdb81108" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_e9e815a1-617a-470c-8808-20ed1b96b707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#CommitmentsandContingenciesScheduleofLeaseCostsDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_db5cb73f-f165-4315-ae02-a0c16057b240" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_a6aac699-b879-4fcb-b461-04eafd57eabe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_db5cb73f-f165-4315-ae02-a0c16057b240" xlink:to="loc_us-gaap_OperatingLeaseCost_a6aac699-b879-4fcb-b461-04eafd57eabe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_FinanceLeaseCostAbstract_875df427-e5bb-41bb-af6c-cc8de0ca49eb" xlink:href="carm-20241231.xsd#carm_FinanceLeaseCostAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_db5cb73f-f165-4315-ae02-a0c16057b240" xlink:to="loc_carm_FinanceLeaseCostAbstract_875df427-e5bb-41bb-af6c-cc8de0ca49eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_375df1d4-f7e0-41ab-9af2-7a1f03c247e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_carm_FinanceLeaseCostAbstract_875df427-e5bb-41bb-af6c-cc8de0ca49eb" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_375df1d4-f7e0-41ab-9af2-7a1f03c247e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_59bc28bb-b29a-4812-b566-127270bcb539" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_carm_FinanceLeaseCostAbstract_875df427-e5bb-41bb-af6c-cc8de0ca49eb" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_59bc28bb-b29a-4812-b566-127270bcb539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_FinanceLeaseCost_b59fd444-1217-4119-b257-56361affc92d" xlink:href="carm-20241231.xsd#carm_FinanceLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_carm_FinanceLeaseCostAbstract_875df427-e5bb-41bb-af6c-cc8de0ca49eb" xlink:to="loc_carm_FinanceLeaseCost_b59fd444-1217-4119-b257-56361affc92d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_730db0e4-8f8c-4c6d-8f15-cf924a8cbac3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_carm_FinanceLeaseCostAbstract_875df427-e5bb-41bb-af6c-cc8de0ca49eb" xlink:to="loc_us-gaap_VariableLeaseCost_730db0e4-8f8c-4c6d-8f15-cf924a8cbac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_57923492-9a93-4857-857a-59063b324df3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_carm_FinanceLeaseCostAbstract_875df427-e5bb-41bb-af6c-cc8de0ca49eb" xlink:to="loc_us-gaap_ShortTermLeaseCost_57923492-9a93-4857-857a-59063b324df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_10e6d2b9-562f-4ee4-8716-c80b99f531fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_db5cb73f-f165-4315-ae02-a0c16057b240" xlink:to="loc_us-gaap_LeaseCost_10e6d2b9-562f-4ee4-8716-c80b99f531fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseTermandDiscountRateInformationDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#CommitmentsandContingenciesScheduleofLeaseTermandDiscountRateInformationDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseTermandDiscountRateInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e363bb35-1398-4052-87aa-b0d0cb7699c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_LeasesWeightedAverageRemainingLeaseTermAbstract_bdc2ed44-e685-4d91-a181-75233c24491f" xlink:href="carm-20241231.xsd#carm_LeasesWeightedAverageRemainingLeaseTermAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e363bb35-1398-4052-87aa-b0d0cb7699c4" xlink:to="loc_carm_LeasesWeightedAverageRemainingLeaseTermAbstract_bdc2ed44-e685-4d91-a181-75233c24491f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8d9e653f-bb19-4271-9dba-0cc1c9f39f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_carm_LeasesWeightedAverageRemainingLeaseTermAbstract_bdc2ed44-e685-4d91-a181-75233c24491f" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8d9e653f-bb19-4271-9dba-0cc1c9f39f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_61338dc2-16e4-413f-8d47-e40f78a63e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_carm_LeasesWeightedAverageRemainingLeaseTermAbstract_bdc2ed44-e685-4d91-a181-75233c24491f" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_61338dc2-16e4-413f-8d47-e40f78a63e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_LeasesWeightedAverageDiscountRateAbstract_722a8d90-336f-4800-9301-6b26cdb6705a" xlink:href="carm-20241231.xsd#carm_LeasesWeightedAverageDiscountRateAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e363bb35-1398-4052-87aa-b0d0cb7699c4" xlink:to="loc_carm_LeasesWeightedAverageDiscountRateAbstract_722a8d90-336f-4800-9301-6b26cdb6705a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_a8ff1e09-c970-4f54-85dc-98d7eb30dbab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_carm_LeasesWeightedAverageDiscountRateAbstract_722a8d90-336f-4800-9301-6b26cdb6705a" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_a8ff1e09-c970-4f54-85dc-98d7eb30dbab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_5a2241b3-2530-4c58-8e01-593a827dda3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_carm_LeasesWeightedAverageDiscountRateAbstract_722a8d90-336f-4800-9301-6b26cdb6705a" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_5a2241b3-2530-4c58-8e01-593a827dda3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/CommitmentsandContingenciesScheduleofSupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#CommitmentsandContingenciesScheduleofSupplementalCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/CommitmentsandContingenciesScheduleofSupplementalCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5c064c68-32e8-4121-a8c9-6dc8c97b4547" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_f90fcc55-48d5-457f-900b-b5faf83526ee" xlink:href="carm-20241231.xsd#carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5c064c68-32e8-4121-a8c9-6dc8c97b4547" xlink:to="loc_carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_f90fcc55-48d5-457f-900b-b5faf83526ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_317b6927-d8ed-4b13-8228-edf1dcd62a49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_f90fcc55-48d5-457f-900b-b5faf83526ee" xlink:to="loc_us-gaap_OperatingLeasePayments_317b6927-d8ed-4b13-8228-edf1dcd62a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_3229fdfc-5545-416f-b495-884a190bd6e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_f90fcc55-48d5-457f-900b-b5faf83526ee" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_3229fdfc-5545-416f-b495-884a190bd6e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_FinancingCashUsedInFinanceLeases_c53661d4-ccfb-4e45-a617-53c11ad076cd" xlink:href="carm-20241231.xsd#carm_FinancingCashUsedInFinanceLeases"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_f90fcc55-48d5-457f-900b-b5faf83526ee" xlink:to="loc_carm_FinancingCashUsedInFinanceLeases_c53661d4-ccfb-4e45-a617-53c11ad076cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6f78feff-22bf-4588-8966-243196482f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_215775eb-595b-4fd9-8758-890757a1f1e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6f78feff-22bf-4588-8966-243196482f8f" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_215775eb-595b-4fd9-8758-890757a1f1e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_cc7157c5-0167-47f6-b917-e2d76ea7d518" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_215775eb-595b-4fd9-8758-890757a1f1e3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_cc7157c5-0167-47f6-b917-e2d76ea7d518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_af82c73e-1b7f-4e19-87e3-2d4a92650a60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_215775eb-595b-4fd9-8758-890757a1f1e3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_af82c73e-1b7f-4e19-87e3-2d4a92650a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_564606e0-7f1d-4366-a916-fc206bad1f32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_215775eb-595b-4fd9-8758-890757a1f1e3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_564606e0-7f1d-4366-a916-fc206bad1f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e0cec776-cbbb-4779-bd51-f0dbaf9a8b71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_215775eb-595b-4fd9-8758-890757a1f1e3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e0cec776-cbbb-4779-bd51-f0dbaf9a8b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_38b0c0d9-16b9-4aed-af61-6105bc2a6027" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_215775eb-595b-4fd9-8758-890757a1f1e3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_38b0c0d9-16b9-4aed-af61-6105bc2a6027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_e6d529bb-d288-4672-8a1a-f932f34459db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_215775eb-595b-4fd9-8758-890757a1f1e3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_e6d529bb-d288-4672-8a1a-f932f34459db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d9afa326-3d5c-4036-9b3d-754917afc5c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_215775eb-595b-4fd9-8758-890757a1f1e3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d9afa326-3d5c-4036-9b3d-754917afc5c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a5ab1523-c15e-494c-96e8-a1e7e7f07d02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_215775eb-595b-4fd9-8758-890757a1f1e3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a5ab1523-c15e-494c-96e8-a1e7e7f07d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_844d4e29-57ff-4ee3-8449-9feeee464684" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_215775eb-595b-4fd9-8758-890757a1f1e3" xlink:to="loc_us-gaap_OperatingLeaseLiability_844d4e29-57ff-4ee3-8449-9feeee464684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_3be33db4-ee08-4c0c-a5dd-577ae319abb1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6f78feff-22bf-4588-8966-243196482f8f" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_3be33db4-ee08-4c0c-a5dd-577ae319abb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_4b889374-769d-4a33-ba98-a1c81d0b0a00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_3be33db4-ee08-4c0c-a5dd-577ae319abb1" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_4b889374-769d-4a33-ba98-a1c81d0b0a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_150fd3a3-1bad-4e5f-bddd-404e1da1ee5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_3be33db4-ee08-4c0c-a5dd-577ae319abb1" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_150fd3a3-1bad-4e5f-bddd-404e1da1ee5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_b35f2240-d01c-44f2-9227-a93f1ad88728" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_3be33db4-ee08-4c0c-a5dd-577ae319abb1" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_b35f2240-d01c-44f2-9227-a93f1ad88728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_e5d3f491-abcf-4826-a1e3-c91dda0da862" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_3be33db4-ee08-4c0c-a5dd-577ae319abb1" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_e5d3f491-abcf-4826-a1e3-c91dda0da862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_440f9155-a9a5-4b1c-9f90-2d1ddf2741b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_3be33db4-ee08-4c0c-a5dd-577ae319abb1" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_440f9155-a9a5-4b1c-9f90-2d1ddf2741b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_53afa26e-865d-488f-a0d2-ed6d38709f55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_3be33db4-ee08-4c0c-a5dd-577ae319abb1" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_53afa26e-865d-488f-a0d2-ed6d38709f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_f88b2077-3c0b-4976-b52f-78d5fe8ca4f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_3be33db4-ee08-4c0c-a5dd-577ae319abb1" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_f88b2077-3c0b-4976-b52f-78d5fe8ca4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_7e066bf8-1bb9-43cc-944c-afc552969dea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_3be33db4-ee08-4c0c-a5dd-577ae319abb1" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_7e066bf8-1bb9-43cc-944c-afc552969dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_d3e55fde-d151-44f3-a39d-b9c622413692" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_3be33db4-ee08-4c0c-a5dd-577ae319abb1" xlink:to="loc_us-gaap_FinanceLeaseLiability_d3e55fde-d151-44f3-a39d-b9c622413692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/StockholdersDeficitEquityDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#StockholdersDeficitEquityDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/StockholdersDeficitEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_475c4e9a-4314-469f-bd9a-c5bf57e0aed6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_e7976733-42b0-411b-907e-8e12fe116483" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_475c4e9a-4314-469f-bd9a-c5bf57e0aed6" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_e7976733-42b0-411b-907e-8e12fe116483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_d3872a91-7d93-40a6-b792-d95d570a5e56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e7976733-42b0-411b-907e-8e12fe116483" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_d3872a91-7d93-40a6-b792-d95d570a5e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5eafc63d-c921-4465-8c86-7e0208890b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d3872a91-7d93-40a6-b792-d95d570a5e56" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5eafc63d-c921-4465-8c86-7e0208890b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AtTheMarketMember_320612e6-7ede-44c6-b45e-a0ab320588ec" xlink:href="carm-20241231.xsd#carm_AtTheMarketMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5eafc63d-c921-4465-8c86-7e0208890b7b" xlink:to="loc_carm_AtTheMarketMember_320612e6-7ede-44c6-b45e-a0ab320588ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_7ca98b39-32e9-4e4e-87d9-d6690f8f4724" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e7976733-42b0-411b-907e-8e12fe116483" xlink:to="loc_us-gaap_ClassOfStockLineItems_7ca98b39-32e9-4e4e-87d9-d6690f8f4724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ddffb9e2-7f77-427c-aa9a-647477ecc457" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ca98b39-32e9-4e4e-87d9-d6690f8f4724" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ddffb9e2-7f77-427c-aa9a-647477ecc457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_07eea54a-47ae-44a1-af4f-89070c11770d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ca98b39-32e9-4e4e-87d9-d6690f8f4724" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_07eea54a-47ae-44a1-af4f-89070c11770d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_98a531c4-57a3-456b-ab12-76f0c783f5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ca98b39-32e9-4e4e-87d9-d6690f8f4724" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_98a531c4-57a3-456b-ab12-76f0c783f5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_9c9b2521-aa5e-492d-a814-eac5b5c1ceb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ca98b39-32e9-4e4e-87d9-d6690f8f4724" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_9c9b2521-aa5e-492d-a814-eac5b5c1ceb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_34fd42c9-eb9f-4e40-af1d-a76aaf297b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ca98b39-32e9-4e4e-87d9-d6690f8f4724" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_34fd42c9-eb9f-4e40-af1d-a76aaf297b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests_af9b8c13-0fef-4d5e-8d62-5a3b6339e6e4" xlink:href="carm-20241231.xsd#carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ca98b39-32e9-4e4e-87d9-d6690f8f4724" xlink:to="loc_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests_af9b8c13-0fef-4d5e-8d62-5a3b6339e6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2320e084-643a-4277-8505-d1af8cc26a57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ca98b39-32e9-4e4e-87d9-d6690f8f4724" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2320e084-643a-4277-8505-d1af8cc26a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_SaleOfStockStockOfferingAmount_971c5910-087d-4221-9dd4-6e6a60f4a966" xlink:href="carm-20241231.xsd#carm_SaleOfStockStockOfferingAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ca98b39-32e9-4e4e-87d9-d6690f8f4724" xlink:to="loc_carm_SaleOfStockStockOfferingAmount_971c5910-087d-4221-9dd4-6e6a60f4a966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_SaleOfStockMaximumOfferingAmount_bb4048be-6916-4483-87d2-eb758893242c" xlink:href="carm-20241231.xsd#carm_SaleOfStockMaximumOfferingAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ca98b39-32e9-4e4e-87d9-d6690f8f4724" xlink:to="loc_carm_SaleOfStockMaximumOfferingAmount_bb4048be-6916-4483-87d2-eb758893242c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_c56d042b-63ad-412f-a6f7-ad822e7b01db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ca98b39-32e9-4e4e-87d9-d6690f8f4724" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_c56d042b-63ad-412f-a6f7-ad822e7b01db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_f6ddb10c-582e-4a54-b783-ec6079d1884b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ca98b39-32e9-4e4e-87d9-d6690f8f4724" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_f6ddb10c-582e-4a54-b783-ec6079d1884b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_07d9a1ef-4905-4bed-9c55-9266f8998d79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ca98b39-32e9-4e4e-87d9-d6690f8f4724" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_07d9a1ef-4905-4bed-9c55-9266f8998d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_3db0916e-d298-40e7-88ba-4d8bf4fda666" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ca98b39-32e9-4e4e-87d9-d6690f8f4724" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_3db0916e-d298-40e7-88ba-4d8bf4fda666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_5998b4ab-f3d5-4ab2-a072-f7702670c416" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ca98b39-32e9-4e4e-87d9-d6690f8f4724" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_5998b4ab-f3d5-4ab2-a072-f7702670c416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_463a429c-b04c-4146-91c4-5e47e0de8f13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ca98b39-32e9-4e4e-87d9-d6690f8f4724" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_463a429c-b04c-4146-91c4-5e47e0de8f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/StockbasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#StockbasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/StockbasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_be9e6c52-5145-4b2a-bdb9-036b4f474ece" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18e2a80e-049a-43f1-b113-0bfd7393878e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_be9e6c52-5145-4b2a-bdb9-036b4f474ece" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18e2a80e-049a-43f1-b113-0bfd7393878e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_760193ce-bc00-4aab-be65-79ebb6e3c5be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18e2a80e-049a-43f1-b113-0bfd7393878e" xlink:to="loc_us-gaap_PlanNameAxis_760193ce-bc00-4aab-be65-79ebb6e3c5be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f9db7c16-6a40-4e29-ad78-bada03b4ba29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_760193ce-bc00-4aab-be65-79ebb6e3c5be" xlink:to="loc_us-gaap_PlanNameDomain_f9db7c16-6a40-4e29-ad78-bada03b4ba29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_TwoThousandSeventeenStockIncentivePlanMember_fe29aa8d-c470-4fe8-9c23-f6ca471bdf21" xlink:href="carm-20241231.xsd#carm_TwoThousandSeventeenStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_f9db7c16-6a40-4e29-ad78-bada03b4ba29" xlink:to="loc_carm_TwoThousandSeventeenStockIncentivePlanMember_fe29aa8d-c470-4fe8-9c23-f6ca471bdf21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_TwoThousandFourteenStockIncentivePlanMember_f02c3760-bffd-4c6a-b63a-4783677afc46" xlink:href="carm-20241231.xsd#carm_TwoThousandFourteenStockIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_f9db7c16-6a40-4e29-ad78-bada03b4ba29" xlink:to="loc_carm_TwoThousandFourteenStockIncentivePlanMember_f02c3760-bffd-4c6a-b63a-4783677afc46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_TwoThousandFourteenEmployeeStockPurchasePlanMember_edb38e18-2812-47c5-9b3d-9e84f7274369" xlink:href="carm-20241231.xsd#carm_TwoThousandFourteenEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_f9db7c16-6a40-4e29-ad78-bada03b4ba29" xlink:to="loc_carm_TwoThousandFourteenEmployeeStockPurchasePlanMember_edb38e18-2812-47c5-9b3d-9e84f7274369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f3ef73fb-963a-4435-b808-e69449d25a44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18e2a80e-049a-43f1-b113-0bfd7393878e" xlink:to="loc_us-gaap_AwardTypeAxis_f3ef73fb-963a-4435-b808-e69449d25a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_462cb4e8-8f83-4b42-a845-614dc535049d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f3ef73fb-963a-4435-b808-e69449d25a44" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_462cb4e8-8f83-4b42-a845-614dc535049d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0efba25d-3c59-4489-af79-5a69994a29e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_462cb4e8-8f83-4b42-a845-614dc535049d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0efba25d-3c59-4489-af79-5a69994a29e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23daa344-1f77-4169-8a72-10653306c7bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18e2a80e-049a-43f1-b113-0bfd7393878e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23daa344-1f77-4169-8a72-10653306c7bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_e1d87c43-8e57-4b47-846d-0d9842c6b2c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23daa344-1f77-4169-8a72-10653306c7bc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_e1d87c43-8e57-4b47-846d-0d9842c6b2c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_190add08-281c-405d-8f13-6998efac17b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23daa344-1f77-4169-8a72-10653306c7bc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_190add08-281c-405d-8f13-6998efac17b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_735f81e1-f543-4d53-888c-d26552d6b895" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23daa344-1f77-4169-8a72-10653306c7bc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_735f81e1-f543-4d53-888c-d26552d6b895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_a2dfccb3-4667-49c7-b0d6-be2482cc2440" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23daa344-1f77-4169-8a72-10653306c7bc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_a2dfccb3-4667-49c7-b0d6-be2482cc2440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#StockbasedCompensationScheduleofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c761bb29-81bb-4247-a2f6-c34aada78f64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_0a6a8e90-292f-4723-bc5f-a7c737730cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c761bb29-81bb-4247-a2f6-c34aada78f64" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_0a6a8e90-292f-4723-bc5f-a7c737730cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a98aea95-951f-4185-aebb-bf860e6abcf0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_0a6a8e90-292f-4723-bc5f-a7c737730cbf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a98aea95-951f-4185-aebb-bf860e6abcf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ae5248ee-a410-4ff9-991e-36cf291f2489" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_0a6a8e90-292f-4723-bc5f-a7c737730cbf" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ae5248ee-a410-4ff9-991e-36cf291f2489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7fd1353c-f23d-4b9e-b7fc-d43db539ba56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_0a6a8e90-292f-4723-bc5f-a7c737730cbf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7fd1353c-f23d-4b9e-b7fc-d43db539ba56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_5e0b5aa9-c75d-45ea-b2a4-33030cdca39b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_0a6a8e90-292f-4723-bc5f-a7c737730cbf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_5e0b5aa9-c75d-45ea-b2a4-33030cdca39b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f7beb346-ef8b-4127-a656-1bc9dd3d1af9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_0a6a8e90-292f-4723-bc5f-a7c737730cbf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f7beb346-ef8b-4127-a656-1bc9dd3d1af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_508ddb73-a2a1-469b-87fe-170ca02333ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_0a6a8e90-292f-4723-bc5f-a7c737730cbf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_508ddb73-a2a1-469b-87fe-170ca02333ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_fcf7530f-d39f-486d-90b0-bd4661de018a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c761bb29-81bb-4247-a2f6-c34aada78f64" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_fcf7530f-d39f-486d-90b0-bd4661de018a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8f3f1c97-9a22-4980-8f38-ad78d23f926b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_fcf7530f-d39f-486d-90b0-bd4661de018a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8f3f1c97-9a22-4980-8f38-ad78d23f926b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1c424a6f-5f76-4b5e-84b2-1d0690ce49e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_fcf7530f-d39f-486d-90b0-bd4661de018a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1c424a6f-5f76-4b5e-84b2-1d0690ce49e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6ed79628-b959-4fbd-951c-f3417e0dd4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_fcf7530f-d39f-486d-90b0-bd4661de018a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6ed79628-b959-4fbd-951c-f3417e0dd4e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_ee1622ff-6f7e-475c-b91d-3f94be127341" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_fcf7530f-d39f-486d-90b0-bd4661de018a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_ee1622ff-6f7e-475c-b91d-3f94be127341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3757cd5d-e527-4023-ae3b-57c0f698038e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_fcf7530f-d39f-486d-90b0-bd4661de018a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3757cd5d-e527-4023-ae3b-57c0f698038e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7214cc1d-5ef4-418e-b58a-da049118e5cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_fcf7530f-d39f-486d-90b0-bd4661de018a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7214cc1d-5ef4-418e-b58a-da049118e5cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a0f13acd-e1e5-47f4-9d22-1ae8a2fa9ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_fcf7530f-d39f-486d-90b0-bd4661de018a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a0f13acd-e1e5-47f4-9d22-1ae8a2fa9ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_bede07ca-338a-45d2-b6d2-1e86550db55f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c761bb29-81bb-4247-a2f6-c34aada78f64" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_bede07ca-338a-45d2-b6d2-1e86550db55f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d5450859-dac3-41f7-a803-23e8a304c6f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_bede07ca-338a-45d2-b6d2-1e86550db55f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d5450859-dac3-41f7-a803-23e8a304c6f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_4c6c45e7-cb09-4ceb-b27e-7b9e21480e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_bede07ca-338a-45d2-b6d2-1e86550db55f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_4c6c45e7-cb09-4ceb-b27e-7b9e21480e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_b5afd9e9-ab1a-402d-a61e-be75218683c9" xlink:href="carm-20241231.xsd#carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c761bb29-81bb-4247-a2f6-c34aada78f64" xlink:to="loc_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_b5afd9e9-ab1a-402d-a61e-be75218683c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_e17854a2-0ac4-46f7-85f8-e31ada4a1338" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_b5afd9e9-ab1a-402d-a61e-be75218683c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_e17854a2-0ac4-46f7-85f8-e31ada4a1338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_71383340-5565-47a9-b2c0-ebf206693a21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_b5afd9e9-ab1a-402d-a61e-be75218683c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_71383340-5565-47a9-b2c0-ebf206693a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_90731447-37cc-40f6-b7ff-26da89a7d96a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_b5afd9e9-ab1a-402d-a61e-be75218683c9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_90731447-37cc-40f6-b7ff-26da89a7d96a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/StockbasedCompensationScheduleofEstimatedUsingTheBlackScholesOptionPricingModelDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#StockbasedCompensationScheduleofEstimatedUsingTheBlackScholesOptionPricingModelDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/StockbasedCompensationScheduleofEstimatedUsingTheBlackScholesOptionPricingModelDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dcfc48a2-5081-4a28-a6b5-066b527e4a59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2be9d12c-a493-4028-a2d1-470fc96b1088" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dcfc48a2-5081-4a28-a6b5-066b527e4a59" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2be9d12c-a493-4028-a2d1-470fc96b1088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_15d3c181-f618-444d-8dd9-e6b89e244fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2be9d12c-a493-4028-a2d1-470fc96b1088" xlink:to="loc_us-gaap_AwardTypeAxis_15d3c181-f618-444d-8dd9-e6b89e244fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a3c8cbf9-d135-46b2-ac0d-851f0800993d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_15d3c181-f618-444d-8dd9-e6b89e244fa5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a3c8cbf9-d135-46b2-ac0d-851f0800993d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9c51efae-6ffe-4f32-8155-3eab2cbf7a35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a3c8cbf9-d135-46b2-ac0d-851f0800993d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9c51efae-6ffe-4f32-8155-3eab2cbf7a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a484cfc2-4e5f-43d4-b80e-0fa4f4ba24a0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2be9d12c-a493-4028-a2d1-470fc96b1088" xlink:to="loc_srt_RangeAxis_a484cfc2-4e5f-43d4-b80e-0fa4f4ba24a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a029f103-4ec1-4c08-a5e8-f61837ef7051" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a484cfc2-4e5f-43d4-b80e-0fa4f4ba24a0" xlink:to="loc_srt_RangeMember_a029f103-4ec1-4c08-a5e8-f61837ef7051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8aafae29-d275-40c9-bca5-9492599967b3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a029f103-4ec1-4c08-a5e8-f61837ef7051" xlink:to="loc_srt_MinimumMember_8aafae29-d275-40c9-bca5-9492599967b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3497c1d1-b217-493f-9fd5-0cad92b49df2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a029f103-4ec1-4c08-a5e8-f61837ef7051" xlink:to="loc_srt_MaximumMember_3497c1d1-b217-493f-9fd5-0cad92b49df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_958767af-1abc-4e88-a63d-2d44937d62e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2be9d12c-a493-4028-a2d1-470fc96b1088" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_958767af-1abc-4e88-a63d-2d44937d62e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1c128f16-a503-4c83-91ea-e92ba3d361ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_958767af-1abc-4e88-a63d-2d44937d62e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1c128f16-a503-4c83-91ea-e92ba3d361ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e0738d6f-cf15-4a5f-9c4b-775a7c616d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_958767af-1abc-4e88-a63d-2d44937d62e6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e0738d6f-cf15-4a5f-9c4b-775a7c616d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8a2652c3-8aef-45d8-8a56-aef28a017741" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_958767af-1abc-4e88-a63d-2d44937d62e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8a2652c3-8aef-45d8-8a56-aef28a017741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4365210e-8a8c-47d3-b5f0-c043b3181a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_958767af-1abc-4e88-a63d-2d44937d62e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4365210e-8a8c-47d3-b5f0-c043b3181a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ff8988da-296c-402c-84a6-6fae384bd72d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_170da086-bdfa-41cb-bea2-d98f240d79c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ff8988da-296c-402c-84a6-6fae384bd72d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_170da086-bdfa-41cb-bea2-d98f240d79c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e15b0b8b-db88-423e-aee6-99b8c034cee2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_170da086-bdfa-41cb-bea2-d98f240d79c7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e15b0b8b-db88-423e-aee6-99b8c034cee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_67402467-deb2-43aa-a4f5-cf31753ed1cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e15b0b8b-db88-423e-aee6-99b8c034cee2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_67402467-deb2-43aa-a4f5-cf31753ed1cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ecad4037-256e-48ca-8b9d-c1aa23285d73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_67402467-deb2-43aa-a4f5-cf31753ed1cb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ecad4037-256e-48ca-8b9d-c1aa23285d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_38843da7-8578-4f22-920a-fb8c7b9c0f19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_67402467-deb2-43aa-a4f5-cf31753ed1cb" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_38843da7-8578-4f22-920a-fb8c7b9c0f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_278d0603-dfbd-4818-adb6-2de0d8c944ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_170da086-bdfa-41cb-bea2-d98f240d79c7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_278d0603-dfbd-4818-adb6-2de0d8c944ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b61440a8-3e90-49f4-af41-3534ac18b1a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_278d0603-dfbd-4818-adb6-2de0d8c944ab" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b61440a8-3e90-49f4-af41-3534ac18b1a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_SesenBioIncMember_e0bd238c-e00b-4ac8-b48d-b144519532be" xlink:href="carm-20241231.xsd#carm_SesenBioIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b61440a8-3e90-49f4-af41-3534ac18b1a1" xlink:to="loc_carm_SesenBioIncMember_e0bd238c-e00b-4ac8-b48d-b144519532be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_c2a92ca7-5a94-441a-a96c-44b12ed114e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_170da086-bdfa-41cb-bea2-d98f240d79c7" xlink:to="loc_us-gaap_PlanNameAxis_c2a92ca7-5a94-441a-a96c-44b12ed114e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9e0afe86-0a56-4a3a-9753-2038509804d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_c2a92ca7-5a94-441a-a96c-44b12ed114e7" xlink:to="loc_us-gaap_PlanNameDomain_9e0afe86-0a56-4a3a-9753-2038509804d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_RevisedOperatingPlanMember_a76c5c06-b42c-4650-ad84-96eb58bcdd90" xlink:href="carm-20241231.xsd#carm_RevisedOperatingPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_9e0afe86-0a56-4a3a-9753-2038509804d1" xlink:to="loc_carm_RevisedOperatingPlanMember_a76c5c06-b42c-4650-ad84-96eb58bcdd90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_001f0c9f-b155-41b0-bf9f-8295f443b01b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_170da086-bdfa-41cb-bea2-d98f240d79c7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_001f0c9f-b155-41b0-bf9f-8295f443b01b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_c69e6100-ab06-40c7-96ba-6c022e02da69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_001f0c9f-b155-41b0-bf9f-8295f443b01b" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_c69e6100-ab06-40c7-96ba-6c022e02da69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6b6162db-1821-40b8-80c8-ac9d064dab07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_001f0c9f-b155-41b0-bf9f-8295f443b01b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6b6162db-1821-40b8-80c8-ac9d064dab07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c20ffd70-cd89-45fe-8651-95b12fd73fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_001f0c9f-b155-41b0-bf9f-8295f443b01b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c20ffd70-cd89-45fe-8651-95b12fd73fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_67825f37-998c-4d04-b724-95cd682c8c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_001f0c9f-b155-41b0-bf9f-8295f443b01b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_67825f37-998c-4d04-b724-95cd682c8c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ef19c5f3-08d6-4917-89ef-1e17102a8ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_989a3dce-5c67-4e3e-892a-3b6de9003e78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ef19c5f3-08d6-4917-89ef-1e17102a8ce5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_989a3dce-5c67-4e3e-892a-3b6de9003e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_f0bb64e9-bebd-4efd-8693-019f9a50f618" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ef19c5f3-08d6-4917-89ef-1e17102a8ce5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_f0bb64e9-bebd-4efd-8693-019f9a50f618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal_00f3afb9-9352-4bd9-b707-ff959db0989f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ef19c5f3-08d6-4917-89ef-1e17102a8ce5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal_00f3afb9-9352-4bd9-b707-ff959db0989f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences_f0c9f2c1-daab-403c-9673-45f165c5943c" xlink:href="carm-20241231.xsd#carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ef19c5f3-08d6-4917-89ef-1e17102a8ce5" xlink:to="loc_carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences_f0c9f2c1-daab-403c-9673-45f165c5943c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_039d7f2e-8d5d-466e-8548-4a49a83928f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ef19c5f3-08d6-4917-89ef-1e17102a8ce5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_039d7f2e-8d5d-466e-8548-4a49a83928f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_4aff2350-483e-4266-ba6e-d96f27121cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ef19c5f3-08d6-4917-89ef-1e17102a8ce5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_4aff2350-483e-4266-ba6e-d96f27121cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_aed48fdf-221f-49f1-bd78-88630bf017c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ef19c5f3-08d6-4917-89ef-1e17102a8ce5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_aed48fdf-221f-49f1-bd78-88630bf017c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f4a4b77a-7a2b-4054-a5fd-b8ba7c08ca2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ef19c5f3-08d6-4917-89ef-1e17102a8ce5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f4a4b77a-7a2b-4054-a5fd-b8ba7c08ca2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_88d15d93-99d9-4181-ae76-5b7966857b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_58169cae-00d4-439b-b748-88cb0e82e7bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_88d15d93-99d9-4181-ae76-5b7966857b9f" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_58169cae-00d4-439b-b748-88cb0e82e7bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_caf68367-2147-4cdf-8448-0f4d77b6bfbd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_58169cae-00d4-439b-b748-88cb0e82e7bd" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_caf68367-2147-4cdf-8448-0f4d77b6bfbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization_0cd4cda5-262d-4cf6-95e0-fd350eedf3fc" xlink:href="carm-20241231.xsd#carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_58169cae-00d4-439b-b748-88cb0e82e7bd" xlink:to="loc_carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization_0cd4cda5-262d-4cf6-95e0-fd350eedf3fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_e7cf7b07-ede6-4362-abec-a0f7fa7d396e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_58169cae-00d4-439b-b748-88cb0e82e7bd" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_e7cf7b07-ede6-4362-abec-a0f7fa7d396e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DeferredTaxAssetsStartUpCosts_d5f27b87-7dac-42a5-8093-a87296acd6fd" xlink:href="carm-20241231.xsd#carm_DeferredTaxAssetsStartUpCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_58169cae-00d4-439b-b748-88cb0e82e7bd" xlink:to="loc_carm_DeferredTaxAssetsStartUpCosts_d5f27b87-7dac-42a5-8093-a87296acd6fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_8f9164fb-7f3e-43a2-899e-8dd5f2d7d5fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_58169cae-00d4-439b-b748-88cb0e82e7bd" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_8f9164fb-7f3e-43a2-899e-8dd5f2d7d5fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DeferredTaxAssetsLeaseLiability_08296edf-72f5-45ba-b112-a92c3e9ef524" xlink:href="carm-20241231.xsd#carm_DeferredTaxAssetsLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_58169cae-00d4-439b-b748-88cb0e82e7bd" xlink:to="loc_carm_DeferredTaxAssetsLeaseLiability_08296edf-72f5-45ba-b112-a92c3e9ef524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_1df1258c-eaaa-4074-bdee-ab2ee776482b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_58169cae-00d4-439b-b748-88cb0e82e7bd" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_1df1258c-eaaa-4074-bdee-ab2ee776482b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DeferredTaxAssetsAmortizableAssetsAndOther_5c9de570-9043-4fc2-b76e-318038cb0a51" xlink:href="carm-20241231.xsd#carm_DeferredTaxAssetsAmortizableAssetsAndOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_58169cae-00d4-439b-b748-88cb0e82e7bd" xlink:to="loc_carm_DeferredTaxAssetsAmortizableAssetsAndOther_5c9de570-9043-4fc2-b76e-318038cb0a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DeferredTaxAssetsEquityCompensation_e63d68e4-6582-4107-9b68-4dca7f3429a5" xlink:href="carm-20241231.xsd#carm_DeferredTaxAssetsEquityCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_58169cae-00d4-439b-b748-88cb0e82e7bd" xlink:to="loc_carm_DeferredTaxAssetsEquityCompensation_e63d68e4-6582-4107-9b68-4dca7f3429a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_5430f1ed-9aa0-4344-9782-281d36b600ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_58169cae-00d4-439b-b748-88cb0e82e7bd" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_5430f1ed-9aa0-4344-9782-281d36b600ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_4dc5517c-676d-4fbc-a1fd-011c789059e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_58169cae-00d4-439b-b748-88cb0e82e7bd" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_4dc5517c-676d-4fbc-a1fd-011c789059e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_bb14dd5f-49bc-4e27-acbe-8f821a364c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_58169cae-00d4-439b-b748-88cb0e82e7bd" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_bb14dd5f-49bc-4e27-acbe-8f821a364c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_b08e8598-cb59-4f83-a1ec-f6b01b39d46f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_88d15d93-99d9-4181-ae76-5b7966857b9f" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_b08e8598-cb59-4f83-a1ec-f6b01b39d46f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DeferredTaxLiabilitiesRightOfUseAsset_8802e38f-dc6a-45ee-8a98-00831d0155a1" xlink:href="carm-20241231.xsd#carm_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_b08e8598-cb59-4f83-a1ec-f6b01b39d46f" xlink:to="loc_carm_DeferredTaxLiabilitiesRightOfUseAsset_8802e38f-dc6a-45ee-8a98-00831d0155a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_bdb26a88-23a9-40f8-9411-058967da4fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_b08e8598-cb59-4f83-a1ec-f6b01b39d46f" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_bdb26a88-23a9-40f8-9411-058967da4fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_3465b34f-4d95-4aa2-9ab4-7b30c46cec9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_b08e8598-cb59-4f83-a1ec-f6b01b39d46f" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_3465b34f-4d95-4aa2-9ab4-7b30c46cec9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_59db647b-dc8d-41a2-8ae9-1c846ca6b100" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_b08e8598-cb59-4f83-a1ec-f6b01b39d46f" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_59db647b-dc8d-41a2-8ae9-1c846ca6b100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_16a1b3e8-c52e-42d1-8d15-3ef02cb56d91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_958a53a0-f1b1-4de8-81c7-991215096b61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_16a1b3e8-c52e-42d1-8d15-3ef02cb56d91" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_958a53a0-f1b1-4de8-81c7-991215096b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_19af8878-9140-4d75-a4ea-a4d76a9b9681" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_958a53a0-f1b1-4de8-81c7-991215096b61" xlink:to="loc_us-gaap_TaxPeriodAxis_19af8878-9140-4d75-a4ea-a4d76a9b9681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_1a46ec2a-220b-415f-9804-cc6adbb7bb94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_19af8878-9140-4d75-a4ea-a4d76a9b9681" xlink:to="loc_us-gaap_TaxPeriodDomain_1a46ec2a-220b-415f-9804-cc6adbb7bb94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_Pre2018Member_04df5146-535a-4fca-8849-d91c7bfec8d9" xlink:href="carm-20241231.xsd#carm_Pre2018Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_1a46ec2a-220b-415f-9804-cc6adbb7bb94" xlink:to="loc_carm_Pre2018Member_04df5146-535a-4fca-8849-d91c7bfec8d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_Post2017Member_a6a2a6b1-5599-4b87-ad64-3ea5fa6f91bb" xlink:href="carm-20241231.xsd#carm_Post2017Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_1a46ec2a-220b-415f-9804-cc6adbb7bb94" xlink:to="loc_carm_Post2017Member_a6a2a6b1-5599-4b87-ad64-3ea5fa6f91bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_59905786-a4fe-43ce-a3ce-f0a8a0931670" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_958a53a0-f1b1-4de8-81c7-991215096b61" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_59905786-a4fe-43ce-a3ce-f0a8a0931670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_a4e76c2f-02f2-425f-a05f-c67ef86f628a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_59905786-a4fe-43ce-a3ce-f0a8a0931670" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_a4e76c2f-02f2-425f-a05f-c67ef86f628a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_6470b18a-eb2f-48b5-ad79-d23ae637cd77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_a4e76c2f-02f2-425f-a05f-c67ef86f628a" xlink:to="loc_us-gaap_DomesticCountryMember_6470b18a-eb2f-48b5-ad79-d23ae637cd77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_StateJurisdictionMember_695b63ff-5ec8-4319-8200-295d6591517e" xlink:href="carm-20241231.xsd#carm_StateJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_a4e76c2f-02f2-425f-a05f-c67ef86f628a" xlink:to="loc_carm_StateJurisdictionMember_695b63ff-5ec8-4319-8200-295d6591517e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_LocalJurisdictionMember_1a027239-9d58-4fd8-a14b-e24a582e11db" xlink:href="carm-20241231.xsd#carm_LocalJurisdictionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_a4e76c2f-02f2-425f-a05f-c67ef86f628a" xlink:to="loc_carm_LocalJurisdictionMember_1a027239-9d58-4fd8-a14b-e24a582e11db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_bf72cc91-52a4-479d-b1ee-94c3ed128ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_958a53a0-f1b1-4de8-81c7-991215096b61" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_bf72cc91-52a4-479d-b1ee-94c3ed128ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_1eb4ff29-3170-4cff-875e-dec2c0d97087" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_bf72cc91-52a4-479d-b1ee-94c3ed128ac1" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_1eb4ff29-3170-4cff-875e-dec2c0d97087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_04c0def1-be17-4335-82b8-17654cec824e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_1eb4ff29-3170-4cff-875e-dec2c0d97087" xlink:to="loc_us-gaap_ResearchMember_04c0def1-be17-4335-82b8-17654cec824e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_12c11eea-7038-40e7-9b7b-bd0cd5a254af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_958a53a0-f1b1-4de8-81c7-991215096b61" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_12c11eea-7038-40e7-9b7b-bd0cd5a254af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_a250cc9b-76aa-4b26-a1aa-a68a5cbf95c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_12c11eea-7038-40e7-9b7b-bd0cd5a254af" xlink:to="loc_us-gaap_OperatingLossCarryforwards_a250cc9b-76aa-4b26-a1aa-a68a5cbf95c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_8642801c-cd75-41f3-8436-7fb414af9491" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_12c11eea-7038-40e7-9b7b-bd0cd5a254af" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_8642801c-cd75-41f3-8436-7fb414af9491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_2553f407-bf06-44db-a81b-232e03e5b09f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_12c11eea-7038-40e7-9b7b-bd0cd5a254af" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_2553f407-bf06-44db-a81b-232e03e5b09f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#ModernaCollaborationandLicenseAgreementNarrativeDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6520c6c0-7ccf-45ce-92df-224a64ed30fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f16071d2-8f30-44af-bf3f-40ea5ab1179f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6520c6c0-7ccf-45ce-92df-224a64ed30fa" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f16071d2-8f30-44af-bf3f-40ea5ab1179f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_62b23f3b-7641-4421-b877-b9c57e372bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f16071d2-8f30-44af-bf3f-40ea5ab1179f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_62b23f3b-7641-4421-b877-b9c57e372bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_24d70e49-32ff-471d-a6e1-bfcea1641b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_62b23f3b-7641-4421-b877-b9c57e372bd9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_24d70e49-32ff-471d-a6e1-bfcea1641b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CollaborationAndLicenseAgreementMember_be41c533-966b-4671-8f50-a061e223a223" xlink:href="carm-20241231.xsd#carm_CollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_24d70e49-32ff-471d-a6e1-bfcea1641b0d" xlink:to="loc_carm_CollaborationAndLicenseAgreementMember_be41c533-966b-4671-8f50-a061e223a223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ModernaLicenseAgreementMember_a4dc61d7-0d15-413b-9265-3ab4e5beb874" xlink:href="carm-20241231.xsd#carm_ModernaLicenseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_24d70e49-32ff-471d-a6e1-bfcea1641b0d" xlink:to="loc_carm_ModernaLicenseAgreementMember_a4dc61d7-0d15-413b-9265-3ab4e5beb874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d5728c66-3d9d-4110-963c-18a66403fade" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f16071d2-8f30-44af-bf3f-40ea5ab1179f" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d5728c66-3d9d-4110-963c-18a66403fade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_0ddd3919-c316-49b9-b99c-0491783ee0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d5728c66-3d9d-4110-963c-18a66403fade" xlink:to="loc_us-gaap_RelatedPartyDomain_0ddd3919-c316-49b9-b99c-0491783ee0d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ModernaMember_39d6688a-84c9-4bee-ab0e-4bce5db58b7b" xlink:href="carm-20241231.xsd#carm_ModernaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_0ddd3919-c316-49b9-b99c-0491783ee0d0" xlink:to="loc_carm_ModernaMember_39d6688a-84c9-4bee-ab0e-4bce5db58b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c5b61ad9-3bcc-42cb-93e1-9bbc9943e2a9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f16071d2-8f30-44af-bf3f-40ea5ab1179f" xlink:to="loc_srt_RangeAxis_c5b61ad9-3bcc-42cb-93e1-9bbc9943e2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f0dc3dfc-d614-4277-944a-f0d338341971" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c5b61ad9-3bcc-42cb-93e1-9bbc9943e2a9" xlink:to="loc_srt_RangeMember_f0dc3dfc-d614-4277-944a-f0d338341971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_df138fbd-cd7f-4761-b4e9-978536c0ecbd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f0dc3dfc-d614-4277-944a-f0d338341971" xlink:to="loc_srt_MinimumMember_df138fbd-cd7f-4761-b4e9-978536c0ecbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_99e9a9c4-b267-4046-a7a3-52f30f1f1ce6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f0dc3dfc-d614-4277-944a-f0d338341971" xlink:to="loc_srt_MaximumMember_99e9a9c4-b267-4046-a7a3-52f30f1f1ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3358ba7d-ae20-46ec-be78-3547b5352a26" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f16071d2-8f30-44af-bf3f-40ea5ab1179f" xlink:to="loc_srt_ProductOrServiceAxis_3358ba7d-ae20-46ec-be78-3547b5352a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_56395771-9fe5-4aa4-8d93-55d3efa5dccd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_3358ba7d-ae20-46ec-be78-3547b5352a26" xlink:to="loc_srt_ProductsAndServicesDomain_56395771-9fe5-4aa4-8d93-55d3efa5dccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ResearchAndDevelopmentServicesMember_d37d046e-bded-4078-9bb2-350ddd73a4e4" xlink:href="carm-20241231.xsd#carm_ResearchAndDevelopmentServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_56395771-9fe5-4aa4-8d93-55d3efa5dccd" xlink:to="loc_carm_ResearchAndDevelopmentServicesMember_d37d046e-bded-4078-9bb2-350ddd73a4e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_OptionRightCollaborationRevenuesMember_d590bb24-abb6-4818-8786-d576b3d6ece6" xlink:href="carm-20241231.xsd#carm_OptionRightCollaborationRevenuesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_56395771-9fe5-4aa4-8d93-55d3efa5dccd" xlink:to="loc_carm_OptionRightCollaborationRevenuesMember_d590bb24-abb6-4818-8786-d576b3d6ece6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_MilestonesMember_d3723a28-3625-4e03-9934-62dd91bc23e9" xlink:href="carm-20241231.xsd#carm_MilestonesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_56395771-9fe5-4aa4-8d93-55d3efa5dccd" xlink:to="loc_carm_MilestonesMember_d3723a28-3625-4e03-9934-62dd91bc23e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_27cc0199-44d1-4846-b5c1-02a3d5551673" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f16071d2-8f30-44af-bf3f-40ea5ab1179f" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_27cc0199-44d1-4846-b5c1-02a3d5551673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3539960c-ec84-450d-ba26-c8ea9d74390c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_27cc0199-44d1-4846-b5c1-02a3d5551673" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3539960c-ec84-450d-ba26-c8ea9d74390c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_0813b886-3a18-4f44-aadb-71814cb44a23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3539960c-ec84-450d-ba26-c8ea9d74390c" xlink:to="loc_us-gaap_SubsequentEventMember_0813b886-3a18-4f44-aadb-71814cb44a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c95218be-bf3f-4f45-9533-a4b74e97b00b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f16071d2-8f30-44af-bf3f-40ea5ab1179f" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c95218be-bf3f-4f45-9533-a4b74e97b00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_MaximumNumberOfResearchTargets_4a747f11-40c9-4f89-8570-d6deebbec791" xlink:href="carm-20241231.xsd#carm_MaximumNumberOfResearchTargets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c95218be-bf3f-4f45-9533-a4b74e97b00b" xlink:to="loc_carm_MaximumNumberOfResearchTargets_4a747f11-40c9-4f89-8570-d6deebbec791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NumberOfResearchTargetsNominatedAutoimmune_1ef04c71-1ce2-490d-a759-ffde85625d33" xlink:href="carm-20241231.xsd#carm_NumberOfResearchTargetsNominatedAutoimmune"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c95218be-bf3f-4f45-9533-a4b74e97b00b" xlink:to="loc_carm_NumberOfResearchTargetsNominatedAutoimmune_1ef04c71-1ce2-490d-a759-ffde85625d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NumberOfResearchTargetsGrossOncology_ad6e3ad2-06e5-4ba2-b52a-e685c4505ea1" xlink:href="carm-20241231.xsd#carm_NumberOfResearchTargetsGrossOncology"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c95218be-bf3f-4f45-9533-a4b74e97b00b" xlink:to="loc_carm_NumberOfResearchTargetsGrossOncology_ad6e3ad2-06e5-4ba2-b52a-e685c4505ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_UpfrontNonRefundablePaymentReceived_d9390baf-9d58-4873-9a59-331c2d3016cb" xlink:href="carm-20241231.xsd#carm_UpfrontNonRefundablePaymentReceived"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c95218be-bf3f-4f45-9533-a4b74e97b00b" xlink:to="loc_carm_UpfrontNonRefundablePaymentReceived_d9390baf-9d58-4873-9a59-331c2d3016cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NumberOfPotentialProductsToDevelopAndCommercialize_7f3ffdad-34ab-48b0-bdf2-581d66cee5c5" xlink:href="carm-20241231.xsd#carm_NumberOfPotentialProductsToDevelopAndCommercialize"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c95218be-bf3f-4f45-9533-a4b74e97b00b" xlink:to="loc_carm_NumberOfPotentialProductsToDevelopAndCommercialize_7f3ffdad-34ab-48b0-bdf2-581d66cee5c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments_66e0dc53-1196-4f2e-8fb5-debcc4d0f439" xlink:href="carm-20241231.xsd#carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c95218be-bf3f-4f45-9533-a4b74e97b00b" xlink:to="loc_carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments_66e0dc53-1196-4f2e-8fb5-debcc4d0f439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts_8c42977a-55f7-4e89-8143-0d0c6d8ec48b" xlink:href="carm-20241231.xsd#carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c95218be-bf3f-4f45-9533-a4b74e97b00b" xlink:to="loc_carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts_8c42977a-55f7-4e89-8143-0d0c6d8ec48b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts_ba56b93b-6e6a-4877-92d6-d7c19aee2613" xlink:href="carm-20241231.xsd#carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c95218be-bf3f-4f45-9533-a4b74e97b00b" xlink:to="loc_carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts_ba56b93b-6e6a-4877-92d6-d7c19aee2613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NumberOfPerformanceObligations_b000d61c-e749-4467-968e-82ec881a3ae1" xlink:href="carm-20241231.xsd#carm_NumberOfPerformanceObligations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c95218be-bf3f-4f45-9533-a4b74e97b00b" xlink:to="loc_carm_NumberOfPerformanceObligations_b000d61c-e749-4467-968e-82ec881a3ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CollaborativeArrangementRightsAndObligationsMilestonePayments_6414a404-9f24-4ecd-82f6-c41efd45f2c0" xlink:href="carm-20241231.xsd#carm_CollaborativeArrangementRightsAndObligationsMilestonePayments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c95218be-bf3f-4f45-9533-a4b74e97b00b" xlink:to="loc_carm_CollaborativeArrangementRightsAndObligationsMilestonePayments_6414a404-9f24-4ecd-82f6-c41efd45f2c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_10c869fa-7f66-40b0-9d78-32b7ba79f325" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c95218be-bf3f-4f45-9533-a4b74e97b00b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_10c869fa-7f66-40b0-9d78-32b7ba79f325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_eacd79a3-c085-4ee2-9f39-797d4d3c4c84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c95218be-bf3f-4f45-9533-a4b74e97b00b" xlink:to="loc_us-gaap_ContractWithCustomerLiability_eacd79a3-c085-4ee2-9f39-797d4d3c4c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_4690b143-9665-486d-ae24-2c46c783e268" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c95218be-bf3f-4f45-9533-a4b74e97b00b" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_4690b143-9665-486d-ae24-2c46c783e268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NumberOfPotentialResearchTargetDesignations_8cae9129-b302-4e51-8cda-c8daa44efbc8" xlink:href="carm-20241231.xsd#carm_NumberOfPotentialResearchTargetDesignations"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c95218be-bf3f-4f45-9533-a4b74e97b00b" xlink:to="loc_carm_NumberOfPotentialResearchTargetDesignations_8cae9129-b302-4e51-8cda-c8daa44efbc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_f511cbae-777d-47e2-b13a-5ab2b7539eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c95218be-bf3f-4f45-9533-a4b74e97b00b" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_f511cbae-777d-47e2-b13a-5ab2b7539eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfOtherReceivables_c1bf981f-6039-4bda-945e-5b1fc21bcb5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromCollectionOfOtherReceivables"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c95218be-bf3f-4f45-9533-a4b74e97b00b" xlink:to="loc_us-gaap_ProceedsFromCollectionOfOtherReceivables_c1bf981f-6039-4bda-945e-5b1fc21bcb5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_VariableConsideration_0f1fdbaf-bcca-4b06-97d5-cbabed537839" xlink:href="carm-20241231.xsd#carm_VariableConsideration"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c95218be-bf3f-4f45-9533-a4b74e97b00b" xlink:to="loc_carm_VariableConsideration_0f1fdbaf-bcca-4b06-97d5-cbabed537839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ContractTerm_773d01e3-07af-45d5-a913-d18c96140497" xlink:href="carm-20241231.xsd#carm_ContractTerm"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c95218be-bf3f-4f45-9533-a4b74e97b00b" xlink:to="loc_carm_ContractTerm_773d01e3-07af-45d5-a913-d18c96140497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_ce99e64f-94bf-4598-8099-76118b21b7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c95218be-bf3f-4f45-9533-a4b74e97b00b" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_ce99e64f-94bf-4598-8099-76118b21b7dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_fd5f718a-247b-4371-b4bb-3c3e709b1c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c95218be-bf3f-4f45-9533-a4b74e97b00b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_fd5f718a-247b-4371-b4bb-3c3e709b1c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/ModernaCollaborationandLicenseAgreementScheduleofEstimatedRevenueExpectedtobeRecognizedinTheFutureRelatedtoPerformanceObligationsDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#ModernaCollaborationandLicenseAgreementScheduleofEstimatedRevenueExpectedtobeRecognizedinTheFutureRelatedtoPerformanceObligationsDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/ModernaCollaborationandLicenseAgreementScheduleofEstimatedRevenueExpectedtobeRecognizedinTheFutureRelatedtoPerformanceObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_57db695a-34b0-4ef9-9e90-75cd68a34a32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationAbstract_957d74aa-c9bd-4ad2-8640-2fee4ed6c1bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuePerformanceObligationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_57db695a-34b0-4ef9-9e90-75cd68a34a32" xlink:to="loc_us-gaap_RevenuePerformanceObligationAbstract_957d74aa-c9bd-4ad2-8640-2fee4ed6c1bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount_8fb69175-1d48-4645-a535-4076e00160cb" xlink:href="carm-20241231.xsd#carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuePerformanceObligationAbstract_957d74aa-c9bd-4ad2-8640-2fee4ed6c1bb" xlink:to="loc_carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount_8fb69175-1d48-4645-a535-4076e00160cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_RevenueRemainingPerformanceObligationOptionRightsAmount_1d3f53f3-221f-470b-9637-778dba848099" xlink:href="carm-20241231.xsd#carm_RevenueRemainingPerformanceObligationOptionRightsAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuePerformanceObligationAbstract_957d74aa-c9bd-4ad2-8640-2fee4ed6c1bb" xlink:to="loc_carm_RevenueRemainingPerformanceObligationOptionRightsAmount_1d3f53f3-221f-470b-9637-778dba848099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_fe8d2f7b-9681-4914-9f85-d42fc6f0c363" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuePerformanceObligationAbstract_957d74aa-c9bd-4ad2-8640-2fee4ed6c1bb" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_fe8d2f7b-9681-4914-9f85-d42fc6f0c363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/ModernaCollaborationandLicenseAgreementScheduleofChangesinDeferredRevenueDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#ModernaCollaborationandLicenseAgreementScheduleofChangesinDeferredRevenueDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/ModernaCollaborationandLicenseAgreementScheduleofChangesinDeferredRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0d8d52e3-0ded-443e-a780-706ba8f53ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInDeferredRevenueRollForward_10d6d9e4-447a-46e1-9103-e927b12015d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MovementInDeferredRevenueRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0d8d52e3-0ded-443e-a780-706ba8f53ee0" xlink:to="loc_us-gaap_MovementInDeferredRevenueRollForward_10d6d9e4-447a-46e1-9103-e927b12015d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_5e1c359c-f821-48a4-bde6-42c0035525ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInDeferredRevenueRollForward_10d6d9e4-447a-46e1-9103-e927b12015d3" xlink:to="loc_us-gaap_ContractWithCustomerLiability_5e1c359c-f821-48a4-bde6-42c0035525ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ContractWithCustomerLiabilityDeferralOfRevenue_d1730b02-16d6-4fb2-ab3f-fb8187e414f3" xlink:href="carm-20241231.xsd#carm_ContractWithCustomerLiabilityDeferralOfRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInDeferredRevenueRollForward_10d6d9e4-447a-46e1-9103-e927b12015d3" xlink:to="loc_carm_ContractWithCustomerLiabilityDeferralOfRevenue_d1730b02-16d6-4fb2-ab3f-fb8187e414f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_40b38e81-8053-4d73-81a1-eea5d8c4c3ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInDeferredRevenueRollForward_10d6d9e4-447a-46e1-9103-e927b12015d3" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_40b38e81-8053-4d73-81a1-eea5d8c4c3ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_0e867dc0-4292-4869-a959-04661b916ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInDeferredRevenueRollForward_10d6d9e4-447a-46e1-9103-e927b12015d3" xlink:to="loc_us-gaap_ContractWithCustomerLiability_0e867dc0-4292-4869-a959-04661b916ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="carm-20241231.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_cbdbfd1f-38ce-4adc-b706-57edf6558c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_2637f56a-9e4a-4974-89b3-8e51ac2e7a24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_cbdbfd1f-38ce-4adc-b706-57edf6558c7e" xlink:to="loc_us-gaap_SubsequentEventTable_2637f56a-9e4a-4974-89b3-8e51ac2e7a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_282904be-9bae-4356-8ab4-536da4115bea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_2637f56a-9e4a-4974-89b3-8e51ac2e7a24" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_282904be-9bae-4356-8ab4-536da4115bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c4d9b522-6bb8-4e1b-a919-016fc243d05f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_282904be-9bae-4356-8ab4-536da4115bea" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c4d9b522-6bb8-4e1b-a919-016fc243d05f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_f7fc66df-0085-4142-91ef-5d3ddb6c446f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c4d9b522-6bb8-4e1b-a919-016fc243d05f" xlink:to="loc_us-gaap_SubsequentEventMember_f7fc66df-0085-4142-91ef-5d3ddb6c446f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_94009c41-a7d5-4244-95ad-9aae46dacb3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_2637f56a-9e4a-4974-89b3-8e51ac2e7a24" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_94009c41-a7d5-4244-95ad-9aae46dacb3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_4f862777-0fa6-4cd1-bc5b-3fe16778d37b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_94009c41-a7d5-4244-95ad-9aae46dacb3e" xlink:to="loc_us-gaap_RelatedPartyDomain_4f862777-0fa6-4cd1-bc5b-3fe16778d37b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ModernaMember_16eeabb2-510f-42cf-8cbe-8aea785d59ca" xlink:href="carm-20241231.xsd#carm_ModernaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_4f862777-0fa6-4cd1-bc5b-3fe16778d37b" xlink:to="loc_carm_ModernaMember_16eeabb2-510f-42cf-8cbe-8aea785d59ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5d37bbcb-440b-4bc2-bc77-447deb5967dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_2637f56a-9e4a-4974-89b3-8e51ac2e7a24" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5d37bbcb-440b-4bc2-bc77-447deb5967dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3d46464f-b738-4b2b-9303-eeb4ab65ade9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5d37bbcb-440b-4bc2-bc77-447deb5967dd" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3d46464f-b738-4b2b-9303-eeb4ab65ade9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CollaborationAndLicenseAgreementMember_356f1225-1e14-4484-9181-1202579dd48e" xlink:href="carm-20241231.xsd#carm_CollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3d46464f-b738-4b2b-9303-eeb4ab65ade9" xlink:to="loc_carm_CollaborationAndLicenseAgreementMember_356f1225-1e14-4484-9181-1202579dd48e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_6078e9a3-adaa-4ab7-9759-a206f94a775a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_2637f56a-9e4a-4974-89b3-8e51ac2e7a24" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_6078e9a3-adaa-4ab7-9759-a206f94a775a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_954ec184-a35f-419a-a84d-6d027924e8a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_6078e9a3-adaa-4ab7-9759-a206f94a775a" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_954ec184-a35f-419a-a84d-6d027924e8a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_7b8bc9d8-95a5-44f2-bf32-6d071e756d80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_954ec184-a35f-419a-a84d-6d027924e8a1" xlink:to="loc_us-gaap_EmployeeSeveranceMember_7b8bc9d8-95a5-44f2-bf32-6d071e756d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_6004a414-aa96-4e20-ae32-af808ab9fcd2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_2637f56a-9e4a-4974-89b3-8e51ac2e7a24" xlink:to="loc_us-gaap_RestructuringPlanAxis_6004a414-aa96-4e20-ae32-af808ab9fcd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_b599aec7-98e3-448d-aa71-acbb8b59d15b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_6004a414-aa96-4e20-ae32-af808ab9fcd2" xlink:to="loc_us-gaap_RestructuringPlanDomain_b599aec7-98e3-448d-aa71-acbb8b59d15b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CashPreservationPlan2025Member_59a4c346-9bb4-4b79-9ff5-614545e07462" xlink:href="carm-20241231.xsd#carm_CashPreservationPlan2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_b599aec7-98e3-448d-aa71-acbb8b59d15b" xlink:to="loc_carm_CashPreservationPlan2025Member_59a4c346-9bb4-4b79-9ff5-614545e07462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_a1125499-e07c-4910-93b3-870f04d35cee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_2637f56a-9e4a-4974-89b3-8e51ac2e7a24" xlink:to="loc_us-gaap_SubsequentEventLineItems_a1125499-e07c-4910-93b3-870f04d35cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NumberOfResearchTargetsNominatedOncology_50b497fb-cd19-429b-af2e-c022264dfd35" xlink:href="carm-20241231.xsd#carm_NumberOfResearchTargetsNominatedOncology"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_a1125499-e07c-4910-93b3-870f04d35cee" xlink:to="loc_carm_NumberOfResearchTargetsNominatedOncology_50b497fb-cd19-429b-af2e-c022264dfd35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NumberOfResearchTargetsNominatedReplacements_25ba2343-18ca-4542-9db1-88ac9e121d24" xlink:href="carm-20241231.xsd#carm_NumberOfResearchTargetsNominatedReplacements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_a1125499-e07c-4910-93b3-870f04d35cee" xlink:to="loc_carm_NumberOfResearchTargetsNominatedReplacements_25ba2343-18ca-4542-9db1-88ac9e121d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NumberOfResearchTargetsTerminatedOncology_6ae5736f-174c-4dda-9692-74bc31e35002" xlink:href="carm-20241231.xsd#carm_NumberOfResearchTargetsTerminatedOncology"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_a1125499-e07c-4910-93b3-870f04d35cee" xlink:to="loc_carm_NumberOfResearchTargetsTerminatedOncology_6ae5736f-174c-4dda-9692-74bc31e35002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NumberOfResearchTargetsTerminatedAutoimmune_e222e840-0b8a-4b46-8bd0-f831c058b06e" xlink:href="carm-20241231.xsd#carm_NumberOfResearchTargetsTerminatedAutoimmune"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_a1125499-e07c-4910-93b3-870f04d35cee" xlink:to="loc_carm_NumberOfResearchTargetsTerminatedAutoimmune_e222e840-0b8a-4b46-8bd0-f831c058b06e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NumberOfResearchTargetsGrossOncology_72bb5258-c272-453f-8255-24290d988a7e" xlink:href="carm-20241231.xsd#carm_NumberOfResearchTargetsGrossOncology"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_a1125499-e07c-4910-93b3-870f04d35cee" xlink:to="loc_carm_NumberOfResearchTargetsGrossOncology_72bb5258-c272-453f-8255-24290d988a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfOtherReceivables_398ac84f-60e3-432a-9efa-c0d55d2cb50b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromCollectionOfOtherReceivables"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_a1125499-e07c-4910-93b3-870f04d35cee" xlink:to="loc_us-gaap_ProceedsFromCollectionOfOtherReceivables_398ac84f-60e3-432a-9efa-c0d55d2cb50b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_8df68323-7994-47a4-a4b2-cca5cfc58743" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_a1125499-e07c-4910-93b3-870f04d35cee" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_8df68323-7994-47a4-a4b2-cca5cfc58743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_971ac957-16d7-4a93-b497-72bfc5b433d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_a1125499-e07c-4910-93b3-870f04d35cee" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_971ac957-16d7-4a93-b497-72bfc5b433d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_6f9bc0a7-f7fc-41d9-a088-5075e8063ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_a1125499-e07c-4910-93b3-870f04d35cee" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_6f9bc0a7-f7fc-41d9-a088-5075e8063ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>carm-20241231_g1.jpg
<TEXT>
begin 644 carm-20241231_g1.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0*R17AI9@  34T *@    @  H=I  0
M   !   !,NH<  <   $,    )@     <Z@    $
M
M
M
M
M
M                              60 P "    %    H"0!  "    %
M I22D0 "     S P  "2D@ "     S P  #J'  '   !#    70     '.H
M   !
M
M
M
M
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M%!04%!04_\  $0@!<@3S P$B  (1 0,1 ?_$ !\   $% 0$! 0$!
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 44E+0 4444 %%%% !129I: "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBDS0 M%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<(Z2NK;.RM=GV9\2/C9H/PW^"][\2IQ+J&A0V4-[ +4#?<"8HL('8;FD09[
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M.%50 .23QZU]:YKFK0C'EY5NK_BSJP\YRYE-W:=OP0M%%%<YV!1110 4444
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M1110!&W"DXSBOCSPY^VU\2?&'@34O&FA? 1]3\+Z?]H,U]%XMMU8"$9D(A,
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M@>E&!2T4!83 ]*,4M% Q-H/848'I2T4"L)@'M2T44#"BBB@ HHHH 3%+110
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M1_T+OC+_ , [3_Y*K\J:*/[(PWG]X?VQB>Z^X_5;_AZU\*/^A=\9?^ =I_\
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MX!VG_P E4?\ #UKX4?\ 0N^,O_ .T_\ DJORIHH_LC#>?WA_;&)[K[C]5O\
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M_*FBC^R,-Y_>']L8GNON/U6_X>M?"C_H7?&7_@':?_)5'_#UKX4?]"[XR_\
M .T_^2J_*FBC^R,-Y_>']L8GNON/U6_X>M?"C_H7?&7_ (!VG_R51_P]:^%'
M_0N^,O\ P#M/_DJORIHH_LC#>?WA_;&)[K[C]5O^'K7PH_Z%WQE_X!VG_P E
M4?\ #UKX4?\ 0N^,O_ .T_\ DJORIHH_LC#>?WA_;&)[K[C]5O\ AZU\*/\
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M\/6OA1_T+OC+_P  [3_Y*K\J:*/[(PWG]X?VQB>Z^X_5;_AZU\*/^A=\9?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K]5O^"4O_)OG
MB/\ [&B?_P!)+2ORIK]5O^"4O_)OGB/_ +&B?_TDM*\3-_\ =_FCW,G_ -Y7
MHS[2HHHKXH^\.$^-OA^_\7_!SQYH.DV_VS5=3T&_LK2WWJGF326\B(NYB%&6
M8#)( SR17Y-_\.^OC_\ ]""?_!Q8?_)%?LZ,T'!KOPN.J82Z@EKW/,Q> IXQ
MIS;5NW_#'XQ?\.^?C_\ ]""?_!QI_P#\D4?\.^?C_P#]""?_  <:?_\ )%?L
M]FC-=O\ ;.(_E7X_YG#_ &)A_P":7WK_ "/QA_X=\_'_ /Z$$_\ @XT__P"2
M*/\ AWS\?_\ H03_ .#C3_\ Y(K]GLT9I_VSB/Y5^/\ F']B8;^:7WK_ "/Q
MA_X=\_'_ /Z$$_\ @XT__P"2*/\ AWS\?_\ H03_ .#C3_\ Y(K]GLT4?VSB
M/Y5^/^8?V)AOYG]Z_P C\8?^'?/Q_P#^A!/_ (.-/_\ DBC_ (=\_'__ *$$
M_P#@XT__ .2*_9[-&:/[9Q'\J_'_ ##^Q,-_-+[U_D?C#_P[Y^/_ /T()_\
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M_P #KK_Y&H_X=5?%S_H.>#O_  .NO_D:OU=S1FC^U<3W7W!_8^%[/[S\HO\
MAU5\7/\ H.>#O_ ZZ_\ D:C_ (=5?%S_ *#G@[_P.NO_ )&K]7<T9H_M7$]U
M]P?V/A>S^\_*+_AU5\7/^@YX._\  ZZ_^1J/^'57Q<_Z#G@[_P #KK_Y&K]7
M<T9H_M7$]U]P?V/A>S^\_*+_ (=5?%S_ *#G@[_P.NO_ )&H_P"'57Q<_P"@
MYX._\#KK_P"1J_5W/O1FC^U<3W7W!_8^%[/[S\HO^'57Q<_Z#G@[_P #KK_Y
M&H_X=5?%S_H.>#O_  .NO_D:OU=S1FC^U<3W7W!_8^%[/[S\HO\ AU5\7/\
MH.>#O_ ZZ_\ D:C_ (=5?%S_ *#G@[_P.NO_ )&K]7<T9]Z/[5Q/=?<']CX7
ML_O/RB_X=5?%S_H.>#O_  .NO_D:E'_!*KXN'/\ Q/?!X_[?KK_Y&K]7,CUH
MR/6C^U<3W7W!_8^%[/[S\HO^'57Q<_Z#G@[_ ,#KK_Y&H_X=5?%S_H.>#O\
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M]:/[5Q/=?<']CX7L_O/RB_X=5?%S_H.>#O\ P.NO_D:C_AU5\7/^@YX._P#
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M@[_P.NO_ )&K]7<CUHR/6C^U<3W7W!_8^%[/[S\HO^'57Q<_Z#G@[_P.NO\
MY&H_X=5?%S_H.>#O_ ZZ_P#D:OU=R/6C(]:/[5Q/=?<']CX7L_O/RB_X=5?%
MS_H.>#O_  .NO_D:C_AU5\7/^@YX._\  ZZ_^1J_5W(]:,CUH_M7$]U]P?V/
MA>S^\_*+_AU5\7/^@YX._P# ZZ_^1J/^'57Q<_Z#G@[_ ,#KK_Y&K]7<CUHR
M/6C^U<3W7W!_8^%[/[S\HO\ AU5\7/\ H.>#O_ ZZ_\ D:C_ (=5?%S_ *#G
M@[_P.NO_ )&K]7<CUHR/6C^U<3W7W!_8^%[/[S\HO^'57Q<_Z#G@[_P.NO\
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M_#1GQ8_Z*?XS_P#"@N__ (Y7GE%'L*7\J^X/;U/YG]YZ'_PT9\6/^BG^,_\
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MB0=%1% "@>@%7P,"@"@G%8[G1MHA:0C(Q2T4#/Q0_;)_9_U+X%_&#5E-N_\
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M/^ART'_P90__ !5?F711_J[3_P"?C^X/^(E8G_H'7WL_33_A<_@3_H<M!_\
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M[_P*3_&ORUX]:./6C_5R'_/Q_=_P0_XB75_Z!E]__ /U*_X3GP]_T'-._P#
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M3_&ORUX]:./6C_5R'_/Q_=_P0_XB75_Z!E]__ /U*_X3GP]_T'-._P# I/\
M&C_A.?#W_0<T[_P*3_&ORUX]:./6C_5R'_/Q_=_P0_XB75_Z!E]__ /U*_X3
MGP]_T'-._P# I/\ &C_A./#W_0<T[_P)3_&ORUX]:,#UH_U<A_S\?W?\$/\
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M>/6CCUH_U<A_S\?W?\$/^(EU?^@9?^!?\ _4K_A./#W_ $'-._\  E/\:/\
MA./#W_0<T[_P)3_&ORUX]:./6C_5R'_/Q_=_P0_XB75_Z!E_X%_P#]2O^$X\
M/?\ 0<T[_P "4_QH_P"$X\/?]!S3O_ E/\:_+7CUHX]:/]7(?\_']W_!#_B)
M=7_H&7_@7_ /U*_X3CP]_P!!S3O_  )3_&C_ (3CP]_T'-._\"4_QK\M>/6C
MCUH_U<A_S\?W?\$/^(EU?^@9?^!?\ _4K_A./#W_ $'-._\  E/\:/\ A./#
MW_0<T[_P)3_&ORUX]:./6C_5R'_/Q_=_P0_XB75_Z!E_X%_P#]2O^$X\/?\
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M_ I/\:/^$Y\/?]!S3O\ P*3_ !K\M>/6CCUH_P!7(?\ /Q_=_P $/^(EU?\
MH&7W_P# /U*_X3GP]_T'-._\"D_QH_X3GP]_T'-._P# I/\ &ORUX]:./6C_
M %<A_P _']W_  0_XB75_P"@9??_ , _4K_A.?#W_0<T[_P*3_&C_A.?#W_0
M<T[_ ,"D_P :_+7CUHX]:/\ 5R'_ #\?W?\ !#_B)=7_ *!E_P"!?\ _4K_A
M.?#W_0<T[_P*3_&C_A.?#W_0<T[_ ,"D_P :_+7CUHX]:/\ 5R'_ #\?W?\
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M\)SX>_Z#FG?^!2?XU^6O'K1QZT?ZN0_Y^/[O^"'_ !$NK_T#+_P+_@'ZE?\
M"<^'O^@YIW_@4G^-*?&WA]<9UO3QGD9N4_QK\M./6CCUI?ZN1_Y^/[O^"'_$
M2ZO_ $#+_P "_P" ?J5_PG/A[_H.:=_X%)_C1_PG/A[_ *#FG?\ @4G^-?EK
MQZT<>M/_ %<A_P _']W_  0_XB75_P"@9?\ @7_ /U*_X3GP]_T'-._\"D_Q
MH_X3GP]_T'-._P# I/\ &ORUX]:./6C_ %<A_P _']W_  0_XB75_P"@9?\
M@7_ /U*_X3GP]_T'-._\"D_QH_X3GP]_T'-._P# I/\ &ORUX]:./6C_ %<A
M_P _']W_  0_XB75_P"@9?\ @7_ /U*_X3GP]_T'-._\"D_QH_X3GP]_T'-.
M_P# I/\ &ORUX]:./6C_ %<A_P _']W_  0_XB75_P"@9?\ @7_ /U*_X3GP
M]_T'-._\"D_QH_X3GP]_T'-._P# I/\ &ORUX]:./6C_ %<A_P _']W_  0_
MXB75_P"@9?\ @7_ /U*_X3GP]_T'-._\"D_QH_X3GP]_T'-._P# I/\ &ORU
MX]:./6C_ %<A_P _']W_  0_XB75_P"@9?\ @7_ /U*_X3GP]_T'-._\"D_Q
MH_X3GP]_T'-._P# I/\ &ORUX]:./6C_ %<A_P _']W_  0_XB75_P"@9?\
M@7_ /U*_X3GP]_T'-._\"D_QH_X3GP]_T'-._P# I/\ &ORUX]:./6C_ %<A
M_P _']W_  0_XB75_P"@9?\ @7_ /U+'C;P^02-;T\@<G%RG'ZTG_"<^'O\
MH.:=_P"!2?XU^6O'K1QZTO\ 5R/_ #\?W?\ !#_B)=7_ *!E_P"!?\ _4K_A
M.?#W_0<T[_P*3_&C_A.?#W_0<T[_ ,"D_P :_+7CUHX]:?\ JY#_ )^/[O\
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M  G/A[_H.:=_X%)_C1_PG/A[_H.:=_X%)_C7Y:\>M''K1_JY#_GX_N_X(?\
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M+O>ZOHEKL7_8&,E"G*"UDFVFTN6TG%W;:6_^1Y0>GM2X)&3TKU2W_9U\1/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M ,D_^V/R;HR:_63R8_[B?E1Y,?\ <3\J/]8W_P ^OQ_X ?\ $,U_T%?^2?\
MVQ^3>317ZR>3'_<3\J/)C_N)^5'^L;_Y]?C_ , /^(9K_H*_\D_^V/R;HK]9
M/)C_ +B?E1Y,?]Q/RI?ZQO\ Y]?C_P  /^(9K_H*_P#)/_MC\FZ*_63R8_[B
M?E1Y,?\ <3\J?^L;_P"?7X_\ /\ B&:_Z"O_ "3_ .V/R;R:,FOUD\F/^XGY
M4>3'_<3\J/\ 6-_\^OQ_X ?\0S7_ $%?^2?_ &Q^3>31DU^LGDQ_W$_*CR8_
M[B?E1_K&_P#GU^/_   _XAFO^@K_ ,D_^V/R;R:,FOUD\F/^XGY4>3'_ '$_
M*C_6-_\ /K\?^ '_ !#-?]!7_DG_ -L?DWDT9-?K)Y,?]Q/RH\F/^XGY4?ZQ
MO_GU^/\ P _XAFO^@O\ \D_^V/R;R:,FOUD\F/\ N)^5'DQ_W$_*C_6-_P#/
MK\?^ '_$,U_T%?\ DG_VQ^3>31DU^LGDQ_W$_*CR8_[B?E1_K&_^?7X_\ /^
M(9K_ *"O_)/_ +8_)O)HR:_63R8_[B?E1Y,?]Q/RH_UC?_/K\?\ @!_Q#-?]
M!?\ Y)_]L?DWDT9-?K)Y,?\ <3\J/)C_ +B?E1_K&_\ GU^/_ #_ (AFO^@K
M_P D_P#MC\F\FC)K]9/)C_N)^5'DQ_W$_*C_ %C?_/K\?^ '_$,U_P!!7_DG
M_P!L?DWDT9-?K)Y,?]Q/RH\F/^XGY4?ZQO\ Y]?C_P  /^(9K_H+_P#)/_MC
M\G#U]:N:5H]_KUV+32["YU&ZVEA#:1-+(0.IVJ"<"OU6\E/[@_*D\A.R*#]*
ME\12MI3_ !_X!<?#2":YL5=?X;?^W,_,7_A5OC/_ *%#7O\ P63_ /Q%'_"K
M?&?_ $*&O?\ @LG_ /B*_3WRU]!^5'EKZ+^59?ZPU?Y%^)V?\0VPG_/^7W(_
M,+_A5OC/_H4->_\ !9/_ /$4?\*M\9_]"AKW_@LG_P#B*_3WRU]!^5'EKZ#\
MJ/\ 6&K_ "+\0_XAMA/^?\ON1^87_"K?&?\ T*&O?^"R?_XBC_A5OC/_ *%#
M7O\ P63_ /Q%?I[L7T7\J/+7T'Y4?ZPU?Y%^(?\ $-L)_P _Y?<C\PO^%6^,
M_P#H4->_\%D__P 11_PJWQG_ -"AKW_@LG_^(K]/?+'H/RH\L>@_*C_6&K_(
MOQ#_ (AMA/\ G_+[D?F%_P *M\9_]"AKW_@LG_\ B*/^%6^,_P#H4->_\%D_
M_P 17Z>^6OHOY4>6/0?E1_K#6_D7XA_Q#;"?\_Y?<C\PO^%6^,_^A0U[_P %
MD_\ \11_PJWQG_T*&O?^"R?_ .(K]/?+'H/RH\L>@_*C_6&K_(OQ#_B&V$_Y
M_P ON1^87_"K?&?_ $*&O?\ @LG_ /B*/^%6^,_^A0U[_P %D_\ \17Z>^6O
MH/RH\M?1?RH_UAJ_R+\0_P"(;83_ )_R^Y'YA?\ "K?&?_0H:]_X+)__ (BC
M_A5OC/\ Z%#7O_!9/_\ $5^GOECT'Y4>6/0?E1_K#5_D7XA_Q#;"?\_Y?<C\
MP3\+O&8_YE'71_W#9_\ XBN<GADMII(9HVBEC8H\;J0RL#@@@]"*_6':/[H-
M-\I"?N*?P%:0XBJ+XJ:?S_X<QJ>&M!V]EB6O5)_JC\G,FC)K]9/)C_N)^5'D
MQ_W$_*K_ -8W_P ^OQ_X!S?\0S7_ $%?^2?_ &Q^3>31DU^LGDQ_W$_*CR8_
M[B?E1_K&_P#GU^/_   _XAFO^@K_ ,D_^V/R;R:,FOUD\F/^XGY4>3'_ '$_
M*C_6-_\ /K\?^ '_ !#-?]!7_DG_ -L?DWDT9-?K)Y,?]Q/RH\F/^XGY4?ZQ
MO_GU^/\ P _XAFO^@K_R3_[8_)O)HR:_63R8_P"XGY4>3'_<3\J/]8W_ ,^O
MQ_X ?\0S7_05_P"2?_;'Y-Y-&37ZR>3'_<3\J/)C_N)^5'^L;_Y]?C_P _XA
MFO\ H*_\D_\ MC\F\FC)K]9/)C_N)^5'DQ_W$_*C_6-_\^OQ_P" '_$,U_T%
M?^2?_;'Y-Y-&37ZR>3'_ '$_*CR8_P"XGY"C_6-_\^OQ_P" '_$,U_T%?^2?
M_;'Y-EU7K@?6F^:G]Y?SK]8GM(90 \,;XZ;E!Q3/[.MA_P N\/\ WP*7^L4N
ME/\ '_@&L?#2FEKB7?\ P_\ !/R@\Q/[R_G1YB?WE_.OU@_L^V_Y]X?^_8H_
ML^V_Y]X?^_8I?ZQ3_P"?:^__ (!7_$-:/_00_N_X)^3_ )B?WE_.CS$_O+^=
M?K!_9]M_S[P_]^Q1_9]M_P ^\/\ W[%'^L4_^?:^_P#X ?\ $-:/_00_N_X)
M^3_F)_>7\Z/,3^\OYU^L']GVW_/O#_W[%']GVW_/O#_W[%'^L4_^?:^__@!_
MQ#6C_P!!#^[_ ()^3_F)_>7\Z/,3^\OYU^L']GVW_/O#_P!^Q1_9]M_S[P_]
M^Q1_K%/_ )]K[_\ @!_Q#6C_ -!#^[_@GY/^8G]Y?SH\Q/[R_G7ZP?V?;?\
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M_$-:/_00_N_X)^3_ )B?WE_.CS$_O+^=?K!_9]M_S[P_]^Q1_9]M_P ^\/\
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M^8G]Y?SH\Q/[R_G7ZP?V?;?\^\/_ '[%']GVW_/O#_W[%'^L4_\ GVOO_P"
M'_$-:/\ T$/[O^"?D_YB?WE_.CS$_O+^=?K!_9]M_P ^\/\ W[%']GVW_/O#
M_P!^Q1_K%/\ Y]K[_P#@!_Q#6C_T$/[O^"?D_P"8G]Y?SH\Q/[R_G7ZP?V?;
M?\^\/_?L4?V?;?\ /O#_ -^Q1_K%/_GVOO\ ^ '_ !#6C_T$/[O^"?D_YB?W
ME_.CS$_O+^=?K!_9]M_S[P_]^Q1_9]M_S[P_]^Q1_K%/_GVOO_X ?\0UH_\
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M;?\ /O#_ -^Q1_9]M_S[P_\ ?L4?ZQ3_ .?:^_\ X ?\0UH_]!#^[_@GY/\
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MW7E\E?5G9:)\2_$L'CVP\*^+O!\>C7&J6TMSIVIZ)J#ZG8N8L>;%,[00/#(
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MO_VFODZBO2_L7!?R?B_\SYC_ %WSW_G_ /\ DL?\CZQ_X;RE_P"A(7_P:_\
MVFC_ (;RE_Z$A?\ P:__ &FODZBC^Q<%_)^+_P P_P!=\]_Y_P#_ )+'_(^L
M?^&\I?\ H2%_\&O_ -IH_P"&\I?^A(7_ ,&O_P!IKY.HH_L7!?R?B_\ ,/\
M7?/?^?\ _P"2Q_R/K'_AO*7_ *$A?_!K_P#::/\ AO*7_H2%_P#!K_\ ::^3
MJ*/[%P7\GXO_ ##_ %WSW_G_ /\ DL?\CZQ_X;RE_P"A(7_P:_\ VFC_ (;R
ME_Z$A?\ P:__ &FODZBC^Q<%_)^+_P P_P!=\]_Y_P#_ )+'_(^L?^&\I?\
MH2%_\&O_ -IH_P"&\I?^A(7_ ,&O_P!IKY.HH_L7!?R?B_\ ,/\ 7?/?^?\
M_P"2Q_R/K'_AO*7_ *$A?_!K_P#::/\ AO*7_H2%_P#!K_\ ::^3J*/[%P7\
MGXO_ ##_ %WSW_G_ /\ DL?\CZQ_X;RD_P"A(7_P:_\ VFC_ (;RE_Z$A?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *3%+10 4444 %%%% !1110 G>L#Q
MWX>E\6>"?$.B03"WGU+3KBR28YPC21,@8X]"V:Z"DVT)V=R6DU9GS9\'OCYX
M1^&OP3\/^'?&6J0>'/&'A?3H-&O?#5VX74I)H(UB3R+<_/.)0$:-HPROO&#P
M</\ VC?$&K>*_P!BCQ=K&N:%)X9U2]T7SYM(EG\Z2UW.I5';:OS;<9&T8)([
M5]'8^E&>HK=54I*:6M[[_@<_LI.#@Y:6ML<,]CXMOO"?AS_A%M:T;1MMG']I
M_M?1YM0\S*)LV>7=0;,?-G.[.1]W!SYQ^V!'<1_!325O)HKB\7Q#H@FEAB,<
M;O\ ;8=S*A9BH)R0"S$#C)ZU] ]*,9J85.6:E;;4N5-2@XWW5CP?]LW_ ))!
M8?\ 8R:-_P"ET5+^V;_R1[3_ /L9=&_]+HJ]X(R.:",CFJC6Y>739W_+_(F5
M'FYM=U8^=?B_JFF>"_CCINNIXLLOAYK-WH36DFK^)[%)M$U&!)BRV^_[3 RW
M,;.7 WC*.>&Q\NI^R#X=O]%^'>O:E>R7TR>(?$>H:U:S:G#Y-S-;S.!'-)'@
M;#($\P+@8#@8KW4B@ XI.K>');M^ HT;3Y[]_P 1U%%%8G4%%%% !1110 E!
M('I2'CFO&/C[H/C/5=7\)W&A6.J:]X7MI9AK.B:#KK:-J$S.$$,Z3B2+>L8\
M[,)FC#%T)W;1M<4I.US.<G"/,E<]G.,5SOC/QSH?P\TB/4]?O?L%C)<PVBR^
M4\F997$<:X12>68#.,#/) KYHT_X@MXPE^&7@/2=?\8:;H^I>(-5L-=;7+HP
MZW;O91&==.:ZB.\!BR'S$D:1HU \TDL#R7QNU'4M!NO&_@$:I?ZUX=TC6O"N
MHV,FJ7DEY<V3W-Z?,MVGD+22*?*#KO8E02,D8QUT\,Y246_^&O8XYXJT6XK_
M (>US[4TO6K?6FO5@CNHS9W+6LINK.:W#.H!)C,BKYB?,,2)N0G(#$@XI6?C
M71M0\8:EX6M[S?KVGVL-[<VAB<>7#*SK&V\KM.3&_ )(QR!D5\HVOCOQ'JWB
MO5/"<_B35K33-:^+%[HT][!>2+/;V46GQ3I9P2YW0*[KC]V5(#/MP237H7PG
M\)P>#OVK/B'I]KJFHZE;'PWI4L8U2^DO9K<&>ZS$9I6:1QD%AYC,0'P#M"@)
MT.5-M]+K[[#CB'-I176S^ZY[BWBW28_%D?AG[8G]NO9-J(L@&+?9Q((S(3C
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MP]G/LPHHHHYEW#V<^S"BBBCF7</9S[,****.9=P]G/LQ<D=.!3@A9@H!=B<
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M_P#C= &]16#]K\2?] [3O_ Q_P#XW1]K\2?] [3O_ Q__C= &]16#]K\2?\
M0.T[_P #'_\ C='VOQ)_T#M._P# Q_\ XW0!O45@_:_$G_0.T[_P,?\ ^-T?
M:_$G_0.T[_P,?_XW0!O45@_:_$G_ $#M._\  Q__ (W1]K\2?] [3O\ P,?_
M .-T ;U%8/VOQ)_T#M._\#'_ /C='VOQ)_T#M._\#'_^-T ;U%8/VOQ)_P!
M[3O_  ,?_P"-T?:_$G_0.T[_ ,#'_P#C= &]16#]K\2?] [3O_ Q_P#XW1]K
M\2?] [3O_ Q__C= &]16#]K\2?\ 0.T[_P #'_\ C='VOQ)_T#M._P# Q_\
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M+:[=EA,\>Y2DC*&94DCDEC+ $J)"0#C!UOMGBW_H#Z+_ .#:;_Y&H^V>+?\
MH#Z+_P"#:;_Y&IIM.Z)E%25F+X9\%Z/X/TJ?3M)L5M[2XN;B\F5Y'F:::>1I
M9G=W+,Q9W8\D\8 P  .'?]E_X:G3;:P&@W$-E;V1TS[/!JMY&DUH79_(F"S#
MSHPSOM23<%!PH XKMOMGBW_H#Z-_X-IO_D:C[;XM_P"@/HW_ (-IO_D:FIRB
M[ILATX2232T\C F^!/@>=;Y)-$,L%[I4.BW5J]W.T$]K%CR0\1?8TB 868CS
M%[.*+3X$^"[/3[NU.F75Y]LO;74;BYU#4[J[NYI[9U>W+W$LK2LL;(I5"^P?
M-Q\S9Z#[9XM_Z ^C?^#:;_Y&H^V>+?\ H#Z-_P"#:;_Y&JN>?=_>'LH=E]QA
MI\$/!L?BW_A(TTE_M_VTZD(?MLYLEO"I4W0M-_D"<@G,HCWY).<DFO*O#O[-
M^KM\2- UG5M-T'2+#0]7N]72?1-6OY5O)'\U46/3YQY%@'\T2RF)Y"SQA>C%
MA[?]M\69_P"0/HW_ (-IO_D:E^W>+/\ H#:-_P"#:;_Y&HC4G&^I$J,)-.WF
M8GA[X(^#/"OB&+6M-TF2"[MS.UK$][<2VMDTS9F:VMGD,-N7).3$BDAF'1B#
MF:1^S9\.=$OK6XM_#S2_98[B&UMKN^N;JUMH9T9)H8H)9&BCB=78&)5"'CY?
ME&.N^V^+/^@/HW_@VF_^1J/MOBS_ * ^C?\ @VF_^1J7//NR_90[+[CD;/X+
MV/@#1M4N/ =JR>*'TX:=87?B'5KR^2UC!^1$:=YFCB4X<QQA0Y1 <8!7L/ /
M@RR^'O@S1/#6G%FL]*M([5))/OR;5 +MZLQRQ/J32?;/%O\ T!]&_P#!M-_\
MC4?;/%O_ $!]&_\ !M-_\C4G)M6;N.,(IWBK'1T5SGVSQ;_T!]%_\&TW_P C
M4?;/%O\ T!]%_P#!M-_\C5)H='17.?;/%O\ T!]%_P#!M-_\C4?;/%O_ $!]
M%_\ !M-_\C4 ='3#$A/**?PKG_MOBS_H#Z+_ .#:;_Y&H^V>+?\ H#Z+_P"#
M:;_Y&H$TGN=!Y,?_ #S7\J/)C_YYK^5<_P#;/%O_ $!]%_\ !M-_\C4?;/%O
M_0'T7_P;3?\ R-3NR>2/8Z#R8_\ GFOY4>3'_P \U_*N?^V>+?\ H#Z+_P"#
M:;_Y&H^V>+?^@/HO_@VF_P#D:B[#DCV.@\F/_GFOY4>3'_SS7\JY_P"V>+?^
M@/HO_@VF_P#D:C[9XM_Z ^B_^#:;_P"1J+L.2/8Z#R8_^>:_E1Y,?_/-?RKG
M_MGBW_H#Z+_X-IO_ )&H^V>+?^@/HO\ X-IO_D:B[#DCV.@\F/\ YYK^5'DQ
M_P#/-?RKG_MGBW_H#Z+_ .#:;_Y&H^V>+?\ H#Z+_P"#:;_Y&HNPY(]CH/)C
M_P">:_E1Y,?_ #S7\JY_[9XM_P"@/HO_ (-IO_D:C[9XM_Z ^B_^#:;_ .1J
M+L.2/8Z#R8_^>:_E1Y,?_/-?RKG_ +9XM_Z ^B_^#:;_ .1J/MGBW_H#Z+_X
M-IO_ )&HNPY(]CH/)C_YYK^5'DQ_\\U_*N?^V>+?^@/HO_@VF_\ D:C[9XM_
MZ ^B_P#@VF_^1J+L.2/8Z#R8_P#GFOY4>3'_ ,\U_*N?^V>+?^@/HO\ X-IO
M_D:C[9XM_P"@/HO_ (-IO_D:B[#DCV.@\F/_ )YK^5'DQ_\ /-?RKG_MGBW_
M * ^B_\ @VF_^1J/MGBW_H#Z+_X-IO\ Y&HNPY(]CH/)C_YYK^5'DQ_\\U_*
MN?\ MGBW_H#Z+_X-IO\ Y&H^V>+?^@/HO_@VF_\ D:B[#DCV.@\F/_GFOY4>
M3'_SS7\JY_[9XM_Z ^B_^#:;_P"1J/MGBW_H#Z+_ .#:;_Y&HNPY(]CH/)C_
M .>:_E1Y,?\ SS7\JY_[9XM_Z ^B_P#@VF_^1J/MGBW_ * ^B_\ @VF_^1J+
ML.2/8Z#R8_\ GFOY4>3'_P \U_*N?^V>+?\ H#Z+_P"#:;_Y&H^V>+?^@/HO
M_@VF_P#D:B[#DCV.@\F/_GFOY4>3'_SS7\JY_P"V>+?^@/HO_@VF_P#D:C[9
MXM_Z ^B_^#:;_P"1J+L.2/8Z#R8_^>:_E1Y,?_/-?RKG_MGBW_H#Z+_X-IO_
M )&H^V>+?^@/HO\ X-IO_D:B[#DCV.@$2#HBC\*=@"N=^V>+?^@/HO\ X-IO
M_D:C[9XM_P"@/HO_ (-IO_D:D4DEL='17.?;/%O_ $!]%_\ !M-_\C4?;/%O
M_0'T7_P;3?\ R-0,Z.BN<^V>+?\ H#Z+_P"#:;_Y&H^V>+?^@/HO_@VF_P#D
M:@#HZ*YS[9XM_P"@/HO_ (-IO_D:C[9XM_Z ^B_^#:;_ .1J .CHKG/MGBW_
M * ^B_\ @VF_^1J/MGBW_H#Z+_X-IO\ Y&H Z.BN<^V>+?\ H#Z+_P"#:;_Y
M&H^V>+?^@/HO_@VF_P#D:@#HZ*YS[9XM_P"@/HO_ (-IO_D:C[9XM_Z ^B_^
M#:;_ .1J .CHKG/MGBW_ * ^B_\ @VF_^1J/MGBW_H#Z+_X-IO\ Y&H Z.BN
M<^V>+?\ H#Z+_P"#:;_Y&H^V>+?^@/HO_@VF_P#D:@#HZ*YS[9XM_P"@/HO_
M (-IO_D:C[9XM_Z ^B_^#:;_ .1J .CHKG/MGBW_ * ^B_\ @VF_^1J/MGBW
M_H#Z+_X-IO\ Y&H Z.BN<^V>+?\ H#Z+_P"#:;_Y&H^V>+?^@/HO_@VF_P#D
M:@#HZ*YS[9XM_P"@/HO_ (-IO_D:C[9XM_Z ^B_^#:;_ .1J .CHKG/MGBW_
M * ^B_\ @VF_^1J/MGBW_H#Z+_X-IO\ Y&H Z.BN<^V>+?\ H#Z+_P"#:;_Y
M&H^V>+?^@/HO_@VF_P#D:@#HZ*YS[9XM_P"@/HO_ (-IO_D:C[9XM_Z ^B_^
M#:;_ .1J .CHKG/MGBW_ * ^B_\ @VF_^1J/MGBW_H#Z+_X-IO\ Y&H Z.BN
M<^V>+?\ H#Z+_P"#:;_Y&H^V>+?^@/HO_@VF_P#D:@#HZ*YS[9XM_P"@/HO_
M (-IO_D:C[9XM_Z ^B_^#:;_ .1J .CHKG/MGBW_ * ^B_\ @VF_^1J/MGBW
M_H#Z+_X-IO\ Y&H Z.BN<^V>+?\ H#Z+_P"#:;_Y&H^V>+?^@/HO_@VF_P#D
M:@#HZ*YS[9XM_P"@/HO_ (-IO_D:C[9XM_Z ^B_^#:;_ .1J .CHKG/MGBW_
M * ^B_\ @VF_^1J/MGBW_H#Z+_X-IO\ Y&H Z.BN<^V>+?\ H#Z+_P"#:;_Y
M&H^V>+?^@/HO_@VF_P#D:@#HZ*YS[9XM_P"@/HO_ (-IO_D:C[9XM_Z ^B_^
M#:;_ .1J .CHKG/MGBW_ * ^B_\ @VF_^1J/MGBW_H#Z+_X-IO\ Y&H Z.BN
M<^V>+?\ H#Z+_P"#:;_Y&H^V>+?^@/HO_@VF_P#D:@#HZ*YS[9XM_P"@/HO_
M (-IO_D:C[9XM_Z ^B_^#:;_ .1J .CHKG/MGBW_ * ^B_\ @VF_^1J/MGBW
M_H#Z+_X-IO\ Y&H Z.BN<^V>+?\ H#Z+_P"#:;_Y&H^V>+?^@/HO_@VF_P#D
M:@#HZ*YS[9XM_P"@/HO_ (-IO_D:C[9XM_Z ^B_^#:;_ .1J .CHKG/MGBW_
M * ^B_\ @VF_^1J/MGBW_H#Z+_X-IO\ Y&H Z.BN<^V>+?\ H#Z+_P"#:;_Y
M&H^V>+?^@/HO_@VF_P#D:@#HZ*YS[9XM_P"@/HO_ (-IO_D:C[9XM_Z ^B_^
M#:;_ .1J .CHKG/MGBW_ * ^B_\ @VF_^1JT=*FU.>)SJ=K:VDH;"+:7+3J1
MZDM&F#[8- &E1110 4444 %87BGQEH'@;31J/B37-.\/Z>9!$+O5+N.VB+D$
MA=[D#) /&<\&MSI7A7[5G^I^$_\ V4+1O_0Y*J$5*23,JDG"+:/2O"?Q2\&>
M/;F>W\,^+M#\17$""2:+2=2ANGC4G 9A&Q(&>,FNJ/3I7@'[54<>B77PL\26
M($'B.T\9:=86ES&#YKP7+F.X@R.2CQY++WV ]J\U3]H#QKXK\/\ BOQ9H>L>
M)5U*RU"ZCT/PKIW@JZO=,NX;:8H(KBZ2S=FEF\MP6CN$6-G7(^5@=U0<XJ<=
MCFEB53ERRW\C[)!H-?,?B']H+Q#\/X?B9;ZT\S:B='M?$'A.UNK:-)U^U*+=
M;)E"KN,5YM4[@7Q,-V>*R'^*7C&Z\<:UX+U?QOXET:Y\)Z586]UJ/A7P>VK2
MZEJ5Q;)-)-.4LIXHHDRH2)%C9M[DMA125"6_]=/\RGB8;?U_6A]03Z_I=MK5
MKI$VIVD.JW<3S6]@\ZK/,B8WND9.YE7(R0,#(SUK3/']*^)M3^,&NP^,O 7Q
M \3Z'<:=K^E^!_$UY=Z;/9S6AD>V>/#"*4;T201JXW=%<9/%>AIXS\>^ M$^
M%WB[6/%LGB:'Q;J=CINJ:')8VT5K:&^P8Y+-XHUE'DMA?WSR[T+$X;!%2P\H
MVUW_ .#_ )$1Q49-Z;?EI_F?2] QFOC[3OB)\4=._9YU3XNWWCIKV;2KZ\G3
M0'TZSCL[JQ@O9(3%*RP^:)BJMM=)%'$8*$[V:?7?B-\1=0T#X[>*K'QS=:7:
M>";R1M'TR'3;)XY42TBN&BN2\+.R'=@%'1AN?+-\H5_597:NM';KO=+MYA];
MC9/E>JOTVM?OY'USVI<YS7S->?$WQ?\ #'Q+X.O]>\2R^)]+\1^'=4UB^TQ[
M*WMXK.6UMX[D+:-'&)!'AVC"S/*V "6)R3R_@WXV^/;O1? WB==2\5>)M1UJ
MZM9-6\-Q>![J'2K>SN7!+6MU]C5LP(ZG?)<2+)L8]&!$?5Y;W5O^'_R*>*@G
M9I_AY?YGU^.M4XM3LYM2N+".[AEOK:..6:U213)$CE@C,N<@,4?!/78V.AKY
M%N/BG\2K?X._$KXDGQQ.9?"GB*_MK'1%TVS^QW-K;WH7RK@^5YI+(60-')&0
M I.YLEO0OA1HM['^U5\9[E_$&H3PI!H[-9216PA<213E 2L(?$8!"X8$ACO+
MG!#=!Q4FVM/\U_F$<2IRBHQ>OIY^?D?0]%%%<QVA1110 444E "TUB%ZTO2O
M"?VR-3O+7X1VNGP3RVFG:WK>G:1JMS"Q1HK&>X5)_F'*AE.PGT<CO50CSR4>
MYE4GR1<NQZ!I?QF\ ZYX@70M.\<>'+_7&D:)=,M=6MY+DNH)91$KEL@*V1C(
MP?2G^*/C!X$\#ZI_9WB+QMX>T#4?+$OV34]5@MI=ASAMCN#@X/..QKS[X_V/
MAWP_\(K_ $"^^'FLZAX)TW36NWNO#1L(1I,=NI8/"LUQ&ZR1JA93&C>V2<5P
M?AGQW=K^U!KFL:)X4UWQ3#J?@C1[A8K*:RCFAC:2=U:7[1<1*2<X.QFYSVYK
MHC24TY+^MCFE6E%J+WT[GTMX:\6Z)XTTM=4\/ZQI^NZ8S,BWFFW*7$+,#@@.
MA(R#U&:RM$^+7@?Q+K\FAZ1XRT#5=:C+A]-LM4@FN%V??S&KEAM[\<=Z^4_B
MWX<\4^'/#7Q-\5ZII\W@[2/B!XBT/3;G2!=1M/;6 <6]S-,\#-&CW ;#;';"
MD9;)-?2WQ%^'W@*?P+86WB%+'PYX>\.SV]]97D4R6$>EO"P\IXI!M6$#[O&!
MAB.]*5*,;.][]O1#A5G.ZM:W?U_R-[6?B1X2\.>(K#0=5\5:-I>NW_E_9-+O
M-0ABN;C>Y1/+B9@S[G!48!R00.:Z4<BO ?VB/AO/;_"GXC1^$O#FDWD_BBWG
MN-?OM4O)7N JP(@D@C=661TC0^5&988T95(/+5R_QO\ B/XL_P"&<-*UWP-'
M$/#%W!H<MKKUQKL]KJI62\ME"O$EL5^<,$=O.'#N=IQM91I<Z7*]W8<JW(Y<
MRV5]#ZIHK \*W/B&]TR1_$FFZ;I.H"4A(=*U&2^B,>!AC))!"0V=WR["!@')
MS@;]<[TT.M.ZN%%%% PHHHH **** "BBB@ HHI,T +1110 444E "T4E&: %
MHI,@TM !1110 4444 1LP R>!ZFN<U?XC>%?#]T;;4_$>E:?..#'=7L<;#ZA
MF!KYM_:M^/>HZ?JT_@OP_=/9+$J'4+R!MLA+#=Y2L.@P5)(YYQZY^4W<MEGR
M[,<DDY)-?3X+))8BFJM27*GLC\FSOCRGEV)EA<-3YW%V;;LK]4O0_3'_ (7/
MX$_Z'+0?_!E#_P#%4?\ "Y_ G_0Y:#_X,H?_ (JOS+HKTO\ 5VG_ ,_']Q\U
M_P 1*Q/_ $#K[V?II_PN?P)_T.6@_P#@RA_^*H_X7/X$_P"ART'_ ,&4/_Q5
M?F711_J[3_Y^/[@_XB5B?^@=?>S]-/\ A<_@3_H<M!_\&4/_ ,51_P +G\"?
M]#EH/_@RA_\ BJ_,NBC_ %=I_P#/Q_<'_$2L3_T#K[V?II_PN?P)_P!#EH/_
M (,H?_BJ/^%S^!/^ART'_P &4/\ \57YET4?ZNT_^?C^X/\ B)6)_P"@=?>S
M]-/^%S^!/^ART'_P90__ !5'_"Y_ G_0Y:#_ .#*'_XJOS+HH_U=I_\ /Q_<
M'_$2L3_T#K[V?II_PN?P)_T.6@_^#*'_ .*H_P"%S^!/^ART'_P90_\ Q5?F
M711_J[3_ .?C^X/^(E8G_H'7WL_33_A<_@3_ *'+0?\ P90__%4?\+G\"?\
M0Y:#_P"#*'_XJOS+HH_U=I_\_']P?\1*Q/\ T#K[V?II_P +G\"?]#EH/_@R
MA_\ BJ/^%S^!/^ART'_P90__ !5?F711_J[3_P"?C^X/^(E8G_H'7WL_33_A
M<_@3_H<M!_\ !E#_ /%4?\+G\"?]#EH/_@RA_P#BJ_,NBC_5VG_S\?W!_P 1
M*Q/_ $#K[V?II_PN?P)_T.6@_P#@RA_^*H_X7/X$_P"ART'_ ,&4/_Q5?F71
M1_J[3_Y^/[@_XB5B?^@=?>S]-/\ A<_@3_H<M!_\&4/_ ,51_P +G\"?]#EH
M/_@RA_\ BJ_,NBC_ %=I_P#/Q_<'_$2L3_T#K[V?II_PN?P)_P!#EH/_ (,H
M?_BJ/^%S^!/^ART'_P &4/\ \57YET4?ZNT_^?C^X/\ B)6)_P"@=?>S]-/^
M%S^!/^ART'_P90__ !5'_"Y_ G_0Y:#_ .#*'_XJOS+HH_U=I_\ /Q_<'_$2
ML3_T#K[V?II_PN?P)_T.6@_^#*'_ .*H_P"%S^!/^ART'_P90_\ Q5?F711_
MJ[3_ .?C^X/^(E8G_H'7WL_4W1?%NB>)HV?2=8L=31>IM+A)0/KM)K7SCVK\
MI]-U6\T6]BO-/NIK&ZB.4GMY"CJ?8BOO#]FGXSS_ !7\-7-OJC)_;FF%$G90
M )D8?+)@="2&! X!'O7CX_*)8.'M8RYH]>Z/M.'>,J6=5OJM6')-[:W3MOZ,
M]LHI!2U\\?I04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8;,_*F2,X ]:^%WAFZ\%?#?PIX=OI(I+[2=)M+&>2W),;210HC%20"5)4XR
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M?Y?E>4,54_.G!.?F7U%43\</AVUKJ4Z^/O#)ATUE2^E&L6^VU9F*J)3OPA+
M@!L9(Q46EYE\\.Z-?_A =%_YXW7_ ('W'_Q='_" Z)_SQNO_  /N/_BZJ?\
M"?Z?=ZAX672]4T*_T[73,8+C^UU66Y5(BX-I&J,+GIEL.NU<MEL8J'2_C'X#
MUO6;32-/\:^';[5;Q=]M86NJV\D\ZX)RD:N6885CP.@/I2Y7V#VD.YH?\(#H
MO_/*Z_\  ^X_^+H_X0'1?^>5U_X'W'_Q=5-:^*W@OPUXB@T#5O%^A:5K<VP1
M:=>ZE!#<R;SA-L3,&.X\# Y[5S^E_'CPYK'QMU?X:PWEG_:VG6,-T6^W1F2:
M5S)O@2('<6C1%=NX#C( Y+4)M72\_D)U8)V;ZV^9UG_" Z+_ ,\;K_P/N/\
MXNC_ (0'1?\ GC=?^!]Q_P#%U!X=^)OA'Q?JUYI>@^*M%UG5+/<;FRT[48;B
M: !MK%T1BRX8@'(Z\5QWQ9_:,\+_  UTK5!:ZKH^N^(K"XLX)O#L6K11WB">
MZA@+,@W.NT3A^5YP!QG--0DW9+4)5(Q7,WH=Q_P@&B_\\;K_ ,#[C_XNC_A
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M4 <Y_P (!HO_ #QNO_ ^X_\ BZ/^$ T7_GC=?^!]Q_\ %UT=% '.?\(!HO\
MSQNO_ ^X_P#BZ/\ A -%_P">-U_X'W'_ ,771T4 <Y_P@&B_\\;K_P #[C_X
MNC_A -%_YXW7_@?<?_%UT=% '.?\(!HO_/&Z_P# ^X_^+H_X0#1?^>-U_P"!
M]Q_\771T4 <Y_P (!HO_ #QNO_ ^X_\ BZ/^$ T7_GC=?^!]Q_\ %UT=% '.
M?\(!HO\ SQNO_ ^X_P#BZ/\ A -%_P">-U_X'W'_ ,7719I: .<_X0#1?^>-
MU_X'W'_Q='_" :+_ ,\;K_P/N/\ XNNCHH YS_A -%_YXW7_ ('W'_Q='_"
M:+_SQNO_  /N/_BZZ.B@#G/^$ T7_GC=?^!]Q_\ %T?\(!HO_/&Z_P# ^X_^
M+KHZ* .<_P"$ T7_ )XW7_@?<?\ Q='_  @&B_\ /&Z_\#[C_P"+KHZ* .<_
MX0#1?^>-U_X'W'_Q='_" :+_ ,\;K_P/N/\ XNNCHH YS_A -%_YXW7_ ('W
M'_Q='_" :+_SQNO_  /N/_BZZ.B@#G/^$ T7_GC=?^!]Q_\ %T?\(!HO_/&Z
M_P# ^X_^+KHJ6@#G/^$ T7_GC=?^!]Q_\71_P@&B_P#/&Z_\#[C_ .+KHZ*
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M[C_XNNCHH YS_A -%_YXW7_@?<?_ !='_" :+_SQNO\ P/N/_BZZ.B@#G/\
MA -%_P">-U_X'W'_ ,71_P (!HO_ #QNO_ ^X_\ BZZ.B@#G/^$ T7_GC=?^
M!]Q_\71_P@&B_P#/&Z_\#[C_ .+KHZ* .<_X0#1?^>-U_P"!]Q_\71_P@&B_
M\\;K_P #[C_XNNCHH YS_A -%_YXW7_@?<?_ !='_" :+_SQNO\ P/N/_BZZ
M.B@#G/\ A -%_P">-U_X'W'_ ,71_P (!HO_ #QNO_ ^X_\ BZZ.B@#G/^$
MT7_GC=?^!]Q_\71_P@&B_P#/&Z_\#[C_ .+KHZ* .<_X0#1?^>-U_P"!]Q_\
M71_P@&B_\\;K_P #[C_XNNCHH YS_A -%_YXW7_@?<?_ !='_" :+_SQNO\
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M^7JGOVO_ )DQPG+?WNC6W>R_0_/OXJ^*[>]\#?'/2F\2:;X-N6U75Q+X(L;
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M_P!)8ZBI24([ZW_ NE6=26BTM^)Z!2'I2TR7_5/CKM-8(ZV[*Y\Y?'S]J,^
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MVP?_ #_E]R/S3T/X'^//$&HQV<'A75(&<@>9>VKP1K[EW %?;/P$^"\7P?\
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M% '._P#"7R?] #6?_ =?_BZ/^$OD_P"@!K/_ (#K_P#%UT5% '._\)?)_P!
M#6?_  '7_P"+H_X2^3_H :S_ . Z_P#Q==%10!SO_"7R?] #6?\ P'7_ .+H
M_P"$OD_Z &L_^ Z__%UT5% '._\ "7R?] #6?_ =?_BZ/^$OD_Z &L_^ Z__
M !==%10!SO\ PE\G_0 UG_P'7_XNC_A+Y/\ H :S_P" Z_\ Q==%10!SO_"7
M/_T -9_\!U_^+H_X2Y_^@!K/_@.O_P 77144 <[_ ,)?)_T -9_\!U_^+H_X
M2^3_ * &L_\ @.O_ ,77144 <[_PE\G_ $ -9_\  =?_ (NC_A+Y/^@!K/\
MX#K_ /%UT5% '._\)?)_T -9_P# =?\ XNC_ (2^3_H :S_X#K_\77144 <[
M_P )?)_T -9_\!U_^+H_X2^3_H :S_X#K_\ %UT5% '._P#"7R?] #6?_ =?
M_BZ/^$OD_P"@!K/_ (#K_P#%UT5% '._\)?)_P! #6?_  '7_P"+H_X2^3_H
M :S_ . Z_P#Q==%10!SO_"7R?] #6?\ P'7_ .+H_P"$OD_Z &L_^ Z__%UT
M5% '._\ "7R?] #6?_ =?_BZ/^$O?_H :S_X#K_\77144 <[_P )?)_T -9_
M\!U_^+H_X2Y_^@!K/_@.O_Q==%10!SO_  E\G_0 UG_P'7_XNC_A+Y/^@!K/
M_@.O_P 77144 <[_ ,)?)_T -9_\!U_^+H_X2^3_ * &L_\ @.O_ ,77144
M<[_PE\G_ $ -9_\  =?_ (NC_A+Y/^@!K/\ X#K_ /%UT5% '._\)>__ $ -
M9_\  =?_ (NC_A+W_P"@!K/_ (#K_P#%UT5% '._\)?)_P! #6?_  '7_P"+
MH_X2^3_H :S_ . Z_P#Q==%10!SO_"7O_P! #6?_  '7_P"+H_X2Y_\ H :S
M_P" Z_\ Q==%10!SO_"7R?\ 0 UG_P !U_\ BZ/^$OD_Z &L_P#@.O\ \771
M44 <[_PE\G_0 UG_ ,!U_P#BZ/\ A+Y/^@!K/_@.O_Q==%10!SO_  E\G_0
MUG_P'7_XNC_A+Y/^@!K/_@.O_P 77144 <[_ ,)?)_T -9_\!U_^+H_X2^3_
M * &L_\ @.O_ ,77144 <[_PE\G_ $ -9_\  =?_ (NC_A+Y/^@!K/\ X#K_
M /%UT5% '._\)?)_T -9_P# =?\ XNC_ (2^3_H :S_X#K_\77144 <[_P )
M?)_T -9_\!U_^+H_X2^3_H :S_X#K_\ %UT5% '._P#"7R?] #6?_ =?_BZ3
M_A+G_P"@!K/_ (#K_P#%UT=% '._\)>__0 UG_P'7_XNC_A+Y/\ H :S_P"
MZ_\ Q==%10!SO_"7R?\ 0 UG_P !U_\ BZ/^$OD_Z &L_P#@.O\ \77144 <
M[_PE\G_0 UG_ ,!U_P#BZ/\ A+Y/^@!K/_@.O_Q==%10!SO_  E\G_0 UG_P
M'7_XNC_A+Y/^@!K/_@.O_P 77144 <[_ ,)?)_T -9_\!U_^+H_X2^3_ * &
ML_\ @.O_ ,77144 <[_PE\G_ $ -9_\  =?_ (NC_A+Y/^@!K/\ X#K_ /%U
MT5% '._\)?)_T -9_P# =?\ XNC_ (2^3_H :S_X#K_\77144 <[_P )?)_T
M -9_\!U_^+H_X2^3_H :S_X#K_\ %UT5% '._P#"7R?] #6?_ =?_BZ/^$OD
M_P"@!K/_ (#K_P#%UT5% '._\)?)_P! #6?_  '7_P"+H_X2^3_H :S_ . Z
M_P#Q==%10!SO_"7R?] #6?\ P'7_ .+H_P"$OD_Z &L_^ Z__%UT5% '._\
M"7R?] #6?_ =?_BZ/^$OD_Z &L_^ Z__ !==%10!SO\ PE\G_0 UG_P'7_XN
MC_A+Y/\ H :S_P" Z_\ Q==%10!SO_"7R?\ 0 UG_P !U_\ BZ/^$OD_Z &L
M_P#@.O\ \77144 <[_PE\G_0 UG_ ,!U_P#BZ/\ A+Y/^@!K/_@.O_Q==%10
M!SO_  E\G_0 UG_P'7_XNC_A+Y/^@!K/_@.O_P 77144 <[_ ,)?)_T -9_\
M!U_^+H_X2^3_ * &L_\ @.O_ ,77144 <[_PE\G_ $ -9_\  =?_ (NC_A+Y
M/^@!K/\ X#K_ /%UT5% '._\)?)_T -9_P# =?\ XNC_ (2^3_H :S_X#K_\
M77144 <[_P )?)_T -9_\!U_^+H_X2^3_H :S_X#K_\ %UT5% '._P#"7R?]
M #6?_ =?_BZ/^$OD_P"@!K/_ (#K_P#%UT5% '._\)?)_P! #6?_  '7_P"+
MH_X2^3_H :S_ . Z_P#Q==%10!SO_"7R?] #6?\ P'7_ .+H_P"$OD_Z &L_
M^ Z__%UT5% '._\ "7R?] #6?_ =?_BZ/^$OD_Z &L_^ Z__ !==%10!SO\
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M (2^3_H :S_X#K_\77144 <[_P )?)_T -9_\!U_^+H_X2^3_H :S_X#K_\
M%UT5% '._P#"7R?] #6?_ =?_BZ/^$OD_P"@!K/_ (#K_P#%UT5% '._\)?)
M_P! #6?_  '7_P"+H_X2^3_H :S_ . Z_P#Q==%10!SO_"7R?] #6?\ P'7_
M .+H_P"$OD_Z &L_^ Z__%UT5% '.?\ "7/_ - #6?\ P'7_ .+I?^$N?_H
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M% #&^\*?110 5$I^4?13^M%% "]S]!_6I*** "BBB@!J\@9]*=110!%'R_\
MP$'^=2T44 1Q<H">30G)YYX%%% $E%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
D !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 26, 2025</div></th>
<th class="th"><div>Jun. 28, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Carisma Therapeutics Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-2025616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3675 Market Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Philadelphia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">491-6422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CARM<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,095,128<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,788,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">The registrant intends to file a definitive proxy statement pursuant to Regulation 14A within 120 days of the end of the fiscal year ended December 31, 2024. Portions of such definitive proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001485003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Philadelphia, Pennsylvania<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 17,909<span></span>
</td>
<td class="nump">$ 77,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other assets</a></td>
<td class="nump">5,916<span></span>
</td>
<td class="nump">2,866<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">23,825<span></span>
</td>
<td class="nump">80,471<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">4,385<span></span>
</td>
<td class="nump">6,764<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets &#8211; operating leases</a></td>
<td class="nump">2,040<span></span>
</td>
<td class="nump">2,173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_DeferredFinancingCostsNoncurrent', window );">Deferred financing costs</a></td>
<td class="nump">208<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">30,458<span></span>
</td>
<td class="nump">89,554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,081<span></span>
</td>
<td class="nump">3,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">7,448<span></span>
</td>
<td class="nump">7,662<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">3,729<span></span>
</td>
<td class="nump">1,413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">832<span></span>
</td>
<td class="nump">1,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="nump">905<span></span>
</td>
<td class="nump">544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">1,060<span></span>
</td>
<td class="nump">965<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">16,055<span></span>
</td>
<td class="nump">15,908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue</a></td>
<td class="nump">41,250<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">724<span></span>
</td>
<td class="nump">860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">318<span></span>
</td>
<td class="nump">926<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">58,367<span></span>
</td>
<td class="nump">63,022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; (deficit) equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock $0.001 par value, 5,000,000 shares authorized, none issued or outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock $0.001 par value, 350,000,000 shares authorized, 41,750,109 and 40,609,915 shares issued and outstanding at December&#160;31, 2024 and 2023, respectively</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">277,629<span></span>
</td>
<td class="nump">271,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(305,579)<span></span>
</td>
<td class="num">(245,102)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; (deficit) equity</a></td>
<td class="num">(27,909)<span></span>
</td>
<td class="nump">26,532<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; (deficit) equity</a></td>
<td class="nump">$ 30,458<span></span>
</td>
<td class="nump">$ 89,554<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_DeferredFinancingCostsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Financing Costs, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_DeferredFinancingCostsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">41,750,109<span></span>
</td>
<td class="nump">40,609,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">41,750,109<span></span>
</td>
<td class="nump">40,609,915<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenues</a></td>
<td class="nump">$ 19,632<span></span>
</td>
<td class="nump">$ 14,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">59,673<span></span>
</td>
<td class="nump">74,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">22,138<span></span>
</td>
<td class="nump">29,525<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">81,811<span></span>
</td>
<td class="nump">103,650<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(62,179)<span></span>
</td>
<td class="num">(88,731)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(84)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income, net</a></td>
<td class="nump">1,702<span></span>
</td>
<td class="nump">1,936<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (60,477)<span></span>
</td>
<td class="num">$ (86,879)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Share information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of common stock, basic (in USD per share)</a></td>
<td class="num">$ (1.46)<span></span>
</td>
<td class="num">$ (2.59)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of common stock, diluted (in USD per share)</a></td>
<td class="num">$ (1.46)<span></span>
</td>
<td class="num">$ (2.59)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares of common stock outstanding, basic (in shares)</a></td>
<td class="nump">41,456,210<span></span>
</td>
<td class="nump">33,524,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares of common stock outstanding, diluted (in shares)</a></td>
<td class="nump">41,456,210<span></span>
</td>
<td class="nump">33,524,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Comprehensive loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (60,477)<span></span>
</td>
<td class="num">$ (86,879)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain on marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Less: reclassification to net loss of previous unrealized gain on marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(399)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (60,477)<span></span>
</td>
<td class="num">$ (86,838)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 15<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/815-15/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479428/808-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; (Deficit) Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated other comprehensive loss</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Noncontrolling interests</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">8,700,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 107,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_ReclassificationsOfTemporaryToPermanentEquityShares', window );">Conversion of convertible preferred stock and non-controlling interests to common stock (in shares)</a></td>
<td class="num">(8,700,885)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity', window );">Conversion of convertible preferred stock and non-controlling interests to common stock</a></td>
<td class="num">$ (107,808)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,217,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="num">(142,670)<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 1,197<span></span>
</td>
<td class="num">$ (41)<span></span>
</td>
<td class="num">$ (158,223)<span></span>
</td>
<td class="nump">$ 14,395<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Stockholders&#8217; (Deficit) Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain on marketable securities</a></td>
<td class="nump">440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Reclassification to net loss of previous unrealized gain on marketable securities</a></td>
<td class="num">(399)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(399)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction', window );">Issuance of common stock for cash in pre-closing financing (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,730,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction', window );">Issuance of common stock for cash in pre-closing financing</a></td>
<td class="nump">30,640<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">30,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon settlement of convertible promissory note, accrued interest, and related derivative liability (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,059,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock upon settlement of convertible promissory note, accrued interest, and related derivative liability</a></td>
<td class="nump">42,447<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">42,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock to Sesen Bio shareholders in reverse capitalization (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,374,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock to Sesen Bio shareholders in reverse capitalization</a></td>
<td class="nump">72,044<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">72,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger', window );">Conversion of convertible preferred stock and non-controlling interests to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,872,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger', window );">Conversion of convertible preferred stock and non-controlling interests to common stock</a></td>
<td class="nump">107,809<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">122,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,395)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock under Open Market Sales Agreement, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock under Open Market Sales Agreement, net of issuance costs</a></td>
<td class="nump">597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(86,879)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(86,879)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,609,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">$ 26,532<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">271,594<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(245,102)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Ending balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending balance at Dec. 31, 2024</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Stockholders&#8217; (Deficit) Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">3,810<span></span>
</td>
<td class="nump">3,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain on marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Reclassification to net loss of previous unrealized gain on marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock under Open Market Sales Agreement, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,136,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock under Open Market Sales Agreement, net of issuance costs</a></td>
<td class="nump">2,383<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">2,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(60,477)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(60,477)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,750,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2024</a></td>
<td class="num">$ (27,909)<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">$ 277,629<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (305,579)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_ReclassificationsOfTemporaryToPermanentEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock classified as temporary equity reclassified or converted to permanent equity during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_ReclassificationsOfTemporaryToPermanentEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock issued during the period upon the conversion of convertible preferred stock and noncontrolling interests upon merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to pre-closing financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of convertible preferred stock and noncontrolling interests upon merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to preclosing financing during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationsOfTemporaryToPermanentEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (60,477,000)<span></span>
</td>
<td class="num">$ (86,879,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustment to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">3,354,000<span></span>
</td>
<td class="nump">2,837,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">159,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">3,649,000<span></span>
</td>
<td class="nump">2,316,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Reduction in the operating right of use assets</a></td>
<td class="nump">4,963,000<span></span>
</td>
<td class="nump">5,428,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,283,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">84,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_AccretionOnMarketableSecurities', window );">Accretion on marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(709,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_WriteOffOfPropertyAndEquipment', window );">Write-off of property and equipment</a></td>
<td class="nump">362,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments', window );">Realized gain on marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(399,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NoncashInterestExpense', window );">Non-cash interest expense</a></td>
<td class="nump">217,000<span></span>
</td>
<td class="nump">139,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_GainLossOnSaleOfEquipment', window );">Loss on sale of equipment</a></td>
<td class="nump">49,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleAndLeasebackTransactionGainLossNet', window );">Gain on sale of sale-leaseback</a></td>
<td class="num">(82,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(3,120,000)<span></span>
</td>
<td class="nump">1,046,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,852,000)<span></span>
</td>
<td class="nump">2,191,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(213,000)<span></span>
</td>
<td class="num">(2,899,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(1,434,000)<span></span>
</td>
<td class="num">(1,046,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(5,525,000)<span></span>
</td>
<td class="num">(4,941,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long term liabilities</a></td>
<td class="nump">192,000<span></span>
</td>
<td class="nump">213,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(59,917,000)<span></span>
</td>
<td class="num">(81,177,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(34,460,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_PaymentsForProceedsFromMarketableSecurities', window );">Proceeds from the sale of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">108,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(123,000)<span></span>
</td>
<td class="num">(1,132,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(123,000)<span></span>
</td>
<td class="nump">72,408,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities', window );">Cash, cash equivalents and restricted cash acquired in connection with the reverse recapitalization</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">37,903,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities', window );">Payment of reverse recapitalization finance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,814,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing', window );">Proceeds from the issuance of common stock in pre-closing financing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">30,640,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment of principal related to finance lease liabilities</a></td>
<td class="num">(1,429,000)<span></span>
</td>
<td class="num">(1,301,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_ProceedsFromFailedSaleLeasebackTransaction', window );">Proceeds from failed sale-leaseback arrangement</a></td>
<td class="nump">686,000<span></span>
</td>
<td class="nump">1,183,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction', window );">Payment of finance liability from failed sale-leaseback arrangements</a></td>
<td class="num">(1,309,000)<span></span>
</td>
<td class="num">(1,069,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payment of deferred financing costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(146,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">187,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Sale of common stock under Open Market Sales Agreement, net of issuance costs</a></td>
<td class="nump">2,392,000<span></span>
</td>
<td class="nump">597,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">344,000<span></span>
</td>
<td class="nump">62,180,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(59,696,000)<span></span>
</td>
<td class="nump">53,411,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of the year</a></td>
<td class="nump">77,605,000<span></span>
</td>
<td class="nump">24,194,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of the year</a></td>
<td class="nump">17,909,000<span></span>
</td>
<td class="nump">77,605,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">192,000<span></span>
</td>
<td class="nump">352,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash financing and investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NoncashOrPartNoncashAcquisitionEquityAssumed', window );">Conversion of convertible preferred stock and non-controlling interests upon Merger</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">122,204,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesReduction', window );">Conversion of convertible promissory note, accrued interest and derivative liability upon Merger</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">42,447,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities', window );">Unrealized gain on marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">41,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts', window );">Reclassification of deferred financing costs to additional paid-in-capital</a></td>
<td class="nump">9,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right-of-use assets obtained in exchange for new financing lease liabilities</a></td>
<td class="nump">1,660,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">6,411,000<span></span>
</td>
<td class="nump">2,779,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NonCashEffectOfModificationOfOperatingLeaseRightOfUseAssetsOperatingLeaseLiabilities', window );">Modification of operating lease right-of-use asset and operating lease liabilities</a></td>
<td class="num">(1,581,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability', window );">Disposal of property and equipment in exchange for reduction in financing lease liability</a></td>
<td class="nump">$ 396,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_AccretionOnMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion on marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_AccretionOnMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash, cash equivalents and restricted cash acquired associated with the reverse capitalization during the period .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Of Property, Plant And Equipment In Exchange For Reduction Of Capital Lease Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_GainLossOnSaleOfEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) on Sale of Equipment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_GainLossOnSaleOfEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NonCashEffectOfModificationOfOperatingLeaseRightOfUseAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Effect of Modification of Operating Lease Right-of-Use Assets Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NonCashEffectOfModificationOfOperatingLeaseRightOfUseAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NoncashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to the increase (decrease) in interest expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NoncashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NoncashOrPartNoncashAcquisitionEquityAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NoncashOrPartNoncashAcquisitionEquityAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash or Part Noncash Transaction, Reclassification of Debt Finance Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on marketable securities in a noncash (or part noncash) transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of reverse recapitalization finance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in a failed sale-leaseback recognized in financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_PaymentsForProceedsFromMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash paid (received) associated with the acquisition or disposal of all investments, including marketable securities and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_PaymentsForProceedsFromMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_ProceedsFromFailedSaleLeasebackTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow received by a seller-lessee in a failed sale-leaseback recognized in financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_ProceedsFromFailedSaleLeasebackTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Issuance of Common Stock, Pre-Closing Financing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_WriteOffOfPropertyAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Write-off of Property and Equipment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_WriteOffOfPropertyAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 15<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/815-15/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of notes retired (or transferred to another entity) in noncash investing or financing transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleAndLeasebackTransactionGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale and leaseback transaction from transfer of asset accounted for as sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479741/842-40-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleAndLeasebackTransactionGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Background<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Background</a></td>
<td class="text">Background<div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Carisma Therapeutics Inc., a Delaware corporation (collectively with its subsidiaries, the Company), biotechnology company focused on applying its industry leading expertise in macrophage engineering to develop transformative therapies to treat serious diseases including liver fibrosis and cancer. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March and December 2024, the Company and its board of directors approved revised operating plans to reduce monthly operating expenses, conserve cash, and refocus its efforts on strategic priorities. As part of these plans, in March 2024 the Company elected to cease further development of its first lead product candidate, CT-0508. In December 2024 as part of the plan, the Company elected to cease further development of its then lead product candidate, CT-0525, following an assessment of the competitive landscape in anti-HER2 treatments and the impact of recently approved therapies on HER2 antigen loss/downregulation, and the effects on the future development strategy of any anti-HER2 product. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of its cost-reduction initiatives in 2024, the Company implemented workforce reductions during 2024, resulting in the termination of 62 full-time employees (representing approximately 58% of the Company's total workforce), across research and development and general and administrative functions. The workforce reduction resulted in $4.1&#160;million of severance related costs, of which $2.0&#160;million and $2.1&#160;million are included within <span style="-sec-ix-hidden:f-325">general and administrative</span> and <span style="-sec-ix-hidden:f-326">research and development</span> expense, respectively, in the accompanying consolidated statement of operations and comprehensive loss. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2024, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.7&#160;million in severance costs were accrued in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accompanying</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consolidated balance sheets. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the 2024 reduction in workforce. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 10, 2024, the Company received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq) notifying the Company that our common stock was not in compliance with Nasdaq Listing Rule 5450(b)(2)(A), or the MVLS Requirement, which requires the Company to maintain a minimum market value of listed securities of $50,000,000. The Company has 180 calendar days, or until April 8, 2025, to regain compliance with the MVLS Requirement. </span></div>On January 6, 2025, the Company received a separate written notice from Nasdaq notifying the Company that, based upon the closing bid price of its common stock for the last 38 consecutive business days, the Company was not in compliance with Nasdaq Listing Rule 5450(a)(1) (the Bid Price Rule), which requires the Company to maintain a minimum bid price of $1.00 per share. The Company has 180 calendar days, or until July 7, 2025, to regain compliance with the Bid Price Rule.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Development-Stage Risks and Liquidity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_DevelopmentStageRisksAndLiquidityAbstract', window );"><strong>Development-Stage Risks and Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_DevelopmentStageRisksAndLiquidityTextBlock', window );">Development-Stage Risks and Liquidity</a></td>
<td class="text">Development-Stage Risks and Liquidity<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred losses and negative cash flows from operations since inception and has an accumulated deficit of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$305.6 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as of December&#160;31, 2024. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales from its product candidates currently in development. As of December 31, 2024, the Company had cash and cash equivalents of $17.9 million. Based on current projections, the Company believes that it does not have sufficient cash and cash equivalents to support its operations for more than one year following the date that these financial statements are issued. As a result of these conditions, substantial doubt exists about the Company&#8217;s ability to continue as a going concern. In addition, changing circumstances could cause the Company to consume capital significantly faster than currently anticipated, and the Company may need to spend more than currently expected because of circumstances beyond its control.  The Company's cash forecast contains estimates and assumptions, and management cannot predict the timing of all cash receipts and expenditures with certainty. The accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments related to </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the recoverability and classification of recorded asset amounts or the amounts and classification of liability that might result from the outcome of this uncertainty. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is currently evaluating different strategies to maximize value and prepare to wind down the Company's business. Potential strategic alternatives to be explored and evaluated may include, among other transactions, the sale, license, monetization or divestiture of one or more of the Company's assets or technologies, a strategic collaboration or partnership with one or more parties or the merger or sale of the Company. There is no assurance regarding when or if this strategic review process will result in any type of transaction.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to those risks associated with any specialty biotechnology company that has substantial expenditures for research and development. There can be no assurance that the Company&#8217;s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_DevelopmentStageRisksAndLiquidityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_DevelopmentStageRisksAndLiquidityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_DevelopmentStageRisksAndLiquidityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development-Stage Risks and Liquidity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_DevelopmentStageRisksAndLiquidityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). Any references in these notes to applicable guidance is meant to refer to GAAP as found in Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) promulgated by the Financial Accounting Standards Board (FASB). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant areas that require management&#8217;s estimates include estimated research and development revenue, stock-based compensation assumptions, the estimated useful lives of property and equipment, and accrued research and development expenses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that the carrying amounts of the Company&#8217;s financial instruments, including cash equivalents and accounts payable, approximate fair value due to the short-term nature of those instruments. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table presents information about the Company&#8217;s assets measured at fair value on a recurring basis:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair value measurement at reporting date using</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents &#8211; money markets accounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents &#8211; money markets accounts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2024 and 2023, there were no transfers between Level 1, Level 2 and Level 3.</span></div><div><span><br/></span></div><div><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue in accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 606). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaboration and licensing agreements with strategic partners, which are within the scope of ASC 606, under which it may exclusively license rights to research, develop, manufacture, and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: (1) non-refundable, upfront license fees (2) reimbursement of certain costs; (3) customer option fees for additional goods or services; (4) development milestone payments, (5) regulatory and commercial milestone payments; and (6) royalties on net sales of licensed products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use its judgment to determine: (a) the number of performance obligations based on the determination under step (i) above; (b) the transaction price under step (iii) above; (c) the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above; and (d) the contract term and pattern of satisfaction of the performance obligations under step (v) above. The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Upfront license fees</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license to the Company's intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, manufacturing, and commercialization capabilities of the customer; the retention of any key rights by the Company; and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promises, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company exercises judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Customer options</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the customer options for material rights or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If an option is not exercised and the research and development target is terminated, the Company will accelerate and recognize all remaining revenue related to the material right performance obligation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Research and development services</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promises under the Company's collaboration agreements may include research and development services to be performed by the Company for or on behalf of the customer. Payments or reimbursements resulting from the Company's research and development efforts are recognized as the services are performed and presented on a gross basis because the Company is the principal for such efforts. Reimbursements from and payments to the customer that are the result of a collaborative relationship with the customer, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Milestone payments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of credit risk</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment information</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (CODM), or decision-making group, in deciding how to allocate resources in assessing performance. The Company has one operating segment. The Company&#8217;s CODM is the chief executive officer. The Company&#8217;s CODM manages the Company&#8217;s operations on a consolidated basis for the purpose of allocating resources.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The accounting policies of its segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance for its segment based on net loss, which is reported on the consolidated statements of operations and comprehensive loss. The measure of segment assets is reported on the balance sheet as total assets. The CODM uses cash forecast models in deciding how to invest into the segment. The CODM analyzes the Company&#8217;s net loss and monitors budget versus actual results to assess the performance of the Company. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The table below summarizes the significant expense categories regularly reviewed by the CODM for the years ended December 31, 2024 and 2023:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,632&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,919&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development, excluding facilities, personnel, depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45,905&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative, excluding facilities and personnel expenses, depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facilities expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personnel expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation, amortization and interest on finance and sale-leaseback lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,894&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other segment items(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,242)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,204)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(60,477)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(86,879)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(a) Other segment items include changes in warrant liability and interest income.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Cash and Cash Equivalents</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly-liquid investments that have maturities of three months or less when acquired to be cash equivalents. As of December&#160;31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2023, cas</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h equivalents consisted of investments in a money market account.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Property and Equipment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets ranging from <span style="-sec-ix-hidden:f-366">two</span> to five years. Leasehold improvements are amortized over the shorter of the life of the lease or the estimated useful life of the assets. Lab equipment that are classified as finance leases are amortized over the lease term.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-lived Assets</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. When events indicate a triggering event occurred, the recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, then an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Considerable management judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could vary significantly from such estimates.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company did not recognize any impairment of long-lived assets during th</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">e years ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December&#160;31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> or 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Financing Costs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes costs that are directly associated with in-process equity financings until such financings are consummated, at which time such costs are recorded against the gross proceeds from the applicable financing. If a financing is abandoned, deferred financing costs are expensed immediately. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether an arrangement is or contains a lease, its classification, and its term at the lease commencement date. Leases with a term greater than one year will be recognized on the balance sheet as right-of-use (ROU) assets, current lease liabilities, and if applicable, long-term lease liabilities. The Company includes renewal options to extend the lease term where it is reasonably certain that it will exercise these options. Lease liabilities and the corresponding ROU assets are recorded based on the present values of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rates, which are the rates that would be incurred to borrow on a collateralized basis, over similar terms, amounts equal to the lease payments in a similar economic environment. Payments for non-lease components or that are variable in nature that do not depend on a rate or index are not included in the lease liability and are typically expensed as incurred. If significant events, changes in circumstances, or other events indicate that the lease term or other inputs have changed, the Company would reassess lease classification, remeasure the lease liability using revised inputs as of the reassessment date, and adjust the ROU assets. Lease expense is recognized on a straight-line basis over the expected lease term for operating classified leases.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to expense as incurred. Up-front and milestone payments made to third parties who perform research and development services on the Company's behalf are expensed as services are rendered.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company measures stock-based awards, including stock options, at their grant-date fair value and records compensation expense over the requisite service period, which is the vesting period of the awards. The Company accounts for forfeitures as they occur.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating the fair value of stock options requires the use of subjective assumptions, including the fair value of the Company's common stock prior to the Merger (as defined in Note 4), and, for stock options, the expected term of the option and expected stock price volatility. The Company uses the Black-Scholes option-pricing model to value its stock option awards. The assumptions used in calculating the fair value of stock options represent management's best estimates and involve inherent uncertainties and the application of management's judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Merger (as defined in Note 4), the fair value of the Company's common stock was estimated by the Company's board of directors, with input by management considering the Company's most recently available third-party valuation of the Company's common stock. The expected term of stock options for employees is estimated using the simplified method, as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The simplified method is the midpoint between the vesting date and the contractual term of the option. The contractual term is used as the expected term for stock options granted to nonemployees. For stock price volatility, the Company uses comparable public companies as a basis for the expected volatility to calculate the fair value of option grants. The risk-free rate is based on the U.S. Treasury yield curve commensurate with the expected term of the option. The expected dividend yield is zero given the Company does not expect to pay dividends for the foreseeable future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Income taxes </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company's assets and liabilities, and the expected benefits of net operating loss and income tax credit carryforwards. The impact of changes in </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tax rates and laws on deferred taxes, if any, applied during the period in which temporary differences are expected to be settled, is reflected in the Company's consolidated financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on weight of the evidence, it is more likely than not that some, or all, of the deferred tax assets will not be realized. As of December 31, 2024 and 2023, the Company has concluded that a full valuation allowance is necessary for all of its net deferred tax assets. The Company had no amounts recorded for uncertain tax positions, interest, or penalties in the accompanying consolidated financial statements. Although there are no unrecognized income tax benefits, when applicable, the Company&#8217;s policy is to report interest and penalties related to unrecognized income tax benefits as a component of income tax expense.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net loss per share</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, potentially dilutive securities are not included in the calculation as their impact is anti-dilutive.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,746,991</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,023,370</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently adopted accounting pronouncements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2023, the FASB issued ASU 2023-07, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (ASU 2023-07), which requires disclosure of incremental segment information on an annual and interim basis. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 on a retrospective basis. The Company incorporated the improved segment disclosures in the summary of significant accounting policies, herein.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently issued but not yet adopted accounting pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2023-09), which expands the disclosures required for income taxes. This ASU is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendment should be applied on a prospective basis while retrospective application is permitted. The Company is currently evaluating the effect of this pronouncement on its disclosures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is intended to provide more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation and amortization) included in certain expense captions presented on the consolidated statement of operations. The guidance in this ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the consolidated financial statements. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its consolidated financial statements and disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger with Sesen Bio<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Merger with Sesen Bio</a></td>
<td class="text">Merger with Sesen Bio<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">On March&#160;7, 2023, the Company (formerly publicly-held Sesen Bio, Inc.) consummated a merger with CTx Operations, Inc. (formerly privately-held CARISMA Therapeutics Inc.) (Legacy Carisma) pursuant to an Agreement and Plan of Merger and Reorganization, as amended (the Merger Agreement), by and among the Company, Legacy Carisma and </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Seahawk Merger Sub, Inc. (Merger Sub), a Delaware corporation and wholly-owned subsidiary of the Company. The Merger Agreement provided for the merger of Merger Sub with and into Legacy Carisma, with Legacy Carisma continuing as a wholly-owned subsidiary of the Company and the surviving corporation of the merger (the Merger). The Merger was accounted for as a reverse recapitalization under GAAP because the primary assets of Sesen Bio were cash, cash equivalents and marketable securities. For financial reporting purposes Legacy Carisma was determined to be the accounting acquirer based upon the terms of the Merger and other factors, including: (i) Legacy Carisma stockholders own approximately 74.2% of the Combined Company, (ii) Legacy Carisma holds the majority (six of seven) of board seats of the Combined Company and (iii) Legacy Carisma management holds all key positions of management. Accordingly, the Merger was treated as the equivalent of Legacy Carisma issuing stock to acquire the net assets of Sesen Bio. As a result of the Merger, the net assets of Sesen Bio were recorded at their acquisition-date fair value in the consolidated financial statements and the reported operating results prior to the Merger are those of Legacy Carisma. Immediately after the Merger, there were 40,254,666 shares of the Company&#8217;s common stock outstanding.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the net assets acquired in the Merger (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 7, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37,873&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,588</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,316</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,499)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total net assets acquired</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80,308</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Transaction costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,264)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total net assets acquired less transaction costs</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72,044&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to March&#160;7, 2023, the Company paid $4.6 million of severance and personnel costs related to Sesen Bio.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsDisclosureTextBlock', window );">Prepaid Expenses and Other Assets</a></td>
<td class="text">Prepaid Expenses and Other Assets<div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets consisted of the following (in thousands):</span></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,715&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">278&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration receivable </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Insurance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,916&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,866&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, net</a></td>
<td class="text">Property and Equipment, net<div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer software</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">508&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">903&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lab equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Office furniture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,272&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,915&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: accumulated depreciation and amortization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,887)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,151)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,385&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,764&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Lab equipment includes failed sale lease-back assets of $3.4&#160;million as of December&#160;31, 2024 and 2023. Lab equipment includes finance lease ROU assets of $3.2&#160;million and $2.9&#160;million, respectively, as of December&#160;31, 2024 and 2023.</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The accumulated amortization balance includes $1.5&#160;million and</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.9&#160;million, respectively, related to failed sale-leaseback assets as of December&#160;31, 2024 and 2023. The accumulated amortization balance includes $2.3&#160;million and $1.7&#160;million, respectively, related to finance lease ROU assets as of December&#160;31, 2024 and 2023.  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense was $3.4&#160;million and $2.8&#160;million for the years ended December&#160;31, 2024 and 2023, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text">Accrued Expenses<div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,845&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,131&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation and related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,879&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,448&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,662&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for its laboratory and office space in Philadelphia, Pennsylvania. The Company&#8217;s operating leases have term end dates ranging from 2025 to 2029. The Company also has obligations under an arrangement for the use of certain laboratory equipment that are classified as finance leases that commenced in 2022 and have end dates ranging from 2025 to 2026. Effective February 2024, the Company renewed an existing operating lease with an end date through 2026. In April 2024, in connection with the revised operating plan, the Company notified the lessor that it would terminate the lease effective August 2024. In July 2024, the Company entered into an amendment extending the </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">termination date of the lease to June 2025 with an option to extend to December 2025. The Company did not incur any penalties or fees in connection with the termination.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2024, the Company modified existing finance leases and failed sale-leaseback arrangements by assigning the rights and obligations of certain underlying assets to an unrelated third party. The modifications resulted in a reduction of its finance lease ROU assets and related lease liability of $0.4&#160;million. In addition, the Company recorded a reduction of its failed sale-leaseback liability and gain on the sale of the corresponding assets of $0.1&#160;million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s operating and finance lease ROU assets and the related lease liabilities are initially measured at the present value of future lease payments over the lease term. The Company is responsible for payment of certain real estate taxes, insurance and other expenses on certain of its leases. These amounts are generally considered to be variable and are not included in the measurement of the ROU assets and lease liability. The Company accounts for non-lease components, such as maintenance, separately from lease components.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company carries laboratory equipment from failed sale-leasebacks, as property and equipment, net on the accompanying consolidated balance sheets. The ongoing lease payments are recorded as reductions to the finance liability and interest expense. As of December&#160;31, 2024, the Company had a $1.4 million financing liability recorded in other current liabilities and other long-term liabilities on the consolidated balance sheets. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The elements of the lease costs were as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,774&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total finance lease cost</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,801&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short term lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,788&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,833&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease term and discount rate information related to leases was as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.5</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information was as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash used in operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,807&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash used in finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash used in finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future maturities of lease liabilities were as follows as of December&#160;31, 2024 (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Operating <br/>Leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Finance <br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fiscal year ending:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,809&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">963&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(253)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Present value of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,556&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">925&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing and Sponsored Research Agreements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under a license agreement with The Trustees of the University of Pennsylvania (Penn), entered into in November 2017 (Penn License Agreement),</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company is required to make annual payments of $25,000. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Penn is eligible to receive up to $10.9 million per product in development upon the achievement of certain clinical, regulatory and commercial milestone events. There are additional milestone payments required to be paid of up to $30.0 million per product in commercial milestones and up to an additional $1.7 million in development and regulatory milestone payments for the first CAR-M product directed to mesothelin. Additionally, the Company is obligated to pay Penn single-digit royalties based on its net sales.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, the Company entered into a manufacturing and supply agreement with Novartis Pharmaceuticals Corporation (Novartis) for the manufacturing of the Company&#8217;s CT-0508 product candidate (Novartis Agreement). The Novartis Agreement had a <span style="-sec-ix-hidden:f-509">five</span> year term. On June 26, 2024, in furtherance of its revised operating plan approved in late March 2024, the Company terminated the Novartis Agreement. Upon termination, the Company incurred a termination fee equal to $4.0&#160;million, which was paid in the third quarter of 2024. A prepaid asset was recorded as the Company separately agreed with Novartis that if Novartis and the Company re-negotiate the agreement for a substitute product on or before December 31, 2024, then the $4.0&#160;million termination fee would be credited in full or in part against any amounts due from the Company to Novartis under such agreement relating to the substitute product. The Company did not re-negotiate the agreement and expensed the $4.0&#160;million prepaid asset in the fourth quarter of 2024 to research and development in the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities for loss contingencies, arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment and/or remediation can be reasonably estimated. As of December&#160;31, 2024, the Company was in negotiations with a vendor to determine the total costs owed for research and development services provided. While the negotiations are ongoing, the Company believes a </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liability is probable. The Company has estimated the amount to be owed to be $1.2&#160;million which is included within accrued expenses on the accompanying consolidated balance sheets. The final amount owed may differ from the estimate as negotiations progress. The Company will continue to evaluate the matter and will adjust the liability as necessary based on any new information or agreements reached with the vendor.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; (Deficit) Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; (Deficit) Equity</a></td>
<td class="text">Stockholders&#8217; (Deficit) Equity<div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;7, 2023, in connection with the closing of the Mer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ger, the following is reflected on the consolidated statements of convertible preferred stock and stockholders&#8217; (deficit) equity for the year ended December 31, 2023: (i) the sale of 3,730,608 shares of common stock in a pre-closing funding at $8.21 per share for total proceeds of $30.6 million, (ii) the issuance of 5,059,338 shares of common stock upon the settlement of the Company&#8217;s $35.0 million convertible promissory note, accrued interest and related derivative liability, (iii) the conversion of convertible preferred stock and exchangeable shares previously presented as noncontrolling interests into 18,872,711 shares of common stock, (iv) the issuance of 10,374,272 shares of common stock to Sesen Bio stockholders as consideration for the Merger.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 17, 2023, the Company filed a universal shelf registration statement on Form S-3, which was declared effective on May 2, 2023 (Registration Statement). Under the Registration Statement, the Company may offer and sell up to $300.0&#160;million of a variety of securities, including debt securities, common stock, preferred stock, depositary shares, subscription rights, warrants and units from time to time in one or more offerings at prices and on terms to be determined at the time of the offering. On May 12, 2023, the Company entered into an Amended and Restated Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (Sale Agreement) with Jefferies LLC, as sales agent, pursuant to which the Company may offer and sell shares of common stock with an aggregate offering price of up to $100.0&#160;million under an &#8220;at-the-market" offering program. During the years ended December 31, 2024 and 2023, the Company sold 1,136,384 and 226,533 shares of common stock, respectively, for gross proceeds of $2.4&#160;million and $0.6&#160;million, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2023, the Company's stockholders approved an amendment to the Company's Restated Certificate of Incorporation to increase the number of authorized shares of the Company's common stock, $0.001 par value, from 100,000,000 shares to 350,000,000 shares and authorized 5,000,000 shares of preferred stock, $0.001 par value.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text">Stock-based Compensation<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2017 Stock Incentive Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted the CARISMA Therapeutics Inc. 2017 Stock Incentive Plan, as amended (the Legacy Carisma Plan), that provided for the grant of incentive stock options to employees, directors, and consultants. The maximum term of options granted under the Legacy Carisma Plan was ten years, and stock options typically vested over a four-year period. The Company&#8217;s stock options vest based on the terms in the awards agreements and generally vest over four years. Upon completion of the Merger, the Company assumed the Legacy Carisma Plan and the outstanding and unexercised options issued thereunder, and ceased granting awards under the Legacy Carisma Plan.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2014 Stock Incentive Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Amended and Restated 2014 Stock Incentive Plan, as amended, provides for the grant of incentive and non-qualified stock options, restricted stock awards and restricted stock units, stock appreciation rights and other stock-based awards to the Company&#8217;s employees, officers, directors, consultants, and advisors, with amounts and terms of grants determined by the Company&#8217;s board of directors at the time of grant. Stock options outstanding under the 2014 Amended and Restated Stock Incentive Plan (the 2014 Plan) generally vest over a four-year period and are exercisable for a period of ten years from the date of grant. As of December&#160;31, 2024, approximately 4.8 million shares of common stock remained available for issuance.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2014 Employee Stock Purchase Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Carisma Therapeutics Inc. 2014 Employee Stock Purchase Plan (the Carisma 2014 ESPP) provides employees with the opportunity to purchase shares of common stock at a 15% discount to the market price through payroll deductions or lump sum cash investments. The purpose of the Carisma 2014 ESPP is to enhance employee interest in the success and progress </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">of the Company by encouraging employee ownership of common stock. The Carisma 2014 ESPP had 0.2 million shares of common stock available for issuance as of December&#160;31, 2024.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>average<br/>exercise<br/>price </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>average<br/>remaining<br/>contractual<br/>term (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate <br/>Intrinsic <br/>Value (in <br/>thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,023,370</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,810)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,805,465</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,078,034)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,746,991</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable as of December 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,414,750</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date per share fair values of options granted during the years ended December 31, 2024 and 2023 were $1.36 and $4.29, respectively. The fair values in the years ended December 31, 2024 and 2023 were estimated using the Black-Scholes option-pricing model based on the following assumptions:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.77% - 4.59%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.92% - 4.76%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86.55% - 112.12%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57.77% - 103.00%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following expense categories in the accompanying consolidated statements of operations:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:71.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.125%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,116&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,242&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,074&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,649&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,316&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the reductions in force, 1,898,297 options were forfeited during the year ended December 31, 2024. The Company recognized stock-based compensation expense of $0.2 million related to the modification of Sesen Bio options assumed in connection with the Merger during the year ended December 31, 2023. Compensation cost for awards not vested as of December&#160;31, 2024 was $7.2 million and will be expensed over a weighted-average period of 2.5 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A reconciliation of income tax benefit at the statutory federal income tax rate and income taxes as reflected in the consolidated financial statements is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.678%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.682%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal tax benefit at statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State and local tax, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State and local tax rate change</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Permanent differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total provision</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are determined based on the differences between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect for years in which differences are expected to reverse.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company's deferred tax assets for federal income taxes consisted of the following (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72,689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized research and development costs, net of amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,608&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Start-up costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,051&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortizable assets and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">155,132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134,749&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(153,855)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(133,580)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets, net of valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,277&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,169&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(848)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(645)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(429)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(524)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,277)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,169)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred tax assets and liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company has net operating loss carryforwards (NOLs) for federal income tax purposes of $374.7&#160;million, which are available to offset future federal taxable income. The pre-2018 federal NOLs of $120.0&#160;million will begin to expire in 2031, if not utilized. The post-2017 federal NOLs of $254.7&#160;million carry forward indefinitely. The Company also has NOLs for state and local income tax purposes of $280.3&#160;million and $65.1&#160;million, respectively that are available to offset future taxable income. The state NOLs will begin to expire in 2031 while the city of Philadelphia NOLs begin to expire in 2042. As of December&#160;31, 2024, the Company also had federal and state research and development tax credit carryforwards of $12.6&#160;million and $0.8&#160;million that will begin to expire in 2029 and 2032, respectively, unless previously utilized.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the need for a valuation allowance, management must determine that there will be sufficient taxable income to allow for the realization of deferred tax assets. Based upon the historical and anticipated future losses, management has determined that the deferred tax assets do not meet the more-likely-than-not threshold for realizability. Accordingly, a full valuation allowance has been recorded against the Company's net deferred tax assets as of December&#160;31, 2024. The valuation allowance increased by $20.3&#160;million and $84.5&#160;million during the years ended December 31, 2024 and 2023, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The NOLs and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOLs and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50 percent, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The Company has not done an analysis to determine whether or not ownership changes have occurred since inception. Certain state NOLs may also be limited, including Pennsylvania, which limits net operating loss utilization as a percentage of apportioned taxable income.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will recognize interest and penalties related to uncertain tax positions as a component of income tax expense/(benefit). As of December&#160;31, 2024, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company's financial statements. Tax years from 2021 and after remain subject to examination by all of the taxing jurisdictions. The NOLs and research credit carryforwards remain subject to review until utilized.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related-Party Transactions</a></td>
<td class="text">Related-Party TransactionsThe Company has a collaboration and license agreement with Moderna, a significant shareholder (Note 13).<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Moderna Collaboration and License Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Moderna Collaboration and License Agreement</a></td>
<td class="text">Moderna Collaboration and License Agreement<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Company entered into the Moderna License Agreement, which provides for a broad strategic collaboration to discover, develop and commercialize </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> engineered CAR-M therapeutics in oncology. Moderna has the right to designate up to twelve research targets as development targets under this collaboration. While the collaboration was initially limited to oncology, in September 2024, the companies agreed to expand the collaboration to discover, develop and commercialize</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> engineered CAR-M therapeutics in specific autoimmune diseases. As a result, Moderna nominated two autoimmune research targets. As of February 2025, in connection with Moderna's nomination of all 12 oncology research targets (Note 14), the Company will not be conducting any additional research activities under the collaboration agreement and will not be receiving any further payments from Moderna for research and development services under the collaboration agreement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to the nomination of a research target, Moderna may designate the research target as a development target. Upon Moderna&#8217;s designation of a development target (and payment of a related development target designation milestone) for commencement of pre-clinical development of a product candidate, the Company will grant Moderna an exclusive worldwide, sublicensable royalty bearing license to develop, manufacture and commercialize the product candidate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Moderna License Agreement, Moderna made an upfront non-refundable payment of $45.0 million to the Company. Assuming Moderna develops and commercializes 12 products, each directed to a different development target, the Company is eligible to receive up to between $247.0 million and $253.0 million per product in development target designation, development, regulatory and commercial milestone payments. Moderna also reimbursed the Company for all costs incurred by the Company in connection with its research and development activities under the Moderna License Agreement plus a reasonable margin for the respective services performed (with a minimum commitment to reimburse $10.0 million in research and development costs over the first three years from execution of the Moderna License Agreement). The Company is also eligible to receive tiered mid-to-high single digit royalties of net sales of any products that are commercialized under the agreement, which may be, subject to reductions. In addition, Moderna has agreed to cover the cost the Company incurs for certain milestone payments and royalties that the Company owes as a licensor under one of its intellectual property in-license agreements with Penn, which is sublicensed to Moderna under the Moderna License Agreement. Moderna may deduct these royalties in part from any royalties owed to the Company. The </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moderna License Agreement terminates on a product-by-product basis upon the latest of expiration of the applicable product patents, expiration of regulatory exclusivity and the tenth anniversary of first commercial sale, unless terminated earlier by the Company or Moderna.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At commencement, the Company identified several potential performance obligations within the Moderna License Agreement, including research and development services on research targets, option rights held by Moderna, a non-exclusive royalty-free license to use the Company&#8217;s intellectual property to conduct research and development activities and participation on the joint steering committee (JSC). The Company determined that there were 2 performance obligations comprised of (i) research and development services and (ii) option rights.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the research and development services, the stand-alone selling price was determined considering the expected passthrough costs and cost of the research and development services and a reasonable margin for the respective services. The material rights from the option rights were valued based on the estimated discount at which the option is priced and the Company&#8217;s estimated probability of the options&#8217; exercise as of the time of the agreement. The transaction price allocated to research and development services is recognized as collaboration revenues as the research and development services are provided to satisfy the underlying obligation related to the research and development target. The transfer of control occurs over this period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price of $45.0&#160;million allocated to the options rights, which are considered material rights, will be recognized in the period that Moderna exercises or determines not to exercise its option right to license and commercialize the designated development target.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2024, the Company received notice from Moderna that Moderna had designated the first development candidate, an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CAR-macrophage targeting GPC3 that is designed to treat solid tumors, including hepatocellular carcinoma. Pursuant to the terms of the Moderna License Agreement, the designation triggered a $2.0&#160;million milestone payment from Moderna to the Company. As a result, the Company recognized collaboration revenue of $2.0&#160;million. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company reduced its $45.0&#160;million deferred revenue liability associated with the option rights by recognizing $3.8&#160;million in collaboration revenue, which represents a proportional reduction based on the 12 potential early-stage research targets. As of December 31, 2024, the Company recorded a collaboration receivable of $2.9&#160;million related to the reimbursement of costs incurred in connection with the Company's research and development activities. The Company received the $2.9&#160;million in January 2025.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company included the $45.0 million up-front and nonrefundable payment and $73.9 million of variable consideration for expected research and development services to be performed during the five-year contract term, inclusive of passthrough costs, in the transaction price as of the outset of the arrangement. During the years ended December 31, 2024 and 2023, the Company recognized $19.6 million and $14.9 million, respectively, of collaboration revenues. Collaboration revenues for the year ended December&#160;31, 2024 include $3.8&#160;million of deferred option rights revenue recognition and $2.0&#160;million of milestones.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized $38.7&#160;million and $3.8&#160;million, respectively, of research and development services and option right collaboration revenues since inception of the Moderna License Agreement through December&#160;31, 2024. The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied as of December&#160;31, 2024 (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Transaction <br/>price unsatisfied</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance obligations:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,301&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total performance obligations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76,551&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due to the Company for satisfying the revenue recognition criteria or that are contractually due based upon the terms of the collaboration agreements are recorded as accounts receivable in the Company&#8217;s consolidated balance sheets. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities consist of amounts received prior to satisfying the revenue recognition criteria, which are recorded as deferred revenue in the Company&#8217;s consolidated balance sheets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in deferred revenue (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at the beginning of the period </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,413&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47,459&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferral of revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recognition of unearned revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(17,632)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14,919)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at the end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,979&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,413&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current portion of deferred revenue represents advanced payments received from Moderna for costs expected to be incurred by the Company within the next twelve months. The noncurrent portion of deferred revenue represents the $41.3 million upfront, non-refundable and non-creditable payment allocated to customer option right which is not expected to be recognized within the next 12 months.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated subsequent events from the balance sheet date through March&#160;31, 2025, the issuance date of these consolidated financial statements, and has identified the following matter requiring disclosure. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Moderna Collaboration and License Agreement</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2025, Moderna nominated ten additional oncology research targets, four of which replaced two oncology research targets and two autoimmune research targets, which Moderna concurrently ceased developing. As of February 2025, Moderna has nominated all 12 oncology research targets under the collaboration for which the Company has the potential to receive future milestones and royalty payments. The Company will not conduct any additional research activities under the collaboration agreement and the Company will not be receiving any further research funding from Moderna under the collaboration agreement. Moderna also agreed to terminate the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> oncology field exclusivity, which would allow the Company to pursue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> in vivo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">CAR-M programs outside of the  12 nominated oncology targets and product polypeptides. The final research and development payment of $2.9&#160;million was received in January 2025 which will be recognized as collaboration revenue for research and development services in the first quarter of 2025. The Company does not expect to recognize any additional unsatisfied research and development performance obligations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">2025 Cash Preservation Plan</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of a further revised plan approved by the Company's board of directors, on Marc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">h 25</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, 2025, to preserve the Company's existing cash resou</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">rces</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">following its reduction in workforce (the "cash preservation plan"), the Company reduced its operations to those necessary to identify and explore a range of strategic alternatives to maximize value and prepare to wind down its business. The cash preservation plan prioritizes payments necessary and appropriate for those reduced operations and those that will help to evaluate our strategic alternatives. </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Potential strategic alternatives to be explored and evaluated may include, among other transactions, the sale, license, monetization or divestiture of one or more of the Company's assets or technologies, a strategic collaboration or partnership with one or more parties or the merger or sale of the Company. Any future resumption of research and development activities would depend on completing a strategic transaction that would support the Company's prior operating plans or otherwise obtaining significant additional funding.</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of the cash preservation plan, the board of directors determined to terminate all of its employees not deemed necessary to pursue strategic alternatives and execute an orderly wind down of our operations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Affected employees were informed of the reduction in workforce on March 25, 2025. The reduction in workforce was effective on March 31, 2025. The reduction in workforce includes 37 of the Company's full-time employees representing approximately 84% of our total workforce, including certain employees engaged in research and development, manufacturing and corporate activities. The Company expects to incur approximately $3.8&#160;million in connection with the reduction in workforce, which primarily represents one-time employee termination benefits directly associated with the workforce reduction. The Company also expects to pay the majority of related reduction in workforce amounts by the end of 2025. The Company may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">with, the reduction in workforce, including (but not limited to) impairment charges relating to the balances of property and equipment, net, prepaid research and development costs and right of use assets &#8211; operating lease.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (60,477)<span></span>
</td>
<td class="num">$ (86,879)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established processes for assessing, identifying and managing cybersecurity risks, which are built into our overall risk management program and are designed to help protect our information assets and operations from internal and external cyber threats, protect employee and patient information from unauthorized access or attack, as well as secure our networks and systems. Such processes include physical, procedural and technical safeguards. We engage certain third parties to enhance and assist with our cybersecurity oversight, including a 24/7 Security Operation Center, or SOC, that monitors network devices and computer systems in real time. We include confidentiality and data protection provisions in certain contracts with third-party service providers to help protect us and our patients from any related vulnerabilities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe that there are currently any known risks from cybersecurity threats that have or are reasonably likely to materially affect us or our business strategy, results of operations or financial condition. However, despite our efforts, we cannot eliminate all risks from cybersecurity threats, or provide assurances that we have not experienced undetected cybersecurity incidents. For more information on the most pertinent risks we may experience from cybersecurity threats, please refer to Part I, Item 1A, &#8220;Risk Factors&#8221; &#8211; &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our internal computer systems, or those of our collaborators, vendors, suppliers, contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs</span>.&#8221;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established processes for assessing, identifying and managing cybersecurity risks, which are built into our overall risk management program and are designed to help protect our information assets and operations from internal and external cyber threats, protect employee and patient information from unauthorized access or attack, as well as secure our networks and systems. Such processes include physical, procedural and technical safeguards. We engage certain third parties to enhance and assist with our cybersecurity oversight, including a 24/7 Security Operation Center, or SOC, that monitors network devices and computer systems in real time. We include confidentiality and data protection provisions in certain contracts with third-party service providers to help protect us and our patients from any related vulnerabilities.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text">The audit committee of our board of directors provides oversight over cybersecurity risk and updates the full board of directors periodically regarding such oversight. The audit committee reviews and discusses with management the Company&#8217;s major risk exposures, including cybersecurity matters, and is notified between such updates regarding significant new cybersecurity threats or incidents, if any.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Chief Executive Officer, or CEO, leads the operational oversight of company-wide cybersecurity strategy, policy, standards and processes and works across relevant departments to assess and help prepare us and our employees to address cybersecurity risks. The consultant that operates our SOC updates the CEO regarding the detection of cybersecurity risk exposure and provides advice on the prevention, mitigation and remediation of such risks.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span>The CEO keeps the senior executive leadership team apprised, including our Vice President of Finance, on assessments of risk exposure to ensure that the highest levels of management are kept abreast of potential risks we are facing.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The audit committee of our board of directors provides oversight over cybersecurity risk and updates the full board of directors periodically regarding such oversight. The audit committee reviews and discusses with management the Company&#8217;s major risk exposures, including cybersecurity matters, and is notified between such updates regarding significant new cybersecurity threats or incidents, if any. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Chief Executive Officer, or CEO, leads the operational oversight of company-wide cybersecurity strategy, policy, standards and processes and works across relevant departments to assess and help prepare us and our employees to address cybersecurity risks. The consultant that operates our SOC updates the CEO regarding the detection of cybersecurity risk exposure and provides advice on the prevention, mitigation and remediation of such risks.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span>The CEO keeps the senior executive leadership team apprised, including our Vice President of Finance, on assessments of risk exposure to ensure that the highest levels of management are kept abreast of potential risks we are facing. The CEO has significant prior business experience in compliance and risk management and coordinates directly with the third party who operates our SOC on issues involving particular cybersecurity expertise.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The audit committee of our board of directors provides oversight over cybersecurity risk and updates the full board of directors periodically regarding such oversight. The audit committee reviews and discusses with management the Company&#8217;s major risk exposures, including cybersecurity matters, and is notified between such updates regarding significant new cybersecurity threats or incidents, if any. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Chief Executive Officer, or CEO, leads the operational oversight of company-wide cybersecurity strategy, policy, standards and processes and works across relevant departments to assess and help prepare us and our employees to address cybersecurity risks. The consultant that operates our SOC updates the CEO regarding the detection of cybersecurity risk exposure and provides advice on the prevention, mitigation and remediation of such risks.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CEO keeps the senior executive leadership team apprised, including our Vice President of Finance, on assessments of risk exposure to ensure that the highest levels of management are kept abreast of potential risks we are facing. The CEO has significant prior business experience in compliance and risk management and coordinates directly with the third party who operates our SOC on issues involving particular cybersecurity expertise. </span></div>In an effort to help deter and detect cyber threats, we regularly provide all employees, including part-time and temporary employees, with data protection cybersecurity and incident prevention training throughout the year, which covers timely and relevant topics, including social engineering, phishing, password protection, confidential data protection, asset use and mobile security, and educates employees on the importance of reporting all incidents immediately. We also use technology-based tools to mitigate cybersecurity risks and to bolster our employee-based cybersecurity programs.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Chief Executive Officer, or CEO, leads the operational oversight of company-wide cybersecurity strategy, policy, standards and processes and works across relevant departments to assess and help prepare us and our employees to address cybersecurity risks. The consultant that operates our SOC updates the CEO regarding the detection of cybersecurity risk exposure and provides advice on the prevention, mitigation and remediation of such risks.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span>The CEO keeps the senior executive leadership team apprised, including our Vice President of Finance, on assessments of risk exposure to ensure that the highest levels of management are kept abreast of potential risks we are facing. The CEO has significant prior business experience in compliance and risk management and coordinates directly with the third party who operates our SOC on issues involving particular cybersecurity expertise.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text">The CEO has significant prior business experience in compliance and risk management and coordinates directly with the third party who operates our SOC on issues involving particular cybersecurity expertise.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The audit committee of our board of directors provides oversight over cybersecurity risk and updates the full board of directors periodically regarding such oversight. The audit committee reviews and discusses with management the Company&#8217;s major risk exposures, including cybersecurity matters, and is notified between such updates regarding significant new cybersecurity threats or incidents, if any. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Chief Executive Officer, or CEO, leads the operational oversight of company-wide cybersecurity strategy, policy, standards and processes and works across relevant departments to assess and help prepare us and our employees to address cybersecurity risks. The consultant that operates our SOC updates the CEO regarding the detection of cybersecurity risk exposure and provides advice on the prevention, mitigation and remediation of such risks.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CEO keeps the senior executive leadership team apprised, including our Vice President of Finance, on assessments of risk exposure to ensure that the highest levels of management are kept abreast of potential risks we are facing. The CEO has significant prior business experience in compliance and risk management and coordinates directly with the third party who operates our SOC on issues involving particular cybersecurity expertise. </span></div>In an effort to help deter and detect cyber threats, we regularly provide all employees, including part-time and temporary employees, with data protection cybersecurity and incident prevention training throughout the year, which covers timely and relevant topics, including social engineering, phishing, password protection, confidential data protection, asset use and mobile security, and educates employees on the importance of reporting all incidents immediately. We also use technology-based tools to mitigate cybersecurity risks and to bolster our employee-based cybersecurity programs.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). Any references in these notes to applicable guidance is meant to refer to GAAP as found in Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) promulgated by the Financial Accounting Standards Board (FASB). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant areas that require management&#8217;s estimates include estimated research and development revenue, stock-based compensation assumptions, the estimated useful lives of property and equipment, and accrued research and development expenses.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div>Management believes that the carrying amounts of the Company&#8217;s financial instruments, including cash equivalents and accounts payable, approximate fair value due to the short-term nature of those instruments.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table presents information about the Company&#8217;s assets measured at fair value on a recurring basis:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair value measurement at reporting date using</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents &#8211; money markets accounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents &#8211; money markets accounts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2024 and 2023, there were no transfers between Level 1, Level 2 and Level 3.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue in accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 606). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaboration and licensing agreements with strategic partners, which are within the scope of ASC 606, under which it may exclusively license rights to research, develop, manufacture, and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: (1) non-refundable, upfront license fees (2) reimbursement of certain costs; (3) customer option fees for additional goods or services; (4) development milestone payments, (5) regulatory and commercial milestone payments; and (6) royalties on net sales of licensed products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use its judgment to determine: (a) the number of performance obligations based on the determination under step (i) above; (b) the transaction price under step (iii) above; (c) the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above; and (d) the contract term and pattern of satisfaction of the performance obligations under step (v) above. The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Upfront license fees</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license to the Company's intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, manufacturing, and commercialization capabilities of the customer; the retention of any key rights by the Company; and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promises, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company exercises judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Customer options</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the customer options for material rights or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If an option is not exercised and the research and development target is terminated, the Company will accelerate and recognize all remaining revenue related to the material right performance obligation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Research and development services</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promises under the Company's collaboration agreements may include research and development services to be performed by the Company for or on behalf of the customer. Payments or reimbursements resulting from the Company's research and development efforts are recognized as the services are performed and presented on a gross basis because the Company is the principal for such efforts. Reimbursements from and payments to the customer that are the result of a collaborative relationship with the customer, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Milestone payments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of credit risk</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of credit risk</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment information</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment information</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (CODM), or decision-making group, in deciding how to allocate resources in assessing performance. The Company has one operating segment. The Company&#8217;s CODM is the chief executive officer. The Company&#8217;s CODM manages the Company&#8217;s operations on a consolidated basis for the purpose of allocating resources.</span></div>The accounting policies of its segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance for its segment based on net loss, which is reported on the consolidated statements of operations and comprehensive loss. The measure of segment assets is reported on the balance sheet as total assets. The CODM uses cash forecast models in deciding how to invest into the segment. The CODM analyzes the Company&#8217;s net loss and monitors budget versus actual results to assess the performance of the Company.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Cash and Cash Equivalents</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly-liquid investments that have maturities of three months or less when acquired to be cash equivalents. As of December&#160;31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2023, cas</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h equivalents consisted of investments in a money market account.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Property and Equipment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets ranging from <span style="-sec-ix-hidden:f-366">two</span> to five years. Leasehold improvements are amortized over the shorter of the life of the lease or the estimated useful life of the assets. Lab equipment that are classified as finance leases are amortized over the lease term.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long-lived Assets</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-lived Assets</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. When events indicate a triggering event occurred, the recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, then an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Considerable management judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could vary significantly from such estimates.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company did not recognize any impairment of long-lived assets during th</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">e years ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December&#160;31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> or 2023.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_DeferredFinancingCostsPolicyPolicyTextBlock', window );">Deferred Financing Costs</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Financing Costs</span></div>The Company capitalizes costs that are directly associated with in-process equity financings until such financings are consummated, at which time such costs are recorded against the gross proceeds from the applicable financing. If a financing is abandoned, deferred financing costs are expensed immediately.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether an arrangement is or contains a lease, its classification, and its term at the lease commencement date. Leases with a term greater than one year will be recognized on the balance sheet as right-of-use (ROU) assets, current lease liabilities, and if applicable, long-term lease liabilities. The Company includes renewal options to extend the lease term where it is reasonably certain that it will exercise these options. Lease liabilities and the corresponding ROU assets are recorded based on the present values of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rates, which are the rates that would be incurred to borrow on a collateralized basis, over similar terms, amounts equal to the lease payments in a similar economic environment. Payments for non-lease components or that are variable in nature that do not depend on a rate or index are not included in the lease liability and are typically expensed as incurred. If significant events, changes in circumstances, or other events indicate that the lease term or other inputs have changed, the Company would reassess lease classification, remeasure the lease liability using revised inputs as of the reassessment date, and adjust the ROU assets. Lease expense is recognized on a straight-line basis over the expected lease term for operating classified leases.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to expense as incurred. Up-front and milestone payments made to third parties who perform research and development services on the Company's behalf are expensed as services are rendered.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company measures stock-based awards, including stock options, at their grant-date fair value and records compensation expense over the requisite service period, which is the vesting period of the awards. The Company accounts for forfeitures as they occur.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating the fair value of stock options requires the use of subjective assumptions, including the fair value of the Company's common stock prior to the Merger (as defined in Note 4), and, for stock options, the expected term of the option and expected stock price volatility. The Company uses the Black-Scholes option-pricing model to value its stock option awards. The assumptions used in calculating the fair value of stock options represent management's best estimates and involve inherent uncertainties and the application of management's judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Merger (as defined in Note 4), the fair value of the Company's common stock was estimated by the Company's board of directors, with input by management considering the Company's most recently available third-party valuation of the Company's common stock. The expected term of stock options for employees is estimated using the simplified method, as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The simplified method is the midpoint between the vesting date and the contractual term of the option. The contractual term is used as the expected term for stock options granted to nonemployees. For stock price volatility, the Company uses comparable public companies as a basis for the expected volatility to calculate the fair value of option grants. The risk-free rate is based on the U.S. Treasury yield curve commensurate with the expected term of the option. The expected dividend yield is zero given the Company does not expect to pay dividends for the foreseeable future.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Income taxes </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company's assets and liabilities, and the expected benefits of net operating loss and income tax credit carryforwards. The impact of changes in </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tax rates and laws on deferred taxes, if any, applied during the period in which temporary differences are expected to be settled, is reflected in the Company's consolidated financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on weight of the evidence, it is more likely than not that some, or all, of the deferred tax assets will not be realized. As of December 31, 2024 and 2023, the Company has concluded that a full valuation allowance is necessary for all of its net deferred tax assets. The Company had no amounts recorded for uncertain tax positions, interest, or penalties in the accompanying consolidated financial statements. Although there are no unrecognized income tax benefits, when applicable, the Company&#8217;s policy is to report interest and penalties related to unrecognized income tax benefits as a component of income tax expense.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net loss per share</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net loss per share</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, potentially dilutive securities are not included in the calculation as their impact is anti-dilutive.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,746,991</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,023,370</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently adopted accounting pronouncements and Recently issued but not yet adopted accounting pronouncements</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently adopted accounting pronouncements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2023, the FASB issued ASU 2023-07, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (ASU 2023-07), which requires disclosure of incremental segment information on an annual and interim basis. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 on a retrospective basis. The Company incorporated the improved segment disclosures in the summary of significant accounting policies, herein.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently issued but not yet adopted accounting pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2023-09), which expands the disclosures required for income taxes. This ASU is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendment should be applied on a prospective basis while retrospective application is permitted. The Company is currently evaluating the effect of this pronouncement on its disclosures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is intended to provide more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation and amortization) included in certain expense captions presented on the consolidated statement of operations. The guidance in this ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the consolidated financial statements. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its consolidated financial statements and disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_DeferredFinancingCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Financing Costs, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_DeferredFinancingCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value Hierarchy of Assets Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table presents information about the Company&#8217;s assets measured at fair value on a recurring basis:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair value measurement at reporting date using</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents &#8211; money markets accounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents &#8211; money markets accounts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Significant Expense Categories by Segment</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The table below summarizes the significant expense categories regularly reviewed by the CODM for the years ended December 31, 2024 and 2023:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,632&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,919&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development, excluding facilities, personnel, depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45,905&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative, excluding facilities and personnel expenses, depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facilities expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personnel expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation, amortization and interest on finance and sale-leaseback lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,894&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other segment items(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,242)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,204)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(60,477)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(86,879)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(a) Other segment items include changes in warrant liability and interest income.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Dilutive Securities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,746,991</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,023,370</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger with Sesen Bio (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Net Assets Acquired in the Merger</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the net assets acquired in the Merger (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 7, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37,873&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,588</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,316</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,499)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total net assets acquired</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80,308</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Transaction costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,264)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total net assets acquired less transaction costs</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72,044&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Assets</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets consisted of the following (in thousands):</span></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,715&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">278&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration receivable </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Insurance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,916&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,866&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer software</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">508&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">903&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lab equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Office furniture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,272&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,915&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: accumulated depreciation and amortization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,887)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,151)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,385&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,764&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Lab equipment includes failed sale lease-back assets of $3.4&#160;million as of December&#160;31, 2024 and 2023. Lab equipment includes finance lease ROU assets of $3.2&#160;million and $2.9&#160;million, respectively, as of December&#160;31, 2024 and 2023.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The accumulated amortization balance includes $1.5&#160;million and</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span>$0.9&#160;million, respectively, related to failed sale-leaseback assets as of December&#160;31, 2024 and 2023. The accumulated amortization balance includes $2.3&#160;million and $1.7&#160;million, respectively, related to finance lease ROU assets as of December&#160;31, 2024 and 2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,845&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,131&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation and related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,879&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,448&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,662&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Costs</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The elements of the lease costs were as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,774&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total finance lease cost</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,801&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short term lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,788&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,833&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock', window );">Schedule of Lease Term and Discount Rate Information</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease term and discount rate information related to leases was as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.5</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock', window );">Schedule of Supplemental Cash Flow Information</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information was as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash used in operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,807&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash used in finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash used in finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock', window );">Schedule of Future Maturities of Lease Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future maturities of lease liabilities were as follows as of December&#160;31, 2024 (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Operating <br/>Leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Finance <br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fiscal year ending:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,809&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">963&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(253)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Present value of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,556&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">925&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of ease term and discount rate information relating to operating and finance leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability and finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of supplemental cash flow information relating to operating and finance leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>average<br/>exercise<br/>price </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>average<br/>remaining<br/>contractual<br/>term (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate <br/>Intrinsic <br/>Value (in <br/>thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,023,370</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,810)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,805,465</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,078,034)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,746,991</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable as of December 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,414,750</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Estimated Using The Black-Scholes Option-Pricing Model</a></td>
<td class="text">The fair values in the years ended December 31, 2024 and 2023 were estimated using the Black-Scholes option-pricing model based on the following assumptions:<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.77% - 4.59%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.92% - 4.76%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86.55% - 112.12%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57.77% - 103.00%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following expense categories in the accompanying consolidated statements of operations:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:71.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.125%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,116&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,242&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,074&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,649&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,316&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A reconciliation of income tax benefit at the statutory federal income tax rate and income taxes as reflected in the consolidated financial statements is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.678%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.682%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal tax benefit at statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State and local tax, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State and local tax rate change</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Permanent differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total provision</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets for Federal Income Taxes</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company's deferred tax assets for federal income taxes consisted of the following (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72,689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized research and development costs, net of amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,608&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Start-up costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,051&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortizable assets and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">155,132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134,749&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(153,855)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(133,580)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets, net of valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,277&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,169&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(848)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(645)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(429)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(524)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,277)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,169)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred tax assets and liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Moderna Collaboration and License Agreement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock', window );">Schedule of Estimated Revenue Expected to be Recognized in The Future Related to Performance Obligations</a></td>
<td class="text">The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied as of December&#160;31, 2024 (in thousands):<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Transaction <br/>price unsatisfied</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance obligations:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,301&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total performance obligations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76,551&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_ScheduleOfChangesInDeferredRevenueTableTextBlock', window );">Schedule of Changes in Deferred Revenue</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in deferred revenue (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at the beginning of the period </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,413&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47,459&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferral of revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recognition of unearned revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(17,632)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14,919)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at the end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,979&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,413&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_ScheduleOfChangesInDeferredRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in deferred revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_ScheduleOfChangesInDeferredRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of expected timing for satisfying remaining performance obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Background (Details) - Employee Severance<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>employee</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSegmentAllocationLineItems', window );"><strong>Background</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Reduction in workforce, number of employees | employee</a></td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Reduction in workforce (as a percent)</a></td>
<td class="nump">58.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 4.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve</a></td>
<td class="nump">2.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSegmentAllocationLineItems', window );"><strong>Background</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 2.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">General and administrative<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSegmentAllocationLineItems', window );"><strong>Background</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 2.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Research and development<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSegmentAllocationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSegmentAllocationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes restructuring charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Development-Stage Risks and Liquidity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_DevelopmentStageRisksAndLiquidityAbstract', window );"><strong>Development-Stage Risks and Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 305,579<span></span>
</td>
<td class="nump">$ 245,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and marketable securities</a></td>
<td class="nump">$ 17,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_DevelopmentStageRisksAndLiquidityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_DevelopmentStageRisksAndLiquidityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Fair Value Hierarchy of Assets Measured on Recurring Basis (Details) - Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents &#8211; money markets accounts</a></td>
<td class="nump">$ 14,887<span></span>
</td>
<td class="nump">$ 62,999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents &#8211; money markets accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents &#8211; money markets accounts</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful lives (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful lives (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Significant Expense Categories by Segment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenues</a></td>
<td class="nump">$ 19,632<span></span>
</td>
<td class="nump">$ 14,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationAdditionalInformationAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(60,477)<span></span>
</td>
<td class="num">(86,879)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=carm_ReportingSegmentMember', window );">Reporting Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenues</a></td>
<td class="nump">19,632<span></span>
</td>
<td class="nump">14,919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationAdditionalInformationAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses', window );">Research and development, excluding facilities, personnel, depreciation and amortization expenses</a></td>
<td class="nump">33,147<span></span>
</td>
<td class="nump">45,905<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses', window );">General and administrative, excluding facilities and personnel expenses, depreciation and amortization expenses</a></td>
<td class="nump">14,829<span></span>
</td>
<td class="nump">19,118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_FacilitiesExpense', window );">Facilities expense</a></td>
<td class="nump">5,917<span></span>
</td>
<td class="nump">7,671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Personnel expense</a></td>
<td class="nump">24,564<span></span>
</td>
<td class="nump">27,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities', window );">Depreciation, amortization and interest on finance and sale-leaseback lease liabilities</a></td>
<td class="nump">3,894<span></span>
</td>
<td class="nump">3,984<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment items(a)</a></td>
<td class="num">(2,242)<span></span>
</td>
<td class="num">(2,204)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (60,477)<span></span>
</td>
<td class="num">$ (86,879)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciation, Amortization And Interest On Finance And Sale-Leaseback Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_FacilitiesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Facilities Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_FacilitiesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General And Administrative, Excluding Facilities And Personnel Expenses, Depreciation And Amortization Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development, Excluding Facilities, Personnel, Depreciation and Amortization Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479428/808-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationAdditionalInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationAdditionalInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=carm_ReportingSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=carm_ReportingSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">7,746,991<span></span>
</td>
<td class="nump">6,023,370<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger with Sesen Bio - Schedule of Net Assets Acquired in the Merger (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>seat </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 07, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Merger with Sesen Bio</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NumberOfBoardMembers', window );">Number of board seats | seat</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Entity common stock, shares outstanding immediately after merger (in shares) | shares</a></td>
<td class="nump">40,609,915<span></span>
</td>
<td class="nump">41,750,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,588<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,499)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total net assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Less: Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,264)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total net assets acquired less transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,044<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=carm_CarismaTherapeuticsInc.Member', window );">Carisma Therapeutics Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Merger with Sesen Bio</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NumberOfBoardMembers', window );">Number of board seats | seat</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance and personnel costs paid</a></td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=carm_CarismaTherapeuticsIncLegacyStockholdersMember', window );">CARISMA Therapeutics Inc, Legacy, Stockholders | Carisma Therapeutics Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Merger with Sesen Bio</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business acquisition percentage of voting interests acquired (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Entity common stock, shares outstanding immediately after merger (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,254,666<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of restricted cash from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NumberOfBoardMembers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Board Members</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NumberOfBoardMembers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=carm_CarismaTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=carm_CarismaTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=carm_CarismaTherapeuticsIncLegacyStockholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=carm_CarismaTherapeuticsIncLegacyStockholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_PrepaidResearchAndDevelopmentCurrent', window );">Research and development</a></td>
<td class="nump">$ 1,715<span></span>
</td>
<td class="nump">$ 278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_ReceivableDueFromCollaborativeArrangementCurrent', window );">Collaboration receivable</a></td>
<td class="nump">2,864<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Insurance</a></td>
<td class="nump">340<span></span>
</td>
<td class="nump">402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Deposits</a></td>
<td class="nump">925<span></span>
</td>
<td class="nump">891<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">1,295<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expense and other assets</a></td>
<td class="nump">$ 5,916<span></span>
</td>
<td class="nump">$ 2,866<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_PrepaidResearchAndDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Research and Development, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_PrepaidResearchAndDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_ReceivableDueFromCollaborativeArrangementCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receivable Due From Collaborative Arrangement, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_ReceivableDueFromCollaborativeArrangementCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, net - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 12,272<span></span>
</td>
<td class="nump">$ 12,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(7,887)<span></span>
</td>
<td class="num">(6,151)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">4,385<span></span>
</td>
<td class="nump">6,764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleLeasebackTransactionAccumulatedDepreciation', window );">Sale leaseback transaction, accumulated depreciation</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization', window );">Finance lease, accumulated amortization</a></td>
<td class="nump">2,300<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Computer software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant and equipment, gross</a></td>
<td class="nump">508<span></span>
</td>
<td class="nump">903<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant and equipment, gross</a></td>
<td class="nump">11,157<span></span>
</td>
<td class="nump">11,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleLeasebackTransactionNetBookValue', window );">Sale lease-back asset</a></td>
<td class="nump">3,400<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization', window );">Finance lease, ROU assets</a></td>
<td class="nump">3,200<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Office furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant and equipment, gross</a></td>
<td class="nump">267<span></span>
</td>
<td class="nump">267<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant and equipment, gross</a></td>
<td class="nump">340<span></span>
</td>
<td class="nump">340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleLeasebackTransactionAccumulatedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The accumulated depreciation and amortization related to the asset(s) sold in connection with the property sold to another party and leased back to the seller.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479741/842-40-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481266/840-40-55-50<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481266/840-40-55-52<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 51<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481266/840-40-55-51<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481192/840-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleLeasebackTransactionAccumulatedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleLeasebackTransactionNetBookValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net book value of the asset(s) sold in connection with the sale of the property to another party and lease back to the seller.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481266/840-40-55-50<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481266/840-40-55-52<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 51<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481266/840-40-55-51<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479741/842-40-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleLeasebackTransactionNetBookValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 3,354<span></span>
</td>
<td class="nump">$ 2,837<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_AccruedResearchAndDevelopmentExpenseCurrent', window );">Research and development</a></td>
<td class="nump">$ 1,845<span></span>
</td>
<td class="nump">$ 3,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">537<span></span>
</td>
<td class="nump">1,366<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and related expenses</a></td>
<td class="nump">4,879<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">187<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 7,448<span></span>
</td>
<td class="nump">$ 7,662<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_AccruedResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Research and Development Expense, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_AccruedResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 26, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_IncreaseDecreaseInFinanceLeaseRightOfUseAssetLeaseModification', window );">Decrease in finance lease, right-of-use asset, lease modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification', window );">Decrease in finance lease, liability, lease modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleAndLeasebackTransactionGainLossNet', window );">Gain on sale of sale-leaseback</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Financing liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss contingency, estimate of possible loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Financing liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=carm_PennLicenseAgreementMember', window );">Penn License Agreement | Penn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_CommitmentsAnnualPaymentsRequiredToBePaid', window );">Annual payments to be made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_AdditionalMilestonePaymentsForFirstCarMProduct', window );">Additional milestone payments for first CAR-M product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=carm_PennLicenseAgreementMember', window );">Penn License Agreement | Penn | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_AdditionalMilestonePaymentsRequiredToBePaid', window );">Additional milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember', window );">Novartis Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_AgreementTerm', window );">Agreement term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossOnContractTermination', window );">Contract termination fee</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid asset</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_AdditionalMilestonePaymentsForFirstCarMProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional amount required to be paid in development and regulatory milestone payments for the first CAR-M product directed to mesothelin.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_AdditionalMilestonePaymentsForFirstCarMProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_AdditionalMilestonePaymentsRequiredToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of additional milestone payments required to be paid per product in commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_AdditionalMilestonePaymentsRequiredToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_AgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_AgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount required to pay per product in development upon the achievement of certain clinical, regulatory and commercial milestone events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_CommitmentsAnnualPaymentsRequiredToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of annual payments required to be paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_CommitmentsAnnualPaymentsRequiredToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Finance Lease, Liability, Lease Modification</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_IncreaseDecreaseInFinanceLeaseRightOfUseAssetLeaseModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Finance Lease, Right-of-Use Asset, Lease Modification</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_IncreaseDecreaseInFinanceLeaseRightOfUseAssetLeaseModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The loss recognized on termination of a contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 275<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479072/912-275-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleAndLeasebackTransactionGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale and leaseback transaction from transfer of asset accounted for as sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479741/842-40-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleAndLeasebackTransactionGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=carm_PennLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=carm_PennLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=carm_TrusteesOfUniversityOfPennsylvaniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=carm_TrusteesOfUniversityOfPennsylvaniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Lease Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 5,245<span></span>
</td>
<td class="nump">$ 5,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_FinanceLeaseCostAbstract', window );"><strong>Finance lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of lease assets</a></td>
<td class="nump">1,584<span></span>
</td>
<td class="nump">1,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">217<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_FinanceLeaseCost', window );">Total finance lease cost</a></td>
<td class="nump">1,801<span></span>
</td>
<td class="nump">1,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">1,071<span></span>
</td>
<td class="nump">1,733<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short term lease cost</a></td>
<td class="nump">671<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 8,788<span></span>
</td>
<td class="nump">$ 8,833<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_FinanceLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of finance lease cost expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_FinanceLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_FinanceLeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_FinanceLeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Lease Term and Discount Rate Information (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_LeasesWeightedAverageRemainingLeaseTermAbstract', window );"><strong>Weighted-average remaining lease term (in years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases</a></td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance leases</a></td>
<td class="text">9 months 18 days<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_LeasesWeightedAverageDiscountRateAbstract', window );"><strong>Weighted-average discount rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases</a></td>
<td class="nump">9.90%<span></span>
</td>
<td class="nump">9.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance leases</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_LeasesWeightedAverageDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_LeasesWeightedAverageDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_LeasesWeightedAverageRemainingLeaseTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_LeasesWeightedAverageRemainingLeaseTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash used in operating leases</a></td>
<td class="nump">$ 5,807<span></span>
</td>
<td class="nump">$ 5,764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash used in finance leases</a></td>
<td class="nump">217<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_FinancingCashUsedInFinanceLeases', window );">Financing cash used in finance leases</a></td>
<td class="nump">$ 1,429<span></span>
</td>
<td class="nump">$ 1,301<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_FinancingCashUsedInFinanceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_FinancingCashUsedInFinanceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Future Maturities of Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 927<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum payments</a></td>
<td class="nump">1,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(253)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">1,556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total future minimum payments</a></td>
<td class="nump">963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 925<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; (Deficit) Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 07, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 06, 2023</div></th>
<th class="th"><div>Jun. 05, 2023</div></th>
<th class="th"><div>May 12, 2023</div></th>
<th class="th"><div>Apr. 17, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued in a pre-closing funding (in shares)</a></td>
<td class="nump">3,730,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Issue price per share (in USD per share)</a></td>
<td class="nump">$ 8.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock under Open Market Sales Agreement, net of issuance costs</a></td>
<td class="nump">$ 30,600,000<span></span>
</td>
<td class="nump">$ 2,383,000<span></span>
</td>
<td class="nump">$ 597,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon settlement of convertible promissory note, accrued interest, and related derivative liability (in shares)</a></td>
<td class="nump">5,059,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock upon settlement of convertible promissory note, accrued interest, and related derivative liability</a></td>
<td class="nump">$ 35,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,447,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests', window );">Shares issued upon conversion of convertible preferred stock and exchangeable shares previously presented as noncontrolling interests (in shares)</a></td>
<td class="nump">18,872,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock to Sesen Bio shareholders in reverse capitalization (in shares)</a></td>
<td class="nump">10,374,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_SaleOfStockStockOfferingAmount', window );">Stock offering, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=carm_AtTheMarketMember', window );">At-the-Market</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_SaleOfStockMaximumOfferingAmount', window );">Sale of stock, maximum aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,136,384<span></span>
</td>
<td class="nump">226,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_SaleOfStockMaximumOfferingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Maximum Offering Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_SaleOfStockMaximumOfferingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_SaleOfStockStockOfferingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Stock Offering, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_SaleOfStockStockOfferingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock issued during the period upon the conversion of convertible preferred stock and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=carm_AtTheMarketMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=carm_AtTheMarketMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Narrative (Details)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=carm_TwoThousandSeventeenStockIncentivePlanMember', window );">2017 Stock Incentive Plan | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Terms (in years)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=carm_TwoThousandFourteenStockIncentivePlanMember', window );">2014 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Terms (in years)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for issuance (in shares)</a></td>
<td class="nump">4.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=carm_TwoThousandFourteenEmployeeStockPurchasePlanMember', window );">2014 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for issuance (in shares)</a></td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Discount to the market price (as a percent)</a></td>
<td class="nump">15.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=carm_TwoThousandSeventeenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=carm_TwoThousandSeventeenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=carm_TwoThousandFourteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=carm_TwoThousandFourteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=carm_TwoThousandFourteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=carm_TwoThousandFourteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding as of December 31, 2023 (in shares)</a></td>
<td class="nump">6,023,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(3,810)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">3,805,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(2,078,034)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding as of December 31, 2024 (in shares)</a></td>
<td class="nump">7,746,991<span></span>
</td>
<td class="nump">6,023,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable as of December 31, 2024 (in shares)</a></td>
<td class="nump">4,414,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding as of December 31, 2023 (in USD per share)</a></td>
<td class="nump">$ 3.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in USD per share)</a></td>
<td class="nump">0.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in USD per share)</a></td>
<td class="nump">1.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in USD per share)</a></td>
<td class="nump">4.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding as of December 31, 2024 (in USD per share)</a></td>
<td class="nump">2.81<span></span>
</td>
<td class="nump">$ 3.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable as of December 31, 2024 (in USD per share)</a></td>
<td class="nump">2.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value (in USD per share)</a></td>
<td class="nump">$ 1.36<span></span>
</td>
<td class="nump">$ 4.29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted average remaining contractual term (years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding as of December 31, 2024</a></td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable as of December 31, 2024</a></td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Exercised</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding as of December 31, 2024</a></td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable as of December 31, 2024</a></td>
<td class="nump">$ 59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Estimated Using The Black-Scholes Option-Pricing Model (Details) - Stock options<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.77%<span></span>
</td>
<td class="nump">2.92%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">86.55%<span></span>
</td>
<td class="nump">57.77%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.59%<span></span>
</td>
<td class="nump">4.76%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">112.12%<span></span>
</td>
<td class="nump">103.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 3,649<span></span>
</td>
<td class="nump">$ 2,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Stock-based options forfeited (in shares)</a></td>
<td class="nump">2,078,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Future compensation cost for awards not vested</a></td>
<td class="nump">$ 7,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period compensation cost of unvested awards to be expensed (in years)</a></td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=carm_RevisedOperatingPlanMember', window );">Revised Operating Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Stock-based options forfeited (in shares)</a></td>
<td class="nump">1,898,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=carm_SesenBioIncMember', window );">Sesen Bio, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,116<span></span>
</td>
<td class="nump">1,242<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,533<span></span>
</td>
<td class="nump">$ 1,074<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=carm_RevisedOperatingPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=carm_RevisedOperatingPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=carm_SesenBioIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=carm_SesenBioIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal tax benefit at statutory rate</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State and local tax, net of federal benefit</a></td>
<td class="num">(8.00%)<span></span>
</td>
<td class="num">(8.50%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal', window );">State and local tax rate change</a></td>
<td class="nump">3.10%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences', window );">Permanent differences</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development</a></td>
<td class="num">(5.80%)<span></span>
</td>
<td class="num">(0.90%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Change in valuation allowance</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="nump">28.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other</a></td>
<td class="num">(1.40%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total provision</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation Permanent Differences</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes- Schedule of Deferred Tax Assets for Federal Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 87,742<span></span>
</td>
<td class="nump">$ 72,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization', window );">Capitalized research and development costs, net of amortization</a></td>
<td class="nump">35,608<span></span>
</td>
<td class="nump">33,778<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">13,269<span></span>
</td>
<td class="nump">9,746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_DeferredTaxAssetsStartUpCosts', window );">Start-up costs</a></td>
<td class="nump">4,051<span></span>
</td>
<td class="nump">4,407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">12,182<span></span>
</td>
<td class="nump">13,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">733<span></span>
</td>
<td class="nump">668<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences', window );">Accrued compensation</a></td>
<td class="nump">405<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_DeferredTaxAssetsAmortizableAssetsAndOther', window );">Amortizable assets and other</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_DeferredTaxAssetsEquityCompensation', window );">Equity compensation</a></td>
<td class="nump">1,115<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">155,132<span></span>
</td>
<td class="nump">134,749<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(153,855)<span></span>
</td>
<td class="num">(133,580)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of valuation allowance</a></td>
<td class="nump">1,277<span></span>
</td>
<td class="nump">1,169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_DeferredTaxLiabilitiesRightOfUseAsset', window );">Right of use asset</a></td>
<td class="num">(848)<span></span>
</td>
<td class="num">(645)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="num">(429)<span></span>
</td>
<td class="num">(524)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="num">(1,277)<span></span>
</td>
<td class="num">(1,169)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets and liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_DeferredTaxAssetsAmortizableAssetsAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Amortizable Assets And Other</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_DeferredTaxAssetsAmortizableAssetsAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Capitalized Research and Development Costs, Net Of Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_DeferredTaxAssetsEquityCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Equity Compensation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_DeferredTaxAssetsEquityCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Lease Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_DeferredTaxAssetsStartUpCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Start Up Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_DeferredTaxAssetsStartUpCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Right Of Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensated absences (includes, but not limited to, sick and personal days).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance</a></td>
<td class="nump">$ 20.3<span></span>
</td>
<td class="nump">$ 84.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">374.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">12.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=carm_StateJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">280.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=carm_StateJurisdictionMember', window );">State | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=carm_LocalJurisdictionMember', window );">Local</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">65.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=carm_Pre2018Member', window );">Pre-2018 | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">120.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=carm_Post2017Member', window );">Post-2017 | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">$ 254.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=carm_StateJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=carm_StateJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=carm_LocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=carm_LocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=carm_Pre2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=carm_Pre2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=carm_Post2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=carm_Post2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Moderna Collaboration and License Agreement - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>target</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($) </div>
<div>target </div>
<div>product</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>target </div>
<div>obligation</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2025 </div>
<div>target</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Moderna Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,600<span></span>
</td>
<td class="nump">$ 14,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,979<span></span>
</td>
<td class="nump">46,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,632<span></span>
</td>
<td class="nump">$ 14,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=carm_OptionRightCollaborationRevenuesMember', window );">Option Right Collaboration Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Moderna Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=carm_MilestonesMember', window );">Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Moderna Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=carm_ModernaMember', window );">Moderna</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Moderna Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Collaboration receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=carm_ModernaMember', window );">Moderna | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Moderna Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollectionOfOtherReceivables', window );">Proceeds from collection of collaboration receivable</a></td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=carm_CollaborationAndLicenseAgreementMember', window );">Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Moderna Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NumberOfPotentialResearchTargetDesignations', window );">Number of potential research target designations | target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=carm_CollaborationAndLicenseAgreementMember', window );">Collaboration and License Agreement | Research and Development Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Moderna Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_VariableConsideration', window );">Variable consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_ContractTerm', window );">Term of contract (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Noncurrent portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=carm_CollaborationAndLicenseAgreementMember', window );">Collaboration and License Agreement | Moderna</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Moderna Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_MaximumNumberOfResearchTargets', window );">Maximum of research targets | target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NumberOfResearchTargetsNominatedAutoimmune', window );">Number of nominated autoimmune target | target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=carm_CollaborationAndLicenseAgreementMember', window );">Collaboration and License Agreement | Moderna | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Moderna Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NumberOfResearchTargetsGrossOncology', window );">Number of oncology research targets | target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=carm_CollaborationAndLicenseAgreementMember', window );">Collaboration and License Agreement | Moderna | Research and Development Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Moderna Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_UpfrontNonRefundablePaymentReceived', window );">Upfront non-refundable payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NumberOfPotentialProductsToDevelopAndCommercialize', window );">Number of potential products to develop and commercialize | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts', window );">Minimum commitment to reimburse research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts', window );">Period of reimbursement of research and development costs (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NumberOfPerformanceObligations', window );">Number of performance obligations | obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=carm_CollaborationAndLicenseAgreementMember', window );">Collaboration and License Agreement | Moderna | Minimum | Research and Development Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Moderna Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments', window );">Amount receivable per product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 247,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=carm_CollaborationAndLicenseAgreementMember', window );">Collaboration and License Agreement | Moderna | Maximum | Research and Development Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Moderna Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments', window );">Amount receivable per product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=carm_ModernaLicenseAgreementMember', window );">Moderna License Agreement | Research and Development Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Moderna Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=carm_ModernaLicenseAgreementMember', window );">Moderna License Agreement | Moderna</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Moderna Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_CollaborativeArrangementRightsAndObligationsMilestonePayments', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Decrease in contract with customer, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount receivable per product in development target designation, development, regulatory and commercial milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_CollaborativeArrangementRightsAndObligationsMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_CollaborativeArrangementRightsAndObligationsMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_ContractTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_ContractTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_MaximumNumberOfResearchTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of research targets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_MaximumNumberOfResearchTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum commitment to reimburse research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Performance Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NumberOfPotentialProductsToDevelopAndCommercialize">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of potential products to develop and commercialize</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NumberOfPotentialProductsToDevelopAndCommercialize</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NumberOfPotentialResearchTargetDesignations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Potential Research Target Designations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NumberOfPotentialResearchTargetDesignations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NumberOfResearchTargetsGrossOncology">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Research Targets, Gross, Oncology</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NumberOfResearchTargetsGrossOncology</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NumberOfResearchTargetsNominatedAutoimmune">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Research Targets Nominated, Autoimmune</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NumberOfResearchTargetsNominatedAutoimmune</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of reimbursement of research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_UpfrontNonRefundablePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront non-refundable payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_UpfrontNonRefundablePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_VariableConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_VariableConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollectionOfOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the collection of receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollectionOfOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479428/808-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=carm_OptionRightCollaborationRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=carm_OptionRightCollaborationRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=carm_MilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=carm_MilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=carm_ModernaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=carm_ModernaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=carm_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=carm_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=carm_ResearchAndDevelopmentServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=carm_ResearchAndDevelopmentServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=carm_ModernaLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=carm_ModernaLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Moderna Collaboration and License Agreement - Schedule of Estimated Revenue Expected to be Recognized in The Future Related to Performance Obligations (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuePerformanceObligationAbstract', window );"><strong>Performance obligations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount', window );">Research and development</a></td>
<td class="nump">$ 35,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_RevenueRemainingPerformanceObligationOptionRightsAmount', window );">Option rights</a></td>
<td class="nump">41,250<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Total performance obligations</a></td>
<td class="nump">$ 76,551<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_RevenueRemainingPerformanceObligationOptionRightsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to option rights performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_RevenueRemainingPerformanceObligationOptionRightsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to research and development performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuePerformanceObligationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuePerformanceObligationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Moderna Collaboration and License Agreement - Schedule of Changes in Deferred Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInDeferredRevenueRollForward', window );"><strong>Movement in Deferred Revenue [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at the beginning of the period</a></td>
<td class="nump">$ 46,413<span></span>
</td>
<td class="nump">$ 47,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_ContractWithCustomerLiabilityDeferralOfRevenue', window );">Deferral of revenue</a></td>
<td class="nump">16,198<span></span>
</td>
<td class="nump">13,873<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Recognition of unearned revenue</a></td>
<td class="num">(17,632)<span></span>
</td>
<td class="num">(14,919)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at the end of the period</a></td>
<td class="nump">$ 44,979<span></span>
</td>
<td class="nump">$ 46,413<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_ContractWithCustomerLiabilityDeferralOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue deferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_ContractWithCustomerLiabilityDeferralOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInDeferredRevenueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInDeferredRevenueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>employee</div>
</th>
<th class="th">
<div>Feb. 28, 2025 </div>
<div>target </div>
<div>item</div>
</th>
<th class="th">
<div>Jan. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>employee</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Severance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Reduction in workforce, number of employees | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Reduction in workforce (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Employee Severance | 2025 Cash Preservation Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Reduction in workforce, number of employees | employee</a></td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Reduction in workforce (as a percent)</a></td>
<td class="nump">84.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected cost with the reduction in workforce | $</a></td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Moderna</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollectionOfOtherReceivables', window );">Proceeds from collection of collaboration receivable | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Moderna | Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NumberOfResearchTargetsNominatedOncology', window );">Number of oncology research targets, nominated | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NumberOfResearchTargetsNominatedReplacements', window );">Number of research targets, replacement nominations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NumberOfResearchTargetsTerminatedOncology', window );">Number of oncology research targets, ceased development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NumberOfResearchTargetsTerminatedAutoimmune', window );">Number of autoimmune research targets, ceased development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NumberOfResearchTargetsGrossOncology', window );">Number of oncology research targets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NumberOfResearchTargetsGrossOncology">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Research Targets, Gross, Oncology</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NumberOfResearchTargetsGrossOncology</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NumberOfResearchTargetsNominatedOncology">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Research Targets Nominated, Oncology</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NumberOfResearchTargetsNominatedOncology</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NumberOfResearchTargetsNominatedReplacements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Research Targets Nominated, Replacements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NumberOfResearchTargetsNominatedReplacements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NumberOfResearchTargetsTerminatedAutoimmune">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Research Targets, Terminated, Autoimmune</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NumberOfResearchTargetsTerminatedAutoimmune</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NumberOfResearchTargetsTerminatedOncology">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Research Targets, Terminated, Oncology</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NumberOfResearchTargetsTerminatedOncology</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollectionOfOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the collection of receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollectionOfOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=carm_CashPreservationPlan2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=carm_CashPreservationPlan2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=carm_ModernaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=carm_ModernaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=carm_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=carm_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>83
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( !6$?UI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( !6$?UI9,,UB\@   "L"   1
M9&]C4')O<',O8V]R92YX;6S-DL%.PS ,AE\%Y=XZ30")J.N%:2>0D)@$XA8E
MWA;1-%%BU.[M:<O6@> !.,;^\_FSY-I$94+"IQ0B)G*8KP;?=EF9N&('HJ@
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MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#
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M"CS<_N\-L,+$CN'MB[\!4$L#!!0    ( !6$?UIK^GL4_@<  / Q   8
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M<<("S/=K8?2O?;%7U=V_)E;_ E!+ P04    "  5A']:5A$ITO,"  !-"@
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ME[.NPARF*ZAS"'[C/,<YH#,@F2VRR"+P:(GC:/F;2ZA*&*4-[&R.ZASB'UI
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M+]HPM^$+-$5M.V)Z2;%UC!-K)7E$]KT=J3,7);S:IL_:@Z]LL^1DN\YPF+I
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MK'$?)L\;\+URX%W_P@;&&_;5/U!+ P04    "  5A']:>?EFL7X>   37P
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MUL1;3ZMQX3E0.G3G+"G/8X0,Y!7QXP/-5&N04A [> P.? Z*K\$..#"!L\P
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M/U">I.+Z1@@*06SF9 THI'E,-O4W%*^Q<V#%8&^>))23B??HQJ1C><Z#N/W
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MS)2>UM:K-9BPE=FP1TUG*:C&JLM:'O63IT\5 ?%5]CCEGA0_*'KR'.QJ;]T
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M>F-0FBO\'?>*$XNR+'!\:[&ZPC<)4U8.3O;\KBE!-.ZJE:7+##3=L;\72UE
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M=^1S']2#P103N*.M#PCA:WPL= \]8L]'XEX;;"*&0^))8>'?=&?5$CQ4AB(
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M),>"VRM=HJ*;3)N".]J:36A+@SRMG H9LB@:A 47*IA/J[.5F4_UUDFA<&7
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M"&D IPH8'G5G@693:9!/?JM<W:CM:2MSB[J[?YO7&OG S48H"Q(S<HVNAOT
M3*T[]<;ILNKUM7:D'-4R)ZE&XPWH/M/:'38^0"O^\U]02P,$%     @ %81_
M6B-K;IN( P  WP@  !D   !X;"]W;W)K<VAE971S+W-H965T,3,N>&ULG59M
M;]LX#/XKA!<,+9#%;WEKEP3HRX8[8,.";KO[<+@/BDTG0F7)D^2FO5]_E)RX
M,=:DM_M@RZ+(AP])2?1LJ_2]V2!:>"R%-/-@8VUU&88FVV#)S$!5*&FE4+ID
MEJ9Z'9I*(\N]42G")(K&8<FX#!8S+UOJQ4S55G")2PVF+DNFGZY1J.T\B(.]
MX(ZO-]8)PL6L8FO\BO9[M=0T"UN4G)<H#5<2-!;SX"J^O!XZ?:_P!\>M.?@&
M%\E*J7LW^3V?!Y$CA (SZQ 8#0]X@T(X(*+Q8X<9M"Z=X>'W'OVCCYUB63&#
M-TK\R7.[F0?3 '(L6"WLG=K^AKMX1@XO4\+X-VP;W2%YS&IC5;DSIGG)93.R
MQUT>#@RFT1&#9&>0>-Z-(\_REEFVF&FU!>VT"<U]^%"]-9'CTA7EJ]6TRLG.
M+I::ZJOM$S"9PX<?-:\HX[8/$NTLM.3 J879#NRZ 4N.@,4)?%;2;@Q\D#GF
M78"0F+7TDCV]Z^0DXBUF TCC/B11,CR!E[;AIAXO?27</BP%D[8;-?QUM3)6
MTT;Y^Z78&^3AR\CN\%R:BF4X#^AT&-0/&"S>OHG'T?L3O(<M[^$I]%\MT_\&
M@\X:=M<R16?16,Q!%6 W"(42=*BY7,,9ER11M2$S<WX)5#<L5ZC;VKE7"C>J
MK&I+8J,*NV4:H0>C:$KOBRB%3VSU[!+.XG.(XWX\FK@AO4C@2U'PC+S66G);
MDW$RGOCG$]*YW"B1 R\KK1[0 1A(AY%_;HBWU75S#1!14EE3B0R\?3--XN0]
MQ"G$23^9)&ZXB$<$:,PEW1A97=:"N8ASI*IFG#57">6&E4I;_D\C.$O.X6S2
MGTXG-(Z),W'OP;"?3D<TCON3\=#'TXV0RTS4.1HH&!?DPS"!(%PL[U8LNP=F
M#%(8E.Q>.AC2Z1?">_>BGS/L6+DL#XZZX9+);.<"[KY\[WI(GCT04B\97.P%
M?;I^387^ A5T=EYGX!+RC7;(80H[&5LQX;FTY'KQ8-0E$!TGH+&!M.HP=^]\
M8(>I>YWH+Y),!FF79#R8_!>2QS+_.L';DQL/'ZD[$^26@+J;I"GAM!50__9G
M]@F9-H#N?C[AMQO+X*4;+#QH.B7JM6^MABZ)6MJF_[32MGM?-4WK6;UI_9^9
M7G-I*#T%F4:#R2@ W;339F)5Y5O82EEJB/YS0W\@J)T"K1=*V?W$.6C_:1;_
M E!+ P04    "  5A']:D5ZE]X<"  "8!0  &0   'AL+W=O<FMS:&5E=',O
M<VAE970Q-"YX;6R-E&]OTS 0QK_**2 $4K7\;5I*&ZG=AN#%1+4)>(%XX2:7
M)IIC!]MIMV_/V6E#05W%F]H^W_W\7-S'\[U4C[I"-/#4<*$77F5,._-]G5?8
M,'TE6Q2T4TK5,$-+M?5UJY 5KJCA?A0$J=^P6GC9W,76*IO+SO!:X%J![IJ&
MJ><5<KE?>*%W#-S7V\K8@)_-6[;%!S1?V[6BE3]0BKI!H6LI0&&Y\);A;)78
M?)?PK<:]/IF#[60CY:-=?"X67F %(<?<6 *C88?7R+D%D8Q?!Z8W'&D+3^='
M^D?7._6R81JO)?]>%Z9:>%,/"BQ9Q\V]W'_"0S]CR\LEU^X7]GUN''N0=]K(
MYE!,"II:]"-[.GR'DX)I\$)!="B(G.[^(*?RAAF6S97<@[+91+,3UZJK)G&U
ML)?R8!3MUE1GLF6>JPX+N'VB:]:HY[XAJMWS\P-AU1.B%PAA!'=2F$K#K2BP
M^!O@DYQ!4W34M(HN$F\POX(X'$$41,D%7CST&#M>_ )OS9[9AJ,&)@IP#3.N
MX<=RHXVB?\7/<SWWQ.0\T3IEIEN6X\(C*VA4._2R-Z_"-/AP06\RZ$TNT?_K
M3BX2SNO[%PO' !X#N22S:4,A68*I$$K)R;6UV,+;6E!$=IJ^H7XW [HC;#:H
MAGNR/S'<TV%,Y97[U 7NR/0M6=C :PA'TV1,8SP*XQ#62I:HK;49AQ+I\'$\
MH9PX3>%:-E80ZVU+((6<F5.AR6@Z>6])00!?2*B"<#J!U.(GHR29NC%-(SAW
M&_Z)6QI46_<FV.8[87KC#-'AV5GV;ON3WK]9=TQM:Z&!8TFEP=5D[('JWX%^
M863KO+>1AISLIA4]G:AL NV74IKCPAXP/,;9;U!+ P04    "  5A']:S.M"
MPU *  "X&@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6RE66MSV[@5
M_2L8K;L3SRBRGK;L.)YQO.OI[B1=3YQLIM/I!XB$1#0@P05(.^JO[[D7($7*
MLM-M/TBB2. ^SGV#EX_6??694I7XEIO"OQUD555>G)SX)%.Y]"-;J@)/UM;E
MLL)?MSGQI5,RY4VY.9F.QZ<GN=3%X.J2[]VYJTM;5T87ZLX)7^>Y=-MWRMC'
MMX/)H+GQ46^RBFZ<7%V6<J/N5?6YO'/X=])2276N"J]M(9Q:OQU<3R[>S6D]
M+_A=JT??N1:DR<K:K_3GE_3M8$P"*:.2BBA(_#RH&V4,$8(8?T2:@Y8E;>Q>
M-]1O67?HLI)>W5CS1:=5]G:P'(A4K65MJH_V\:\JZK,@>HDUGK_%8UB[F Y$
M4OO*YG$S),AU$7[EMXA#9\-R_,R&:=PP9;D#(Y;R)UG)JTMG'X6CU:!&%ZPJ
M[X9PNB"CW%<.3S7V55<W-L]U!90K+V21BAM;5+K8J"+1RE^>5&!!"T^22.Y=
M(#=]AMQD*CZ 0N;%ST6JTCZ!$\C6"CAM!'PW?9'B3RH9B=ED**;CZ?P%>K-6
MX1G3F_TO"HN?M$^,];53XA_7*U\Y>,T_#\$0F,P/,Z%(NO"E3-3; 4+%*_>@
M!E<__C Y';]Y085YJ\+\)>I_WF;_!SGQ7L'GO?B4*3S(2UEL12:]0%9PDI8)
M$Q8@/P@-"D:N+)Y8MV5B=KW6B1(,AM"%N,NTD:DR9:;E4-RIHO!;\R ++4==
M'C_^L)Q.SMX<X)/)!R4JY7*A0#Z5%>XY66QHR=K9G/QD(2I+O^<]FD(:;X/P
M*Z,WDK*"%S7\U$%4(1V1480#*U-A9^T5-!")<A7R6U<W]4>M2UY;9;+"9B42
M([W7:ZU2 1YK7<@".D>Q>54"I $K%H 8Y)LR1*S1]Y4Y'8F?UVO%64S<JI6K
MD40Y*H8L:Z.E4X5Z)!D*H;YIS]CMH8@<4V6\('(% 6?K31;Y_%*(Z])I$ZE#
MV,061<RCO)<8.O6@/1CMB)=&%GUA"EL%1.BF4=XSL(!"5TC7M4G9E("*98AH
M"=7J>5UOD -9#A;KU]H<TAEV4(YA!59D2\"<LG74MPJ7)!RM;YB1'JPWC+MC
MB[V_UH4*H#<0V9)7XUD@15?(22I?P6UH9=_'4IV2TI DJ<FMM@+E4YJ*0@FZ
MKQ5^G\&S(QSK>J_*JF6SIW!NTX!K:^(]?R/'6DMML,1+HU[S[95,OG;]W(L5
MH@).NRD:A!Q5L;"]&R6=(." ,5O:@*T*BP/F=>&4 :9D:^U244I7;0,X0=HD
MTD)"1,D,02#Q+ZT#$.!!":2GB/CXV^>&#<G4L @/C98K;72UI;U'X]$<%=*8
M!C^9IIH([X='8EU*\7& ]4' =EQ(@@UA0 X!FK2P<2%0A6*E#<X610YB379B
MO9SBV&@OJ1_"[A $Y%^4A'2!:VD0)3F>UQ04LN)]7(@0$0_2U"SUNJZHS@4Z
MI=P&C[ /RG5C D[9]W#-%H2B7J^@/J7*N+GK)6@0C5"^XL"6WY2G- )Y6#?V
M+O!P<%^$!_DK$&VV1F,$1V;>D$/FMN8"!8E1FH 8Z9B0%"F'/IQPI:"< R F
ML*"U,19-G0:'(\TB,HW(=&L/YSWWVBLC21)D(=4+6P17H>0.4 C#(5K<)*,B
M0%TQD@8IC9L*(0$\(#?G]OUM?2X)XI2,>K#F\/Z#W@KFX%LZ<JKHL>VVH2C0
MY4??)2V8$SD>X6B-3MFQ5M*PE;BIC%+98F-WY:-U%D)X%U!^%U&<%(A-Z\Z]
M(-*<KWW5V'\DKCE8VL3:-'S]V,TDA>W19!?HD3Z+UG)H)2)G8C=#+G:$6R]:
M6B<TT.XUMQ3=YQ&G[T*# 2-&3K>6)-;CUB.TY&; &DP_7KQB#[2U!W-_?"'^
MKJ2+K?)3W>EK)G[;*]U$6!R)Q7 Z7_#OV=E<W/:2!BVY$->Y=97^MVP27'@6
MG7PR7"SG^)XLSY JHS&P[FE208X2D]FY^&0K1/3Z"2,068XG^)Y-3\7O3?CU
MGH_/Z/G9;";N,\@4NK?.BE,\YVPX?1/9]%1=#L^62_Y=@L3[-BVQ!5,T[!2-
M@B(+!@]C:I@88S6R34U\A"5VQKAX#O$O/,FI]#7Z,H?!%)0HCG<F8.9DRBV9
M[WC?1,!L=(;/:=\L7HQ'2S$9+9XRZ"OQA-SYZ%S\!=]+?.^1/!^-^1%]W]=E
M&7P1"";29V(-/7N8]!%XT1UW>-P0J5*BL:&$UR3B[R35)XYTT=&+A:M]C-!]
M=<FIE^.SX-RG\^?V[34\1^RI1^RKMVU2>'G'9#B?GO/O#"Y\&^HAH*I=3 $'
M]'@2T_)PYGH"[DZ-QH:W,#M,15XD0I-Z$7K/(W$^)5W.YU/NR,44-Z<3NH9C
M(0B::,&-I9C.Q]T;YV*"T&[C"0E.R35<MKW5#[78!:#SU'F=[U([A?6Y.#^E
MB/,P=U[6H6>+R>+5=#$[%J]FRV-QM]]9/ 6-,%XL3EFSA7B/D1"%.W8\]]1+
M6*KA'T%'.I3.ZXU3,:M^#O,9J-$>(-\\"HTS9>!/#C."4FT&_EQ@=' ^]H7=
M&5.\HG_'P_[  $/]#6U/;+7A1;PJ2JEVPASWJQ$W0JBML?O(Y5=J.XH:H.ZZ
M*32 T\5P/!Z/6!#:I-!6<^N$32A5BN:<NJ1_1Y,Q0KTI;? 7*N1444G$5#TH
M8T/]K\NVBF<:]_>[KP0S/OIM,P2#36UVXSA/H"Y!ATAL8$>T'@($FO:#7)L^
ML77N+6N5ZFJ]4B$U@'G4839&-GI&AT/L0R4.FV7198U"?]92VD,@# .M;@>D
M;&;XM79PUYOKCZ\_M**D$#^)Q2%7GMH ((8NI&5NMD^,'>>AL ML@D')C=&
MI; I\K?=QEF/3@I3JJC4RE+;16V:Y[GD [LXI=:7AECX4U&O94+)* :*IP2_
MW8\ N"XF+<AWETGD^435%9G>@ZXKJ74D]%XUJXY;7/KT8^CLSR8WGUZ/%^-E
M"UP".;@7VE'LQ$=HB)X^B(W;FCQ][W2IDR-(,&.1:Y+N$O2S3OOV0"0Q4N?<
MY"*%^SRTVT0@3*I#2O*TJ9VZAYU&S]O:)6JO;7W,%%F)+ PM5]R^A#.=3DM)
MIT8K10L+[B73=AP+];#!;R<6+3B!1E024QVL /0H8)"0/7QL!5O":75./O5?
M=L!4P!$)A=K82L=Y.IQ4" 1Q2J:UB)-PE!".5"I.\Z$?M70PM&:I8J;E'JH3
M5W16J0DC8/& T0J"?<FT":1Z; G$.!;T95PAED#1]P#LH#MZ<IC8HM!%-"07
MECA<(AU,VW3PF&E(KSM]",% )PI)XFH^&-E-EG]^WJ%6P;2V)1ER28<[ZS5,
MPXY(-!NYJ0?H80-5X?M^;Z1[A.S1N6O._HHJ9G/T!4(5GT2F8:%,_T5'7SQ2
M[(8G8@3S>#K[:W,,G[2I?JM'K=JNBL+EDBR"Q"2#MXP.G4:?=-XF(%MO^)T)
M126P""\6VKOM:YGK\#9BMSR\TT&JVV#L1T.PQM;QZ&PQ""=,S9_*EOQN8F6K
MRN9\F2F)BD\+\'QM;=7\(0;MRZJK_P!02P,$%     @ %81_6MZN2AZF!0
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MPVF&$$A,+;Z5V.+,X;6"P/HG$E@K3)1AM380HD)0E@B,%<LAJ!.]P-26]!:
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MW)^,>F&@;!=.-_X^O= .;^?^M<*?0V!( +^7&L_.;D$.=C^P9G\#4$L#!!0
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M6FF+E#X@->L.\(25P K.PNDK((K)D'$=GV%2O!?8"X"Z\$"K9K-E-3]H511
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M&OCI=.2&YN[&JIJ^@:R4M:JDRZW@,%GB!EA?*V6[&SR@_RAV]1]02P,$%
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M-6'Z*JDIW%,B:RHJTOCRG$S);EDPI1UKG/09V(I&-I#LQ7/9R7S/BD &:]F
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MQ[7 ]&AH _XOM';=#U+0O\B^_A]02P,$%     @ %81_6O+J!O9" @  *@4
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MQA#W5EA6/,S0^@#V;PTK[0U_P# >LU]02P,$%     @ %81_6B)V5OPW#
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M1.(_F4:_.\)/1*'B3= @')ZM%$;(G">1=;=3/A7+JV@Y6]"'ZVAY>0MYM#G
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MX[>FN_*)Y3"]?*B",&P,I-I2@Z5GBV_?S J\_4/RO7QP6?N4?"<_6](0/)Z
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M@9*1"I@DG"$!>>RL_.5Z8>)MP"\"K3P9(U/)GO-G,]EDL>,9(:"0*D/ ^G:
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MU\ZW0YPV_OT!$Q+\_D%K=PQ"@>E%*W\!4$L#!!0    ( !6$?UK1X4NR\0@
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M%E1\HC-R.X>8%,^,.C3(^-).+.F1%=,PD'1PK_0BJYR.,XB!5;67"[.?Y+N
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M678! \J69'Q! 1R'[2Q++RC\#;TGA$D*%:2=M_M_O_LB2KI&2ZH*&*5>DAB
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M&L;?I/T!9E-_,@GA3*],]KTR>7>OW)1,%)1S"O06<U3JT#6G2GT6^/VE[AX
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MNPWT?:64W4T<0=NE1_\!4$L#!!0    ( !6$?UK#BR&J6@(   $&   9
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M?FTGA&:WK0H*-TT<S_][/GM<S7#-Q;-, 11ZS2B3(R=5:CEP71FGD&%YP9?
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M (59H)_/.%>KB7%0_V^$?P!02P,$%     @ %81_6F->/=Y1!   :A   !D
M  !X;"]W;W)K<VAE971S+W-H965T-# N>&ULM5C;;N,V$/T50ET4">!$HB3+
M5FH;R&6W#;#;!G&W?2CZ0$MCFPA%>DG:SO;K2TJ*?*/4F_L2B]3,T3DSO,QD
MM!7R12T!-'HM&%=C;ZGUZL;W5;:$@JAKL0)NWLR%+(@V0[GPU4H"R4NG@OEA
M$"1^02CW)J-R[DE.1F*M&>7P))%:%P617^^ B>W8P][;Q#-=++6=\">C%5G
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M$V>V@6Y__6PG1)2DJ ][(;9S][W/7>PSDQWC3Z( D.BYI)686H64]95MBZR
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MA^K>R:2'TIW2HJB#S1,4C%>_Y'M=$7L!>/A,0%@'A(<!HV<"!G7 X*49AG7
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MH&A=/5N/*?1Z&S/;3B5)*SD9+_<2H!5U.@\UZF!;Q\$HL_ G/%DF4-L(E)9
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M.]ANN_U[KITT:J<T#&U?&MNYY_B>X^O>)#NI'G0!8,@C+X6>>X4QU87OZZP
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MULR\UFZ?JAU(6  )"X%@%>VXI7;<@V$J>_DU_2S-)54JSM22/T_75"CV%)O
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MMH/=:E*+[+ B._QKLC15-#F2O7,-H9 C5[*^>4!DCJZ[6!?0;I.0-1I;SN"
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MQ]VZZL5_H6F*P,]4'9G0A$..E,%TB9>7:NJJIF-DY4J3@S18Z+AF@;4H*!N
MWW,IS7/'3M!5M\G?4$L#!!0    ( !6$?UKMS,,^1 0  ! 0   9    >&PO
M=V]R:W-H965T<R]S:&5E=#4X+GAM;*U8;6_;-A#^*X16#"U01Z+>G=D"4F?M
M"FQ#$+?=9UJF;:*2Z)*4G?;7[R@ILBU1B@OT2ZR7N^/SG([W'#,[<O%5[BA5
MZ"G/"CFW=DKM;VU;ICN:$WG#][2 -QLN<J+@5FQMN1>4K"NG/+-=QPGMG+#"
M2F;5LP>1S'BI,E;0!X%DF>=$?']',WZ<6]AZ?O#(MCNE']C);$^V=$G5Y_V#
M@#N[C;)F.2TDXP42=#.W[O#M D^U0V7QA=&C/+M&FLJ*\Z_ZYN-Z;CD:$<UH
MJG0( C\'NJ!9IB,!CF]-4*M=4SN>7S]'?U^1!S(K(NF"9_^QM=K-K=A":[HA
M9:8>^?$OVA *=+R49[+ZBXZ-K6.AM)2*YXTS(,A94?^2IR819P[8'W!P&P?W
M6@>O<? JHC6RBM8]4229"7Y$0EM#-'U1Y:;R!C:LT)]QJ02\9>"GDH]%RG.*
M/I$G*B=H"56R+C.*^ ;=TPT5@J[U.W0G)5420=F@]W1-!<G0N2=Z?4\589E\
M@R;H\_(>O7[U!KU"K$"?=KR4I%C+F:T KE[43AMH[VIH[@"T>YK>( ^_1:[C
M^@;WQ?7NWJ6[#4EJ,^6VF7*K>-Y@O"8?"O)!JGR8.-5!?',0O2EOY9ZD=&[!
MKI-4'*B5_/X;#IT_3 Q_4; +OE[+UQN+GOP+/02ZA2"*%5N4<6!L)%Q'":HH
MNFD<DCB*?'=F'\Z9]*TB-XRGK=4%1+^%Z(]"7) ]4R1C/^"KZ 00D>X0%!OL
MXP,TJ#VT&X52+I5\BPI-9X-(SH5B/XCN(28V]8+A&4XO")VXP\9@Y451;&83
MM&R"43:/@PR@ZIBYVH(>$.RYX;0#MV\UC?S0C#9LT8:C:)>*"#4I]W5^3=C"
MWJJ^$^ .-(.1[T1F:%$++1J%UNY4 4DL2FH"%_43Y^*X6[4&*\\+/#.\N(47
MC\+[FX+LH(R1%<N8^FY"%_?6C3RO@ZUO$X8#%3AMD4U'D=VEJ2@A;]#884R0
M@YMD:OJR'7A]&\<,#CLGJ7+&X35[=P4"53?@:JMPM:/"*"].#X,;=6":;/
MT#--Q:- __Q6PH=],8U-E(ORPKB;2(-5/+!!\$G+\*AT)!\$]',][EPC:4VL
M"YQ! (VFB]1@Y_F1/]#E\4F)\+@4?2%92>JI+X.YDQ2I<4\W4<[7G^# BX->
M2DV&L+'CH1(]"1(>5R3#D-!*S^%*%GUQP6[4JUN#%0Z',GV2(!Q</^0\MRAF
M%GX\*F<_.^K\JFB7Q$]JAL?EK#J_Z*]4RJ:Y&"GWY6H2^]WIP&05^L' MSFI
M&GY)UH!YRH;;25^M)K[;G05,5H&>KXW@3IJ&QT7MIPJG+UT34XF;S(9K_"1R
M>%SE]&!KZ'R5EKR$?-H;8YTNZC&3&K%]=ES39^5_B-BR0J*,;L#'N8G 6=3'
MS_I&\7UU@EMQ!>?!ZG('1W8JM &\WW"NGF_TH;#])T#R/U!+ P04    "  5
MA']:/5/@HSX$   L&0  &0   'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6RU
M6>]OVC@8_E>LW#1MTHW$!L*/ 5(+-UVE=D/M;??AM ]N8B!:$C/;0"?='W]V
MDB8QI#ZHG'XHB>/W\?N\?F(_F,F!LA]\0X@ 3TF<\JFS$6([=ET>;$B">8=N
M22J?K"A+L)"W;.WR+2,XS(*2V$6>Y[L)CE)G-LG:EFPVH3L11RE9,L!W28+9
MKVL2T\/4@<YSPWVTW@C5X,XF6[PF#T1\W2Z9O'-+E#!*2,HCF@)&5E/G"H[G
MJ*\"LA[?(G+@M6N@J#Q2^D/=W(13QU,9D9@$0D%@^;$G<Q+'"DGF\;, =<HQ
M56#]^AG]4T9>DGG$G,QI_'<4BLW4&3H@)"N\B\4]/?Q)"D)9@@&->?8?'/*^
M_9$#@AT7-"F"909)E.:?^*DH1"T ^B\$H"( '0?T7@CH%@'=C&B>649K@06>
M31@] *9Z2S1UD=4FBY9LHE1-XX-@\FDDX\3L)@UH0L!?^(EP\ %\QHQA55CP
M;D$$CF+^7K9^?5B =V_>@S<@2L%=%,=R OC$%7)\A>(&Q5C7^5CHA;$@ G<T
M%1L._DA#$NH KDR\S!X]9W^-C(@+$G1 %_X.D(=Z#0G-SP_O&M+IEL7L9GC=
M%_"^;(FJ7KH&MY1S,)?%_"7?M -F(0?_W,K>X$:0A']OJET.W6N&5F_SF&]Q
M0*:.?%TY87OBS-[^!GWO8Q-O2V!:%7IE%7HF]-DW'.]P_H[&<I7 :4":^.8@
MT,M0U&JSGR&O(Z=A7R?2T&O8Z_3+7EJ&_3+#OC'#3R24$Q4W964,O'06+(%I
M'/V2H]^>%GV;5; $IE5A4%9A8)SISU]N05"GWL0VAX"PIK'NH-<9'$G1.-(K
M>0Q+'L-S% O^!?<2&[-@ W :@@79RXUX*[=5T43,B'GI-%H"T^B/2OJC]L0\
MLED%2V!:%:!7;=:>409RFP8!(V$D-%4W;L7>J:HAZOA'HC8/^%I"-?<!C80>
M!!:-NX,Y[M)9LX6FLT052]2>? ML6Y6PA*97HC)(T.@\SEN/"PQ-NFAXZ@W,
M8[V62V5SH-GG9-J]<$4V0UX\F9;0] )4+@KV6Y2U5:=E"TVO1.6UH-'$7+0N
M^Z?B]CK#8VFW89I@Y9J@V3;=TJ#9'IOC+IZU-BP5K#P5'+:H7ZOFRA::7HG*
M7D&C;SES61Z=*M?O=[Q1_>]8QVWX)53Y)63V2TM&/B /#N4J;?C.9P:Y="IM
MH>F4*T>%8'NB1E9=ERTTO1*5ZT)&+W.>J L,7W/)WI&*S0.]EDAEFI#9-"TI
M%TK&@_^1L=43)%MH.N?*7*%>BS*VZK)LH>F5J%P6,A]6G2?C?L-I6O_T#,,\
MUJ5<W-JY<T+8.CN.YR"@NU3DA[AE:W[D?PW'\^QD_*C]"HZOL@-PMX+)?T>X
MPVP=I1S$9"4AO<Y $F#YT7Q^(^@V.]U^I$+0)+O<$"Q?$M5!/E]1*IYOU #E
M#R2S_P!02P,$%     @ %81_6O*0U&&W"P  BYH  !D   !X;"]W;W)K<VAE
M971S+W-H965T-C N>&ULM=UO<Z)( @;PKT)Y6U>S5;NC_(O)7&+59.BF^^HR
M-S79V7N-V%%J$5S 9'*U'_X:1-M6[,C<XYN9:.37F#R2E@?P]B4O_B@70E36
M]V6:E7>#156M/@R'9;P0RZA\GZ]$)K_SE!?+J)(WB_FP7!4BFC4++=.A,QI=
M#9=1D@TFM\U]7XK);;ZNTB037PJK7"^74?%Z+]+\Y6Y@#[9W?$WFBZJ^8SBY
M745S\2BJ;ZLOA;PUW"FS9"FR,LDSJQ!/=X./]@?N^_4"S2-^3\1+N?>U53^5
M:9[_4=_@L[O!J%XCD8JXJHE(_O<L/HDTK26Y'G^VZ& W9KW@_M=;G39/7CZ9
M:52*3WGZGV16+>X&UP-K)IZB=5I]S5^8:)]0LX)QGI;-O]9+^]C1P(K7994O
MVX7E&BR3;/-_]+W]0>PMX#@G%G#:!9S#!>P3"[CM NZY(WCM M[! N[XQ )^
MNX!_L(!WZDE?M0M<G;M*XW:!\;E/^KI=X/K<$6[:!6Z:.&Q^?\TO/XBJ:');
MY"]643]::O4738*:I>7O/,GJL#]6A?QN(I>K)@_Y3!199,FPI-$T+Z)-!+.9
M]:\DEID6UL=Y(82,=V7]:GV.BOH1S\)Z%X@J2M+R9^LG*\FLWQ;YNI1+E;?#
M2JY5;0_C=@WN-VO@G%@#VWK(LVI16B2;B5G'\O2-Y1T#,)0_CMW/Q-G^3.X=
MH_C/*'MON?8OEC-R?.O;8V"]^^GGCA7[9&8>Q4HRHX;QK"HJYJ+J4((W5F:=
M[2FG5X:<_YR<+=.NE+4J\MDZ[EHY:E8#$>]4[U#-IVDR;_+4 8?GPZ[A63,S
M0\7TO>5<M[_)D[\"?O[*.-TKH^7,W;WVW,9U___77M?+:H-[W7C]1_)#N8IB
M<3>0?P5+43R+P>3O?[.O1O_HBC(2"Y 806(4B85(C"$Q#L*T5'N[5'LF?:*G
MN1#/(EN+SK\+1J=O@)%8@,0($J,;S&^P>B+[/+%OKD:CV^'S?C(['N7='#Z*
M(5>,@S M<OXN<KXQ<H%X$D4A9MNT66D239,TJ5Z[8F>T^L8.B05(C" QNL&N
M]@+E>3?CFX/8=3SJRK/=@]@A5XS[1TGWQIZO5DS+T]4N3U>@39C1Z9LE)!8@
M,8+$Z-512N0FS'4.LG35M0FS#Q+'D"O&09@6N?$N<F-CY/Z]:K+6[&PXF!!^
M->3/B/;-'Q(+D!A!8A2)A4B,(3$.PK0T7^_2?'W)=S;7R%0CL0")$21&D5B(
MQ!@2XR!,2_7-+M4WH&F!T>D;8"06(#&"Q.C-T;3 O3YZ8X,<D2$Q#L*T8-HC
MM1=W9(SF0Y**LLJS[CB:%^Z;1Z@60#4"U2A4"Z$:@VH<I>GQW2LA[$O.%UH=
ME6^D%D U M4H5 NA&H-J'*7I^794OAW0S,$,]8XR4@N@&H%JM-7VIP_.Z&CZ
M !V3036.TO2(JB[*-I8"VTUP9R:A31-4"Z :@6H4JH50C4$UCM+T[*K&R?8N
M.GV %E%0+8!J!*I1J!9"-0;5.$K3\ZWJ+=O<;QU.'V*1/$?35'2&&5IO0;4
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M;- PZS!< \&L]@TL5 N@&H%J%*J%4(U!-8[2]%RK%M*_Z*<0^M!6$:H%4(U
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M45D'.M]*:5XW=I[[USCY#5!+ P04    "  5A']:\,6,J?P"   ("   &0
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M)J:>C%@]OV9K.P2480+*R%=BL'3M,,;$!)01"PC%['DRPP24$0L(Q^Q]Y)B
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MZEW'ST.IUYZO-3[_.ZD>S_>6Z^,ORZ^3DU?E@G.ZK:C/?P%02P,$%     @
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M4$L! A0#%     @ %81_6C*VW]S@!0  IA@  !@              ("!QA(
M 'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( !6$?UI6$2G2
M\P(  $T*   8              " @=P8  !X;"]W;W)K<VAE971S+W-H965T
M-"YX;6Q02P$"% ,4    "  5A']:$$/P+@ %  !\$P  &
M@($%'   >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ %81_
M6@/H6^#0"0  EU@  !@              ("!.R$  'AL+W=O<FMS:&5E=',O
M<VAE970V+GAM;%!+ 0(4 Q0    ( !6$?UH;@/9TO0D  &\N   8
M      " @4$K  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M"  5A']:A; 1MC(&  #"#0  &               @($T-0  >&PO=V]R:W-H
M965T<R]S:&5E=#@N>&UL4$L! A0#%     @ %81_6HHQ1 &&!@  ;0\  !@
M             ("!G#L  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4
M Q0    ( !6$?UIY^6:Q?AX  !-?   9              " @5A"  !X;"]W
M;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ %81_6MI4*?/"!0
M<0T  !D              ("!#6$  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX
M;6Q02P$"% ,4    "  5A']:OAA>K;4"   (!@  &0              @($&
M9P  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( !6$?UHC
M:VZ;B ,  -\(   9              " @?)I  !X;"]W;W)K<VAE971S+W-H
M965T,3,N>&UL4$L! A0#%     @ %81_6I%>I?>' @  F 4  !D
M     ("!L6T  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !6$?UKRZ@;V0@(  "H%   9              "
M@<V1  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ %81_
M6B)V5OPW#   CB0  !D              ("!1I0  'AL+W=O<FMS:&5E=',O
M<VAE970R,"YX;6Q02P$"% ,4    "  5A']:4OD<OK8'  "-$P  &0
M        @(&TH   >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0
M   ( !6$?UH6TI,X1@(  )L%   9              " @:&H  !X;"]W;W)K
M<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ %81_6BQU:+Y# @  B@8
M !D              ("!'JL  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q0
M2P$"% ,4    "  5A']:/*4S.!$"  #=!   &0              @(&8K0
M>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( !6$?UK1X4NR
M\0@  %\M   9              " @>"O  !X;"]W;W)K<VAE971S+W-H965T
M,C4N>&UL4$L! A0#%     @ %81_6EO*HYDY'0  T&   !D
M ("!"+D  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    "  5
MA']:MBUH) 8%  #7"P  &0              @(%XU@  >&PO=V]R:W-H965T
M<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( !6$?UK<(7L)^@(  ( &   9
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M970S,BYX;6Q02P$"% ,4    "  5A']:W$2/3D($   S"@  &0
M    @('[[   >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (
M !6$?UIMYUBHH00  ,(*   9              " @73Q  !X;"]W;W)K<VAE
M971S+W-H965T,S0N>&UL4$L! A0#%     @ %81_6J5_&K=] P  2P@  !D
M             ("!3/8  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"
M% ,4    "  5A']:B;_EXU(#  "Q"P  &0              @($ ^@  >&PO
M=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( !6$?UK#BR&J6@(
M  $&   9              " @8G]  !X;"]W;W)K<VAE971S+W-H965T,S<N
M>&UL4$L! A0#%     @ %81_6LK(/3WK @  5@L  !D              ("!
M&@ ! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    "  5A']:
MR\79K#P#  ![#   &0              @($\ P$ >&PO=V]R:W-H965T<R]S
M:&5E=#,Y+GAM;%!+ 0(4 Q0    ( !6$?UIC7CW>400  &H0   9
M      " @:\& 0!X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%
M  @ %81_6L 6(IF' @  P08  !D              ("!-PL! 'AL+W=O<FMS
M:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    "  5A']:NJA'9T8%  "5&P
M&0              @('U#0$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+
M 0(4 Q0    ( !6$?UH%OE&^Z (  $0(   9              " @7(3 0!X
M;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ %81_6KK#&M1J
M!   ZA8  !D              ("!D18! 'AL+W=O<FMS:&5E=',O<VAE970T
M-"YX;6Q02P$"% ,4    "  5A']:W)4$Z70"  #3!0  &0
M@($R&P$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( !6$
M?UI/ E='L (  '\'   9              " @=T= 0!X;"]W;W)K<VAE971S
M+W-H965T-#8N>&UL4$L! A0#%     @ %81_6B)8OU;,!0  72T  !D
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M=#4Q+GAM;%!+ 0(4 Q0    ( !6$?UK4(SWJN@8  "PQ   9
M  " @=4S 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @
M%81_6M6OB^(D P  J0L  !D              ("!QCH! 'AL+W=O<FMS:&5E
M=',O<VAE970U,RYX;6Q02P$"% ,4    "  5A']:>=LK+>D$  #F%P  &0
M            @($A/@$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4
M Q0    ( !6$?UK.! 9B4P,  /X,   9              " @4%# 0!X;"]W
M;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ %81_6N%OZF <!
MH1,  !D              ("!RT8! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX
M;6Q02P$"% ,4    "  5A']:0D#OW&<#  #I"@  &0              @($>
M2P$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( !6$?UKM
MS,,^1 0  ! 0   9              " @;Q. 0!X;"]W;W)K<VAE971S+W-H
M965T-3@N>&UL4$L! A0#%     @ %81_6CU3X*,^!   +!D  !D
M     ("!-U,! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !6$?UH&!=U%2 ,  ,H4   -              "
M >-N 0!X;"]S='EL97,N>&UL4$L! A0#%     @ %81_6I>*NQS     $P(
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9>&UL4$L%!@    !' $< :!,  -Q\ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>123</ContextCount>
  <ElementCount>391</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>47</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952151 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952152 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952153 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952154 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders??? (Deficit) Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity</Role>
      <ShortName>Consolidated Statements of Convertible Preferred Stock and Stockholders??? (Deficit) Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952155 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952156 - Disclosure - Background</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/Background</Role>
      <ShortName>Background</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - Development-Stage Risks and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/DevelopmentStageRisksandLiquidity</Role>
      <ShortName>Development-Stage Risks and Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Merger with Sesen Bio</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/MergerwithSesenBio</Role>
      <ShortName>Merger with Sesen Bio</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Prepaid Expenses and Other Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/PrepaidExpensesandOtherAssets</Role>
      <ShortName>Prepaid Expenses and Other Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Property and Equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/PropertyandEquipmentnet</Role>
      <ShortName>Property and Equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Stockholders??? (Deficit) Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/StockholdersDeficitEquity</Role>
      <ShortName>Stockholders??? (Deficit) Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/StockbasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Related-Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related-Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Moderna Collaboration and License Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/ModernaCollaborationandLicenseAgreement</Role>
      <ShortName>Moderna Collaboration and License Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://carismatx.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://carismatx.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Merger with Sesen Bio (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/MergerwithSesenBioTables</Role>
      <ShortName>Merger with Sesen Bio (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://carismatx.com/role/MergerwithSesenBio</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Prepaid Expenses and Other Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/PrepaidExpensesandOtherAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://carismatx.com/role/PrepaidExpensesandOtherAssets</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Property and Equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/PropertyandEquipmentnetTables</Role>
      <ShortName>Property and Equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://carismatx.com/role/PropertyandEquipmentnet</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://carismatx.com/role/AccruedExpenses</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://carismatx.com/role/CommitmentsandContingencies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/StockbasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://carismatx.com/role/StockbasedCompensation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://carismatx.com/role/IncomeTaxes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Moderna Collaboration and License Agreement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/ModernaCollaborationandLicenseAgreementTables</Role>
      <ShortName>Moderna Collaboration and License Agreement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://carismatx.com/role/ModernaCollaborationandLicenseAgreement</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Background (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/BackgroundDetails</Role>
      <ShortName>Background (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://carismatx.com/role/Background</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Development-Stage Risks and Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/DevelopmentStageRisksandLiquidityDetails</Role>
      <ShortName>Development-Stage Risks and Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://carismatx.com/role/DevelopmentStageRisksandLiquidity</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value Hierarchy of Assets Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsMeasuredonRecurringBasisDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Fair Value Hierarchy of Assets Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Summary of Significant Accounting Policies - Schedule of Significant Expense Categories by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofSignificantExpenseCategoriesbySegmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Significant Expense Categories by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Summary of Significant Accounting Policies - Schedule of Dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofDilutiveSecuritiesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Merger with Sesen Bio - Schedule of Net Assets Acquired in the Merger (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails</Role>
      <ShortName>Merger with Sesen Bio - Schedule of Net Assets Acquired in the Merger (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Prepaid Expenses and Other Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/PrepaidExpensesandOtherAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://carismatx.com/role/PrepaidExpensesandOtherAssetsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Property and Equipment, net - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, net - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - Property and Equipment, net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/PropertyandEquipmentnetNarrativeDetails</Role>
      <ShortName>Property and Equipment, net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/AccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://carismatx.com/role/AccruedExpensesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/CommitmentsandContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Commitments and Contingencies - Schedule of Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - Commitments and Contingencies - Schedule of Lease Term and Discount Rate Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseTermandDiscountRateInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Lease Term and Discount Rate Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/CommitmentsandContingenciesScheduleofSupplementalCashFlowInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - Commitments and Contingencies - Schedule of Future Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Future Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - Stockholders??? (Deficit) Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/StockholdersDeficitEquityDetails</Role>
      <ShortName>Stockholders??? (Deficit) Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://carismatx.com/role/StockholdersDeficitEquity</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - Stock-based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/StockbasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - Stock-based Compensation - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails</Role>
      <ShortName>Stock-based Compensation - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - Stock-based Compensation - Schedule of Estimated Using The Black-Scholes Option-Pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/StockbasedCompensationScheduleofEstimatedUsingTheBlackScholesOptionPricingModelDetails</Role>
      <ShortName>Stock-based Compensation - Schedule of Estimated Using The Black-Scholes Option-Pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - Income Taxes- Schedule of Deferred Tax Assets for Federal Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails</Role>
      <ShortName>Income Taxes- Schedule of Deferred Tax Assets for Federal Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - Moderna Collaboration and License Agreement - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails</Role>
      <ShortName>Moderna Collaboration and License Agreement - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - Moderna Collaboration and License Agreement - Schedule of Estimated Revenue Expected to be Recognized in The Future Related to Performance Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/ModernaCollaborationandLicenseAgreementScheduleofEstimatedRevenueExpectedtobeRecognizedinTheFutureRelatedtoPerformanceObligationsDetails</Role>
      <ShortName>Moderna Collaboration and License Agreement - Schedule of Estimated Revenue Expected to be Recognized in The Future Related to Performance Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9955547 - Disclosure - Moderna Collaboration and License Agreement - Schedule of Changes in Deferred Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/ModernaCollaborationandLicenseAgreementScheduleofChangesinDeferredRevenueDetails</Role>
      <ShortName>Moderna Collaboration and License Agreement - Schedule of Changes in Deferred Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="carm-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9955548 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://carismatx.com/role/SubsequentEvents</ParentRole>
      <Position>63</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="carm-20241231.htm">carm-20241231.htm</File>
    <File>carm-20241231.xsd</File>
    <File>carm-20241231_cal.xml</File>
    <File>carm-20241231_def.xml</File>
    <File>carm-20241231_lab.xml</File>
    <File>carm-20241231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>carm-20241231_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="526">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>90
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "carm-20241231.htm": {
   "nsprefix": "carm",
   "nsuri": "http://carismatx.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "carm-20241231.htm"
     ]
    },
    "schema": {
     "local": [
      "carm-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "carm-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "carm-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "carm-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "carm-20241231_pre.xml"
     ]
    }
   },
   "keyStandard": 316,
   "keyCustom": 75,
   "axisStandard": 22,
   "axisCustom": 0,
   "memberStandard": 23,
   "memberCustom": 23,
   "hidden": {
    "total": 8,
    "http://fasb.org/us-gaap/2024": 3,
    "http://xbrl.sec.gov/dei/2024": 4,
    "http://carismatx.com/20241231": 1
   },
   "contextCount": 123,
   "entityCount": 1,
   "segmentCount": 47,
   "elementCount": 665,
   "unitCount": 11,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 526,
    "http://xbrl.sec.gov/dei/2024": 39,
    "http://xbrl.sec.gov/cyd/2024": 15,
    "http://xbrl.sec.gov/ecd/2024": 5
   },
   "report": {
    "R1": {
     "role": "http://carismatx.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://carismatx.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://carismatx.com/role/ConsolidatedBalanceSheets",
     "longName": "9952151 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://carismatx.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "9952152 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:PreferredStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockSharesIssued",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
     "longName": "9952153 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity",
     "longName": "9952154 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders\u2019 (Deficit) Equity",
     "shortName": "Consolidated Statements of Convertible Preferred Stock and Stockholders\u2019 (Deficit) Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:TemporaryEquitySharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:TemporaryEquitySharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://carismatx.com/role/ConsolidatedStatementsofCashFlows",
     "longName": "9952155 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GainLossOnSaleOfPropertyPlantEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://carismatx.com/role/Background",
     "longName": "9952156 - Disclosure - Background",
     "shortName": "Background",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://carismatx.com/role/DevelopmentStageRisksandLiquidity",
     "longName": "9952157 - Disclosure - Development-Stage Risks and Liquidity",
     "shortName": "Development-Stage Risks and Liquidity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "carm:DevelopmentStageRisksAndLiquidityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "carm:DevelopmentStageRisksAndLiquidityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://carismatx.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "9952158 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://carismatx.com/role/MergerwithSesenBio",
     "longName": "9952159 - Disclosure - Merger with Sesen Bio",
     "shortName": "Merger with Sesen Bio",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://carismatx.com/role/PrepaidExpensesandOtherAssets",
     "longName": "9952160 - Disclosure - Prepaid Expenses and Other Assets",
     "shortName": "Prepaid Expenses and Other Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://carismatx.com/role/PropertyandEquipmentnet",
     "longName": "9952161 - Disclosure - Property and Equipment, net",
     "shortName": "Property and Equipment, net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://carismatx.com/role/AccruedExpenses",
     "longName": "9952162 - Disclosure - Accrued Expenses",
     "shortName": "Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://carismatx.com/role/CommitmentsandContingencies",
     "longName": "9952163 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://carismatx.com/role/StockholdersDeficitEquity",
     "longName": "9952164 - Disclosure - Stockholders\u2019 (Deficit) Equity",
     "shortName": "Stockholders\u2019 (Deficit) Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://carismatx.com/role/StockbasedCompensation",
     "longName": "9952165 - Disclosure - Stock-based Compensation",
     "shortName": "Stock-based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://carismatx.com/role/IncomeTaxes",
     "longName": "9952166 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://carismatx.com/role/RelatedPartyTransactions",
     "longName": "9952167 - Disclosure - Related-Party Transactions",
     "shortName": "Related-Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://carismatx.com/role/ModernaCollaborationandLicenseAgreement",
     "longName": "9952168 - Disclosure - Moderna Collaboration and License Agreement",
     "shortName": "Moderna Collaboration and License Agreement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://carismatx.com/role/SubsequentEvents",
     "longName": "9952169 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R23": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-123",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-123",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "a",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "a",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://carismatx.com/role/MergerwithSesenBioTables",
     "longName": "9955513 - Disclosure - Merger with Sesen Bio (Tables)",
     "shortName": "Merger with Sesen Bio (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://carismatx.com/role/PrepaidExpensesandOtherAssetsTables",
     "longName": "9955514 - Disclosure - Prepaid Expenses and Other Assets (Tables)",
     "shortName": "Prepaid Expenses and Other Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://carismatx.com/role/PropertyandEquipmentnetTables",
     "longName": "9955515 - Disclosure - Property and Equipment, net (Tables)",
     "shortName": "Property and Equipment, net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://carismatx.com/role/AccruedExpensesTables",
     "longName": "9955516 - Disclosure - Accrued Expenses (Tables)",
     "shortName": "Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://carismatx.com/role/CommitmentsandContingenciesTables",
     "longName": "9955517 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://carismatx.com/role/StockbasedCompensationTables",
     "longName": "9955518 - Disclosure - Stock-based Compensation (Tables)",
     "shortName": "Stock-based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://carismatx.com/role/IncomeTaxesTables",
     "longName": "9955519 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementTables",
     "longName": "9955520 - Disclosure - Moderna Collaboration and License Agreement (Tables)",
     "shortName": "Moderna Collaboration and License Agreement (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://carismatx.com/role/BackgroundDetails",
     "longName": "9955521 - Disclosure - Background (Details)",
     "shortName": "Background (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-32",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated",
      "unitRef": "employee",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-32",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://carismatx.com/role/DevelopmentStageRisksandLiquidityDetails",
     "longName": "9955522 - Disclosure - Development-Stage Risks and Liquidity (Details)",
     "shortName": "Development-Stage Risks and Liquidity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsMeasuredonRecurringBasisDetails",
     "longName": "9955523 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value Hierarchy of Assets Measured on Recurring Basis (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Fair Value Hierarchy of Assets Measured on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-36",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-36",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "longName": "9955524 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofSignificantExpenseCategoriesbySegmentDetails",
     "longName": "9955525 - Disclosure - Summary of Significant Accounting Policies - Schedule of Significant Expense Categories by Segment (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Significant Expense Categories by Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-42",
      "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofDilutiveSecuritiesDetails",
     "longName": "9955526 - Disclosure - Summary of Significant Accounting Policies - Schedule of Dilutive Securities (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Dilutive Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-46",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-46",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails",
     "longName": "9955527 - Disclosure - Merger with Sesen Bio - Schedule of Net Assets Acquired in the Merger (Details)",
     "shortName": "Merger with Sesen Bio - Schedule of Net Assets Acquired in the Merger (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "carm:NumberOfBoardMembers",
      "unitRef": "seat",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "carm:NumberOfBoardMembers",
      "unitRef": "seat",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://carismatx.com/role/PrepaidExpensesandOtherAssetsDetails",
     "longName": "9955528 - Disclosure - Prepaid Expenses and Other Assets (Details)",
     "shortName": "Prepaid Expenses and Other Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "carm:PrepaidResearchAndDevelopmentCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "carm:PrepaidResearchAndDevelopmentCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://carismatx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails",
     "longName": "9955529 - Disclosure - Property and Equipment, net - Schedule of Property and Equipment, Net (Details)",
     "shortName": "Property and Equipment, net - Schedule of Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://carismatx.com/role/PropertyandEquipmentnetNarrativeDetails",
     "longName": "9955530 - Disclosure - Property and Equipment, net - Narrative (Details)",
     "shortName": "Property and Equipment, net - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R46": {
     "role": "http://carismatx.com/role/AccruedExpensesDetails",
     "longName": "9955531 - Disclosure - Accrued Expenses (Details)",
     "shortName": "Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "carm:AccruedResearchAndDevelopmentExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "carm:AccruedResearchAndDevelopmentExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://carismatx.com/role/CommitmentsandContingenciesNarrativeDetails",
     "longName": "9955532 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-62",
      "name": "carm:IncreaseDecreaseInFinanceLeaseRightOfUseAssetLeaseModification",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-62",
      "name": "carm:IncreaseDecreaseInFinanceLeaseRightOfUseAssetLeaseModification",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails",
     "longName": "9955533 - Disclosure - Commitments and Contingencies - Schedule of Lease Costs (Details)",
     "shortName": "Commitments and Contingencies - Schedule of Lease Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseTermandDiscountRateInformationDetails",
     "longName": "9955534 - Disclosure - Commitments and Contingencies - Schedule of Lease Term and Discount Rate Information (Details)",
     "shortName": "Commitments and Contingencies - Schedule of Lease Term and Discount Rate Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "carm:LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "carm:LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://carismatx.com/role/CommitmentsandContingenciesScheduleofSupplementalCashFlowInformationDetails",
     "longName": "9955535 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Cash Flow Information (Details)",
     "shortName": "Commitments and Contingencies - Schedule of Supplemental Cash Flow Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "carm:LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "carm:LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails",
     "longName": "9955536 - Disclosure - Commitments and Contingencies - Schedule of Future Maturities of Lease Liabilities (Details)",
     "shortName": "Commitments and Contingencies - Schedule of Future Maturities of Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "carm:LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "carm:LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://carismatx.com/role/StockholdersDeficitEquityDetails",
     "longName": "9955537 - Disclosure - Stockholders\u2019 (Deficit) Equity (Details)",
     "shortName": "Stockholders\u2019 (Deficit) Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-70",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-70",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://carismatx.com/role/StockbasedCompensationNarrativeDetails",
     "longName": "9955538 - Disclosure - Stock-based Compensation - Narrative (Details)",
     "shortName": "Stock-based Compensation - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-77",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-77",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails",
     "longName": "9955539 - Disclosure - Stock-based Compensation - Schedule of Stock Option Activity (Details)",
     "shortName": "Stock-based Compensation - Schedule of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://carismatx.com/role/StockbasedCompensationScheduleofEstimatedUsingTheBlackScholesOptionPricingModelDetails",
     "longName": "9955540 - Disclosure - Stock-based Compensation - Schedule of Estimated Using The Black-Scholes Option-Pricing Model (Details)",
     "shortName": "Stock-based Compensation - Schedule of Estimated Using The Black-Scholes Option-Pricing Model (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-86",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-86",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://carismatx.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails",
     "longName": "9955541 - Disclosure - Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details)",
     "shortName": "Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://carismatx.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails",
     "longName": "9955542 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "shortName": "Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails",
     "longName": "9955543 - Disclosure - Income Taxes- Schedule of Deferred Tax Assets for Federal Income Taxes (Details)",
     "shortName": "Income Taxes- Schedule of Deferred Tax Assets for Federal Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://carismatx.com/role/IncomeTaxesNarrativeDetails",
     "longName": "9955544 - Disclosure - Income Taxes - Narrative (Details)",
     "shortName": "Income Taxes - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails",
     "longName": "9955545 - Disclosure - Moderna Collaboration and License Agreement - Narrative (Details)",
     "shortName": "Moderna Collaboration and License Agreement - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementScheduleofEstimatedRevenueExpectedtobeRecognizedinTheFutureRelatedtoPerformanceObligationsDetails",
     "longName": "9955546 - Disclosure - Moderna Collaboration and License Agreement - Schedule of Estimated Revenue Expected to be Recognized in The Future Related to Performance Obligations (Details)",
     "shortName": "Moderna Collaboration and License Agreement - Schedule of Estimated Revenue Expected to be Recognized in The Future Related to Performance Obligations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "carm:RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "carm:RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementScheduleofChangesinDeferredRevenueDetails",
     "longName": "9955547 - Disclosure - Moderna Collaboration and License Agreement - Schedule of Changes in Deferred Revenue (Details)",
     "shortName": "Moderna Collaboration and License Agreement - Schedule of Changes in Deferred Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "carm:ScheduleOfChangesInDeferredRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "carm:ContractWithCustomerLiabilityDeferralOfRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "carm:ScheduleOfChangesInDeferredRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://carismatx.com/role/SubsequentEventsDetails",
     "longName": "9955548 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-32",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated",
      "unitRef": "employee",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-122",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated",
      "unitRef": "employee",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20241231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://carismatx.com/role/AccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r56",
      "r59",
      "r863"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r654"
     ]
    },
    "carm_AccretionOnMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "AccretionOnMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accretion on marketable securities",
        "label": "Accretion on Marketable Securities",
        "documentation": "Amount of accretion on marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      },
      "http://carismatx.com/role/AccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://carismatx.com/role/AccruedExpensesDetails",
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Professional fees",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "carm_AccruedResearchAndDevelopmentExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "AccruedResearchAndDevelopmentExpenseCurrent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Accrued Research and Development Expense, Current",
        "documentation": "Accrued Research and Development Expense, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r9",
      "r16",
      "r413",
      "r416",
      "r466",
      "r523",
      "r524",
      "r799",
      "r800",
      "r801",
      "r809",
      "r810",
      "r811",
      "r812"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "carm_AdditionalMilestonePaymentsForFirstCarMProduct": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "AdditionalMilestonePaymentsForFirstCarMProduct",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional milestone payments for first CAR-M product",
        "label": "Additional Milestone Payments for the First CAR-M Product",
        "documentation": "Additional amount required to be paid in development and regulatory milestone payments for the first CAR-M product directed to mesothelin."
       }
      }
     },
     "auth_ref": []
    },
    "carm_AdditionalMilestonePaymentsRequiredToBePaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "AdditionalMilestonePaymentsRequiredToBePaid",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional milestone payments",
        "label": "Additional Milestone Payments Required to be Paid",
        "documentation": "Amount of additional milestone payments required to be paid per product in commercial milestones."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r654",
      "r925"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r809",
      "r810",
      "r811",
      "r812",
      "r873",
      "r926"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r323"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r693",
      "r704",
      "r714",
      "r747"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r696",
      "r707",
      "r717",
      "r750"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "carm_AgreementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "AgreementTerm",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement term (in years)",
        "label": "Agreement term",
        "documentation": "The period of agreement."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r697",
      "r708",
      "r718",
      "r742",
      "r751",
      "r755",
      "r763"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r364"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://carismatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt discount",
        "label": "Amortization of Debt Discount (Premium)",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r74",
      "r271",
      "r881"
     ]
    },
    "carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payments",
        "label": "Amount Payable upon Achievement of Certain Clinical, Regulatory and Commercial Milestone Events",
        "documentation": "Amount required to pay per product in development upon the achievement of certain clinical, regulatory and commercial milestone events."
       }
      }
     },
     "auth_ref": []
    },
    "carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount receivable per product",
        "label": "Amount Receivable Per Product in Development Target Designation, Development, Regulatory and Commercial Milestone Payments",
        "documentation": "Amount receivable per product in development target designation, development, regulatory and commercial milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Anti-dilutive securities (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails",
      "http://carismatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r107",
      "r130",
      "r154",
      "r180",
      "r184",
      "r208",
      "r211",
      "r219",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r408",
      "r410",
      "r434",
      "r487",
      "r567",
      "r626",
      "r627",
      "r654",
      "r671",
      "r833",
      "r834",
      "r885"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r135",
      "r154",
      "r219",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r408",
      "r410",
      "r434",
      "r654",
      "r833",
      "r834",
      "r885"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets:",
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "carm_AtTheMarketMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "AtTheMarketMember",
     "presentation": [
      "http://carismatx.com/role/StockholdersDeficitEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At-the-Market",
        "label": "At-the-Market [Member]",
        "documentation": "At-the-Market"
       }
      }
     },
     "auth_ref": []
    },
    "carm_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://carismatx.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r676",
      "r677",
      "r700"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://carismatx.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r676",
      "r677",
      "r700"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://carismatx.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r676",
      "r677",
      "r700"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationNarrativeDetails",
      "http://carismatx.com/role/StockbasedCompensationScheduleofEstimatedUsingTheBlackScholesOptionPricingModelDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r327",
      "r328",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation and Principles of Consolidation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails",
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Acquiree [Domain]",
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r403",
      "r640",
      "r641"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails",
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Axis]",
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r47",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r403",
      "r640",
      "r641"
     ]
    },
    "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Transaction costs",
        "label": "Business Acquisition, Transaction Costs",
        "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails",
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Line Items]",
        "verboseLabel": "Merger with Sesen Bio",
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "presentation": [
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business acquisition percentage of voting interests acquired (as a percent)",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://carismatx.com/role/MergerwithSesenBio"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger with Sesen Bio",
        "label": "Business Combination Disclosure [Text Block]",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r404"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total net assets acquired",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "documentation": "Amount of assets acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails_1": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails_1": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities",
        "documentation": "Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails_1": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails_1": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts payable and accrued expenses",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities",
        "documentation": "Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total net assets acquired less transaction costs",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_BusinessCombinationSegmentAllocationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationSegmentAllocationLineItems",
     "presentation": [
      "http://carismatx.com/role/BackgroundDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Background",
        "label": "Business Combination Segment Allocation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails_1": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredRestrictedCash",
        "documentation": "The amount of restricted cash from business combination."
       }
      }
     },
     "auth_ref": []
    },
    "carm_CarismaTherapeuticsInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "CarismaTherapeuticsInc.Member",
     "presentation": [
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carisma Therapeutics Inc.",
        "label": "Carisma Therapeutics Inc. [Member]",
        "documentation": "Represents Carisma Therapeutics Inc."
       }
      }
     },
     "auth_ref": []
    },
    "carm_CarismaTherapeuticsIncLegacyStockholdersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "CarismaTherapeuticsIncLegacyStockholdersMember",
     "presentation": [
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CARISMA Therapeutics Inc, Legacy, Stockholders",
        "label": "CARISMA Therapeutics Inc, Legacy, Stockholders [Member]",
        "documentation": "Represents the stockholders of legacy CARISMA Therapeutics, prior to the merger."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r129",
      "r618"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents \u2013 money markets accounts",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r874",
      "r875"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents and restricted cash acquired in connection with the reverse recapitalization",
        "label": "Cash, Cash Equivalents and Restricted Cash Acquired in Reverse Recapitalization, Financing Activities",
        "documentation": "Amount of cash, cash equivalents and restricted cash acquired associated with the reverse capitalization during the period ."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/DevelopmentStageRisksandLiquidityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents and marketable securities",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning of the year",
        "periodEndLabel": "Cash and cash equivalents at end of the year",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r76",
      "r151"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (decrease) increase in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r76"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of non-cash financing and investing activities:",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:",
        "label": "Cash Paid for Amounts Included in the Measurement of Lease Liabilities [Abstract]",
        "documentation": "No definition available."
       }
      }
     },
     "auth_ref": []
    },
    "carm_CashPreservationPlan2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "CashPreservationPlan2025Member",
     "presentation": [
      "http://carismatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025 Cash Preservation Plan",
        "label": "Cash Preservation Plan, 2025 [Member]",
        "documentation": "Cash Preservation Plan, 2025"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://carismatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://carismatx.com/role/StockholdersDeficitEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r132",
      "r133",
      "r182",
      "r273",
      "r274",
      "r275",
      "r277",
      "r280",
      "r285",
      "r287",
      "r533",
      "r534",
      "r535",
      "r536",
      "r635",
      "r785",
      "r806"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "carm_CollaborationAndLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "CollaborationAndLicenseAgreementMember",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails",
      "http://carismatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration and License Agreement",
        "label": "Collaboration and License Agreement [Member]",
        "documentation": "Represents the information pertaining to collaboration and license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "carm_CollaborativeArrangementRightsAndObligationsMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "CollaborativeArrangementRightsAndObligationsMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment",
        "label": "Collaborative Arrangement, Rights and Obligations, Milestone Payments",
        "documentation": "Collaborative Arrangement, Rights and Obligations, Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Moderna Collaboration and License Agreement",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 8)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r101",
      "r489",
      "r554"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r251",
      "r252",
      "r611",
      "r825",
      "r828"
     ]
    },
    "carm_CommitmentsAnnualPaymentsRequiredToBePaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "CommitmentsAnnualPaymentsRequiredToBePaid",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual payments to be made",
        "label": "Commitments, Annual Payments Required to be Paid",
        "documentation": "Amount of annual payments required to be paid."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r661",
      "r662",
      "r663",
      "r665",
      "r666",
      "r667",
      "r668",
      "r809",
      "r810",
      "r812",
      "r873",
      "r924",
      "r926"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://carismatx.com/role/StockholdersDeficitEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in USD per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://carismatx.com/role/StockholdersDeficitEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r555"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "verboseLabel": "Entity common stock, shares outstanding immediately after merger (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r66",
      "r555",
      "r573",
      "r926",
      "r927"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock $0.001 par value, 350,000,000 shares authorized, 41,750,109 and 40,609,915 shares issued and outstanding at December\u00a031, 2024 and 2023, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r491",
      "r654"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r137",
      "r139",
      "r144",
      "r485",
      "r498",
      "r499"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of credit risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r115"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://carismatx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in progress",
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "carm_ContractTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "ContractTerm",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of contract (in years)",
        "label": "Contract Term",
        "documentation": "Period of contract."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails",
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementScheduleofChangesinDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue liability",
        "periodStartLabel": "Balance at the beginning of the period",
        "periodEndLabel": "Balance at the end of the period",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r290",
      "r309"
     ]
    },
    "carm_ContractWithCustomerLiabilityDeferralOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "ContractWithCustomerLiabilityDeferralOfRevenue",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementScheduleofChangesinDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferral of revenue",
        "label": "Contract With Customer Liability, Deferral of Revenue",
        "documentation": "Amount of revenue deferred."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncurrent portion of deferred revenue",
        "label": "Contract with Customer, Liability, Noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r290",
      "r309"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementScheduleofChangesinDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recognition of unearned revenue",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://carismatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r685",
      "r774"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r685",
      "r774"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r687",
      "r776"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r687",
      "r776"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r689",
      "r778"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r687",
      "r776"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r680",
      "r769"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r681",
      "r770"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r681",
      "r770"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r679",
      "r768"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r679",
      "r768"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r679",
      "r768"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r682",
      "r771"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r684",
      "r773"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r684",
      "r773"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r685",
      "r774"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r688",
      "r777"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r686",
      "r775"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r683",
      "r772"
     ]
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://carismatx.com/role/PrepaidExpensesandOtherAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Prepaid Expenses and Other Assets",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "carm_DeferredFinancingCostsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "DeferredFinancingCostsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred financing costs",
        "label": "Deferred Financing Costs, Noncurrent",
        "documentation": "Deferred Financing Costs, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "carm_DeferredFinancingCostsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "DeferredFinancingCostsPolicyPolicyTextBlock",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Financing Costs",
        "label": "Deferred Financing Costs, Policy [Policy Text Block]",
        "documentation": "Deferred Financing Costs, Policy"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r62",
      "r100",
      "r383"
     ]
    },
    "us-gaap_DeferredRevenueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenueCurrent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Deferred Revenue, Current",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenueNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Deferred Revenue, Noncurrent",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "carm_DeferredTaxAssetsAmortizableAssetsAndOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "DeferredTaxAssetsAmortizableAssetsAndOther",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortizable assets and other",
        "label": "Deferred Tax Assets, Amortizable Assets And Other",
        "documentation": "Deferred Tax Assets, Amortizable Assets And Other"
       }
      }
     },
     "auth_ref": []
    },
    "carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized research and development costs, net of amortization",
        "label": "Deferred Tax Assets, Capitalized Research and Development Costs, Net Of Amortization",
        "documentation": "Deferred Tax Assets, Capitalized Research and Development Costs, Net Of Amortization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsDeferredIncome",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Deferred Tax Assets, Deferred Income",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "carm_DeferredTaxAssetsEquityCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "DeferredTaxAssetsEquityCompensation",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity compensation",
        "label": "Deferred Tax Assets, Equity Compensation",
        "documentation": "Deferred Tax Assets, Equity Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGrossAbstract",
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets",
        "label": "Deferred Tax Assets, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "carm_DeferredTaxAssetsLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "DeferredTaxAssetsLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Deferred Tax Assets, Lease Liability",
        "documentation": "Deferred Tax Assets, Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets and liabilities",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets, net of valuation allowance",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating losses",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "carm_DeferredTaxAssetsStartUpCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "DeferredTaxAssetsStartUpCosts",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Start-up costs",
        "label": "Deferred Tax Assets, Start Up Costs",
        "documentation": "Deferred Tax Assets, Start Up Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Compensated Absences",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensated absences (includes, but not limited to, sick and personal days)."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Depreciation",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "carm_DeferredTaxLiabilitiesRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Right of use asset",
        "label": "Deferred Tax Liabilities, Right Of Use Asset",
        "documentation": "Deferred Tax Liabilities, Right Of Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepositsAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepositsAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/PrepaidExpensesandOtherAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/PrepaidExpensesandOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposits",
        "label": "Deposits Assets, Current",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter."
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "carm_DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofSignificantExpenseCategoriesbySegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofSignificantExpenseCategoriesbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation, amortization and interest on finance and sale-leaseback lease liabilities",
        "label": "Depreciation, Amortization And Interest On Finance And Sale-Leaseback Lease Liabilities",
        "documentation": "Depreciation, Amortization And Interest On Finance And Sale-Leaseback Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows",
      "http://carismatx.com/role/PropertyandEquipmentnetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization expense",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r34"
     ]
    },
    "carm_DevelopmentStageRisksAndLiquidityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "DevelopmentStageRisksAndLiquidityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development-Stage Risks and Liquidity",
        "label": "Development-Stage Risks and Liquidity",
        "documentation": "No definition available."
       }
      }
     },
     "auth_ref": []
    },
    "carm_DevelopmentStageRisksAndLiquidityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "DevelopmentStageRisksAndLiquidityTextBlock",
     "presentation": [
      "http://carismatx.com/role/DevelopmentStageRisksandLiquidity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development-Stage Risks and Liquidity",
        "label": "Development-Stage Risks and Liquidity [Text Block]",
        "documentation": "Development-Stage Risks and Liquidity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r325",
      "r356",
      "r357",
      "r359",
      "r643"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "carm_DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal of property and equipment in exchange for reduction in financing lease liability",
        "label": "Disposal Of Property, Plant And Equipment In Exchange For Reduction Of Capital Lease Liability",
        "documentation": "Disposal Of Property, Plant And Equipment In Exchange For Reduction Of Capital Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://carismatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r676",
      "r677",
      "r700"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://carismatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r676",
      "r677",
      "r700",
      "r743"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://carismatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://carismatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://carismatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://carismatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://carismatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://carismatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share information:",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share of common stock, basic (in USD per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r170",
      "r172",
      "r174",
      "r175",
      "r176",
      "r179",
      "r401",
      "r406",
      "r420",
      "r421",
      "r486",
      "r500",
      "r621"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share of common stock, diluted (in USD per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r172",
      "r174",
      "r175",
      "r176",
      "r179",
      "r401",
      "r406",
      "r420",
      "r421",
      "r486",
      "r500",
      "r621"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r178"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://carismatx.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total provision",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r645"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://carismatx.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Federal tax benefit at statutory rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r371",
      "r393",
      "r645"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "calculation": {
      "http://carismatx.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r645",
      "r808",
      "r864"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "calculation": {
      "http://carismatx.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent",
        "documentation": "Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences": {
     "xbrltype": "percentItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferences",
     "calculation": {
      "http://carismatx.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Permanent differences",
        "label": "Effective Income Tax Rate Reconciliation Permanent Differences",
        "documentation": "Effective Income Tax Rate Reconciliation Permanent Differences"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://carismatx.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "State and local tax, net of federal benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r645",
      "r808",
      "r864"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal",
     "calculation": {
      "http://carismatx.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "State and local tax rate change",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, State and Local, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax contingency."
       }
      }
     },
     "auth_ref": [
      "r808",
      "r864"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "calculation": {
      "http://carismatx.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r645",
      "r808",
      "r864",
      "r866"
     ]
    },
    "us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows",
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of derivative liability",
        "negatedLabel": "Change in fair value of derivative liability",
        "label": "Embedded Derivative, Gain (Loss) on Embedded Derivative, Net",
        "documentation": "Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period."
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation and related expenses",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based Compensation",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future compensation cost for awards not vested",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average period compensation cost of unvested awards to be expensed (in years)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "us-gaap_EmployeeSeveranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeSeveranceMember",
     "presentation": [
      "http://carismatx.com/role/BackgroundDetails",
      "http://carismatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Severance",
        "label": "Employee Severance [Member]",
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationNarrativeDetails",
      "http://carismatx.com/role/StockbasedCompensationScheduleofEstimatedUsingTheBlackScholesOptionPricingModelDetails",
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofDilutiveSecuritiesDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://carismatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://carismatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://carismatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://carismatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://carismatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://carismatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://carismatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://carismatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity [Domain]",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://carismatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://carismatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://carismatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://carismatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://carismatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://carismatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://carismatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://carismatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://carismatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://carismatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://carismatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquipmentMember",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://carismatx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab equipment",
        "verboseLabel": "Laboratory Equipment",
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r123",
      "r141",
      "r142",
      "r143",
      "r156",
      "r157",
      "r158",
      "r160",
      "r165",
      "r167",
      "r169",
      "r181",
      "r220",
      "r221",
      "r239",
      "r288",
      "r391",
      "r392",
      "r398",
      "r399",
      "r400",
      "r402",
      "r405",
      "r406",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r419",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r442",
      "r444",
      "r466",
      "r497",
      "r523",
      "r524",
      "r525",
      "r543",
      "r595"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r693",
      "r704",
      "r714",
      "r747"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r690",
      "r701",
      "r711",
      "r744"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "carm_FacilitiesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "FacilitiesExpense",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofSignificantExpenseCategoriesbySegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofSignificantExpenseCategoriesbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Facilities expense",
        "label": "Facilities Expense",
        "documentation": "Facilities Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value hierarchy",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r424",
      "r431",
      "r646"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r424",
      "r431",
      "r646"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r422",
      "r424",
      "r425",
      "r426",
      "r427",
      "r430",
      "r431",
      "r433",
      "r476",
      "r477",
      "r478",
      "r633",
      "r634",
      "r637",
      "r638",
      "r639",
      "r646",
      "r649"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r424",
      "r425",
      "r427",
      "r646",
      "r877",
      "r879"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r313",
      "r318",
      "r424",
      "r431",
      "r476",
      "r637",
      "r638",
      "r639",
      "r646"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r313",
      "r318",
      "r424",
      "r425",
      "r431",
      "r477",
      "r633",
      "r634",
      "r637",
      "r638",
      "r639",
      "r646"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r424",
      "r425",
      "r426",
      "r427",
      "r431",
      "r478",
      "r633",
      "r634",
      "r637",
      "r638",
      "r639",
      "r646",
      "r649"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r424",
      "r425",
      "r427",
      "r646",
      "r877",
      "r879"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r422",
      "r424",
      "r425",
      "r426",
      "r427",
      "r430",
      "r431",
      "r433",
      "r476",
      "r477",
      "r478",
      "r633",
      "r634",
      "r637",
      "r638",
      "r639",
      "r646",
      "r649"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r646",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "carm_FinanceLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "FinanceLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total finance lease cost",
        "label": "Finance Lease Cost",
        "documentation": "The amount of finance lease cost expense."
       }
      }
     },
     "auth_ref": []
    },
    "carm_FinanceLeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "FinanceLeaseCostAbstract",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease cost:",
        "label": "Finance Lease Cost [Abstract]",
        "documentation": "No definition available."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails": {
       "parentTag": "carm_FinanceLeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest on lease liabilities",
        "label": "Finance Lease, Interest Expense",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r447",
      "r453",
      "r653"
     ]
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash used in finance leases",
        "label": "Finance Lease, Interest Payment on Liability",
        "documentation": "Amount of interest paid on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r458"
     ]
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Leases",
        "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing liability",
        "verboseLabel": "Present value of lease liabilities",
        "label": "Finance Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r462"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease liabilities",
        "label": "Finance Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease liabilities",
        "label": "Finance Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total future minimum payments",
        "label": "Finance Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Finance Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Finance Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less imputed interest",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of principal related to finance lease liabilities",
        "label": "Finance Lease, Principal Payments",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r458"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAssetAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease, accumulated amortization",
        "label": "Finance Lease, Right-of-Use Asset, Accumulated Amortization",
        "documentation": "Amount of accumulated amortization of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r789",
      "r791"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails": {
       "parentTag": "carm_FinanceLeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of lease assets",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r447",
      "r453",
      "r653"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease, ROU assets",
        "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization",
        "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseTermandDiscountRateInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance leases",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r653"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseTermandDiscountRateInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance leases",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r653"
     ]
    },
    "carm_FinancingCashUsedInFinanceLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "FinancingCashUsedInFinanceLeases",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing cash used in finance leases",
        "label": "Financing cash used in finance leases",
        "documentation": "Amount of cash outflow for payment on finance lease."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r697",
      "r708",
      "r718",
      "r751"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r697",
      "r708",
      "r718",
      "r751"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r697",
      "r708",
      "r718",
      "r751"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r697",
      "r708",
      "r718",
      "r751"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r697",
      "r708",
      "r718",
      "r751"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r731"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://carismatx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office furniture",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "carm_GainLossOnSaleOfEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "GainLossOnSaleOfEquipment",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss on sale of equipment",
        "label": "Gain (Loss) on Sale of Equipment",
        "documentation": "Gain (Loss) on Sale of Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss on disposal of property and equipment",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "carm_GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofSignificantExpenseCategoriesbySegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofSignificantExpenseCategoriesbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative, excluding facilities and personnel expenses, depreciation and amortization expenses",
        "label": "General And Administrative, Excluding Facilities And Personnel Expenses, Depreciation And Amortization Expenses",
        "documentation": "General And Administrative, Excluding Facilities And Personnel Expenses, Depreciation And Amortization Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r577"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://carismatx.com/role/BackgroundDetails",
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://carismatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r676",
      "r677",
      "r700"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of long-lived assets",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r33",
      "r82",
      "r647"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r83"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://carismatx.com/role/BackgroundDetails",
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r242",
      "r245",
      "r428",
      "r429",
      "r432",
      "r520",
      "r522",
      "r580",
      "r614",
      "r648",
      "r895"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://carismatx.com/role/BackgroundDetails",
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r245",
      "r428",
      "r429",
      "r432",
      "r520",
      "r522",
      "r580",
      "r614",
      "r648",
      "r895"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction [Axis]",
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r371",
      "r372",
      "r379",
      "r388",
      "r645",
      "r869"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction [Domain]",
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r371",
      "r372",
      "r379",
      "r388",
      "r645",
      "r869"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://carismatx.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r368",
      "r371",
      "r376",
      "r377",
      "r378",
      "r380",
      "r387",
      "r394",
      "r395",
      "r396",
      "r397",
      "r538",
      "r645"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r369",
      "r370",
      "r380",
      "r381",
      "r386",
      "r390",
      "r532"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease in contract with customer, liability",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r483",
      "r804"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Increase (Decrease) in Deferred Revenue",
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "carm_IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Decrease in finance lease, liability, lease modification",
        "label": "Increase (Decrease) in Finance Lease, Liability, Lease Modification",
        "documentation": "Increase (Decrease) in Finance Lease, Liability, Lease Modification"
       }
      }
     },
     "auth_ref": []
    },
    "carm_IncreaseDecreaseInFinanceLeaseRightOfUseAssetLeaseModification": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "IncreaseDecreaseInFinanceLeaseRightOfUseAssetLeaseModification",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Decrease in finance lease, right-of-use asset, lease modification",
        "label": "Increase (Decrease) in Finance Lease, Right-of-Use Asset, Lease Modification",
        "documentation": "Increase (Decrease) in Finance Lease, Right-of-Use Asset, Lease Modification"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r792",
      "r804"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long term liabilities",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 (Deficit) Equity",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r697",
      "r708",
      "r718",
      "r742",
      "r751",
      "r755",
      "r763"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r678",
      "r767"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r678",
      "r767"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r678",
      "r767"
     ]
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income, net",
        "label": "Interest Income (Expense), Nonoperating",
        "documentation": "Amount of interest income (expense) classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r626",
      "r803",
      "r815"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash paid for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r148",
      "r149"
     ]
    },
    "us-gaap_LaborAndRelatedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LaborAndRelatedExpense",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofSignificantExpenseCategoriesbySegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofSignificantExpenseCategoriesbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Personnel expense",
        "label": "Labor and Related Expense",
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit."
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r653"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Lease Costs",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://carismatx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r463"
     ]
    },
    "carm_LeasesWeightedAverageDiscountRateAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "LeasesWeightedAverageDiscountRateAbstract",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseTermandDiscountRateInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate",
        "label": "Leases, Weighted Average Discount Rate [Abstract]",
        "documentation": "No definition available."
       }
      }
     },
     "auth_ref": []
    },
    "carm_LeasesWeightedAverageRemainingLeaseTermAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "LeasesWeightedAverageRemainingLeaseTermAbstract",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseTermandDiscountRateInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term (in years)",
        "label": "Leases, Weighted Average Remaining Lease Term [Abstract]",
        "documentation": "No definition available."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity [Axis]",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Lease Term and Discount Rate Information",
        "label": "Lessee, Operating and Finance Lease, Lease term and Discount Rate Information [Table Text Block]",
        "documentation": "The tabular disclosure of ease term and discount rate information relating to operating and finance leases."
       }
      }
     },
     "auth_ref": []
    },
    "carm_LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Maturities of Lease Liabilities",
        "label": "Lessee, Operating and Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability and finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": []
    },
    "carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Supplemental Cash Flow Information",
        "label": "Lessee, Operating and Finance Lease, Supplemental Cash flow Information [Table Text Block]",
        "documentation": "The tabular disclosure of supplemental cash flow information relating to operating and finance leases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total future minimum payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r55",
      "r56",
      "r57",
      "r58",
      "r59",
      "r60",
      "r63",
      "r154",
      "r219",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r409",
      "r410",
      "r411",
      "r434",
      "r553",
      "r622",
      "r671",
      "r833",
      "r885",
      "r886"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 (deficit) equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r102",
      "r493",
      "r654",
      "r807",
      "r820",
      "r880"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and Stockholders' (Deficit) Equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r128",
      "r154",
      "r219",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r409",
      "r410",
      "r411",
      "r434",
      "r654",
      "r833",
      "r885",
      "r886"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "carm_LocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "LocalJurisdictionMember",
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local",
        "label": "Local Jurisdiction [Member]",
        "documentation": "Local Jurisdiction"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://carismatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r254",
      "r255",
      "r259",
      "r365",
      "r632",
      "r829",
      "r830"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Table]",
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r254",
      "r255",
      "r259",
      "r365",
      "r632",
      "r829",
      "r830"
     ]
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss contingency, estimate of possible loss",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r255",
      "r258",
      "r259",
      "r365",
      "r632"
     ]
    },
    "us-gaap_LossOnContractTermination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossOnContractTermination",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract termination fee",
        "label": "Loss on Contract Termination",
        "documentation": "The loss recognized on termination of a contract."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Novartis Agreement",
        "label": "Manufacturing and Supply Agreement with Novartis Pharmaceuticals Corporation [Member]",
        "documentation": "Represents the information pertaining to manufacturing and supply agreement with Novartis Pharmaceuticals Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Realized gain on marketable securities",
        "label": "Marketable Security, Realized Gain (Loss)",
        "documentation": "Amount of realized gain (loss) on investment in marketable security."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails",
      "http://carismatx.com/role/StockbasedCompensationScheduleofEstimatedUsingTheBlackScholesOptionPricingModelDetails",
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r254",
      "r255",
      "r256",
      "r257",
      "r320",
      "r365",
      "r427",
      "r481",
      "r519",
      "r521",
      "r528",
      "r545",
      "r546",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r612",
      "r613",
      "r629",
      "r635",
      "r642",
      "r649",
      "r650",
      "r651",
      "r652",
      "r656",
      "r835",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892"
     ]
    },
    "carm_MaximumNumberOfResearchTargets": {
     "xbrltype": "integerItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "MaximumNumberOfResearchTargets",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum of research targets",
        "label": "Maximum Number of Research Targets",
        "documentation": "Maximum number of research targets."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "carm_MilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "MilestonesMember",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestones",
        "label": "Milestones [Member]",
        "documentation": "Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "MinimumCommitmentToReimburseResearchAndDevelopmentCosts",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum commitment to reimburse research and development costs",
        "label": "Minimum Commitment to Reimburse Research and Development Costs",
        "documentation": "Minimum commitment to reimburse research and development costs."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails",
      "http://carismatx.com/role/StockbasedCompensationScheduleofEstimatedUsingTheBlackScholesOptionPricingModelDetails",
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r254",
      "r255",
      "r256",
      "r257",
      "r320",
      "r365",
      "r427",
      "r481",
      "r519",
      "r521",
      "r528",
      "r545",
      "r546",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r612",
      "r613",
      "r629",
      "r635",
      "r642",
      "r649",
      "r650",
      "r651",
      "r656",
      "r835",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "carm_ModernaLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "ModernaLicenseAgreementMember",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Moderna License Agreement",
        "label": "Moderna License Agreement [Member]",
        "documentation": "Represents the information pertaining to moderna license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "carm_ModernaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "ModernaMember",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails",
      "http://carismatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Moderna",
        "label": "Moderna [Member]",
        "documentation": "Represents the information pertaining to Moderna, a significant shareholder."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MovementInDeferredRevenueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MovementInDeferredRevenueRollForward",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementScheduleofChangesinDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Movement in Deferred Revenue [Roll Forward]",
        "label": "Movement in Deferred Revenue [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used in) provided by investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77",
      "r78"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 3.0
      },
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofSignificantExpenseCategoriesbySegmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows",
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity",
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofSignificantExpenseCategoriesbySegmentDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r78",
      "r103",
      "r126",
      "r136",
      "r138",
      "r143",
      "r154",
      "r159",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r168",
      "r169",
      "r173",
      "r219",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r401",
      "r406",
      "r421",
      "r434",
      "r496",
      "r575",
      "r593",
      "r594",
      "r669",
      "r833"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently adopted accounting pronouncements and Recently issued but not yet adopted accounting pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "carm_NonCashEffectOfModificationOfOperatingLeaseRightOfUseAssetsOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "NonCashEffectOfModificationOfOperatingLeaseRightOfUseAssetsOperatingLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Modification of operating lease right-of-use asset and operating lease liabilities",
        "label": "Non-Cash Effect of Modification of Operating Lease Right-of-Use Assets Operating Lease Liabilities",
        "documentation": "Non-Cash Effect of Modification of Operating Lease Right-of-Use Assets Operating Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r697",
      "r708",
      "r718",
      "r742",
      "r751"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "carm_NoncashInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "NoncashInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash interest expense",
        "label": "Noncash Interest Expense",
        "documentation": "Amount of expense (income) related to the increase (decrease) in interest expenses."
       }
      }
     },
     "auth_ref": []
    },
    "carm_NoncashOrPartNoncashAcquisitionEquityAssumed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "NoncashOrPartNoncashAcquisitionEquityAssumed",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of convertible preferred stock and non-controlling interests upon Merger",
        "label": "Noncash or Part Noncash Acquisition, Equity Assumed",
        "documentation": "The amount of equity that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "carm_NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification of deferred financing costs to additional paid-in-capital",
        "label": "Noncash or Part Noncash Transaction, Reclassification of Debt Finance Costs",
        "documentation": "Noncash or Part Noncash Transaction, Reclassification of Debt Finance Costs"
       }
      }
     },
     "auth_ref": []
    },
    "carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain on marketable securities",
        "label": "Noncash or Part Noncash, Unrealized Gain (Loss) on Marketable Securities",
        "documentation": "Amount of unrealized gain (loss) on marketable securities in a noncash (or part noncash) transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interests",
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r288",
      "r809",
      "r810",
      "r811",
      "r812",
      "r926"
     ]
    },
    "us-gaap_NotesReduction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesReduction",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of convertible promissory note, accrued interest and derivative liability upon Merger",
        "label": "Notes Reduction",
        "documentation": "The value of notes retired (or transferred to another entity) in noncash investing or financing transactions."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r24"
     ]
    },
    "carm_NumberOfBoardMembers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "NumberOfBoardMembers",
     "presentation": [
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of board seats",
        "label": "Number of Board Members",
        "documentation": "Number of Board Members"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r627",
      "r814"
     ]
    },
    "carm_NumberOfPerformanceObligations": {
     "xbrltype": "integerItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "NumberOfPerformanceObligations",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of performance obligations",
        "label": "Number of Performance Obligations",
        "documentation": "Number of Performance Obligations"
       }
      }
     },
     "auth_ref": []
    },
    "carm_NumberOfPotentialProductsToDevelopAndCommercialize": {
     "xbrltype": "integerItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "NumberOfPotentialProductsToDevelopAndCommercialize",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of potential products to develop and commercialize",
        "label": "Number of Potential Products to Develop and Commercialize",
        "documentation": "Number of potential products to develop and commercialize"
       }
      }
     },
     "auth_ref": []
    },
    "carm_NumberOfPotentialResearchTargetDesignations": {
     "xbrltype": "integerItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "NumberOfPotentialResearchTargetDesignations",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of potential research target designations",
        "label": "Number of Potential Research Target Designations",
        "documentation": "Number of Potential Research Target Designations"
       }
      }
     },
     "auth_ref": []
    },
    "carm_NumberOfResearchTargetsGrossOncology": {
     "xbrltype": "integerItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "NumberOfResearchTargetsGrossOncology",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails",
      "http://carismatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of oncology research targets",
        "label": "Number of Research Targets, Gross, Oncology",
        "documentation": "Number of Research Targets, Gross, Oncology"
       }
      }
     },
     "auth_ref": []
    },
    "carm_NumberOfResearchTargetsNominatedAutoimmune": {
     "xbrltype": "integerItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "NumberOfResearchTargetsNominatedAutoimmune",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of nominated autoimmune target",
        "label": "Number of Research Targets Nominated, Autoimmune",
        "documentation": "Number of Research Targets Nominated, Autoimmune"
       }
      }
     },
     "auth_ref": []
    },
    "carm_NumberOfResearchTargetsNominatedOncology": {
     "xbrltype": "integerItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "NumberOfResearchTargetsNominatedOncology",
     "presentation": [
      "http://carismatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of oncology research targets, nominated",
        "label": "Number of Research Targets Nominated, Oncology",
        "documentation": "Number of Research Targets Nominated, Oncology"
       }
      }
     },
     "auth_ref": []
    },
    "carm_NumberOfResearchTargetsNominatedReplacements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "NumberOfResearchTargetsNominatedReplacements",
     "presentation": [
      "http://carismatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of research targets, replacement nominations",
        "label": "Number of Research Targets Nominated, Replacements",
        "documentation": "Number of Research Targets Nominated, Replacements"
       }
      }
     },
     "auth_ref": []
    },
    "carm_NumberOfResearchTargetsTerminatedAutoimmune": {
     "xbrltype": "integerItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "NumberOfResearchTargetsTerminatedAutoimmune",
     "presentation": [
      "http://carismatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of autoimmune research targets, ceased development",
        "label": "Number of Research Targets, Terminated, Autoimmune",
        "documentation": "Number of Research Targets, Terminated, Autoimmune"
       }
      }
     },
     "auth_ref": []
    },
    "carm_NumberOfResearchTargetsTerminatedOncology": {
     "xbrltype": "integerItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "NumberOfResearchTargetsTerminatedOncology",
     "presentation": [
      "http://carismatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of oncology research targets, ceased development",
        "label": "Number of Research Targets, Terminated, Oncology",
        "documentation": "Number of Research Targets, Terminated, Oncology"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r623",
      "r813",
      "r815",
      "r816",
      "r817",
      "r818"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r454",
      "r653"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Present value of lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash used in operating leases",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r458"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right of use assets \u2013 operating leases",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction in the operating right of use assets",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseTermandDiscountRateInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r653"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseTermandDiscountRateInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r653"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NOL carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Line Items]",
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Table]",
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "carm_OptionRightCollaborationRevenuesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "OptionRightCollaborationRevenuesMember",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Right Collaboration Revenues",
        "label": "Option Right Collaboration Revenues [Member]",
        "documentation": "Option Right Collaboration Revenues"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://carismatx.com/role/Background"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Background",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r96",
      "r529",
      "r530"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_OtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://carismatx.com/role/PrepaidExpensesandOtherAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid Expenses and Other Assets",
        "label": "Other Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity",
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain on marketable securities",
        "verboseLabel": "Unrealized gain on marketable securities",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r9",
      "r97"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r654"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/PrepaidExpensesandOtherAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/PrepaidExpensesandOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r796",
      "r821"
     ]
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration receivable",
        "label": "Other Receivables, Net, Current",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r695",
      "r706",
      "r716",
      "r749"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r698",
      "r709",
      "r719",
      "r752"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r698",
      "r709",
      "r719",
      "r752"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of reverse recapitalization finance costs",
        "label": "Payment of Finance Costs, Reverse Recapitalization, Financing Activities",
        "documentation": "Amount of cash outflow for payment of reverse recapitalization finance costs."
       }
      }
     },
     "auth_ref": []
    },
    "carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of finance liability from failed sale-leaseback arrangements",
        "label": "Payment of Finance Liability, Failed Sale Leaseback Transaction",
        "documentation": "Amount of cash outflow in a failed sale-leaseback recognized in financing activities."
       }
      }
     },
     "auth_ref": []
    },
    "carm_PaymentsForProceedsFromMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "PaymentsForProceedsFromMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Proceeds from the sale of marketable securities",
        "label": "Payments for (Proceeds from) Marketable Securities",
        "documentation": "The net cash paid (received) associated with the acquisition or disposal of all investments, including marketable securities and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfFinancingCosts",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of deferred financing costs",
        "label": "Payments of Financing Costs",
        "documentation": "The cash outflow for loan and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of marketable securities",
        "label": "Payments to Acquire Marketable Securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "carm_PennLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "PennLicenseAgreementMember",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Penn License Agreement",
        "label": "Penn License Agreement [Member]",
        "documentation": "Represents the information pertaining to Penn License Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts": {
     "xbrltype": "durationItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "PeriodOfReimbursementOfResearchAndDevelopmentCosts",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period of reimbursement of research and development costs (in years)",
        "label": "Period of Reimbursement of Research and Development Costs",
        "documentation": "Period of reimbursement of research and development costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationNarrativeDetails",
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationNarrativeDetails",
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "carm_Post2017Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "Post2017Member",
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Post-2017",
        "label": "Post-2017 [Member]",
        "documentation": "Post-2017"
       }
      }
     },
     "auth_ref": []
    },
    "carm_Pre2018Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "Pre2018Member",
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-2018",
        "label": "Pre-2018 [Member]",
        "documentation": "Pre-2018"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://carismatx.com/role/StockholdersDeficitEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in USD per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r273"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://carismatx.com/role/StockholdersDeficitEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r555"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r273"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r555",
      "r573",
      "r926",
      "r927"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock $0.001 par value, 5,000,000 shares authorized, none issued or outstanding",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r490",
      "r654"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://carismatx.com/role/PrepaidExpensesandOtherAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets",
      "http://carismatx.com/role/PrepaidExpensesandOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other assets",
        "totalLabel": "Prepaid expense and other assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid asset",
        "label": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r222",
      "r223",
      "r619"
     ]
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/PrepaidExpensesandOtherAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/PrepaidExpensesandOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance",
        "label": "Prepaid Insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r620",
      "r630",
      "r821"
     ]
    },
    "carm_PrepaidResearchAndDevelopmentCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "PrepaidResearchAndDevelopmentCurrent",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/PrepaidExpensesandOtherAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/PrepaidExpensesandOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Prepaid Research and Development, Current",
        "documentation": "Prepaid Research and Development, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromCollectionOfOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromCollectionOfOtherReceivables",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails",
      "http://carismatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from collection of collaboration receivable",
        "label": "Proceeds from Collection of Other Receivables",
        "documentation": "Amount of cash inflow from the collection of receivables classified as other."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "carm_ProceedsFromFailedSaleLeasebackTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "ProceedsFromFailedSaleLeasebackTransaction",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from failed sale-leaseback arrangement",
        "label": "Proceeds from Failed Sale Leaseback Transaction",
        "documentation": "Amount of cash inflow received by a seller-lessee in a failed sale-leaseback recognized in financing activities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of common stock under Open Market Sales Agreement, net of issuance costs",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "ProceedsFromIssuanceOfCommonStockPreClosingFinancing",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the issuance of common stock in pre-closing financing",
        "label": "Proceeds from Issuance of Common Stock, Pre-Closing Financing",
        "documentation": "Proceeds from Issuance of Common Stock, Pre-Closing Financing"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the exercise of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r13"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r215",
      "r484",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r617",
      "r636",
      "r655",
      "r656",
      "r657",
      "r659",
      "r660",
      "r831",
      "r832",
      "r836",
      "r894",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r215",
      "r484",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r617",
      "r636",
      "r655",
      "r656",
      "r657",
      "r659",
      "r660",
      "r831",
      "r832",
      "r836",
      "r894",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation and amortization",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization",
        "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r789",
      "r791",
      "r824"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://carismatx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets",
      "http://carismatx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r791",
      "r822"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, gross",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization",
        "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r788",
      "r793",
      "r823"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://carismatx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r463"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://carismatx.com/role/PropertyandEquipmentnet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment, net",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r116",
      "r120",
      "r121"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://carismatx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r463"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r116",
      "r120",
      "r495"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://carismatx.com/role/PropertyandEquipmentnetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment, Net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://carismatx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r463"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, estimated useful lives (in years)",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails",
      "http://carismatx.com/role/StockbasedCompensationScheduleofEstimatedUsingTheBlackScholesOptionPricingModelDetails",
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r254",
      "r255",
      "r256",
      "r257",
      "r312",
      "r320",
      "r351",
      "r352",
      "r353",
      "r365",
      "r427",
      "r479",
      "r480",
      "r481",
      "r519",
      "r521",
      "r528",
      "r545",
      "r546",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r612",
      "r613",
      "r629",
      "r635",
      "r642",
      "r649",
      "r650",
      "r651",
      "r652",
      "r656",
      "r663",
      "r826",
      "r835",
      "r877",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails",
      "http://carismatx.com/role/StockbasedCompensationScheduleofEstimatedUsingTheBlackScholesOptionPricingModelDetails",
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r254",
      "r255",
      "r256",
      "r257",
      "r312",
      "r320",
      "r351",
      "r352",
      "r353",
      "r365",
      "r427",
      "r479",
      "r480",
      "r481",
      "r519",
      "r521",
      "r528",
      "r545",
      "r546",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r612",
      "r613",
      "r629",
      "r635",
      "r642",
      "r649",
      "r650",
      "r651",
      "r652",
      "r656",
      "r663",
      "r826",
      "r835",
      "r877",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892"
     ]
    },
    "carm_ReceivableDueFromCollaborativeArrangementCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "ReceivableDueFromCollaborativeArrangementCurrent",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/PrepaidExpensesandOtherAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/PrepaidExpensesandOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration receivable",
        "label": "Receivable Due From Collaborative Arrangement, Current",
        "documentation": "Receivable Due From Collaborative Arrangement, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity",
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: reclassification to net loss of previous unrealized gain on marketable securities",
        "negatedLabel": "Reclassification to net loss of previous unrealized gain on marketable securities",
        "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r16"
     ]
    },
    "us-gaap_ReclassificationsOfTemporaryToPermanentEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReclassificationsOfTemporaryToPermanentEquity",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of convertible preferred stock and non-controlling interests to common stock",
        "label": "Reclassifications of Temporary to Permanent Equity",
        "documentation": "The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r98"
     ]
    },
    "carm_ReclassificationsOfTemporaryToPermanentEquityShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "ReclassificationsOfTemporaryToPermanentEquityShares",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of convertible preferred stock and non-controlling interests to common stock (in shares)",
        "label": "Reclassifications of Temporary to Permanent Equity, Shares",
        "documentation": "Number of stock classified as temporary equity reclassified or converted to permanent equity during the period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r690",
      "r701",
      "r711",
      "r744"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails",
      "http://carismatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Domain]",
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r319",
      "r470",
      "r471",
      "r488",
      "r494",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r572",
      "r574",
      "r602"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions [Abstract]",
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails",
      "http://carismatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Axis]",
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r319",
      "r470",
      "r471",
      "r488",
      "r494",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r572",
      "r574",
      "r602",
      "r884"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://carismatx.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related-Party Transactions",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r468",
      "r469",
      "r471",
      "r472",
      "r539",
      "r540",
      "r541",
      "r578",
      "r579",
      "r580",
      "r599",
      "r601"
     ]
    },
    "carm_ReportingSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "ReportingSegmentMember",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofSignificantExpenseCategoriesbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reporting Segment",
        "label": "Reporting Segment [Member]",
        "documentation": "Reporting Segment"
       }
      }
     },
     "auth_ref": []
    },
    "carm_ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofSignificantExpenseCategoriesbySegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofSignificantExpenseCategoriesbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development, excluding facilities, personnel, depreciation and amortization expenses",
        "label": "Research and Development, Excluding Facilities, Personnel, Depreciation and Amortization Expenses",
        "documentation": "Research and Development, Excluding Facilities, Personnel, Depreciation and Amortization Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r614",
      "r626",
      "r893"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://carismatx.com/role/BackgroundDetails",
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Costs",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "carm_ResearchAndDevelopmentServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "ResearchAndDevelopmentServicesMember",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Services",
        "label": "Research and Development Services [Member]",
        "documentation": "Represents the information pertaining to research and development services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchMember",
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "label": "Research Tax Credit Carryforward [Member]",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r691",
      "r702",
      "r712",
      "r745"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r692",
      "r703",
      "r713",
      "r746"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r699",
      "r710",
      "r720",
      "r753"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected cost with the reduction in workforce",
        "label": "Restructuring and Related Cost, Expected Cost",
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r246",
      "r248",
      "r250"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated",
     "presentation": [
      "http://carismatx.com/role/BackgroundDetails",
      "http://carismatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction in workforce, number of employees",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated",
        "documentation": "The number of positions eliminated during the period as a result of restructuring activities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "presentation": [
      "http://carismatx.com/role/BackgroundDetails",
      "http://carismatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction in workforce (as a percent)",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/BackgroundDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring charges",
        "label": "Restructuring Charges",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r247",
      "r248",
      "r827"
     ]
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://carismatx.com/role/BackgroundDetails",
      "http://carismatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Type [Axis]",
        "label": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r244",
      "r248",
      "r249"
     ]
    },
    "us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://carismatx.com/role/BackgroundDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes restructuring charges."
       }
      }
     },
     "auth_ref": [
      "r786",
      "r787"
     ]
    },
    "us-gaap_RestructuringPlanAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringPlanAxis",
     "presentation": [
      "http://carismatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Plan [Axis]",
        "label": "Restructuring Plan [Axis]",
        "documentation": "Information by individual restructuring plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringPlanDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringPlanDomain",
     "presentation": [
      "http://carismatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Plan [Domain]",
        "label": "Restructuring Plan [Domain]",
        "documentation": "Identification of the individual restructuring plans."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringReserve",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/BackgroundDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring reserve",
        "label": "Restructuring Reserve",
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r249"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets",
      "http://carismatx.com/role/DevelopmentStageRisksandLiquidityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r90",
      "r492",
      "r526",
      "r527",
      "r537",
      "r556",
      "r654"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r156",
      "r157",
      "r158",
      "r160",
      "r165",
      "r167",
      "r169",
      "r220",
      "r221",
      "r239",
      "r391",
      "r392",
      "r398",
      "r399",
      "r400",
      "r402",
      "r405",
      "r406",
      "r412",
      "r414",
      "r415",
      "r417",
      "r419",
      "r442",
      "r444",
      "r523",
      "r525",
      "r543",
      "r926"
     ]
    },
    "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      },
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofSignificantExpenseCategoriesbySegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails",
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofSignificantExpenseCategoriesbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration revenues",
        "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer",
        "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r871"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer [Abstract]",
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Collaboration revenues",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r105",
      "r180",
      "r185",
      "r186",
      "r206",
      "r211",
      "r215",
      "r216",
      "r217",
      "r307",
      "r308",
      "r484"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r616"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Moderna Collaboration and License Agreement",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r311"
     ]
    },
    "us-gaap_RevenuePerformanceObligationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuePerformanceObligationAbstract",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementScheduleofEstimatedRevenueExpectedtobeRecognizedinTheFutureRelatedtoPerformanceObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance obligations:",
        "label": "Revenue, Performance Obligation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligation",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementScheduleofEstimatedRevenueExpectedtobeRecognizedinTheFutureRelatedtoPerformanceObligationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementScheduleofEstimatedRevenueExpectedtobeRecognizedinTheFutureRelatedtoPerformanceObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total performance obligations",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Revenue Expected to be Recognized in The Future Related to Performance Obligations",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]",
        "documentation": "Tabular disclosure of expected timing for satisfying remaining performance obligation."
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "carm_RevenueRemainingPerformanceObligationOptionRightsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "RevenueRemainingPerformanceObligationOptionRightsAmount",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementScheduleofEstimatedRevenueExpectedtobeRecognizedinTheFutureRelatedtoPerformanceObligationsDetails": {
       "parentTag": "us-gaap_RevenueRemainingPerformanceObligation",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementScheduleofEstimatedRevenueExpectedtobeRecognizedinTheFutureRelatedtoPerformanceObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option rights",
        "label": "Revenue, Remaining Performance Obligation, Option Rights, Amount",
        "documentation": "Amount of transaction price allocated to option rights performance obligation that has not been recognized as revenue."
       }
      }
     },
     "auth_ref": []
    },
    "carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementScheduleofEstimatedRevenueExpectedtobeRecognizedinTheFutureRelatedtoPerformanceObligationsDetails": {
       "parentTag": "us-gaap_RevenueRemainingPerformanceObligation",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementScheduleofEstimatedRevenueExpectedtobeRecognizedinTheFutureRelatedtoPerformanceObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Revenue, Remaining Performance Obligation, Research and Development, Amount",
        "documentation": "Amount of transaction price allocated to research and development performance obligation that has not been recognized as revenue."
       }
      }
     },
     "auth_ref": []
    },
    "carm_RevisedOperatingPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "RevisedOperatingPlanMember",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revised Operating Plan",
        "label": "Revised Operating Plan [Member]",
        "documentation": "Revised Operating Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets obtained in exchange for new financing lease liabilities",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r653"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r653"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "us-gaap_SaleAndLeasebackTransactionGainLossNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleAndLeasebackTransactionGainLossNet",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gain on sale of sale-leaseback",
        "terseLabel": "Gain on sale of sale-leaseback",
        "label": "Sale and Leaseback Transaction, Gain (Loss), Net",
        "documentation": "Amount of gain (loss) on sale and leaseback transaction from transfer of asset accounted for as sale."
       }
      }
     },
     "auth_ref": [
      "r457",
      "r465",
      "r653"
     ]
    },
    "us-gaap_SaleLeasebackTransactionAccumulatedDepreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleLeasebackTransactionAccumulatedDepreciation",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale leaseback transaction, accumulated depreciation",
        "label": "Sale Leaseback Transaction, Accumulated Depreciation",
        "documentation": "The accumulated depreciation and amortization related to the asset(s) sold in connection with the property sold to another party and leased back to the seller."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r109",
      "r110",
      "r111",
      "r464"
     ]
    },
    "us-gaap_SaleLeasebackTransactionNetBookValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleLeasebackTransactionNetBookValue",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale lease-back asset",
        "label": "Sale Leaseback Transaction, Net Book Value",
        "documentation": "The net book value of the asset(s) sold in connection with the sale of the property to another party and lease back to the seller."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r883"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/StockholdersDeficitEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds",
        "label": "Sale of Stock, Consideration Received Per Transaction",
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor."
       }
      }
     },
     "auth_ref": []
    },
    "carm_SaleOfStockMaximumOfferingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "SaleOfStockMaximumOfferingAmount",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/StockholdersDeficitEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, maximum aggregate offering price",
        "label": "Sale of Stock, Maximum Offering Amount",
        "documentation": "Sale of Stock, Maximum Offering Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://carismatx.com/role/StockholdersDeficitEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://carismatx.com/role/StockholdersDeficitEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "carm_SaleOfStockStockOfferingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "SaleOfStockStockOfferingAmount",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/StockholdersDeficitEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock offering, amount",
        "label": "Sale of Stock, Stock Offering, Amount",
        "documentation": "Sale of Stock, Stock Offering, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://carismatx.com/role/AccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Dilutive Securities",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://carismatx.com/role/BackgroundDetails",
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails",
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r47",
      "r403"
     ]
    },
    "carm_ScheduleOfChangesInDeferredRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "ScheduleOfChangesInDeferredRevenueTableTextBlock",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Changes in Deferred Revenue",
        "label": "Schedule of Changes in Deferred Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of changes in deferred revenue."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Tax Assets for Federal Income Taxes",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r645",
      "r864"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value Hierarchy of Assets Measured on Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r874",
      "r875"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://carismatx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r463"
     ]
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "presentation": [
      "http://carismatx.com/role/MergerwithSesenBioTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Net Assets Acquired in the Merger",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofSignificantExpenseCategoriesbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Significant Expense Categories by Segment",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationNarrativeDetails",
      "http://carismatx.com/role/StockbasedCompensationScheduleofEstimatedUsingTheBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r324",
      "r326",
      "r327",
      "r328",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r91"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Using The Black-Scholes Option-Pricing Model",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://carismatx.com/role/StockholdersDeficitEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock, Class of Stock [Table]",
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r85",
      "r88",
      "r89",
      "r90",
      "r131",
      "r132",
      "r133",
      "r182",
      "r273",
      "r274",
      "r275",
      "r277",
      "r280",
      "r285",
      "r287",
      "r533",
      "r534",
      "r535",
      "r536",
      "r635",
      "r785",
      "r806"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://carismatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://carismatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofSignificantExpenseCategoriesbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r107",
      "r180",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r217",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r238",
      "r246",
      "r250",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r625",
      "r626",
      "r627",
      "r631",
      "r658",
      "r894",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923"
     ]
    },
    "us-gaap_SegmentReportingInformationAdditionalInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationAdditionalInformationAbstract",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofSignificantExpenseCategoriesbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less:",
        "label": "Segment Reporting Information, Additional Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofSignificantExpenseCategoriesbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information [Line Items]",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofSignificantExpenseCategoriesbySegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofSignificantExpenseCategoriesbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other segment items(a)",
        "label": "Segment Reporting, Other Segment Item, Amount",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r197",
      "r198",
      "r211",
      "r626"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r214",
      "r216",
      "r624",
      "r625",
      "r628"
     ]
    },
    "carm_SesenBioIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "SesenBioIncMember",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sesen Bio, Inc.",
        "label": "Sesen Bio, Inc [Member]",
        "documentation": "Represents the entity Sesen Bio, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance and personnel costs paid",
        "label": "Severance Costs",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount to the market price (as a percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date",
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofEstimatedUsingTheBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofEstimatedUsingTheBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofEstimatedUsingTheBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationNarrativeDetails",
      "http://carismatx.com/role/StockbasedCompensationScheduleofEstimatedUsingTheBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based Compensation",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r324",
      "r326",
      "r327",
      "r328",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for issuance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual term (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]",
        "documentation": "No definition available."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable as of December 31, 2024 (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable as of December 31, 2024 (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails",
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "terseLabel": "Stock-based options forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding as of December 31, 2024",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding as of December 31, 2023 (in shares)",
        "periodEndLabel": "Outstanding as of December 31, 2024 (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r331"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding as of December 31, 2023 (in USD per share)",
        "periodEndLabel": "Outstanding as of December 31, 2024 (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r331"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationNarrativeDetails",
      "http://carismatx.com/role/StockbasedCompensationScheduleofEstimatedUsingTheBlackScholesOptionPricingModelDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r327",
      "r328",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in USD per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r335"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in USD per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in USD per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r329",
      "r348",
      "r349",
      "r350",
      "r351",
      "r354",
      "r360",
      "r361",
      "r362",
      "r363"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Terms (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofEstimatedUsingTheBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable as of December 31, 2024",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable as of December 31, 2024",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding as of December 31, 2024",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssued",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Shares, Issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://carismatx.com/role/StockholdersDeficitEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issue price per share (in USD per share)",
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short term lease cost",
        "label": "Short-Term Lease, Cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r653"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r152"
     ]
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SoftwareDevelopmentMember",
     "presentation": [
      "http://carismatx.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer software",
        "label": "Software Development [Member]",
        "documentation": "Internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "carm_StateJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "StateJurisdictionMember",
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "State Jurisdiction [Member]",
        "documentation": "State Jurisdiction"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofSignificantExpenseCategoriesbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r107",
      "r125",
      "r180",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r217",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r238",
      "r241",
      "r246",
      "r250",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r625",
      "r626",
      "r627",
      "r631",
      "r658",
      "r894",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r66",
      "r69",
      "r70",
      "r123",
      "r141",
      "r142",
      "r143",
      "r156",
      "r157",
      "r158",
      "r160",
      "r165",
      "r167",
      "r169",
      "r181",
      "r220",
      "r221",
      "r239",
      "r288",
      "r391",
      "r392",
      "r398",
      "r399",
      "r400",
      "r402",
      "r405",
      "r406",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r419",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r442",
      "r444",
      "r466",
      "r497",
      "r523",
      "r524",
      "r525",
      "r543",
      "r595"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r157",
      "r158",
      "r181",
      "r444",
      "r484",
      "r531",
      "r544",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r555",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r574",
      "r576",
      "r577",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r595",
      "r664"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r157",
      "r158",
      "r181",
      "r218",
      "r444",
      "r484",
      "r531",
      "r544",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r555",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r574",
      "r576",
      "r577",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r595",
      "r664"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r694",
      "r705",
      "r715",
      "r748"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity",
      "http://carismatx.com/role/StockholdersDeficitEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock to Sesen Bio shareholders in reverse capitalization (in shares)",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r66",
      "r90"
     ]
    },
    "carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests",
     "presentation": [
      "http://carismatx.com/role/StockholdersDeficitEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued upon conversion of convertible preferred stock and exchangeable shares previously presented as noncontrolling interests (in shares)",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Preferred Stock and Non-Controlling Interests",
        "documentation": "Number of stock issued during the period upon the conversion of convertible preferred stock and noncontrolling interests."
       }
      }
     },
     "auth_ref": []
    },
    "carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of convertible preferred stock and non-controlling interests to common stock",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Preferred Stock and Non-controlling Interests Upon Merger",
        "documentation": "Number of stock issued during the period upon the conversion of convertible preferred stock and noncontrolling interests upon merger."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity",
      "http://carismatx.com/role/StockholdersDeficitEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon settlement of convertible promissory note, accrued interest, and related derivative liability (in shares)",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r37",
      "r66",
      "r69",
      "r90",
      "r270"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity",
      "http://carismatx.com/role/StockholdersDeficitEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Sale of common stock under Open Market Sales Agreement, net of issuance costs (in shares)",
        "terseLabel": "Shares issued in a pre-closing funding (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r65",
      "r66",
      "r90",
      "r533",
      "r595",
      "r608"
     ]
    },
    "carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesPreclosureFinancingTransaction",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for cash in pre-closing financing (in shares)",
        "label": "Stock Issued During Period, Shares, Pre-closing, Financing Transaction",
        "documentation": "Number of shares of stock issued during the period pursuant to pre-closing financing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity",
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options (in shares)",
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r65",
      "r66",
      "r90",
      "r335"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock to Sesen Bio shareholders in reverse capitalization",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "documentation": "Value of stock issued pursuant to acquisitions during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r66",
      "r69",
      "r70",
      "r90"
     ]
    },
    "carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of convertible preferred stock and non-controlling interests to common stock (in shares)",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Preferred Stock and Non-controlling Interests Upon Merger",
        "documentation": "Value of stock issued during the period upon the conversion of convertible preferred stock and noncontrolling interests upon merger."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity",
      "http://carismatx.com/role/StockholdersDeficitEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon settlement of convertible promissory note, accrued interest, and related derivative liability",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r66",
      "r69",
      "r70",
      "r90"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity",
      "http://carismatx.com/role/StockholdersDeficitEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of common stock under Open Market Sales Agreement, net of issuance costs",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r65",
      "r66",
      "r90",
      "r543",
      "r595",
      "r608",
      "r670"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r66",
      "r69",
      "r70",
      "r90"
     ]
    },
    "carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "StockIssuedDuringPeriodValuesPreclosureFinancingTransaction",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for cash in pre-closing financing",
        "label": "Stock Issued During Period, Values, Pre-closing Financing Transaction",
        "documentation": "Value of stock issued pursuant to preclosing financing during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets",
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 (deficit) equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50",
      "r51",
      "r123",
      "r124",
      "r142",
      "r156",
      "r157",
      "r158",
      "r160",
      "r165",
      "r167",
      "r220",
      "r221",
      "r239",
      "r288",
      "r391",
      "r392",
      "r398",
      "r399",
      "r400",
      "r402",
      "r405",
      "r406",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r419",
      "r435",
      "r436",
      "r440",
      "r443",
      "r466",
      "r524",
      "r525",
      "r542",
      "r557",
      "r573",
      "r596",
      "r597",
      "r609",
      "r670",
      "r807",
      "r820",
      "r880",
      "r926"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 (deficit) equity:",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity Note [Abstract]",
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://carismatx.com/role/StockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 (Deficit) Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r153",
      "r272",
      "r274",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r286",
      "r288",
      "r418",
      "r598",
      "r600",
      "r610"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://carismatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Line Items]",
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r474"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails",
      "http://carismatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r474"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://carismatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Table]",
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r474"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails",
      "http://carismatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r474"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails",
      "http://carismatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r474"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events [Abstract]",
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://carismatx.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r473",
      "r475"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://carismatx.com/role/StockholdersDeficitEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosures of cash flow information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforward",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Axis]",
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward, Name [Domain]",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Period [Axis]",
        "label": "Tax Period [Axis]",
        "documentation": "Information by period subject to enacted tax law."
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Period [Domain]",
        "label": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests",
        "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r154",
      "r219",
      "r434"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Temporary Equity, Shares Issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://carismatx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "carm_TrusteesOfUniversityOfPennsylvaniaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "TrusteesOfUniversityOfPennsylvaniaMember",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Penn",
        "label": "Trustees of the University of Pennsylvania [Member]",
        "documentation": "Represents the information pertaining to Trustees of the University of Pennsylvania ."
       }
      }
     },
     "auth_ref": []
    },
    "carm_TwoThousandFourteenEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "TwoThousandFourteenEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2014 Employee Stock Purchase Plan",
        "label": "Two Thousand Fourteen Employee Stock Purchase Plan [Member]",
        "documentation": "Represents Two Thousand Fourteen Employee Stock Purchase Plan."
       }
      }
     },
     "auth_ref": []
    },
    "carm_TwoThousandFourteenStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "TwoThousandFourteenStockIncentivePlanMember",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2014 Stock Incentive Plan",
        "label": "Two Thousand Fourteen Stock Incentive Plan [Member]",
        "documentation": "Represents Two Thousand Fourteen Stock Incentive Plan."
       }
      }
     },
     "auth_ref": []
    },
    "carm_TwoThousandSeventeenStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "TwoThousandSeventeenStockIncentivePlanMember",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2017 Stock Incentive Plan",
        "label": "Two Thousand Seventeen Stock Incentive Plan [Member]",
        "documentation": "Represents the Two Thousand Seventeen Stock Incentive, a Legacy Plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails",
      "http://carismatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://carismatx.com/role/BackgroundDetails",
      "http://carismatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Type of Restructuring [Domain]",
        "label": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r244",
      "r248",
      "r249"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "carm_UpfrontNonRefundablePaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "UpfrontNonRefundablePaymentReceived",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront non-refundable payment received",
        "label": "Upfront Non-Refundable Payment Received",
        "documentation": "Upfront non-refundable payment received."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r113",
      "r114",
      "r117",
      "r118"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "carm_VariableConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "VariableConsideration",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable consideration",
        "label": "Variable Consideration",
        "documentation": "Amount of variable consideration."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease cost",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r653"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average shares of common stock outstanding, diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r176"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average shares of common stock outstanding, basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r176"
     ]
    },
    "carm_WriteOffOfPropertyAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20241231",
     "localname": "WriteOffOfPropertyAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Write-off of property and equipment",
        "label": "Write-off of Property and Equipment",
        "documentation": "Write-off of Property and Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805/tableOfContent"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-3"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481192/840-30-45-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481266/840-40-55-50"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "51",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481266/840-40-55-51"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481266/840-40-55-52"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479428/808-10-45-3"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479741/842-40-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479741/842-40-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "275",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479072/912-275-50-4"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(1)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "15",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/815-15/tableOfContent"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479741/842-40-50-2"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>91
<FILENAME>0001628280-25-015673-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-25-015673-xbrl.zip
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M#U(D$FW8T^DLCJXY,O1DV*!TMN43.8-[Y(->:0/Y.YW!211R:B<,<1K"3Z]
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M)-3!FR_?\7]K%V<+GT:)>.+]Y_./SD]P0X91^"F;PB"NHR[2<Q3'H$(<.*%
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MN"DF*?J\]7$>.?431S@W,@CJ7\/H!J8I10(;X\$728:VJT@<3X[]D .KYUF
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M+3 IFE]V !>>P!^&B=+&7#'S4SA&^A",-DX$^3/S8Y5'0?X/<HM@")E_ O_
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MWH)]7(GW2)@Q:!*OP7E4=]?A'0BO)3__'4W/<Y(#0 !6WF"=9?<)JO=GW%&
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MP<&8L%B[ ?-$:73HO#6$QO=.@9QM^%2T[,DY;_S9EW7R \O;B4!1@5N?8!A
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M]M4W7V;A@9"0&4[?)Z=4ON7-'[;[?YO9&"^FCV!*IOW1QT\2G,8-"8BI9Y\
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M"NB+NOJEO^1Z>7057>W&OX3[6 K3WF11H05$9"E5U!5CL=M^6]RJ%7O45)U
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M_6CXXX$DOGD 2?S!01)'XPZ1-10,)1T-CDJ8].QP2D5DP+B KM;DH/,S4'U
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M2]) TI7!95-)\T<JHF%-8]2F-N+J"2$7T\](X\E7DNB6S1,^!DR TI[+%&%
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M=,LSE1)YITJ!QFK]T[NS$&-Q1WE;N_I-C%23,4E#;-)PF!E9T7 XYV'_<'_
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MQ@E2:XF:/((]%:B)LS##G)7;7;XP']85UDS;R(.0$X)XG9D_L'#7&:&B+^T
M[W!M%Q(PGG<3 IP^E^H(@V%59K-E[<A^TYW.7E(WR(><?*S@Y4>2\UV.JO@B
MI_P@Z@"D5^%6#[EL[;JG3I/KRJ#:,AB7Z_;+P8I5<3UVV@%!UUMSXF_5-QN
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M-D4BX_VMY2![H5.$69"V1=6[SE5 U9)S?,(I_G5;X(  E3H3>RUZ**>"16#
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MDBX*>O4FQ[H2-]\IC20Y@4@FQ4>8=:)N*":FY]M 3@_>9UPS84FT_NBA;SY
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M([BON&'VM\6:$'W5Y6BK'0Q5WC$,W76&T,U0NN)K)N7^//I1GJ[-BM^)C-[
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M)^'2)BJ8Z)*\P5 =VMK,U"9YU[UCGS6X58-A,@>T*SQ+!(@=),U]T5QFW!O
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MNCRWMAKR]/=[^EU8BE#B-GJ#>TRD[OL(SB8BO];ET2P-S7V63!:/^I,V9S)
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MSH5[*WY:%L1!@P83Y+O0=4-]\3)_6^UK4,(&@\7GE. *W^^XK>3Q%\-FD-V
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MHTY-'XBJ_!O#?Z SLRBS$HZ@A1YA5@Q+0ER?XG#9,VW&','.B/^UJ'+NG"Z
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MJPK\*0*4F[H4AZ:*+4VUR#'DJPMR>GC,C &5DV8KE I,4E5H/X+S^]$#=3Q
MG^8 [5$@'+@BTMY._LQ/^+.7_&<O%!W OUL3IH7<X2AYX[6+]4RZW8H0+CF
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M TZO/&$SQ&_GX?MP=6YI]9J1+3*5;.X\+S9;YO95KIK(8!BYXQG/.#-)02
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M.:-3P! 5XZ$5D]&L@Y.JFJ3D0S7,;OMP=\D+NA=_7\OAH>U42=G_@UM\/$I
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MTI5"-\ZQ34<IO-=;W9OH:5^B,J/.#!9 WQ#H=,XM*=II6FN?/O2<N>J_B&@
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M:&SOM"Z)N7 I VYR)3#%82[Z+0N1+Z-8."DAK:!(/= FU39Z\Q@ [C#??[_
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M5<RS;[[GP9@_ ITLQI;-W3&]0 -V">KD"#=B$Y4G2"ZJ'Z$X0;GW BSLN4B
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M'$"0:2KE\&O=7_W9G9Y]2JT0R :T2-L+@@%0B$#?)!0W/*]D!;C)"E3).34
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M>8XN00:NNZH\KX80)B-1$&.JB'2>\S;4X>?)Q;)F].3B_O!+S8 E "&O2,V
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MPP!.S$^GUE*ZJC(>-C8JFC5HG.H<;?MN3O57)5.PL/ -MP6S6?)1G\-!>9:
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M#1QV8+-Y/6?+>X;3\AW&X3L!_H27)V3;UQZB\%8@"L_RG/K95 &Q%RHG?.8
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M!R'(9ZZ<P:Z>.?OKK];YHTG1L8#=/-NBJ*W6QJ2JK1046CM^<B<-G^AZ%[5
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M:>GA2<<.V0*K<=9A\K!4D$QC2DK,L.M\#S[XCKXKHM>QHA07(B&\JA1'@;*
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M<Y2N2U/A<T_*UMH<O00P&*ZT.J3FAOZ#=<O"2"'%+ZUA<7S<@6@))6VO]N<
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MGX2[2D"3(%UDD?Y/^,(J[-%!WH.^09=>-?EUOAV4(/4W%L0-J\8T=T E0PM
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M%T510>&C9?M>>N+0U!L06!0'\FB:)78FRC+9'=K%9; Q+H^O,PUO!&X/\"Y
MRV/0E M5']Z>$$ST1K/A%^>)QO:C%[V*-GOQ^.L3"BR-/-P;*LKJ[_H=8!KD
M@QJ+3O"WR 6B<DM9Y5I>I<9P/EP>/QI]-]BO!I90J%P)GH>,M[16J7VK2/SF
M'AX4-I4\K%-6PN4VR#4W!:)49DQ(BY4",4K0<M-.)R#.Q(IMZCJL2D[+[*G?
MFJ!4\%;^^NZU<LZH.\SYNG5-( FK'FP2.F:S55A\G/[CYPEN<!VNT/,1DQDQ
MHE/1=;M?OAB&)!N^#BV-RSY\@$0*&2).E8GUD&037Q]_.6$R_KW/[/QP_NZ/
MKRU[3:_E+HD@A,?$-"=H<JB\DTMQ!YC4JL4'M/;7?:NH4OQAC96*]!!?.6S,
M<D_,[VS4]TVYH],"-[ FJC#H U9-X;V$\>(N3\T>3;X<7L4-EN#=I+3(AI'M
M4,2Y%48BY%Y,$OR";]I32XS +'9]);S,<IR?CE>"HV/6D;2LH)"R@\XGG (%
M3]6V9*J+4N?&3EG%-&5L&R,O-#*6&K>%P['BXX\KDD3J7U3*!Z[=R_?0.B@+
M3]@_+ . QF5> L)Z5%,)GH;]H@ZAEC<@[(I17E.)_-7SZA C2?0_HF5U\&\O
M"0O7_+*\*$WM9V^"V-Y]@3"*LL8I0*YPD+#PR!OXJ:S"H6&2N*@"=H[U'9%M
M"*<H_8B#5'  XO025*J6.^6)02T?TQ&GBY<UQ#T$M)+H:.'51,W0'+XI!HR&
M G]PPK/B %6[+O-_4:I@F1 SS.E7D1^H>Y6U8UP5*]GY4@Y.D^FYEO8XV'<2
M#%.=$//H?,XG.X<O1(S 7Z,,SKV3;",(.6%)#"-BORJ,P4>K\U *H=1%(@?B
MU87M;."?KEB1;\!'>7%P(+Y&&2#]+Z[5P=5:GOA(\D!</JT.*CMT#_?\60O>
M"*[ZS#=8L*&+\E)Q-C/?UN&)%D02RVQKFW;)0SE!<G*;</G]F'["T?+3?#+\
M3!V%L=S+8&M/79VV!-4[XN7HR;!-=OUVP[P8!Y%<5N=X="/+C.FQPRU$@MA.
MI6O 8YU9?P1KM+C@AQ15P]\51S&M9Z.%#GZ)P3+.QALTT7J9%+F<F6CJ%I$G
M\=BA5._$4T#6*3;O=/%4GV5$/)"QLA8W!(%\J>V&BIB#\;9;)A$ODUCE+J#0
M-XGL*FJYW*A/M?H[C1R]QHTD,_<!__&1)?6S>%*DB@U'28-B93Q"0CVK4BH2
M/(1P.B:!(?$;NGH*/94\);K# CHN2Z1=:;T9O/9@PM634(&ZD1\YS"=QJP5'
MI=QKI3F8G9UXAF0V8/?C("F7W,WJ\O=AO1P_(CYZ=63#5NU48] <N6Q@63SM
MOR9#O/RITSI5S!#+G0J3W544)/33-9U3FFA%#%^J>:WZQ;+V,.B/4$&-)U4B
M7<!=]@[7!*\B2A<IMCG9/3Y!Q4]#>23NI')P5@ENAN^0I<_@LZP/M7FKS7_S
M4)O_G=?F[XS)':2J_]GG<%TD814_R-M@(W,ELP]#)F*>S/6#F)7]^O6"-:4%
ME:O)_9%AT,H0V;B$*Q8VBB#'[.I>'MIP5N:5-O<ZO>K3A0K$WR355QI; 'M^
M":5;:ID3G[.21)(69OJV\$I3/D,I5S)FPMH:A*C.6)HN03RY4B)I-SS"IBVB
M=?GB#27-!VBWEY%W^"T9Y6+#A$%@SOWM>@A:?_30UWIX\D'=+YQJV\/P<--C
M'XF1@4@J='F:JR(<UISK#2Y^796=T>(X33CH!2=+C/.?TXV*PZE^2LR(IC_Z
M-QI0ZL=8;NN6H<J2ZH%SXAXA=6'<FO<."GB#-&\ZR+(B AWF4K.X9K%C=2]Z
M;=^X9Y![75G3!$>)(TTYV1A7I;D=R174SXJ#QM/80F$CA*5(_7@OODI2_X:]
ML<0M?RU:E7J]/L%=H B(IURSIR]^?^IHHB4_RD@#$='Z8L0JFXX3KG, @;G]
M8J3CQ/P<]B@V8Z>+_UO6VP1VJ7G%YS55G0@"R4GJ\[K=(:VI:AS/GYZ?>4X#
MU3D9$=.'15TLSCG]AQ][9TPF2):,)#',X\42<HA,EH#F?$4^KO>U++:U+>P_
MUXLK?4'\UWJ4-94..7"@K9N\Y\677]!T@48B?A7IG1T*LI3ZQ!/15W[#9BX!
MNI M0._ DI*J!YD=K?KWU?N*>B<&U<S8NCB*+R<C+)K<^1A<NY&23<C"P)/A
MUB M<XM(F1.;AY)D3Z(*/*7U_,K^RW]\RO<TSM7F9%NLN[]\^<UDPI0_*B'+
M\Y>3Q]_NN\^T+/[W__/G;[YZ\MUGXL(CESD9KL=?G7[U#0W&T%:G(?%M%\UW
M#Y/T:TX2'0%Z$"\2QM14FOUA6G[5:5'KG,9$4#9^F(E//!,NAG"0V5O'$ _S
M\TGG1WQMH\! D8=:H2BBX,\>9N#3SL"(DSGAB8V%E8=Y^,26:MVW ID7L)RJ
MIB24!JA.["61U+JOK]+O*<H%I8*'R?O4D[=TP@T/3M;G<+(025//#(IL9;,Z
MH8S<@<C0ZH=3Y!-/QIK0,!D2?-J@5"._L:F;3:%IT; QUF4GN \ )1[FY=/.
M2]NW1*,J\Y&>]1-R&@^S\6N=\1"\-G0@NCH@*UA'G8J'8^37F!/U=MNB_%??
M%-^%>7@8\$\YX"1)744DE^X !GP N0^U80K%FW+' BB*UOIME@= R?=VBJP0
MVB):VYE!2SMI#*Z]4;,RT[SE\Y(]7O K3>;GBP8-L*CZN^R)P]/* PUP!G:O
M;%"&@O87'3@C11L%.0FNZ2]3O8OAO:(ZB94214:EOBHW)==V(3*&>B[#FP!C
MZK>.-I\J@EQ:YJIK,B(>/>8PN%*K10HU,HU_-X%+H_&..J_C=\U<<2;W2GHQ
MDV[O&0::R,_!,TX=351:^<X:D8Y4B=T3H,#G^X9X7;EBM,DL3 @&T@^405$+
MH\]^7KSD#E[P<'+!;J@3YI?2L-TU7"!94C0CN,DD;-@@FKR&Q&;<;Q/P;T!K
MIQ#-$:J<& (%)0+OPFV*L02N# ,#J"N5>:U7CAF4PZJX\K7L8=.4F:C86A-7
M8/) :^3S+$'1 [5Y/8WX'5O[+('L(L2(-5!;$(QPR'>@2[BFYK_[O41NQ,JD
M4S%7__>0D8EIP*0SF? 'P<E, J73=@$'8,U(ZBF#>-1QANLQ ];CV"4*#@RT
M#'&[OW\WMEPK8!8NN'6T.^RY [R@IG+KWL3IR*2\:1]Y260C'71[=;%:GR2A
M$G!&>B'@T\7K"$YC.4."4%P66R*Q$ #%Q4 ],*)!>!9*TIOK2B6OL*9&Q:"$
MTXX>L.V8+E:.N11) S%$?M84.N9.2)P'C8CS"<EHF[1.>J 0/3*=Q%X6A'\H
MS;1SW3-N3DX7/]4=_3W*@L/$Z\WCQ-H^G>(^9*37MMC@U"8M<M_,%A]'R$H*
M:^8K5A]G;#"*.&$B?TXZ(E'51%9.' +F\3[$SC#AE)D8EP'V\=:[\#=LJ286
M2HH32;-W<0_9X'F>O.-8>1%LC\3K"?-MUX1OKOMMMJCJZF17MN1M&(D#?>8[
M 5HT]) 3,D2B2?>JO$R9.N!"+9URD3^0USF _)\> /(/ /G[;=/^+KVJ.%&4
M!HO@CL&Z$+-.?E5NE)#4$W)'\)MK.+8F8U-?@<N;$Y>RPNJ6K,0A'<NQJQG&
MT8[W8="<V-9(;#M[<OY*'MK9+_/0B$-%>&*Y1;X&X1[>>)^W;;XQ1=/737%B
MFMXO7//3LP_"[D4,I.'63\,(.U[62$'C\=:FM\H.1%%%5TV8\- ]1C#O>&)P
M5SI*3W8V)&U88$#P)XCOZR5M@F*[1X?AJB0'B/U))6?N]PY5-*\![]BQOIZ?
M45N(X8FV/ U4I#&W)ZZ@R;Z.>%XF/$BUP(%5$9F60Z/,#\-@Q'HH'$&(9!;2
M1Z0RJVO1&YS0'+[.G?<<YMCC,E<DPMY<G&SIKJ-2KG^75'QH\K7P:XF4N+6@
M:] &WDH_*@O\B1,9)JM<E=*Q%T;24YR/%PE]F@[8"'QOT<L+L"B*X^HD%Z9&
M:RH(T8%V.@O"TJ1F2U?1C/H![9$.PM-3MR3.9;4+)$Y5;?/K,%.#')8),9L5
M&/4KZ O_=OWG%ZF>5C80Y(A:'@-!:5I2"9^(<XLCS1=,==Z0\%BX1%E14DY#
MG$$?0 CY]?P:0_ZC/Y[YWUT5R &WI%U1-TH"DSL-#2))(:"72$XL21:"VP!\
ML\EM<QFQ<P(!KN.'ND67CFQ)?D4HSIX%+[NIBH/UI#!SK*S^2"/[@J67B(,*
MG "& /GAA[>V4[*D%^0=]$%!M]E&'B;ZPKOS+'D2'F![%'<+/$M,G2>S)<+@
M%%NO!@T;\[-HS1F)@Q*'3@AGB"^OD;QSF+HF#)^[13:X';_^N;[_J'6EF^0(
M?VEY"9"$PSAWY<G[<OG^(E^^CX\J[5CC-_VEJXE6;KG4\^(EY?%SUMXC-3G^
M[Y*&JMQ=D#@*D]*\%)'9;FI2PA;8$(D<1,B%@_T3U^5F$\W3UB;L_V /=I^O
M6$CU2B:B5YV;R"0_7#NGBY]G_\;"S8[#&.*,POF!=4S9AHOB,M^N=97Z%!6M
M)Q/NR1U_'ZS503A_PQQ#(8I(?^G^<N&&>6:'G[-;PD"\CH.&P6W!<,BBC4*Z
MQO?%@_.S/ZR7H<9.VY=(IQ8*&&;5MLN<F??RBCDFN;\J' U%UVUEM]ZMP?Q_
M[\A@(OIL:U$U1J%P7312(HZ6*T1];1C)"Z+";.2'MGDQ]L%S"TN72)\Z<A]4
M%+"&V@=U_5G6E6.6.S8?=V5Q9T,SL:,3E_G:C>E,(X\K(M.3>C#\+H['EZ ]
M#&%!B5]N&:>G'?!B(Q'&AK.LC[]!'N*>\Q@=]Z\CJ[RP'@_K%2K0=U#N>'B:
M4RW!.=$HM^#2,W*@O.'!U+H: IN'=3YIQ+D5E6RYYH(TK P#R:X=QWS,Z/B+
M"I^S]6=?]1Q#D*SZG%2:D\A#Z]&J[$7Q-2T2\(@9:6RSKX'[H$V[:9 $4"6<
MEC=AS@F@J KLR(FN)QY<>8>")QUBP.K@.09DA&82A:Z8-14"A$!(J:L$WRMO
M/5&$OW:R:M6,G)I@?C,3-,N0WJF6PL*&8$J?8M^+/.*=9$7\2!S'W[D9NRV*
M]Y8-Y#JM,4LW,ZQZ/@[[G@HC2J?X3HE3G^<MR7U2=$1#]SI$>5A7;YAS*KF/
M 'X2.5V:#R9$A1("97!4D05S[R\@ E-"T7)-9+;9^%LF$ZRX'O*'0:#KDYQU
MLQBS(WJ1!>DBOILKX*9"P2WFNT+Y>U>SOSK+GFE4JI8-'@G2A\&*R(RP;2=7
MBF?.615K&%FHM!L!HN$3./7&Q8B"R4\7HH@3H^KD^9670*!N9)61!22D&Z<=
MC#(G$S>EV,*V-DXOR)*#FEUT*@&>E&=5[%C^%"R,#JVR@Z7GY44*NL4'(33K
MC+>>C)%[<KTW)8-=?BT,P+XN06*@]MS?""^'VRCAO;#6AUG*F^TA$2U)V&N?
MU\U4;0%9.5TB/#$3<RC$,V$GJ><A%)V68PT7ZJXUPZ>U<_@A7-M(U%<0'*/0
M0%[D"HEQ7D:[NNV8%(?I+?,PWVO?'>LW,BOT@DF?N8/I"BY!J5B8_39?,N@P
MK#T,&^AY:U91("ZZ<+G[N-U'#$8VD6YWT? Y4ZURG&OQ?.*F4\_^W]Y\FBV/
MBY0EWV4C$DUKN2Y.PM(*?V?J<2%(9R+C9)\B;K#=)KJ@QIT*Z4,(N00_:U=T
MC'L%YVJQ<H6:?/(.O!O<H,1WL%(<C2EVR 9/V_CE/Z9>MW_3S]1M=^*0;;&T
M!&4^<>>HH1Q[*<.6(J)O+4#8QZ4@IH++2DD;@E37VZW39A5JH?PJ+[=PLIR2
ME3FZ=*02TB$QB$4D!B- O&VZO,M='DE,O@Q5ICFK\5L91;=NNB/ E#N[R>1,
M95 R':RTM<35:4:NSNU/6-7?'DR+90!'\C=U&$4LS'^0L\+<U^Q9Q?W6:&V0
MSM?X^37$Z2O:-,4_>X$*X&S&0>7*:P_ (0,.??L '/J= X?NK$UB7U3/>N^E
M1G.!W'YJJ,A#/V:[=D5>.<]W4XLVEQJ'*+Z75\,CJ2T_4/#?75([;LXIPLN\
M$E""J$4J%3T$D5A^JI)?W4_W"YJ!+KZB[)O3FB:B-9)L<]Q\B).\EKT+:E-)
MM>I8>$::R>P4+<-LDIB\SM3@D;+$-0D/A+2/%-Q#;)ROXN'#* KJ\7@_CL&=
MI)9[9(W8<_]5I<0/?]I'^8GA*3EUQFD [Y16?DD(SQB$1O5\HE@C0& B6F0_
MXLK?DD0Z*T'E K=$UUI!XHQI: NA<VR1W K/6>[@<D^%Q DT2L?M=A$XZ'+7
M2@U^T\P*LQ\GZ4?!J[ML\ ((ZA>^#-WM+F65I5O)C65OU^.KAA=657H.+]"H
M,YH$ ^90WO"R;L)F+U;C?7[G\O>_(,GV^LV+E\\63]U*GVYU.Y9WNZ-9L4^3
MKG_R;PZZ;/#/5=B8?JC?9MD*;<(OM-?7R&O=>A]:]K;>'3-LB0K'J5RCI(CE
M*H0&54>1J'3V+/+P$I#O+JI+RMA+EN?9RXAR#M%OP:Y)R24RCPUUI05:URIE
M20(NS8K+F/6^HP12HO[+&ZN"STC8URV45U8#Z4[""TK#K05N;-(Y2!.E9>&G
M10*A:!WJ\;;Y#!7$XR%9UTL&KU;#FPNR;F#.C5^\*23<HS.@#=/5LB3J0;0'
MX:-8S#AMN B1(O9&$BSR6PTD2X[Z$:RB!>T??'B%:!-008Y<.Z"FTTRIWKEU
M2T([2B%0JN\ZTN:2AIK.MR'/MQAS,.QSDYP#4U(KX:D&CW.)V9GK9O<NL"9,
M<9Z&9VI(N8BKA^P]A$D$'H>6T[X3WP,OFDV[0E1TMR,Z>(:;4K2 S..#WA*J
M5T!3=NWQ=2=Y*IN)LJJ"9>=4$S02ZQ0KKGGY9;[7X"GFHJT+ET%ZO$0OP@G/
M3#N4YAH;!T4Z2TJ+$MTQ3]CDV)M%WS@,5MCH_Z>-,N$8M!\@%_G2.MU?.XIR
M27\@NUM6I&&L6Y[>7G/.%WVY72V(['A;K*BJ>BGJC?/,!6ZN,\FUK\+:J#=]
M,0!X0\.+X)W=XGUQ2-9I,,QA(NI*M3A'1H!=+R<LCI7H#! ?S!E"-4[YB2JE
M+GA51R<7399QO2]Y[YKD<A25HK9KUGJF=RJY,V*8<=2"F,PHVT6RU[J!.A:S
MI$5&] +;;;&EF9L:%,P"UJ6#"CNS*M\CN4+6/46$&]XF#+@RKB_Y:9Z-PY#I
M\T@PDG,.%R(U'P9/!"'DX5/I@HS#V'G:1VVUD=_D0Y DMJ !BK&%"Z],6FSB
M=8;1!ZR7Z(71>T!LN[RLV9K[8Q*B%4?7^'\P!"?,+"G85:L3\5#6^+_O/J>;
M#LPS*Y5OM_D%)93J1MC".;-K@N1*02DP'9Y#&$'5WISI" V3#)4 MV63A9)W
MEY0?/!( "%_"W,.J)+L2HM#=F"-;+IWIC\/SF\;C4..0&W@BW<A0P>*B.-2P
M3W5;1,>&C"I!Z/*.ZT7@>T>).%F#5"^NN%O$J>0A=H;.7IH<R%R?RP0U6,8[
MW+V1[O6.].5S8&=GXNR\2ITWRP[P4,'GM"()QG)NU,6K\5&45L57<P0YB8WQ
M%D&>^?XEO!S\^>DYU[V,(( /(P?C]\D)MCV3<X%X=.S]3!3RI^J'YNKR(K7B
MAQR/U./C/1[Q3]CS=%,?B]SH<,LM)>8<(9].(30V0?(,9D3EL2;XY_3H6L(W
M\5;R7"$^87 #_89Z6+1W:CI5#VS #UY;UGXF3Q^53C21U0)CGGY+#O=<9#BO
MBF0@Y,G-PXM@!#=RX@E@UW^0HV-3TMZ2HFK$*)0-@:P:UL7=U<T%]YEQDJN#
M[!,773&*?<,*+73%B36130\G(D18B";>.%_8-CVH^AX+O#;YJJ2 :7])KBZ!
MYS)1@*)N^["9LH@GDQ_:> 2[!Q#QD5E FD9EX[NVV.)@E>OXXJG-VEEUTW(H
MDXE,5PGZ"0J]0W37D&1/UN(MYN)V"^^CKVKC.1HL-S.\CHXMQIB>/?IX''P,
M;F1]N[Q+CII_.1K1.4%8A[SEY$04Y'*QJO8'<D_PE/TXV!&!?;<*QRT_Y43H
M*XLG]SN/^1C)4'HX$5R1/#;B$H0I">^H96.OY76 \( J#?X,P)G8)Y.;;-['
MT%9I1%!ZM<6Z*%;HA?I([TC95PRS>EU"6T9DZ</]]7 OP[]<;,(^&2NUQ03H
MU,O<@Z3RT>S:.Z0D9(M3F=X4\A2-C"GAG TX;"3G[D5O(EZS8KEGE<S"-1A?
M/CUZL,S%!RCE37>V/W_ZZLW91.?ZN<C4!R.PHEK%RF"'[OZQD7MR.X9;8%-)
M!RDZ[5TW]MNPN+5OFKT*>CU'2>"S/K%2^1?3N4["5$!Z2BX"K4O*=-0>",CP
M-*0?KF$=@,"9?&S:O@1+9D7WX:T2V/T#F.)/?WX 4_S.P11WQMBJ$R\JGK-A
M"0/>..U.)D[4B^$,@:=B2@1:VD+(!A7H (RXB,47)#&R%41$OSIX)-^*:38I
MFH^!I:L\4V.&L&C/6M$PE-__>$:!K[%"Q4H I!J+SA\3G C/8VX@L8G\B,3:
MB+M?T6 ?)(IWQ"OBC=&O1[Y8([<P>/48T1FAX>0XM9<D/R=]J_FZ$(E,0>S&
MK' J@]JW18R)#*L7$R,SHSB3'"C7SHS;ZUO.I#K$\1HO :/3T!?#8;KJ"0H2
MECX-0C(#0INSEY8:Z71TK]?RZ1=1EV^IJX=*9*?:^_A.CD3WGC[/;@<Q#MH>
MV2/-Q)*'_V&_S8>H# K/5HZV740BD4COJZA7GJ- 86]"MXL4 X3";D:?63Y2
M^ +E01;7#27XD:$N<,.1^#E(]1A3(!1(3']TC/EUH&(^V:$_+"2E6^HPE9P@
MARJ%9TQ[I9/>YV<KX+[,F[ =@N/VI:-3X>1_F.9U%^ENA*:P0]LFNTO22TM3
M\5Y)"O"B.<5*]8QCJ;MRP-K2W12:L67D;F#$9PE0A_)LU9)+!ZPGNNJ-'5K3
M12PK/\@7A86N\3F]:!.B\BT'^PM2*]T6)WFSTR1H;)!(GP5G@Q259M(7X6A9
MU3NXI-)G@$9Q>)>EFC[M<K9AI$2*2V+EC!!JZHM>NR)(*IAIB<$X[>LF-!]$
M1\CK4:)/#LW*5EB*R.8-HU;4)3$K1;5R1)H\^RL+QUT'$6]=9'7%+EJ&-YB2
M[0'-& "- [G$HVG$.C<,7YM,KPN?*1;H+UJJ,Q$[638,1[[" TQS3\DR=QGO
MP8KW?9VS2[F-1$5M/ 43QK6RN(:'<"WD1 *I= =(>LKRDAB?$EPHJZ]YJW [
M,!GJ >63]FQ(+9Z/(.Z!X%/40AD/W7+2X<&HHHNF&[P=TOV\YXFLN>+6(AXT
MJA!S)9V,L>+?MI;[(/%>,LP7)5-P(AT?GK1B5BW:%:[1HCOL)0$BK4PZ:;%R
M92Q<HFIMN8$I$Z(%OXG*ROW+N+^80C&0@1EZ"OE6W8&Y K9DN]3KM827>(';
MK=1EQ+=1"T,X&+4\V-):@#I0)5:-"2&+W;,<X__WU-O1S^'5&@[T=0E32;.X
M ?,0K@+W08T*6%%:9K_7PI,]L&0:VX]X(M"B6>,&T5[Q[LOUL<(N**ZA:1YL
MRQ9"R>3(R]-:4G-+S63;@G)\[M5.%Z_X2+6:.AE?U5@S^O](ZT;]C[=Z=,X7
M+0EL90M"H=8WK(;3Q0_U=0$B0VD.&H0*-,-Q-ARDF0S(NLEW=-!VZI2"DAO]
M>S./RAE%KA#Z(;V'6_*&7-W'YT69VA.H;&ZQDX3H*#$K!C&;*(ZT-Q>;F!/<
MD! ^YSJH_LJ?D'@\FB)67'"M+!YHNT/43#=RIZU'D\RYRRD?!@X9XO.T:-CY
MZ5- B^ =L)2)I F/3)*VOOW"C/9'I=#C"#F(V:<8!8&1D.N8V6&(66DU"AQT
M;QQ]%/<]CK_SBA\M/I(;FF$3P+&= I_%/UAZ-Q652/!RP1Z)Q#2#$HAM\K9#
M8U?4(Q!U6X$67>1M*67Z^UJ=/_-R* R\^!0K["AVO1Z*O4W4]C/!C'AXE70D
M^,8"/F/! MH04X<>)=I.,G'=Y1B+LJ2&<DI\>*C[W!6DK9T916A8>C8%1<<5
M=%.+DK.03SNTE]_-]?+O=3)H"5-0,;*4ZF9/I6:4:HH/RVW?$CG,X8B_K4AQ
M&?O);@4./-WE] 'V8&U)SE/Q-*0DBN586HY(YJG:Q-+1G9R26P)L7O%H@YO2
M:"NMBVNBS9\1*7Z2K,5_3&2=!..*LVG([YMNES];M"83%K'TR\MBISQA;9J=
MX<<P%&MT$Z=QV:?*,HJP?M)J"'-0^HH>&=FZW(!6C#G3$J)M@E*/L&76VQC%
MBAQ@OF28S["=)AOFK5,:P-C:&._GEK>BYL+J1H:VO<7ZU@,W>8'D\$;:BUQR
MS_E@'Z:0[U7Z0_)8H]$5T(0/4_ Z%+9AXX(3>)+-A_',PZ\,I_D=X(%QM^OU
M)\'ZXCD XBQYH_*#7M\ODK2E;:(M<F;-((5$S+SELJ?%7:Z'D]OVRD6RA85;
M!UM*X])*RDP0R?Z52M]BQ^:DO)>!S@OMD1FT  N0>.8X #'8L/O'PP$IEQFE
M=P;C'?/$,V0B$?"')"<;*]$/5(S,OM[W445L75PK3.K)HT=9&#-'06@+]:%4
MK]/^[:.'4OWOO%1_9TU2<N*D-5]229*:9S[H:O:F(I[OUP4GD><,F75:2 ]6
MV1J/0=)Z<AOW6$W<$7_7RMQ\T'2"'8Q'.CD%%HR '0BDS^'-J-5.NE"DP9T/
M3N.?3-P!Y]:-0?.<%QDZDJU=*M7&NGU;A,)UU<6A)TP<-KG!#:Y,G-(RH5'%
MY869W=UUO":X2]X=.)Z&K8<W(AU07+ZA21]@$IJ,RW(1ET 8V/P]%^S0?X>2
MGVJ50(^%#R8B=#]5UWZT4@RY0"44"EO3=Z1A&]($:<:>&J]B84[R)WGKNY96
MA7M<N;+7@*57[2N-^:2[*+H_5.YF)O(!P &=F=*DR(4G_8+2KUFA?3[ N)?.
MT9-'C_^4";Y!4)"$FG0HQ#=%F@5'(,=\"6_.S'R].9M".U V0R"5PWI8"!Y.
MK&W6;;A4,S/3KKQ2@>T2!RJVQ9,9)EAJW0@RVP-KH##M".6U[2FLCL45%>#C
MIF9-X'0G)VO!=V,KUG?&GBH'?[VKP@9K$QRHZ$]>')3NFV0>0"^X>-?TN_VP
M8/PHLPTD&)$!+PE%'%2#G1P91$F,*6(,@L>OROZ4EUG-!JT",(70ECJYG2X+
M>EY>9 07-RDH*KRE<E#HC(%R\\J3C]Q]\'/"8DCC%_'$P1BN.9,=1M' XA.I
M$6$+3%3.$FTS(<F3^F<,]ZB0W/18?5MP;7#O0+%DM)35!,Y#((,_G@&:9'0L
MB\>/@V$[)^'%$FG,5,H,08Y*.D1R1&E^X9QD*D#6+D/TR[E8ES! $!2^9Q4^
MVCY35M1*?L+B%)M:P[*0'\^:8"/2MPRH9 '-J"1KB\V^T#O)M5UN(5R90'D1
MH=9+!+C$6.JYO,IFW2:WN^AWE&1IDA>:>HD1\=2-3V;H'ZY51,2/V96K0@!Q
M.0,!*=M%\N[L$>IJP=L=!G)M*I\7AK FHFNJ!$=\RI?9 (I%2K%]M12,%'(3
MX?SNJ+W+VC'=(E&"7EJ;9#SCA4:U)ZXXT1X9'AM<>S]P385FXF0JH*<+,^5$
MXS)( W:)9"K)^5#SY&K-80*>%Q<-!N#Q5YF ='*3!F*1MZ6^5QB!O^<M'8<=
M#?'3T_-3P?R%;=;D2SD;N4L([[!VJ\QV,NJ>?+;:9\M+ZE*O-J.]-WOND)FB
M;D=[>]PL60-JB<+7<NZ:&A[=UBYIZ8G)9"_MTK 4MH B2/"!(NX]])3^3HE^
M; KB6PBN)YAFN?M. 4[BXB;67Q03ARMKSLJGK#+&(0NO5N'0=#LJ5?"E6Z%8
MRJ7'K6^,(/Z4%+L$H:%@+OV13\2#*(T 62C W_R067*7* <@O/7<! :C\=ND
M$E+7.4:=T_6EU02!%C,/<>E0 <"I"\L!T6U8;E9EOJEJ5'RESB1G0Y)M3),(
MX3D0:%E#,%4'V \;L\[\O*@96H/(=$"1@]#+V$LB4IRKTU2==(3@KIV7N_%Y
MN>IIG'<^H&=L"F>@)WK(;+E)E">!&]7BE:'Q1KJ,TT_, W9<MN-S:H88/X=6
M+V]:N7,DAX,5[5CR;&+"97%I3$ZR&TSDQ9- 4)22&0!:U[P[8<*"G,[,9.,T
MO'O0]LAJM/A^T P;*_8IB\V@T#;/SS2 #ME%C(;"V'HF5^@<!?[$0]R#MM&/
MK."_L.5A0,[HM&?((:7PIHE5<7!&&2X(B_2F^'M5>P4G#5M3JB]VE(F:Z+,8
M]E3,D\-ASQ!US%[6KM4N8RV)I6W5K;!=2)^%=5\PS0@\@DBE<^1-!L]O#'>#
M3>FA*'.DN^@\(>F<V,4L*-9"96@T$'6Y.3KT::Y^RX?^K19F?I>79F;2PC,7
MM_,572(K!BC3M9 O%L;V%0GGML6(<2<GN P!06?[E":A4',<0N]$^Q%464+F
M(<90NW?\]1QN9L#4.%* Z- I,#4*K'$UA8=,V[:4Z3!W8AV1*2QC8C :FRQ9
M ]3/4V\H?J5ATP .2&_E4Z:KDV^N'0/9M/2!ID,GIS*,$K7'$;*C;2,SFR'.
M^8A=%PJ-U^9$%8VOPGFXG3)<-#*L,*WG3PS9-PI_B>Z KX@<N=K4G_PQJV[L
MQ)M*TR5J#CZ7B)U%<7OPU*V3E-)<.W(3J3ODBW5"&$"M'?GTDZ1]/Q]'Z1/3
M"T-/?DR](2X_MYQ64NNY*%@7PR"OB8AWTB=#2>MVN#SU,:6U $U$?\@HC.1T
MA@\%=;JFQX%VCFJJ@X%=\E9$IQ7V2%70;1XP"(9!>/R 0?B=8Q#NC.<RU](R
MZVG ;B)EMP1'UBU\$U7LX8[R>$=?FF*_?5<B/7$/(I>C@WI>GPP0V9,.Q8BR
MUH)!&EV*8)=\.I-=%0=++T@02\[U*G,P]3IRNZ0J-*VT+3+89FIG&@+%N1M
M40.4@*6R;/+H(?0FKR\>X!>%]GIR/BA?7.>2J<'9[FA-770R. IF%EV,I*<.
M&664S=NV7O+KS:S/V84(2K#(%&G:;+&8?UDSE00!%"(GE^8%4#3CJJ?Z2A'Z
MPH1TG>O9:\KV/3.&:].V"GA>X6XH*$N?0$).;8@_PVY.# CW,=6J20JB!=)&
M-4_D]I>:*M_E*^PA3UW-W<.7$/$0$B]K3/14%BQ"VETZO3S*)MK03V"5I<%P
M-OKP[FJLM,^[J7,OR7WQ\F=43_]OSG-S \0';J3\#4F8J[)KZKE]W1K#.?O;
MV.J947S0$+O[H.'PNF[>:V>5K+P(;[!-EW#O26PURA07@_;6."L:!7(9(7GF
M83>#P<BH=483N/I$;4%A;)>\Q73$NE?*MG%\AQQ9C6BK)T315 OS_;+[ B^_
MZ3S,6^Q'$XT<KU6KJ,'+IYT"JOA6:Y5'?LH09;);&-O$M(6IA.^/)2+$8V3;
MZQT]U;83&@1 OD0HV'_LL(<3;T5%45D]6KX@F)\7@ON(3(BLM/:C$R&W8,16
M6@&&IX#E(9(!)%D3V-B4!V< $/-]7UR7^R,U\O'^FF!B+BJL=BK6EH0^(WX!
M3D4,\A<WY?:B:LZD#3)1A:5L^W@],H-DTHU <=J($9%'R:C$MM_%M$H;1BF"
M4QT>*K'Q-UC(A"ZCV!H<U*]6L3ATJFG[R121KB3,7E.3=EONPH"RES&<RZD]
M8Q?B%WJMG.5M0CA(O]H >R'A-D'4S IC5!(M21.'C=V?S/.(9D.?&"2@: <Y
M*@JYP^^Y_8,2!^BP")N''(JK>GL% &93;NJ&3BMZ NG.4*4SSM]$P(("X="2
M$+Z_1W$!&L$L(L!@"E T"0]IX<IJ,EI\?ID]FCU86'$KJBN$92\) <DX*7J
MUD-=89+#QL^1V)I&",H/N3Z4.3BGT;&H=3Q=G#&RUZ6W1!:W]KV,8+H. 4=8
M+PE3@Z\!)3)!TP24">U2I'],.DO):<%S#AZ;,2 ,GLVB)T25VGI7\Z?Z6IF0
MIF9DN/&_#06KJY/W1;&/G#3>J10:-QJ3WW"V'9FW8):9KE=ZI8^;'%T9!DIP
MTP\Z.Q;7@9OK=.W(X[_[ P*.L!+;UDGWGI])DV1L&X- >1D#_!\CN_13.[K?
MH4H4+,>/3]\Y=),G&KK[0P(NG@6@;&%=G 4W=,LL2DAVKV;GFU^;[5FN'0OF
M]_O&ZBDW_]_8=)^K"3?LH#A&F;QT,Y12V!6,[QNN,(_Z2L=@SH B67#WAZ<E
M FM'6H;ROZ+NV/%>DU^)@SK"YH:HMS"Z843="(OA,3D<3J4XM,O='QH &CX4
MRQZA]BM&9;Z)L_V\*8I_!2=*D&5O1,M';$9P>X: ]=KA11\Q7%(=Z'"ONS\@
MU#*R+/><BF(\'Z&MBYQ$"R[+/66#R&I&9D\J:>4K D4C6"\3W=%KI2K396,P
M.^Y09I14\!;O_LA$8OV7(>;Y)D)A8TD4&:E": BMW,F.,RC67#<.;24_&M4L
MJ/8>&.!W$=E\66R)'/0RV!+!8G:,Y2=<= HG_K.-886&=<[*2!Z3=AA%!SU2
M!6U]K.?HWGM_9]5!E';JQCAA+HB\DED&RN @T^(Z#(KTR$C QT$1GZ/&&_-7
M\XD&-NCV),KHX7EHHDQ;3'E*7@+U35>M]>B&",5SGLNC$=TC&1,C#ZQ'"01+
M'4U'X S?BUD@Q21-<5,Z<)*/@I#2JU:*LW?$EXN+<'J2T8L/03IZ20=#;%.?
MO%7DP_58_Z151H'H<N#ZL5!NFZDP(*'#Y:3IYB!M-'8-^IMD<6BX&1C@B;0X
ME^6Y>"?SQI3ST>?L!YJT1W-8,P"RV,$2"88B(.SFY8S<FYU5'!-X,2!&)7!^
MC# 8]2R2!!W#+BF\.JKZ]7=#AMV@U>6HQL?+B5=1+9BC*F^:^AK<W/2QK&CJ
MN_4L"42"V]:&'PUF#(./-XPM?#Y[WT14'-\8 U4.5[.0E7(/KDLYRK(9 3+<
M+"[)K426S-I-'"Y/Z344460;X%:KFGE4&2^(ZRDNB1*YEG&_X2*R+9@&#BDE
M7G1#*/^-<$#;,FV^-=Z,V3+/;_G8LB5.+$ R-TT!^ED^M<PET@*79KZ&-LLU
M-L_5EJ5H=J,.WP(X&([Q)!>L9R9T[XFW4?)?"N:^H >C]A%LHTHRG2T=IRC)
MUGNM%TB6L.92A]L:Z<'\"7+?+SJU-E%]#]VW+652^0"-;?N<@$8CU!_U0$1S
M(NB>N0H/%E6!M34%CZ<HUF:,*I,,\ /,R6!.3QY@3@\PI[MA?>/VG4?CK"("
M=FAQ;U'F1M6([.K+X)K4R)@J&2!SQ=-!F!2.C!RY6HGD\@@U32W9C7>%;N\_
M3E)3XDGTC$:1CL$_PQNC/STOM_[6P-Y$@YB4O=+AG2L1PPO4'H+)H^"V%5*O
M(GSCW*RI62TIPTP"Q*<7A3(#6H.:=F$,Q4UF_/4P%KMPOEP52>PD!Q#7)X&H
MN<V;9'J#4HE"A_PE6$Z=;U)JE^1W,9V]%D-#2$DN&B0^NH-UQTGK21CHC0RM
M4Z3> QO]&_;/8@M'Y(F)#09;0\8<":>/T,92NJ8I125(H[55S>F:;&1SYAN(
M%$MI?KBFD+-COW"-1&/PE74<167PV 1$[YXTO9F>^XV]3BRS,G?7$)9%^%O:
M.9S)IXQ;4'>2#26E1BL\24326TW/-1T1PZV _&,[;I[F;V@>!21P?1FL\S6K
MP384US 62@G J4*D05BKL/MF8%1FD3%HG]$VU9@T7O0M<_R/^F&&Q\]D;\QT
M=YGEEFC$* >-"S+-Y_C=Z2T=TXWD 0H+UP<]8BY8"*$W)1%VD0/)2 C&MXDH
M#3I,P'PA30L4DU8<:PP';,UD%K?5-?J(_B$PIM7$<EE7[G<H]!D2@@9C-OB5
MIGHI5D3=[P%Z5D#-DX\UC0R;!@3?>96/C^SC?#58I+*"6/)UZ<0B"#7%JL9E
M7BE>.B9X]_G!VJ_2DKXC>:4-=_*^7+XG+OR,P);]BLN[%WVBIN5NO\VO6^_X
M28+&K05"9+2TA9&@";%C,*/+IMRA<L.PC%CF(7'78+7D,FIC>N"%2+H9%F\O
MB+OP*>BYH457XB*7A24CF:75G,8*TF%W<DT</6U_^"53O:?M1OYMN:/ OJFW
MELQ,D]("=X*4T=Y0#Y7*:B5LB4<.JE<NJ3<R>^.'S"87,C]+?$&XNGX1(=6X
M/?BEVW;:=:O5KG][]2Z$T!=4DK0J9<",K8.**7:V)J_)5_*[M;ML0"MD@Z?P
MJA8]GEBX G,J_HWQ?H?4CE?Y6]>D_16^]9=;+_4]'?O5YF1;K+N_?/G-Y.+G
MCTJDLOYR\OC;??>9M@,(F[[Y[A/S/\Q:Z<FT03* C[\Z_9I&YXR,Z?^(,053
M*4WQR6=EK@C+YK*\*-$Z/P$C) 5Q]1X+#9(0C1-C#\GB'4SNBSW]%GPV#,NK
MB7Z4 7KY@3]I7 M(4^SZ2AS43&3IM@=EDN+_RD2-ZI(_7KPOH41'M0.B_N8+
MDM;RHBCER<F0D7R>*9^Z8AG"V=BOL;S,6WFNE3QIB!WY(][&])SZ([./UK\R
M>04"H/)%POTS;.%-7:-]ED3,".83-W,8&'@[UOF_@@HH^=3;0MZ9[*/V/\3:
M?6HG-TV^LYSL2X"*&OR>_UVNOIO=_ ^;_5-L]N?Y-MCA<ZYU$1?AR>?<YGP0
MR,J!Q\5^OSI=:SRM5.;H"!Q"N/DWPY?BZ/<<?WM95Q"?)0Q3SFFG'_/KJ&K
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M.-V<!J^I#_MLR0"I\BI<_P\/^^A7WD?8#S1A/[QX]^S\A\^\-60[4._SCEO
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M.BU&*HX2:TBS"1V.Y+VZ%-]R1+Y5NYRM:I>S.U6+VQ^;U<&=K@[NM'MP'98
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M3,M'Z-7DJ5FR23KQ.IA>]-]<;PPB#>8#5>Y@B8XM0(X#4C(7>4VR6<V^([[
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M5QDFM^!J1(O8I/=50J\/^(T!8WQHQ>=7_"YL;6"77F02R=2.@*V!"8)W9C[
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MK]=&)#)[^+'^,NC>L&2GS-0V:O$JT6,MKZ0 GYEM8<^B9!NX9RTOH$H:)B;
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M[[=="IBWY-%5RV$<Z(#*..>U^4%_^#'-ZGF>+'_("AHS?>E'>9BH1CS7Y$N
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ML.7P]W?#MG?#\6"-!_%5,HXO?S5L 0:0U;H>-& "_^#^D$ZAY][W&%MM''H
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MJ(=+XW%.I.+1EV,LOU^PBAY!_A#TY QOR1/BI&DPA"WWB"H<W3EYH5=2$ N
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M*2G+XVCQ7S ]ZWSI? X4-J77N!RTLC\J"IO2:%[6^ZMQ4_+_O5WOEC>HUL[
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M]M_/V1X-SB=G^_T"'FCATBAVOW?-?J\"!#M:?K1V'_#N[.3NPW;*W:N.<I]
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M5MPIZQ9#1<#X#L3@+J,TTY[MML"5>.'U]T72A\+>2*M:= [:J7T_I[8D">(
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M&)5+.HBV8C3WN.1<HL>0)5-"BG@[Z]^*9!23BXG47RM6\_89W,N\W07=>.G
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M2$CJ /6<@7*\3?D+XP7,93 /4_#5\-REWEF,_ZA!]=DG^!?*HB5+8;1.V%@
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MS#(@K@?!SHQ?G./5!56Q:-D\:_SVUQ*%D*O$Z8U],""8%QO.'2S[859HCL!
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M1I\Y/BVLPZ;$%XBOI6W!;# X^[\B>L=%ZLFDA//<,JU;M&'1"6.%T:K1B96
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MN@R?NHHN,KV^$-EB+Q15'7R -7Y>=P"9HIO681\T&B1>,2&7B5U(V2^DJ6;
MB5( QW'&U^:OZZEI&,Q^CS@[NKB9 /,6E\K+^0$D+VWIARW]-0!L5/J\0TJ+
M6IL%+FS9I>X'L'V3N-"K28@2M92864BC,]C_*V^(9N'FHROHIJ\ WP:Z."%E
M[DG:TN_$9L5S -H%O+;UP,5+U)+/2!,&'/5?*/PK<\-A/IN(?,^.Y_VP<;0.
MKO8S?F<Y,1]S#+ES<=,MG-HEV$9+>IN: #D<,4(L7O2#]Z>F:TAP0!=.C9>!
MH 7Z![QA])SF>4"T^#,7!PIA*WGX=Q)R'CR(XXA#!#<6L-N?:L"2)_$'2!')
M!5QV;;-GQS?Q@DD.1NA'K>R!?,9 ^7X 7X?H#,"'K\8,'F!1,QXI[,-#5\L/
M6-,[DTO<6081WYS ,E!(ZX"HIB_Z! :6A;" ?\(]@$!X!IW!0\$PCZ8 & &P
M?]=Y29.,$U\)38@". .&Q,#GL\J %.%)_&'V&CC;"!<$_B+9CK_L/O'JV:\9
M6@7&&M<S6GX]#QQG/_,7W"$]H]^]XM4H9:XF31Z"F"8.,K9%:N+:K3 D$0!)
M\2U^J2='-WG1P"9<0G!$>"#4^>#=4S1705NV "'K*4LK6N!(4X!JS-:3GO@Z
M'6AY8#;1, QY%MZ+F)XESM0"5=PD%P,1HFYIY@M^"/CC>739+0D7>!:R:0+O
M@(\ D[DBU:+;1P4-Z!3P3$=U%GA?Q)7?D..!Z@74#-0YIG9BQ'JU*,@Q!W$.
M&AG#!R-Q)Y@Q9Q6A-A%O"Q]X!R?"F2&&R7D1Z!+(A5RF>: BCH'Q@\X)Y 3(
M"Z)C27^TM,A%H0+X'_(*0G$2'9H$-HR!VHX#Q,*Y(.<D/J4PZ8Z'M/'&^*R3
M0N*"RWPU$5"H1)@&[NX?4]/B2Z5>BY!T[&<'[B>]QS'HP["BATI0>GI:,_HQ
M@?]RHC"B&?W8C'YL1C_N9>>[&OW8/9(6GK%@2TB]M%**$B^23DE)Q]U=)$3X
M/RNIH@4NQZ2A$*LT\\]B S\F#_ %NCSQ@<J:*09XVT5M?$+-E-MY9F+T%\I4
MD+.:KKL!B_1O3XJ\CCJ'%;4@3R+26+/(1O>FC F7(K4EMR)M :'WHJ'J/YF
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M>IS L^;X3\S)Y2$%. B"U07>39Q;[,[C4;5MX2L%:==!UH?P>/3C6]OX[O!
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MBKBF(N[X*^)R',.U$=SI6"A:3LP&4>)JSVCN1.S<>0-SQ9N:LT6Q*OQ/&;&
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M)!*@HH6[<IE%@6??(7"\.(8Y,7F8'T_QQ#QF2Q]-)P(EU=###\Q\Q/O&W&<
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M)UU^__'5NRH8OR/- G?FB#E-_UX%_T?=% 'T%@E@TU;2_9@ L,_MH-LN2F:
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MC96]/M<^X3:8<>N+SW!M!HKA#'D'H#X.8J.UKVEQ*;EZ)HY9Q(06;ZDV3*G
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M@95A)M%BH"OE$;K__B55AO<-%)Z7X 5H#M2^'Y-P^N!/6BL=D04HZ.@J>7-
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MD0H7<=Z8"/UQ_0X6X^?!13 &2#S 9Y8%^\>X^$RT$H%/KS,.>X]S HSPAB"
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M/%T<'W*VJJQ@%X"J)JX&<AE],=GQ*:TKA_JU0'%_+7R1Y17M0O<!"*6,!0V
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M=Z*SR: [[!I#M2LKZF"H#_M#V3 Z?W1ITOCAHVT?VQ(5,0+)1$[G8MH_P_R
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MCXONGM:@W?NRLGL3XGNAFZF+RQ-8T&3--KOLMG*8J7+ ?SZF!5FMFLTB3K1
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M'GGHC43J[?N7=?=:MJUJN9V44A:-U^KZZD-13LS GM)?;C0:?OT?4$L#!!0
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M!$!!"I.SQ"KC#992-LN:-Y6]7QGWZ!N3?>^1N:@?O2(K(!IKLP.V5+53=[Y
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MILXG7;+33H?6=.NF.L)C"4*?1I3-&+<M1OX.PVCX;\QKP!>Y- M_X<.G,/Z
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MTLD+;3HH87I\ Y?%0KQT=WLC:8I6X_K&U9O50JMGO)?LDDM7<NOB<RD8M%$
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M5?%,&^"%=(#*-,TN>0<8G7/6!1MR3R;WKJ'T*4OVGE?!56NP#^1IYE&L![-
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M: .5'GQ@<J^=N65-O5Y)Y-DTO6VF+S8DP_S^M9G^!NUG:$<QQ)2+X#1C&JT
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M1ZM?J;X#SE,CR$.T<* 51*R@Y>0#I2:1$'TY7O62N*09X5E'8/B?H+73%>^
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M\[T0GS"QAM#9 #=T[YH6]X,7,B?)HR-0FMNCW"BNJEVBFO8^<V>"JUV(9B_
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MKWX.(\]3CC'@L+1&@;MH2*!)DP!<6AXCEW(00V2@\?P@_;'(L?56^M!):NO
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MI15)DN4\&@C-7N:2\"5]KU#3/;WI+Q[X-"VVA\N\8NCR L2*?WU@[&)<]:%
M_67A?CMH#^'?5-\>DJNX!]R"0[G+C"(9(2(/(T5&*K#=5BD,9$-5K]JTQU;@
M%H-@ /WM(+#*>OL-)76V.%L!L=[C!L!Q8^$&-Q8:'0G1*^*DX\HYIWL>U]ZC
MN6L//=R>O)?8FQHRJ[QMKLICK8O<2V<BPY4_<%8"\:6!5TZ*T.B3XT&ZE'D-
MY5U]Z'>HO ?+[#$=4;_RX[8K%O!L-EN<=5;<[,-X]L>K%F!=)?-#.9UAD7&;
MF4;A%%E%*XACX G@Z+Q(0K/H*UO?@P_J$5KQ X=X'Q5-'E/.W*8!ECZ5<0ZI
M-"IE(Z!&V*0SB9F5>BNX2;LH S%&>1,UTTE5O_8_V&B>)O./3XS'OO2O1_:O
M9H(?,QG/S[M9;3W7BD=!K"_5R%2R^)W"20Z96T^9,;)ZDXCAA_4T)\$CHLIC
M2E^Z:XB_CK^-$TQ3-T I<'P,'3/K+2K )$&"RI1$*D40S#+/#Q[ZWG=0/V;"
M46GR"+*9-K^^ZM0]8.Y2K^<.G:FT^^ KY25=Q-"A_3:.L(65D^Z#QJ7%P0>(
MS>=IJ?^WS(U^T<SF5_IO4\HRC2Z34.+MDH5R.1U_M-RI+)%XE-4N\UMY"/4R
MENH 6UT"-C1Y:C4)*7N4:RS%0WSI#FDSES09%ZLW7QAB((?*9#HFK[>G-1V+
M$8\EQ>GU%%=$Z I$EH][LQIG%WT&I@(--I 4<!^57 !:;*")*^U1J) 1H%?,
M;P>&WP'G^(=I1^-*,XS.!G \MT!;'2WW 3=0AM.=P(Z3JE1-C?WHL8<.#DX4
M;20J4!L48N!$"N^)EUF1F 4S2D#"^?+]$^2>G*#C\&,7T0_ BP\P _S +\^F
MZ5?X!I/F:\&X,KO7U72B3Y(*0[C20*2-GMC@$HG,>RZX5<G4OO?9 ];A_>6*
MBFR&U<( 4?U_PA1:/T&$S](9BGHV7]99O@Y26"M%\J4;E\%YDCDGCE-/,DZ3
MTF*09E:[R&$O8*=$EOJ:&&!=>;Z8H><PN]JUK5M(N;&):BI(RB$ABYDE/@5-
M> *:;'12^MH[S18H/^S;FKH:((R\"5;YMH5UZF0?@ /9M_>".XZ-6T65/>BQ
MOQX.M.9<!QHTDY)Z2P0X2J3+LG2#9T0H(7UD-C!?^PSM2$2YQ]8]#D]V$7_M
M:IT?T<2:/A\WN"^O#2H:$A<V$J T$ 1@29 VD8 @%7-*\)M5V;<U<;SYT8>W
M-BK+OJDFN $LT6LEI2/WCD<T<Y1WDDC)T)!R.N)W@7$THYB$VE'AQU5:_[$8
M$0_6RM:#MVJ5U_N@>2IE]G?2S-TEV!\BUN'+[#N@/@-RF):,!^F%)PX]*E2-
ML(HZ2V6JO<4_@OML0^EX%VG6WK$_P+<QKF/OOG8M/*>?K]1W]D9'%2DN5)+C
MN+2BI>>K)$Y#4#;$E!SMM75O?\;1ZV7O)/JFOMP&V+E7VQ"DS;O4*H QBMJ!
M9A2Q!80J:30(,'BB(^4<*$_^9I7T_2_^]T)V>$X\ID/< ;3WF"H>+J]/SEXU
M;8;Q?%%:3J^+.&HTGC5/@3#+&0XI6&(I6KT^.O269,*15D\]J#^,I\W>8_-B
MR&O:=XGW;3/]!C.<M=U@9I^:N9]<?;V(^&TS_[\POQ0^6A TYV0HB<DZ(E4&
M8K5BQ"FT($K-_1QJ&U&##>9IT_YQ<&2 Z/!@ UNJ *?[ZE?E?6RDC>4J"]S+
M7$DE3;0TBN=H.:F8M.711E4[X_BP(_PQ31XIFPZ0F+P\J_SD_X)9C0; =WW<
MOFG$O:%6R@Z^\*+>-+/9"WSB>6[:3OV7Q&,\,@;@B4'7;-D8W@432$@T)N6Y
MDCY77AMZP-IW@=W^B&6PT"GKE?"49!;0^$FE\C\KQKYCG*&#6HRC@XWZH)FU
MM3EQ<S&J*?G'DO>*,W:Y%"X++CF?K366.%9Z@26CB)=0<B"2T=X%IVUM[EP#
M<*RP?57--K4D/(!K<@%F78>M!YR!0O WH!PG!K^'<K:I>0_)'D+A7FJ(W!/.
MRQDA*Q=R+9HY,6J? JZ$P=5N>G<01=\3AQ]0SSL(M'8D_GT+G#*[;LDC4U9,
M:J*$\D3FDHAHI2/)X5(5,D2;^C6QO/:QA_<_]I)P4T4\M9O2OD</!*&8=;A?
M>^XU[B1*.731@S7$)RU+$3B5O<Z.A=!/4]<^]WM6U<,%-%A2/@[NV6+^I6G'
M\_-NV4 L5!FK2THH$%D:9OOR)5-O/76":5.[0\-F)*=H)E60^0#1K-NH5DSO
M@VO0*SRW,1WS]LY^>KN7"GL(_2#+P[IDJ 2C(\^$\LR)Y+C\>8I?HC:0K<Z:
MV]IUH Y+AEXW=0[#A5UD/0 '$$7IPQ5?E,XM[?EJW]+2T,"L)Q 0F;1!E5[:
MI6J=\*"%B<G4/I#<".18URKVU5-36\BU#;GNWLC_NVC'LS2.1:)K3$X%+7(F
M"NU(I#ASQ')*"7<J:>688J9GSNKF!WSG"JTFN]H>U!M\>;(!$_.4&RX<<4F5
M6SK)$L]D(,"E5Y8#8ZF?A;[E :>@SQJR&\!DPR&^:"&-YU<-U&X?"MGP&!UZ
M%=Q+(HTKJ=$ Q,E8;G;A.., T<W-8$[1A*\C^0'RCC<"NY+2UP?><%'0NZ =
M+2I:0Y%]Z+&G%H:)F-X)DT&0.7-'!#.4R(@;ES4*)Q]$'FERAMK:-MY12')_
M1/4('-E%^ />RK\(*>(S(3,2H!0V%D*AY1(L848K&=&:X;)VV=/K"(X2\:NG
MH"VW[1\@W0$25K?OE"//%46&!V*T]T0&CJXM*U?%-6Z>I6>(JE[R:CN:PW/@
M>.?L.TE^ $YL7O3.BGLZLEIR2UDDL9PG298%L5)H8G*0#$?KI#N,==G!.3U6
MU)+] -M"*7IYD17WIY]&^!4RM(BV^%NS&<Q??"GIS*^G*[Q<*9$E-23DDHLO
M4R#>LD"XX$ %J$!=[<RD73&>'H$&U=)61[9>-F#I!-Q._8MF@A1LVFXH?IK>
MC&.YW_'L<PM=:E"-3,&'/FK?+,(J0ZR487@%Q#>XVBGJV32];:9QR\N?\+N9
M[^(A5W@;G>+,HHL>LLA$9JF(4T(0+X.1X$R@M'9YE9KXZU4>K8!J&:C(3%/#
M$B<V"S0T<=ZO9$O!*Q\8,]67T/JC.%1FY-&XO+W@Z%&(\&BR+O%][_*5876.
ML^:!BRR*<2L9CH2CZV,-;C\N*@/"\' S@6=_"W(3D.,73S@..6X:G'LK:0!3
M\[8P_.;QKP]7>L =*+2Y(]0CA3KW5_+-Z[@'T- C(!:7R5"0C@B><3[A)$,G
M'!![CN"9+M=\:E^\>A2$NB\L>G0^[:*8VL>IUPSW9[<-]Q7$ )+%8C(XK0.1
MVC!<GTO- ZH9<"X\_K_7Z6J_YQW>E1U49\VP J^=,K'RZ;8@\S)%S9(A-)4&
M40SGB.-:$>&#1 \;<)K(7E2X\S$GS(!ZXAWDO&12"E.\]^W\_.J@GY]??:5;
M(I,RW$:MB4@N(5)&D:PB$F:]UI**[%/]LY2^Z'Y8Q$.J<X DD*MX5B=3?1 -
M9 G?1G,<8W<H_=U!DSV$/_!ZM$)&4TK",4>B8)I(%QQ:92X2*ATS5@#05#NI
M_U!TN,=4/1X;=I%Y;1-UM5^NJW&[I+6UGE@9RT43@%(>"?"[""J5VENF7Y[?
MM8\]O+FQKY W6!0/D%#ESMN7_=^C"IKYA-91B)%('M&,$6@=N1"B<U( ][TB
M8WV:W?_8[_<0?L7DO9N]R/O V&7_[L.%8T2F]A#^3?7M(;F*R^Y-.)FF*%*.
M)&DF$8XQI-2O)OA[(:R0S)E>B1+'5N"6[;6^_G816&6]_8:2.EN<K8"DS(0M
M!<AC,L5)U>B?2G#$&:N$CA1BZ!7SNT=SUQYZN+UT+[$W-616>?_\S?]U!8AS
MX+R+D@2N#2[_4A-OO""*X\:066;QLB7L/LJ[^M#O4'D/EEGEF?>^;=(BSM^U
MJ])7W6HB!-I;WB3B@>-FKB&2 ,82H:0)2BCN>0T=;GKV#Y-H?Y7<IHBL0)$R
M_A6BV<KV[P.JHJVT%<CA+:?]=71;X94$/,P"L0&<TL(I8]#(R*"(]%X2FQRN
M6BH)A*12C#6VZ0-K_0YSZT!*WT6N]8NN;^I$MP:XMC6$2;A' 0D)$BYGI<)-
M"!R'7((!1G@)_0Y3^CSML'M[):TT0XJT]LG9LL+QA_'G+_-KYWP?$.UT<0E1
M.8J0)/$AZ&5O(%MNVR=E=! )B7_3L-NB]7[/^^[U/H!8JP<IQQ.8S9OI51J6
M4UI<O33'P0(5Q#DAB>8I.18B%]"OMM/-3_[NM;F7J 8X>?JX"#/XKT5I$_JM
M6)_X9ZL.7C%25JH9R<203NA*!!49H=R+I)1BNGJSUBU0GK@E7U-1M_FC!N#/
M13>_^X$-=("Y%=1QSC&KJ.Y^.NPA]P'.+K<#%$HXIVDD$*TD$BT3$M"X)=&"
M=\E(X6C\O@EQSTGF8?FPB[B'Y\'ZLJQE(E@T3X1GI>B&1+O%IT ,LTS&@$OC
MS92ZVAPXUM%G)47=K?X'2+EZ'MTR,OEV49"4HOM+[^63;S_#?#:2WDB366EW
M4LYILW6EPS0E22> $"":F]=/MUF(=S[G\/H]^MV5VM*O38PMF-XV9^-I20IX
MMI@WX[.SQ11&##*5$:UL%H$3Z7!&>*,<R3F!56@O)]$O\;;_,Y\J80;22FU/
M<PO,?[;-;/:NR*KY?#[RZ.T*CV8VU<4YPT44]U'N"6BK(JZK"FZV9]Z--M>>
M]H,PE311T;GM /[^%44WG;\MD9*\F*;B@:T:<GV ""B<-$*7W=& ;MBR]I<U
MZ'Q[I+(0+/(D*-.Q7SY5CX<]5:+4UD/%G)UK1'[?S!'2V$_649]/S2K.BN)Z
MT9R=01OQU?%_P\B@"'+RB0CI0RGI2$NK8TZ494GK"*"BVFF!Z?_LI\JB@;54
M\:BS@[LLR;#D=T=X:%> 7T^O1.^7B^:O,!M_GG9!W2NO?8#/BTEYQOFUD5T$
M$%=S:#;2&FB*2A#&G$:9<B V!T42A!AEHAD]AUYL/"#HITKCQ\J+BI'!59B[
M2RHJ\,;S;D3-!QB?A44[@\T'65T7MI&-DCMC/%$J&R*A."9,"D(3C3I9B#B-
M>QX</ C 4^7E(?1UFV-ZORX572N'8H&N@!98EP;I)KC!*QV<"$2#]L7.,,3Q
MI$DRD3D/P#7KYU#N_NRGRJR!M72;5*:.-0AM;MJS4G;I79B,/W>K,$*CE";-
M(@$C2YQ6EZ[4%A=6#M%:YH6'W5S+S<]YJF2I*/W;Q+"U[HI?DT!W,%^D= 7H
MAKVXU'635!*7N<1U,B8$G36)DD%.4F4>:2_>[ 7CJ=+J<+J[S3JW_R7 +L_C
M%<KV!?K1+8KE/\?S+R\6B!)MOY=_Q<DBC:>?2TDX_*]4AQLQ&JUVV1.3M2X=
MQ2EZUB69C <3O'%9\!L.:H5;@CO#?()T/)12-\1=]ZXFN@GHF[$/X\EX?CX"
M'Y-Q7I!(;<EC 8[S13ABG$DRB2BCK=VI[TY 3YA<]12U@48UVA&UX&?P*RS_
M?3V]&Z_4CH;B4SBM$:_578JL)#Q*'<O-4*YM96+M"/$)4VU(96X@WWXG K=B
MB-?/+JZ$6XICZ\$Q[D@0E.,L48S8F#R)-GDO)>00[6Z&_OT/?8(\&E0O&PBT
M=V^.=_,OT%[&[V9O8?YBT;:(>Y058S%X(,:81*3!A34PX8GR 7=H)1P$7GFA
MVH[F"7*ILHHVL.?!9P)K:._;)@*DV=+NFTR@&_>[?!/R*+*0G669:"I*&0-D
MN),*B HL1\Y"#*IV:[Z^V)XPLP91WP:>[1=[_Y=OQP4&[L2S<8+E;8%1N?^9
MRA%KB+&T(J":H,&G"$Z' $D)W'S[G1)M_/@G2(I*LMZ@_OW"XFL#[!/@#\:(
M1!D(0@W"D0I!>,<$2<Q&IYFDTIE>6K_ZJ4]5V0^6[ 8=/SA*O3&"L'GX%U&$
M>Z(-HPC.@989%ZE0QN(LL=2A2Z@9"@K7*Y-J%T>M"/\)TO'8)-A Z ='UWM%
M+8I4US9<4MF4?JI<FD"D,*5"10A$1 &&NL"BJ4W6GM">,!&'4-X&DKG:34IN
MY,W/]FA"LNVC]FTRT@MBI28B-YYUR0W/&%<25P.@)A+I2D4]$02QAF8JDU!H
M%P][7^--M>8>-RY@=#?SN!8F*XUF.DBTV)R1Q+HR/E#,1P[&\]K1ZTTX#M5@
MHXJ>[[N"M+-@'TN[BZWWLRQW5.("Z4H(00JEB?5!$B5T\I(Q%:"V4_[8[L3N
MK>*^MUIW$/5!+R_V ?;$;[7NHKK^MUH?(/>#$B/*Y(+BG.@0+)' 0O$'':%,
MY\@E.HNJ>H.G[^-6ZR!\V$7<![O5FDV.6J=,:'>TRB0GCD$F*HF4@HY2ZH$Y
M\/ANM>ZDJ%ZW6G>1<L7+BP^H0^TDI2Y*1GR)_DDN)7I4/A'G/4AD?PSB"38)
MJ&U##*20PY3Y[X/H1YG_!^GO_L+N#Q'^8<K\RVPU-\80FKTF,B9&0E2!B Q,
M&V.3N%GH_;NA0[TR_Y79L(O,ARWSSS2 +V7;%*.Y5&'.Q$9<7:T';ZQ*RL4;
MCN9W4^9_)R%O+_._BX0&L &*?7.[;9HJX$,,1$H:2L<!CF/#H4II$@3E=/UC
ME(U 3F9GWU_,%2\+KT'MVBJK#]P?+2WW4O*>+0@?HJ$!S(!=88LDM2P'=L&4
MYO*!EUK]5!" ('W0N!/>++)X&H1Z4$O+0_)I%\74-B1Z=E@42F?&N2(,2KUY
M:=%T8I81ABI7QJ4D[;T'7B?5TG(GG3V@I>4N A\D:#&;MXLX7[3CZ>=RRQ*1
MEBS;]MLR2*>IL5 N!?CD<9?VP1!7:OIX3G5VTAM3/=_P'D@G8\34%'W%,A77
ME\MK(%>F>A]@ QDN6T$=*T)1484;;=Q:\A_ +-D.T"D)D>%*YH5")XPY3[R5
MB>A$N7%<@KU99^M[(\:]L8IC\&(7L0_ AY=G7R?-.<!'^ 9MN:&]VN%,L"&Z
M9$L,1N$.EWE)).(%EF%@E$ZV=F?*+5 .;VU44E937])#VQ+O)WZZXCJ57K)2
M8;14FRE-+#P@*)\MM3ZX'%/MVR\;@9RFW? @,0]0[OL6J(N]ZGY8@QUC;(3T
M""R%ARGM/AKL(?%!SBXVPT.7VGF(N.%9$,7?20C4,.)CP-5+N<14_0., Q)A
M%\M@4![L(NCJP08_^_*^[0R>SOTML(H_NXZK.2^CD+JTH$&?-QA'7,Z*:":5
M5$"-U#>VA&U!ACN?<XQSC0JZ:(81Y*'+-5_4>E4TX :7 XF).2*Y"\AK#B12
MSKF6*2>Q6U',^YYX]"R7-WNES0XGW4-3X -\G?BXC+6-N J>"RD(L^7NFRK9
M.2DP8JV/#AAGZ68F]0-I</6I3X$*#Y;R@6IPEUMQ-TBK/2@C=";,2)1%*M=@
MM>/$R! % Z$H[;<!]'[D"1-A3_G6+J]]+\HK%>,!URBPDA(:;+D/BSN9#8F2
M; 6+5-E =;_3AAT>^B28\$ 9#U5"^\Y:\(:'H+BR)'+#<<D2F5BN%.&XF='D
M<.4R>Y'@R%7Y#Z;]ATMU@-.#WA41A,.=R<I2$:&8QH*7F$CV:+\DI1*/0=':
M_N#C+6@QR/6K050Q= BI"YAW26(E?'Y9"&C6:6#V<C)>K70CF[*V@@MBG$,?
MR'A9+J9R$J-7,4=EC:S=,>IA2$^$3@=04\6"T/NA7M8HQJ^QW%%VAJ$1K0QA
M.ADBO1.D^%X$EUH<0)!")/,HF'8-]I.FW<,56+%^=(\AO/SK*R[+R^_92&<7
M(O6&E!LM1++DB*?6$D6- DNU@.H)7'VQG3Z;'JZ*K96E'UB6X)8>.['A5G[V
MR\MRK7\VQFW[Y71QMBHO]&9<RLE? [.I0L$.7"D/G%V2I3QZM[(%%890J8+!
M:S2,S^#C'-7<Y?Z%65>7HO(TVO:4_5>.#47Q"U.GL_H7Q>YZUL&G_SUZVS"Q
M[Y?4!OO"L3NGZNK7Y4OP,_B/?_O_ 5!+ P04    "  5A']:,1JD-S_3   0
M0 $ %    &-A<FTM,C R-#$R,S%?9S$N:G!G[+P'7-//MB_ZHTD'$1"0$I6F
M]-XAHB("(H)2I$5$I FA" 0,A(YT!06EJ@@H"%%Z#QT%%>E-2HB"](02 FDO
M[OW?>Y^[S[GOE/?>>?=^[G_X33*_^<V:M;YK9JU9"TBHD]0%X*CI)9-+ !T=
M'?"(]@-0T?151C#/NP!@;@[(  #  M G> *,M!8=[5)9%0&8:>\<M'LI6@5$
M5O_ZY,]"*TR/& !ZVCL? -!'/F+\>_M)QN._M!F4E  @(^,?[7]HD^[^[PG^
MU.8_BHJ2BKJ.DJJ.BOI))4T=)27:]6_V_67/OO.X?]]/1U'1-U#!Y0[TMIN"
M*]1'$>;BIZBLH*0(Z(%A?BZNWF[W3]YV<_?TU9?>:D9)G_2\HR]MJVZN9.YW
MP<W#\W)8@-OUL*LW7,.\7;7O2(,-.-GT8#HP'S\?M_LN)V$^]WP#=6#ZI_\R
MNPZM_;M;\;2!7L"=NSI6%R_],8)VIW_Z#UE"0D(40E05H 'NBLK:VMJ*2BJ*
M*BKRM!'R@:&^]UU@\KZ!XG],<-$MT#7 T^^^)]3WY.][E]O0H/OZIX."/._H
MW'6YJW[[SAUU^=LNJG?DE97ON,B[W%%5EK^CJGI'4UU92^6N\NW3?[!WHUGN
MW_G_#[KX_>0ORJ!Q_-W6N>ARW^V&IX^;18 G324N]PQ^ZU9>255>1?W&WW2K
MI_AO#]53_">A_^BAZ8'6^KO6:"H\^=]0_E=F\H^=Y^9+VVXAM'U%G0$N  ST
M]+\O6F&D74PL3$R,C$QLS,Q'6#C8.#C8V=C9.;F.'>7DXN%B9S]Z_"@/+Q\_
M/S\'MX#@<3[!8WS\?+\GH6.@T3 RL3(QL?)QLG/R_:<+M1W@8:$+8-QAH#L-
MT//0,?#04;L!$,T#,=']I?S-%.GH:3(>869A96.G#:@]"M#3,3#0,S+\EIKV
M-)SV'&#D83IV2MGP"*^E"_-I?SZ5J,<O6<3/?^C@MQK"2JC>#HAF93LN("AT
M0E)*^LQ9&35U#4TM;9T+%XTN&5\V,;U^P]K&UNZFO>L=M[ON'IY>@?>#@D-@
MH6$QL7'Q"0\3DS(RGSS-RG[V/.=5T>OBDM(W;\NJJFMJZ^H;&ILZN[I[>OL^
M?NH?'AD=&Y^8G)I&+V)^_%Q:_K6RBMO>V=W#[Q,.#G_CH@,8Z/Y6_DU</#1<
M](R,#(S,OW'1T8?\'L##R'1*^<@Q0TMF%W_>TRI1+'SG'[_\T,$JKFJ%Y;\=
M,,1V7$(-+8G[#>TOR/YCP*+_2\C^#NP?N*8!#@8ZVN(Q\ !@@'S]5=(9@%;I
M7L1<9D$^1_A DPID">Y0[.)\EYAB0@<K$A:MKT$%[!IJZAN2IF=[3]CR1K^\
M+CDHV[G=;LN.Q6 24N];3%_HF&,%"^Q:I)W@0GGZ361ZGO"I:/;T.:$JFU5W
MUSDX32B=D?1B0[I,\.95D95*)-+B*8HW'M9POK3:<S/[*DJWT!/#/!R5-[&T
MWU68CCJFYXT-WN_5J=\P?@%S<*A/6KJ(_;*96"R<>.7<$P9)R/XSX+9*Z()Z
M6%'$*.A82_@"=TR$"+:U-CX5)[O(6=O3??CTNW;]^]K(!N\GB57L.LAG+^(=
MZ95"SIX89++BFG"8VBK)7D7)/NL2O6H_M1%4US2#6@HON'2&(>E UQK7UY,^
M5=I'8:_'[:?>:Y."Z?8T/;%7=<X7DU=9,VL*GV%[)U'>.\54?X>4YT-1<$ ?
M+\)A,+.#W69D:8P5P7GF/$YR,]VSU 3]0+A85HCC^9.R]X*W6N+UW N>YG0.
M9!<^#]B?&*FE @P6%>7;VVV^TQ!4X,8K%9V[T=K(6!"^B1!51K!MU]AVFO%H
MDZTE)(-B6J[(511EL(_:".> E1UNW?(S?10BRU-S5'8:X6F1U'8&R]P#B3YQ
M*>XM.<8<)]8R'O8.Y)YD4=/)<5)AV>KZ5OT9P^4*Z;@\^ZL3(21F$2=M:<D'
MLA'2WT:?'UBH;X,3X)ZX!'P!3C-5G9L.MMJ'+HW1TRTS?S5)!;IS1$TQ5@4G
M2TPD57 G2/TW2MT[.&YD_CHAD-"F0YA9F'OJ7D&HOT+PP1 ?8/#Y9F8C+\>L
M5L?XAR[TG.+IW3Y6=2PVDN^6PF*B0H)TCT2A=65APL\ S,/E<66?^V$W*>#G
M6W:O5[8@ A'])Y9[42DZ);7EWF#!D!6#$SBY)O/Q#+BR&Q7@%7PU^87X@VT(
MRIG&P#,AU3;$+%[I)3.,5_GIH_D3,29NJMY:$_K$WCF8S&QIQ/_X&Y^E$?#_
M>K6R^D9GQ'?MKU7*TP/XPW#^G7KE&_V0$1]@^?]'-3$[Q\1G^3^IUIP.-E7?
M[J]5&%NUU(^LR[MZ5BI4%MN]BE<7NAMRF_Z-2,95)N%DUW8JX*T8T[3<,^N*
ME@@+3N!J?>UI(%O7-HYN@%WTOBT$'UZ1Y58VW60";AL+JJ_-\1"<%K8 ,W_%
M.)+T2T* =QRK6L[5?,[RRR]^'%%^\Y'Y U(?B]C(QGKWS<G48I>2,>5FJ;>7
M(%(L=^L:ZDQ>?[R6*/&A3%7YI$R\9*)PH)-%#S(]@I' [U/J",,XGY (2VX)
M+OQ5_5VM&%",2Q2)U%24H/M8F57^H.;=Q-/"M]WY[/UEGOLA]O>_'RBV%[YW
M^UI!/)LO ,'.%L8;R-G-.D(\I_/,&:[>L97G"/C"J^0Q"6^0"[ZC)"18N=4-
MX6Q3(?29$MQQEO?-1&4Q C''%^?VS[<V1<YX876>0!7L\A\+C>8=D>%_[7O.
M6OH7$@1WQF9W@9BX!6"9M@[<7!\>RF\;RJW.N1]6'9>\>_)'8%+Y8F$JA15[
M-PI= ;6=L.*4[L[L@!8[]3!6%X]\SEV<^5ET2V5;Z+W^&N*=[9O-L<UY"WFK
M[6UE.Z^C-E:U&:O-O\C0#VB=TDB*'&4$Q*,GY(^A DQ3<!6L;6RM8&VF"QEY
MO#2HS.GL[2CGH_SBCD!'76$>)B+BJBOZ2#YN?D%TL%M75'&AC% RX8B3W_S@
M_0:<=,^'W^H\?<2O+ F7"P$W=E(X;*L(7?A9@N("F'?566Q"SQTO"C'/KZBL
M0%5MW=G^X5S>>$HFXL5C)XTBHBE<?;A-L /'!N6?^;1P\./R=<OZ^)OMCYO$
MC4^H/9PKZV?;IR^?MK'\>9\\X2VK&S+BL&I1_>K'4AFQ?S_$=J,RGSM''30Y
MWU>'8/2I%3;9': "R3R$=L+F [!215Z]"!5X)2["U1]@FMJ3'?Q=/5C X"BA
M&;>/L>A*#>R%<%=$G""$=&1;K4H6.L9<+\#;L!U7VXYD4TG.;_=OB+[*=VC;
MK3@CC.;N1 FLB@GBC)._/J^<#$5XUE ^M^0.S)_X6*CG5Y57]':AH&$M9ZM-
MF'0#6]I#!3BE6A?( 3..(T*??>2$GQ;YCTFD1L)F!'7M&**YSW.>G:@8^**U
M7UT]3&[B4CNC^4G(Q_OU>-TF? T]R$1R(3^#FV/,P>W.3!\(V0OS/%Z9WC9@
MG':"><.(]),S&=H76RZC9.)8IU1,LTX^R&YO1CS$PO5JP7R;-0/(X^9RF4V>
M_O?,8'F;ET5B:F=5;E1QW#HS\.@.C"1 O #7(\1AOKAW1(C@Y.S3$^^G:VYD
MF4%5[FW_X/E4.T5O(!BUK;Q6D#<AM B>*5I(CVTQ*?,(JT_E+"DO<3)S"^'&
MF^\<7+_T4S1$3O*JT.6/$B)^YFY@;]O9'_OUOE^7'N'5PK<\-]>?CJ&05MGK
M4)HNP&R[R(=^L%)3G3M-R*3*/=E3RSU*6;-C]*C-J;IE3_3[\/)?[WBV('IF
MM&U(1V ]=G$+\^JX]5P"48P*+ DG+9.-RPK[FY&QA36(+F1:=EAJ?13I KG>
M("]1<IB<M#1_N_'45;=4ND_71_1E9,_7Y+[5JMT.5GNIHYQ4S%JZ,[I[>.95
M8]JWW^%(::G8T^VOK42HJ$ '2$#OO)Z@E & 8_D6\87\MG[CH$'IH+DE\^?]
MV7KNE8*]/651[VU,GR.<AUR)6'^I2,DS#W$Y>[[(R^L0V3-5<%>EPM1$2]>#
M)O3+O=)$E ^GN#F!=V$K,4PJF5SOL\AI-6^2T8&\R.VF^J[@5C!/G:G:'5<&
MOU-10,I8&[FL!5%&NH%#Q< YL=X47D7"Q<U3T=L[E&,/Y0*7RM7<[WS@:@9%
M?DEMP9QN,R&7M@EX@QF#$%Q3'@/I\7.J8[OD(/E(7;F@RQ/WWC2@^<>MVOT?
M 2)&SI^P._A8+',[8CH;'T<%8I>==:3QE46EX>G'0P3$H$_Y:&[DS;RO7O=:
MRG+*PL2]]Z,8KC#OG)6:VLULXY'KT5IE5862)@%3K^?R<U>;?H5=?4L,G%J9
M9]*SP&ABPV=1B2W*;PQ+O)UY42U'3;S5TOAXE%+KI>>Z[@E-?N>J'8.?([^I
MW(4>7S%@QX*CMB).PE8W._5MEDWKVY*^L@O;.&[F+)VS=I \9U6DFW#R*2<N
MNX=H-B]$.D5^$2$GE1]2"G/M:1I_+):,G[QBY72!\9DFG86N<,#"_D$"=J)>
M.ED>?-=B^KH=;B+M9&L-5C-53[^DPV=1T$>BH;ZF*9IE9'T[U.MS<?>5=B#P
M<2\#_W.7MY*P\M;[S7,#%D^G_+O'?8>#[;W=:N=0NN)S%$92:"NA.GS12< )
M:_-V <$'"T#?&KVG\-UQ)AH3$!HB\]+QR?1D.WJT\J=N>0S!ENAC!S<GH,%1
M??%N(_>]DY.)Y@+=/N%M^E8.5L6=W:Y.+U[*<>%_'5&YJHT$46;J3NQW6"09
M2& WX]Y._<I23E4UQ,D/"[X<\[U[1*\[M;8CM;Y-*>+& )]K58M +XBI395T
ME""] .*=]:1P)%\A! ;GC(*F?(+5X8,J:I_ S]H<Z$V9&5Z<.W)^]/I+9H3'
MN[E$B#MTIZ[ ;;1[-%VQ.L3,9J,)=>!XZ("!;KCCN!<*6A[-TPS>.?%!.:?T
MY3&+))^1C6UE@YO;L5>&?-DL!B-U<\:QZ1N&&'9D2AL_(0AC$8?"QGDUD6Q#
ME,$D":7Y9^AX*3]"DGQIH'@E.[W&<EX2&NQ#!8[9P0;0@QV<B"O9@R-[8(&5
M[*QM1)CVZ6#G?*R1 V&B1-0!OTNPO"VA%%[>=>*U@5?*TUFF_DW0E:5BJY*%
MQE>97DZ'\#Z96E?- :EA[[K!'[Y=1 BANL_6?G:^LS"F*:%;D6U%I;5Y;=M;
MR7/%7X:W>1W7I'JE 8A&*7^GNW:YG["#7_NFIXL5ZUKTC4,3\WW/!KU\.>>Q
M7P]R:?S0L#T[*W$@(?SD-*GHC5^ CFTN91!4@XA#W:$"<?/8=P:R70@TF!\6
MX%"2!%H_*#&W/RN==2.+E<?TO<03CIX;&R)[,S^=-;$:C:4D=@-)G$:B1C0<
MBO,5]>(\=J#1<GSXW<S%AQ$KVBXUZ4UE#\;+N<T*AE.+@MQ#RBBUW[[:)96)
M##W],=)4-43NFVR3(Y?7I$I&''7ZI>..ISS&"5BF];*C:@^.?-:]5/Q<0V/)
MZ@=?_\);(23L*V?$;<(^.JT1"\*7$JP78 .?L)MKO<&'RPDW.\#N*N9LWQV.
M[)X7/PAGJ[?U(NM@I*<;/JB]';'T&]-%]5UH9K<OME7T+#*7A:,L=RV-_ L>
MTH(UNG82E) 7P067P0FD4(%J!"T_J#IYD]*U?"#FZV0KC*^;;RUL"K.-GH^8
M-M# !D>](-3W4@'&3;CF@O[5RWQK=7.2]2B/HOP0XU-1XIS1ROM)&*W5<P8)
M1&@@419^D0H@^:C T-!$/ER6G +77MRBAS'8X2"I>D&+&]IR<GL2V/':RM!I
M^_Y;3.=B+['<F#L?.7N$R_#D_E JOUE!V>J$PWI=M=F67M-F<_DGDYF+APX1
M];;Z@>CTOFH<:)&6*1324P$7A#NB4U2^!0$ENN= ]<9<"Q5O'\!FR$M?']@,
M]A4FCT/H(XY[1ZBAZH@!GA^CA4\I/O%U"[EQN<OE0\;W_%* -TWVQR! "L>"
MV@NG,1A2F]8$XCUF%"F7\8V<MHCY?"8-0KX!38$Z-ZSU@/$IA"+F#6^,8IP!
M(\$,4;)6M_W=?-'L>>W#S5L?7+R<7-/0YUF#527ZSP$9GZ)5&SSWW#9<8;7"
M4O/FE7NJAS-X>2?MV==-6VXOM^99J( 'V8$&HPO$OZ8#C?I1CZM/@$J-E&*#
M>E\GGFJXXG-!M[<LM^J2Z0*_RU?9034J,,.\V%:!$[;!2I:NTPX_ M*LUFRF
M%4SAU37\>9$87/_,93*P%<9AH:\S(8G-0HB0N,A5FW*4T]()&PBTQY1:.15@
M&7 ,3]@8IP+W*21?KG/P-$//T9CI9HL$Q/;C]*26^]C6PNVZLOLK/9^V2RJ"
MRK=MAC90S]DJ;EZ2?5[Z0%\@MZW\&X2-,H'@,SBYVB9=A\UN1VS\NL]IY2.U
MN@!K&Y_AO=3-4V?W9+<#(UY0.TFZ2"ZM5:0?6-CBF('1[SL3RA=UU5K$N*I'
M3\_<:>R.]V[A8WE]F2%.!E[WR?(+G H0-> TO<0A%Y$I$U0 ^[XE=(&V,V'S
MEC'K<WSC;3V,A=H^F\W"@3LIAW1.\SVR;\%WMZ:1EPFEB[).QM<(" 0Z%KNQ
MV?)8?6"E.O'1N\PX1G1=WPY=EHH6\#AZ^6IV[8\4FV2?H. 91']GG/W<8(%5
ML._$B%$X7E\57;@A^\:;YL!XT?OI)/8'V)G>$+_6N5Q/]=T0_ 2V;!.JL*C$
MUQ3YHX2+'I2KQZU%RRGR<;J+ C%(N"T:%9E@C=TKNEKEC$R1+P(W"67RM)SZ
MRGRK5+_ZAFTO'E%;N&&,'81@F6I_;D63CM37GTA/_%&;,<=:DB,QXP-Z5O:Y
MO>S.42[1-"4ZL#Y<C<"+412@?&R:2&[AQT#YIE>/-\5M3;><A;X=$,L-]RI<
M>^R2\G9'R$1:8JO#\4ZT6BJ;3<NPA;GH;BMIJP)9V1O8;=/Z8L;TL-PKP]EF
MJ+YN>8@&#+7P\A :W<*.7>L)LXC>K"6#>_ 3(4?.*K9]D7]>]]CUN?]/+;@&
M):"(M8 4!*YEWD"61@P>I_!F7L42<)G>X[2L*&1IU/">W@>1UP<6CY;.,S-L
MYAST=0<2&# &M43E%0/N$5MC[%-R7?7K@=<'J;*3S;W):E<^AZ@>"9A)'#C"
MV;NZ;8XPQDD_C& DF4ZTV+Q3U./GREX0UI_2M6'_LG-V\-23=^(4QG!EAR[6
M!'A%.?3^7.7FP.:V4H'BT<:,D*&;Q:^JS,G+:S]3!V?D*I9GJK^DWIG)PXAK
ME:L;7Z "C^03R _ZJ,"+I%8(6'ZP..WCF5=)1IS20I7B&.-N!.$&F!UNC '1
M3&<#LO[@>B!>$?QII^V6QM;T3-C>M'>]/LW"?7BH@& ]3IC2D4 %+M@//[E1
M=DGQ[E#<7<Q5J[05U:\6&YF806[8=5-<?3+ER/RO0FY?3'2H^@:XVV8Z]I&A
M2@Q?R2P/Q/-[XW=;X<9EX- ]#N61"Q6(^!9""_KOW7^=U<_-9;0H&QZF^V7
M7R25Y0;//4'&*UP;RZ5780>9W86UTI$D*%%B!<$.%P]!+"(?ZB0DO*O1JM'E
MU%G^S/O0]:9)<,HIU@^?9*[Z]PF)(_!P;,]R%,J'!SW3FC'_BPJPW9.3DID7
M-^.I2GT?BI$)19K><!F0/K-=^T ^S'[0)M2RVR)'.:4QLW:N(,1>_'4CN4U!
M?J$%9TN2E3\/B3N>TS$LA0OP>G30OQ"GB-=OQF^*$SY$:\]N3[PF72<7^\*5
M<?0C[0:,6*?Y[G3A3U[J[*D&TX>RLMYFY[DDLA;/6=OE-]]($<4L,;Z!)K1
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M">[S$P:ZH@+X1]C]SO1U"UTBQ#C3EC)!=)Z7=3750TF[S!;*;D%!#TI%2*?
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MC7[6W:R.U_X!R"*GON4YV-O/Y<Q_:>OCKND>R;!PF#=7+*[W=&C<[8L%>PV
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M:Q+S33-.\J7FR, -F3.O6HJFV<Z\BOQ;Y1UOH_F,Z"1R-46H'ZHX2/E(F?A
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M?/SUWJ(=P9'M/%;M@03KK03#L0>#9,\UKO"=+X^X<,5D8UTL7K-51$=8L:=
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M,P[[B2]TA8L\X8"C\0 2X+4U<E&0!"#WI&O1[;7)X@X[<;_R_!4["6 \C3_
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M7'5$#0O5.<&F?$<U>.;/8L]$*7ULV,C2\2DP70?=]0NBSK=+?F52G.;@Z]2
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MV.?';(B,=^:%2NE9]"_PJ+V 2FI?"9T3P@8MMH0@"(B6)!+@S5_8)JY-'06
M].]_OQY(=?[(E$TKN3;_Q-MW)CI041#-7EXDHQE+5^.N8-*\AV :&Y7L2DH>
M&YV[-I[(.]<<=LN:FSTPZ;U_%^RTA_:*:3B401)I%87F,G6H64DI,+6U4=?,
M#*.UM,T.'1QAC[_!HPQ^:U%\Z!P.^EM3"/VM+A(5#S\3WBJ(5LX])=*-X"C5
M!T44:>S;T2']P6F/O=#<)IO[PA8T<S?MIJRC^&3=SSU6?7O=]871)PQ#H% ]
M#T[B)F8H]4'A=L&M-7U-97S*O6-KR]_<F@_B-/\=;_\]TPCP#Z94SI[(]2[@
M_E^ZO;ZMA\=?PD?MWPD?@(='$Q-SQQ6\(.Q7P/^>VP=(IB^HS)'KG.+PT79\
MH@_\QT,2X*?5@$^QSN12 ?ZM5*RWST5;9&Q:D #I#D>_(?B%N!CZT\K1?ZQN
M(DVQ_Q][[QW5UM;D"PJ##9ADDS/81)MD;(+)#I=D,I@<9 P8A"QDLHBRP>0,
M!DPV)D>9('+.&9-SD# Y222+)!ZWN[]^?;\WTV_6S*R>6:OO'^>/(^USZE=[
M[ZI=M4]5;;E(_W^EH!S'<7$([*O]/UD!_Z&%ZBE53J2I>!5.UYK_S  X'(0_
M7,?_M<E?9?K[CA37],:?(?OKR?A_R4,8%K\HROC/!3_LQ]_<_,W-_RUNB%2D
M[T>UI7T42/O/V8A1Y2D;&3%;_\_%BGQCH]3Y/V<-\'>3OYO\W>3O)O]O-:ET
M*4!*H9T+9F=G7[&05"4*2<=LJ2E]E9\6(\CY1RUF(XL'V(1/RQ Q>WGN*;%]
MJLVUYW?J)X17JH)KB0(6?Y%'4S$-WZJ6-@SPG<C8\J6Y LR\&&D^DGJ82?>
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M3(GS6P::@3#SG5!G*]<RG0794?H_HN_'2MY@9/T =FZ%8])A01;-$PVJ(*I
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MN\)M,2^(:6=RI:=\FJ,[VQ?WQTI[?H9$^6]#W<(%J <# -8Q%E3+:5:FV"O
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M45DB_0;VH[HF=HE'=8/K7/VS)T!.8$I0P78XZ,27AED*,Q$Q0,&Q+_PN6'P
M$6D#:KK6J.GN?B1RHAH:C=126V_X+:?D0$V&?'36".NX^BD-[LIF'\VS.:.R
MQC=5OZL.RV+0'4Y%;#T?MC]Z%BQ'9C4"EZ<"??N9!>_ F,\':WPTP1QW[&,4
M?3[,K29>WOO2,[B0 HC; L]C" ;-@(_5#[$U,!1XZ+/YSJZ7R<K&]]"LX'\_
M1D=:=^09AX#O? :Y-_LU9^)PZHS;=A%H)J2&$,_$4!K5[*];>R0]H*I]SKP^
M)]]]-@'3KD7>D:8;L&([=OIJ#%_;Y>.#(8&\.L@#X=)C<$)*;^3BDD9E,DO(
M[5]QO"S[-_51P4=7@$C@;:TN>-"4/ /SMY&.:K=$H#T]WE<V:112+RFR.!.^
M'KZ>'A^!5O!OXKQVO/,*8.MMOH(5/_>1&L)"P@=+KT>&,MFGTY*E[@G(\DJP
MS-VK+EA>"=W]C$8Q]N["Q_"DZZ]SQ*5>D7GY5LOVMP,KNR-\[QE=/"C_65RI
M(6",-5]$Y-D;,D>D#?PPZ7]#"K(*&@A5?ZITG^]-G_GKZAXU!PMO8UQ&D1W\
MCG@SI62 8J*?B8:\G3@+2T*<84-5@'4#;,8!@ P3*A>W?$+]N0+0SM#$YMLO
MA+D"Z&.$1K!F=84P0[U))-&3Z8"$'6 !B[4C+^&]MVH![5< 5P$_7&+6=K+0
M5*<Y<1L%VN>^ JT65V\6!_&PK_ ^SR<KCQWDT^QSN4J]*$')6:>W-C%8QOLE
MYP]>_9S#4YTRF51:#4KL;_]JUM.'VV\WFNIBNB(7>3&&'TOW9$4L$?;)B%#&
MK\G@_-]"R)+:VH 4QG?O'J=]^];*)SYL=&%R[8 V!V<0ND*>O!YQ60\SF"P6
M^58=J78N65=5%<^3S*0+ZRA3I7G'%9Z75)/(\>!HG^3BQM0%"U6@>!0E++*_
M'<_KW^XF38^\>9(\&Q"!J0HFF;^O05:4Q4#@OUSTIF!Y,LR;:.)-2HM)?'.$
M ^)"&94R5S]S+.<[LV^ 6_AC9.B[>+("SS/H0J'$=-LG9"V/LT[$[OJIPKB4
M0*_ ;V"RSSEKGA_<#G@'5M1MI5J+)?8[HM"E@%2>#]_8OEZ#3!K<YE*LH^=E
MZQVX81>U7WB:NB@9/"_/SM19IT)P[<N&H?+WYHSMFOBPG0D(5)BYB9#.:YP/
MUX1IW]=^6KB]\6<5Y;Z E6HE?I(AXZ_G=HSH6ONG]4_3*E]/C'=^#Q7@ROZ'
M# @D8Q$?Q42"DU^;N#6_$7GCMR;3[T%M&.@%#A[2M7L7D:"2;1;-QF1*%+Z<
M>E2IG:*Y\><A4C0H^&=Y1DQDID>^L8GY@KV[&WK(7-E@O!3)4N% :GE[V)D[
M5M#K:U7GFUJI+H_\$GDRG'QW&SL;ID%:8I"L?<KM=YU-WFRN@FTRJ6P/T,-G
M$'G:3DWU@J1T'6%O=KO40S[[0-%%.1%6?P+!>:R$19B86[U(L)X8VE4:HGBU
MMSAZH%'_1_E<Y\..@T]^W _-Z'09Z8@LQN4)82SZ&0;)ZW\L.!<@OR0RD+I+
MORHW+ITSON_ZX6<O(Q_578/U6/#/D)Q;&97I4];G_-"^II7ARJA/OJ2C0N(U
M"F5+>LSS:K=RA*N]' N&W:G#!:%" [%2SX?^1WMG'@Q7ML?Q*W8B&%M(I&.+
M+0B#MC1-,A@1^Q:$3D822UN&#FUI6@B&1 P2,AHM"!$$:23:%D(P@A!+!)%N
M>VQM:1JM^W5FIMY+Y4U-IEZ]5S-3;_XX=?^XO_.[G[/<<W[?4[^Z5R#XI>G1
MBS,XXAZ&"N#=RHO&O,"9-\0*<_#V7>_#VI86)]QYGKBTJ[]23S&I2ZU\%&T@
MJW60O'^W#QNF5[!;N2N'5H LM($ J@!QMP^)OC=N=&7HE'FF*]BNKA*.L3HA
MD=6L$#K'SG1QC,VR^,7.;#.(?>&QLV_G*^4KU[-U&"L0+@1M@^]W56)B5>IR
M-N7WO'7C@::]VJC!&&(B43?SW-KRLY%GKL*-)MEC5&;281J(M)PB'+^7#2>,
M3XRHS2/37H\[K=@\"D6>P)^&/+5@!-9;UZ:WCGC[4ZQSV.C -3"-WW]1D-:^
MZ\@0',-=F]CJE8E-;-7*>OW>V/;H%AVH=MV:-9DU@=15;%HM-D[&D62;>SE1
MX$&RJ^/)BB?Q]H,V6BOE#\G<F,[E:S[3^U,MI7 GU@_ZR6J]J6VY+]XCMR>G
MH6SA_#C8SOU@B<Q%)4%KPPOG5J[7\^11WO-H\@1WP)X5P9H?N$C<[K.9$1X7
M^+X4S I9\BF>/$K$*YP6\!K_HM_[Q904Q8EPIXSJNL]K38%2F4V.%['E5#9K
MD="*V,W?>Q.[3ZTN("6FV]]31P8;5^7"(VL>Y3P_Q&<"]^5*_2I ,M:()=5"
MD*GWGI>-U6AXA77BH%0RGF)-,.M-2,?R'>LCIK5MILM:Q-BHZ<^]DTFPPM1X
MS%ZH\UM4%6T70EN0C*\74))AP[X^F]Z9<U'> E4W:2&Q7,::E0JY\E)<@+;T
M5"H\=S3%6'[==+G3*MEH)N ('T7[7>^^$#9+EKFW1ZH?DZI*CB.\<'Y/G-)/
M(A/$;+J/&;:_L "XM  .E C)M@7*2_9?TE.TQ*?9N%S$Q:W;,5XG4=^E@52)
MV.5+W[=DK57>YHGMT#76';,V[['8\N]](:15XJ2DN:8*<2'P'&K/$6]XB3(L
M'(6+Z:V%(H61 ?$W#3BD8E[&,5T]_--W%0+#T$]56%][EQ4WY.07OX==3N]1
M''=W:1R0K4DT4CP:;9:0G7N\(+KOMC2RW'@JJ$W%6;N@)MB (*K;>>P%E"/$
MQ(0$BJOJY?5T,"ORW/'A]H7[E'9/Y\Z!58^W#Z2:0E+-$?JB%(%W:'9XNO/S
ME+Q#YB>?PT>6SKE9S'.[/JKN&?#BBIH67&+F[GFIAIC[:MWDV$TOQ84G@8:C
M1H5O3>1+J>JDE>_J/?)":M8M95N=U4R%TN^RME9T5#9-)&VJ)?!-+G\M:B@=
MQ:GAWQ;)WH?RR[2!.UPF7\D^R>/P@M,-JO#^BS.!J%+P^;2U&KLM-KR"/$)/
MX[6V^T-,EC-5BI0)"WF^=.7L9.TJRI2M5CU0!S-P-E.&G6>-(!IGZ]4E,#"#
MY^6=T]07?KDQ#CKS>%<?4^1BX@%G"D8KRPU(*L](9\DQ2Z>&9[[J%L3X!VMP
MM%]4DA!EL>DS].B8J))=;"A^K[,TFU OY2_>/P[27+&P$3XE(8LH##E*.DWN
M"9MI#$?'ZFLF)8*O:4PF+\_C^+=CRU^5,K5)6!EK]?8WQO/F.-XUM_4ZW3[C
ME,%T7I62\(V$O&&7P^TR=$[[#(BJT"O&T*K8<O2[1_XTR62*?0Y#Q]^%NM&!
MYHL35*/(G$68X;9UI1[[M"MZ@0<V!4N81K=J-C/$]W9$!Y4APF.=)F$[ N05
MJC!#=+=:TP$NW/.F#=F%"<IQAI;^KOS5>,(<5$%3-I=ZGPZ<]:8#DM13-(D:
M7AJZ:]ED1N1W %C^ F"R\\QQ6X0(6N6I0*_38('0$TT$AY!AVK6]<#K FH9>
M%42WE*Z6[W'N;-&XC]$!HN+&UC=AO#\F?0" #HDU=33Q,8A\8QC+U-INRG;L
MIZSY-"&/)/2<Y7 3R0E,!_AA174"+R/M?#X T"H&:4:4>.HI'Q"5#F2,);]0
M^1051"J!P.G R<@&.A#=V41)W--[G1.SEO^!(9D<5[ZFT@HE'CI/!V:IC5.1
M%SZ!E?NT*QWGEULW0+</B3 0T*4:Z)1("3K -\I.!Z#36U+KEJ<HH,E>/F_5
MD6:"JPU;(/L/X=XDX\;I,2:8#Y6%HB+"&*/]G?M[Q7MP8<W+RWP7++ZL%H$0
M#*$VIBMN!>RYS/,&:#?%[N>7JRLKIKSDMH/T,=*$_0=,'1?X_1 C8%\]?AG!
M6]5$;,C'_X/\X\K7GDR:B9/4@'<2DTKN+1EER$W8HM(9;T-4P]M@R52];.,)
M\@^]>CH(5\3A".]J<N*$9(F9NJ$%8G\LYP[Q.BPB,=:I#[7!V''T>F!$E6>$
M23*)!'[>OBOE6#-H+#DQ<^=.=K8QV&,%D7S*@I+Q3H:20%AP52HW3TY#PU$R
M:_4O[APS#9Z4>CCF ?%H\*^Y+EJE20<\ZT;J(E>_W:5A<%GA=NX&"3XS-2+@
MV,M3M;6!"S'8V[@4BNUTS/CM_0Z2F.LWLQ[#?47;* L$]1W&9"M#61(:(OVY
M*'D<^C]N58Z6M8)/>"!OJY\Q^):SXVBTVK?>($ZJS$#>JH^^W&I&PJ$VY_$\
M2#"WT/WJZD<'3DQ+[A\)5 -7RK(+C383.GS/UW[G"M/IP9B&UW*KX+.F+9_<
M7T2ILEZ]4S9S5S55[9HY4@K@#4AKWCJ<**[E6I=9VG6P^(&# \ZQ?SZXH=SC
MS69-_"%B^37\C48E;)O^@55%BJUS?=*% ?XEX??]V[;7O+[Y$:MJ+/AU*8?U
M32/W$11+4]WJ;!SU$A%T\!P<OYP,>5A;?3:7'W(FQRZ@Y!M]EP!$+<:3_5Z8
M,>;=KJ_RRA)W^/V>I_PUQ$U3@91DO(4"C^[3(?RE1:0\NN1,W\;-B)-._$^6
M[U6@Q<05?!M0-/<BS(P@,5\P_:;2?+@&'):^Y/1F6-M?@"H_@&W;BI0C(1.:
M",*#*_U:Y(.%.)<ZEXGCOL8A7?*.]MM(Q0,G.+2*ZP5(#Q>,AE>H1D0H7S<Q
M^8NQT;TD%>FKY^/>\(S>L&HM6&*-3I=.'77,40R&QF]Z%7,/#@1%$V'J7[VY
M-0.9U1JI8XW NR=>FGV&T1VW,)L=(-]_:[(N)A=DFGXB8E_<TR,M93;WPM>A
M"QVSH87GY\/!0GU7&M*[,.F;KN4UT:CC)#&4&B4BG^+DW_@6CSK&']BW?6G-
MM&<L*XB<3T!&,93XU46(5D;<GJ_;Y=U3)A6/?_BR<RLP((FR,*H.!QWP(3><
MAH]HF'N/3SV?6PHRS4OZ%MBV=V$N\MLN6H#QEFF,#C[!V SYNKK;C7@5=W-E
M(15*V2(LPX1T3K_=LA@-/3C8[OY@U\*SJ%M&]H%CV$(-IJF^L[^1;SZ]1E^S
M8J" -E2Q:K_Q.(//[$BS6+UJJSN+0%9H*$^SZ&8W8FB"@^I_J:@P0:1UMX!$
M+/K^;M7<A/79J*-'\4HW)IE#;SP61W0'ORE_UF7N=D@ZPW;H[NYQ22'--UFK
M&<R4K!)4-ZUOJM\;=&"1+*[?TD<V]Q/".=BGBMM<# 4C4V(N=;2S;-Q;G-=U
M,U[M_I(+-92(Q#GBAHWR H*]@IQO-?)2E:LI9@1M=5W=X89J^,AR?JA=G'U*
M%XMTZMG[1_WT K*XEMN/X2!Z=]L(X\J*6@^5'Z:H?961P0N)EZVKE!XJU-ZX
M/VW=KZL4?2_L2;'.X/BL$JQ$W$C0RE"P?+IU40CK*>L=I/_L;443026-%B76
M2V,N_Y#;*R3(U$,'6F"R>X &ELH.^Y A;#9%!W+9<'0@:N&GS%XC -%$RNBD
M P8\'G2 :?BG%.$OMJ%S3*5TX)T.'5@-ZK,V.+Q"E5E#OV1VH@-/@WY)$6ZT
MW '@4,J!)JKK%3LK=ETZP(G";@!#:)(XFH*WI)AA/T(1_QGE'!WXIP64H(S^
M+0_0/T]C_F,4Z,<6V+]Z:_XG*)^9 W_@'%GYQ&;KO^5H]O]QG'\;)>W37C'Y
M&:7ISPC[-\K?*'^C_(WR.11M!@J"#OS+9A[]Z7[V:R:_!OS9P"G\8R<?6&KI
MP+\#]_Z>G>AS0<O'+)\/\_K[JZ6*7:H*>V8ZXD>GQW.-(<S?,T$0.V(O\Z*X
MY'Y'2:+0@49S0:M].5]2;.?RH@Z.^6T*YA?-&@D";^G U:*K3_,2 0_$!FBH
MX)>#>@7UJ9H(1@V66[]H;2&QP!@2XT9JHEPN1[L,[G6BS\4?M+6WF6A7K UX
M_3AVKGZ=E48+SY3+Y?Q0/S:,>:-HD\KP .BO,H3M:5!40#M;HAR3C!;S8<0>
MCRGCT<]W6[",B]WI2.L-VYT^(T#E8P+O-;8(^0%K WZ3+L:0&-*"E!@T 8%1
M.>:<G;,YK!^A_54+FC[R#U!+ P04    "  5A']:*^R S-@C 0"I40L %0
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M?!H&L9=&,$D"87?X-(%Y@$(8(Y+RC*!8&!\Z1RL73#JV-+8L2V.A&G@&*]:
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M3QF*$^@3$J<D"XF/M=)^]<B[OK/M"ZFTCEK=L X]'-54@SMT-&]?=RO,#*R
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M5KD"E600EARNQ<>XZ[G;W3<_C=C4R"&\<(JF5<]<B)N5,SEL52P!W[.![@?
M!8=#D^.NR<7G-P%<(YES/N#-DCQGF0"];% [D$UFB5Y(8K[L43M8[&256AI2
M;R>BK%@,/MJA'<D7_,06*",T#0F#B :!/.C&,.<A@GZ6>UD:IGE.E?+O3Q%P
M'>O0D]QVY9%$U33124RF];D-2?64M*:0RJO]G"034;SBU<XT%#]L+<*3 \ZR
M8,^),ZS"L\]9K&(\=7G.DBR(,D^>]J($HMBG$&.Q_I(D29,@$6:?IY=!I,G
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MXL=%YD<YIC2%,8XSZ;2*((Y"'PH,T\2/68HBI8/F-!G'*N7FW<=[T%,&(])
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MA+"DN_9'GU4_G1!M7P>=>DS_V'"SJ@OQY$-%[\IE00I6WU4EN:;E<\-HVU]
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M:9Z$&8]Y%.BYY9WRZ]R#_XG5]5\!WC(S'<:C>]OI<BI5KT[?>GH,[V$[MJ]
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MY2Y*J=RQB!&O*"M$F(M2&)5&W!O5]VVZBA)OUG/E@AAXND'IE?LHC&M(:]F
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MI2ZBU'%'WTB)'=VKBQBXG#(SD^O'F0B8\CI5-.$FV+$>#'EO@ZZ:H.=>3]Z
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M'H,=D]OF/QV?+H.5G('F+(+I>HXF#FMR!N%QK).[H>WTZ =1B;H6_)[\-6P
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M^J#*RQQA1ADB*<D0SHHRBDH<EP4SN?4\.?HD5YQ52S18Z/QE5:,3X'8[PL/
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M^,__*.(H^N_@:;44K\$3J?\IY$\)8\HW!;Q+-8?7;)U[ 0VV_#5>K>=._F'
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MZ#C,41&F"2))68D\);A@H!H2YJ0]JXF>$94YW;%R^0KL6C0-O29>, *Z0$[
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M>8!,J'I6JCL>E.]CH:Y9%OJ:A5@D@)G!:.@(<@T.3*?NR-\$@\LGS<!-H#A
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MG(4!2;(TCE@!<K4-$1MYV>[J.CD$3IU'R&ZM^I(;MF![I:QV=$?J#&(CH;_
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MF%%V"EP[J^M*R&"JZ""0?[3J0@-">;*+3E&8U/ 9$/'0LAEZU,%%U,;SZ[K
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MS+YHSK7LC*RU#AG0]OPV#[ M'6%:L&E6M.%/A9CKY^@"Z<*7>+[$G+[,&[J
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M"5]G-"CY:4]MCN <G>-<QW$/GFM+,7Y<B@^TD3/.LXB$(<62$XI)S#G.X[+
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MW(?[!A%^%7X X@08VMDLGI$!GDTZ4#[V0.E*5AH&1H@W \CKR2*QH3BI&0*
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MWR0,2E%B*A'!&B1WQ=D,C@N$F@GFI?%1IB/MO*O%QFE$-JCPG\S#/D3_>M?
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M#Z:KL[#^^M>T.-M^]B\A_?%QN3B?WS*@5M.SS[/O%IM?^]<_7RU_F[#=A]S
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MM5?"6WNW(14GN8)B#;G'R!"<-(E<UT(6**8ZTV"O I[&A(W[C#L\)D<79M]
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MM(RNS0>CA%A%#$<B@0O"E0_(!1X1M2YQQV.(XF)-S%Y3DYNCH'!*DYLC]-(
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MTA "CU;4:P%@3GYRCI,A0L!.LB+7P4,\GPS.,]!"2%1QXDK?L'2EK>[-2DL
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M92254O<VC(K(O@40/9+_R=[ ;[]-[7@&NRRW\IGD7HL#$<&1DRP@;V@^E*5
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M !M7!TF1L,Q)QDR4<2NZW9/HZ)/*NB4\Y;#;ECK;-<$K6;SQ_UX,9\.LYMF
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MS+/OJ;KZDYVNIEZ4*9M^MES1>NC#Q%Z@T)E("^")@"I!\_.D0%!V]A&+"5-
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MEDE27?H5^CY:&HE)SM#SB] Y0>@-@ >HCK/YT+^=+,;SZ=W:@DJNL"/:HNB
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M1?P V,[M=7-EU_\,Y]_?+F;SR4V</E1[24&QEQXCY7U"7'@(.NFRZ3.WDL?
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M,%O[WT(R(Y2"0S3%93LLCG3N3BE$8#%9$;PO<:SL):#>$7.^3I\#Y$P!UXY
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MKJZ6RE7)=_I M4K14[5ZC-@J:_AJ,0<;#^?X^+J@*=V_:K72T5-U^:* VCD
M/TWF_XP/)W4L5<;=Y0/5*DD+')8OBJVRAC_ HI-QO.>TQ(7HGB6K592>JL7#
MHFE+;^\6\=LDOUD=SR+P.4Z3Z:I?U[G&]ICO5+OL+J3A+D)L4.U_#"<CNVI
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MD4ZP1*J$.G.Z!L81\"] AGL=6RV0R;=R3,^R9-J %T4O#!I(HF'#KH;NGBL
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M:F)G=AA6K16<$%G>6V:1^,M%6[]??L1$B8/71(F6)DH<M0<O@E#08Q  '],
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M58,G/*@'8_[T-1O\5XD;MS\HX^;'Z!M02P,$%     @ %81_6D%IS(<+"
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M.9A&"FRC112T:$@$!-SC%XM+%LC?;P;!X38AV*?BP9BGI<M7%%X1QZ")<HS
MF#5T[YE1;)!__>-Z!N@ BX[(G<;SS)$J[>L6;%(A^+.T(!(=?W[?PT8S>N[6
MH/ S 7L<WFB MX"Y:)LP5V5-'\Y56-#VNR)OKF4M]KX@5U))5V%8:@K^0OU<
MHS53QN(]G5I"EPFAZ+<2Y1>J]U[I$@/%R&(OI"O#L6L2[N2 #A7<R9"W:]];
ME7#S3#8H_SG4B\@5!C<?5=*>LE0^BK0Z1G@A7_OJ*?I*I&_5=JS[=K9C[G@Q
MFJV2VCQ14=Y<1.H\9Q'6OH!_K%#99^LXZ*Q5VCR7?/<"*K-,6BO$[U2%D0*I
MH/9(PCZG9 ]X1A(VE.3QFTCU;!&*WTH)\]V"*_/0'3CL_W_7]<>5^GX*F@;:
M*($VVNG2GCF4 MBHRO7S[F<B^"/57T_;7 5VA-.=>\Y.A[X(<=5&Q9\SK,EM
M/$)'(YY3VZOHK&@JN@!B8),U3P(,&( I,P $L^2<J4K*VG.T-U7@MW!;U$<=
MCS421PUQ%R[= 3GNG+J"6,V709F/53H65 MS_E =M^LJ0XJL2-54H'62*)\3
M^1*  ;AO0A0:7_"IS[J=5-4\ @"%KF.N4UX8T9O]<8+<7:1\VI.YFS'7Z:12
M-E+6JJQ'W_7'5 - 'JI/I@Y2OGG^R;_1])_]K<;_:#9RU=QP30<V6FWK=!NM
MP_:KS<U&\&K;[ZD]; 1'K6^NU1G;W4CM@9L(/QF8;U/P_,-.>V?6H0)DKU4\
ML6#YT@!A].64^]E>O%7Q9Z_?"ZP(5_78SUR'R;O=X+!YT@YJ[N;)B]L=U=Q\
M0[>_A\<?I\M5_FUX]6ZW@Z3C?JY\F%]R=4, -YDKVIM,SP:B5:9RB:S W- I
M):-).=G..5Y_K6/[YG4[9V\]0O^)30;[I,'DHNJS]J6KA8+ND>U]\L=MJ(N7
MSQ7RQF],]M?-\\SZV1!=7QZ_P]POB3KK#ES!75//%R_5%<JX;Y\]?[X_%BO7
M[.:+QU7LYKP+'V$%E7:URV=NYE4__27! W<Y\;]02P,$%     @ %81_6OD2
M?RY]!   ]Q(  !@   !C87)M+3(P,C0Q,C,Q>&5X>#,R,2YH=&WM6&UOXD80
M_MY?,25J+I$PV.8M,2021XB*K@U1(+KV4[78:UC%WO7M+DG<7]_9M9V$(VDY
MZ7I)3T4(8<_+SCSS>&;DP4JGR>E@14ET^L/@1\>!,Q&N4\HUA)(232-8*\:7
M\#&BZ@8<I]0:B2R7;+G2X+M^!SX*><-N22'73"?TM/(S:!;7@Z8]9+ 047XZ
MB-@ML.BDQA;'K:.PTZ8MVHW:7N@>>7@C<GLNZ;F+MD__\&IHBNJ%C=)Y0D]J
M*>/.BIKS@W8GT_T[%NE5X+GN3S6K=SJ(!==XF$3CXF_A8]L3D4MTID46>#YZ
MTO1>.R1A2Q[8_&J%JTH]%(F0P9YK/WTC<6*2LB0/WLU92A5<T#NX$BGA[^J*
M<.4H*EE<*"KV)\48\1![>5?$WT,_">.TRL?S31+C^Q5;, TMO^%M9K!;["$B
M3^4K!3\:7\TGYY/1<#Z97L#E]=7L>G@QA_GTQ4S>2N3>$5PW9HU1 V;CD8W>
M:W7<.@QG,#R;7L['9_^I=*HDCMTN3,]A_O,89L.K]\.+\<R9_O;+^'<8CN9&
MXKNNORO-_O5<VL_F,N$0"LYIJ)G@<,?T"O2*PI#S-4G@BF9":A QC(AD*B4P
M7U%),KK6+%0PX6$##HS^_MZ1[[O]D4@SPG-[Y?4/ 5V>"YF"YSH?(!;2^LXI
MD4!YA$WPC(8T75"YO^=UW7[+JYN^UP:B(&8)RA_BF=%P+9EFF#CA$8SOPQ7A
M2XH-,TV94B9V_!K-"+LK8) 4@WX:6I%*%5D=)A!2J5F<UR%;2[4FB+T6\$A5
M$U.O7S(5(R*1R$SC?JI=ZA@BX'$V4"(7A%/E3.\3FL,PM.@9(M113G3=F*4Y
MW'!QAQDNZ?Y>YZB_<R_*2!3AW' 2&NN@U:VZ$T,TN0X<<^>5B'3@'599?/OC
M-W'QVXU6VP"!9*TH'*^3)$>JIUEB2/1 +$D_K9FD9J0J4RE5/@E>ZX @?R5X
MG8/H\*&ZCS1\H&!98ARP;:SE<=\0]'NHI_\VZ\DX]I&4V")AY]($32.\:^M3
M%9LPB=7.)%6FKG4C)DD":(;18%]#08:%5G5K%3-.>&CNH\.(6=>FRZ#6.BEH
M(3)L>T:@*BJ4K:[Q!?U=DT5"*_%"R(A*!_%,2*9H4/WI1TQE"<D#QBTJUJA?
M.EL(K44:F-WLUG2OD"3E0+2T*<2/:UO#+58WC?N:CJJ32W'#BIHZVI:U.PV_
MVWI1[#:\%V5_Y[;;\'K^5_=J@^WLY+9I@2C 0+P5%O"DUJI5!B7I C^[!V]S
M\3,\_!SR NVGF_&W?D;/D,]V?L"O1(:KC2G:^6Q#+['YBFF_1L;O\\UY^7UD
MM;_7[O65_869IK>4PP>*\VHCS1W)ZYIL:SM!LX-JV:5L$\L0%Y&P" P@_;>)
M[PL+^YO"]&TB]SPS+W$&,K.+V($X6C$:X^:#6Y!FMQ2F<<QPB_X?TB]:K"XE
MPVTCPW5C"\G#;2B;=@%X9K]X^J(F$\JN+8&D"3$.MU[=/#[0=H-P'TW( I_J
MM=XV^8>W/>5O\>*I:5]X_0502P,$%     @ %81_6OX<'UJ)!   9A(  !@
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ME7YJ\@^7*]5G><_3LO=+?P%02P,$%     @ %81_6G8LWM0U#@  8TH  !<
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MR/;()TM12OB'3-M=0A3 )@KO%42@2)#Y&[B- .*'4V(_/5/HTCV G4A4A2%
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M8[W.;4=Y_*7_D:>7_.-2_P=02P,$%     @ %81_6I?[:^JY'P  L-H   \
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MMVPM;Z2/K(+;@KTW#/:VM% M+]0ZR1K\V?LHWJQ N8_,A^J6R&WUV7VEV!K
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M([_RH^K]J9PIOE_FVY#&B2S6CV?]@!Z'F_/WD8D7\,^TF"6O_Q]02P,$%
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M'1J9,TD<0S13MT;&T(?;,: DO71N,AYZD\G/FAH["C#3A +,E-E"$[B=W-;
M(1O:J:ZTI+GY,&SX=:F*=%GX+$Y)&Y9#;9DE]M+4B/OP=UYTGW)OA]N,G4Q,
M;%!/-%2,@-8F,2O%CG\\CR(/Y29:A"A(PS#@1X0 0Z<,0A5D;_":?\IIZG8^
MP*LKV)D//L1$_LL59Q&V8Y6A-A-LF?Q%SA\AW)$3DRU[A',GL 68%Y.:(N1#
MT >RIT1;,.%AF[AD86(N9T\XSZWMX>C7$";6<W7)PP3F/&9"719T5&T6WJ63
MD$8V.K6(,PKG8_]6B(P>: UL$M.X\'Q5_C[2B 3L=8*??VMR0_XGFDPP9W1*
M@:F LP6]+X'O;N$;&A/YG^0>^HQNH9!KV.]N"L3W?<+B'XSM<.1UQ!HT4-W)
M^?C-J=1.XYO;U)S33>J'=9)WX0^0U.45XP(S0R(X](,CKZ)D-DE])BZ\T@ ]
MMH@$X,A-:T7.%%(";W#ENCPXV#J<Q0#C@R4E8)PQ[2)C;21?>HNQ\3'D+F*9
MP=*$9"A8&YIX3GD%M<.J-8'11W,Q<,0#/75,.#<?+":<Y387G-@U @4Y >PV
M$(^6<$C(=R%EZH\5.W'7<=8+EXSR\'A,J0RBJF[)A*:HZ\4M; VPE 9;[\&R
M!HV&#:RNS]M2MQ9$3TFZQ,V Z&PR1=-:K49BO/;5(==B+;:' K6G*)LE*MLR
M,,>86YB*C![/[U.V2ZH=#="A7HR+45(=Q=^0*%"5BJ,FSS#)DJ-&B<V:5"M\
MD].C,=_46 ^*%]$$Q#! N 79WD+L@#H# @ZH2U_!BM=[<](X=8FU-='.H^,_
M[0;RB/B:A-[K+EBOBP;CY6UO4H)C2T8H,"C01R*=B31!1=^;H:5/-W/?[D>O
MBQKAYWQ 'BYM"451TYMCG6*=;#I7H>[6K*36828K[S["HV2=$L&$2:^B/!#.
MVO096=._YAP$X7^G@_!*IL-$*]8\R<11X=G()K)@BJ#3>H&F#:@BYV?_<_'3
MY+6#<SJ<MG[05I0)03Z&SR.LJ"Z=50>-DB5W2-N6,YE1,V--#G]&:%-@6"%9
ML#B8F[0!#EJNH[2IUS%:HO;A(0;NCABPKBJXM!9GRK3=XTF;DKI>7EK LLBY
M\#!52X4V'P6+ !=X9?UUL49J%Q;W:*^-1TSJD5EB5 8C]LA/'3R07[33'SP_
MIQV;*AB+-PPLF#,$4&NB]&F8D"N(;'PL@'>)) >V;-H^!'QG$VSG;)61K\)F
MV0J7![9"1%<LP1ZT[(S= V[ !.M'R1@HQ81C.>)VZK:Y'YU]9$V>\>D:,#X;
M?*X$;B,ZD@XA.#."FS';1AU@SH.#WXB1=GHVRL2[$IK]&IC;D*GZ49! 1T3Q
MQ=3)G>+?035!'X#6<X!K7>;.*?2E55A--C7X12*^J/,&62(J$&_+(M$ZI=3$
M-T1!(!A(1Z;0'"'>.[(.^VA_]QF9?12RJ+/F" =3.^@@!=5YDR\+:!D=E9SC
MM*!N-SD3Z0S5(\ _^X P/O]0# ,RLT?EHUBN,DW>OX0UL@K *A5( E0?\TS0
MMP@F=4D, OY2*?R!X4A6MS@2"NS!7/(7.X4_#OQ?8HT7?S#ER,&0.P?=09[M
M>:5P07-5Y/HF5J^JF$4*0.:RU!846* :M_@>LCXLC1MB@;' E@=$4^^*?<#=
M@<GK$$>B?*"2ABQQ+"TO$+<R=TQGD^,?&N!?K#7MI\8Z-_QS'@N T'D$B <F
M6J)6*D$^SNJ<RAFR+4-$!JT69A5'OQ4&,!HUJ(:\[U1#YYS85.D'\JV",_)^
M:!+&=D$S0)8YX,(J4W 8.XB8) <9'2M)\75&, ;>G!N$\E5L/>\9HS/LS!<G
MH?(4'J_(9F*4(O)M)(_*ZFOU7N<BN.LZ<$];N !(+I7)*S:7OF6G##6,^KWY
MF_X G :KZ4(4 TB6N5Y74K4:S;6N=F.GJ% D+"NP" ]PN$DOJ:E #&ILWAY(
M?T@0>VOU04(=,)?*:LX+-95OKH(T>6J1^IW&PF?2XM!675+SCH:<)2^X%NOP
MR:,'4CVGEEC96G'V%B*<KL' HY<!5]G;S[$C1&/0W:D[3E.*ZP"Q%9B=!IX^
M9^/8TL%0>##P50PQ85X04LG*.DR ],IB&6.V;#"T2H0\+HLB!9:)8TM$4EFW
M)9NSP4O!#F:@_H'A966)R26N!NM98;DJ_L"&]DR3D8O%O-5@W@I!,1[4PZT(
ML43?$3@+A6X!ORSTQ3>5YC71^J(%,VIF@E0Y2TR[R3F/CF4KAQM;(=<-((8S
MLQB'FTZ1/_LSY\B;<>OE"AI@CUKAV-/4EG)8 ?FX4;TN]5UJ.]:(19?&E<H(
MHB[#/J8L][K2V3R6[GT(6\":1@*;)/<#E$T-^X51)_@*L'T3JK/*<P.^3]V@
MF&QEEA@4"%PV*;X"NP&1+D#X8=.!O3"?TWH@I;SA\,O-&CYY/H ,L#V"<IS7
MMBB9JZNNDMBV 4)Q^LT(^#V,@'^YVKZ]PLB\=G/:1/Q-@?MDD299@41P>=%S
M:CF?(3$-JV]3?SW)8>AT.B!IF"F#N^8,RA+>K<5FA!7W=A:$3PFE5(J<PFUO
MU&=N@X"LRA>Y+TQC=(E]]. $6X10NO8"0\[<Q\]W[&,3(J&'3"XK#$.+ENLA
MOYB518/LCI?M$]Y86URM,@LZKD], 32&$T=X9_9GZY;V#EQ,B8'IKXPF;ZH-
M1B6F3)HE.O 3[<XP496..QP2,*GLXWL8M9+3E;XQ-/TM*#+LE'(#/&EHR[OP
M60LMO42* 4*>?L;"9 NBSCHTBF=Y:H\1TXN:!#"EPG9!;U'&WZTFLVW(N16_
M/#W[VT\7/W7Y/X>+\Q#M75O&RFTZMG&F)2Q9@D$VXX@2 U(]1UAM82^&OB]X
MT34F/.0NA*/+9K'>F6>$*]8V]XF%D0@/2E1V"<2;7+<]3CH+0A/4A.OCQ._G
M%)\N<6,DZS/(\30W'@K .S45"SK2H49/N[5-><DX>8ZK /N36++>C=UWV+>)
MDVK\\^P*52GFY9(L\EN-N0>3RMOLO:O!HNC8(,I@#!S$.1LN&Y.Q\W^:/&A*
M;H?9NG,<5S<?Q_;.!1^)V*2"]36P6_@4HAU8\4:W0DCP-VWM)F?##7Z&88Y"
MZ28I=?6S-0FNNYVMX@[M C!(D7EXKMS9']<>3-ZG,=DJ2Y"J0>094.BE%S8G
M*&CN5NB_H&8,@%W&%B8D.I4<DI8 ]ZTM;7)O6WS%+  #E%RBA9L7U+V\ZV]
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MM,'4M69K-;#HX\WD/8B/IJI O</NK^:N]:&+,(I\"TT(^)7M8C8<]PJ:4^3
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M_@F&%9)G]'>=9>O6'O^ 1_T:%(EM#UO8#RSV*>P)'>0FC>P2OY@=?SO]P-N
M.NI71^MO,0A!C?<I]WG88NL?_?<D-B>;,??]K$C7\*]%O<Q^^']02P,$%
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M]2]0PPJ68$8.;C&3SXCTEYN)6*>-GGHM:92$E(C9#U CJ0!LH<R[LO/L!DV
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M68,:L D^X1TA@]">IQ.7'A,N*WSF JGQH!/3'6[U/=S<(Z-DXMMK:EYY]JT
MI:[D_7DS*ZX+,MS YJQY,YY2RS1V!+5$1]U=FD7G//B*IKKSK+[8ZWUMU"]7
MQUI\#JW+R&"[2S9K]V"C*E%?+U*,US!\(^VA4;M6?V>YE3OP RRS!9!K?V,.
ML/8SS_'3*+35$Y,&'KM>EK*L2K5NA^@N2FW3IN);G#>'6_7'"5BM]Q^1M-XW
MWV8PG@+Q4RL_NH[Z]&V!$SI5V5B.">QF(O"L"1O66*]6]0V\O^EBW1^(XU6O
M4*\;1QZI&!;GCT4RMA/JDW0=?0$,!,W4--9,,R0)V%)?[2XIT+C.2]=\Y7L
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MS9#LN[RBUX':G&+8%< 9>T[I^SS5A;'?!'8EOJS710$)RUT4%=Y4,>9@@3[
M)/[[")W=F.3&1^KY!J'5%KP<5#[H*/+0161E H$#?2_&#P1<,6(]P)+16#6=
MRI&V[<O=T7 A1_>?.RU"//STMF@RR>^B_0*B;0$Z+/_AEQ9-WMZC"LF*_*!N
MXVR:GXM:,7R [2#X=G?V<O%_%_L7M.BV7%<[6I+XQ-T]*.J[=L5A@ _6S^A^
ME\.?R[=AGZ^V<:\E?3?IOSN8WW"^U'<76EN94'Q7CH]4#OXX)50Z+V]GO1<?
MBZST%IX8BZZ#>R/@KW$E0=5*A7]SO+!-P !,AAU&,O&K4.<BU9H*4XT7BIFK
M/VI\&"#[9_Z/H?U,_Q&V_P-02P$"% ,4    "  5A']:K5P#(*C$ P",X1P
M$0              @ $     8V%R;2TR,#(T,3(S,2YH=&U02P$"% ,4
M"  5A']:I@Y/VWX4  "+Y   $0              @ '7Q , 8V%R;2TR,#(T
M,3(S,2YX<V102P$"% ,4    "  5A']:5U2<P%(E  !(>0$ %0
M    @ &$V0, 8V%R;2TR,#(T,3(S,5]C86PN>&UL4$L! A0#%     @ %81_
M6C*V*[!510  ,?D" !4              ( !"?\# &-A<FTM,C R-#$R,S%?
M9&5F+GAM;%!+ 0(4 Q0    ( !6$?UHQ&J0W/],  !!  0 4
M  "  9%$! !C87)M+3(P,C0Q,C,Q7V<Q+FIP9U!+ 0(4 Q0    ( !6$?UHK
M[(#,V",! *E1"P 5              "  0(8!0!C87)M+3(P,C0Q,C,Q7VQA
M8BYX;6Q02P$"% ,4    "  5A']:.UR(:I*;  #<0P< %0
M@ $-/ 8 8V%R;2TR,#(T,3(S,5]P<F4N>&UL4$L! A0#%     @ %81_6A:@
MNM0<%0  WJ\  !D              ( !TM<& &-A<FTM,C R-#$R,S%X97AX
M,3 Q-RYH=&U02P$"% ,4    "  5A']:XN?P>^$"  #1#@  &
M    @ $E[08 8V%R;2TR,#(T,3(S,7AE>'@R,3$N:'1M4$L! A0#%     @
M%81_6KIL;2/G @  'PD  !@              ( !// & &-A<FTM,C R-#$R
M,S%X97AX,C,Q+FAT;5!+ 0(4 Q0    ( !6$?UI!:<R'"P@  "\I   8
M          "  5GS!@!C87)M+3(P,C0Q,C,Q>&5X>#,Q,2YH=&U02P$"% ,4
M    "  5A']:S*B3@14(  "C*   &               @ &:^P8 8V%R;2TR
M,#(T,3(S,7AE>'@S,3(N:'1M4$L! A0#%     @ %81_6OD2?RY]!   ]Q(
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M&P< 8V%R;2UE>'@Q.3$N:'1M4$L! A0#%     @ %81_6ET0K-ER)0  ?.,
M  X              ( !ISL' &-A<FTM97AX,S$N:'1M4$L! A0#%     @
M%81_6I8C>X"^#P  BTT   X              ( !16$' &-A<FTM97AX-#$N
9:'1M4$L%!@     2 !( L00  "]Q!P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>carm-20241231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:carm="http://carismatx.com/20241231"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="carm-20241231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2024-06-28</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2025-03-26</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">carm:CashPreservationPlan2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">carm:ReportingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">carm:ReportingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">carm:CarismaTherapeuticsIncLegacyStockholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">carm:CarismaTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-07</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">carm:CarismaTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2023-03-07</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">carm:CarismaTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-07</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:TrusteesOfUniversityOfPennsylvaniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:PennLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:TrusteesOfUniversityOfPennsylvaniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:PennLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:TrusteesOfUniversityOfPennsylvaniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:PennLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-26</startDate>
            <endDate>2024-06-26</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-26</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2023-03-07</startDate>
            <endDate>2023-03-07</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2023-04-17</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">carm:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-12</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">carm:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">carm:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2023-06-05</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2023-06-06</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:TwoThousandSeventeenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:TwoThousandFourteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:TwoThousandFourteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:TwoThousandFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:TwoThousandFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:RevisedOperatingPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">carm:SesenBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">carm:Pre2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">carm:Post2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">carm:StateJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">carm:LocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">carm:StateJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:ModernaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:ModernaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:ModernaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:ModernaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:OptionRightCollaborationRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:MilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:ModernaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-02-28</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">carm:CashPreservationPlan2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-31</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="employee">
        <measure>carm:employee</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>carm:segment</measure>
    </unit>
    <unit id="seat">
        <measure>carm:seat</measure>
    </unit>
    <unit id="target">
        <measure>carm:target</measure>
    </unit>
    <unit id="product">
        <measure>carm:product</measure>
    </unit>
    <unit id="obligation">
        <measure>carm:obligation</measure>
    </unit>
    <unit id="item">
        <measure>carm:item</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-33">0001485003</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-34">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-35">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-36">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-33" id="f-325">http://fasb.org/us-gaap/2024#GeneralAndAdministrativeExpense</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-34" id="f-326">http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-44" id="f-366">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <carm:AgreementTerm contextRef="c-67" id="f-509">P5Y</carm:AgreementTerm>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-4">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-36296</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">Carisma Therapeutics Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">26-2025616</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">3675 Market Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-11">Suite 401</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-12">Philadelphia</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-13">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-14">19104</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-15">267</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-16">491-6422</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">CARM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-20">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-21">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-22">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-23">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-24">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-25">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-26">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-27">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-28">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-29">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="0" id="f-30" unitRef="usd">53095128</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-31" unitRef="shares">41788096</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-32">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;The registrant intends to file a definitive proxy statement pursuant to Regulation 14A within 120 days of the end of the fiscal year ended December 31, 2024. Portions of such definitive proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="c-1" id="f-37">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have established processes for assessing, identifying and managing cybersecurity risks, which are built into our overall risk management program and are designed to help protect our information assets and operations from internal and external cyber threats, protect employee and patient information from unauthorized access or attack, as well as secure our networks and systems. Such processes include physical, procedural and technical safeguards. We engage certain third parties to enhance and assist with our cybersecurity oversight, including a 24/7 Security Operation Center, or SOC, that monitors network devices and computer systems in real time. We include confidentiality and data protection provisions in certain contracts with third-party service providers to help protect us and our patients from any related vulnerabilities.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not believe that there are currently any known risks from cybersecurity threats that have or are reasonably likely to materially affect us or our business strategy, results of operations or financial condition. However, despite our efforts, we cannot eliminate all risks from cybersecurity threats, or provide assurances that we have not experienced undetected cybersecurity incidents. For more information on the most pertinent risks we may experience from cybersecurity threats, please refer to Part I, Item 1A, &#x201c;Risk Factors&#x201d; &#x2013; &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Our internal computer systems, or those of our collaborators, vendors, suppliers, contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs&lt;/span&gt;.&#x201d;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="c-1" id="f-39">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have established processes for assessing, identifying and managing cybersecurity risks, which are built into our overall risk management program and are designed to help protect our information assets and operations from internal and external cyber threats, protect employee and patient information from unauthorized access or attack, as well as secure our networks and systems. Such processes include physical, procedural and technical safeguards. We engage certain third parties to enhance and assist with our cybersecurity oversight, including a 24/7 Security Operation Center, or SOC, that monitors network devices and computer systems in real time. We include confidentiality and data protection provisions in certain contracts with third-party service providers to help protect us and our patients from any related vulnerabilities.&lt;/span&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="c-1" id="f-38">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="c-1" id="f-40">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="c-1" id="f-41">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="c-1" id="f-42">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="c-1" id="f-46">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The audit committee of our board of directors provides oversight over cybersecurity risk and updates the full board of directors periodically regarding such oversight. The audit committee reviews and discusses with management the Company&#x2019;s major risk exposures, including cybersecurity matters, and is notified between such updates regarding significant new cybersecurity threats or incidents, if any. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Chief Executive Officer, or CEO, leads the operational oversight of company-wide cybersecurity strategy, policy, standards and processes and works across relevant departments to assess and help prepare us and our employees to address cybersecurity risks. The consultant that operates our SOC updates the CEO regarding the detection of cybersecurity risk exposure and provides advice on the prevention, mitigation and remediation of such risks.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The CEO keeps the senior executive leadership team apprised, including our Vice President of Finance, on assessments of risk exposure to ensure that the highest levels of management are kept abreast of potential risks we are facing. The CEO has significant prior business experience in compliance and risk management and coordinates directly with the third party who operates our SOC on issues involving particular cybersecurity expertise. &lt;/span&gt;&lt;/div&gt;In an effort to help deter and detect cyber threats, we regularly provide all employees, including part-time and temporary employees, with data protection cybersecurity and incident prevention training throughout the year, which covers timely and relevant topics, including social engineering, phishing, password protection, confidential data protection, asset use and mobile security, and educates employees on the importance of reporting all incidents immediately. We also use technology-based tools to mitigate cybersecurity risks and to bolster our employee-based cybersecurity programs.</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-45">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The audit committee of our board of directors provides oversight over cybersecurity risk and updates the full board of directors periodically regarding such oversight. The audit committee reviews and discusses with management the Company&#x2019;s major risk exposures, including cybersecurity matters, and is notified between such updates regarding significant new cybersecurity threats or incidents, if any. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Chief Executive Officer, or CEO, leads the operational oversight of company-wide cybersecurity strategy, policy, standards and processes and works across relevant departments to assess and help prepare us and our employees to address cybersecurity risks. The consultant that operates our SOC updates the CEO regarding the detection of cybersecurity risk exposure and provides advice on the prevention, mitigation and remediation of such risks.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The CEO keeps the senior executive leadership team apprised, including our Vice President of Finance, on assessments of risk exposure to ensure that the highest levels of management are kept abreast of potential risks we are facing. The CEO has significant prior business experience in compliance and risk management and coordinates directly with the third party who operates our SOC on issues involving particular cybersecurity expertise. &lt;/span&gt;&lt;/div&gt;In an effort to help deter and detect cyber threats, we regularly provide all employees, including part-time and temporary employees, with data protection cybersecurity and incident prevention training throughout the year, which covers timely and relevant topics, including social engineering, phishing, password protection, confidential data protection, asset use and mobile security, and educates employees on the importance of reporting all incidents immediately. We also use technology-based tools to mitigate cybersecurity risks and to bolster our employee-based cybersecurity programs.</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-43">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The audit committee of our board of directors provides oversight over cybersecurity risk and updates the full board of directors periodically regarding such oversight. The audit committee reviews and discusses with management the Company&#x2019;s major risk exposures, including cybersecurity matters, and is notified between such updates regarding significant new cybersecurity threats or incidents, if any. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Chief Executive Officer, or CEO, leads the operational oversight of company-wide cybersecurity strategy, policy, standards and processes and works across relevant departments to assess and help prepare us and our employees to address cybersecurity risks. The consultant that operates our SOC updates the CEO regarding the detection of cybersecurity risk exposure and provides advice on the prevention, mitigation and remediation of such risks.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;The CEO keeps the senior executive leadership team apprised, including our Vice President of Finance, on assessments of risk exposure to ensure that the highest levels of management are kept abreast of potential risks we are facing. The CEO has significant prior business experience in compliance and risk management and coordinates directly with the third party who operates our SOC on issues involving particular cybersecurity expertise.</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="c-1" id="f-44">The audit committee of our board of directors provides oversight over cybersecurity risk and updates the full board of directors periodically regarding such oversight. The audit committee reviews and discusses with management the Company&#x2019;s major risk exposures, including cybersecurity matters, and is notified between such updates regarding significant new cybersecurity threats or incidents, if any.</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="c-1" id="f-47">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-49">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Chief Executive Officer, or CEO, leads the operational oversight of company-wide cybersecurity strategy, policy, standards and processes and works across relevant departments to assess and help prepare us and our employees to address cybersecurity risks. The consultant that operates our SOC updates the CEO regarding the detection of cybersecurity risk exposure and provides advice on the prevention, mitigation and remediation of such risks.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;The CEO keeps the senior executive leadership team apprised, including our Vice President of Finance, on assessments of risk exposure to ensure that the highest levels of management are kept abreast of potential risks we are facing.</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-48">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Chief Executive Officer, or CEO, leads the operational oversight of company-wide cybersecurity strategy, policy, standards and processes and works across relevant departments to assess and help prepare us and our employees to address cybersecurity risks. The consultant that operates our SOC updates the CEO regarding the detection of cybersecurity risk exposure and provides advice on the prevention, mitigation and remediation of such risks.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;The CEO keeps the senior executive leadership team apprised, including our Vice President of Finance, on assessments of risk exposure to ensure that the highest levels of management are kept abreast of potential risks we are facing. The CEO has significant prior business experience in compliance and risk management and coordinates directly with the third party who operates our SOC on issues involving particular cybersecurity expertise.</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="c-1" id="f-50">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="c-1" id="f-51">The CEO has significant prior business experience in compliance and risk management and coordinates directly with the third party who operates our SOC on issues involving particular cybersecurity expertise.</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1 contextRef="c-4" decimals="-5" id="f-52" unitRef="usd">3800000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <dei:AuditorFirmId contextRef="c-1" id="f-53">185</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c-1" id="f-54">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-55">Philadelphia, Pennsylvania</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="-3" id="f-56" unitRef="usd">17909000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-6" decimals="-3" id="f-57" unitRef="usd">77605000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-5" decimals="-3" id="f-58" unitRef="usd">5916000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-6" decimals="-3" id="f-59" unitRef="usd">2866000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-5" decimals="-3" id="f-60" unitRef="usd">23825000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-6" decimals="-3" id="f-61" unitRef="usd">80471000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-5" decimals="-3" id="f-62" unitRef="usd">4385000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-6" decimals="-3" id="f-63" unitRef="usd">6764000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-64" unitRef="usd">2040000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-6" decimals="-3" id="f-65" unitRef="usd">2173000</us-gaap:OperatingLeaseRightOfUseAsset>
    <carm:DeferredFinancingCostsNoncurrent contextRef="c-5" decimals="-3" id="f-66" unitRef="usd">208000</carm:DeferredFinancingCostsNoncurrent>
    <carm:DeferredFinancingCostsNoncurrent contextRef="c-6" decimals="-3" id="f-67" unitRef="usd">146000</carm:DeferredFinancingCostsNoncurrent>
    <us-gaap:Assets contextRef="c-5" decimals="-3" id="f-68" unitRef="usd">30458000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-6" decimals="-3" id="f-69" unitRef="usd">89554000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-5" decimals="-3" id="f-70" unitRef="usd">2081000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-6" decimals="-3" id="f-71" unitRef="usd">3933000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-72" unitRef="usd">7448000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-73" unitRef="usd">7662000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="c-5" decimals="-3" id="f-74" unitRef="usd">3729000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="c-6" decimals="-3" id="f-75" unitRef="usd">1413000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-76" unitRef="usd">832000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-6" decimals="-3" id="f-77" unitRef="usd">1391000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-78" unitRef="usd">905000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-6" decimals="-3" id="f-79" unitRef="usd">544000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-80" unitRef="usd">1060000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-81" unitRef="usd">965000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-82" unitRef="usd">16055000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-83" unitRef="usd">15908000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRevenueNoncurrent contextRef="c-5" decimals="-3" id="f-84" unitRef="usd">41250000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent contextRef="c-6" decimals="-3" id="f-85" unitRef="usd">45000000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-86" unitRef="usd">724000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-6" decimals="-3" id="f-87" unitRef="usd">860000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-88" unitRef="usd">20000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-6" decimals="-3" id="f-89" unitRef="usd">328000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-5" decimals="-3" id="f-90" unitRef="usd">318000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-6" decimals="-3" id="f-91" unitRef="usd">926000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-5" decimals="-3" id="f-92" unitRef="usd">58367000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-6" decimals="-3" id="f-93" unitRef="usd">63022000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-5" id="f-94" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-6" id="f-95" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="INF"
      id="f-96"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-97"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-5" decimals="INF" id="f-98" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-6" decimals="INF" id="f-99" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-6" decimals="INF" id="f-100" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="c-5" decimals="INF" id="f-101" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-6" decimals="INF" id="f-102" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-103" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c-5" decimals="-3" id="f-104" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-6" decimals="-3" id="f-105" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="INF"
      id="f-106"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-107"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-5" decimals="INF" id="f-108" unitRef="shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-6" decimals="INF" id="f-109" unitRef="shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-5" decimals="INF" id="f-110" unitRef="shares">41750109</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-111" unitRef="shares">41750109</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-6" decimals="INF" id="f-112" unitRef="shares">40609915</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-6" decimals="INF" id="f-113" unitRef="shares">40609915</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="c-5" decimals="-3" id="f-114" unitRef="usd">41000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-6" decimals="-3" id="f-115" unitRef="usd">40000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-5" decimals="-3" id="f-116" unitRef="usd">277629000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-6" decimals="-3" id="f-117" unitRef="usd">271594000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-5" decimals="-3" id="f-118" unitRef="usd">-305579000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-6" decimals="-3" id="f-119" unitRef="usd">-245102000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-120" unitRef="usd">-27909000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-6" decimals="-3" id="f-121" unitRef="usd">26532000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-5" decimals="-3" id="f-122" unitRef="usd">30458000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-6" decimals="-3" id="f-123" unitRef="usd">89554000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-1" decimals="-3" id="f-124" unitRef="usd">19632000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-7" decimals="-3" id="f-125" unitRef="usd">14919000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-126" unitRef="usd">59673000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-7" decimals="-3" id="f-127" unitRef="usd">74125000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-128" unitRef="usd">22138000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-7" decimals="-3" id="f-129" unitRef="usd">29525000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-130" unitRef="usd">81811000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-7" decimals="-3" id="f-131" unitRef="usd">103650000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-132" unitRef="usd">-62179000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-7" decimals="-3" id="f-133" unitRef="usd">-88731000</us-gaap:OperatingIncomeLoss>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet contextRef="c-1" decimals="-3" id="f-134" unitRef="usd">0</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet contextRef="c-7" decimals="-3" id="f-135" unitRef="usd">-84000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-1" decimals="-3" id="f-136" unitRef="usd">1702000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-7" decimals="-3" id="f-137" unitRef="usd">1936000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-138" unitRef="usd">-60477000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-139" unitRef="usd">-86879000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-140"
      unitRef="usdPerShare">-1.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-141"
      unitRef="usdPerShare">-1.46</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-7"
      decimals="2"
      id="f-142"
      unitRef="usdPerShare">-2.59</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-7"
      decimals="2"
      id="f-143"
      unitRef="usdPerShare">-2.59</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-144" unitRef="shares">41456210</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-145" unitRef="shares">41456210</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-7" decimals="0" id="f-146" unitRef="shares">33524197</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-7" decimals="0" id="f-147" unitRef="shares">33524197</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-148" unitRef="usd">-60477000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-149" unitRef="usd">-86879000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-150" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-7" decimals="-3" id="f-151" unitRef="usd">440000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-1" decimals="-3" id="f-152" unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-7" decimals="-3" id="f-153" unitRef="usd">399000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-154" unitRef="usd">-60477000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-7" decimals="-3" id="f-155" unitRef="usd">-86838000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:TemporaryEquitySharesIssued contextRef="c-8" decimals="INF" id="f-156" unitRef="shares">8700885</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="c-8" decimals="-3" id="f-157" unitRef="usd">107808000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesIssued contextRef="c-9" decimals="INF" id="f-158" unitRef="shares">2217737</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-9" decimals="-3" id="f-159" unitRef="usd">2000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-10" decimals="-3" id="f-160" unitRef="usd">1197000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-11" decimals="-3" id="f-161" unitRef="usd">-41000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-12" decimals="-3" id="f-162" unitRef="usd">-158223000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-13" decimals="-3" id="f-163" unitRef="usd">14395000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-8" decimals="-3" id="f-164" unitRef="usd">-142670000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-14"
      decimals="INF"
      id="f-165"
      unitRef="shares">128716</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-15" decimals="-3" id="f-166" unitRef="usd">187000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-7" decimals="-3" id="f-167" unitRef="usd">187000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-15" decimals="-3" id="f-168" unitRef="usd">2316000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-7" decimals="-3" id="f-169" unitRef="usd">2316000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-16" decimals="-3" id="f-170" unitRef="usd">440000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-7" decimals="-3" id="f-171" unitRef="usd">440000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-16" decimals="-3" id="f-172" unitRef="usd">399000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-7" decimals="-3" id="f-173" unitRef="usd">399000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <carm:StockIssuedDuringPeriodSharesPreclosureFinancingTransaction
      contextRef="c-14"
      decimals="INF"
      id="f-174"
      unitRef="shares">3730608</carm:StockIssuedDuringPeriodSharesPreclosureFinancingTransaction>
    <carm:StockIssuedDuringPeriodValuesPreclosureFinancingTransaction contextRef="c-14" decimals="-3" id="f-175" unitRef="usd">4000</carm:StockIssuedDuringPeriodValuesPreclosureFinancingTransaction>
    <carm:StockIssuedDuringPeriodValuesPreclosureFinancingTransaction contextRef="c-15" decimals="-3" id="f-176" unitRef="usd">30636000</carm:StockIssuedDuringPeriodValuesPreclosureFinancingTransaction>
    <carm:StockIssuedDuringPeriodValuesPreclosureFinancingTransaction contextRef="c-7" decimals="-3" id="f-177" unitRef="usd">30640000</carm:StockIssuedDuringPeriodValuesPreclosureFinancingTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-14"
      decimals="INF"
      id="f-178"
      unitRef="shares">5059338</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-14" decimals="-3" id="f-179" unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-15" decimals="-3" id="f-180" unitRef="usd">42442000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-7" decimals="-3" id="f-181" unitRef="usd">42447000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="c-14"
      decimals="INF"
      id="f-182"
      unitRef="shares">10374272</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-14" decimals="-3" id="f-183" unitRef="usd">10000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-15" decimals="-3" id="f-184" unitRef="usd">72034000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-7" decimals="-3" id="f-185" unitRef="usd">72044000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <carm:ReclassificationsOfTemporaryToPermanentEquityShares contextRef="c-7" decimals="INF" id="f-186" unitRef="shares">-8700885</carm:ReclassificationsOfTemporaryToPermanentEquityShares>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity contextRef="c-7" decimals="-3" id="f-187" unitRef="usd">-107808000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <carm:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger
      contextRef="c-14"
      decimals="INF"
      id="f-188"
      unitRef="shares">18872711</carm:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger>
    <carm:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger contextRef="c-14" decimals="-3" id="f-189" unitRef="usd">19000</carm:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger>
    <carm:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger contextRef="c-15" decimals="-3" id="f-190" unitRef="usd">122185000</carm:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger>
    <carm:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger contextRef="c-17" decimals="-3" id="f-191" unitRef="usd">-14395000</carm:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger>
    <carm:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger contextRef="c-7" decimals="-3" id="f-192" unitRef="usd">107809000</carm:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-14"
      decimals="INF"
      id="f-193"
      unitRef="shares">226533</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-15" decimals="-3" id="f-194" unitRef="usd">597000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-7" decimals="-3" id="f-195" unitRef="usd">597000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss contextRef="c-18" decimals="-3" id="f-196" unitRef="usd">-86879000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-197" unitRef="usd">-86879000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesIssued contextRef="c-6" decimals="INF" id="f-198" unitRef="shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="c-6" decimals="-3" id="f-199" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesIssued
      contextRef="c-19"
      decimals="INF"
      id="f-200"
      unitRef="shares">40609915</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-19" decimals="-3" id="f-201" unitRef="usd">40000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-20" decimals="-3" id="f-202" unitRef="usd">271594000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-21" decimals="-3" id="f-203" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-22" decimals="-3" id="f-204" unitRef="usd">-245102000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-23" decimals="-3" id="f-205" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-6" decimals="-3" id="f-206" unitRef="usd">26532000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-24"
      decimals="INF"
      id="f-207"
      unitRef="shares">3810</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-25" decimals="-3" id="f-208" unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-1" decimals="-3" id="f-209" unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-25" decimals="-3" id="f-210" unitRef="usd">3649000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-211" unitRef="usd">3649000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-24"
      decimals="INF"
      id="f-212"
      unitRef="shares">1136384</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-24" decimals="-3" id="f-213" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-25" decimals="-3" id="f-214" unitRef="usd">2382000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-1" decimals="-3" id="f-215" unitRef="usd">2383000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss contextRef="c-26" decimals="-3" id="f-216" unitRef="usd">-60477000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-217" unitRef="usd">-60477000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesIssued contextRef="c-5" decimals="INF" id="f-218" unitRef="shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="c-5" decimals="-3" id="f-219" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesIssued
      contextRef="c-27"
      decimals="INF"
      id="f-220"
      unitRef="shares">41750109</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-27" decimals="-3" id="f-221" unitRef="usd">41000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-28" decimals="-3" id="f-222" unitRef="usd">277629000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-29" decimals="-3" id="f-223" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-30" decimals="-3" id="f-224" unitRef="usd">-305579000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-31" decimals="-3" id="f-225" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-226" unitRef="usd">-27909000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-227" unitRef="usd">-60477000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-228" unitRef="usd">-86879000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization contextRef="c-1" decimals="-3" id="f-229" unitRef="usd">3354000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-7" decimals="-3" id="f-230" unitRef="usd">2837000</us-gaap:DepreciationAndAmortization>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-1" decimals="-3" id="f-231" unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-7" decimals="-3" id="f-232" unitRef="usd">-159000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-233" unitRef="usd">3649000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-7" decimals="-3" id="f-234" unitRef="usd">2316000</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-1" decimals="-3" id="f-235" unitRef="usd">4963000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-7" decimals="-3" id="f-236" unitRef="usd">5428000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-1" decimals="-3" id="f-237" unitRef="usd">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-7" decimals="-3" id="f-238" unitRef="usd">1283000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet contextRef="c-1" decimals="-3" id="f-239" unitRef="usd">0</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet contextRef="c-7" decimals="-3" id="f-240" unitRef="usd">-84000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <carm:AccretionOnMarketableSecurities contextRef="c-1" decimals="-3" id="f-241" unitRef="usd">0</carm:AccretionOnMarketableSecurities>
    <carm:AccretionOnMarketableSecurities contextRef="c-7" decimals="-3" id="f-242" unitRef="usd">709000</carm:AccretionOnMarketableSecurities>
    <carm:WriteOffOfPropertyAndEquipment contextRef="c-1" decimals="-3" id="f-243" unitRef="usd">362000</carm:WriteOffOfPropertyAndEquipment>
    <carm:WriteOffOfPropertyAndEquipment contextRef="c-7" decimals="-3" id="f-244" unitRef="usd">0</carm:WriteOffOfPropertyAndEquipment>
    <us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments contextRef="c-1" decimals="-3" id="f-245" unitRef="usd">0</us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments>
    <us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments contextRef="c-7" decimals="-3" id="f-246" unitRef="usd">399000</us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments>
    <carm:NoncashInterestExpense contextRef="c-1" decimals="-3" id="f-247" unitRef="usd">217000</carm:NoncashInterestExpense>
    <carm:NoncashInterestExpense contextRef="c-7" decimals="-3" id="f-248" unitRef="usd">139000</carm:NoncashInterestExpense>
    <carm:GainLossOnSaleOfEquipment contextRef="c-1" decimals="0" id="f-249" unitRef="usd">-49000</carm:GainLossOnSaleOfEquipment>
    <carm:GainLossOnSaleOfEquipment contextRef="c-7" decimals="0" id="f-250" unitRef="usd">0</carm:GainLossOnSaleOfEquipment>
    <us-gaap:SaleAndLeasebackTransactionGainLossNet contextRef="c-1" decimals="-3" id="f-251" unitRef="usd">82000</us-gaap:SaleAndLeasebackTransactionGainLossNet>
    <us-gaap:SaleAndLeasebackTransactionGainLossNet contextRef="c-7" decimals="-3" id="f-252" unitRef="usd">0</us-gaap:SaleAndLeasebackTransactionGainLossNet>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-253" unitRef="usd">3120000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-7" decimals="-3" id="f-254" unitRef="usd">-1046000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-255" unitRef="usd">-1852000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-7" decimals="-3" id="f-256" unitRef="usd">2191000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="-3" id="f-257" unitRef="usd">-213000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-7" decimals="-3" id="f-258" unitRef="usd">-2899000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c-1" decimals="-3" id="f-259" unitRef="usd">-1434000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c-7" decimals="-3" id="f-260" unitRef="usd">-1046000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-261" unitRef="usd">-5525000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-7" decimals="-3" id="f-262" unitRef="usd">-4941000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="c-1" decimals="-3" id="f-263" unitRef="usd">192000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="c-7" decimals="-3" id="f-264" unitRef="usd">213000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-265" unitRef="usd">-59917000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-7" decimals="-3" id="f-266" unitRef="usd">-81177000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-1" decimals="-3" id="f-267" unitRef="usd">0</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-7" decimals="-3" id="f-268" unitRef="usd">34460000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <carm:PaymentsForProceedsFromMarketableSecurities contextRef="c-1" decimals="-3" id="f-269" unitRef="usd">0</carm:PaymentsForProceedsFromMarketableSecurities>
    <carm:PaymentsForProceedsFromMarketableSecurities contextRef="c-7" decimals="-3" id="f-270" unitRef="usd">-108000000</carm:PaymentsForProceedsFromMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-271" unitRef="usd">123000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-7" decimals="-3" id="f-272" unitRef="usd">1132000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-273" unitRef="usd">-123000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-7" decimals="-3" id="f-274" unitRef="usd">72408000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <carm:CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities contextRef="c-1" decimals="-3" id="f-275" unitRef="usd">0</carm:CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities>
    <carm:CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities contextRef="c-7" decimals="-3" id="f-276" unitRef="usd">37903000</carm:CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities>
    <carm:PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities contextRef="c-1" decimals="-3" id="f-277" unitRef="usd">0</carm:PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities>
    <carm:PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities contextRef="c-7" decimals="-3" id="f-278" unitRef="usd">5814000</carm:PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities>
    <carm:ProceedsFromIssuanceOfCommonStockPreClosingFinancing contextRef="c-1" decimals="-3" id="f-279" unitRef="usd">0</carm:ProceedsFromIssuanceOfCommonStockPreClosingFinancing>
    <carm:ProceedsFromIssuanceOfCommonStockPreClosingFinancing contextRef="c-7" decimals="-3" id="f-280" unitRef="usd">30640000</carm:ProceedsFromIssuanceOfCommonStockPreClosingFinancing>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-1" decimals="-3" id="f-281" unitRef="usd">1429000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-7" decimals="-3" id="f-282" unitRef="usd">1301000</us-gaap:FinanceLeasePrincipalPayments>
    <carm:ProceedsFromFailedSaleLeasebackTransaction contextRef="c-1" decimals="-3" id="f-283" unitRef="usd">686000</carm:ProceedsFromFailedSaleLeasebackTransaction>
    <carm:ProceedsFromFailedSaleLeasebackTransaction contextRef="c-7" decimals="-3" id="f-284" unitRef="usd">1183000</carm:ProceedsFromFailedSaleLeasebackTransaction>
    <carm:PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction contextRef="c-1" decimals="-3" id="f-285" unitRef="usd">1309000</carm:PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction>
    <carm:PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction contextRef="c-7" decimals="-3" id="f-286" unitRef="usd">1069000</carm:PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction>
    <us-gaap:PaymentsOfFinancingCosts contextRef="c-1" decimals="-3" id="f-287" unitRef="usd">0</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts contextRef="c-7" decimals="-3" id="f-288" unitRef="usd">146000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-289" unitRef="usd">4000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-7" decimals="-3" id="f-290" unitRef="usd">187000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-291" unitRef="usd">2392000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-7" decimals="-3" id="f-292" unitRef="usd">597000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-293" unitRef="usd">344000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-7" decimals="-3" id="f-294" unitRef="usd">62180000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-295" unitRef="usd">-59696000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c-7" decimals="-3" id="f-296" unitRef="usd">53411000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-6" decimals="-3" id="f-297" unitRef="usd">77605000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-8" decimals="-3" id="f-298" unitRef="usd">24194000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-299" unitRef="usd">17909000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-6" decimals="-3" id="f-300" unitRef="usd">77605000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-301" unitRef="usd">192000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-7" decimals="-3" id="f-302" unitRef="usd">352000</us-gaap:InterestPaidNet>
    <carm:NoncashOrPartNoncashAcquisitionEquityAssumed contextRef="c-1" decimals="-3" id="f-303" unitRef="usd">0</carm:NoncashOrPartNoncashAcquisitionEquityAssumed>
    <carm:NoncashOrPartNoncashAcquisitionEquityAssumed contextRef="c-7" decimals="-3" id="f-304" unitRef="usd">122204000</carm:NoncashOrPartNoncashAcquisitionEquityAssumed>
    <us-gaap:NotesReduction contextRef="c-1" decimals="-3" id="f-305" unitRef="usd">0</us-gaap:NotesReduction>
    <us-gaap:NotesReduction contextRef="c-7" decimals="-3" id="f-306" unitRef="usd">42447000</us-gaap:NotesReduction>
    <carm:NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities contextRef="c-1" decimals="-3" id="f-307" unitRef="usd">0</carm:NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities>
    <carm:NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities contextRef="c-7" decimals="-3" id="f-308" unitRef="usd">41000</carm:NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities>
    <carm:NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts contextRef="c-1" decimals="-3" id="f-309" unitRef="usd">9000</carm:NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts>
    <carm:NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts contextRef="c-7" decimals="-3" id="f-310" unitRef="usd">0</carm:NoncashOrPartNoncashTransactionReclassificationOfDebtFinanceCosts>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability contextRef="c-1" decimals="-3" id="f-311" unitRef="usd">1660000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability contextRef="c-7" decimals="-3" id="f-312" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-313" unitRef="usd">6411000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-7" decimals="-3" id="f-314" unitRef="usd">2779000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <carm:NonCashEffectOfModificationOfOperatingLeaseRightOfUseAssetsOperatingLeaseLiabilities contextRef="c-1" decimals="-3" id="f-315" unitRef="usd">-1581000</carm:NonCashEffectOfModificationOfOperatingLeaseRightOfUseAssetsOperatingLeaseLiabilities>
    <carm:NonCashEffectOfModificationOfOperatingLeaseRightOfUseAssetsOperatingLeaseLiabilities contextRef="c-7" decimals="-3" id="f-316" unitRef="usd">0</carm:NonCashEffectOfModificationOfOperatingLeaseRightOfUseAssetsOperatingLeaseLiabilities>
    <carm:DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability contextRef="c-1" decimals="-3" id="f-317" unitRef="usd">396000</carm:DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability>
    <carm:DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability contextRef="c-7" decimals="-3" id="f-318" unitRef="usd">0</carm:DisposalOfPropertyPlantAndEquipmentInExchangeForReductionOfCapitalLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c-1" id="f-319">Background&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Carisma Therapeutics Inc., a Delaware corporation (collectively with its subsidiaries, the Company), biotechnology company focused on applying its industry leading expertise in macrophage engineering to develop transformative therapies to treat serious diseases including liver fibrosis and cancer. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March and December 2024, the Company and its board of directors approved revised operating plans to reduce monthly operating expenses, conserve cash, and refocus its efforts on strategic priorities. As part of these plans, in March 2024 the Company elected to cease further development of its first lead product candidate, CT-0508. In December 2024 as part of the plan, the Company elected to cease further development of its then lead product candidate, CT-0525, following an assessment of the competitive landscape in anti-HER2 treatments and the impact of recently approved therapies on HER2 antigen loss/downregulation, and the effects on the future development strategy of any anti-HER2 product. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of its cost-reduction initiatives in 2024, the Company implemented workforce reductions during 2024, resulting in the termination of 62 full-time employees (representing approximately 58% of the Company's total workforce), across research and development and general and administrative functions. The workforce reduction resulted in $4.1&#160;million of severance related costs, of which $2.0&#160;million and $2.1&#160;million are included within &lt;span style="-sec-ix-hidden:f-325"&gt;general and administrative&lt;/span&gt; and &lt;span style="-sec-ix-hidden:f-326"&gt;research and development&lt;/span&gt; expense, respectively, in the accompanying consolidated statement of operations and comprehensive loss. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2024, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$2.7&#160;million in severance costs were accrued in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;accompanying&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; consolidated balance sheets. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the 2024 reduction in workforce. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 10, 2024, the Company received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq) notifying the Company that our common stock was not in compliance with Nasdaq Listing Rule 5450(b)(2)(A), or the MVLS Requirement, which requires the Company to maintain a minimum market value of listed securities of $50,000,000. The Company has 180 calendar days, or until April 8, 2025, to regain compliance with the MVLS Requirement. &lt;/span&gt;&lt;/div&gt;On January 6, 2025, the Company received a separate written notice from Nasdaq notifying the Company that, based upon the closing bid price of its common stock for the last 38 consecutive business days, the Company was not in compliance with Nasdaq Listing Rule 5450(a)(1) (the Bid Price Rule), which requires the Company to maintain a minimum bid price of $1.00 per share. The Company has 180 calendar days, or until July 7, 2025, to regain compliance with the Bid Price Rule.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="c-32"
      decimals="INF"
      id="f-320"
      unitRef="employee">62</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent contextRef="c-32" decimals="2" id="f-321" unitRef="number">0.58</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RestructuringCharges contextRef="c-32" decimals="-5" id="f-322" unitRef="usd">4100000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-33" decimals="-5" id="f-323" unitRef="usd">2000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-34" decimals="-5" id="f-324" unitRef="usd">2100000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringReserve contextRef="c-35" decimals="-5" id="f-327" unitRef="usd">2700000</us-gaap:RestructuringReserve>
    <carm:DevelopmentStageRisksAndLiquidityTextBlock contextRef="c-1" id="f-328">Development-Stage Risks and Liquidity&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred losses and negative cash flows from operations since inception and has an accumulated deficit of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$305.6 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as of December&#160;31, 2024. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales from its product candidates currently in development. As of December 31, 2024, the Company had cash and cash equivalents of $17.9 million. Based on current projections, the Company believes that it does not have sufficient cash and cash equivalents to support its operations for more than one year following the date that these financial statements are issued. As a result of these conditions, substantial doubt exists about the Company&#x2019;s ability to continue as a going concern. In addition, changing circumstances could cause the Company to consume capital significantly faster than currently anticipated, and the Company may need to spend more than currently expected because of circumstances beyond its control.  The Company's cash forecast contains estimates and assumptions, and management cannot predict the timing of all cash receipts and expenditures with certainty. The accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments related to &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the recoverability and classification of recorded asset amounts or the amounts and classification of liability that might result from the outcome of this uncertainty. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management is currently evaluating different strategies to maximize value and prepare to wind down the Company's business. Potential strategic alternatives to be explored and evaluated may include, among other transactions, the sale, license, monetization or divestiture of one or more of the Company's assets or technologies, a strategic collaboration or partnership with one or more parties or the merger or sale of the Company. There is no assurance regarding when or if this strategic review process will result in any type of transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to those risks associated with any specialty biotechnology company that has substantial expenditures for research and development. There can be no assurance that the Company&#x2019;s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants.&lt;/span&gt;&lt;/div&gt;</carm:DevelopmentStageRisksAndLiquidityTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-5" decimals="-5" id="f-329" unitRef="usd">-305600000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-5" decimals="-5" id="f-330" unitRef="usd">17900000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-331">Summary of Significant Accounting Policies&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). Any references in these notes to applicable guidance is meant to refer to GAAP as found in Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) promulgated by the Financial Accounting Standards Board (FASB). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant areas that require management&#x2019;s estimates include estimated research and development revenue, stock-based compensation assumptions, the estimated useful lives of property and equipment, and accrued research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management believes that the carrying amounts of the Company&#x2019;s financial instruments, including cash equivalents and accounts payable, approximate fair value due to the short-term nature of those instruments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following fair value hierarchy table presents information about the Company&#x2019;s assets measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair value measurement at reporting date using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents &#x2013; money markets accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents &#x2013; money markets accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;62,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December 31, 2024 and 2023, there were no transfers between Level 1, Level 2 and Level 3.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue in accordance with ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 606). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into collaboration and licensing agreements with strategic partners, which are within the scope of ASC 606, under which it may exclusively license rights to research, develop, manufacture, and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: (1) non-refundable, upfront license fees (2) reimbursement of certain costs; (3) customer option fees for additional goods or services; (4) development milestone payments, (5) regulatory and commercial milestone payments; and (6) royalties on net sales of licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use its judgment to determine: (a) the number of performance obligations based on the determination under step (i) above; (b) the transaction price under step (iii) above; (c) the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above; and (d) the contract term and pattern of satisfaction of the performance obligations under step (v) above. The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Upfront license fees&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the license to the Company's intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, manufacturing, and commercialization capabilities of the customer; the retention of any key rights by the Company; and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promises, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company exercises judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Customer options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates the customer options for material rights or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If an option is not exercised and the research and development target is terminated, the Company will accelerate and recognize all remaining revenue related to the material right performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Research and development services&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The promises under the Company's collaboration agreements may include research and development services to be performed by the Company for or on behalf of the customer. Payments or reimbursements resulting from the Company's research and development efforts are recognized as the services are performed and presented on a gross basis because the Company is the principal for such efforts. Reimbursements from and payments to the customer that are the result of a collaborative relationship with the customer, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Milestone payments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of credit risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment information&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (CODM), or decision-making group, in deciding how to allocate resources in assessing performance. The Company has one operating segment. The Company&#x2019;s CODM is the chief executive officer. The Company&#x2019;s CODM manages the Company&#x2019;s operations on a consolidated basis for the purpose of allocating resources.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The accounting policies of its segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance for its segment based on net loss, which is reported on the consolidated statements of operations and comprehensive loss. The measure of segment assets is reported on the balance sheet as total assets. The CODM uses cash forecast models in deciding how to invest into the segment. The CODM analyzes the Company&#x2019;s net loss and monitors budget versus actual results to assess the performance of the Company. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The table below summarizes the significant expense categories regularly reviewed by the CODM for the years ended December 31, 2024 and 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collaboration revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development, excluding facilities, personnel, depreciation and amortization expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative, excluding facilities and personnel expenses, depreciation and amortization expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Facilities expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Personnel expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation, amortization and interest on finance and sale-leaseback lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other segment items(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,242)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(60,477)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(86,879)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(a) Other segment items include changes in warrant liability and interest income.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly-liquid investments that have maturities of three months or less when acquired to be cash equivalents. As of December&#160;31, 2024&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and 2023, cas&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;h equivalents consisted of investments in a money market account.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets ranging from &lt;span style="-sec-ix-hidden:f-366"&gt;two&lt;/span&gt; to five years. Leasehold improvements are amortized over the shorter of the life of the lease or the estimated useful life of the assets. Lab equipment that are classified as finance leases are amortized over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Long-lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. When events indicate a triggering event occurred, the recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, then an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Considerable management judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could vary significantly from such estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company did not recognize any impairment of long-lived assets during th&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;e years ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; or 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Financing Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes costs that are directly associated with in-process equity financings until such financings are consummated, at which time such costs are recorded against the gross proceeds from the applicable financing. If a financing is abandoned, deferred financing costs are expensed immediately. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines whether an arrangement is or contains a lease, its classification, and its term at the lease commencement date. Leases with a term greater than one year will be recognized on the balance sheet as right-of-use (ROU) assets, current lease liabilities, and if applicable, long-term lease liabilities. The Company includes renewal options to extend the lease term where it is reasonably certain that it will exercise these options. Lease liabilities and the corresponding ROU assets are recorded based on the present values of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rates, which are the rates that would be incurred to borrow on a collateralized basis, over similar terms, amounts equal to the lease payments in a similar economic environment. Payments for non-lease components or that are variable in nature that do not depend on a rate or index are not included in the lease liability and are typically expensed as incurred. If significant events, changes in circumstances, or other events indicate that the lease term or other inputs have changed, the Company would reassess lease classification, remeasure the lease liability using revised inputs as of the reassessment date, and adjust the ROU assets. Lease expense is recognized on a straight-line basis over the expected lease term for operating classified leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are charged to expense as incurred. Up-front and milestone payments made to third parties who perform research and development services on the Company's behalf are expensed as services are rendered.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company measures stock-based awards, including stock options, at their grant-date fair value and records compensation expense over the requisite service period, which is the vesting period of the awards. The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimating the fair value of stock options requires the use of subjective assumptions, including the fair value of the Company's common stock prior to the Merger (as defined in Note 4), and, for stock options, the expected term of the option and expected stock price volatility. The Company uses the Black-Scholes option-pricing model to value its stock option awards. The assumptions used in calculating the fair value of stock options represent management's best estimates and involve inherent uncertainties and the application of management's judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the Merger (as defined in Note 4), the fair value of the Company's common stock was estimated by the Company's board of directors, with input by management considering the Company's most recently available third-party valuation of the Company's common stock. The expected term of stock options for employees is estimated using the simplified method, as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The simplified method is the midpoint between the vesting date and the contractual term of the option. The contractual term is used as the expected term for stock options granted to nonemployees. For stock price volatility, the Company uses comparable public companies as a basis for the expected volatility to calculate the fair value of option grants. The risk-free rate is based on the U.S. Treasury yield curve commensurate with the expected term of the option. The expected dividend yield is zero given the Company does not expect to pay dividends for the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Income taxes &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are accounted for under the asset and liability method. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company's assets and liabilities, and the expected benefits of net operating loss and income tax credit carryforwards. The impact of changes in &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;tax rates and laws on deferred taxes, if any, applied during the period in which temporary differences are expected to be settled, is reflected in the Company's consolidated financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on weight of the evidence, it is more likely than not that some, or all, of the deferred tax assets will not be realized. As of December 31, 2024 and 2023, the Company has concluded that a full valuation allowance is necessary for all of its net deferred tax assets. The Company had no amounts recorded for uncertain tax positions, interest, or penalties in the accompanying consolidated financial statements. Although there are no unrecognized income tax benefits, when applicable, the Company&#x2019;s policy is to report interest and penalties related to unrecognized income tax benefits as a component of income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net loss per share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, potentially dilutive securities are not included in the calculation as their impact is anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,746,991&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,023,370&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently adopted accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In November 2023, the FASB issued ASU 2023-07, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; (ASU 2023-07), which requires disclosure of incremental segment information on an annual and interim basis. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 on a retrospective basis. The Company incorporated the improved segment disclosures in the summary of significant accounting policies, herein.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently issued but not yet adopted accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2023-09), which expands the disclosures required for income taxes. This ASU is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendment should be applied on a prospective basis while retrospective application is permitted. The Company is currently evaluating the effect of this pronouncement on its disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which is intended to provide more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation and amortization) included in certain expense captions presented on the consolidated statement of operations. The guidance in this ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the consolidated financial statements. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-332">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). Any references in these notes to applicable guidance is meant to refer to GAAP as found in Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) promulgated by the Financial Accounting Standards Board (FASB). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-333">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant areas that require management&#x2019;s estimates include estimated research and development revenue, stock-based compensation assumptions, the estimated useful lives of property and equipment, and accrued research and development expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c-1" id="f-334">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;Management believes that the carrying amounts of the Company&#x2019;s financial instruments, including cash equivalents and accounts payable, approximate fair value due to the short-term nature of those instruments.</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c-1" id="f-335">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following fair value hierarchy table presents information about the Company&#x2019;s assets measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair value measurement at reporting date using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents &#x2013; money markets accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents &#x2013; money markets accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;62,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December 31, 2024 and 2023, there were no transfers between Level 1, Level 2 and Level 3.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-336">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following fair value hierarchy table presents information about the Company&#x2019;s assets measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair value measurement at reporting date using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents &#x2013; money markets accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents &#x2013; money markets accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;62,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-36" decimals="-3" id="f-337" unitRef="usd">14887000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-37" decimals="-3" id="f-338" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-38" decimals="-3" id="f-339" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-39" decimals="-3" id="f-340" unitRef="usd">62999000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-40" decimals="-3" id="f-341" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-41" decimals="-3" id="f-342" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-343">&lt;div&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue in accordance with ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 606). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into collaboration and licensing agreements with strategic partners, which are within the scope of ASC 606, under which it may exclusively license rights to research, develop, manufacture, and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: (1) non-refundable, upfront license fees (2) reimbursement of certain costs; (3) customer option fees for additional goods or services; (4) development milestone payments, (5) regulatory and commercial milestone payments; and (6) royalties on net sales of licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use its judgment to determine: (a) the number of performance obligations based on the determination under step (i) above; (b) the transaction price under step (iii) above; (c) the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above; and (d) the contract term and pattern of satisfaction of the performance obligations under step (v) above. The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Upfront license fees&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the license to the Company's intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, manufacturing, and commercialization capabilities of the customer; the retention of any key rights by the Company; and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promises, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company exercises judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Customer options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates the customer options for material rights or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If an option is not exercised and the research and development target is terminated, the Company will accelerate and recognize all remaining revenue related to the material right performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Research and development services&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The promises under the Company's collaboration agreements may include research and development services to be performed by the Company for or on behalf of the customer. Payments or reimbursements resulting from the Company's research and development efforts are recognized as the services are performed and presented on a gross basis because the Company is the principal for such efforts. Reimbursements from and payments to the customer that are the result of a collaborative relationship with the customer, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Milestone payments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-344">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of credit risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c-1" id="f-345">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment information&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (CODM), or decision-making group, in deciding how to allocate resources in assessing performance. The Company has one operating segment. The Company&#x2019;s CODM is the chief executive officer. The Company&#x2019;s CODM manages the Company&#x2019;s operations on a consolidated basis for the purpose of allocating resources.&lt;/span&gt;&lt;/div&gt;The accounting policies of its segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance for its segment based on net loss, which is reported on the consolidated statements of operations and comprehensive loss. The measure of segment assets is reported on the balance sheet as total assets. The CODM uses cash forecast models in deciding how to invest into the segment. The CODM analyzes the Company&#x2019;s net loss and monitors budget versus actual results to assess the performance of the Company.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-346"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-347">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The table below summarizes the significant expense categories regularly reviewed by the CODM for the years ended December 31, 2024 and 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collaboration revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development, excluding facilities, personnel, depreciation and amortization expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative, excluding facilities and personnel expenses, depreciation and amortization expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Facilities expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Personnel expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation, amortization and interest on finance and sale-leaseback lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other segment items(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,242)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(60,477)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(86,879)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(a) Other segment items include changes in warrant liability and interest income.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-42" decimals="-3" id="f-348" unitRef="usd">19632000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-43" decimals="-3" id="f-349" unitRef="usd">14919000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <carm:ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses contextRef="c-42" decimals="-3" id="f-350" unitRef="usd">33147000</carm:ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses>
    <carm:ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses contextRef="c-43" decimals="-3" id="f-351" unitRef="usd">45905000</carm:ResearchAndDevelopmentExcludingFacilitiesPersonnelDepreciationAndAmortizationExpenses>
    <carm:GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses contextRef="c-42" decimals="-3" id="f-352" unitRef="usd">14829000</carm:GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses>
    <carm:GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses contextRef="c-43" decimals="-3" id="f-353" unitRef="usd">19118000</carm:GeneralAndAdministrativeExcludingFacilitiesAndPersonnelExpensesDepreciationAndAmortizationExpenses>
    <carm:FacilitiesExpense contextRef="c-42" decimals="-3" id="f-354" unitRef="usd">5917000</carm:FacilitiesExpense>
    <carm:FacilitiesExpense contextRef="c-43" decimals="-3" id="f-355" unitRef="usd">7671000</carm:FacilitiesExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="c-42" decimals="-3" id="f-356" unitRef="usd">24564000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="c-43" decimals="-3" id="f-357" unitRef="usd">27324000</us-gaap:LaborAndRelatedExpense>
    <carm:DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities contextRef="c-42" decimals="-3" id="f-358" unitRef="usd">3894000</carm:DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities>
    <carm:DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities contextRef="c-43" decimals="-3" id="f-359" unitRef="usd">3984000</carm:DepreciationAmortizationAndInterestOnFinanceAndSaleLeasebackLeaseLiabilities>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-42" decimals="-3" id="f-360" unitRef="usd">-2242000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-43" decimals="-3" id="f-361" unitRef="usd">-2204000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:NetIncomeLoss contextRef="c-42" decimals="-3" id="f-362" unitRef="usd">-60477000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-43" decimals="-3" id="f-363" unitRef="usd">-86879000</us-gaap:NetIncomeLoss>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-364">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly-liquid investments that have maturities of three months or less when acquired to be cash equivalents. As of December&#160;31, 2024&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and 2023, cas&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;h equivalents consisted of investments in a money market account.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-365">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets ranging from &lt;span style="-sec-ix-hidden:f-366"&gt;two&lt;/span&gt; to five years. Leasehold improvements are amortized over the shorter of the life of the lease or the estimated useful life of the assets. Lab equipment that are classified as finance leases are amortized over the lease term.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-45" id="f-367">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c-1" id="f-368">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Long-lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. When events indicate a triggering event occurred, the recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, then an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Considerable management judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could vary significantly from such estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company did not recognize any impairment of long-lived assets during th&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;e years ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; or 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-1" decimals="INF" id="f-369" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-7" decimals="INF" id="f-370" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <carm:DeferredFinancingCostsPolicyPolicyTextBlock contextRef="c-1" id="f-371">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Financing Costs&lt;/span&gt;&lt;/div&gt;The Company capitalizes costs that are directly associated with in-process equity financings until such financings are consummated, at which time such costs are recorded against the gross proceeds from the applicable financing. If a financing is abandoned, deferred financing costs are expensed immediately.</carm:DeferredFinancingCostsPolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-372">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines whether an arrangement is or contains a lease, its classification, and its term at the lease commencement date. Leases with a term greater than one year will be recognized on the balance sheet as right-of-use (ROU) assets, current lease liabilities, and if applicable, long-term lease liabilities. The Company includes renewal options to extend the lease term where it is reasonably certain that it will exercise these options. Lease liabilities and the corresponding ROU assets are recorded based on the present values of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rates, which are the rates that would be incurred to borrow on a collateralized basis, over similar terms, amounts equal to the lease payments in a similar economic environment. Payments for non-lease components or that are variable in nature that do not depend on a rate or index are not included in the lease liability and are typically expensed as incurred. If significant events, changes in circumstances, or other events indicate that the lease term or other inputs have changed, the Company would reassess lease classification, remeasure the lease liability using revised inputs as of the reassessment date, and adjust the ROU assets. Lease expense is recognized on a straight-line basis over the expected lease term for operating classified leases.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-373">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are charged to expense as incurred. Up-front and milestone payments made to third parties who perform research and development services on the Company's behalf are expensed as services are rendered.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-374">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company measures stock-based awards, including stock options, at their grant-date fair value and records compensation expense over the requisite service period, which is the vesting period of the awards. The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimating the fair value of stock options requires the use of subjective assumptions, including the fair value of the Company's common stock prior to the Merger (as defined in Note 4), and, for stock options, the expected term of the option and expected stock price volatility. The Company uses the Black-Scholes option-pricing model to value its stock option awards. The assumptions used in calculating the fair value of stock options represent management's best estimates and involve inherent uncertainties and the application of management's judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the Merger (as defined in Note 4), the fair value of the Company's common stock was estimated by the Company's board of directors, with input by management considering the Company's most recently available third-party valuation of the Company's common stock. The expected term of stock options for employees is estimated using the simplified method, as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The simplified method is the midpoint between the vesting date and the contractual term of the option. The contractual term is used as the expected term for stock options granted to nonemployees. For stock price volatility, the Company uses comparable public companies as a basis for the expected volatility to calculate the fair value of option grants. The risk-free rate is based on the U.S. Treasury yield curve commensurate with the expected term of the option. The expected dividend yield is zero given the Company does not expect to pay dividends for the foreseeable future.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-375">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Income taxes &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are accounted for under the asset and liability method. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company's assets and liabilities, and the expected benefits of net operating loss and income tax credit carryforwards. The impact of changes in &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;tax rates and laws on deferred taxes, if any, applied during the period in which temporary differences are expected to be settled, is reflected in the Company's consolidated financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on weight of the evidence, it is more likely than not that some, or all, of the deferred tax assets will not be realized. As of December 31, 2024 and 2023, the Company has concluded that a full valuation allowance is necessary for all of its net deferred tax assets. The Company had no amounts recorded for uncertain tax positions, interest, or penalties in the accompanying consolidated financial statements. Although there are no unrecognized income tax benefits, when applicable, the Company&#x2019;s policy is to report interest and penalties related to unrecognized income tax benefits as a component of income tax expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-376">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net loss per share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, potentially dilutive securities are not included in the calculation as their impact is anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,746,991&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,023,370&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-377">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,746,991&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,023,370&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-46" decimals="0" id="f-378" unitRef="shares">7746991</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-47" decimals="0" id="f-379" unitRef="shares">6023370</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-380">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently adopted accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In November 2023, the FASB issued ASU 2023-07, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; (ASU 2023-07), which requires disclosure of incremental segment information on an annual and interim basis. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 on a retrospective basis. The Company incorporated the improved segment disclosures in the summary of significant accounting policies, herein.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently issued but not yet adopted accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2023-09), which expands the disclosures required for income taxes. This ASU is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendment should be applied on a prospective basis while retrospective application is permitted. The Company is currently evaluating the effect of this pronouncement on its disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which is intended to provide more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation and amortization) included in certain expense captions presented on the consolidated statement of operations. The guidance in this ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the consolidated financial statements. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="c-1" id="f-381">Merger with Sesen Bio&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;On March&#160;7, 2023, the Company (formerly publicly-held Sesen Bio, Inc.) consummated a merger with CTx Operations, Inc. (formerly privately-held CARISMA Therapeutics Inc.) (Legacy Carisma) pursuant to an Agreement and Plan of Merger and Reorganization, as amended (the Merger Agreement), by and among the Company, Legacy Carisma and &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Seahawk Merger Sub, Inc. (Merger Sub), a Delaware corporation and wholly-owned subsidiary of the Company. The Merger Agreement provided for the merger of Merger Sub with and into Legacy Carisma, with Legacy Carisma continuing as a wholly-owned subsidiary of the Company and the surviving corporation of the merger (the Merger). The Merger was accounted for as a reverse recapitalization under GAAP because the primary assets of Sesen Bio were cash, cash equivalents and marketable securities. For financial reporting purposes Legacy Carisma was determined to be the accounting acquirer based upon the terms of the Merger and other factors, including: (i) Legacy Carisma stockholders own approximately 74.2% of the Combined Company, (ii) Legacy Carisma holds the majority (six of seven) of board seats of the Combined Company and (iii) Legacy Carisma management holds all key positions of management. Accordingly, the Merger was treated as the equivalent of Legacy Carisma issuing stock to acquire the net assets of Sesen Bio. As a result of the Merger, the net assets of Sesen Bio were recorded at their acquisition-date fair value in the consolidated financial statements and the reported operating results prior to the Merger are those of Legacy Carisma. Immediately after the Merger, there were 40,254,666 shares of the Company&#x2019;s common stock outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the net assets acquired in the Merger (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 7, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;44,588&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,316&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,499)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80,308&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8,264)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total net assets acquired less transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;72,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to March&#160;7, 2023, the Company paid $4.6 million of severance and personnel costs related to Sesen Bio.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired contextRef="c-48" decimals="3" id="f-382" unitRef="number">0.742</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <carm:NumberOfBoardMembers contextRef="c-49" decimals="INF" id="f-383" unitRef="seat">6</carm:NumberOfBoardMembers>
    <carm:NumberOfBoardMembers contextRef="c-5" decimals="INF" id="f-384" unitRef="seat">7</carm:NumberOfBoardMembers>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-48"
      decimals="INF"
      id="f-385"
      unitRef="shares">40254666</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="c-1" id="f-386">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the net assets acquired in the Merger (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 7, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;44,588&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,316&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,499)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80,308&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8,264)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total net assets acquired less transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;72,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c-50" decimals="-3" id="f-387" unitRef="usd">37873000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities contextRef="c-50" decimals="-3" id="f-388" unitRef="usd">44588000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets contextRef="c-50" decimals="-3" id="f-389" unitRef="usd">1316000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <carm:Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash contextRef="c-50" decimals="-3" id="f-390" unitRef="usd">30000</carm:Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities contextRef="c-50" decimals="-3" id="f-391" unitRef="usd">3499000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="c-50" decimals="-3" id="f-392" unitRef="usd">80308000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts contextRef="c-50" decimals="-3" id="f-393" unitRef="usd">8264000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="c-50" decimals="-3" id="f-394" unitRef="usd">72044000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:SeveranceCosts1 contextRef="c-51" decimals="-5" id="f-395" unitRef="usd">4600000</us-gaap:SeveranceCosts1>
    <us-gaap:OtherAssetsDisclosureTextBlock contextRef="c-1" id="f-396">Prepaid Expenses and Other Assets&lt;div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other assets consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collaboration receivable &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherAssetsDisclosureTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="c-1" id="f-397">&lt;div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other assets consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collaboration receivable &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <carm:PrepaidResearchAndDevelopmentCurrent contextRef="c-5" decimals="-3" id="f-398" unitRef="usd">1715000</carm:PrepaidResearchAndDevelopmentCurrent>
    <carm:PrepaidResearchAndDevelopmentCurrent contextRef="c-6" decimals="-3" id="f-399" unitRef="usd">278000</carm:PrepaidResearchAndDevelopmentCurrent>
    <carm:ReceivableDueFromCollaborativeArrangementCurrent contextRef="c-5" decimals="-3" id="f-400" unitRef="usd">2864000</carm:ReceivableDueFromCollaborativeArrangementCurrent>
    <carm:ReceivableDueFromCollaborativeArrangementCurrent contextRef="c-6" decimals="-3" id="f-401" unitRef="usd">0</carm:ReceivableDueFromCollaborativeArrangementCurrent>
    <us-gaap:PrepaidInsurance contextRef="c-5" decimals="-3" id="f-402" unitRef="usd">340000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance contextRef="c-6" decimals="-3" id="f-403" unitRef="usd">402000</us-gaap:PrepaidInsurance>
    <us-gaap:DepositsAssetsCurrent contextRef="c-5" decimals="-3" id="f-404" unitRef="usd">925000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent contextRef="c-6" decimals="-3" id="f-405" unitRef="usd">891000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c-5" decimals="-3" id="f-406" unitRef="usd">72000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c-6" decimals="-3" id="f-407" unitRef="usd">1295000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-5" decimals="-3" id="f-408" unitRef="usd">5916000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-6" decimals="-3" id="f-409" unitRef="usd">2866000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-410">Property and Equipment, net&lt;div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lab equipment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Office furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7,887)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6,151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) Lab equipment includes failed sale lease-back assets of $3.4&#160;million as of December&#160;31, 2024 and 2023. Lab equipment includes finance lease ROU assets of $3.2&#160;million and $2.9&#160;million, respectively, as of December&#160;31, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2) The accumulated amortization balance includes $1.5&#160;million and&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$0.9&#160;million, respectively, related to failed sale-leaseback assets as of December&#160;31, 2024 and 2023. The accumulated amortization balance includes $2.3&#160;million and $1.7&#160;million, respectively, related to finance lease ROU assets as of December&#160;31, 2024 and 2023.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense was $3.4&#160;million and $2.8&#160;million for the years ended December&#160;31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-411">&lt;div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lab equipment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Office furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7,887)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6,151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) Lab equipment includes failed sale lease-back assets of $3.4&#160;million as of December&#160;31, 2024 and 2023. Lab equipment includes finance lease ROU assets of $3.2&#160;million and $2.9&#160;million, respectively, as of December&#160;31, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2) The accumulated amortization balance includes $1.5&#160;million and&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;$0.9&#160;million, respectively, related to failed sale-leaseback assets as of December&#160;31, 2024 and 2023. The accumulated amortization balance includes $2.3&#160;million and $1.7&#160;million, respectively, related to finance lease ROU assets as of December&#160;31, 2024 and 2023.</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-52" decimals="-3" id="f-412" unitRef="usd">508000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-53" decimals="-3" id="f-413" unitRef="usd">903000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-54" decimals="-3" id="f-414" unitRef="usd">11157000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-55" decimals="-3" id="f-415" unitRef="usd">11392000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-56" decimals="-3" id="f-416" unitRef="usd">267000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-57" decimals="-3" id="f-417" unitRef="usd">267000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-58" decimals="-3" id="f-418" unitRef="usd">340000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-59" decimals="-3" id="f-419" unitRef="usd">340000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-60" decimals="-3" id="f-420" unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-61" decimals="-3" id="f-421" unitRef="usd">13000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-5" decimals="-3" id="f-422" unitRef="usd">12272000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-6" decimals="-3" id="f-423" unitRef="usd">12915000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization contextRef="c-5" decimals="-3" id="f-424" unitRef="usd">7887000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization contextRef="c-6" decimals="-3" id="f-425" unitRef="usd">6151000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-5" decimals="-3" id="f-426" unitRef="usd">4385000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-6" decimals="-3" id="f-427" unitRef="usd">6764000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:SaleLeasebackTransactionNetBookValue contextRef="c-55" decimals="-5" id="f-428" unitRef="usd">3400000</us-gaap:SaleLeasebackTransactionNetBookValue>
    <us-gaap:SaleLeasebackTransactionNetBookValue contextRef="c-54" decimals="-5" id="f-429" unitRef="usd">3400000</us-gaap:SaleLeasebackTransactionNetBookValue>
    <us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization contextRef="c-54" decimals="-5" id="f-430" unitRef="usd">3200000</us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization contextRef="c-55" decimals="-5" id="f-431" unitRef="usd">2900000</us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <us-gaap:SaleLeasebackTransactionAccumulatedDepreciation contextRef="c-5" decimals="-5" id="f-432" unitRef="usd">1500000</us-gaap:SaleLeasebackTransactionAccumulatedDepreciation>
    <us-gaap:SaleLeasebackTransactionAccumulatedDepreciation contextRef="c-6" decimals="-5" id="f-433" unitRef="usd">900000</us-gaap:SaleLeasebackTransactionAccumulatedDepreciation>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization contextRef="c-5" decimals="-5" id="f-434" unitRef="usd">2300000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization contextRef="c-6" decimals="-5" id="f-435" unitRef="usd">1700000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-1" decimals="-5" id="f-436" unitRef="usd">3400000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-7" decimals="-5" id="f-437" unitRef="usd">2800000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c-1" id="f-438">Accrued Expenses&lt;div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Compensation and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-439">&lt;div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Compensation and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <carm:AccruedResearchAndDevelopmentExpenseCurrent contextRef="c-5" decimals="-3" id="f-440" unitRef="usd">1845000</carm:AccruedResearchAndDevelopmentExpenseCurrent>
    <carm:AccruedResearchAndDevelopmentExpenseCurrent contextRef="c-6" decimals="-3" id="f-441" unitRef="usd">3131000</carm:AccruedResearchAndDevelopmentExpenseCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-5" decimals="-3" id="f-442" unitRef="usd">537000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-6" decimals="-3" id="f-443" unitRef="usd">1366000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-444" unitRef="usd">4879000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-445" unitRef="usd">3100000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-446" unitRef="usd">187000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-447" unitRef="usd">65000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-448" unitRef="usd">7448000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-449" unitRef="usd">7662000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-450">Commitments and Contingencies&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has operating leases for its laboratory and office space in Philadelphia, Pennsylvania. The Company&#x2019;s operating leases have term end dates ranging from 2025 to 2029. The Company also has obligations under an arrangement for the use of certain laboratory equipment that are classified as finance leases that commenced in 2022 and have end dates ranging from 2025 to 2026. Effective February 2024, the Company renewed an existing operating lease with an end date through 2026. In April 2024, in connection with the revised operating plan, the Company notified the lessor that it would terminate the lease effective August 2024. In July 2024, the Company entered into an amendment extending the &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;termination date of the lease to June 2025 with an option to extend to December 2025. The Company did not incur any penalties or fees in connection with the termination.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2024, the Company modified existing finance leases and failed sale-leaseback arrangements by assigning the rights and obligations of certain underlying assets to an unrelated third party. The modifications resulted in a reduction of its finance lease ROU assets and related lease liability of $0.4&#160;million. In addition, the Company recorded a reduction of its failed sale-leaseback liability and gain on the sale of the corresponding assets of $0.1&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s operating and finance lease ROU assets and the related lease liabilities are initially measured at the present value of future lease payments over the lease term. The Company is responsible for payment of certain real estate taxes, insurance and other expenses on certain of its leases. These amounts are generally considered to be variable and are not included in the measurement of the ROU assets and lease liability. The Company accounts for non-lease components, such as maintenance, separately from lease components.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company carries laboratory equipment from failed sale-leasebacks, as property and equipment, net on the accompanying consolidated balance sheets. The ongoing lease payments are recorded as reductions to the finance liability and interest expense. As of December&#160;31, 2024, the Company had a $1.4 million financing liability recorded in other current liabilities and other long-term liabilities on the consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The elements of the lease costs were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total finance lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease term and discount rate information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash used in operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash used in finance leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financing cash used in finance leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future maturities of lease liabilities were as follows as of December&#160;31, 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Operating &lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Finance &lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fiscal year ending:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total future minimum payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Licensing and Sponsored Research Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under a license agreement with The Trustees of the University of Pennsylvania (Penn), entered into in November 2017 (Penn License Agreement),&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the Company is required to make annual payments of $25,000. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Penn is eligible to receive up to $10.9 million per product in development upon the achievement of certain clinical, regulatory and commercial milestone events. There are additional milestone payments required to be paid of up to $30.0 million per product in commercial milestones and up to an additional $1.7 million in development and regulatory milestone payments for the first CAR-M product directed to mesothelin. Additionally, the Company is obligated to pay Penn single-digit royalties based on its net sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2023, the Company entered into a manufacturing and supply agreement with Novartis Pharmaceuticals Corporation (Novartis) for the manufacturing of the Company&#x2019;s CT-0508 product candidate (Novartis Agreement). The Novartis Agreement had a &lt;span style="-sec-ix-hidden:f-509"&gt;five&lt;/span&gt; year term. On June 26, 2024, in furtherance of its revised operating plan approved in late March 2024, the Company terminated the Novartis Agreement. Upon termination, the Company incurred a termination fee equal to $4.0&#160;million, which was paid in the third quarter of 2024. A prepaid asset was recorded as the Company separately agreed with Novartis that if Novartis and the Company re-negotiate the agreement for a substitute product on or before December 31, 2024, then the $4.0&#160;million termination fee would be credited in full or in part against any amounts due from the Company to Novartis under such agreement relating to the substitute product. The Company did not re-negotiate the agreement and expensed the $4.0&#160;million prepaid asset in the fourth quarter of 2024 to research and development in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liabilities for loss contingencies, arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment and/or remediation can be reasonably estimated. As of December&#160;31, 2024, the Company was in negotiations with a vendor to determine the total costs owed for research and development services provided. While the negotiations are ongoing, the Company believes a &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;liability is probable. The Company has estimated the amount to be owed to be $1.2&#160;million which is included within accrued expenses on the accompanying consolidated balance sheets. The final amount owed may differ from the estimate as negotiations progress. The Company will continue to evaluate the matter and will adjust the liability as necessary based on any new information or agreements reached with the vendor.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <carm:IncreaseDecreaseInFinanceLeaseRightOfUseAssetLeaseModification contextRef="c-62" decimals="-5" id="f-451" unitRef="usd">-400000</carm:IncreaseDecreaseInFinanceLeaseRightOfUseAssetLeaseModification>
    <carm:IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification contextRef="c-62" decimals="-5" id="f-452" unitRef="usd">-400000</carm:IncreaseDecreaseInFinanceLeaseLiabilityLeaseModification>
    <us-gaap:SaleAndLeasebackTransactionGainLossNet contextRef="c-63" decimals="-5" id="f-453" unitRef="usd">100000</us-gaap:SaleAndLeasebackTransactionGainLossNet>
    <us-gaap:FinanceLeaseLiability contextRef="c-54" decimals="-5" id="f-454" unitRef="usd">1400000</us-gaap:FinanceLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-455">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The elements of the lease costs were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total finance lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-3" id="f-456" unitRef="usd">5245000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-7" decimals="-3" id="f-457" unitRef="usd">5774000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-1" decimals="-3" id="f-458" unitRef="usd">1584000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-7" decimals="-3" id="f-459" unitRef="usd">1187000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-1" decimals="-3" id="f-460" unitRef="usd">217000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-7" decimals="-3" id="f-461" unitRef="usd">139000</us-gaap:FinanceLeaseInterestExpense>
    <carm:FinanceLeaseCost contextRef="c-1" decimals="-3" id="f-462" unitRef="usd">1801000</carm:FinanceLeaseCost>
    <carm:FinanceLeaseCost contextRef="c-7" decimals="-3" id="f-463" unitRef="usd">1326000</carm:FinanceLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-1" decimals="-3" id="f-464" unitRef="usd">1071000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-7" decimals="-3" id="f-465" unitRef="usd">1733000</us-gaap:VariableLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-1" decimals="-3" id="f-466" unitRef="usd">671000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-7" decimals="-3" id="f-467" unitRef="usd">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost contextRef="c-1" decimals="-3" id="f-468" unitRef="usd">8788000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-7" decimals="-3" id="f-469" unitRef="usd">8833000</us-gaap:LeaseCost>
    <carm:LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock contextRef="c-1" id="f-470">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease term and discount rate information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</carm:LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-5" id="f-471">P2Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-6" id="f-472">P2Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-5" id="f-473">P0Y9M18D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-6" id="f-474">P1Y6M</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-5" decimals="3" id="f-475" unitRef="number">0.099</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-6" decimals="3" id="f-476" unitRef="number">0.098</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent contextRef="c-5" decimals="3" id="f-477" unitRef="number">0.090</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent contextRef="c-6" decimals="3" id="f-478" unitRef="number">0.090</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <carm:LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock contextRef="c-1" id="f-479">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash used in operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash used in finance leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financing cash used in finance leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</carm:LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-3" id="f-480" unitRef="usd">5807000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-7" decimals="-3" id="f-481" unitRef="usd">5764000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c-1" decimals="-3" id="f-482" unitRef="usd">217000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c-7" decimals="-3" id="f-483" unitRef="usd">139000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <carm:FinancingCashUsedInFinanceLeases contextRef="c-1" decimals="-3" id="f-484" unitRef="usd">1429000</carm:FinancingCashUsedInFinanceLeases>
    <carm:FinancingCashUsedInFinanceLeases contextRef="c-7" decimals="-3" id="f-485" unitRef="usd">1301000</carm:FinancingCashUsedInFinanceLeases>
    <carm:LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock contextRef="c-1" id="f-486">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future maturities of lease liabilities were as follows as of December&#160;31, 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Operating &lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Finance &lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fiscal year ending:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total future minimum payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</carm:LesseeOperatingAndFinanceLeaseLiabilityFiscalYearMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-5" decimals="-3" id="f-487" unitRef="usd">927000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-5" decimals="-3" id="f-488" unitRef="usd">942000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-5" decimals="-3" id="f-489" unitRef="usd">225000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo contextRef="c-5" decimals="-3" id="f-490" unitRef="usd">21000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-5" decimals="-3" id="f-491" unitRef="usd">233000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree contextRef="c-5" decimals="-3" id="f-492" unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-5" decimals="-3" id="f-493" unitRef="usd">240000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour contextRef="c-5" decimals="-3" id="f-494" unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-5" decimals="-3" id="f-495" unitRef="usd">184000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive contextRef="c-5" decimals="-3" id="f-496" unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-5" decimals="-3" id="f-497" unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-5" decimals="-3" id="f-498" unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-5" decimals="-3" id="f-499" unitRef="usd">1809000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue contextRef="c-5" decimals="-3" id="f-500" unitRef="usd">963000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-5" decimals="-3" id="f-501" unitRef="usd">253000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount contextRef="c-5" decimals="-3" id="f-502" unitRef="usd">38000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-5" decimals="-3" id="f-503" unitRef="usd">1556000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability contextRef="c-5" decimals="-3" id="f-504" unitRef="usd">925000</us-gaap:FinanceLeaseLiability>
    <carm:CommitmentsAnnualPaymentsRequiredToBePaid contextRef="c-64" decimals="-3" id="f-505" unitRef="usd">25000000</carm:CommitmentsAnnualPaymentsRequiredToBePaid>
    <carm:AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents contextRef="c-65" decimals="-5" id="f-506" unitRef="usd">10900000</carm:AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents>
    <carm:AdditionalMilestonePaymentsRequiredToBePaid contextRef="c-66" decimals="-5" id="f-507" unitRef="usd">30000000.0</carm:AdditionalMilestonePaymentsRequiredToBePaid>
    <carm:AdditionalMilestonePaymentsForFirstCarMProduct contextRef="c-64" decimals="-5" id="f-508" unitRef="usd">1700000</carm:AdditionalMilestonePaymentsForFirstCarMProduct>
    <us-gaap:LossOnContractTermination contextRef="c-68" decimals="-5" id="f-510" unitRef="usd">4000000</us-gaap:LossOnContractTermination>
    <us-gaap:LossOnContractTermination contextRef="c-68" decimals="-5" id="f-511" unitRef="usd">4000000</us-gaap:LossOnContractTermination>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-69" decimals="-5" id="f-512" unitRef="usd">4000000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:LossContingencyEstimateOfPossibleLoss contextRef="c-5" decimals="-5" id="f-513" unitRef="usd">1200000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-514">Stockholders&#x2019; (Deficit) Equity&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March&#160;7, 2023, in connection with the closing of the Mer&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ger, the following is reflected on the consolidated statements of convertible preferred stock and stockholders&#x2019; (deficit) equity for the year ended December 31, 2023: (i) the sale of 3,730,608 shares of common stock in a pre-closing funding at $8.21 per share for total proceeds of $30.6 million, (ii) the issuance of 5,059,338 shares of common stock upon the settlement of the Company&#x2019;s $35.0 million convertible promissory note, accrued interest and related derivative liability, (iii) the conversion of convertible preferred stock and exchangeable shares previously presented as noncontrolling interests into 18,872,711 shares of common stock, (iv) the issuance of 10,374,272 shares of common stock to Sesen Bio stockholders as consideration for the Merger.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On April 17, 2023, the Company filed a universal shelf registration statement on Form S-3, which was declared effective on May 2, 2023 (Registration Statement). Under the Registration Statement, the Company may offer and sell up to $300.0&#160;million of a variety of securities, including debt securities, common stock, preferred stock, depositary shares, subscription rights, warrants and units from time to time in one or more offerings at prices and on terms to be determined at the time of the offering. On May 12, 2023, the Company entered into an Amended and Restated Open Market Sale Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;SM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; (Sale Agreement) with Jefferies LLC, as sales agent, pursuant to which the Company may offer and sell shares of common stock with an aggregate offering price of up to $100.0&#160;million under an &#x201c;at-the-market" offering program. During the years ended December 31, 2024 and 2023, the Company sold 1,136,384 and 226,533 shares of common stock, respectively, for gross proceeds of $2.4&#160;million and $0.6&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 6, 2023, the Company's stockholders approved an amendment to the Company's Restated Certificate of Incorporation to increase the number of authorized shares of the Company's common stock, $0.001 par value, from 100,000,000 shares to 350,000,000 shares and authorized 5,000,000 shares of preferred stock, $0.001 par value.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-70"
      decimals="INF"
      id="f-515"
      unitRef="shares">3730608</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c-50"
      decimals="2"
      id="f-516"
      unitRef="usdPerShare">8.21</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-70" decimals="-5" id="f-517" unitRef="usd">30600000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-70"
      decimals="INF"
      id="f-518"
      unitRef="shares">5059338</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-70" decimals="-5" id="f-519" unitRef="usd">35000000.0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <carm:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests
      contextRef="c-70"
      decimals="INF"
      id="f-520"
      unitRef="shares">18872711</carm:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="c-70"
      decimals="INF"
      id="f-521"
      unitRef="shares">10374272</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <carm:SaleOfStockStockOfferingAmount contextRef="c-71" decimals="-5" id="f-522" unitRef="usd">300000000</carm:SaleOfStockStockOfferingAmount>
    <carm:SaleOfStockMaximumOfferingAmount contextRef="c-72" decimals="INF" id="f-523" unitRef="usd">100000000</carm:SaleOfStockMaximumOfferingAmount>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-73"
      decimals="INF"
      id="f-524"
      unitRef="shares">1136384</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-74"
      decimals="INF"
      id="f-525"
      unitRef="shares">226533</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction contextRef="c-73" decimals="-5" id="f-526" unitRef="usd">2400000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction contextRef="c-74" decimals="-5" id="f-527" unitRef="usd">600000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-528"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-75"
      decimals="INF"
      id="f-529"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-76"
      decimals="INF"
      id="f-530"
      unitRef="shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-76"
      decimals="INF"
      id="f-531"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-76"
      decimals="INF"
      id="f-532"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-533">Stock-based Compensation&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2017 Stock Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company adopted the CARISMA Therapeutics Inc. 2017 Stock Incentive Plan, as amended (the Legacy Carisma Plan), that provided for the grant of incentive stock options to employees, directors, and consultants. The maximum term of options granted under the Legacy Carisma Plan was ten years, and stock options typically vested over a four-year period. The Company&#x2019;s stock options vest based on the terms in the awards agreements and generally vest over four years. Upon completion of the Merger, the Company assumed the Legacy Carisma Plan and the outstanding and unexercised options issued thereunder, and ceased granting awards under the Legacy Carisma Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2014 Stock Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Amended and Restated 2014 Stock Incentive Plan, as amended, provides for the grant of incentive and non-qualified stock options, restricted stock awards and restricted stock units, stock appreciation rights and other stock-based awards to the Company&#x2019;s employees, officers, directors, consultants, and advisors, with amounts and terms of grants determined by the Company&#x2019;s board of directors at the time of grant. Stock options outstanding under the 2014 Amended and Restated Stock Incentive Plan (the 2014 Plan) generally vest over a four-year period and are exercisable for a period of ten years from the date of grant. As of December&#160;31, 2024, approximately 4.8 million shares of common stock remained available for issuance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2014 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Carisma Therapeutics Inc. 2014 Employee Stock Purchase Plan (the Carisma 2014 ESPP) provides employees with the opportunity to purchase shares of common stock at a 15% discount to the market price through payroll deductions or lump sum cash investments. The purpose of the Carisma 2014 ESPP is to enhance employee interest in the success and progress &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;of the Company by encouraging employee ownership of common stock. The Carisma 2014 ESPP had 0.2 million shares of common stock available for issuance as of December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise&lt;br/&gt;price &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&lt;br/&gt;term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate &lt;br/&gt;Intrinsic &lt;br/&gt;Value (in &lt;br/&gt;thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,023,370&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,810)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,805,465&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,078,034)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,746,991&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercisable as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,414,750&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant-date per share fair values of options granted during the years ended December 31, 2024 and 2023 were $1.36 and $4.29, respectively. The fair values in the years ended December 31, 2024 and 2023 were estimated using the Black-Scholes option-pricing model based on the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.77% - 4.59%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.92% - 4.76%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86.55% - 112.12%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;57.77% - 103.00%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense in the following expense categories in the accompanying consolidated statements of operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.407%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.407%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.125%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the reductions in force, 1,898,297 options were forfeited during the year ended December 31, 2024. The Company recognized stock-based compensation expense of $0.2 million related to the modification of Sesen Bio options assumed in connection with the Merger during the year ended December 31, 2023. Compensation cost for awards not vested as of December&#160;31, 2024 was $7.2 million and will be expensed over a weighted-average period of 2.5 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-77" id="f-534">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-77" id="f-535">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-77" id="f-536">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-78" id="f-537">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-78" id="f-538">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="c-79" decimals="-5" id="f-539" unitRef="shares">4800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate contextRef="c-80" decimals="2" id="f-540" unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="c-81" decimals="-5" id="f-541" unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-542">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise&lt;br/&gt;price &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&lt;br/&gt;term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate &lt;br/&gt;Intrinsic &lt;br/&gt;Value (in &lt;br/&gt;thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,023,370&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,810)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,805,465&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,078,034)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,746,991&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercisable as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,414,750&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-6" decimals="INF" id="f-543" unitRef="shares">6023370</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-6"
      decimals="2"
      id="f-544"
      unitRef="usdPerShare">3.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-545" unitRef="shares">3810</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-546"
      unitRef="usdPerShare">0.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-1" decimals="-3" id="f-547" unitRef="usd">4000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-548" unitRef="shares">3805465</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-549"
      unitRef="usdPerShare">1.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-1" decimals="INF" id="f-550" unitRef="shares">2078034</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-551"
      unitRef="usdPerShare">4.17</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-5" decimals="INF" id="f-552" unitRef="shares">7746991</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-553"
      unitRef="usdPerShare">2.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-554">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-5" decimals="-3" id="f-555" unitRef="usd">59000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c-5" decimals="INF" id="f-556" unitRef="shares">4414750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-557"
      unitRef="usdPerShare">2.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-558">P6Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-5" decimals="-3" id="f-559" unitRef="usd">59000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-560"
      unitRef="usdPerShare">1.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-7"
      decimals="2"
      id="f-561"
      unitRef="usdPerShare">4.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-562">The fair values in the years ended December 31, 2024 and 2023 were estimated using the Black-Scholes option-pricing model based on the following assumptions:&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.77% - 4.59%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.92% - 4.76%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86.55% - 112.12%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;57.77% - 103.00%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-82" decimals="4" id="f-563" unitRef="number">0.0377</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-83" decimals="4" id="f-564" unitRef="number">0.0459</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-84" decimals="4" id="f-565" unitRef="number">0.0292</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-85" decimals="4" id="f-566" unitRef="number">0.0476</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-86" id="f-567">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-87" id="f-568">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-82" decimals="4" id="f-569" unitRef="number">0.8655</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-83" decimals="4" id="f-570" unitRef="number">1.1212</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-84" decimals="4" id="f-571" unitRef="number">0.5777</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-85" decimals="4" id="f-572" unitRef="number">1.0300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-86" decimals="0" id="f-573" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-87" decimals="0" id="f-574" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-575">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense in the following expense categories in the accompanying consolidated statements of operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.407%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.407%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.125%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-88" decimals="-3" id="f-576" unitRef="usd">1116000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-89" decimals="-3" id="f-577" unitRef="usd">1242000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-90" decimals="-3" id="f-578" unitRef="usd">2533000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-91" decimals="-3" id="f-579" unitRef="usd">1074000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-580" unitRef="usd">3649000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-7" decimals="-3" id="f-581" unitRef="usd">2316000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-92"
      decimals="INF"
      id="f-582"
      unitRef="shares">1898297</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-93" decimals="-5" id="f-583" unitRef="usd">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-5" decimals="-5" id="f-584" unitRef="usd">7200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-1" id="f-585">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-586">Income Taxes&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;A reconciliation of income tax benefit at the statutory federal income tax rate and income taxes as reflected in the consolidated financial statements is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.678%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.769%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal tax benefit at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State and local tax, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State and local tax rate change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets and liabilities are determined based on the differences between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect for years in which differences are expected to reverse.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the Company's deferred tax assets for federal income taxes consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;87,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;72,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitalized research and development costs, net of amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Start-up costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortizable assets and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;155,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;134,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(153,855)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(133,580)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right of use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(848)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(645)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(524)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net deferred tax assets and liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, the Company has net operating loss carryforwards (NOLs) for federal income tax purposes of $374.7&#160;million, which are available to offset future federal taxable income. The pre-2018 federal NOLs of $120.0&#160;million will begin to expire in 2031, if not utilized. The post-2017 federal NOLs of $254.7&#160;million carry forward indefinitely. The Company also has NOLs for state and local income tax purposes of $280.3&#160;million and $65.1&#160;million, respectively that are available to offset future taxable income. The state NOLs will begin to expire in 2031 while the city of Philadelphia NOLs begin to expire in 2042. As of December&#160;31, 2024, the Company also had federal and state research and development tax credit carryforwards of $12.6&#160;million and $0.8&#160;million that will begin to expire in 2029 and 2032, respectively, unless previously utilized.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In assessing the need for a valuation allowance, management must determine that there will be sufficient taxable income to allow for the realization of deferred tax assets. Based upon the historical and anticipated future losses, management has determined that the deferred tax assets do not meet the more-likely-than-not threshold for realizability. Accordingly, a full valuation allowance has been recorded against the Company's net deferred tax assets as of December&#160;31, 2024. The valuation allowance increased by $20.3&#160;million and $84.5&#160;million during the years ended December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The NOLs and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOLs and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50 percent, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The Company has not done an analysis to determine whether or not ownership changes have occurred since inception. Certain state NOLs may also be limited, including Pennsylvania, which limits net operating loss utilization as a percentage of apportioned taxable income.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will recognize interest and penalties related to uncertain tax positions as a component of income tax expense/(benefit). As of December&#160;31, 2024, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company's financial statements. Tax years from 2021 and after remain subject to examination by all of the taxing jurisdictions. The NOLs and research credit carryforwards remain subject to review until utilized.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-587">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;A reconciliation of income tax benefit at the statutory federal income tax rate and income taxes as reflected in the consolidated financial statements is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.678%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.769%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal tax benefit at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State and local tax, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State and local tax rate change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="INF" id="f-588" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-7" decimals="INF" id="f-589" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="3" id="f-590" unitRef="number">0.080</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-7" decimals="3" id="f-591" unitRef="number">0.085</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal contextRef="c-1" decimals="3" id="f-592" unitRef="number">-0.031</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal contextRef="c-7" decimals="3" id="f-593" unitRef="number">-0.016</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal>
    <carm:EffectiveIncomeTaxRateReconciliationPermanentDifferences contextRef="c-1" decimals="3" id="f-594" unitRef="number">-0.001</carm:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
    <carm:EffectiveIncomeTaxRateReconciliationPermanentDifferences contextRef="c-7" decimals="3" id="f-595" unitRef="number">-0.004</carm:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-1" decimals="3" id="f-596" unitRef="number">-0.058</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-7" decimals="3" id="f-597" unitRef="number">-0.009</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="c-1" decimals="3" id="f-598" unitRef="number">-0.330</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="c-7" decimals="3" id="f-599" unitRef="number">-0.284</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent contextRef="c-1" decimals="3" id="f-600" unitRef="number">0.014</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent contextRef="c-7" decimals="3" id="f-601" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-602" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-7" decimals="3" id="f-603" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-604">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the Company's deferred tax assets for federal income taxes consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;87,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;72,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitalized research and development costs, net of amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Start-up costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortizable assets and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;155,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;134,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(153,855)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(133,580)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right of use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(848)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(645)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(524)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net deferred tax assets and liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-5" decimals="-3" id="f-605" unitRef="usd">87742000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-6" decimals="-3" id="f-606" unitRef="usd">72689000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <carm:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization contextRef="c-5" decimals="-3" id="f-607" unitRef="usd">35608000</carm:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization>
    <carm:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization contextRef="c-6" decimals="-3" id="f-608" unitRef="usd">33778000</carm:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-5" decimals="-3" id="f-609" unitRef="usd">13269000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-6" decimals="-3" id="f-610" unitRef="usd">9746000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <carm:DeferredTaxAssetsStartUpCosts contextRef="c-5" decimals="-3" id="f-611" unitRef="usd">4051000</carm:DeferredTaxAssetsStartUpCosts>
    <carm:DeferredTaxAssetsStartUpCosts contextRef="c-6" decimals="-3" id="f-612" unitRef="usd">4407000</carm:DeferredTaxAssetsStartUpCosts>
    <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c-5" decimals="-3" id="f-613" unitRef="usd">12182000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c-6" decimals="-3" id="f-614" unitRef="usd">13353000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <carm:DeferredTaxAssetsLeaseLiability contextRef="c-5" decimals="-3" id="f-615" unitRef="usd">733000</carm:DeferredTaxAssetsLeaseLiability>
    <carm:DeferredTaxAssetsLeaseLiability contextRef="c-6" decimals="-3" id="f-616" unitRef="usd">668000</carm:DeferredTaxAssetsLeaseLiability>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences contextRef="c-5" decimals="-3" id="f-617" unitRef="usd">405000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences contextRef="c-6" decimals="-3" id="f-618" unitRef="usd">0</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences>
    <carm:DeferredTaxAssetsAmortizableAssetsAndOther contextRef="c-5" decimals="-3" id="f-619" unitRef="usd">27000</carm:DeferredTaxAssetsAmortizableAssetsAndOther>
    <carm:DeferredTaxAssetsAmortizableAssetsAndOther contextRef="c-6" decimals="-3" id="f-620" unitRef="usd">21000</carm:DeferredTaxAssetsAmortizableAssetsAndOther>
    <carm:DeferredTaxAssetsEquityCompensation contextRef="c-5" decimals="-3" id="f-621" unitRef="usd">1115000</carm:DeferredTaxAssetsEquityCompensation>
    <carm:DeferredTaxAssetsEquityCompensation contextRef="c-6" decimals="-3" id="f-622" unitRef="usd">87000</carm:DeferredTaxAssetsEquityCompensation>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-5" decimals="-3" id="f-623" unitRef="usd">155132000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-6" decimals="-3" id="f-624" unitRef="usd">134749000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-3" id="f-625" unitRef="usd">153855000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-6" decimals="-3" id="f-626" unitRef="usd">133580000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-5" decimals="-3" id="f-627" unitRef="usd">1277000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-6" decimals="-3" id="f-628" unitRef="usd">1169000</us-gaap:DeferredTaxAssetsNet>
    <carm:DeferredTaxLiabilitiesRightOfUseAsset contextRef="c-5" decimals="-3" id="f-629" unitRef="usd">848000</carm:DeferredTaxLiabilitiesRightOfUseAsset>
    <carm:DeferredTaxLiabilitiesRightOfUseAsset contextRef="c-6" decimals="-3" id="f-630" unitRef="usd">645000</carm:DeferredTaxLiabilitiesRightOfUseAsset>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-631" unitRef="usd">429000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-6" decimals="-3" id="f-632" unitRef="usd">524000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-5" decimals="-3" id="f-633" unitRef="usd">1277000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-6" decimals="-3" id="f-634" unitRef="usd">1169000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-5" decimals="-3" id="f-635" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-6" decimals="-3" id="f-636" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards contextRef="c-94" decimals="-5" id="f-637" unitRef="usd">374700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-95" decimals="-5" id="f-638" unitRef="usd">120000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-96" decimals="-5" id="f-639" unitRef="usd">254700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-97" decimals="-5" id="f-640" unitRef="usd">280300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-98" decimals="-5" id="f-641" unitRef="usd">65100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-99" decimals="-5" id="f-642" unitRef="usd">12600000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-100" decimals="-5" id="f-643" unitRef="usd">800000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-1" decimals="-5" id="f-644" unitRef="usd">20300000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-7" decimals="-5" id="f-645" unitRef="usd">84500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c-1" id="f-646">Related-Party TransactionsThe Company has a collaboration and license agreement with Moderna, a significant shareholder (Note 13).</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-647">Moderna Collaboration and License Agreement&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2022, the Company entered into the Moderna License Agreement, which provides for a broad strategic collaboration to discover, develop and commercialize &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;in vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; engineered CAR-M therapeutics in oncology. Moderna has the right to designate up to twelve research targets as development targets under this collaboration. While the collaboration was initially limited to oncology, in September 2024, the companies agreed to expand the collaboration to discover, develop and commercialize&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; in vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; engineered CAR-M therapeutics in specific autoimmune diseases. As a result, Moderna nominated two autoimmune research targets. As of February 2025, in connection with Moderna's nomination of all 12 oncology research targets (Note 14), the Company will not be conducting any additional research activities under the collaboration agreement and will not be receiving any further payments from Moderna for research and development services under the collaboration agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to the nomination of a research target, Moderna may designate the research target as a development target. Upon Moderna&#x2019;s designation of a development target (and payment of a related development target designation milestone) for commencement of pre-clinical development of a product candidate, the Company will grant Moderna an exclusive worldwide, sublicensable royalty bearing license to develop, manufacture and commercialize the product candidate.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Moderna License Agreement, Moderna made an upfront non-refundable payment of $45.0 million to the Company. Assuming Moderna develops and commercializes 12 products, each directed to a different development target, the Company is eligible to receive up to between $247.0 million and $253.0 million per product in development target designation, development, regulatory and commercial milestone payments. Moderna also reimbursed the Company for all costs incurred by the Company in connection with its research and development activities under the Moderna License Agreement plus a reasonable margin for the respective services performed (with a minimum commitment to reimburse $10.0 million in research and development costs over the first three years from execution of the Moderna License Agreement). The Company is also eligible to receive tiered mid-to-high single digit royalties of net sales of any products that are commercialized under the agreement, which may be, subject to reductions. In addition, Moderna has agreed to cover the cost the Company incurs for certain milestone payments and royalties that the Company owes as a licensor under one of its intellectual property in-license agreements with Penn, which is sublicensed to Moderna under the Moderna License Agreement. Moderna may deduct these royalties in part from any royalties owed to the Company. The &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Moderna License Agreement terminates on a product-by-product basis upon the latest of expiration of the applicable product patents, expiration of regulatory exclusivity and the tenth anniversary of first commercial sale, unless terminated earlier by the Company or Moderna.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At commencement, the Company identified several potential performance obligations within the Moderna License Agreement, including research and development services on research targets, option rights held by Moderna, a non-exclusive royalty-free license to use the Company&#x2019;s intellectual property to conduct research and development activities and participation on the joint steering committee (JSC). The Company determined that there were 2 performance obligations comprised of (i) research and development services and (ii) option rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the research and development services, the stand-alone selling price was determined considering the expected passthrough costs and cost of the research and development services and a reasonable margin for the respective services. The material rights from the option rights were valued based on the estimated discount at which the option is priced and the Company&#x2019;s estimated probability of the options&#x2019; exercise as of the time of the agreement. The transaction price allocated to research and development services is recognized as collaboration revenues as the research and development services are provided to satisfy the underlying obligation related to the research and development target. The transfer of control occurs over this period and, in management&#x2019;s judgment, is the best measure of progress towards satisfying the performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transaction price of $45.0&#160;million allocated to the options rights, which are considered material rights, will be recognized in the period that Moderna exercises or determines not to exercise its option right to license and commercialize the designated development target.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2024, the Company received notice from Moderna that Moderna had designated the first development candidate, an &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;in vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; CAR-macrophage targeting GPC3 that is designed to treat solid tumors, including hepatocellular carcinoma. Pursuant to the terms of the Moderna License Agreement, the designation triggered a $2.0&#160;million milestone payment from Moderna to the Company. As a result, the Company recognized collaboration revenue of $2.0&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company reduced its $45.0&#160;million deferred revenue liability associated with the option rights by recognizing $3.8&#160;million in collaboration revenue, which represents a proportional reduction based on the 12 potential early-stage research targets. As of December 31, 2024, the Company recorded a collaboration receivable of $2.9&#160;million related to the reimbursement of costs incurred in connection with the Company's research and development activities. The Company received the $2.9&#160;million in January 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company included the $45.0 million up-front and nonrefundable payment and $73.9 million of variable consideration for expected research and development services to be performed during the five-year contract term, inclusive of passthrough costs, in the transaction price as of the outset of the arrangement. During the years ended December 31, 2024 and 2023, the Company recognized $19.6 million and $14.9 million, respectively, of collaboration revenues. Collaboration revenues for the year ended December&#160;31, 2024 include $3.8&#160;million of deferred option rights revenue recognition and $2.0&#160;million of milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized $38.7&#160;million and $3.8&#160;million, respectively, of research and development services and option right collaboration revenues since inception of the Moderna License Agreement through December&#160;31, 2024. The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied as of December&#160;31, 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Transaction &lt;br/&gt;price unsatisfied&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Performance obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Option rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total performance obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts due to the Company for satisfying the revenue recognition criteria or that are contractually due based upon the terms of the collaboration agreements are recorded as accounts receivable in the Company&#x2019;s consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities consist of amounts received prior to satisfying the revenue recognition criteria, which are recorded as deferred revenue in the Company&#x2019;s consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in deferred revenue (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at the beginning of the period &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;46,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferral of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Recognition of unearned revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(17,632)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(14,919)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at the end of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;44,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;46,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The current portion of deferred revenue represents advanced payments received from Moderna for costs expected to be incurred by the Company within the next twelve months. The noncurrent portion of deferred revenue represents the $41.3 million upfront, non-refundable and non-creditable payment allocated to customer option right which is not expected to be recognized within the next 12 months.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <carm:MaximumNumberOfResearchTargets
      contextRef="c-101"
      decimals="INF"
      id="f-648"
      unitRef="target">12</carm:MaximumNumberOfResearchTargets>
    <carm:NumberOfResearchTargetsNominatedAutoimmune
      contextRef="c-102"
      decimals="INF"
      id="f-649"
      unitRef="target">2</carm:NumberOfResearchTargetsNominatedAutoimmune>
    <carm:NumberOfResearchTargetsGrossOncology
      contextRef="c-103"
      decimals="INF"
      id="f-650"
      unitRef="target">12</carm:NumberOfResearchTargetsGrossOncology>
    <carm:UpfrontNonRefundablePaymentReceived contextRef="c-104" decimals="-5" id="f-651" unitRef="usd">45000000.0</carm:UpfrontNonRefundablePaymentReceived>
    <carm:NumberOfPotentialProductsToDevelopAndCommercialize
      contextRef="c-104"
      decimals="INF"
      id="f-652"
      unitRef="product">12</carm:NumberOfPotentialProductsToDevelopAndCommercialize>
    <carm:AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments contextRef="c-105" decimals="-5" id="f-653" unitRef="usd">247000000.0</carm:AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments>
    <carm:AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments contextRef="c-106" decimals="-5" id="f-654" unitRef="usd">253000000.0</carm:AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments>
    <carm:MinimumCommitmentToReimburseResearchAndDevelopmentCosts contextRef="c-107" decimals="-5" id="f-655" unitRef="usd">10000000.0</carm:MinimumCommitmentToReimburseResearchAndDevelopmentCosts>
    <carm:PeriodOfReimbursementOfResearchAndDevelopmentCosts contextRef="c-104" id="f-656">P3Y</carm:PeriodOfReimbursementOfResearchAndDevelopmentCosts>
    <carm:NumberOfPerformanceObligations
      contextRef="c-108"
      decimals="INF"
      id="f-657"
      unitRef="obligation">2</carm:NumberOfPerformanceObligations>
    <carm:UpfrontNonRefundablePaymentReceived contextRef="c-104" decimals="-5" id="f-658" unitRef="usd">45000000</carm:UpfrontNonRefundablePaymentReceived>
    <carm:CollaborativeArrangementRightsAndObligationsMilestonePayments contextRef="c-109" decimals="-5" id="f-659" unitRef="usd">2000000</carm:CollaborativeArrangementRightsAndObligationsMilestonePayments>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-110" decimals="-5" id="f-660" unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability contextRef="c-111" decimals="-5" id="f-661" unitRef="usd">45000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-112" decimals="-5" id="f-662" unitRef="usd">3800000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <carm:NumberOfPotentialResearchTargetDesignations
      contextRef="c-113"
      decimals="INF"
      id="f-663"
      unitRef="target">12</carm:NumberOfPotentialResearchTargetDesignations>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-114" decimals="-5" id="f-664" unitRef="usd">2900000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:ProceedsFromCollectionOfOtherReceivables contextRef="c-115" decimals="-5" id="f-665" unitRef="usd">2900000</us-gaap:ProceedsFromCollectionOfOtherReceivables>
    <carm:UpfrontNonRefundablePaymentReceived contextRef="c-108" decimals="-5" id="f-666" unitRef="usd">45000000.0</carm:UpfrontNonRefundablePaymentReceived>
    <carm:VariableConsideration contextRef="c-116" decimals="-5" id="f-667" unitRef="usd">73900000</carm:VariableConsideration>
    <carm:ContractTerm contextRef="c-116" id="f-668">P5Y</carm:ContractTerm>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-5" id="f-669" unitRef="usd">19600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-5" id="f-670" unitRef="usd">14900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-117" decimals="-5" id="f-671" unitRef="usd">3800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-118" decimals="-5" id="f-672" unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-119" decimals="-5" id="f-673" unitRef="usd">38700000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-117" decimals="-5" id="f-674" unitRef="usd">3800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock contextRef="c-1" id="f-675">The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied as of December&#160;31, 2024 (in thousands):&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Transaction &lt;br/&gt;price unsatisfied&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Performance obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Option rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total performance obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock>
    <carm:RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount contextRef="c-5" decimals="-3" id="f-676" unitRef="usd">35301000</carm:RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount>
    <carm:RevenueRemainingPerformanceObligationOptionRightsAmount contextRef="c-5" decimals="-3" id="f-677" unitRef="usd">41250000</carm:RevenueRemainingPerformanceObligationOptionRightsAmount>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-5" decimals="-3" id="f-678" unitRef="usd">76551000</us-gaap:RevenueRemainingPerformanceObligation>
    <carm:ScheduleOfChangesInDeferredRevenueTableTextBlock contextRef="c-1" id="f-679">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in deferred revenue (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at the beginning of the period &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;46,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferral of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Recognition of unearned revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(17,632)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(14,919)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at the end of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;44,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;46,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</carm:ScheduleOfChangesInDeferredRevenueTableTextBlock>
    <us-gaap:ContractWithCustomerLiability contextRef="c-6" decimals="-3" id="f-680" unitRef="usd">46413000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-8" decimals="-3" id="f-681" unitRef="usd">47459000</us-gaap:ContractWithCustomerLiability>
    <carm:ContractWithCustomerLiabilityDeferralOfRevenue contextRef="c-1" decimals="-3" id="f-682" unitRef="usd">16198000</carm:ContractWithCustomerLiabilityDeferralOfRevenue>
    <carm:ContractWithCustomerLiabilityDeferralOfRevenue contextRef="c-7" decimals="-3" id="f-683" unitRef="usd">13873000</carm:ContractWithCustomerLiabilityDeferralOfRevenue>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-1" decimals="-3" id="f-684" unitRef="usd">-17632000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-7" decimals="-3" id="f-685" unitRef="usd">-14919000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability contextRef="c-5" decimals="-3" id="f-686" unitRef="usd">44979000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-6" decimals="-3" id="f-687" unitRef="usd">46413000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-120" decimals="-5" id="f-688" unitRef="usd">41300000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-689">Subsequent Events&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has evaluated subsequent events from the balance sheet date through March&#160;31, 2025, the issuance date of these consolidated financial statements, and has identified the following matter requiring disclosure. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Moderna Collaboration and License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In February 2025, Moderna nominated ten additional oncology research targets, four of which replaced two oncology research targets and two autoimmune research targets, which Moderna concurrently ceased developing. As of February 2025, Moderna has nominated all 12 oncology research targets under the collaboration for which the Company has the potential to receive future milestones and royalty payments. The Company will not conduct any additional research activities under the collaboration agreement and the Company will not be receiving any further research funding from Moderna under the collaboration agreement. Moderna also agreed to terminate the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;in vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; oncology field exclusivity, which would allow the Company to pursue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt; in vivo &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;CAR-M programs outside of the  12 nominated oncology targets and product polypeptides. The final research and development payment of $2.9&#160;million was received in January 2025 which will be recognized as collaboration revenue for research and development services in the first quarter of 2025. The Company does not expect to recognize any additional unsatisfied research and development performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;2025 Cash Preservation Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As part of a further revised plan approved by the Company's board of directors, on Marc&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;h 25&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, 2025, to preserve the Company's existing cash resou&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;rces&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;following its reduction in workforce (the "cash preservation plan"), the Company reduced its operations to those necessary to identify and explore a range of strategic alternatives to maximize value and prepare to wind down its business. The cash preservation plan prioritizes payments necessary and appropriate for those reduced operations and those that will help to evaluate our strategic alternatives. &lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Potential strategic alternatives to be explored and evaluated may include, among other transactions, the sale, license, monetization or divestiture of one or more of the Company's assets or technologies, a strategic collaboration or partnership with one or more parties or the merger or sale of the Company. Any future resumption of research and development activities would depend on completing a strategic transaction that would support the Company's prior operating plans or otherwise obtaining significant additional funding.&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As part of the cash preservation plan, the board of directors determined to terminate all of its employees not deemed necessary to pursue strategic alternatives and execute an orderly wind down of our operations. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Affected employees were informed of the reduction in workforce on March 25, 2025. The reduction in workforce was effective on March 31, 2025. The reduction in workforce includes 37 of the Company's full-time employees representing approximately 84% of our total workforce, including certain employees engaged in research and development, manufacturing and corporate activities. The Company expects to incur approximately $3.8&#160;million in connection with the reduction in workforce, which primarily represents one-time employee termination benefits directly associated with the workforce reduction. The Company also expects to pay the majority of related reduction in workforce amounts by the end of 2025. The Company may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;with, the reduction in workforce, including (but not limited to) impairment charges relating to the balances of property and equipment, net, prepaid research and development costs and right of use assets &#x2013; operating lease.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <carm:NumberOfResearchTargetsNominatedOncology contextRef="c-121" decimals="INF" id="f-690" unitRef="item">10</carm:NumberOfResearchTargetsNominatedOncology>
    <carm:NumberOfResearchTargetsNominatedReplacements
      contextRef="c-121"
      decimals="INF"
      id="f-691"
      unitRef="target">4</carm:NumberOfResearchTargetsNominatedReplacements>
    <carm:NumberOfResearchTargetsTerminatedOncology
      contextRef="c-121"
      decimals="INF"
      id="f-692"
      unitRef="target">2</carm:NumberOfResearchTargetsTerminatedOncology>
    <carm:NumberOfResearchTargetsTerminatedAutoimmune
      contextRef="c-121"
      decimals="INF"
      id="f-693"
      unitRef="target">2</carm:NumberOfResearchTargetsTerminatedAutoimmune>
    <carm:NumberOfResearchTargetsGrossOncology
      contextRef="c-103"
      decimals="INF"
      id="f-694"
      unitRef="target">12</carm:NumberOfResearchTargetsGrossOncology>
    <carm:NumberOfResearchTargetsGrossOncology
      contextRef="c-103"
      decimals="INF"
      id="f-695"
      unitRef="target">12</carm:NumberOfResearchTargetsGrossOncology>
    <us-gaap:ProceedsFromCollectionOfOtherReceivables contextRef="c-115" decimals="-5" id="f-696" unitRef="usd">2900000</us-gaap:ProceedsFromCollectionOfOtherReceivables>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="c-122"
      decimals="INF"
      id="f-697"
      unitRef="employee">37</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent contextRef="c-122" decimals="2" id="f-698" unitRef="number">0.84</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1 contextRef="c-4" decimals="-5" id="f-699" unitRef="usd">3800000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-123" id="f-700">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-123" id="f-701">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-123" id="f-702">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-123" id="f-703">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c-1" id="f-704">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
